studies O
on O
magnesiums O
mechanism O
of O
action O
in O
digitalis B-Plant
induced O
arrhythmias B-Disease

the O
mechanism O
by O
which O
magnesium O
affects O
digitalis B-Plant
induced O
arrhythmias B-Disease
was O
studied O
in O
dogs O
with O
and O
without O
beta O
receptor O
blockade O

magnesium O
direct O
effect O
on O
calcium O
and O
potassium O
fluxes O
across O
the O
myocardial O
cell O
membrane O
may O
be O
the O
mechanism O
of O
its O
antiarrhythmic O
action O
in O
digitalis B-Plant
toxic O
arrhythmias B-Disease

inhibitory O
effect O
of O
green B-Plant
tea I-Plant
on O
the O
growth O
of O
established O
skin B-Disease
papillomas I-Disease
in O
mice O

in O
10 O
separate O
experiments O
mice O
with O
established O
chemically O
induced O
or O
uv O
light O
induced O
skin B-Disease
papillomas I-Disease
were O
treated O
continuously O
with O
green B-Plant
tea I-Plant
in O
the O
drinking O
water O
or O
with O
injections O
of O
a O
green B-Plant
tea I-Plant
polyphenol O
fraction O
or O
epigallocatechin O
gallate O
three O
times O
a O
week O
for O
4 O
10 O

examination O
of O
the O
data O
from O
all O
ten O
experiments O
revealed O
that O
complete O
tumor B-Disease
regression O
occurred O
in O
14 O
of O
346 O
papilloma O
bearing O
mice O
4 O
that O
were O
treated O
with O
green B-Plant
tea I-Plant
in O
the O
drinking O
water O
or O
with O
ip O
injections O
of O
green B-Plant
tea I-Plant
constituents O
whereas O
none O
of O
the O
220 O
papilloma O
bearing O
control O
mice O
treated O
with O
only O
vehicle O
exhibited O
complete O
tumor B-Disease
regression O

these O
observations O
indicate O
that O
oral O
administration O
of O
green B-Plant
tea I-Plant
administration O
of O
a O
green B-Plant
tea I-Plant
polyphenol O
fraction O
or O
administration O
of O
epigallocatechin O
gallate O
inhibited O
the O
growth O
and O
or O
caused O
the O
regression O
of O
established O
experimentally O
induced O
skin B-Disease
papillomas I-Disease

the O
consumption O
of O
coffee B-Plant
is O
a O
self O
reinforcing O
behavior O
and O
caffeine O
dependence O
and O
addiction B-Disease
are O
common O

initial O
trials O
showing O
coffee B-Plant
association O
with O
coronary B-Disease
disease I-Disease
and O
myocardial B-Disease
infarction I-Disease
have O
been O
difficult O
to O
reproduce O
and O
have O
many O
confounding O
variable O

at O
present O
there O
is O
no O
convincing O
evidence O
that O
caffeine O
or O
coffee B-Plant
consumption O
increases O
the O
risk O
for O
any O
solid B-Disease
tumor I-Disease

our O
data O
suggest O
that O
long O
term O
exposure O
to O
hemp B-Plant
dust O
may O
cause O
the O
development O
of O
chronic O
respiratory B-Disease
symptoms I-Disease
and O
impairment O
of O
ventilatory O
capacity O

atrial B-Disease
tachyarrhythmias I-Disease
are O
a O
common O
manifestation O
of O
digitalis B-Plant
toxicity O

halothane O
is O
known O
to O
oppose O
digitalis B-Plant
induced O
ventricular B-Disease
arrhythmias I-Disease

its O
effect O
on O
digitalis B-Plant
caused O
atrial B-Disease
arrhythmias I-Disease
is O
unknown O

first O
increasing O
ouabain O
concentrations O
would O
enhance O
automaticity O
of O
sap O
compared O
to O
the O
sa O
node O
and O
that O
such O
enhanced O
automaticity O
could O
explain O
digitalis B-Plant
caused O
atrial B-Disease
tachyarrhythmias I-Disease

second O
halothane O
would O
oppose O
such O
enhanced O
automaticity O
of O
sap O
thereby O
opposing O
digitalis B-Plant
caused O
atrial B-Disease
tachyarrhythmias I-Disease

both O
cases O
proved O
to O
be O
cotton B-Plant
material O
induced O
granulomas B-Disease

coffee B-Plant
caffeine O
and O
cardiovascular B-Disease
disease I-Disease
in O
men O

coffee B-Plant
consumption O
and O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
has O
been O
suspected O

recent O
coffee B-Plant
drinking O
and O
the O
incidence O
of O
cardiovascular B-Disease
disease I-Disease

methods O
we O
examined O
prospectively O
the O
relation O
of O
coffee B-Plant
consumption O
with O
the O
risk O
of O
myocardial B-Disease
infarction I-Disease
need O
for O
coronary O
artery O
bypass O
grafting O
or O
angioplasty O
and O
risk O
of O
stroke B-Disease
in O
a O
cohort O
of O
45 O
589 O
us O
men O
who O
were O
40 O
to O
75 O
years O
old O
in O
1986 O
and O
who O
had O
no O
history O
of O
cardiovascular B-Disease
diasease I-Disease

total O
coffee B-Plant
consumption O
was O
not O
associated O
with O
an O
increased O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
or O
stroke B-Disease

the O
age O
adjusted O
relative O
risk O
for O
all O
cardiovascular B-Disease
disease I-Disease
among O
participants O
who O
drank O
four O
or O
more O
cups O
of O
coffee B-Plant
per O
day O
was O
1 O
4 O
95 O
percent O
confidence O
intervals O
74 O
to O
146 O

increasing O
levels O
of O
consumption O
of O
caffeinated O
coffee B-Plant
were O
not O
associated O
with O
higher O
risks O
of O
cardiovascular B-Disease
disease I-Disease

higher O
consumption O
of O
decaffeinated O
coffee B-Plant
however O
was O
associated O
with O
a O
marginally O
significant O
increase O
in O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
relative O
risk O
163 O
95 O
percent O
confidence O
interval O
102 O
to O
260 O

conclusions O
these O
findings O
do O
not O
support O
the O
hypothesis O
that O
coffee B-Plant
or O
caffeine O
consumption O
increases O
the O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
or O
stroke B-Disease

a O
wide O
variety O
of O
tobacco B-Plant
habits O
prevalent O
in O
the O
country O
are O
primarily O
responsible O
for O
the O
occurrence O
of O
these O
cancers B-Disease

among O
them O
bidi O
smoking O
tobacco B-Plant
chewing O
and O
cigarette O
smoking O
in O
that O
order O
account O
for O
a O
large O
majority O
of O
these O
cancers B-Disease

the O
government O
of O
india O
has O
accorded O
a O
high O
priority O
to O
prevention O
of O
tobacco B-Plant
related O
cancers B-Disease
by O
the O
turn O
of O
the O
century O
in O
its O
national O
cancer B-Disease
control O
programme O

intragastric O
bile O
acid O
concentrations O
in O
healthy O
subjects O
and O
in O
patients O
with O
gastric B-Disease
and O
duodenal B-Disease
ulcer I-Disease
and O
the O
influence O
of O
fiber O
enriched O
wheat B-Plant
bran O
in O
patients O
with O
gastric B-Disease
ulcer I-Disease

fiber O
enriched O
wheat B-Plant
bran O
reduced O
bile O
acid O
concentrations O
significantly O
in O
patients O
with O
gastric B-Disease
ulcer I-Disease
disease I-Disease

approximately O
90 O
of O
indian O
oral B-Disease
cancers I-Disease
are O
tobacco B-Plant
related O
the O
possibility O
of O
developing O
the O
lesion O
being O
ten O
times O
higher O
if O
the O
habit O
is O
formed O
below O
the O
age O
of O
14 O
years O

public O
awareness O
about O
tobacco B-Plant
related O
oral B-Disease
cancer I-Disease
is O
low O
at O
present O
and O
new O
approaches O
to O
this O
problem O
should O
include O
education O
in O
the O
schools O
on O
oral B-Disease
cancer I-Disease
formulation O
of O
legislative O
action O
to O
ban O
the O
sale O
of O
tobacco B-Plant
near O
schools O
and O
colleges O
and O
imposition O
of O
societal O
barriers O
that O
would O
make O
the O
nonchewing O
of O
tobacco B-Plant
socially O
more O
acceptable O
than O
chewing O
it O

the O
effects O
of O
vitamin O
c O
on O
the O
growth O
of O
human O
lung O
cultures O
and O
of O
vitamin O
c O
or O
l O
cysteine O
on O
a O
human O
breast B-Disease
cancer I-Disease
culture O
sk O
br O
3 O
were O
assessed O
with O
and O
without O
exposure O
to O
fresh O
smoke O
from O
tobacco B-Plant
or O
marijuana B-Plant
cigarettes O

nonexposed O
or O
tobacco B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O
when O
grown O
in O
the O
presence O
of O
vitamin O
c O
also O
showed O
acceleration O
of O
growth O
of O
epithelial O
cells O
significant O
reduction O
in O
mitotic O
abnormalities O
and O
occurrence O
of O
pseudoglandular O
structures O
indicating O
differentiation O

in O
contrast O
vitamin O
c O
did O
not O
reduce O
mitotic O
abnormalities O
in O
marijuana B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O
but O
stimulated O
abnormal O
growth O
and O
dedifferentiation O

in O
nonexposed O
tobacco B-Plant
or O
marijuana B-Plant
smoke O
exposed O
breast B-Disease
cancer I-Disease
cultures O

efficacy O
of O
cancer B-Disease
prevention O
by O
high O
selenium O
garlic B-Plant
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O

we O
reported O
previously O
that O
garlic B-Plant
cultivated O
with O
selenite O
fertilization O
showed O
powerful O
chemopreventive O
activity O
in O
the O
rat O
dimethylbenz O
anthracene O
dmba O
induced O
mammary B-Disease
tumor I-Disease
model O

in O
order O
to O
ascertain O
that O
the O
efficacy O
of O
the O
high O
selenium O
garlic B-Plant
in O
cancer B-Disease
protection O
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O
we O
compared O
the O
effects O
of O
two O
batches O
of O
garlic B-Plant
powder O
with O
marked O
differences O
in O
their O
level O
of O
selenium O
enrichment O
112 O
or O
1355 O

furthermore O
the O
magnitude O
tumor B-Disease
suppression O
as O
well O
as O
the O
extent O
of O
dmba O
dna O
adduct O
inhibition O
were O
very O
similar O
with O
the O
two O
batches O
of O
garlic B-Plant
even O
though O
the O
amounts O
of O
garlic B-Plant
in O
the O
diet O
varied O
considerably O
between O
them O
18 O
for O
the O
112 O

thus O
based O
on O
the O
results O
of O
several O
biological O
responses O
it O
appears O
that O
the O
ability O
of O
the O
high O
selenium O
garlic B-Plant
to O
protect O
against O
tumorigenesis B-Disease
is O
primarily O
dependent O
on O
increased O
intake O
of O
selenium O
provided O
by O
the O
vegetable O

coffee B-Plant
consumption O
not O
associated O
with O
risk O
of O
pancreas B-Disease
cancer I-Disease
in O
finland O

background O
coffee B-Plant
consumption O
has O
been O
brought O
to O
focus O
as O
a O
possible O
risk O
factor O
for O
pancreas B-Disease
cancer I-Disease

after O
having O
reviewed O
the O
available O
evidence O
an O
international O
agency O
for O
research O
on O
cancer B-Disease
working O
group O
concluded O
in O
1991 O
that O
the O
evidence O
in O
humans O
that O
coffee B-Plant
drinking O
is O
carcinogenic O
in O
the O
pancreas O
is O
inadequate O
since O
the O
available O
data O
were O
considered O
suggestive O
of O
a O
weak O
relationship O
with O
high O
levels O
of O
coffee B-Plant
consumption O
but O
the O
possibility O
that O
this O
was O
due O
to O
bias O
or O
confounding O
was O
judged O
tenable O

methods O
the O
association O
between O
coffee B-Plant
consumption O
and O
pancreas B-Disease
cancer I-Disease
risk O
was O
examined O
in O
a O
case O
referent O
study O
in O
finland O

data O
on O
coffee B-Plant
consumption O
20 O
years O
prior O
to O
the O
diagnosis O
of O
cancer B-Disease
were O
obtained O
from O
the O
next O
of O
kin O
of O
662 O
cases O
of O
pancreas B-Disease
cancer I-Disease
and O
1 O
770 O
referent O
stomach B-Disease
colon B-Disease
and O
rectum B-Disease
cancers B-Disease

the O
results O
were O
expressed O
as O
crude O
and O
age O
gender O
and O
tobacco B-Plant
smoking O
adjusted O
odds O
ratios O
and O
95 O
confidence O
intervals O
for O
three O
daily O
coffee B-Plant
dose O
categories O
20 O
years O
prior O
to O
cancer B-Disease
diagnosis O

results O
the O
data O
failed O
to O
demonstrate O
any O
association O
between O
coffee B-Plant
consumption O
and O
risk O
for O
pancreas B-Disease
cancer I-Disease

conclusions O
the O
results O
are O
unlikely O
to O
be O
negatively O
biased O
and O
are O
compatible O
with O
the O
majority O
of O
epidemiologic O
results O
advanced O
suggesting O
no O
positive O
association O
between O
coffee B-Plant
consumption O
and O
the O
risk O
of O
pancreas B-Disease
cancer I-Disease

past O
and O
current O
salted O
meat O
consumption O
was O
associated O
with O
increased O
risks O
of O
laryngeal B-Disease
cancer I-Disease
after O
controlling O
for O
the O
effects O
of O
tobacco B-Plant
and O
alcohol O

optimal O
dose O
of O
garlic B-Plant
to O
inhibit O
dimethylhydrazine O
induced O
colon B-Disease
cancer I-Disease

this O
study O
was O
designed O
to O
investigate O
the O
optimal O
dose O
of O
garlic B-Plant
during O
long O
term O
feeding O
and O
its O
preventive O
and O
therapeutic O
effects O
on O
colon B-Disease
cancer I-Disease
in O
rats O
induced O
by O
dimethylhydrazine O

the O
incidence O
of O
colon B-Disease
tumor I-Disease
was O
significantly O
decreased O
in O
the O
groups O
fed O
with O
2 O
5 O
and O
10 O
garlic B-Plant
diets O
p O

therefore O
the O
minimal O
optimal O
dose O
of O
garlic B-Plant
to O
inhibit O
colon B-Disease
cancer I-Disease
was O
25 O

in O
a O
therapeutic O
study O
the O
tumor B-Disease
inducing O
interval O
in O
nude O
mice O
subcutaneously O
injected O
with O
colon O
cancer O
cells O
cc O
m2 O
was O
prolonged O
by O
a O
2 O
5 O
garlic B-Plant
diet O
p O

thus O
smaller O
tumor B-Disease
volume O
and O
longer O
survival O
time O
were O
found O
in O
the O
garlic B-Plant
group O
than O
in O
the O
controls O
p O

however O
the O
growth O
rate O
of O
tumors B-Disease
was O
not O
markedly O
inhibited O
by O
garlic B-Plant

this O
study O
suggested O
that O
a O
25 O
garlic B-Plant
dose O
may O
be O
used O
mainly O
as O
an O
inhibitor O
to O
prevent O
colon B-Disease
cancers I-Disease
and O
improve O
survival O
time O

the O
evidence O
for O
soybean B-Plant
products O
as O
cancer B-Disease
preventive O
agents O

there O
is O
much O
evidence O
to O
suggest O
that O
diets O
containing O
large O
amounts O
of O
soybean B-Plant
products O
are O
associated O
with O
overall O
low O
cancer B-Disease
mortality O
rates O
particularly O
for O
cancers B-Disease
of O
the O
colon B-Disease
breast B-Disease
and O
prostate B-Disease

it O
is O
believed O
that O
supplementation O
of O
human O
diets O
with O
certain O
soybean B-Plant
products O
shown O
to O
suppress O
carcinogenesis B-Disease
in O
animals O
could O
markedly O
reduce O
human O
cancer B-Disease
mortality O
rates O
there O

is O
much O
evidence O
suggesting O
that O
compounds O
present O
in O
soybeans B-Plant
can O
prevent O
cancer B-Disease
in O
many O
different O
organ O
systems O

the O
evidence O
for O
specific O
soybean B-Plant
derived O
compounds O
having O
a O
suppressive O
effect O
on O
carcinogenesis B-Disease
in O
animal O
model O
systems O
is O
limited O
however O

there O
is O
evidence O
that O
the O
following O
isolated O
soybean B-Plant
derived O
products O
suppress O
carcinogenesis B-Disease
in O
vivo O
a O
protease O
inhibitor O
the O
bowman O
birk O
inhibitor O
inositol O
hexaphosphate O
phytic O
acid O
and O
the O
sterol O
beta O

sitosterol O
other O
compounds O
that O
may O
be O
able O
to O
suppress O
carcinogenesis B-Disease
in O
animals O
are O
the O
soybean B-Plant
isoflavones O

detection O
and O
cloning O
of O
potent O
transforming O
genes O
from O
chewing O
tobacco B-Plant
related O
human O
oral B-Disease
carcinomas I-Disease

the O
lack O
of O
association O
of O
the O
nude O
mice O
tumour B-Disease
dna O
with O
myc O
ras O
egf O
showing O
aberrations O
in O
the O
primary O
human O
tumour B-Disease
implies O
activation O
of O
an O
alternative O
potent O
transforming O
genes O
in O
the O
chewing O
tobacco B-Plant
related O
oral B-Disease
carcinomas I-Disease
in O
india O

policy O
advocacy O
strategies O
have O
proven O
themselves O
effective O
in O
cancer B-Disease
prevention O
efforts O
involving O
tobacco B-Plant
use O
and O
nutrition O

after O
injection O
of O
garlic B-Plant
oil O
in O
tumor B-Disease
focus O
a O
large O
amount O
of O
neutrophils O
macrophages O
and O
lymphocytes O
appeared O

this O
result O
showed O
that O
garlic B-Plant
oil O
could O
induce O
neutrophils O
and O
macrophages O
against O
tumor B-Disease

induced O
cytotoxicity B-Disease
and O
cell O
proliferation O
in O
the O
hepatocarcinogenicity O
of O
chloroform O
in O
female O
b6c3f1 O
mice O
comparison O
of O
administration O
by O
gavage O
in O
corn B-Plant
oil O
vs O
ad O
libitum O
in O
drinking O
water O

chloroform O
increases O
the O
incidence O
of O
liver B-Disease
tumors I-Disease
in O
b6c3f1 O
mice O
when O
administered O
in O
by O
gavage O
in O
corn B-Plant
oil O
but O
not O
when O
given O
in O
the O
drinking O
water O
at O
similar O
daily O
doses O

dose O
dependent O
changes O
included O
centrilobular O
necrosis B-Disease
and O
markedly O
elevated O
li O
in O
mice O
given O
238 O
or O
477 O
mg O
kg O
chloroform O
in O
corn B-Plant
oil O
the O
average O
daily O
doses O
that O
produced O
tumors B-Disease
in O
the O
cancer B-Disease
bioassay O

the O
sustained O
increase O
in O
li O
in O
the O
livers O
of O
mice O
administered O
hepatocarcinogenic B-Disease
doses O
of O
chloroform O
in O
corn B-Plant
oil O
but O
not O
for O
chloroform O
in O
drinking O
water O
is O
evidence O
that O
chloroform O
induced O
mouse O
liver B-Disease
cancer I-Disease
is O
secondary O
to O
events O
associated O
with O
induced O
cytolethality O
and O
cell O
proliferation O

preventive O
action O
of O
garlic B-Plant
on O
aflatoxin O
b1 O
induced O
carcinogenesis B-Disease
in O
the O
toad O
bufo O
regularis O

the O
action O
of O
fresh O
minced O
garlic B-Plant
and O
garlic B-Plant
oil O
on O
aflatoxin O
b1 O
afb1 O
induced O
carcinogenesis B-Disease
in O
the O
toad O
bufo O
regularis O
was O
studied O

animals O
given O
afb1 O
together O
with O
fresh O
garlic B-Plant
or O
garlic B-Plant
oil O
showed O
a O
significant O
reduction O
in O
tumor B-Disease
incidence O

the O
tumor B-Disease
incidences O
were O
3 O
and O
9 O
in O
animals O
given O
afb1 O
plus O
garlic B-Plant
and O
afb1 O
plus O
garlic B-Plant
oil O
respectively O

in O
all O
three O
groups O
the O
tumors B-Disease
were O
located O
in O
the O
liver O
hepatocellular B-Disease
carcinomas I-Disease
in O
addition O
to O
the O
kidney O
in O
animals O
treated O
with O
afb1 O
alone O
and O
together O
with O
garlic B-Plant

it O
is O
speculated O
that O
one O
or O
more O
constituents O
of O
garlic B-Plant
may O
be O
responsible O
for O
inhibition O
of O
afb1 O
induced O
carcinogenesis B-Disease
in O
b O
regularis O

ten O
organosulfur O
compounds O
from O
garlic B-Plant
and O
onions B-Plant
were O
studied O
for O
their O
modifying O
effects O
on O
diethylnitrosamine O
induced O
neoplasia B-Disease
of O
liver I-Disease
in O
male O
f344 O
rats O
using O
the O
medium O
term O
bioassay O
system O
of O
ito O
based O
on O
the O
two O
step O
model O
of O
hepatocarcinogenesis B-Disease

in O
evaluating O
relationships O
between O
diet O
and O
cancer B-Disease
it O
is O
appropriate O
to O
consider O
not O
only O
the O
possible O
protective O
role O
of O
garlic B-Plant
and O
onions B-Plant
but O
also O
their O
enhancing O
effects O

we O
examined O
the O
risk O
of O
obstructive O
respiratory B-Disease
disease I-Disease
associated O
with O
tobacco B-Plant
smoke O
in O
indoor O
air O
independent O
of O
active O
smoking O
ambient O
air O
pollution O
and O
some O
of O
the O
other O
sources O
of O
residential O
indoor O
air O
pollution O

the O
majority O
of O
all O
sixth O
grade O
students O
surveyed O
were O
aware O
of O
the O
health O
risks O
of O
smokeless O
tobacco B-Plant
use O
in O
that O
it O
is O
an O
increased O
risk O
for O
cancer B-Disease

alcohol O
and O
tobacco B-Plant
habits O
have O
been O
identified O
as O
strong O
risk O
factors O
for O
esophageal B-Disease
cancer I-Disease

this O
study O
examined O
whether O
they O
may O
prevent O
the O
occurrence O
of O
upper O
aerodigestive B-Disease
cancer I-Disease
in O
subjects O
heavily O
exposed O
to O
tobacco B-Plant
smoking O
such O
as O
patients O
already O
cured O
of O
an O
early O
stage O
lung B-Disease
cancer I-Disease

conclusion O
daily O
oral O
administration O
of O
high O
dose O
vitamin O
a O
is O
effective O
in O
reducing O
the O
number O
of O
new O
primary O
tumors B-Disease
related O
to O
tobacco B-Plant
consumption O
and O
may O
improve O
the O
disease O
free O
interval O
in O
patients O
curatively O
resected O
for O
stage O
i O
lung B-Disease
cancer I-Disease

here O
we O
report O
that O
genistein O
a O
soybean B-Plant
isoflavone O
strongly O
inhibits O
tumor B-Disease
promoter O
induced O
h2o2 O
formation O
both O
in O
vivo O
and O
in O
vitro O

garlic B-Plant
and O
its O
significance O
for O
the O
prevention O
of O
cancer B-Disease
in O
humans O
a O
critical O
view O

recently O
published O
results O
of O
epidemiologic O
case O
control O
studies O
in O
china O
and O
italy O
on O
gastric B-Disease
carcinoma I-Disease
in O
relation O
to O
diet O
suggest O
that O
consuming O
garlic B-Plant
may O
reduce O
the O
risk O
of O
gastric B-Disease
cancer I-Disease

chemical O
constituents O
of O
garlic B-Plant
have O
been O
tested O
for O
their O
inhibiting O
effect O
on O
carcinogenesis B-Disease
using O
in O
vitro O
and O
in O
vivo O
models O

in O
most O
experiments O
inhibition O
of O
tumour B-Disease
growth O
was O
established O
using O
fresh O
garlic B-Plant
extract O
garlic B-Plant
compounds O
or O
synthetically O
prepared O
analogs O

in O
this O
review O
the O
strengths O
and O
weaknesses O
of O
the O
experiments O
are O
discussed O
and O
the O
outcomes O
are O
evaluated O
to O
assess O
the O
possible O
significance O
of O
garlic B-Plant
or O
garlic B-Plant
compounds O
for O
the O
prevention O
of O
cancer B-Disease
in O
humans O

however O
the O
available O
evidence O
warrants O
further O
research O
into O
the O
possible O
role O
of O
garlic B-Plant
in O
the O
prevention O
of O
cancer B-Disease
in O
humans O

consumption O
of O
black B-Plant
tea I-Plant
and O
cancer B-Disease
risk O
a O
prospective O
cohort O
study O

despite O
indications O
from O
experimental O
studies O
that O
tea B-Plant
may O
protect O
against O
cancer B-Disease
epidemiologic O
evidence O
has O
been O
inconclusive O

purpose O
the O
association O
between O
black B-Plant
tea I-Plant
consumption O
and O
the O
subsequent O
risk O
of O
stomach B-Disease
colorectal B-Disease
lung I-Disease
and O
breast B-Disease
cancers I-Disease
was O
investigated O
in O
the O
netherlands O
cohort O
study O
on O
diet O
and O
cancer B-Disease
among O
58 O
279 O
men O
and O
62 O
573 O
women O
aged O
55 O
69 O
years O

the O
questionnaire O
data O
of O
case O
subjects O
and O
those O
of O
a O
random O
subcohort O
n O
3500 O
were O
used O
to O
calculate O
rate O
ratios O
rrs O
of O
cancer B-Disease
in O
categories O
of O
consumers O
of O
black B-Plant
tea I-Plant
compared O
with O
nonconsumers O

no O
association O
was O
observed O
between O
tea B-Plant
consumption O
and O
risk O
of O
colorectal B-Disease
cancer I-Disease
the O
risk O
among O
tea B-Plant
drinkers O
in O
each O
consumption O
category O
was O
similar O
to O
that O
among O
nondrinkers O

the O
rr O
of O
breast B-Disease
cancer I-Disease
among O
consumers O
of O
five O
or O
more O
cups O
of O
tea B-Plant
per O
day O
was O
13 O
95 O
confidence O
interval O
9 O
20 O
no O
dose O
response O
association O
was O
observed O

in O
age O
and O
sex O
adjusted O
analyses O
consumption O
of O
tea B-Plant
was O
inversely O
associated O
with O
stomach O
two O
sided O
p O
for O
trend O
147 O
and O
lung O
two O
sided O
p O
for O
trend O
< O
1 O
cancers B-Disease

when O
smoking O
and O
dietary O
factors O
were O
taken O
into O
account O
tea B-Plant
in O
itself O
did O
not O
appear O
to O
protect O
against O
stomach B-Disease
and O
lung B-Disease
cancers I-Disease
the O
rrs O
in O
all O
consumption O
categories O
were O
close O
to O
unity O

analysis O
of O
the O
tea B-Plant
and O
cancer B-Disease
relationship O
in O
a O
subgroup O
that O
included O
subjects O
in O
the O
lowest O
two O
quintiles O
of O
consumption O
of O
vegetables O
and O
fruits O
also O
failed O
to O
reveal O
a O
protective O
effect O
of O
tea B-Plant
consumption O
on O
the O
risk O
of O
three O
cancer O
types O
studied O
colorectal B-Disease
lung B-Disease
and O
breast B-Disease
cancers I-Disease

conclusions O
this O
investigation O
does O
not O
support O
the O
hypothesis O
that O
consumption O
of O
black B-Plant
tea I-Plant
protects O
against O
four O
of O
the O
major O
cancers B-Disease
in O
humans O
a O
cancer B-Disease
enhancing O
effect O
was O
not O
evident O

3 O
different O
malignancies B-Disease
of O
the O
aerodigestive O
tract O
after O
chronic O
abuse O
of O
cannabis B-Plant
products O

the O
occurrence O
of O
multilocular O
malignant B-Disease
tumors I-Disease
in O
the O
upper O
aerodigestive O
tract O
in O
young O
patients O
with O
known O
marijuana B-Plant
abuse O
has O
been O
described O
by O
other O
authors O

this O
case O
is O
the O
first O
reported O
that O
shows O
the O
occurrence O
of O
three O
separate O
malignant B-Disease
tumors I-Disease
with O
different O
histologies O
in O
the O
aerodigestive O
tract O
which O
could O
be O
related O
to O
a O
chronic O
abuse O
of O
cannabis B-Plant

consumption O
of O
corn B-Plant
contaminated O
at O
these O
high O
levels O
has O
been O
associated O
with O
a O
high O
incidence O
of O
esophageal B-Disease
cancer I-Disease
in O
these O
areas O

tobacco B-Plant
related O
cancers B-Disease
in O
madras O
india O

tobacco B-Plant
related O
cancer B-Disease
trc O
cases O
constitute O
482 O
in O
men O
and O
201 O
in O
women O
of O
the O
total O
cancers B-Disease
seen O
in O
india O
per O
year O

the O
feeding O
of O
the O
lactobacillus O
gg O
before O
and O
during O
carcinogen O
treatment O
resulted O
in O
a O
significant O
decrease O
in O
the O
incidence O
of O
colon B-Disease
tumors I-Disease
and O
the O
number O
of O
small O
intestinal O
and O
colon B-Disease
tumors I-Disease
per O
tumor B-Disease
bearing O
animal O
for O
rats O
fed O
a O
20 O
corn B-Plant
oil O
diet O

animals O
fed O
a O
5 O
corn B-Plant
oil O
diet O
had O
a O
lower O
tumor B-Disease
incidence O
and O
number O
of O
tumors B-Disease
resulting O
from O
the O
decrease O
in O
dietary O
fat O
in O
addition O
the O
feeding O
of O
lactobacillus O
gg O
before O
the O
carcinogen O
challenge O
resulted O
in O
a O
lower O
incidence O
of O
colon B-Disease
tumors I-Disease

the O
importance O
of O
the O
pecan B-Plant
tree O
pollen O
in O
allergic B-Disease
manifestations O
objective O
to O
study O
the O
role O
of O
pecan B-Plant
tree O
pollen O
in O
the O
development O
of O
allergy B-Disease

of O
the O
pecan B-Plant
atopics B-Disease
65 O
2 O
had O
clinical O
symptoms O
coinciding O
only O
with O
the O
pecan B-Plant
pollen O
season O
and O
an O
additional O
10 O
9 O
had O
perennial O
symptonms O

conclusion O
pecan B-Plant
tree O
releases O
highly O
allergenic O
pollen O
grains O
which O
are O
correlated O
to O
the O
incidence O
of O
hay B-Disease
fever I-Disease
in O
the O
exposed O
population O

in O
children O
the O
pecan B-Plant
tree O
constitutes O
a O
possible O
etiologic O
agent O
for O
the O
development O
of O
asthma B-Disease

effectiveness O
of O
oleum O
menthae B-Plant
piperitae I-Plant
and O
paracetamol O
in O
therapy O
of O
headache B-Disease
of O
the O
tension O
type O

the O
effect O
of O
a O
locally O
applied O
peppermint B-Plant
oil O
preparation O
on O
tension B-Disease
type I-Disease
headache I-Disease
was O
examined O
in O
the O
design O
of O
a O
randomized O
placebo O
controlled O
double O
blind O
crossover O
study O
for O
the O
first O
time O

each O
headache B-Disease
attack O
was O
treated O
by O
the O
application O
of O
2 O
capsules O
of O
the O
oral O
medication O
1 O
0 O
mg O
of O
acetaminophen O
or O
placebo O
and O
the O
cutaneous O
application O
of O
the O
oil O
preparation O
peppermint B-Plant
oil O
or O
placebo O
solution O

compared O
to O
the O
application O
of O
placebo O
a O
10 O
peppermint B-Plant
oil O
in O
ethanol O
solution O
significantly O
reduced O
the O
clinical O
headache B-Disease
intensity O
already O
after O
15 O
minutes O
p O

this O
controlled O
study O
showed O
for O
the O
first O
time O
that O
a O
10 O
peppermint B-Plant
oil O
in O
ethanol O
solution O
efficiently O
alleviates O
tension O
type B-Disease
headache I-Disease

effect O
on O
an O
aqueous O
extract O
of O
selenium O
enriched O
garlic B-Plant
on O
in O
vitro O
markers O
and O
in O
vivo O
efficacy O
in O
cancer B-Disease
prevention O

previous O
work O
has O
shown O
that O
the O
efficacy O
of O
cancer B-Disease
prevention O
by O
selenium O
enriched O
garlic B-Plant
se O
garlic B-Plant
is O
primarily O
dependent O
on O
the O
action O
of O
selenium O

the O
chemopreventive O
efficacy O
of O
the O
two O
garlic B-Plant
extracts O
was O
also O
investigated O
in O
the O
rat O
methylnitrosourea O
mammary O
tumor B-Disease
model O

significant O
cancer B-Disease
protection O
was O
observed O
with O
treatment O
by O
the O
se O
garlic B-Plant
extract O
at O
3 O
ppm O

data O
from O
a O
large O
hospital O
based O
case O
control O
study O
are O
used O
to O
examine O
the O
association O
of O
smoking O
related O
risk O
factors O
amount O
smoked O
filter O
status O
mentholation O
and O
differences O
in O
smoking O
habits O
between O
blacks O
and O
whites O
and O
selected O
factors O
other O
than O
smoking O
environmental O
tobacco B-Plant
smoke O
previous O
primary O
cancer B-Disease
and O
radiotherapy O
reproductive O
and O
endocrine O
factors O
and O
body O
mass O
index O
with O
lung B-Disease
cancer I-Disease

in O
blacks O
and O
whites O
of O
both O
sexes O
odds O
ratios O
for O
lung B-Disease
cancer I-Disease
increased O
with O
increasing O
cumulative O
tobacco B-Plant
tar O
intake O
and O
decreased O
with O
years O
since O
quitting O
smoking O

exposure O
to O
environmental O
tobacco B-Plant
smoke O
generally O
showed O
little O
relation O
to O
lung B-Disease
cancer I-Disease
risk O

in O
conclusion O
variation O
in O
lung B-Disease
cancer I-Disease
rates O
between O
populations O
may O
be O
due O
to O
1 O
differences O
in O
effective O
exposure O
to O
tobacco B-Plant
smoke O
carcinogens O
2 O
differences O
in O
factors O
which O
modify O
the O
effect O
of O
tobacco B-Plant
smoke O
including O
differences O
in O
host O
susceptibility O
and O
metabolism O
of O
carcinogens O
or O
3 O
differences O
in O
exposure O
to O
other O
independent O
risk O
factors O
for O
lung B-Disease
cancer I-Disease

the O
overall O
findings O
of O
this O
study O
suggest O
that O
eppl O
is O
a O
valuable O
indicator O
of O
lung B-Disease
cancer I-Disease
risk O
and O
that O
exposure O
to O
environmental O
tobacco B-Plant
smoke O
is O
associated O
with O
higher O
eppl O
levels O
and O
therefore O
with O
higher O
lung B-Disease
cancer I-Disease

in O
a O
tribal O
village O
in O
kerala O
india O
local O
volunteers O
were O
trained O
to O
work O
in O
a O
programme O
for O
the O
primary O
prevention O
of O
tobacco B-Plant
related O
cancers B-Disease
and O
the O
secondary O
prevention O
of O
common O
cancers B-Disease

they O
gathered O
data O
on O
the O
use O
of O
tobacco B-Plant
and O
alcohol O
in O
a O
population O
of O
some O
19 O
0 O
people O
and O
identified O
one O
or O
more O
warning O
signals O
of O
cancer B-Disease
in O
430 O
persons O
who O
were O
subsequently O
examined O
by O
physicians O

sabal B-Plant
serrulata I-Plant
extract O
in O
the O
management O
of O
symptoms O
of O
prostatic B-Disease
hypertrophy I-Disease

the O
effectiveness O
of O
sabal B-Plant
serrulata I-Plant
dwarf B-Plant
palm I-Plant
extract O
was O
evaluated O
in O
the O
treatment O
of O
38 O
patients O
with O
symptomatic O
prostatic B-Disease
hyperplasia I-Disease

on O
the O
basis O
of O
their O
favorable O
experience O
the O
authors O
recommend O
the O
administration O
of O
sabal B-Plant
serrulata I-Plant
extract O
in O
the O
treatment O
of O
patients O
with O
mild O
or O
moderate O
symptoms O
of O
prostatic B-Disease
hyperplasia I-Disease

the O
incidence O
of O
stomach B-Disease
cancer I-Disease
is O
lower O
in O
individuals O
and O
populations O
with O
high O
allium B-Plant
vegetable O
intakes O

as O
part O
of O
our O
study O
of O
the O
role O
of O
allium B-Plant
vegetable O
intake O
on O
cancer B-Disease
prevention O
we O
wished O
to O
investigate O
its O
antimicrobial O
activity O
against O
h O
pylori O

it O
is O
plausible O
that O
the O
sensitivity O
of O
h O
pylori O
to O
garlic B-Plant
extract O
at O
such O
low O
concentration O
may O
be O
related O
to O
the O
reported O
lower O
risk O
of O
stomach B-Disease
cancer I-Disease
in O
those O
with O
a O
high O
allium B-Plant
vegetable O
intake O

influence O
of O
dietary O
capsaicin O
and O
onion B-Plant
on O
the O
metabolic B-Disease
abnormalities B-Disease
associated O
with O
streptozotocin O
induced O
diabetes B-Disease
mellitus I-Disease

effect O
of O
feeding O
15 O
mg O
capsaicin O
diet O
or O
3 O
freeze O
dried O
onion B-Plant
powder O
containing O
diet O
were O
examined O
in O
albino O
rats O
rendered O
diabetic B-Disease
with O
streptozotocin O
injection O

diabetic B-Disease
rats O
maintained O
on O
onion B-Plant
diet O
for O
8 O
weeks O
excreted O
comparatively O
less O
amounts O
of O
albumin O
urea O
creatinine O
and O
inorganic O
phosporus O

dietary O
onion B-Plant
also O
partially O
reversed O
the O
abnormalities O
in O
plasma O
albumin O
urea O
creatinine O
and O
inorganic O
phosphorus O
in O
diabetic B-Disease
animals O

onion B-Plant
also O
produced O
a O
significant O
reduction O
in O
hyperglycemic B-Disease
status O
of O
diabetic O
animals O

diabetic B-Disease
rats O
maintained O
on O
onion B-Plant
diet O
had O
a O
lowered O
relative O
liver O
weight O
at O
the O
end O
of O
the O
study O
compared O
to O
diabetic B-Disease
control O
group O

diabetic B-Disease
rats O
fed O
onion B-Plant
diet O
also O
exhibited O
lowered O
lipid O
peroxides O
in O
circulation O
and O
in O
urine O
when O
compared O
to O
diabetic B-Disease
control O
group O

blood O
cholesterol O
was O
lowered O
significantly O
by O
dietary O
onion B-Plant
in O
diabetic B-Disease
animals O

hepatic O
cholesterol O
triglycerides O
phospholipids O
which O
were O
elevated O
under O
diabetic B-Disease
condition O
were O
countered O
significantly O
by O
dietary O
onion B-Plant

thus O
the O
study O
reveals O
that O
onion B-Plant
feeding O
improves O
the O
metabolic O
status O
in O
diabetic B-Disease
condition O
probably O
because O
of O
its O
hypoglycemic B-Disease
as O
well O
as O
hypocholesterolemic B-Disease
effect O

garlic B-Plant
prevents O
hypertension B-Disease
induced O
by O
chronic O
inhibition O
of O
nitric O
oxide O
synthesis O

it O
has O
been O
reported O
that O
garlic B-Plant
activates O
nitric O
oxide O
synthase O
in O
vitro O
and O
that O
chronic O
inhibition O
of O
nitric O
oxide O
no O
synthesis O
by O
n O
omega O
nitro O
l O
arginine O
methyl O
ester O
l O
name O
induces O
arterial B-Disease
hypertension I-Disease
in O
rats O

it O
was O
found O
that O
l O
name O
induced O
arterial B-Disease
hypertension I-Disease
on O
weeks O
1 O
4 O
inch O
control O
rats O
but O
not O
in O
garlic B-Plant
fed O
rats O
whose O
blood O
pressure O
remained O
essentially O
as O
the O
basal O

it O
was O
concluded O
that O
garlic B-Plant
blocks O
the O
l O
name O
induced O
hypertension B-Disease
by O
antagonizing O
in O
vivo O
the O
inhibitory O
effect O
of O
l O
name O
on O
no O
production O

we O
studied O
whether O
common O
shared O
environmental O
or O
behavioral O
risk O
factors O
other O
than O
tobacco B-Plant
smoking O
underlie O
both O
atherosclerotic B-Disease
diseases I-Disease
and O
cancer B-Disease

there O
was O
no O
consistent O
excess O
over O
the O
expected O
figures O
for O
any O
of O
the O
categories O
of O
cancer B-Disease
not O
related O
to O
tobacco B-Plant
smoking O

we O
found O
a O
moderate O
increase O
in O
the O
risk O
for O
tobacco B-Plant
related O
cancers B-Disease
which O
was O
strongest O
for O
patients O
with O
early O
onset O
of O
acute O
myocardial B-Disease
infarct I-Disease
and O
for O
female O
patients O

an O
excess O
risk O
of O
dying O
of O
lung B-Disease
cancer I-Disease
and O
heart B-Disease
diseases I-Disease
probably O
reflects O
a O
high O
tobacco B-Plant
consumption O

epidemiologic O
and O
clinical O
studies O
suggest O
that O
tomato B-Plant
consumption O
may O
reduce O
the O
risk O
of O
cancer B-Disease

lycopene O
a O
hydrocarbon O
carotenoid O
is O
the O
major O
carotenoid O
in O
tomato B-Plant
es O
and O
as O
a O
potent O
singlet O
oxygen O
quencher O
has O
been O
considered O
by O
some O
to O
be O
the O
biologically O
active O
agent O
responsible O
for O
the O
reduction O
of O
cancer B-Disease
risk O
associated O
with O
tomato B-Plant
consumption O

objective O
to O
determine O
the O
lipid O
lowering O
effect O
of O
garlic B-Plant
powder O
tablets O
in O
patients O
with O
hypercholesterolemia B-Disease

conclusion O
garlic B-Plant
powder O
900 O
mg O
d O
treatment O
for O
12 O
weeks O
was O
ineffective O
in O
lowering O
cholesterol O
levels O
in O
patients O
with O
hypercholesterolemia B-Disease

the O
effects O
of O
phenethyl O
isothiocyanate O
n O
acetylcysteine O
and O
green B-Plant
tea I-Plant
on O
tobacco B-Plant
smoke O
induced O
lung B-Disease
tumors I-Disease
in O
strain O
mice O

exposure O
to O
tobacco B-Plant
smoke O
increased O
lung B-Disease
tumor I-Disease
multiplicity O
to O
11 O
16 O
tumors B-Disease
lung B-Disease
significantly O
higher O
than O
control O
values O
tumors B-Disease
lung B-Disease

in O
positive O
control O
experiments O
peitc O
significantly O
reduced O
both O
lung B-Disease
tumor I-Disease
multiplicity O
and O
incidence O
in O
mice O
treated O
with O
the O
tobacco B-Plant
smoke O
specific O
carcinogen O
methylnitrosamino O
pyridyl O
butanone O
nnk O

green B-Plant
tea I-Plant
extract O
did O
not O
reduce O
lung B-Disease
tumor I-Disease
multiplicity O
in O
animals O
treated O
with O
a O
single O
dose O
of O
nnk O

the O
efficacy O
of O
ginkgo B-Plant
biloba I-Plant
on O
cognitive O
function O
in O
alzheimer B-Disease
disease I-Disease

objective O
to O
determine O
the O
effect O
of O
treatment O
with O
ginkgo B-Plant
biloba I-Plant
extract O
on O
objective O
measures O
of O
cognitive O
function O
in O
patients O
with O
alzheimer B-Disease
disease I-Disease
ad B-Disease
based O
on O
formal O
review O
of O
the O
current O
literature O

methods O
an O
attempt O
was O
made O
to O
identify O
all O
english O
and O
non O
english O
language O
articles O
in O
which O
g B-Plant
biloba I-Plant
extract O
was O
given O
to O
subjects O
with O
dementia B-Disease
or O
cognitive B-Disease
impairment I-Disease

inclusion O
criteria O
for O
the O
meta O
analysis O
were O
1 O
sufficiently O
characterized O
patients O
such O
that O
it O
was O
clearly O
stated O
there O
was O
a O
diagnosis O
of O
ad B-Disease
by O
either O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
revised O
third O
edition O
or O
national O
institute O
of O
neurological B-Disease
disorders I-Disease
and O
stroke B-Disease
alzheimer B-Disease
disease I-Disease
and O
related O
disorders O
association O
criteria O
or O
there O
was O
enough O
clinical O
detail O
to O
determine O
this O
by O
our O
review O
2 O
clearly O
stated O
study O
exclusion O
criteria O
ie O
those O
studies O
that O
did O
not O
have O
stated O
exclusions O
for O
depression B-Disease
other O
neurologic B-Disease
disease I-Disease
and O
central O
nervous O
system O
active O
medications O
were O
excluded O
3 O
use O
of O
standardized O
ginkgo B-Plant
extract O
in O
any O
stated O
dose O
4 O
randomized O
placebo O
controlled O
and O

double O
blind O
study O
design O
5 O
at O
least O
1 O
outcome O
measure O
was O
an O
objective O
assessment O
of O
cognitive O
function O
and O
6 O
sufficient O
statistical O
information O
to O
allow O
for O
meta O
analysis O

conclusions O
based O
on O
a O
quantitative O
analysis O
of O
the O
literature O
there O
is O
a O
small O
but O
significant O
effect O
of O
3 O
to O
6 O
month O
treatment O
with O
120 O
to O
240 O
mg O
of O
g B-Plant
biloba I-Plant
extract O
on O
objective O
measures O
of O
cognitive O
function O
in O
ad B-Disease

additional O
research O
will O
be O
needed O
to O
define O
which O
ingredients O
in O
the O
ginkgo B-Plant
extract O
are O
producing O
its O
effect O
in O
individuals O
with O
ad B-Disease

wheat B-Plant
bran O
decreases O
aberrant B-Disease
crypt I-Disease
foci I-Disease
preserves O
normal O
proliferation O
and O
increases O
intraluminal O
butyrate O
levels O
in O
experimental O
colon B-Disease
cancer I-Disease

background O
dietary O
wheat B-Plant
bran O
protects O
against O
colon B-Disease
cancer I-Disease
but O
the O
mechanisms O
of O
this O
effect O
is O
not O
known O

butyrate O
produced O
by O
colonic O
bacterial O
fermentation O
of O
dietary O
polysaccharides O
such O
as O
wheat B-Plant
bran O
induces O
apoptosis O
and O
decreases O
proliferation O
in O
colon B-Disease
cancer I-Disease
cell O
lines O

results O
during O
tumor B-Disease
initiation O
wheat B-Plant
bran O
produced O
greater O
apoptosis O
p O
1 O
a O
trend O
toward O
less O
proliferation O
and O
preserved O
the O
normal O
zone O
of O
proliferation O
p O

at O
tumor B-Disease
promotion O
wheat B-Plant
bran O
decreased O
the O
number O
of O
acf B-Disease
proximal O
colon O
p O
5 O
distal O
colon O
p O
47 O
and O
maintained O
the O
normal O
proliferative O
zone O

wheat B-Plant
bran O
produced O
significantly O
higher O
fecal O
butyrate O
p O
1 O
4 O
1 O
levels O
than O
the O
fiber O
free O
diet O
throughout O
the O
tumor B-Disease
promotion O
study O

conclusions O
wheat B-Plant
bran O
increased O
apoptosis O
and O
controlled O
proliferation O
during O
tumor B-Disease
initiation O
and O
resulted O
in O
decreased O
acf B-Disease

among O
specific O
foods O
high O
in O
carotenoids O
broccoli B-Plant
and O
spinach B-Plant
were O
most O
consistently O
associated O
with O
a O
lower O
risk O
of O
cataract B-Disease

effects O
of O
soybean B-Plant
diet O
on O
the O
beta O
cells O
in O
the O
streptozotocin O
treated O
rats O
for O
induction O
of O
diabetes B-Disease

moreover O
a O
prolonged O
hyperglycemia B-Disease
was O
not O
observed O
in O
rats O
fed O
raw O
soybean B-Plant
even O
when O
this O
was O
substituted O
by O
the O
normal O
diet O
after O
streptozotocin O
injection O

in O
the O
present O
study O
we O
showed O
that O
dietary O
soybean B-Plant
prevents O
induction O
of O
experimental O
hyperglycemia B-Disease
by O
retaining O
beta O
cell O
activity O

therefore O
we O
suggest O
that O
dietary O
soybean B-Plant
protected O
the O
streptozotocin O
induced O
beta O
cell O
damage O
and O
restrained O
the O
development O
of O
hyperglycemia B-Disease
in O
rats O

several O
epidemiologic O
studies O
have O
suggested O
a O
role O
of O
tomato B-Plant
products O
in O
protecting O
against O
cancer B-Disease
and O
chronic B-Disease
diseases I-Disease

histopathological O
studies O
of O
the O
specimens O
obtained O
from O
basilar O
arteries O
showed O
that O
pathological O
signs O
of O
proliferative B-Disease
vasculopathy I-Disease
including O
narrowing O
of O
the O
vessel B-Disease
lumen I-Disease
corrugation O
of O
the O
lamina O
elastica O
and O
subendothelial O
thickening O
were O
present O
in O
all O
the O
animals O
in O
the O
control O
group O
while O
they O
could O
not O
be O
demonstrated O
in O
the O
ginkgo B-Plant
biloba I-Plant
group O

these O
results O
suggest O
that O
ginkgo B-Plant
biloba I-Plant
may O
have O
a O
protective O
effect O
against O
subarachnoid B-Disease
hemorrhage I-Disease
induced O
vasospasm B-Disease
and O
vasculopathy B-Disease
as O
a O
result O
of O
antioxidants O

hepatitis B-Disease
was O
induced O
by O
the O
oral O
administration O
of O
10 O
solution O
ccl4 O
in O
olive B-Plant
oil O
at O
a O
dosage O
of O
3 O
ml O
kg O
body O
weight O
every O
day O
during O
7 O
days O

prevalence O
extent O
and O
severity O
of O
periodontitis B-Disease
as O
well O
as O
tooth B-Disease
loss I-Disease
and O
edentulism B-Disease
are O
influenced O
by O
tobacco B-Plant
consumption O
in O
a O
dose O
dependent O
manner O

the O
effect O
of O
unfiltered O
coffee B-Plant
on O
potential O
biomarkers O
for O
colonic B-Disease
cancer I-Disease
risk O
in O
healthy O
volunteers O
a O
randomized O
trial O

background O
epidemiologic O
studies O
suggest O
that O
coffee B-Plant
use O
might O
protect O
against O
colorectal B-Disease
cancer I-Disease

inconsistencies O
as O
to O
the O
effect O
of O
coffee B-Plant
use O
and O
colorectal B-Disease
cancer I-Disease
between O
epidemiologic O
studies O
might O
be O
related O
to O
the O
type O
of O
coffee B-Plant
brew O

objective O
we O
studied O
the O
effect O
of O
unfiltered O
coffee B-Plant
consumption O
on O
putative O
biomarkers O
for O
colonic B-Disease
cancer I-Disease
risk O

garlic B-Plant
consumption O
and O
cancer B-Disease
prevention O
meta O
analyses O
of O
colorectal O
and O
stomach B-Disease
cancer I-Disease

objective O
the O
objective O
was O
to O
conduct O
meta O
analyses O
of O
the O
epidemiologic O
literature O
on O
the O
association O
between O
garlic B-Plant
consumption O
and O
risk O
of O
stomach B-Disease
colon B-Disease
head B-Disease
and O
neck B-Disease
lung B-Disease
breast B-Disease
and O
prostate B-Disease
cancers I-Disease

design O
meta O
analyses O
were O
conducted O
for O
all O
cancers B-Disease
mutually O
and O
separately O
for O
colorectal B-Disease
and O
stomach B-Disease
cancers I-Disease
in O
relation O
to O
consumption O
of O
exclusively O
raw O
garlic B-Plant
cooked O
garlic B-Plant
or O
both O
rc O
garlic B-Plant

a O
relative O
risk O
estimate O
for O
rc O
garlic B-Plant
consumption O
and O
cancer B-Disease
risk O

the O
random O
effects O
relative O
risk O
rr O
estimate O
of O
colorectal B-Disease
cancer I-Disease
and O
rc O
garlic B-Plant
consumption O
excluding O
garlic B-Plant
supplements O
was O
69 O
95 O
ci O
55 O

an O
indication O
of O
publication O
bias O
for O
all O
cancers B-Disease
combined O
is O
evident O
from O
a O
funnel O
plot O
of O
rc O
garlic B-Plant
consumption O
and O
cancer O
risk O
and O
from O
the O
results O
of O
the O
begg O
and O
mazumdar O
test O
p O

conclusions O
high O
intake O
of O
rc O
garlic B-Plant
may O
be O
associated O
with O
a O
protective O
effect O
against O
stomach O
and O
colorectal B-Disease
cancers I-Disease

in O
animal O
models O
cow O
milk O
proteins O
are O
modestly O
and O
variably O
diabetogenic B-Disease
wheat B-Plant
or O
soybean B-Plant
proteins O
in O
the O
diet O
cause O
higher O
rates O
of O
autoimmune B-Disease
diabetes I-Disease

association O
of O
coffee B-Plant
consumption O
with O
gallbladder B-Disease
disease I-Disease

coffee B-Plant
consumption O
was O
recently O
shown O
to O
protect O
against O
symptomatic O
gallbladder B-Disease
disease I-Disease
in O
men O

the O
authors O
examined O
the O
relation O
of O
ultrasound O
documented O
gallbladder B-Disease
disease I-Disease
with O
coffee B-Plant
drinking O
in O
13 O
938 O
adult O
participants O
in O
the O
third O
national O
health O
and O
nutrition O
examination O
survey O

the O
prevalence O
of O
total O
gallbladder B-Disease
disease I-Disease
was O
unrelated O
to O
coffee B-Plant
consumption O
in O
either O
men O
or O
women O

however O
among O
women O
a O
decreased O
prevalence O
of O
previously O
diagnosed O
gallbladder B-Disease
disease I-Disease
was O
found O
with O
increasing O
coffee B-Plant
drinking O
p O

these O
findings O
do O
not O
support O
a O
protective O
effect O
of O
coffee B-Plant
consumption O
on O
total O
gallbladder B-Disease
disease I-Disease
although O
coffee B-Plant
may O
decrease O
the O
risk O
of O
symptomatic O
gallstones B-Disease
in O
women O

mutational O
hotspots O
within O
the O
p53 O
gene O
e O
g O
codon O
157 O
have O
been O
identified O
for O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease
whereas O
these O
same O
mutations O
are O
found O
rarely O
in O
other O
cancers B-Disease

because O
limited O
data O
exist O
concerning O
the O
p53 O
mutation O
frequency O
and O
spectra O
in O
ex O
smokers O
and O
nonsmokers O
we O
have O
analyzed O
p53 O
and O
k O
ras O
mutations O
in O
126 O
lung B-Disease
cancers I-Disease
from O
a O
population O
based O
case O
control O
study O
of O
nonsmoking O
n O
117 O
or O
ex O
smoking O
n O
9 O
women O
from O
missouri O
with O
quantitative O
assessments O
of O
exposure O
to O
environmental O
tobacco B-Plant
smoke O

such O
comparisons O
provide O
additional O
evidence O
of O
genetic O
damage O
caused O
by O
tobacco B-Plant
smoke O
during O
lung B-Disease
carcinogenesis I-Disease

background O
the O
goals O
for O
health O
project O
is O
designed O
to O
change O
the O
cancer B-Disease
related O
behaviors O
of O
tobacco B-Plant
use O
and O
dietary O
fat O
and O
fiber O
consumption O

a O
low O
familial O
income O
and O
tobacco B-Plant
smoking O
were O
associated O
with O
wheezing B-Disease
asthma B-Disease
chronic B-Disease
bronchitis I-Disease
and O
emphysema B-Disease

this O
study O
emphasizes O
the O
role O
of O
reducing O
tobacco B-Plant
smoking O
in O
the O
prevention O
of O
chronic O
respiratory B-Disease
diseases I-Disease

suppressive O
effect O
of O
coffee B-Plant
on O
lipopolysaccharide O
induced O
hepatitis B-Disease
in O
d O
galactosamine O
sensitized O
rats O

a O
coffee B-Plant
extract O
significantly O
suppressed O
lipopolysaccharide O
lps O
induced O
hepatitis B-Disease
in O
d O
galactosamine O
sensitized O
rats O
as O
assessed O
by O
the O
plasma O
alanine O
and O
aspartate O
aminotransferase O
activities O
when O
it O
was O
added O
to O
the O
diet O
30 O
g O
kg O
and O
fed O
to O
rats O
for O
14 O
days O

the O
coffee B-Plant
extract O
suppressed O
lps O
induced O
hepatitis B-Disease
when O
singly O
force O
fed O
12 O
g O
kg O
15 O
h O
prior O
to O
the O
injection O
of O
the O
drugs O
whereas O
a O
decaffeinated O
coffee B-Plant
extract O
had O
no O
significant O
effect O

these O
results O
indicate O
that O
coffee B-Plant
can O
protect O
animals O
from O
lps O
induced O
hepatitis B-Disease
and O
that O
the O
effect O
of O
coffee B-Plant
might O
be O
mainly O
due O
to O
caffeine B-Plant

for O
females O
in O
contrast O
both O
the O
absolute O
number O
of O
lung B-Disease
cancer I-Disease
deaths O
and O
the O
age O
standardized O
rate O
of O
79 O
100000 O
were O
among O
the O
highest O
values O
ever O
registered O
reflecting O
the O
different O
pattern O
of O
spread O
of O
the O
tobacco B-Plant
related O
lung B-Disease
cancer I-Disease
epidemic O
in O
the O
two O
sexes O

among O
neoplasms B-Disease
showing O
favorable O
trends O
there O
were O
other O
tobacco B-Plant
related O
neoplasms B-Disease
in O
men O
plus O
the O
continuing O
fall O
in O
stomach O
and O
cervix O
uteri O

conclusions O
the O
fall O
in O
cancer O
mortality O
observed O
over O
the O
last O
decade O
in O
italy O
is O
attributable O
to O
a O
decline O
in O
lung O
and O
other O
tobacco B-Plant
related O
neoplasms B-Disease
in O
males O
together O
with O
a O
persistent O
fall O
in O
stomach B-Disease
and O
uterine B-Disease
cervical I-Disease
cancer I-Disease

mortality O
trends O
in O
cancer B-Disease
attributable O
to O
tobacco B-Plant
in O
mexico O

objective O
to O
describe O
the O
mortality O
trends O
of O
cancer B-Disease
attributable O
to O
tobacco B-Plant
smoking O
particularly O
lung B-Disease
cancer I-Disease
for O
the O
1980 O
1997 O
period O
in O
mexico O

material O
and O
methods O
mortality O
trends O
were O
analyzed O
for O
each O
type O
of O
cancer B-Disease
associated O
to O
tobacco B-Plant
smoking O
according O
to O
the O
international O
classification O
of O
diseases O
icd O

the O
gender O
ratio O
for O
laryngeal B-Disease
cancer I-Disease
was O
striking O
421 O
100 O
probably O
due O
to O
the O
higher O
prevalence O
of O
male O
tobacco B-Plant
smokers O

previous O
tobacco B-Plant
smoking O
was O
correlated O
with O
the O
mortality O
rate O
trends O
for O
lung B-Disease
cancer I-Disease
beta O
910 O
ic O
95 O
1097 O
1797 O
r2 O
827 O

conclusions O
in O
mexico O
increased O
tobacco B-Plant
smoking O
improved O
cancer B-Disease
diagnosis O
and O
the O
demographic O
transition O
are O
probably O
the O
main O
factors O
determining O
cancer B-Disease
mortality O
rates O

although O
tobacco B-Plant
related O
cancer B-Disease
is O
a O
fast O
growing O
public O
health O
problem O
having O
a O
poor O
prognosis O
tobacco B-Plant
smoking O
the O
main O
risk O
factor O
could O
be O
eliminated O
by O
health O
education O
and O
promotion O
together O
with O
publicity O
regulation O
and O
healthy O
taxation O
policies O

inhibition O
of O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
oral B-Disease
carcinogenesis I-Disease
in O
hamsters O
by O
tea B-Plant
and O
curcumin B-Plant

in O
this O
study O
we O
studied O
the O
effects O
of O
tea B-Plant
and O
curcumin O
on O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
oral B-Disease
carcinogenesis I-Disease
in O
hamster O

the O
combination O
of O
tea B-Plant
and O
curcumin O
significantly O
decreased O
the O
oral O
visible O
tumor B-Disease
incidence O
from O
92 O
3 O
24 O
26 O
to O
69 O
2 O
18 O
26 O
and O
the O
squamous B-Disease
cell I-Disease
carcinoma I-Disease
scc B-Disease
incidence O
from O
769 O
20 O
26 O
to O
423 O

the O
combination O
of O
tea B-Plant
and O
curcumin B-Plant
also O
decreased O
the O
number O
of O
visible O
tumors B-Disease
and O
the O
tumor B-Disease
volume O
by O
524 O
and O
698 O
as O
well O
as O
the O
numbers O
of O
scc B-Disease
dysplasic B-Disease
lesions I-Disease
and O
papillomas B-Disease
by O
62 O
375 O
and O
487 O
respectively O

green B-Plant
tea I-Plant
or O
curcumin B-Plant
treatment O
decreased O
the O
number O
of O
visible O
tumors B-Disease
by O
351 O
or O
396 O
the O
tumor B-Disease
volume O
by O
416 O
or O
613 O
and O
the O
number O
of O
scc B-Disease
by O
533 O
or O
513 O
respectively O

green B-Plant
tea I-Plant
also O
decreased O
the O
number O
of O
dysplasic B-Disease
lesions I-Disease

tea B-Plant
and O
curcumin O
singly O
or O
in O
combination O
decreased O
the O
proliferation O
index O
in O
hyperplasia B-Disease
dysplasia B-Disease
and O
papillomas B-Disease

tea B-Plant
alone O
and O
in O
combination O
with O
curcumin O
significantly O
increased O
the O
apoptotic O
index O
in O
dysplasia B-Disease
and O
scc B-Disease

curcumin O
alone O
and O
in O
combination O
with O
tea B-Plant
significantly O
inhibited O
the O
angiogenesis O
in O
papilloma B-Disease
and O
scc B-Disease

the O
results O
suggested O
that O
green B-Plant
tea I-Plant
and O
curcumin O
had O
inhibitory O
effects O
against O
oral B-Disease
carcinogenesis I-Disease
at O
the O
post O
initiation O
stage O
and O
such O
inhibition O
may O
be O
related O
to O
the O
suppression O
of O
cell O
proliferation O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O

cigarette O
smoking O
use O
of O
other O
tobacco B-Plant
products O
and O
stomach B-Disease
cancer O
mortality O
in O
us O
adults O
the O
cancer B-Disease
prevention O
study O

cigarette O
smoking O
is O
associated O
with O
increased O
risk O
of O
stomach B-Disease
cancer I-Disease
in O
many O
studies O
but O
there O
are O
limited O
data O
on O
this O
relationship O
in O
women O
and O
on O
risk O
associated O
with O
use O
of O
tobacco B-Plant
products O
other O
than O
cigarettes O

we O
examined O
stomach B-Disease
cancer I-Disease
death O
rates O
in O
relation O
to O
cigarette O
smoking O
in O
women O
and O
use O
of O
cigarette O
cigar O
pipe O
or O
smokeless O
tobacco B-Plant
in O
men O
in O
a O
nationwide O
prospective O
mortality O
study O
in O
the O
united O
states O
us O

if O
causal O
the O
estimated O
proportion O
of O
stomach B-Disease
cancer I-Disease
deaths O
attributable O
to O
tobacco B-Plant
use O
would O
be O
28 O
in O
us O
men O
and O
14 O
in O
women O

we O
conclude O
that O
prolonged O
use O
of O
tobacco B-Plant
products O
is O
associated O
with O
increased O
stomach B-Disease
cancer I-Disease
mortality O
in O
men O
and O
women O

the O
accumulated O
evidence O
from O
this O
and O
other O
studies O
support O
reconsidering O
stomach B-Disease
cancer I-Disease
as O
a O
tobacco B-Plant
related O
cancer B-Disease

on O
the O
other O
hand O
high O
intake O
of O
nonhydrogenated O
soybean B-Plant
cooking O
oil O
was O
related O
to O
a O
reduced O
risk O
of O
breast B-Disease
cancer I-Disease
among O
women O
who O
never O
deep O
fried O
animal O
foods O
odds O
ratio O
48 O
95 O
confidence O
interval O
28 O
82 O
for O
the O
highest O
versus O
the O
lowest O
quintile O
p O
for O
trend O

this O
study O
also O
suggests O
that O
nonhydrogenated O
soybean B-Plant
oil O
if O
not O
used O
in O
high O
temperature O
cooking O
may O
be O
associated O
with O
a O
reduced O
risk O
of O
breast B-Disease
cancer I-Disease

tobacco B-Plant
smoke O
carcinogens O
dna O
damage O
and O
p53 O
mutations O
in O
smoking O
associated O
cancers B-Disease

it O
is O
estimated O
that O
cigarette O
smoking O
kills O
over O
1 O
0 O
0 O
people O
each O
year O
by O
causing O
lung B-Disease
cancer I-Disease
as O
well O
as O
many O
other O
neoplasmas B-Disease
p53 O
mutations O
are O
frequent O
in O
tobacco B-Plant
related O
cancers B-Disease
and O
the O
mutation O
load O
is O
often O
higher O
in O
cancers B-Disease
from O
smokers O
than O
from O
nonsmokers O

at O
several O
p53 O
mutational O
hotspots O
common O
to O
all O
cancers B-Disease
such O
as O
codons O
248 O
and O
273 O
a O
large O
fraction O
of O
the O
mutations O
are O
g O
to O
t O
events O
in O
lung B-Disease
cancers I-Disease
but O
are O
almost O
exclusively O
g O
to O
a O
transitions O
in O
non O
tobacco B-Plant
related O
cancers B-Disease

patients O
with O
anaphylaxis O
to O
pea B-Plant
can O
have O
pea B-Plant
nut O
allergy O
caused O
by O
cross O
reactive O
ige O
to O
vicilin O
ara O
h O

in O
this O
study O
3 O
patients O
with O
a O
history O
of O
anaphylaxis B-Disease
to O
pea B-Plant
are O
described O
who O
subsequently O
had O
symptoms O
after O
ingestion O
of O
peanut B-Plant

results O
peanut B-Plant
related O
symptoms O
consisted O
of O
oral O
symptoms O
in O
all O
patients O
with O
additional O
urticaria O
and O
dyspnea O
or O
angioedema B-Disease
in O
2 O
patients O

results O
seven O
patients O
had O
TRUE O
juxta O
anastomotic O
aneurysms O
40 O
mm O
in O
the O
residual O
infra O
renal O
abdominal O
aorta O
the O
occurrence O
of O
which O
was O
associated O
with O
tobacco B-Plant
smoking O
and O
hypertension B-Disease

tobacco B-Plant
smoking O
and O
hypertension B-Disease
are O
significant O
factors O
associated O
with O
the O
development O
of O
these O
aneurysms B-Disease

conversely O
soy B-Plant
beverage O
was O
associated O
with O
an O
increased O
risk O
of O
current O
asthma B-Disease
205 O
119 O
353 O
doctor O
diagnosed O
asthma B-Disease
169 O
104 O
277 O
and O
bhr O
165 O
100 O
271 O

apples B-Plant
and O
pears B-Plant
appeared O
to O
protect O
against O
current O
asthma B-Disease
83 O
71 O
98 O
asthma B-Disease
88 O
78 O
100 O
and O
bhr B-Disease
88 O
77 O
100 O

conclusions O
the O
consumption O
of O
dairy O
products O
soy B-Plant
beverages O
and O
apples B-Plant
and O
pears B-Plant
but O
not O
of O
nutrients O
per O
se O
was O
associated O
with O
a O
range O
of O
asthma B-Disease
definitions O

the O
herbal O
medicine O
dipsacus B-Plant
asper I-Plant
wall O
extract O
reduces O
the O
cognitive B-Disease
deficits I-Disease
and O
overexpression O
of O
beta O
amyloid O
protein O
induced O
by O
aluminum O
exposure O

in O
the O
present O
study O
we O
sought O
to O
evaluate O
the O
protective O
effects O
of O
the O
herbal O
medicine O
dipsacus B-Plant
asper I-Plant
extract O
against O
the O
cognitive B-Disease
impairment I-Disease
and O
overexpression O
of O
hippocampal O
beta O
amyloid O
protein O
abeta O
induced O
by O
chronic O
al O
exposure O
in O
rats O

the O
present O
results O
suggest O
that O
dipsacus B-Plant
asper I-Plant
extract O
may O
possess O
therapeutic O
effects O
against O
alzheimer B-Disease
disease I-Disease

since O
the O
increasing O
epidemic B-Disease
of O
lung B-Disease
cancer I-Disease
in O
men O
as O
well O
as O
other O
tobacco B-Plant
related O
cancers B-Disease
is O
observed O
in O
portugal O
the O
important O
component O
of O
such O
a O
programme O
should O
be O
a O
nationwide O
tobacco B-Plant
control O
programme O

coffee B-Plant
consumption O
and O
risk O
of O
rheumatoid B-Disease
arthritis I-Disease

objective O
recent O
reports O
have O
suggested O
an O
association O
between O
consumption O
of O
coffee B-Plant
or O
decaffeinated O
coffee B-Plant
and O
the O
risk O
of O
rheumatoid B-Disease
arthritis I-Disease
ra B-Disease
although O
data O
are O
sparse O
and O
somewhat O
inconsistent O

we O
studied O
whether O
coffee B-Plant
decaffeinated O
coffee B-Plant
total O
coffee B-Plant
tea B-Plant
or O
overall O
caffeine O
consumption O
was O
associated O
with O
the O
risk O
of O
ra B-Disease
using O
the O
nurses O
health O
study O
a O
longitudinal O
cohort O
study O
of O
121 O
701 O
women O

results O
we O
did O
not O
find O
a O
significant O
association O
between O
decaffeinated O
coffee B-Plant
consumption O
of O
4 O
cups O
day O
compared O
with O
no O
decaffeinated O
coffee B-Plant
consumption O
and O
subsequent O
risk O
of O
incident O
ra B-Disease
in O
either O
an O
adjusted O
multivariate O
model O
relative O
risk O
rr O
11 O
95 O
confidence O
interval O
95 O
ci O
5 O
22 O
or O
a O
multivariate O
model O
using O
only O
baseline O
reports O
of O
decaffeinated O
coffee B-Plant
consumption O
rr O
10 O
95 O
ci O
6 O
17 O

similarly O
there O
was O
no O
relationship O
between O
cumulative O
caffeinated O
coffee B-Plant
consumption O
and O
ra B-Disease
risk O
rr O
11 O
95 O
ci O
8 O
16 O
for O
4 O
cups O
per O
day O
versus O
none O
or O
between O
tea B-Plant
consumption O
and O
ra B-Disease
risk O
rr O
11 O
95 O
ci O
7 O
18 O
for O
3 O
cups O
day O
versus O
none O

total O
coffee B-Plant
and O
total O
caffeine O
consumption O
were O
also O
not O
associated O
with O
the O
risk O
of O
ra B-Disease

conclusion O
in O
this O
large O
prospective O
study O
we O
find O
little O
evidence O
of O
an O
association O
between O
coffee B-Plant
decaffeinated O
coffee B-Plant
or O
tea B-Plant
consumption O
and O
the O
risk O
of O
ra B-Disease
among O
women O

while O
alcohol O
was O
initially O
described O
as O
a O
risk O
enhancer O
only O
in O
smokers O
a O
number O
of O
epidemiological O
studies O
have O
now O
shown O
that O
chronic O
alcohol O
consumption O
increases O
the O
risk O
of O
head B-Disease
and O
neck B-Disease
cancer I-Disease
independently O
of O
exposure O
to O
tobacco B-Plant

the O
study O
was O
part O
of O
a O
community O
based O
comprehensive O
cross O
sectional O
study O
designed O
to O
assess O
a O
broad O
array O
of O
knowledge O
attitudes O
and O
behaviors O
on O
tobacco B-Plant
use O
and O
tobacco B-Plant
related O
cancer B-Disease
issues O
in O
the O
target O
multi O
ethnic O
and O
multi O
lingual O
asian O
american O
community O

increased O
consumption O
of O
tomato B-Plant
products O
is O
associated O
with O
a O
decreased O
risk O
of O
cancer B-Disease

phase O
ii O
double O
blind O
randomized O
study O
comparing O
oral O
aloe B-Plant
vera I-Plant
versus O
placebo O
to O
prevent O
radiation O
related O
mucositis O
in O
patients O
with O
head B-Disease
and O
neck O
neoplasms I-Disease

purpose O
in O
a O
single O
institution O
double O
blind O
prospective O
randomized O
trial O
we O
determined O
whether O
oral O
aloe B-Plant
vera I-Plant
gel O
can O
reduce O
radiation O
induced O
mucositis B-Disease
in O
head B-Disease
and O
neck B-Disease
cancer I-Disease
patients O

methods O
and O
materials O
we O
randomized O
58 O
head B-Disease
and O
neck B-Disease
cancer I-Disease
patients O
between O
oral O
aloe B-Plant
vera I-Plant
and O
placebo B-Plant

oral O
aloe B-Plant
vera I-Plant
did O
not O
improve O
tolerance O
to O
head O
and O
neck O
radiotherapy O
decrease O
mucositis B-Disease
reduce O
soreness B-Disease
or O
otherwise O
improve O
patient O
well O
being O

with O
the O
highest O
tobacco B-Plant
abuse O
prevalence O
among O
all O
minorities O
american O
indians O
incur O
high O
rates O
of O
tobacco B-Plant
related O
cancers B-Disease

effects O
of O
ginkgo B-Plant
biloba I-Plant
on O
exhaled O
nasal O
nitric O
oxide O
during O
normobaric B-Disease

hypoxia I-Disease
in O
humans O
ginkgo B-Plant
biloba I-Plant
an O
extract O
of O
the O
ginkgo B-Plant
tree O
may O
prevent O
or O
lessen O
symptoms O
of O
acute B-Disease
mountain I-Disease
sickness I-Disease
in O
humans O

we O
measured O
exhaled O
nasal O
no O
output O
in O
humans O
n O
9 O
during O
normoxia O
and O
then O
during O
acute O
normobaric O
hypoxia B-Disease
goal O
oxyhemoglobin O
saturation O
75 O
to O
85 O
before O
and O
after O
administration O
of O
a O
standardized O
extract O
of O
ginkgo B-Plant
biloba I-Plant
120 O
mg O
twice O
daily O
for O
5 O
days O

exhaled O
nasal O
no O
output O
was O
increased O
during O
normoxia O
following O
ginkgo B-Plant
p O
2 O
and O
reduced O
during O
normobaric O
hypoxia B-Disease
both O
before O
p O
2 O
and O
following O
p O
3 O
ginkgo B-Plant

exhaled O
nasal O
no O
output O
during O
normobaric O
hypoxia B-Disease
was O
lowest O
following O
ginkgo B-Plant
p O

we O
conclude O
that O
ginkgo B-Plant
biloba I-Plant
increases O
exhaled O
nasal O
no O
output O
during O
normoxia O
and O
enhances O
reduced O
exhaled O
nasal O
no O
output O
during O
normobaric O
hypoxia B-Disease

we O
investigated O
whether O
tobacco B-Plant
use O
causes O
cutaneous B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
cscc B-Disease
in O
a O
large O
cohort O
study O
with O
complete O
and O
long O
term O
follow O
up O

a O
total O
of O
756 O
incident O
cases O
occurred O
in O
a O
cohort O
of O
337 O
311 O
men O
during O
a O
30 O
year O
follow O
up O
period O
but O
no O
association O
was O
found O
between O
any O
kind O
of O
smoking O
tobacco B-Plant
use O
and O
cscc B-Disease
risk O
nor O
any O
risk O
change O
with O
increasing O
dose O
duration O
or O
time O
since O
smoking O
cessation O

overall O
our O
study O
provides O
no O
evidence O
that O
tobacco B-Plant
use O
increases O
the O
risk O
of O
cscc B-Disease

experimental O
study O
on O
treatment O
of O
minimal B-Disease
change I-Disease
nephropathy I-Disease
with O
lespedeza B-Plant
michx I-Plant

objective O
to O
study O
the O
therapeutic O
effect O
of O
lespedeza B-Plant
michx I-Plant
in O
experimental O
rat O
model O
of O
minimal B-Disease
change I-Disease
nephropathy I-Disease
mcn B-Disease

result O
lespedeza B-Plant
michx I-Plant
could O
decrease O
the O
contents O
of O
urine B-Disease
proteinuria I-Disease
mda O
il O
8 O
and O
tnf O
alpha O
in O
serum O
increase O
sod O
level O
and O
improved O
the O
pathological O
change O
of O
glomeruli O

conclusion O
lespedeza B-Plant
michx I-Plant
was O
effective O
on O
mcn B-Disease

coffee B-Plant
and O
risk O
of O
death O
from O
hepatocellular B-Disease
carcinoma I-Disease
in O
a O
large O
cohort O
study O
in O
japan O

we O
examined O
the O
relation O
between O
coffee B-Plant
drinking O
and O
hepatocellular B-Disease
carcinoma I-Disease
hcc B-Disease
mortality O
in O
the O
japan O
collaborative O
cohort O
study O
for O
evaluation O
of O
cancer O
risk O
jacc O
study O

cox O
proportional O
hazards O
model O
by O
sas O
was O
used O
to O
obtain O
hazard O
ratio O
of O
hcc B-Disease
mortality O
for O
each O
coffee B-Plant
consumption O
category O

the O
hazard O
ratio O
of O
death O
due O
to O
hcc B-Disease
for O
drinkers O
of O
one O
and O
more O
cups O
of O
coffee B-Plant
per O
day O
compared O
with O
non O
coffee B-Plant
drinkers O
was O
50 O
95 O
confidence O
interval O
31 O
79 O
and O
the O
ratio O
for O
drinkers O
of O
less O
than O
one O
cup O
per O
day O
was O
83 O
95 O
confidence O
interval O

our O
data O
confirmed O
an O
inverse O
association O
between O
coffee B-Plant
consumption O
and O
hcc B-Disease
mortality O

plantago B-Plant
major I-Plant
plantaginaceae B-Plant
is O
popularly O
used O
to O
treat O
tumors B-Disease
infections O
and O
as O
a O
blood O
purifier O

results O
after O
adjustment O
for O
other O
food O
items O
vegetables O
fruits O
different O
types O
of O
meat O
processed O
meat O
and O
fish O
dairy O
and O
starchy O
products O
coffee B-Plant
green B-Plant
tea I-Plant
that O
were O
related O
to O
outcome O
smoking O
alcohol O
use O
family O
history O
on O
cancer B-Disease
education O
level O
and O
residence O
stomach B-Disease
cancer I-Disease
risk O
was O
inversely O
associated O
with O
consumption O
of O
raw O
vegetables O
such O
as O
cabbage B-Plant
carrots B-Plant
and O
garlic B-Plant

there O
were O
no O
statistically O
significant O
associations O
between O
stomach B-Disease
cancer I-Disease
risk O
and O
consumption O
of O
citrus B-Plant
or O
others O
fruits O

in O
conclusion O
higher O
consumption O
of O
raw O
vegetables O
such O
as O
cabbage B-Plant
carrots B-Plant
garlic B-Plant
as O
well O
as O
broccoli B-Plant
may O
decrease O
a O
risk O
of O
stomach B-Disease
cancer I-Disease
whereas O
intake O
of O
citrus B-Plant
fruits O
has O
no O
relation O
with O
a O
reduced O
risk O
of O
the O
disease O

components O
of O
olive B-Plant
oil O
and O
chemoprevention O
of O
colorectal B-Disease
cancer I-Disease

higher O
consumption O
of O
olive B-Plant
oil O
is O
considered O
the O
hallmark O
of O
the O
traditional O
mediterranean O
diet O
which O
has O
been O
associated O
with O
low O
incidence O
and O
prevalence O
of O
cancer B-Disease
including O
colorectal B-Disease
cancer I-Disease

nevertheless O
there O
is O
a O
growing O
interest O
in O
studying O
the O
role O
of O
olive B-Plant
oil O
phenolics O
in O
carcinogenesis B-Disease

this O
review O
aims O
to O
provide O
an O
overview O
of O
the O
relationship O
between O
olive B-Plant
oil O
phenolics O
and O
colorectal B-Disease
cancer I-Disease
in O
particular O
summarizing O
the O
epidemiologic O
in O
vitro O
cellular O
and O
animal O
studies O
on O
antioxidant O
and O
anticarcinogenic O
effects O
of O
olive B-Plant
oil O
phenoloc O

methods O
il O
10 O
mice O
were O
fed O
chow O
supplemented O
with O
corn B-Plant
oil O
co O
control O
n O
28 O
olive B-Plant
oil O
oo O
n O
29 O
or O
fish O
oil O
fo O
n O
35 O
for O
12 O
wk O
and O
their O
colons O
were O
studied O
for O
colitis B-Disease
score O
premalignant O
changes O
and O
cox O
2 O

conversely O
olive B-Plant
oil O
inhibits O
cox O
2 O
immunostaining O
and O
decreases O
the O
risk O
of O
neoplasia B-Disease
associated O
with O
chronic O
colitics O

role O
of O
dau O
c O
1inch O
three O
different O
patterns O
of O
carrot B-Plant
induced O
asthma B-Disease

objective O
to O
assess O
the O
role O
of O
dau O
c O
1inch O
three O
patients O
with O
carrot B-Plant
induced O
asthma B-Disease

material O
and O
methods O
patient O
1 O
had O
asthma B-Disease
when O
handling O
raw O
carrots B-Plant

she O
had O
asthma B-Disease
due O
to O
raw O
carrot B-Plant
ingestion O
and O
inhalation O

she O
had O
asthma B-Disease
when O
handling O
raw O
carrots B-Plant

conclusions O
airborne O
carrot B-Plant
allergens O
are O
able O
to O
sensitize O
without O
the O
implication O
of O
a O
previous O
pollen B-Disease
allergy I-Disease

allergy B-Disease
to O
carrot B-Plant
in O
patient O
3 O
seems O
to O
be O
related O
to O
her O
allergy B-Disease
to O
different O
pollens O
however O
it O
wasnt O
related O
to O
birch B-Plant
pollen O

we O
examined O
the O
relationship O
of O
environmental O
tobacco B-Plant
smoke O
ets O
and O
visible O
mold O
exposures O
on O
the O
development O
of O
allergic B-Disease
rhinitis I-Disease
rhinitis B-Disease
and O
upper B-Disease
respiratory I-Disease
infection I-Disease
uri O
in O
a O
birth O
cohort O
where O
at O
least O
one O
parent O
was O
skin O
prick O
test O
spt O
positive O

the O
use O
of O
tobacco B-Plant
products O
is O
associated O
with O
an O
increased O
incidence O
of O
periodontal O
disease O
poor O
response O
to O
periodontal O
therapy O
and O
a O
high O
risk O
for O
developing O
head B-Disease
and O
neck B-Disease
cancer I-Disease

elucidation O
of O
this O
novel O
mechanism O
of O
nicotine O
dependent O
nuclear O
transactivation O
of O
stat O
3 O
identifies O
oral O
alpha7 O
nachr O
as O
a O
promising O
molecular O
target O
to O
prevent O
reverse O
or O
retard O
tobacco B-Plant
related O
periodontal O
disease O
and O
progression O
of O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
by O
receptor O
inhibitors O

coffee B-Plant
consumption O
and O
the O
risk O
of O
gestational B-Disease
diabetes I-Disease
mellitus I-Disease

background O
coffee B-Plant
consumption O
has O
been O
associated O
with O
a O
decreased O
risk O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
mellitus I-Disease

we O
examined O
the O
relationship O
between O
coffee B-Plant
consumption O
and O
the O
risk O
of O
gestational B-Disease
diabetes I-Disease
mellitus I-Disease
gdm B-Disease

we O
studied O
the O
association O
of O
coffee B-Plant
consumption O
before O
and O
during O
pregnancy O
and O
the O
subsequent O
risk O
of O
gdm B-Disease

results O
women O
who O
reported O
moderate O
pre O
pregnancy O
caffeinated O
coffee B-Plant
intake O
had O
a O
significantly O
reduced O
risk O
of O
gdm B-Disease
adjusted O
compared O
with O
non O
consumers O

conclusions O
moderate O
pre O
pregnancy O
caffeinated O
coffee B-Plant
consumption O
may O
have O
a O
protective O
association O
with O
gdm B-Disease

the O
effect O
of O
lifestyle O
factors O
including O
tobacco B-Plant
chewing O
smoking O
and O
alcohol O
drinking O
diet O
and O
dental O
care O
on O
the O
risk O
of O
oral B-Disease
cancer I-Disease
was O
investigated O
in O
a O
case O
control O
study O
conducted O
in O
rajah O
muthiah O
dental O
college O
and O
hospital O
annamalainagar O
annamalai O
university O
chidambaram O
tamil O
nadu O
india O
during O
the O
period O
1991 O
2003 O

all O
participants O
were O
interviewed O
using O
a O
structured O
questionnaire O
that O
contained O
data O
on O
demographic O
factors O
family O
history O
of O
cancer B-Disease
tobacco B-Plant
habits O
use O
of O
alcohol O
frequency O
duration O
cessation O
of O
these O
habits O
dietary O
practices O
and O
oral O
hygiene O

intraperitoneal O
injection O
of O
ginkgo B-Plant
biloba I-Plant
extract O
enhances O
antioxidation O
ability O
of O
retina O
and O
protects O
photoreceptors O
after O
light O
induced O
retinal B-Disease
damage I-Disease
in O
rats O

purpose O
to O
investigate O
the O
effect O
of O
ginkgo B-Plant
biloba I-Plant
extract O
egb O
761 O
a O
free O
radical O
scavenger O
on O
the O
antioxidation O
capability O
of O
retina O
after O
light O
induced O
retinal B-Disease
damage I-Disease
in O
rats O
in O
an O
attempt O
to O
understand O
the O
mechanism O
by O
which O
egb O
761 O
protects O
the O
photoreceptors O
after O
light O
induced O
retinal B-Disease
damage I-Disease

tobacco B-Plant
smoke O
induced O
lung B-Disease
cancer I-Disease
in O
animals O
a O
challenge O
to O
toxicology O

tobacco B-Plant
smoke O
is O
a O
known O
human O
carcinogen O
that O
primarily O
produces O
malignant B-Disease
lesions I-Disease
in O
the O
respiratory O
tract O
although O
it O
also O
affects O
multiple O
other O
sites O

a O
reliable O
and O
practical O
animal O
model O
of O
tobacco B-Plant
smoke O
induced O
lung B-Disease
cancer I-Disease
would O
be O
helpful O
for O
in O
studies O
of O
product O
modification O
and O
chemoprevention O

over O
the O
years O
many O
attempts O
to O
reproduce O
lung B-Disease
cancer I-Disease
in O
experimental O
animals O
exposed O
to O
tobacco B-Plant
smoke O
have O
been O
made O
most O
often O
with O
negative O
or O
only O
marginally O
positive O
results O

female O
rats O
and O
female O
b6c3f1 O
mice O
when O
exposed O
over O
lifetime O
to O
tobacco B-Plant
smoke O
develop O
tumors B-Disease
in O
the O
nasal O
passages O
and O
also O
in O
the O
lung B-Disease

male O
and O
female O
strain O
a O
mice O
exposed O
to O
5 O
months O
to O
tobacco B-Plant
smoke O
and O
then O
kept O
for O
another O
4 O
months O
in O
air O
respond O
to O
tobacco B-Plant
smoke O
with O
increased O
lung B-Disease
tumor I-Disease
multiplicities O

background O
vr3848 O
is O
a O
novel O
cycloheptapeptide O
isolated O
from O
a O
euphorbiaceae B-Plant
plant I-Plant
which O
can O
suppress O
proliferation O
of O
various O
tumor B-Disease
cells O
at O
nanomolar O
concentration O

findings O
results O
indicate O
that O
differences O
in O
risk O
indicators O
along O
the O
tobacco B-Plant
disease O
continuum O
do O
not O
explain O
fully O
tobacco B-Plant
related O
cancer B-Disease
consequences O
among O
some O
minority O
racial O
ethnic O
groups O
particularly O
among O
the O
aggregate O
groups O
blacks O
african O
americans O
and O
american O
indians O
alaska O
natives O

our O
findings O
provide O
insights O
into O
the O
mechanisms O
leading O
to O
reversible O
and O
persistent O
effects O
of O
tobacco B-Plant
smoke O
that O
may O
explain O
former O
smokers O
increased O
risk O
for O
developing O
tobacco B-Plant
induced O
lung B-Disease
disease I-Disease
and O
provide O
novel O
targets O
for O
chemoprophylaxis O

the O
anti O
inflammatory O
activity O
in O
vivo O
of O
the O
methylene O
chloride O
methanol O
extract O
methanol O
and O
methylene O
chloride O
fractions O
of O
stem O
barks O
of O
allanblackia B-Plant
monticola I-Plant
administered O
orally O
at O
doses O
of O
375 O
75 O
150 O
and O
300 O
mg O
kg O
was O
evaluated O
on O
carrageenan O
induced O
oedema B-Disease
in O
rats O
to O
determine O
the O
most O
active O
fraction O

the O
results O
showed O
that O
the O
methylene O
chloride O
fraction O
of O
allanblackia B-Plant
monticola I-Plant
was O
more O
effective O
on O
the O
oedema B-Disease
caused O
by O
the O
carrageenan O

allanblackia B-Plant
monticola I-Plant
75 O
300 O
mg O
kg O
did O
not O
cause O
significant O
modification O
of O
the O
oedema B-Disease
induced O
by O
serotonin O

we O
recently O
showed O
that O
nexrutine O
a O
phellodendron B-Plant
amurense I-Plant
bark O
extract O
suppresses O
proliferation O
of O
prostate B-Disease
cancer I-Disease
cell O
lines O
and O
tumor B-Disease
development O
in O
the O
transgenic O
adenocarcinoma O
of O
mouse O
prostate O
tramp O
model O

here O
we O
report O
ehrlich B-Disease
ascites I-Disease
carcinoma I-Disease
eac B-Disease
induced O
hepatotoxicity O
and O
its O
protection O
by O
antitumor O
dose O
of O
black B-Plant
tea I-Plant
in O
mice O

treatment O
with O
antitumor O
dose O
of O
black B-Plant
tea I-Plant
could O
replenish O
the O
hosts O
antioxidant O
system O
and O
regress O
cancer B-Disease
induced O
ros O
significantly O
thereby O
protecting O
the O
hosts O
liver O
from O
lipid O
peroxidation O
and O
subsequent O
degenaration O

thus O
unlike O
many O
other O
anticancer O
agents O
black B-Plant
tea I-Plant
not O
only O
has O
antitumor O
and O
immunorestoring O
properties O
but O
it O
also O
protects O
host O
liver O
from O
tumor B-Disease
induced O
toxicity B-Disease

these O
results O
thus O
raise O
the O
possibility O
of O
inclusion O
of O
black B-Plant
tea I-Plant
in O
a O
successful O
therapeutic O
regimen O
against O
cancer B-Disease

association O
of O
tnf O
alpha O
and O
tnfr1 O
promoters O
and O
3 O
utr O
region O
of O
tnfr2 O
gene O
polymorphisms O
with O
genetic O
susceptibility O
to O
tobacco B-Plant
related O
oral B-Disease
carcinoma I-Disease
in O
asian O
indians O

tobacco B-Plant
related O
oral B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
is O
a O
common O
malignancy B-Disease
in O
asian O
indians O

smokeless O
tobacco B-Plant
has O
been O
shown O
to O
induce O
tumor O
necrosis O
factor O
alpha O
tnf O
alpha O
which O
along O
with O
its O
receptors O
is O
over O
expressed O
in O
people O
with O
oral B-Disease
carcinoma I-Disease

single O
nucleotide O
polymorphisms O
snps O
in O
tnf O
alpha O
and O
tnf O
receptor O
genes O
may O
affect O
their O
expression O
and O
may O
be O
a O
potential O
determinant O
of O
susceptibility O
to O
tobacco B-Plant
related O
oral B-Disease
carcinomas I-Disease

it O
seems O
that O
tnf O
alpha O
308 O
ga O
may O
be O
related O
to O
susceptibility O
whereas O
609 O
tt O
tnfr1 O
and O
1690 O
ct O
tnfr2 O
snps O
may O
be O
protective O
to O
tobacco B-Plant
related O
oral B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease

joint O
effects O
of O
coffee B-Plant
consumption O
and O
serum O
gamma O
glutamyltransferase O
on O
the O
risk O
of O
liver B-Disease
cancer I-Disease

only O
three O
japanese O
prospective O
studies O
have O
suggested O
an O
inverse O
association O
between O
coffee B-Plant
drinking O
and O
liver B-Disease
cancer I-Disease

we O
aimed O
to O
determine O
the O
single O
and O
joint O
associations O
of O
coffee B-Plant
consumption O
and O
serum O
ggt O
with O
the O
risk O
of O
primary O
liver B-Disease
cancer I-Disease

the O
multivariable O
adjusted O
age O
sex O
alcohol O
consumption O
education O
smoking O
diabetes B-Disease
and O
chronic B-Disease
liver I-Disease
disease I-Disease
at O
baseline O
and O
during O
follow O
up O
and O
body O
mass O
index O
hazards O
ratios O
of O
liver B-Disease
cancer I-Disease
in O
participants O
who O
drank O
0 O
1 O
2 O
3 O
4 O
5 O
6 O
7 O
and O
or O
8 O
cups O
of O
coffee B-Plant
daily O
were O
100 O
66 O
44 O
38 O
and O
32 O
p O
for O
trend O
3 O
respectively O

the O
multivariable O
adjusted O
and O
coffee B-Plant
adjusted O
hazard O
ratio O
of O
liver B-Disease
cancer I-Disease
for O
the O
highest O
versus O
the O
lowest O
quartile O
of O
serum O
ggt O
was O
313 O
95 O
confidence O
interval O
122 O
807 O

the O
multivariable O
adjusted O
inverse O
association O
between O
coffee B-Plant
consumption O
and O
liver B-Disease
cancer I-Disease
risk O
persisted O
when O
stratified O
by O
baseline O
factors O
age O
more O
less O
than O
50 O
years O
current O
smoker O
never O
smoked O
ever O
smoked O
alcohol O
drinker O
never O
drinker O
obese B-Disease
non B-Disease
obese I-Disease
and O
the O
highest O
lowest O
three O
quartiles O
of O
serum O
ggt O

conclusion O
coffee B-Plant
drinking O
has O
an O
inverse O
and O
graded O
association O
with O
the O
risk O
of O
liver B-Disease
cancer I-Disease

with O
interest O
in O
complementary O
medicine O
for O
hypertension B-Disease
increasing O
it O
is O
timely O
to O
update O
a O
systematic O
review O
and O
meta O
analysis O
from O
1994 O
of O
studies O
investigating O
the O
effect O
of O
garlic B-Plant
preparations O
on O
blood O
pressure O

meta O
analysis O
of O
all O
studies O
showed O
a O
mean O
decrease O
of O
46 O
28 O
mm O
hg O
for O
sbp O
in O
the O
garlic B-Plant
group O
compared O
to O
placebo O
n O
10 O
p O
1 O
while O
the O
mean O
decrease O
in O
the O
hypertensive B-Disease
subgroup O
was O
84 O
28 O
mm O
hg O
for O
sbp O
n O
4 O
p O
1 O
and O
73 O
15 O
mm O
hg O
for O
dbp O
n O
3 O
p O

conclusion O
our O
meta O
analysis O
suggests O
that O
garlic B-Plant
preparations O
are O
superior O
to O
placebo O
in O
reducing O
blood O
pressure O
in O
individuals O
with O
hypertension B-Disease

the O
antioxidant O
response O
induced O
by O
lonicera B-Plant
caerulaea I-Plant
berry I-Plant
extracts O
in O
animals O
bearing O
experimental O
solid B-Disease
tumors I-Disease

the O
aim O
of O
our O
work O
was O
to O
investigate O
the O
in O
vivo O
effects O
of O
the O
antioxidant O
action O
of O
lonicera B-Plant
caerulea I-Plant
berry I-Plant
extracts O
on O
the O
dynamics O
of O
experimentally O
induced O
tumors B-Disease

our O
data O
showed O
that O
aqueous O
lonicera B-Plant
caerulaea I-Plant
extracts O
reduced O
the O
tumor B-Disease
volume O
when O
administered O
continuously O
during O
the O
tumor B-Disease
growth O
and O
development O
stages O
but O
augmented O
the O
tumor B-Disease
growth O
when O
the O
administration O
of O
extracts O
started O
three O
weeks O
before O
tumor B-Disease
grafting O

prolonged O
administration O
of O
lonicera B-Plant
caerulaea I-Plant
berry I-Plant
extracts O
induced O
the O
antioxidant O
defense O
mechanism O
in O
the O
tumor B-Disease
tissues O
while O
surprisingly O
amplifying O
the O
peripheral O
oxidative O
stress O

beneficial O
effects O
of O
lepidium B-Plant
meyenii I-Plant
maca B-Plant
on O
psychological B-Disease
symptoms I-Disease
and O
measures O
of O
sexual B-Disease
dysfunction I-Disease
in O
postmenopausal O
women O
are O
not O
related O
to O
estrogen O
or O
androgen O
content O

the O
greene O
climacteric O
scale O
revealed O
a O
significant O
reduction O
in O
scores O
in O
the O
areas O
of O
psychological B-Disease
symptoms I-Disease
including O
the O
subscales O
for O
anxiety B-Disease
and O
depression B-Disease
and O
sexual B-Disease
dysfunction I-Disease
after O
maca B-Plant
consumption O
compared O
with O
both O
baseline O
and O
placebo O
p O

conclusions O
preliminary O
findings O
show O
that O
lepidium B-Plant
meyenii I-Plant
maca B-Plant
35 O
gd O
reduces O
psychological B-Disease
symptoms I-Disease
including O
anxiety B-Disease
and O
depression B-Disease
and O
lowers B-Disease
measures I-Disease
of O
sexual B-Disease
dysfunction I-Disease
in O
postmenopausal O
women O
independent O
of O
estrogenic O
and O
androgenic O
activity O

ccsps O
4870 O
patients O
follow O
up O
4 O
years O
a O
secondary O
prevention O
trial O
using O
xuezhikang O
a O
commercial O
red O
yeast O
rice B-Plant
preparation O
produced O
a O
46 O
reduction O
in O
nonfatal O
myocardial B-Disease
infarction I-Disease
and O
coronary B-Disease
death I-Disease

red O
yeast O
rice B-Plant
reduces O
adverse O
cardiac B-Disease
events I-Disease
to O
a O
similar O
degree O
as O
the O
statins O

it O
is O
unlikely O
that O
garlic B-Plant
is O
useful O
in O
preventing O
cardiovascular B-Disease
disease I-Disease

evaluation O
of O
the O
use O
of O
coconut B-Plant
to O
treat O
chronic O
diarrhea B-Disease
in O
rhesus O
macaques O
macaca O
mulatta O

coconut B-Plant
has O
been O
used O
as O
a O
dietary O
supplement O
for O
people O
with O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
with O
anecdotal O
reports O
of O
decreased O
diarrhea B-Disease
following O
the O
dietary O
addition O

a O
dietary O
trial O
in O
rhesus O
macaques O
was O
initiated O
to O
evaluate O
the O
hypothesis O
that O
dietary O
coconut B-Plant
decreases O
symptoms O
of O
chronic O
diarrhea B-Disease
in O
rhesus O
macaqus O

results O
and O
conclusions O
data O
of O
chi O
squared O
analysis O
obtained O
from O
eight O
rhesus O
macaques O
with O
chronic O
diarrhea B-Disease
showed O
that O
the O
use O
of O
coconut B-Plant
macaroons O
as O
a O
dietary O
supplement O
did O
not O
have O
a O
statistically O
significant O
effect O
on O
their O
diarrhea B-Disease

coffee B-Plant
consumption O
and O
risk O
of O
type O
2 O
diabetes B-Disease
cardiovascular B-Disease
diseases I-Disease
and O
cancer B-Disease

numerous O
epidemiological O
studies O
have O
evaluated O
the O
association O
between O
coffee B-Plant
consumption O
and O
risk O
of O
type O
2 O
diabetes O
coronary O
heart O
disease O
and O
various O
cancers B-Disease

several O
early O
studies O
suggested O
that O
coffee B-Plant
consumption O
could O
result O
in O
a O
marked O
increase O
in O
risk O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
and O
several O
types O
of O
cancer B-Disease

however O
evidence O
has O
been O
accumulating O
that O
frequent O
consumption O
of O
coffee B-Plant
may O
reduce O
risk O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
and O
liver B-Disease
cancer I-Disease

in O
sum O
the O
currently O
available O
evidence O
on O
coffee B-Plant
and O
risk O
of O
cardiovascular B-Disease
diseases I-Disease
and O
cancer B-Disease
is O
largely O
reassuring O
and O
suggests O
that O
for O
the O
general O
population O
addressing O
other O
health O
related O
behaviors O
has O
priority O
for O
the O
prevention O
of O
chronic B-Disease
diasease I-Disease

estrogen O
activities O
and O
the O
cellular O
effects O
of O
natural O
progesterone O
from O
wild O
yam B-Plant
extract O
in O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease

we O
studied O
the O
estrogenic O
activity O
and O
cellular O
effect O
of O
wild O
yam B-Plant
extract O
in O
mcf O
7 O
human O
breast B-Disease
cancer I-Disease

these O
data O
indicate O
that O
wild O
yam B-Plant
extract O
acts O
as O
a O
weak O
phytoestrogen O
and O
protects O
against O
proliferation O
in O
human O
breast B-Disease
carcinoma I-Disease
mcf O
7 O
cells O

relationship O
between O
long O
term O
coffee B-Plant
consumption O
and O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease
the O
amsterdam O
growth O
and O
health O
longitudinal O
study O

it O
is O
known O
that O
the O
risk O
of O
dm B-Disease
ii I-Disease
can O
be O
decreased O
by O
coffee B-Plant
consumption O

therefore O
we O
examined O
the O
association O
between O
coffee B-Plant
consumption O
and O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease

prospective O
data O
from O
the O
amsterdam O
growth O
and O
health O
longitudinal O
study O
agahls O
is O
used O
to O
analyse O
the O
associations O
between O
coffee B-Plant
consumption O
averaged O
over O
a O
period O
from O
27 O
till O
42 O
years O
and O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease
at O
the O
age O
of O
42 O
years O

for O
men O
coffee B-Plant
consumption O
was O
not O
associated O
with O
any O
of O
the O
components O
of O
the O
metabolic B-Disease
syndrome I-Disease

the O
species O
of O
passiflora B-Plant
are O
popularly O
used O
as O
a O
sedative O
or O
tranquillizer O
and O
also O
against O
intermittent O
fever O
and O
skin B-Disease
inflammation I-Disease

in O
this O
study O
we O
evaluated O
the O
anti O
inflammatory O
activity O
of O
four O
sub O
fractions O
and O
three O
isolated O
compounds O
from O
the O
butanolic O
fraction O
of O
p B-Plant
edulis I-Plant
var I-Plant
flavicarpa I-Plant
leaves O
using O
the O
mouse O
model O
of O
pleurisy B-Disease
induced O
by O
carrageenan O

the O
present O
study O
showed O
that O
the O
c O
glucosylflavones O
isolated O
from O
p B-Plant
edulis I-Plant
leaves O
can O
be O
responsible O
for O
the O
anti O
inflammatory O
effect O
of O
p B-Plant
edulis I-Plant
on O
the O
mouse O
model O
of O
pleurisy B-Disease

chinese O
green B-Plant
tea I-Plant
ameliorates O
lung B-Disease
injury I-Disease
in O
cigarette O
smoke O
exposed O
rats O

this O
study O
was O
to O
investigate O
whether O
cigarette O
smoke O
cs O
exposure O
would O
induce O
lung O
morphological O
changes O
and O
oxidative O
stress O
in O
the O
cs O
exposed O
rat O
model O
and O
whether O
chinese O
green O
tea B-Plant
lung O
chen O
tea B-Plant
with O
egcg O
as O
its O
main O
active O
ingredient O
consumption O
would O
alter O
oxidative O
stress O
in O
sera O
and O
lung O
leading O
to O
protection O
of O
cs O
induced O
lung B-Disease
damage I-Disease

results O
airspace O
enlargement O
and O
goblet B-Disease
cell I-Disease
hyperplasia I-Disease
were O
observed O
after O
56 O
day O
cs O
exposure O
alone O
which O
were O
abolished O
in O
the O
presence O
of O
green B-Plant
tea I-Plant
consumption O

chinese O
green B-Plant
tea I-Plant
may O
have O
the O
ability O
to O
suppress O
cs O
induced O
oxidative O
stress O
that O
leads O
to O
protection O
of O
lung B-Disease
injury I-Disease

olive B-Plant
oil O
consumption O
is O
protective O
against O
risk O
factors O
for O
cardiovascular B-Disease
and I-Disease
cancer I-Disease
diseases I-Disease

garlic B-Plant
is O
generally O
used O
as O
a O
therapeutic O
reagent O
against O
various O
diseases O
and O
numerous O
studies O
have O
indicated O
that O
garlic B-Plant
and O
its O
derivatives O
can O
reduce O
the O
risk O
of O
various O
types O
of O
human O
cancer B-Disease

diallyl O
trisulfide O
dats O
a O
major O
member O
of O
garlic B-Plant
derivatives O
could O
inhibit O
the O
cell O
proliferation O
by O
triggering O
either O
cell O
cycle O
arrest O
or O
apoptosis O
in O
a O
variety O
of O
cancer B-Disease
cell O
lines O
as O
shown O
in O
many O
studies O

background O
garlic B-Plant
or O
allium B-Plant
sativum I-Plant
as B-Plant
shows O
therapeutic O
effects O
such O
as O
reduction O
of O
blood O
pressure O
or O
hypercholesterolemia B-Disease
but O
side O
effects O
on O
reproductive O
functions O
remain O
poorly O
investigated O

induction O
of O
apoptosis O
by O
tea B-Plant
polyphenols O
mediated O
through O
mitochondrial O
cell O
death O
pathway O
in O
mouse O
skin B-Disease
tumors I-Disease

in O
the O
present O
study O
cancer B-Disease
chemopreventive O
properties O
of O
both O
black B-Plant
tea I-Plant
polyphenols O
btp O
and O
green B-Plant
tea I-Plant
polyphenols O
gtp O
on O
712 O
dimethylbenz O
a O
anthracene O
dmba O
induced O
mouse O
skin B-Disease
carcinogenesis I-Disease
were O
studied O

thus O
we O
can O
conclude O
that O
the O
polyphenolic O
constituents O
present O
in O
black O
tea O
and O
green B-Plant
tea I-Plant
induce O
mitochondrial O
pathway O
of O
apoptosis O
and O
hence O
can O
be O
used O
as O
a O
potential O
chemopreventive O
agents O
against O
skin B-Disease
cancer I-Disease

background O
consumption O
of O
plantago B-Plant
ovata I-Plant
may O
protect O
against O
colorectal B-Disease
cancer I-Disease

to O
test O
this O
hypothesis O
an O
ecological O
study O
was O
performed O
to O
determine O
mortality O
rates O
and O
distribution O
of O
colorectal B-Disease
cancer I-Disease
and O
the O
consumption O
and O
distribution O
of O
p B-Plant
ovata I-Plant
in O
different O
provinces O
in O
spain O

the O
putative O
association O
between O
p B-Plant
ovata I-Plant
consumption O
and O
mortality O
from O
colorectal B-Disease
cancer I-Disease
was O
then O
evaluated O

results O
consumption O
of O
p B-Plant
ovata I-Plant
tended O
to O
be O
inversely O
correlated O
with O
mortality O
from O
colorectal B-Disease
cancer I-Disease

conclusions O
our O
results O
show O
an O
inverse O
trend O
between O
the O
consumption O
of O
p B-Plant
ovata I-Plant
and O
colorectal B-Disease
cancer I-Disease

neuroprotective O
evaluation O
of O
extract O
of O
ginger O
zingiber B-Plant
officinale I-Plant
root O
in O
monosodium O
glutamate O
induced O
toxicity B-Disease
in O
different O
brain O
areas O
male O
albino O
rats O

in O
this O
study O
the O
neuroprotective O
effect O
of O
the O
extract O
of O
ginger O
zingiber B-Plant
officinale I-Plant
was O
investigated O
against O
msg O
induced O
neurotoxicity B-Disease
of O
male O
albino O
rats O

from O
these O
results O
we O
can O
say O
that O
the O
ginger B-Plant
extract O
has O
a O
neuroprotective O
role O
against O
monosodium O
glutamate O
toxicity B-Disease
effect O

green B-Plant
tea I-Plant
and O
death O
from O
pneumonia B-Disease
in O
japan O
the O
ohsaki O
cohort O
study O

no O
data O
are O
available O
on O
the O
association O
between O
green B-Plant
tea I-Plant
consumption O
and O
the O
risk O
of O
pneumonia B-Disease
in O
humans O

objective O
we O
examined O
the O
association O
between O
green B-Plant
tea I-Plant
consumption O
and O
death O
from O
pneumonia B-Disease
in O
humans O

we O
excluded O
participants O
for O
whom O
data O
on O
green B-Plant
tea I-Plant
consumption O
frequency O
were O
missing O
or O
who O
had O
reported O
a O
history O
of O
cancer O
myocardial B-Disease
infarction I-Disease
stroke B-Disease
and O
extreme O
daily O
energy O
intake O
at O
baseline O

we O
used O
cox O
proportional O
hazards O
regression O
analysis O
to O
calculate O
hazard O
ratios O
hrs O
and O
their O
95 O
cis O
for O
death O
from O
pneumonia B-Disease
according O
to O
green B-Plant
tea I-Plant
consumption O

in O
women O
the O
multivariate O
hrs O
of O
death O
from O
pneumonia B-Disease
that O
were O
associated O
with O
different O
frequencies O
of O
green B-Plant
tea I-Plant
consumption O
were O
100 O
reference O
for O
1 O
cup O
d O
59 O
95 O
ci O
36 O
98 O
for O
1 O
2 O
cups O
d O
55 O
95 O
ci O
33 O
91 O
for O
3 O
4 O
cups O
d O
and O
53 O
95 O
ci O
33 O
83 O
for O
or O
5 O
cups O
respectively O
p O
for O
trend O

conclusion O
green B-Plant
tea I-Plant
consumption O
was O
associated O
with O
a O
lower O
risk O
of O
death O
from O
pneumonia B-Disease
in O
japanese O
women O

recent O
studies O
have O
documented O
a O
role O
for O
stabilized O
rice B-Plant
bran O
srb B-Plant
in O
treating O
diabetes B-Disease
and O
arthritis B-Disease
although O
little O
is O
known O
of O
the O
bioactive O
compounds O
that O
impart O
these O
health O
benefits O

here O
we O
characterize O
the O
chemical O
composition O
of O
three O
extracts O
of O
srb B-Plant
and O
identify O
the O
functional O
bioactives O
contributing O
to O
the O
inhibitory O
properties O
against O
three O
key O
pro O
inflammatory O
enzymes O
cyclooxygenase O
cox O
1 O
cox2 O
and O
5 O
lipoxygenase O
5 O
lox O
that O
control O
the O
inflammatory O
cascade O
involved O
in O
impaired O
joint O
health O
pain B-Disease
and O
arthritis B-Disease

these O
srb B-Plant
extracts O
have O
applications O
for O
functional O
foods O
and O
dietary O
supplements O
for O
control O
of O
inflammation B-Disease
and O
joint O
health O

systematic O
review O
of O
the O
relation O
between O
smokeless O
tobacco B-Plant
and O
cancer B-Disease
in O
europe O
and O
north O
america O

background O
interest O
is O
rising O
in O
smokeless O
tobacco B-Plant
as O
a O
safer O
alternative O
to O
smoking O
but O
published O
reviews O
on O
smokeless O
tobacco B-Plant
and O
cancer B-Disease
are O
limited O

methods O
we O
obtained O
papers O
from O
medline O
searches O
published O
reviews O
and O
secondary O
references O
describing O
epidemiological O
cohort O
and O
case O
control O
studies O
relating O
any O
form O
of O
cancer B-Disease
to O
smokeless O
tobacco B-Plant
use O

for O
each O
study O
details O
were O
abstracted O
on O
design O
smokeless O
tobacco B-Plant
exposure O
cancers B-Disease
studied O
analysis O
methods O
and O
adjustment O
for O
smoking O
and O
other O
factors O

for O
seven O
cancers B-Disease
smoking O
attributable O
deaths O
in O
us O
men O
in O
2005 O
were O
compared O
with O
deaths O
attributable O
to O
introducing O
smokeless O
tobacco B-Plant
into O
a O
population O
of O
never O
smoking O

some O
meta O
analyses O
suggest O
a O
possible O
effect O
for O
oesophagus B-Disease
pancreas B-Disease
larynx B-Disease
and O
kidney B-Disease
cancer I-Disease
but O
other O
cancers B-Disease
show O
no O
effect O
of O
smokeless O
tobacco B-Plant

conclusion O
an O
increased O
risk O
of O
oropharyngeal B-Disease
cancer I-Disease
is O
evident O
most O
clearly O
for O
past O
smokeless O
tobacco B-Plant
use O
in O
the O
usa O
but O
not O
for O
scandinavian O
nuff O

effects O
of O
smokeless O
tobacco B-Plant
use O
on O
other O
cancers B-Disease
are O
not O
clearly O
demonstrated O

antitumor O
effects O
of O
a O
water O
soluble O
extract O
from O
maitake B-Plant
grifola O
frondosa O
on O
human O
gastric B-Disease
cancer I-Disease
cell O
lines O

we O
investigated O
the O
effects O
of O
a O
water O
soluble O
extract O
of O
maitake B-Plant
grifola B-Plant
frondosa I-Plant
a O
japanese O
edible O
mushroom B-Plant
on O
the O
proliferation O
and O
cell O
death O
of O
four O
human O
gastric B-Disease
cancer I-Disease
cell O
lines O
tmk O
1 O
mkn28 O
mkn45 O
and O
mkn74 O

taken O
together O
these O
results O
suggest O
that O
me B-Plant
induces O
apoptosis O
of O
tmk O
1 O
cells O
by O
caspase O
3 O
dependent O
and O
independent O
pathways O
resulting O
in O
potential O
antitumor O
effects O
on O
ena O
me B-Plant
x O
gastric B-Disease
cancer I-Disease

coffee B-Plant
intake O
is O
associated O
with O
lower O
rates O
of O
liver O
disease O
progression O
in O
chronic B-Disease
hepatitis I-Disease
c I-Disease

higher O
coffee B-Plant
consumption O
has O
been O
associated O
inversely O
with O
the O
incidence O
of O
chronic B-Disease
liver I-Disease
disease I-Disease
in O
population O
studies O

we O
examined O
the O
relationship O
of O
coffee B-Plant
consumption O
with O
liver B-Disease
disease I-Disease
progression O
in O
individuals O
with O
advanced O
hepatitis B-Disease
c I-Disease
related O
liver B-Disease
disease I-Disease

baseline O
coffee B-Plant
and O
tea B-Plant
intake O
were O
assessed O
in O
766 O
participants O
of O
the O
hepatitis B-Disease
c I-Disease
antiviral O
long O
term O
treatment O
against O
cirrhosis O
halt O
c O
trial O
who O
had O
hepatitis B-Disease
c I-Disease
related O
bridging O
fibrosis B-Disease
or O
cirrhosis O
on O
liver O
biopsy O
and O
failed O
to O
achieve O
a O
sustained O
virological O
response O
to O
peginterferon O
plus O
ribavirin O
treatment O

at O
baseline O
higher O
coffee B-Plant
consumption O
was O
associated O
with O
less O
severe O
steatosis B-Disease
on O
biopsy O
lower O
serum O
aspartate O
aminotransferase O
ast O
alanine O
aminotransferase O
alt O
ratio O
alpha O
fetoprotein O
insulin O
and O
homeostatic O
model O
assessment O
homa2 O
score O
and O
higher O
albumin O
p O
5 O
for O
all O

conclusion O
in O
a O
large O
prospective O
study O
of O
participants O
with O
advanced O
hepatitis B-Disease
c I-Disease
related O
liver B-Disease
disease I-Disease
regular O
coffee B-Plant
consumption O
was O
associated O
with O
lower O
rates O
of O
disease O
progression O

hawthorn B-Plant
extract O
reduces O
infarct B-Disease
volume O
and O
improves O
neurological O
score O
by O
reducing O
oxidative O
stress O
in O
rat O
brain O
following O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion I-Disease

in O
our O
present O
investigation O
the O
neuroprotective O
effect O
of O
alcoholic O
extract O
of O
hawthorn B-Plant
crataegus B-Plant
oxycantha I-Plant
was O
evaluated O
against O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion O
induced O
ischemia B-Disease
reperfusion I-Disease
injury I-Disease
in O
rats O

conclusion O
our O
results O
suggest O
that O
hawthorn B-Plant
extract O
which O
is O
a O
well O
known O
prophylactic O
for O
cardiac O
conditions O
may O
very O
well O
protect O
the O
brain O
against O
ischemia B-Disease
reperfusion I-Disease

the O
reduced O
brain B-Disease
damage I-Disease
and O
improved O
neurological O
behavior O
after O
24 O
h O
of O
reperfusion B-Disease
in O
hawthorn B-Plant
extract O
pretreated O
group O
may O
be O
attributed O
to O
its O
antioxidant O
property O
which O
restores O
glutathione O
levels O
circumvents O
the O
increase O
in O
lipid O
peroxidation O
and O
nitric O
oxide O
levels O
thereby O
reducing O
peroxynitrite O
formation O
and O
free O
radical O
induced O
brain B-Disease
damage I-Disease

the O
mediterranean O
diet O
in O
which O
olive B-Plant
oil O
is O
the O
primary O
source O
of O
fat O
is O
associated O
with O
a O
low O
mortality O
for O
cardiovascular B-Disease
disease I-Disease

data O
concerning O
olive B-Plant
oil O
consumption O
and O
primary O
end O
points O
for O
cardiovascular B-Disease
disease I-Disease
are O
scarce O

the O
wide O
range O
of O
benefits O
associated O
with O
olive B-Plant
oil O
consumption O
could O
contribute O
to O
explaining O
the O
low O
rate O
of O
cardiovascular B-Disease
mortality I-Disease
found O
in O
southern O
european O
mediterranean O
countries O
in O
comparison O
with O
other O
westernized O
countries O
despite O
a O
high O
prevalence O
of O
coronary B-Disease
heart I-Disease
disease I-Disease
risk O
factors O

effective O
tobacco B-Plant
control O
efforts O
have O
resulted O
in O
substantial O
declines O
in O
tobacco B-Plant
use O
and O
tobacco B-Plant
related O
cancer B-Disease
deaths O
in O
the O
united O
states O

clinical O
observation O
on O
therapeutic O
effect O
of O
combination O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
for O
treatment O
of O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease

objective O
to O
compare O
the O
therapeutic O
effect O
of O
the O
combined O
method O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
with O
that O
of O
routine O
western O
medicine O
on O
the O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease

conclusion O
the O
therapeutic O
effect O
of O
the O
combined O
method O
of O
acupuncture O
and O
ginger B-Plant
partition O
moxibustion O
on O
the O
patients O
with O
cardiac B-Disease
arrhythmia I-Disease
is O
obviously O
better O
than O
that O
of O
routine O
western O
medicine O

confronting O
a O
neglected O
epidemic O
tobacco B-Plant
cessation O
for O
persons O
with O
mental B-Disease
illnesses I-Disease
and O
substance B-Disease
abuse I-Disease
problems I-Disease
tobacco B-Plant
use O
exerts O
a O
huge O
toll O
on O
persons O
with O
mental B-Disease
illnesses I-Disease
and O
substance B-Disease
abuse I-Disease
disorders I-Disease
accounting O
for O

200000 O
of O
the O
annual O
443 O
0 O
annual O
tobacco B-Plant
related O
deaths O
in O
the O
united O
states O

hypolipidemic O
effect O
of O
ginger B-Plant
in O
12 O
dimethyl O
hydrazine O
induced O
experimental O
colon B-Disease
carcinogenesis I-Disease

in O
our O
laboratory O
we O
studied O
the O
chemopreventive O
and O
hypolipidemic O
effect O
of O
ginger B-Plant
a O
dietary O
spice O
in O
12 O
dimethylhydrazine O
dmh O
induced O
colon B-Disease
cancer I-Disease

ginger B-Plant
50 O
mg O
kg O
body O
weight O
po O
was O
given O
at O
the O
initiation O
and O
also O
at O
the O
postinitiation O
stages O
of O
carcinogenesis B-Disease

on O
administering O
ginger B-Plant
at O
the O
initiation O
and O
also O
at O
the O
postinitiation O
stages O
of O
colon B-Disease
carcinogenesis I-Disease
the O
levels O
of O
fecal O
bile O
acids O
neutral O
sterols O
tissue O
cholesterol O
hmg O
coa O
reductase O
free O
fatty O
acids O
triglycerides O
phospholipase O
a O
and O
phospholipase O
c O
were O
significantly O
decreased O
whereas O
the O
levels O
of O
phospholipids O
were O
increased O
as O
compared O
to O
unsupplemented O
dmh O
treated O
rats O

thus O
ginger B-Plant
supplementation O
was O
found O
to O
reduce O
the O
risk O
of O
colon B-Disease
cancer I-Disease
markedly O
by O
virtue O
of O
its O
hypolipidemic O
and O
antioxidative O
effects O

aloe B-Plant
emodin O
induces O
cell O
death O
through O
phase O
arrest O
and O
caspase O
dependent O
pathways O
in O
human O
tongue B-Disease
squamous I-Disease
cancer B-Disease
scc O
4 O
cells O
lines O

aloe B-Plant
emodin O
promoted O
the O
release O
of O
apoptosis O
inducing O
factor O
aif O
endonuclease O
g O
endo O
g O
pro O
caspase O
9 O
and O
cytochrome O
c O
from O
the O
mitochondria O
via O
a O
loss O
of O
the O
mitochondrial O
membrane O
potential O
deltapsi O
m O
which O
was O
associated O
with O
a O
increase O
in O
the O
ratio O
of O
b B-Disease
cell I-Disease
lymphoma I-Disease
2 O
associated O
x O
protein O
bax O
b O
cell O
lymphoma B-Disease
leukemia B-Disease
2 O
bcl O
2 O
and O
activation O
of O
caspase O
9 O
and O
3 O

aloe B-Plant
emodin O
could O
be O
a O
novel O
chemotherapeutic O
drug O
candidate O
for O
the O
treatment O
of O
human O
tongue B-Disease
squamous I-Disease
cancer I-Disease
in O
the O
future O

mutagen O
sensitivity O
tobacco B-Plant
smoking O
and O
breast B-Disease
cancer I-Disease
risk O
a O
case O
control O
study O

the O
mutagen O
sensitivity O
assay O
msa O
a O
phenotypic O
marker O
of O
dna O
damage O
response O
and O
repair O
capacity O
has O
been O
consistently O
shown O
to O
associate O
with O
the O
risk O
of O
tobacco B-Plant
related O
cancers B-Disease

our O
data O
also O
suggest O
that O
bleomycin O
sensitivity O
may O
modulate O
the O
effect O
of O
tobacco B-Plant
smoking O
on O
breast B-Disease
cancer I-Disease
risk O

among O
women O
with O
hypersensitivity O
to O
bleomycin O
ever O
smokers O
had O
a O
16 O
fold O
increased O
risk O
of O
breast B-Disease
cancer I-Disease
for O
interaction O
between O
tobacco B-Plant
smoking O
and O
bleomycin O
sensitivity O

our O
observation O
that O
the O
effect O
of O
tobacco B-Plant
smoking O
on O
breast B-Disease
cancer I-Disease
risk O
may O
differ O
based O
on O
mutagen O
sensitivity O
status O
warrants O
further O
investigation O

further O
associations O
between O
almond B-Plant
oil O
and O
improved O
bowel O
transit O
have O
been O
made O
which O
consequently O
reduces O
irritable B-Disease
bowel I-Disease
syndrome I-Disease
symptoms O

historically O
almond B-Plant
oil O
had O
been O
used O
in O
ancient O
chinese O
ayurvedic O
and O
greco O
persian O
schools O
of O
medicine O
to O
treat O
dry O
skin O
conditions O
such O
as O
psoriasis B-Disease
and O
eczema B-Disease

further O
it O
is O
through O
anecdotal O
evidence O
and O
clinical O
experiences O
that O
almond B-Plant
oil O
seemingly O
reduces O
hypertrophic B-Disease
scarring O
post O
operatively O
smoothes O
and O
rejuvenates O
skin O

a O
lipid O
soluble O
red O
ginseng B-Plant
extract O
inhibits O
the O
growth O
of O
human O
lung B-Disease
tumor I-Disease
xenografts O
in O
nude O
mice O

balb O
c O
nu O
mice O
were O
inoculated O
with O
human O
lung B-Disease
cancer I-Disease
nci O
h460 O
cells O
to O
establish O
a O
human O
tumor B-Disease
xenograft O
model O
in O
nude O
mice O
and O
the O
lipid O
soluble O
ginseng B-Plant
extract O
was O
orally O
administered O

the O
tumor B-Disease
inhibitory O
rates O
of O
the O
lipid O
soluble O
ginseng B-Plant
extract O
at O
doses O
of O
1 O
3 O
and O
10 O
g O
kg O
day O
were O
189 O
p O
5 O
600 O
p O
1 O
and O
675 O
p O
1 O
respectively O

the O
oral O
administration O
of O
the O
lipid O
soluble O
extract O
of O
red O
ginseng B-Plant
showed O
a O
potent O
anticancer O
effect O
in O
nude O
mice O
bearing O
human O
lung B-Disease
cancer I-Disease
cells O
in O
a O
dose O
dependent O
manner O
without O
any O
apparent O
toxicity B-Disease

this O
lipid O
soluble O
ginseng B-Plant
extract O
is O
a O
potential O
nontoxic O
anticancer O
supplement O
for O
the O
prevention O
and O
intervention O
of O
lung B-Disease
tumor I-Disease
growth O
through O
an O
oral O
administration O
route O

epidemiological O
data O
suggest O
that O
consumption O
of O
coffee B-Plant
and O
tea B-Plant
is O
associated O
with O
a O
reduced O
risk O
of O
several O
chronic O
and O
degenerative B-Disease
diseases I-Disease
including O
cardiovascular B-Disease
disorders I-Disease
diabetes B-Disease
obesity B-Disease
and O
neurodegenerative B-Disease
disorder I-Disease

cancer B-Disease
chemoprevention O
by O
pomegranate B-Plant
laboratory O
and O
clinical O
evidence O

recent O
research O
has O
shown O
that O
pomegranate B-Plant
extracts O
selectively O
inhibit O
the O
growth O
of O
breast B-Disease
prostate B-Disease
colon B-Disease
and O
lung B-Disease
cancer I-Disease
cells O
in O
culture O

in O
preclinical O
animal O
studies O
oral O
consumption O
of O
pomegranate B-Plant
extract O
inhibited O
growth O
of O
lung B-Disease
skin B-Disease
colon B-Disease
and O
prostate B-Disease
tumors I-Disease

an O
initial O
phase O
ii O
clinical O
trial O
of O
pomegranate B-Plant
juice O
in O
patients O
with O
prostate B-Disease
cancer I-Disease
reported O
significant O
prolongation O
of O
prostate O
specific O
antigen O
doubling O
time O

this O
review O
focuses O
on O
recent O
investigations O
into O
the O
effects O
of O
pomegranate B-Plant
fruit I-Plant
on O
cancer B-Disease

caffeine O
and O
coffee B-Plant
as O
therapeutics O
against O
alzheimers B-Disease
disease I-Disease

epidemiologic O
studies O
have O
increasingly O
suggested O
that O
caffeine O
coffee B-Plant
could O
be O
an O
effective O
therapeutic O
against O
alzheimer B-Disease
disease I-Disease
ad B-Disease

we O
have O
utilized O
a O
transgenic O
mouse O
model O
for O
ad B-Disease
in O
well O
controlled O
studies O
to O
determine O
if O
caffeine O
and O
or O
coffee B-Plant
have O
beneficial O
actions O
to O
protect O
against O
or O
reverse O
ad B-Disease
like O
cognitive O
impairment O
and O
ad B-Disease
pathology O

caffeinated O
coffee B-Plant
provided O
to O
ad B-Disease
mice O
also O
quickly O
decreased O
plasma O
abeta O
levels O
but O
not O
decaffeinated O
coffee B-Plant
suggesting O
that O
caffeine O
is O
critical O
to O
decreasing O
blood O
abeta O
level O

these O
results O
indicate O
a O
surprising O
ability O
of O
moderate O
caffeine O
intake O
the O
human O
equivalent O
of O
500 O
mg O
caffeine O
or O
5 O
cups O
of O
coffee B-Plant
per O
day O
to O
protect O
against O
or O
treat O
ad B-Disease
in O
a O
mouse O
model O
for O
the O
disease O
and O
a O
therapeutic O
potential O
for O
caffeine O
against O
ad B-Disease
in O
humans O

protective O
effects O
of O
nigella B-Plant
sativa I-Plant
on O
intestinal B-Disease
ischemia O
reperfusion I-Disease
injury I-Disease
in O
rats O

background O
in O
previous O
studies O
it O
has O
been O
demonstrated O
that O
nigella B-Plant
sativa I-Plant
ns B-Plant
has O
protective O
effects O
against O
ischemia B-Disease
reperfusion I-Disease
injury I-Disease
on O
various O
organs O

we O
aimed O
to O
determine O
whether O
ns B-Plant
prevents O
intestinal B-Disease
ischemia O
reperfusion I-Disease
injury I-Disease
in O
rats O

rats O
in O
the O
group O
3 O
received O
ns B-Plant
2 O
ml O
kg O
intraperitoneally O
before O
ischemia B-Disease
and O
before O
reperfusion O

conclusion O
our O
results O
suggest O
that O
ns B-Plant
treatment O
protected O
the O
rats O
intestinal O
tissue O
against O
intestinal B-Disease
ischemia I-Disease
reperfusion I-Disease
injury I-Disease

introduction O
garlic B-Plant
allium B-Plant
sativum I-Plant
traditionally O
being O
used O
as O
a O
spice O
worldwide O
has O
different O
applications O
and O
is O
claimed O
to O
possess O
beneficial O
effects O
in O
several O
health O
ailments O
such O
as O
tumor B-Disease
and O
atherosclerosis B-Disease

cytotoxicity B-Disease
of O
macrophages O
supernatant O
on O
wehi O
164 O
fibrosarcoma B-Disease
cells I-Disease
was O
not O
affected O
by O
garlic B-Plant
protein O
fractions O
p O
66 O
for O
14 O
kda O
and O
p O
85 O
for O
47 O
kda O
fraction O

study O
on O
antiinflammatory O
effect O
of O
different O
chemotype O
of O
cinnamomum B-Plant
camphora I-Plant
on O
rat O
arthritis B-Disease
model O
induced O
by O
freunds O
adjuvant O

objective O
to O
study O
the O
antiinflammatory O
effects O
of O
naphtha O
from O
different O
chemotypes O
of O
cinnamomum B-Plant
camphora I-Plant
and O
natural O
borneol O
on O
the O
rat O
arthritis B-Disease
model O
induced O
by O
freunds O

a O
population O
based O
twin O
study O
of O
the O
genetic O
and O
environmental O
relationship O
of O
major B-Disease
depression I-Disease
regular O
tobacco B-Plant
use O
and O
nicotine B-Disease
dependence I-Disease

background O
numerous O
epidemiological O
studies O
have O
reported O
a O
positive O
association O
between O
major O
depression O
md O
and O
regular O
tobacco B-Plant
use O
ru O
or O
nicotine B-Disease
dependence I-Disease
nd B-Disease

method O
we O
assessed O
md B-Disease
ru B-Plant
and O
nd B-Disease
in O
same O
sex O
twins O
from O
the O
population O
based O
swedish O
twin O
registry O

we O
used O
structural O
equation O
modeling O
to O
examine O
the O
relationship O
between O
md B-Disease
ru B-Plant
and O
nd B-Disease
given O
ru B-Plant

results O
the O
results O
suggest O
modest O
correlations O
between O
md B-Disease
and O
ru B-Plant
and O
between O
md B-Disease
and O
nd B-Disease

in O
males O
the O
liability O
shared O
between O
md B-Disease
and O
ru B-Plant
is O
solely O
genetic O
for O
both O
cigarettes O
and O
snus O
while O
md B-Disease
and O
nd B-Disease
share O
both O
genetic O
and O
unique O
environmental O
influences O

the O
continuation O
to O
nd B-Disease
given O
ru B-Plant
differed O
considerably O
between O
cigarette O
and O
snus O
users O

in O
females O
both O
md B-Disease
ru B-Plant
and O
md B-Disease
nd B-Disease
relationships O
are O
partially O
attributable O
to O
genetic O
and O
unique O
environmental O
correlations O

onclusions O
the O
relationship O
among O
md O
ru B-Plant
and O
nd B-Disease
is O
at O
least O
partially O
attributable O
to O
shared O
genetic O
and O
environmental O
risk O
factors O

in O
this O
study O
we O
assessed O
the O
anti O
arthritic O
effects O
of O
red O
ginseng B-Plant
saponin O
extract O
rgse B-Plant
including O
ginsenosides O
rg3 O
rk1 O
and O
rg5 O
as O
major O
components O
on O
a O
murine O
type O
ii O
collagen O
cii O
induced O
arthritis B-Disease
cia B-Disease
which O
is O
a O
valid O
animal O
model O
of O
human O

arthritis B-Disease
oral O
administration O
of O
rgse B-Plant
at O
10 O
mg O
kg O
reduced O
the O
clinical O
arthritis B-Disease
score O
and O
paw O
swelling O
in O
the O
cia B-Disease
mice O
and O
inhibited O
joint O
space O
narrowing O
and O
histological O
arthritis B-Disease
illustrating O
the O
severity O
of O
synovial B-Disease
hyperplasia I-Disease
inflammatory B-Disease
cell B-Disease
infiltration B-Disease
pannus O
formation O
and O
erosion B-Disease
of O
cartilage I-Disease

rgse B-Plant
inhibited O
the O
expression O
of O
matrix O
metalloproteinase O
3 O
and O
nitrotyrosine O
formation O
and O
recovered O
the O
expression O
of O
superoxide O
dismutase O
in O
the O
joints O
of O
the O
cia B-Disease
mice O

orally O
administered O
rgse B-Plant
also O
reduced O
the O
levels O
of O
serum O
tumor O
necrosis O
factor O
alpha O
and O
interleukin O
1beta O
in O
the O
cia B-Disease

mice O
cii O
or O
lipopolysaccharide O
stimulated O
cytokine O
production O
in O
addition O
to O
cii O
specific O
proliferation O
was O
reduced O
in O
the O
spleen O
cells O
of O
the O
rgse B-Plant
treated O
cia B-Disease
mice O
as O
compared O
with O
those O
from O
vehicle O
treated O
cia B-Disease
mice O

krg B-Plant
treatment O
reversed O
abnormal B-Disease
locomotor I-Disease
activity I-Disease
and O
sensitivity O
to O
electric O
shock O
to O
control O
level O

in O
vivo O
prophylactic O
effects O
of O
oleanolic O
acid O
isolated O
from O
chloroform O
extract O
of O
flaveria B-Plant
trinervia I-Plant
against O
ethanol O
induced O
liver B-Disease
toxicity I-Disease
in O
rats O

the O
prophylactic O
effects O
of O
oleanolic O
acid O
oa O
isolated O
from O
chloroform O
extract O
ce O
of O
flaveria B-Plant
trinervia I-Plant
against O
ethanol O
induced O
liver B-Disease
toxicity I-Disease
was O
investigated O
using O
rats O

interpretation O
our O
data O
confirmed O
the O
north O
west O
to O
south O
east O
europe O
gradient O
of O
increasing O
incidence O
and O
mortality O
rates O
of O
tobacco B-Plant
related O
cancers B-Disease
as O
well O
as O
increasing O
mortality O
rates O
of O
screen O
detectable O
cancers B-Disease

nhibitory O
effects O
of O
onion O
allium B-Plant
cepa I-Plant
l I-Plant
extract O
on O
proliferation O
of O
cancer B-Disease
cells O
and O
adipocytes O
via O
inhibiting O
fatty O
acid O
synthase O

our O
studies O
showed O
that O
ethyl O
acetate O
extract O
of O
onion B-Plant
eeo B-Plant
had O
potent O
inhibitory O
effects O
on O
animal O
fatty O
acid O
synthase O
fas O
and O
could O
induce O
apoptosis O
in O
fas O
over O
expressing O
human O
breast B-Disease
cancer I-Disease
mda O
cells O

since O
obesity B-Disease
is O
closely O
related O
to O
breast B-Disease
cancer I-Disease
and O
obese B-Disease
patients O
are O
at O
elevated O
risk O
of O
developing O
various O
cancers B-Disease
these O
findings O
suggested O
that O
onion B-Plant
might O
be O
useful O
for O
preventing O
obesity B-Disease
related O
malignancy B-Disease

20 O
glucopyranosyl O
20 O
protopanaxadiol O
a O
metabolite O
of O
ginseng B-Plant
inhibits O
colon B-Disease
cancer I-Disease
growth O
by O
targeting O
trpc O
channel O
mediated O
calcium O
influx O

here O
we O
show O
that O
20 O
glucopyranosyl O
20 O
protopanaxadiol O
20 O
gppd O
a O
metabolite O
of O
ginseng B-Plant
saponin O
causes O
apoptosis O
of O
colon B-Disease
cancer I-Disease
cells O
through O
the O
induction O
of O
cytoplasmic O
ca O

inonotus B-Plant
obliquus I-Plant
is O
a O
medicinal O
mushroom B-Plant
used O
in O
russian O
and O
eastern O
european O
folk O
medicine O
for O
the O
treatment O
of O
gastrointestinal B-Disease
cancer I-Disease
cardiovascular B-Disease
disease I-Disease
and O
diabetes B-Disease

previous O
studies O
in O
our O
laboratory O
have O
demonstrated O
that O
the O
mycelium O
powders O
of O
i B-Plant
obliquus I-Plant
possess O
significant O
antihyperglycemic O
effects O
in O
a O
mouse O
model O
of O
diabetic B-Disease
disease I-Disease
induced O
by O
alloxan O

this O
study O
aims O
to O
identify O
the O
active O
ingredients O
of O
i B-Plant
obliquus I-Plant
mycelium O
powders O
by O
a O
bioassay O
guided O
fractionation O
approach O
and O
explore O
the O
mechanism O
of O
action O
of O
these O
active O
ingredients O
by O
using O
a O
well O
established O
dpp O
4 O
an O
important O
enzyme O
as O
a O
new O
therapeutic O
target O
for O
diabetes B-Disease
inhibitory O
assay O
model O

gardenia B-Plant
jasminoides I-Plant
attenuates O
hepatocellular B-Disease
injury O
and O
fibrosis B-Disease
in O
bile O
duct O
ligated O
rats O
and O
human O
hepatic O
stellate O
cells O

aim O
to O
investigate O
the O
anti O
hepatofibrotic O
effects O
of O
gardenia B-Plant
jasminoides I-Plant
in O
liver B-Disease
fibrosis I-Disease

the O
effects O
of O
gardenia B-Plant
jasminoides I-Plant
on O
liver B-Disease
fibrosis I-Disease
and O
the O
detailed O
molecular O
mechanisms O
were O
also O
assessed O
in O
human O
hepatic O
stellate O
cells O
lx O
2 O
in O

conclusion O
gardenia B-Plant
jasminoides I-Plant
exerts O
antifibrotic O
effects O
in O
the O
liver B-Disease
fibrosis I-Disease
and O
may O
represent O
a O
novel O
antifibrotic O
agent O

secnidazole O
was O
89 O
5 O
effective O
for O
the O
treatment O
of O
equine O
balantidiasis B-Disease
compared O
to O
40 O
0 O
for O
nigella B-Plant
sativa I-Plant

tea B-Plant
and O
coffee B-Plant
consumption O
and O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
results O
of O
a O
large O
population O
based O
case O
control O
study O
the O
icare O
study O

background O
results O
on O
the O
relationship O
between O
coffee B-Plant
and O
tea O
drinking O
and O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
are O
contrasted O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relation O
between O
coffee B-Plant
and O
tea B-Plant
drinking O
and O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
in O
france O
a O
high O
incidence O
area O

results O
we O
observed O
inverse O
associations O
between O
oral B-Disease
cavity I-Disease
cancer I-Disease
and O
tea B-Plant
or O
coffee B-Plant
consumption O
odds O
ratio O
39 O
95 O
ci O
21 O
70 O
for O
the O
highest O
quartile O
of O
tea B-Plant
consumption O
and O
60 O
95 O
ci O
34 O
105 O
for O
the O
highest O
quartile O
of O
coffee B-Plant
consumption O

exclusive O
tea B-Plant
or O
coffee B-Plant
consumption O
was O
associated O
with O
a O
reduced O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
and O
their O
joint O
effect O
was O
multiplicative O

conclusions O
tea B-Plant
and O
coffee B-Plant
drinking O
may O
decrease O
the O
risk O
of O
oral B-Disease
cavity I-Disease
cancer I-Disease
through O
antioxidant O
components O
which O
play O
a O
role O
in O
the O
repair O
of O
cellular O
damages O

scope O
the O
molecular O
mechanisms O
underlying O
the O
potential O
health O
benefit O
effects O
of O
soybean B-Plant
proteins O
on O
obesity B-Disease
associated O
metabolic B-Disease
disorders I-Disease
have O
not O
been O
fully O
clarified O

these O
effects O
of O
sph O
might O
be O
important O
for O
the O
health O
benefit O
effects O
of O
soybean B-Plant
proteins O
on O
obesity B-Disease
associated O
metabolic B-Disease
disorders I-Disease

cardioprotective O
effects O
of O
sour B-Plant
cherry I-Plant
seed O
extract O
scse B-Plant
on O
the O
hypercholesterolemic B-Disease
rabbit O
heart O

hypothesis O
the O
present O
study O
evaluates O
the O
hypothesis O
that O
sour B-Plant
cherry I-Plant
seed O
extract O
scse B-Plant
protects O
against O
cardiovascular B-Disease
disease I-Disease
and O
inflammation B-Disease
in O
hypercholesterolemic B-Disease
rabbits O
and O
that O
this O
protection O
correlates O
with O
scse B-Plant
induced O
activity O
of O
heme O
oxygenase O
1 O
ho O
1 O
a O
cytoprotective O
enzyme O
contributing O
to O
oxidative O
stress O
responses O

results O
relative O
to O
cholesterol O
treated O
animals O
not O
receiving O
scse B-Plant
scse B-Plant
treated O
animals O
exhibited O
significantly O
improved O
cardiac O
function O
and O
improved O
peak O
early O
diastolic O
velocity O
to O
peak O
atrial O
velocity O
ratio O
along O
with O
decreased O
atherosclerotic B-Disease
plaque I-Disease
formation O
and O
infarct B-Disease
size O

coffee B-Plant
consumption O
delays O
the O
hepatitis B-Disease
and O
suppresses O
the O
inflammation B-Disease
related O
gene O
expression O
in O
the O
long O
evans O
cinnamon O
rat O

background O
and O
aims O
large O
scale O
epidemiological O
studies O
have O
shown O
that O
drinking O
more O
than O
two O
cups O
of O
coffee B-Plant
per O
day O
reduces O
the O
risks O
of O
hepatitis B-Disease
and O
liver B-Disease
disease I-Disease

however O
the O
heterogeneity O
of O
the O
human O
genome O
requires O
studies O
of O
experimental O
animal O
models O
with O
defined O
genetic O
backgrounds O
to O
evaluate O
the O
coffee B-Plant
effects O
on O
liver B-Disease
diseases I-Disease

results O
coffee B-Plant
administration O
for O
25 O
weeks O
delayed O
the O
occurrence O
of O
hepatitis B-Disease
by O
two O
weeks O
significantly O
improved O
survival O
reduced O
the O
expression O
of O
inflammatory O
cytokines O
and O
reduced O
the O
incidence O
of O
small O
pre O
neoplastic O
liver O
foci O
in O
lec O
rats O

these O
findings O
indicate O
that O
drinking O
coffee B-Plant
potentially O
prevents O
hepatitis B-Disease
and O
liver B-Disease
carcinogenesis I-Disease
through O
its O
anti O
inflammatory O
effects O

conclusion O
this O
study O
showed O
the O
efficacy O
of O
coffee B-Plant
in O
the O
prevention O
of O
hepatitis B-Disease
and O
liver B-Disease
carcinogenesis I-Disease
in O
the O
lec O
model O

tobacco B-Plant
related O
cancer B-Disease
mortality O
projections O
for O
different O
geographical O
regions O
in O
switzerland O

this O
study O
aimed O
to O
project O
gender O
specific O
tobacco B-Plant
related O
cancer B-Disease
mortality O
in O
switzerland O
at O
different O
geographical O
levels O
for O
the O
periods O
2009 O
2013 O
and O
2014 O
2018 O

methods O
in O
this O
analysis O
data O
on O
swiss O
tobacco B-Plant
related O
cancer B-Disease
mortality O
from O
1984 O
until O
2008 O
were O
used O

bayesian O
age O
period O
cohort O
models O
were O
formulated O
to O
assess O
past O
trends O
of O
gender O
specific O
tobacco B-Plant
related O
cancer B-Disease
mortality O
and O
to O
project O
them O
up O
to O
2018 O
at O
cantonal O
and O
language O
region O
levels O

results O
model O
based O
estimates O
at O
cantonal O
level O
identified O
regions O
with O
low O
and O
high O
tobacco B-Plant
related O
cancer B-Disease
mortality O
rates O
for O
the O
observed O
and O
projected O
periods O

the O
gap O
in O
tobacco B-Plant
related O
cancer B-Disease
mortality O
rates O
between O
younger O
and O
older O
males O
seems O
to O
be O
shrinking O

conclusion O
our O
findings O
indicate O
region O
sex O
and O
age O
related O
differences O
in O
tobacco B-Plant
related O
cancer B-Disease
mortality O
in O
switzerland O
and O
this O
could O
be O
useful O
for O
healthcare O
planning O
and O
for O
evaluating O
the O
impact O
of O
canton O
specific O
tobacco B-Plant
related O
policies O
and O
interventions O

gliadin O
from O
wheat B-Plant
is O
a O
common O
food O
allergen O
that O
can O
induce O
baker O
asthma B-Disease
wheat B-Plant
dependent O
exercise O
induced O
anaphylaxis B-Disease
atopic B-Disease
dermatitis I-Disease
and O
celiac B-Disease
disease I-Disease

the O
increased O
risk O
is O
mainly O
expected O
to O
be O
observed O
in O
tobacco B-Plant
related O
tumours B-Disease
among O
women O
and O
in O
colorectal B-Disease
and O
liver B-Disease
cancers I-Disease
among O
men O

many O
epidemiological O
studies O
have O
indicated O
that O
coffee B-Plant
consumption O
may O
reduce O
the O
risks O
of O
developing O
obesity B-Disease
and O
diabetes B-Disease
but O
the O
underlying O
mechanisms O
of O
these O
effects O
are O
poorly O
understood O

this O
mechanism O
may O
play O
an O
important O
part O
in O
the O
suppressive O
effects O
of O
coffee B-Plant
consumption O
on O
obesity O
inflammation B-Disease
and O
hepatosteatosis B-Disease

this O
study O
newly O
revealed O
global O
metabolic O
alterations O
induced O
by O
coffee B-Plant
intake O
providing O
significant O
insights O
into O
the O
association O
between O
coffee B-Plant
intake O
and O
the O
prevention O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
utilizing O
the O
benefits O
of O
multi O
omics O
analyses O

effect O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
extract O
and O
magnesium O
supplementation O
alone O
and O
in O
combination O
on O
osteogenic O
and O
angiogenic O
factors B-Disease
and O
fracture B-Disease
healing O
in O
women O
with O
long O
bone O
fracture B-Disease

background O
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
the O
combination O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
extract O
as O
a O
source O
of O
phytoestrogens O
plus O
magnesium O
supplementation O
on O
osteogenic O
and O
angiogenic O
factors O
and O
callus O
formation O
in O
women O
with O
long O
bone B-Disease
fracture I-Disease

material O
and O
methods O
in O
a O
double O
blind O
randomized O
placebo O
controlled O
trial O
64 O
women O
with O
long O
bone B-Disease
fracture I-Disease
20 O
45 O
years O
old O
were O
randomly O
allocated O
to O
receive O
1 O
one O
agnugol O
tablet O
4 O
mg O
dried O
fruit O
extract O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
plus O
250 O
mg O
magnesium O
oxide O
vac O
mg O
group O
n O
10 O
2 O
one O
agnugol O
tablet O
plus O
placebo O
vac O
group O
n O
15 O
3 O
placebo O
plus O
250 O
mg O
magnesium O
oxide O
mg O
group O
n O
12 O
or O
4 O
placebo O
plus O
placebo O
placebo O
group O
n O
14 O
per O
day O
for O
8 O
weeks O

conclusion O
our O
results O
suggest O
that O
administration O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
plus O
magnesium O
may O
promote O
fracture B-Disease
healing O

however O
more O
studies O
need O
to O
further O
explore O
the O
roles O
of O
vitex B-Plant
agnus I-Plant
castus I-Plant
in O
fracture B-Disease
repair O
processes O

additional O
information O
on O
xerostomia B-Disease
oral O
health O
behaviors O
coffee B-Plant
tea B-Plant
intake O
and O
nasal O
congestion O
was O
collected O
via O
a O
questionnaire O

xerostomia B-Disease
was O
associated O
with O
coffee B-Plant
tea O
intake O
p O
0 O
1 O
and O
nasal O
congestion O
p O
0 O
1 O

nasal O
congestion O
and O
coffee B-Plant
tea B-Plant
intake O
also O
affected O
xerostomia B-Disease

serenoa B-Plant
repens I-Plant
induces O
growth O
arrest O
apoptosis O
and O
inactivation O
of O
stat3 O
signaling O
in O
human O
glioma B-Disease
cells O

serenoa B-Plant
repens I-Plant
the O
extract O
of O
berry O
in O
southeastern O
united O
states O
is O
one O
of O
several O
phytotherapeutic O
agents O
available O
for O
the O
treatment O
of O
benign B-Disease
prostatic I-Disease
hyperplasia I-Disease
bph B-Disease

flow O
cytometry O
assay O
showed O
that O
serenoa B-Plant
repens I-Plant
induced O
apoptosis O
of O
u87 O
and O
u251 O
glioma B-Disease
cells O
in O
a O
dose O
dependent O
manner O

in O
addition O
we O
found O
that O
serenoa B-Plant
repens I-Plant
down O
regulated O
basal O
level O
of O
phosphorylated O
form O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
stat O
3 O
in O
both O
u87 O
and O
u251 O
glioma B-Disease
cells O

furthermore O
it O
was O
discovered O
that O
a O
janus O
family O
of O
tyrosine O
kinase O
jak O
inhibitor O
ag490 O
inhibit O
the O
growth O
of O
human O
u87 O
and O
u251 O
glioma B-Disease
cells O
and O
ag490 O
enhanced O
the O
ability O
of O
serenoa B-Plant
repens I-Plant
to O
inhibit O
the O
growth O
of O
u87 O
and O
u251 O
glioma B-Disease
cells O
as O
measured O
by O
the O
dimethylthiazol O
diphenyltetrazolium O
bromide O
mtt O
assay O

these O
results O
indicate O
that O
serenoa B-Plant
repens I-Plant
reduces O
the O
growth O
causes O
apoptosis O
of O
glioma B-Disease
cells O
and O
inhibits O
stat O
3 O
signaling O

a O
randomized O
controlled O
clinical O
trial O
of O
ocimum B-Plant
sanctum I-Plant
and O
chlorhexidine O
mouthwash O
on O
dental B-Disease
plaque I-Disease
and O
gingival O
inflammation O

objective O
in O
the O
present O
study O
we O
assessed O
the O
effectiveness O
of O
ocimum B-Plant
sanctum I-Plant
on O
dental B-Disease
plaque I-Disease
gingival B-Disease
inflammation I-Disease
and O
comparison O
with O
gold O
standard O
chlorhexidine O
and O
normal O
saline O
placebo O

results O
our O
result O
showed O
that O
ocimum B-Plant
sanctum I-Plant
mouthrinse O
is O
equally O
effective O
in O
reducing O
plaque B-Disease
and O
gingivitis B-Disease
as O
chlorhexidine O

conclusion O
the O
results O
of O
the O
present O
study O
indicate O
that O
ocimum B-Plant
sanctum I-Plant
mouthrinse O
may O
prove O
to O
be O
an O
effective O
mouthwash O
owing O
to O
its O
ability O
in O
decreasing O
periodontal O
indices O
by O
reducing O
plaque B-Disease
accumulation O
gingival B-Disease
inflammation I-Disease
and O
bleeding B-Disease

genetic O
predisposition O
to O
schizophrenia B-Disease
associated O
with O
increased O
use O
of O
cannabis B-Plant

one O
established O
association O
is O
that O
between O
cannabis B-Plant
use O
and O
schizophrenia B-Disease
a O
debilitating O
psychiatric B-Disease
disorder I-Disease
affecting O
1 O
of O
the O
population O
over O
their O
lifetime O

although O
considerable O
evidence O
implicates O
cannabis B-Plant
use O
as O
a O
component O
cause O
of O
schizophrenia B-Disease
it O
remains O
unclear O
whether O
this O
is O
entirely O
due O
to O
cannabis B-Plant
directly O
raising O
risk O
of O
psychosis B-Disease
or O
whether O
the O
same O
genes O
that O
increases O
psychosis B-Disease
risk O
may O
also O
increase O
risk O
of O
cannabis B-Plant

an O
individuals O
burden O
of O
schizophrenia B-Disease
risk O
alleles O
and O
use O
of O
cannabis B-Plant

although O
directly O
predicting O
only O
a O
small O
amount O
of O
the O
variance O
in O
cannabis B-Plant
use O
these O
findings O
suggest O
that O
part O
of O
the O
association O
between O
schizophrenia B-Disease
and O
cannabis B-Plant
is O
due O
to O
a O
shared O
genetic O
aetiology O

schizophrenia B-Disease
and O
cannabis B-Plant
is O
due O
to O
shared O
genetic O
aetiology O

identification O
of O
apc2 O
, O
a O
homologue O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
tumour I-Disease
suppressor O
. O

the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
apc I-Disease
) I-Disease
tumour I-Disease
- O
suppressor O
protein O
controls O
the O
wnt O
signalling O
pathway O
by O
forming O
a O
complex O
with O
glycogen O
synthase O
kinase O
3beta O
( O
gsk O
- O
3beta O
) O
, O
axin O
/ O
conductin O
and O
betacatenin O
. O

in O
colon B-Disease
carcinoma I-Disease
cells O
, O
loss O
of O
apc O
leads O
to O
the O
accumulation O
of O
betacatenin O
in O
the O
nucleus O
, O
where O
it O
binds O
to O
and O
activates O
the O
tcf O
- O
4 O
transcription O
factor O
( O
reviewed O
in O
[ O
1 O
] O
[ O
2 O
] O
) O
. O

like O
apc O
, O
apc2 O
regulates O
the O
formation O
of O
active O
betacatenin O
- O
tcf O
complexes O
, O
as O
demonstrated O
using O
transient O
transcriptional O
activation O
assays O
in O
apc O
- O
/ O
- O
colon B-Disease
carcinoma I-Disease
cells O
. O

apc O
and O
apc2 O
may O
therefore O
have O
comparable O
functions O
in O
development O
and O
cancer B-Disease
. O

a O
common O
msh2 O
mutation O
in O
english O
and O
north O
american O
hnpcc B-Disease
families O
: O
origin O
, O
phenotypic O
expression O
, O
and O
sex O
specific O
differences O
in O
colorectal B-Disease
cancer I-Disease
. O

the O
frequency O
, O
origin O
, O
and O
phenotypic O
expression O
of O
a O
germline O
msh2 O
gene O
mutation O
previously O
identified O
in O
seven O
kindreds O
with O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
cancer I-Disease
syndrome I-Disease
( O
hnpcc B-Disease
) O
was O
investigated O
. O

although O
this O
mutation O
was O
initially O
detected O
in O
four O
of O
33 O
colorectal B-Disease
cancer I-Disease
families O
analysed O
from O
eastern O
england O
, O
more O
extensive O
analysis O
has O
reduced O
the O
frequency O
to O
four O
of O
52 O
( O
8 O
% O
) O
english O
hnpcc B-Disease
kindreds O
analysed O
. O

in O
contrast O
, O
the O
msh2 O
mutation O
was O
identified O
in O
10 O
of O
20 O
( O
50 O
% O
) O
separately O
identified O
colorectal B-Disease
families O
from O
newfoundland O
. O

to O
investigate O
the O
origin O
of O
this O
mutation O
in O
colorectal B-Disease
cancer I-Disease
families O
from O
england O
( O
n O
= O
4 O
) O
, O
newfoundland O
( O
n O
= O
10 O
) O
, O
and O
the O
united O
states O
( O
n O
= O
3 O
) O
, O
haplotype O
analysis O
using O
microsatellite O
markers O
linked O
to O
msh2 O
was O
performed O
. O

these O
findings O
suggested O
a O
founder O
effect O
within O
newfoundland O
similar O
to O
that O
reported O
by O
others O
for O
two O
mlh1 O
mutations O
in O
finnish O
hnpcc B-Disease
families O
. O

we O
calculated O
age O
related O
risks O
of O
all O
, O
colorectal B-Disease
, I-Disease
endometrial I-Disease
, I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
in O
nt943 O
+ O
3 O
a O
- O
- O
> O
t O
msh2 O
mutation O
carriers O
( O
n O
= O
76 O
) O
for O
all O
patients O
and O
for O
men O
and O
women O
separately O
. O

for O
both O
sexes O
combined O
, O
the O
penetrances O
at O
age O
60 O
years O
for O
all O
cancers B-Disease
and O
for O
colorectal B-Disease
cancer I-Disease
were O
0 O
. O

the O
risk O
of O
colorectal B-Disease
cancer I-Disease
was O
significantly O
higher O
( O
p O
< O
0 O
. O
01 O
) O
in O
males O
than O
females O
( O
0 O
. O
63 O
v O
0 O
. O
30 O
and O
0 O
. O
84 O
v O
0 O
. O
44 O
at O
ages O
50 O
and O
60 O
years O
, O
respectively O
) O
. O

for O
females O
there O
was O
a O
high O
risk O
of O
endometrial B-Disease
cancer I-Disease
( O
0 O
. O
5 O
at O
age O
60 O
years O
) O
and O
premenopausal B-Disease
ovarian I-Disease
cancer I-Disease
( O
0 O
. O
2 O
at O
50 O
years O
) O
. O

these O
intersex O
differences O
in O
colorectal B-Disease
cancer I-Disease
risks O
have O
implications O
for O
screening O
programmes O
and O
for O
attempts O
to O
identify O
colorectal B-Disease
cancer I-Disease
susceptibility O
modifiers O
. O

age O
of O
onset O
in O
huntington B-Disease
disease I-Disease
: O
sex O
specific O
influence O
of O
apolipoprotein O
e O
genotype O
and O
normal O
cag O
repeat O
length O
. O

age O
of O
onset O
( O
ao O
) O
of O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
is O
known O
to O
be O
correlated O
with O
the O
length O
of O
an O
expanded O
cag O
repeat O
in O
the O
hd B-Disease
gene O
. O

apolipoprotein O
e O
( O
apoe O
) O
genotype O
, O
in O
turn O
, O
is O
known O
to O
influence O
ao O
in O
alzheimer B-Disease
disease I-Disease
, O
rendering O
the O
apoe O
gene O
a O
likely O
candidate O
to O
affect O
ao O
in O
other O
neurological B-Disease
diseases I-Disease
too O
. O

we O
therefore O
determined O
apoe O
genotype O
and O
normal O
cag O
repeat O
length O
in O
the O
hd B-Disease
gene O
for O
138 O
hd B-Disease
patients O
who O
were O
previously O
analysed O
with O
respect O
to O
cag O
repeat O
length O
. O

our O
findings O
suggest O
that O
subtle O
differences O
in O
the O
course O
of O
the O
neurodegeneration B-Disease
in O
hd B-Disease
may O
allow O
interacting O
genes O
to O
exert O
gender O
specific O
effects O
upon O
ao O
. O

familial B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
associated O
with O
recurrent O
bacteremic B-Disease
infections I-Disease
due I-Disease
to I-Disease
neisseria I-Disease
. O

the O
serum O
of O
a O
29 O
- O
year O
old O
woman O
with O
a O
recent O
episode O
of O
disseminated B-Disease
gonococcal I-Disease
infection I-Disease
and O
a O
history O
of O
meningococcal B-Disease
meningitis I-Disease
and O
arthritis B-Disease
as O
a O
child O
was O
found O
to O
lack O
serum O
hemolytic O
complement O
activity O
. O

the O
absence B-Disease
of I-Disease
functional I-Disease
c7 I-Disease
activity O
could O
not O
be O
accounted O
for O
on O
the O
basis O
of O
an O
inhibitor O
. O

complete B-Disease
absence I-Disease
of I-Disease
c7 I-Disease
was O
also O
found O
in O
one O
sibling O
who O
had O
the O
clinical O
syndrome O
of O
meningococcal B-Disease
meningitis I-Disease
and O
arthritis B-Disease
as O
a O
child O
and O
in O
this O
siblings O
clinically O
well O
eight O
- O
year O
- O
old O
son O
. O

hla O
histocompatibility O
typing O
of O
the O
family O
members O
did O
not O
demonstrate O
evidence O
for O
genetic O
linkage O
of O
c7 B-Disease
deficiency I-Disease
with O
the O
major O
histocompatibility O
loci O
. O

this O
report O
represents O
the O
first O
cases O
of O
c7 B-Disease
deficiency I-Disease
associated O
with O
infectious O
complications O
and O
suggests O
that O
bactericidal O
activity O
may O
be O
important O
in O
host O
defense O
against O
bacteremic B-Disease
neisseria I-Disease
infections I-Disease
. O

increased O
incidence O
of O
cancer B-Disease
in O
patients O
with O
cartilage B-Disease
- I-Disease
hair I-Disease
hypoplasia I-Disease
. O

objective O
previous O
reports O
have O
suggested O
an O
increased O
risk O
of O
cancer B-Disease
among O
patients O
with O
cartilage B-Disease
- I-Disease
hair I-Disease
hypoplasia I-Disease
( O
chh B-Disease
) O
. O

this O
study O
was O
carried O
out O
to O
further O
evaluate O
this O
risk O
among O
patients O
with O
chh B-Disease
and O
their O
first O
- O
degree O
relatives O
. O

study O
design O
one O
hundred O
twenty O
- O
two O
patients O
with O
chh B-Disease
were O
identified O
through O
2 O
countrywide O
epidemiologic O
surveys O
in O
1974 O
and O
in O
1986 O
. O

this O
cohort O
underwent O
follow O
- O
up O
for O
cancer B-Disease
incidence O
through O
the O
finnish O
cancer O
registry O
to O
the O
end O
of O
1995 O
. O

results O
a O
statistically O
significant O
excess O
risk O
of O
cancer B-Disease
was O
seen O
among O
the O
patients O
with O
chh B-Disease
( O
standardized O
incidence O
ratio O
6 O
. O
9 O
, O
95 O
% O
confidence O
interval O
2 O
. O
3 O
to O
16 O
) O
, O
which O
was O
mainly O
attributable O
to O
non B-Disease
- I-Disease
hodgkins I-Disease
lymphoma I-Disease
( O
standardized O
incidence O
ratio O
90 O
, O
95 O
% O
confidence O
interval O
18 O
to O
264 O
) O
. O

in O
addition O
, O
a O
significant O
excess O
risk O
of O
basal B-Disease
cell I-Disease
carcinoma I-Disease
was O
seen O
( O
standardized O
incidence O
ratio O
35 O
, O
95 O
% O
confidence O
interval O
7 O
. O
2 O
to O
102 O
) O
. O

the O
cancer B-Disease
incidence O
among O
the O
siblings O
or O
the O
parents O
did O
not O
differ O
from O
the O
average O
cancer B-Disease
incidence O
in O
the O
finnish O
population O
. O

conclusions O
this O
study O
confirms O
an O
increased O
risk O
of O
cancer B-Disease
, O
especially O
non B-Disease
- I-Disease
hodgkins I-Disease
lymphoma I-Disease
, O
probably O
attributable O
to O
defective O
immunity O
, O
among O
patients O
with O
chh B-Disease
. O

genotype O
and O
phenotype O
in O
patients O
with O
dihydropyrimidine B-Disease
dehydrogenase I-Disease
deficiency I-Disease
. O

dihydropyrimidine B-Disease
dehydrogenase I-Disease
( I-Disease
dpd I-Disease
) I-Disease
deficiency I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disease I-Disease
characterised O
by O
thymine O
- O
uraciluria O
in O
homozygous O
deficient O
patients O
and O
has O
been O
associated O
with O
a O
variable O
clinical O
phenotype O
. O

in O
order O
to O
understand O
the O
genetic O
and O
phenotypic O
basis O
for O
dpd B-Disease
deficiency I-Disease
, O
we O
have O
reviewed O
17 O
families O
presenting O
22 O
patients O
with O
complete O
deficiency B-Disease
of I-Disease
dpd I-Disease
. O

a O
large O
phenotypic O
variability O
has O
been O
observed O
, O
with O
convulsive B-Disease
disorders I-Disease
, O
motor B-Disease
retardation I-Disease
and O
mental B-Disease
retardation I-Disease
being O
the O
most O
abundant O
manifestations O
. O

an O
altered O
beta O
- O
alanine O
, O
uracil O
and O
thymine O
homeostasis O
might O
underlie O
the O
various O
clinical B-Disease
abnormalities I-Disease
encountered O
in O
patients O
with O
dpd B-Disease
deficiency I-Disease
. O

fibroblast O
growth O
factor O
homologous O
factor O
2 O
( O
fhf2 O
) O
: O
gene O
structure O
, O
expression O
and O
mapping O
to O
the O
borjeson B-Disease
- I-Disease
forssman I-Disease
- I-Disease
lehmann I-Disease
syndrome I-Disease
region O
in O
xq26 O
delineated O
by O
a O
duplication O
breakpoint O
in O
a O
bfls B-Disease
- O
like O
patient O
. O

borjeson B-Disease
- I-Disease
forssman I-Disease
- I-Disease
lehmann I-Disease
syndrome I-Disease
( O
bfls B-Disease
) O
is O
a O
syndromal O
x B-Disease
- I-Disease
linked I-Disease
mental I-Disease
retardation I-Disease
, O
which O
maps O
by O
linkage O
to O
the O
q26 O
region O
of O
the O
human O
x O
chromosome O
. O

we O
have O
identified O
a O
male O
patient O
with O
bfls B-Disease
- O
like O
features O
and O
a O
duplication O
, O
46 O
, O
y O
, O
dup O
( O
x O
) O
( O
q26q28 O
) O
, O
inherited O
from O
his O
phenotypically O
normal O
mother O
. O

the O
fhf2 O
gene O
localisation O
and O
tissue O
- O
specific O
expression O
pattern O
suggest O
it O
to O
be O
a O
candidate O
gene O
for O
familial O
cases O
of O
the O
bfls B-Disease
syndrome I-Disease
and O
other O
syndromal O
and O
non O
- O
specific O
forms O
of O
x B-Disease
- I-Disease
linked I-Disease
mental I-Disease
retardation I-Disease
mapping O
to O
the O
region O
. O

germline O
e O
- O
cadherin O
gene O
( O
cdh1 O
) O
mutations O
predispose O
to O
familial B-Disease
gastric I-Disease
cancer I-Disease
and O
colorectal B-Disease
cancer I-Disease
. O

inherited O
mutations O
in O
the O
e O
- O
cadherin O
gene O
( O
cdh1 O
) O
were O
described O
recently O
in O
three O
maori O
kindreds O
with O
familial B-Disease
gastric I-Disease
cancer I-Disease
. O

familial B-Disease
gastric I-Disease
cancer I-Disease
is O
genetically O
heterogeneous O
and O
it O
is O
not O
clear O
what O
proportion O
of O
gastric B-Disease
cancer I-Disease
susceptibility O
in O
non O
- O
maori O
populations O
is O
due O
to O
germline O
cdh1 O
mutations O
. O

therefore O
, O
we O
screened O
eight O
familial B-Disease
gastric I-Disease
cancer I-Disease
kindreds O
of O
british O
and O
irish O
origin O
for O
germline O
cdh1 O
mutations O
, O
by O
sscp O
analysis O
of O
all O
16 O
exons O
and O
flanking O
sequences O
. O

each O
family O
contained O
( O
i O
) O
two O
cases O
of O
gastric B-Disease
cancer I-Disease
in O
first O
degree O
relatives O
with O
one O
affected O
before O
age O
50 O
years O
; O
or O
( O
ii O
) O
three O
or O
more O
cases O
of O
gastric B-Disease
cancer I-Disease
. O

in O
one O
family O
there O
was O
evidence O
of O
non O
- O
penetrance O
and O
susceptibility O
to O
both O
gastric B-Disease
and I-Disease
colorectal I-Disease
cancer I-Disease
; O
thus O
, O
in O
addition O
to O
six O
cases O
of O
gastric B-Disease
cancer I-Disease
, O
a O
cdh1 O
mutation O
carrier O
developed O
colorectal B-Disease
cancer I-Disease
at O
age O
30 O
years O
. O

we O
have O
confirmed O
that O
germline O
mutations O
in O
the O
cdh1 O
gene O
cause O
familial B-Disease
gastric I-Disease
cancer I-Disease
in O
non O
- O
maori O
populations O
. O

however O
, O
only O
a O
minority O
of O
familial O
gastric B-Disease
cancers I-Disease
can O
be O
accounted O
for O
by O
cdh1 O
mutations O
. O

loss O
of O
e O
- O
cadherin O
function O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
sporadic O
colorectal B-Disease
and I-Disease
other I-Disease
cancers I-Disease
, O
and O
our O
findings O
provide O
evidence O
that O
germline O
cdh1 O
mutations O
predispose O
to O
early O
onset O
colorectal B-Disease
cancer I-Disease
. O

thus O
, O
cdh1 O
should O
be O
investigated O
as O
a O
cause O
of O
inherited O
susceptibility O
to O
both O
gastric B-Disease
and I-Disease
colorectal I-Disease
cancers I-Disease
. O

a O
zinc O
finger O
truncation O
of O
murine O
wt1 O
results O
in O
the O
characteristic O
urogenital B-Disease
abnormalities I-Disease
of O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
. O

the O
wilms B-Disease
tumor I-Disease
- O
suppressor O
gene O
, O
wt1 O
, O
plays O
a O
key O
role O
in O
urogenital O
development O
, O
and O
wt1 B-Disease
dysfunction I-Disease
is O
implicated O
in O
both O
neoplastic B-Disease
( O
wilms B-Disease
tumor I-Disease
, O
mesothelioma B-Disease
, O
leukemias B-Disease
, O
and O
breast B-Disease
cancer I-Disease
) O
and O
nonneoplastic B-Disease
( O
glomerulosclerosis B-Disease
) O
disease O
. O

the O
analysis O
of O
diseases O
linked O
specifically O
with O
wt1 O
mutations O
, O
such O
as O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
( O
dds B-Disease
) O
, O
can O
provide O
valuable O
insight O
concerning O
the O
role O
of O
wt1 O
in O
development O
and O
disease O
. O

dds B-Disease
is O
a O
rare O
childhood O
disease O
characterized O
by O
a O
nephropathy B-Disease
involving O
mesangial B-Disease
sclerosis I-Disease
, O
xy O
pseudohermaphroditism B-Disease
, O
and O
/ O
or O
wilms B-Disease
tumor I-Disease
( O
wt B-Disease
) O
. O

dds B-Disease
patients O
are O
constitutionally O
heterozygous O
for O
exonic O
point O
mutations O
in O
wt1 O
, O
which O
include O
mutations O
predicted O
to O
truncate O
the O
protein O
within O
the O
c O
- O
terminal O
zinc O
finger O
( O
zf O
) O
region O
. O

we O
report O
that O
heterozygosity O
for O
a O
targeted O
murine O
wt1 O
allele O
, O
wt1 O
( O
tmt396 O
) O
, O
which O
truncates O
zf3 O
at O
codon O
396 O
, O
induces O
mesangial B-Disease
sclerosis I-Disease
characteristic O
of O
dds B-Disease
in O
adult O
heterozygous O
and O
chimeric O
mice O
. O

male B-Disease
genital I-Disease
defects I-Disease
also O
were O
evident O
and O
there O
was O
a O
single O
case O
of O
wilms B-Disease
tumor I-Disease
in O
which O
the O
transcript O
of O
the O
nontargeted O
allele O
showed O
an O
exon O
9 O
skipping O
event O
, O
implying O
a O
causal O
link O
between O
wt1 B-Disease
dysfunction I-Disease
and O
wilms B-Disease
tumorigenesis I-Disease
in O
mice O
. O

however O
, O
the O
mutant O
wt1 O
( O
tmt396 O
) O
protein O
accounted O
for O
only O
5 O
% O
of O
wt1 O
in O
both O
heterozygous O
embryonic O
stem O
cells O
and O
the O
wt B-Disease
. O

mechanism O
of O
increased O
iron O
absorption O
in O
murine O
model O
of O
hereditary B-Disease
hemochromatosis I-Disease
: O
increased O
duodenal O
expression O
of O
the O
iron O
transporter O
dmt1 O
. O

hereditary B-Disease
hemochromatosis I-Disease
( O
hh B-Disease
) O
is O
a O
common O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
tissue O
iron O
deposition O
secondary O
to O
excessive O
dietary O
iron O
absorption O
. O

the O
positive O
control O
for O
dmt1 O
up O
- O
regulation O
was O
a O
murine O
model O
of O
dietary B-Disease
iron I-Disease
deficiency I-Disease
that O
demonstrated O
greatly O
increased O
levels O
of O
duodenal O
dmt1 O
( O
ire O
) O
mrna O
. O

neurophysiologic O
follow O
- O
up O
of O
long O
- O
term O
dietary O
treatment O
in O
adult O
- O
onset O
adrenoleukodystrophy B-Disease
. O

objective O
to O
monitor O
the O
effects O
of O
dietary O
treatment O
in O
adult O
- O
onset O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
by O
means O
of O
somatosensory O
evoked O
potentials O
( O
seps O
) O
and O
motor O
evoked O
potentials O
( O
meps O
) O
. O

background O
seps O
and O
meps O
have O
proved O
useful O
in O
revealing O
signs O
of O
progressively O
severe O
, O
central O
dying B-Disease
- I-Disease
back I-Disease
axonopathy I-Disease
in O
early O
stages O
of O
adult O
- O
onset O
ald B-Disease
. O

methods O
eight O
patients O
with O
adult O
- O
onset O
ald B-Disease
underwent O
clinical O
examination O
, O
brain O
and O
spine O
mri O
, O
and O
sep O
and O
mep O
studies O
before O
and O
after O
3 O
years O
of O
lorenzos O
oil O
dietary O
therapy O
. O

three O
of O
these O
patients O
had O
pure O
spinal B-Disease
sep I-Disease
abnormalities I-Disease
and O
in O
the O
remaining O
two O
patients O
seps O
showed O
signs O
of O
involvement O
of O
both O
the O
spinal O
and O
cerebral O
somatosensory O
tracts O
. O

after O
treatment O
, O
the O
three O
patients O
with O
pure O
spinal B-Disease
abnormalities I-Disease
showed O
clinical O
and O
neurophysiologic O
worsening O
, O
whereas O
the O
two O
patients O
with O
a O
more O
advanced O
stage O
of O
disease O
( O
exhibited O
by O
seps O
) O
showed O
substantially O
unchanged O
clinical O
and O
neurophysiologic O
features O
. O

conclusions O
lorenzos O
oil O
therapy O
had O
no O
effect O
on O
patients O
with O
evidence O
of O
inflammatory B-Disease
brain I-Disease
lesions I-Disease
. O

gch1 O
mutation O
in O
a O
patient O
with O
adult O
- O
onset O
oromandibular B-Disease
dystonia I-Disease
. O

the O
authors O
report O
a O
mutation O
in O
exon O
5 O
of O
gch1 O
in O
a O
patient O
with O
adult O
- O
onset O
oromandibular B-Disease
dystonia I-Disease
and O
no O
obvious O
family O
history O
of O
dystonia B-Disease
. O

these O
findings O
demonstrate O
that O
gch1 O
mutations O
must O
be O
considered O
even O
in O
patients O
with O
dystonic B-Disease
symptoms O
not O
typical O
of O
dopa B-Disease
- I-Disease
responsive I-Disease
dystonia I-Disease
. O

germline O
mutations O
of O
the O
apc B-Disease
gene O
in O
korean O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
patients O
. O

we O
extensively O
analyzed O
genomic O
dna O
and O
messenger O
rna O
( O
mrna O
) O
from O
62 O
unrelated O
korean O
patients O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
for O
identification O
of O
germline O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
mutations O
. O

using O
this O
combined O
approach O
, O
we O
identified O
germline O
apc B-Disease
gene O
mutations O
in O
29 O
of O
the O
48 O
fap B-Disease
patients O
( O
60 O
% O
) O
, O
including O
6 O
patients O
in O
whom O
sscp O
analysis O
failed O
to O
distinguish O
the O
mutant O
allele O
. O

our O
results O
confirm O
that O
the O
mutation O
detection O
rate O
with O
ptt O
was O
superior O
to O
that O
with O
sscp O
, O
and O
suggest O
that O
ptt O
would O
be O
a O
more O
practical O
screening O
method O
to O
detect O
germline O
mutations O
of O
the O
apc B-Disease
gene O
in O
fap B-Disease
patients O
. O

molecular O
epidemiology O
of O
c9 B-Disease
deficiency I-Disease
heterozygotes O
with O
an O
arg95stop O
mutation O
of O
the O
c9 O
gene O
in O
japan O
. O

deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency I-Disease
in O
japan O
, O
with O
an O
incidence O
of O
approximately O
one O
homozygote O
in O
1000 O
, O
but O
is O
very O
rare O
in O
other O
countries O
. O

genetic O
analyses O
of O
japanese O
c9 B-Disease
deficiency I-Disease
have O
shown O
that O
a O
c O
- O
to O
- O
t O
transition O
leading O
to O
tga O
stop O
codon O
for O
arg95 O
in O
exon O
4 O
of O
the O
c9 O
gene O
( O
arg95stop O
) O
is O
common O
in O
japanese O
c9 B-Disease
deficiency I-Disease
. O

an O
estimated O
frequency O
( O
0 O
. O
12 O
% O
) O
of O
complete O
c9 B-Disease
deficiency I-Disease
due O
to O
homozygous O
arg95stop O
mutation O
was O
consistent O
with O
frequencies O
determined O
by O
serological O
studies O

the O
hereditary B-Disease
hemochromatosis I-Disease
protein O
, O
hfe O
, O
specifically O
regulates O
transferrin O
- O
mediated O
iron O
uptake O
in O
hela O
cells O
. O

hfe O
is O
the O
protein O
product O
of O
the O
gene O
mutated O
in O
the O
autosomal B-Disease
recessive I-Disease
disease I-Disease
hereditary B-Disease
hemochromatosis I-Disease
( O
feder O
, O
j O
. O

these O
results O
also O
have O
implications O
for O
the O
understanding O
of O
cellular O
iron O
homeostasis O
in O
organs O
such O
as O
the O
liver O
, O
pancreas O
, O
heart O
, O
and O
spleen O
that O
are O
iron O
loaded O
in O
hereditary B-Disease
hemochromatotic I-Disease
individuals O
lacking O
functional O
hfe O
. O

mutation O
and O
haplotype O
studies O
of O
familial B-Disease
mediterranean I-Disease
fever I-Disease
reveal O
new O
ancestral O
relationships O
and O
evidence O
for O
a O
high O
carrier O
frequency O
with O
reduced O
penetrance O
in O
the O
ashkenazi O
jewish O
population O
. O

familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
is O
a O
recessive B-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever O
with O
serositis B-Disease
or O
synovitis B-Disease
. O

the O
fmf B-Disease
gene O
( O
mefv O
) O
was O
cloned O
recently O
, O
and O
four O
missense O
mutations O
were O
identified O
. O

autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
with O
defective O
fas O
: O
genotype O
influences O
penetrance O
. O

autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
( O
alps B-Disease
) O
is O
a O
disorder B-Disease
of I-Disease
lymphocyte I-Disease
homeostasis I-Disease
and I-Disease
immunological I-Disease
tolerance I-Disease
. O

of O
17 O
unique O
apt1 O
mutations O
in O
unrelated O
alps B-Disease
probands O
, O
12 O
( O
71 O
% O
) O
occurred O
in O
exons O
7 O
- O
9 O
, O
which O
encode O
the O
intracellular O
portion O
of O
fas O
. O

two O
missense O
fas O
variants O
, O
not O
restricted O
to O
patients O
with O
alps B-Disease
, O
were O
identified O
. O

among O
the O
alps B-Disease
- O
associated O
fas O
mutants O
, O
dominant O
inhibition O
of O
apoptosis O
was O
much O
more O
pronounced O
in O
mutants O
affecting O
the O
intracellular O
, O
versus O
extracellular O
, O
portion O
of O
the O
fas O
receptor O
. O

mutations O
causing O
disruption O
of O
the O
intracellular O
fas O
death O
domain O
also O
showed O
a O
higher O
penetrance O
of O
alps B-Disease
phenotype O
features O
in O
mutation O
- O
bearing O
relatives O
. O

significant O
alps B-Disease
- O
related O
morbidity O
occurred O
in O
44 O
% O
of O
relatives O
with O
intracellular O
mutations O
, O
versus O
0 O
% O
of O
relatives O
with O
extracellular O
mutations O
. O

thus O
, O
the O
location O
of O
mutations O
within O
apt1 O
strongly O
influences O
the O
development O
and O
the O
severity O
of O
alps B-Disease
. O

multicentric O
origin O
of O
hemochromatosis B-Disease
gene O
( O
hfe O
) O
mutations O
. O

genetic B-Disease
hemochromatosis I-Disease
( O
gh B-Disease
) O
is O
believed O
to O
be O
a O
disease O
restricted O
to O
those O
of O
european O
ancestry O
. O

in O
northwestern O
europe O
, O
> O
80 O
% O
of O
gh B-Disease
patients O
are O
homozygous O
for O
one O
mutation O
, O
the O
substitution O
of O
tyrosine O
for O
cysteine O
at O
position O
282 O
( O
c282y O
) O
in O
the O
unprocessed O
protein O
. O

in O
a O
proportion O
of O
gh B-Disease
patients O
, O
two O
mutations O
are O
present O
, O
c282y O
and O
h63d O
. O

these O
selection O
pressures O
could O
be O
due O
to O
infectious B-Disease
diseases I-Disease
, O
environmental O
conditions O
, O
or O
other O
genetic B-Disease
disorders I-Disease
such O
as O
anemia B-Disease
. O

we O
have O
retrospectively O
analyzed O
837 O
random O
anonymized O
dried O
blood O
spot O
( O
dbs O
) O
samples O
from O
neonatal O
screening O
programs O
in O
scandinavia O
for O
mutations O
in O
hfe O
, O
the O
candidate O
gene O
for O
hemochromatosis B-Disease
. O

identification O
of O
the O
mutation O
in O
the O
alkaptonuria B-Disease
mouse O
model O
. O

alkaptonuria B-Disease
( O
aku B-Disease
) O
, O
an O
inborn B-Disease
error I-Disease
of I-Disease
metabolism I-Disease
caused O
by O
the O
loss O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
hgd O
) O
, O
has O
been O
described O
in O
a O
mouse O
model O
created O
by O
ethylnitrosourea O
mutagenesis O
but O
the O
mutation O
in O
these O
mice O
has O
not O
previously O
been O
identified O
. O

non B-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
associated O
with O
enlarged B-Disease
vestibular I-Disease
aqueduct I-Disease
is O
caused O
by O
pds B-Disease
mutations O
. O

enlarged B-Disease
vestibular I-Disease
aqueduct I-Disease
( O
eva B-Disease
) O
, O
known O
as O
the O
most O
common O
form O
of O
inner B-Disease
ear I-Disease
abnormality I-Disease
, O
has O
recently O
been O
of O
particular O
genetic O
interest O
because O
this O
anomaly O
is O
inherited O
in O
a O
recessive O
manner O
. O

the O
locus O
for O
non B-Disease
- I-Disease
syndromic I-Disease
sensorineural I-Disease
hearing I-Disease
loss I-Disease
with O
eva B-Disease
has O
been O
mapped O
to O
the O
same O
chromosomal O
region O
, O
7q31 O
, O
as O
the O
pendred B-Disease
syndrome I-Disease
locus O
. O

in O
the O
present O
study O
, O
seven O
mutations O
in O
the O
pds B-Disease
gene O
( O
pds O
) O
, O
the O
gene O
responsible O
for O
pendred B-Disease
syndrome I-Disease
, O
have O
been O
found O
in O
families O
of O
non B-Disease
- I-Disease
syndromic I-Disease
sensorineural I-Disease
hearing I-Disease
loss I-Disease
with O
eva B-Disease
. O

the O
present O
results O
provide O
evidence O
that O
mutations O
in O
pds O
cause O
both O
syndromic B-Disease
and I-Disease
non I-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
. O
. O

mutational O
analysis O
and O
genotype O
- O
phenotype O
correlation O
of O
29 O
unrelated O
japanese O
patients O
with O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
. O

background O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
is O
an O
inherited B-Disease
disease I-Disease
characterized O
by O
progressive O
neurologic B-Disease
dysfunction I-Disease
, O
occasionally O
associated O
with O
adrenal B-Disease
insufficiency I-Disease
. O

the O
classic O
form O
of O
ald B-Disease
usually O
has O
onset O
in O
childhood O
( O
childhood B-Disease
cerebral I-Disease
ald I-Disease
) O
, O
with O
rapid O
neurologic B-Disease
deterioration I-Disease
leading O
to O
a O
vegetative O
state O
. O

adult O
- O
onset O
cerebral B-Disease
ald I-Disease
also O
presents O
with O
rapidly O
progressive O
neurologic B-Disease
dysfunction I-Disease
. O

milder O
phenotypes O
such O
as O
adrenomyeloneuropathy B-Disease
and O
addison B-Disease
disease I-Disease
only O
also O
have O
been O
recognized O
. O

objectives O
to O
conduct O
mutational O
analyses O
in O
29 O
japanese O
patients O
with O
ald B-Disease
from O
29 O
unrelated O
families O
, O
to O
obtain O
knowledge O
of O
the O
spectrum O
of O
mutations O
in O
this O
gene O
, O
and O
to O
study O
genotype O
- O
phenotype O
correlations O
in O
japanese O
patients O
. O

methods O
the O
29 O
patients O
comprised O
13 O
patients O
with O
childhood B-Disease
cerebral I-Disease
ald I-Disease
, O
11 O
patients O
with O
adult O
- O
onset O
cerebral B-Disease
ald I-Disease
, O
and O
5 O
patients O
with O
adrenomyeloneuropathy B-Disease
. O

we O
conducted O
detailed O
mutational O
analyses O
of O
29 O
unrelated O
japanese O
patients O
with O
ald B-Disease
by O
genomic O
southern O
blot O
analysis O
and O
direct O
nucleotide O
sequence O
analysis O
of O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
products O
derived O
from O
total O
rna O
that O
was O
extracted O
from O
cultured O
skin O
fibroblasts O
, O
lymphoblastoid O
cells O
, O
or O
peripheral O
blood O
leukocytes O
. O

results O
three O
patients O
with O
adult O
- O
onset O
cerebral B-Disease
ald I-Disease
were O
identified O
as O
having O
large O
genomic O
rearrangements O
. O

the O
remaining O
26 O
patients O
were O
identified O
as O
having O
21 O
independent O
mutations O
, O
including O
12 O
novel O
mutations O
resulting O
in O
small O
nucleotide O
alterations O
in O
the O
ald B-Disease
gene O
. O

conclusions O
there O
are O
no O
obvious O
correlations O
between O
the O
phenotypes O
of O
patients O
with O
ald B-Disease
and O
their O
genotypes O
, O
suggesting O
that O
other O
genetic O
or O
environmental O
factors O
modify O
the O
phenotypic O
expressions O
of O
ald B-Disease
. O
. O

a O
common O
human O
skin B-Disease
tumour I-Disease
is O
caused O
by O
activating O
mutations O
in O
beta O
- O
catenin O
. O

one O
of O
the O
target O
genes O
for O
beta O
- O
catenin O
/ O
tcf O
encodes O
c O
- O
myc O
, O
explaining O
why O
constitutive O
activation O
of O
the O
wnt O
pathway O
can O
lead O
to O
cancer B-Disease
, O
particularly O
in O
the O
colon O
. O

most O
colon B-Disease
cancers I-Disease
arise O
from O
mutations O
in O
the O
gene O
encoding O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
, O
a O
protein O
required O
for O
ubiquitin O
- O
mediated O
degradation O
of O
beta O
- O
catenin O
, O
but O
a O
small O
percentage O
of O
colon B-Disease
and I-Disease
some I-Disease
other I-Disease
cancers I-Disease
harbour O
beta O
- O
catenin O
- O
stabilizing O
mutations O
. O

recently O
, O
we O
discovered O
that O
transgenic O
mice O
expressing O
an O
activated O
beta O
- O
catenin O
are O
predisposed O
to O
developing O
skin B-Disease
tumours I-Disease
resembling O
pilomatricomas B-Disease
. O

given O
that O
the O
skin O
of O
these O
adult O
mice O
also O
exhibits O
signs O
of O
de O
novo O
hair O
- O
follicle O
morphogenesis O
, O
we O
wondered O
whether O
human O
pilomatricomas B-Disease
might O
originate O
from O
hair O
matrix O
cells O
and O
whether O
they O
might O
possess O
beta O
- O
catenin O
- O
stabilizing O
mutations O
. O

here O
, O
we O
explore O
the O
cell O
origin O
and O
aetiology O
of O
this O
common O
human O
skin B-Disease
tumour I-Disease
. O

we O
found O
nuclear O
lef O
- O
1 O
in O
the O
dividing O
tumour B-Disease
cells O
, O
providing O
biochemical O
evidence O
that O
pilomatricomas B-Disease
are O
derived O
from O
hair O
matrix O
cells O
. O

at O
least O
75 O
% O
of O
these O
tumours B-Disease
possess O
mutations O
affecting O
the O
amino O
- O
terminal O
segment O
, O
normally O
involved O
in O
phosphorylation O
- O
dependent O
, O
ubiquitin O
- O
mediated O
degradation O
of O
the O
protein O
. O

this O
percentage O
of O
ctnnb1 O
mutations O
is O
greater O
than O
in O
all O
other O
human O
tumours B-Disease
examined O
thus O
far O
, O
and O
directly O
implicates O
beta O
- O
catenin O
/ O
lef O
misregulation O
as O
the O
major O
cause O
of O
hair O
matrix O
cell O
tumorigenesis O
in O
humans O
. O
. O

the O
pendred B-Disease
syndrome I-Disease
gene O
encodes O
a O
chloride O
- O
iodide O
transport O
protein O
. O

pendred B-Disease
syndrome I-Disease
is O
the O
most O
common O
form O
of O
syndromic B-Disease
deafness I-Disease
and O
characterized O
by O
congenital O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
and O
goitre B-Disease
. O

this O
disorder O
was O
mapped O
to O
chromosome O
7 O
and O
the O
gene O
causing O
pendred B-Disease
syndrome I-Disease
( O
pds B-Disease
) O
was O
subsequently O
identified O
by O
positional O
cloning O
. O

pendrin O
is O
closely O
related O
to O
a O
family O
of O
sulfate O
transport O
proteins O
that O
includes O
the O
rat O
sulfate O
- O
anion O
transporter O
( O
encoded O
by O
sat O
- O
1 O
; O
29 O
% O
amino O
acid O
sequence O
identity O
) O
, O
the O
human O
diastrophic B-Disease
dysplasia I-Disease
sulfate O
transporter O
( O
encoded O
by O
dtd O
; O
32 O
% O
) O
and O
the O
human O
sulfate O
transporter O
downregulated O
in O
adenoma B-Disease
( O
encoded O
by O
dra O
; O
45 O
% O
) O
. O

our O
results O
demonstrate O
that O
pendrin O
functions O
as O
a O
transporter O
of O
chloride O
and O
iodide O
, O
but O
not O
sulfate O
, O
and O
may O
provide O
insight O
into O
thyroid O
physiology O
and O
the O
pathophysiology O
of O
pendred B-Disease
syndrome I-Disease
. O
. O

hfe O
mutations O
analysis O
in O
711 O
hemochromatosis B-Disease
probands O
: O
evidence O
for O
s65c O
implication O
in O
mild O
form O
of O
hemochromatosis B-Disease
. O

hereditary B-Disease
hemochromatosis I-Disease
( O
hh B-Disease
) O
is O
a O
common O
autosomal B-Disease
recessive I-Disease
genetic I-Disease
disorder I-Disease
of O
iron O
metabolism O
. O

two O
missense O
mutations O
have O
been O
described O
c282y O
, O
accounting O
for O
80 O
% O
to O
90 O
% O
of O
hh B-Disease
chromosomes O
, O
and O
h63d O
, O
which O
is O
associated O
with O
a O
milder O
form O
of O
the O
disease O
representing O
40 O
% O
to O
70 O
% O
of O
non O
- O
c282y O
hh B-Disease
chromosomes O
. O

the O
results O
confirm O
that O
the O
c282y O
substitution O
was O
the O
main O
mutation O
involved O
in O
hemochromatosis B-Disease
, O
accounting O
for O
85 O
% O
of O
carrier O
chromosomes O
, O
whereas O
the O
h63d O
substitution O
represented O
39 O
% O
of O
the O
hh B-Disease
chromosomes O
that O
did O
not O
carry O
the O
c282y O
mutation O
. O

8 O
% O
of O
hh B-Disease
chromosomes O
that O
were O
neither O
c282y O
nor O
h63d O
. O

this O
enrichment O
of O
s65c O
among O
hh B-Disease
chromosomes O
suggests O
that O
the O
s65c O
substitution O
is O
associated O
with O
the O
mild O
form O
of O
hemochromatosis B-Disease
. O

germline O
brca1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
ovarian B-Disease
cancer I-Disease
cases O
. O

the O
objective O
of O
this O
study O
was O
to O
provide O
more O
accurate O
frequency O
estimates O
of O
breast B-Disease
cancer I-Disease
susceptibility O
gene O
1 O
( O
brca1 O
) O
germline O
alterations O
in O
the O
ovarian B-Disease
cancer I-Disease
population O
. O

to O
achieve O
this O
, O
we O
determined O
the O
prevalence O
of O
brca1 O
alterations O
in O
a O
population O
- O
based O
series O
of O
consecutive O
ovarian B-Disease
cancer I-Disease
cases O
. O

this O
is O
the O
first O
population O
- O
based O
ovarian B-Disease
cancer I-Disease
study O
reporting O
brca1 O
alterations O
derived O
from O
a O
comprehensive O
screen O
of O
the O
entire O
coding O
region O
. O

one O
hundred O
and O
seven O
ovarian B-Disease
cancer I-Disease
cases O
were O
analyzed O
for O
brca1 O
alterations O
using O
the O
rnase O
mismatch O
cleavage O
assay O
followed O
by O
direct O
sequencing O
. O

both O
patients O
had O
a O
family O
history O
of O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

several O
novel O
as O
well O
as O
previously O
reported O
uncharacterized O
variants O
were O
also O
identified O
, O
some O
of O
which O
were O
associated O
with O
a O
family O
history O
of O
cancer B-Disease
. O

the O
frequency O
distribution O
of O
common O
polymorphisms O
was O
determined O
in O
the O
91 O
caucasian O
cancer B-Disease
cases O
in O
this O
series O
and O
24 O
sister O
controls O
using O
allele O
- O
specific O
amplification O
. O

the O
rare O
form O
of O
the O
q356r O
polymorphism O
was O
significantly O
( O
p O
= O
0 O
. O
03 O
) O
associated O
with O
a O
family O
history O
of O
ovarian B-Disease
cancer I-Disease
, O
suggesting O
that O
this O
polymorphism O
may O
influence O
ovarian B-Disease
cancer I-Disease
risk O
. O

in O
summary O
, O
our O
data O
suggest O
a O
role O
for O
some O
uncharacterized O
variants O
and O
rare O
forms O
of O
polymorphisms O
in O
determining O
ovarian B-Disease
cancer I-Disease
risk O
, O
and O
highlight O
the O
necessity O
to O
screen O
for O
missense O
alterations O
as O
well O
as O
truncating O
mutations O
in O
this O
population O
. O

adrenoleukodystrophy O
- O
related O
protein O
can O
compensate O
functionally O
for O
adrenoleukodystrophy B-Disease
protein I-Disease
deficiency I-Disease
( O
x B-Disease
- I-Disease
ald I-Disease
) O
: O
implications O
for O
therapy O
. O

inherited B-Disease
defects I-Disease
in O
the O
peroxisomal O
atp O
- O
binding O
cassette O
( O
abc O
) O
transporter O
adrenoleukodystrophy B-Disease
protein O
( O
aldp O
) O
lead O
to O
the O
lethal O
peroxisomal B-Disease
disorder I-Disease
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
x B-Disease
- I-Disease
ald I-Disease
) O
, O
for O
which O
no O
efficient O
treatment O
has O
been O
established O
so O
far O
. O

these O
results O
suggest O
that O
a O
correction O
of O
the O
biochemical O
defect O
in O
x B-Disease
- I-Disease
ald I-Disease
could O
be O
possible O
by O
drug O
- O
induced O
overexpression O
or O
ectopic O
expression O
of O
aldrp O
. O

germline O
mutations O
of O
the O
brca1 O
tumor B-Disease
suppressor O
gene O
predispose O
women O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

however O
, O
a O
defective O
g2 O
- O
m O
checkpoint O
in O
these O
cells O
is O
accompanied O
by O
extensive O
chromosomal B-Disease
abnormalities I-Disease
. O

mutant O
fibroblasts O
contain O
multiple O
, O
functional O
centrosomes O
, O
which O
lead O
to O
unequal O
chromosome O
segregation O
, O
abnormal O
nuclear O
division O
, O
and O
aneuploidy B-Disease
. O

defective O
cd95 O
/ O
apo O
- O
1 O
/ O
fas O
signal O
complex O
formation O
in O
the O
human O
autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
, I-Disease
type I-Disease
ia I-Disease
. O

heterozygous O
mutations O
in O
the O
cd95 O
( O
apo O
- O
1 O
/ O
fas O
) O
receptor O
occur O
in O
most O
individuals O
with O
autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
( O
alps B-Disease
) O
and O
dominantly O
interfere O
with O
apoptosis O
by O
an O
unknown O
mechanism O
. O

we O
show O
that O
local O
or O
global O
alterations O
in O
the O
structure O
of O
the O
cytoplasmic O
death O
domain O
from O
nine O
independent O
alps B-Disease
cd95 O
death O
- O
domain O
mutations O
result O
in O
a O
failure O
to O
bind O
the O
fadd O
/ O
mort1 O
signaling O
protein O
. O

these O
data O
suggest O
that O
intracytoplasmic O
cd95 O
mutations O
in O
alps B-Disease
impair O
apoptosis O
chiefly O
by O
disrupting O
death O
- O
domain O
interactions O
with O
the O
signaling O
protein O
fadd O
/ O
mort1 O
. O
. O

analysis O
of O
alkaptonuria B-Disease
( O
aku B-Disease
) O
mutations O
and O
polymorphisms O
reveals O
that O
the O
ccc O
sequence O
motif O
is O
a O
mutational O
hot O
spot O
in O
the O
homogentisate O
1 O
, O
2 O
dioxygenase O
gene O
( O
hgo O
) O
. O

we O
recently O
showed O
that O
alkaptonuria B-Disease
( O
aku B-Disease
) O
is O
caused O
by O
loss O
- O
of O
- O
function O
mutations O
in O
the O
homogentisate O
1 O
, O
2 O
dioxygenase O
gene O
( O
hgo O
) O
. O

herein O
we O
describe O
haplotype O
and O
mutational O
analyses O
of O
hgo O
in O
seven O
new O
aku B-Disease
pedigrees O
. O

these O
analyses O
identified O
two O
novel O
single O
- O
nucleotide O
polymorphisms O
( O
inv4 O
+ O
31a O
- O
- O
> O
g O
and O
inv11 O
+ O
18a O
- O
- O
> O
g O
) O
and O
six O
novel O
aku B-Disease
mutations O
( O
inv1 O
- O
1g O
- O
- O
> O
a O
, O
w60g O
, O
y62c O
, O
a122d O
, O
p230t O
, O
and O
d291e O
) O
, O
which O
further O
illustrates O
the O
remarkable O
allelic O
heterogeneity O
found O
in O
aku B-Disease
. O

fabry B-Disease
disease I-Disease
: O
identification O
of O
novel O
alpha O
- O
galactosidase O
a O
mutations O
and O
molecular O
carrier O
detection O
by O
use O
of O
fluorescent O
chemical O
cleavage O
of O
mismatches O
. O

fabry B-Disease
disease I-Disease
( O
fd B-Disease
) O
( O
angiokeratoma B-Disease
corporis I-Disease
diffusum I-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
inborn I-Disease
error I-Disease
of I-Disease
glycosphingolipid I-Disease
metabolism I-Disease
caused O
by O
defects O
in O
the O
lysosomal O
alpha O
- O
galactosidase O
a O
gene O
( O
gla O
) O
. O

clinically O
, O
affected O
hemizygous O
males O
have O
angiokeratoma B-Disease
, O
severe B-Disease
acroparesthesia I-Disease
, O
renal B-Disease
failure I-Disease
, O
and O
vasculopathy B-Disease
of I-Disease
the I-Disease
heart I-Disease
and I-Disease
brain I-Disease
. O

while O
demonstration O
of O
alpha B-Disease
- I-Disease
galactosidase I-Disease
deficiency I-Disease
in O
leukocytes O
is O
diagnostic O
in O
affected O
males O
, O
enzymatic O
detection O
of O
female O
carriers O
is O
often O
inconclusive O
, O
due O
to O
random O
x O
- O
chromosomal O
inactivation O
, O
underlining O
the O
need O
of O
molecular O
investigations O
for O
accurate O
genetic O
counseling O
. O

by O
use O
of O
chemical O
cleavage O
of O
mismatches O
adapted O
to O
fluorescence O
- O
based O
detection O
systems O
, O
we O
have O
characterized O
the O
mutations O
underlying O
alpha B-Disease
- I-Disease
gal I-Disease
a I-Disease
deficiency I-Disease
in O
16 O
individuals O
from O
six O
unrelated O
families O
with O
fd B-Disease
. O

prenatal O
diagnosis O
by O
fish O
in O
a O
family O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
caused O
by O
duplication O
of O
plp O
gene O
. O

a O
diagnosis O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
mim O
312080 O
) O
was O
made O
in O
a O
young O
boy O
. O

the O
proband O
was O
found O
to O
carry O
the O
duplication O
, O
thus O
confirming O
the O
diagnosis O
of O
pelizaeus B-Disease
merzbacher I-Disease
disease I-Disease
, O
but O
neither O
the O
aunt O
nor O
the O
fetus O
carried O
a O
duplication O
. O
. O

dominant O
negative O
effect O
of O
the O
apc1309 O
mutation O
: O
a O
possible O
explanation O
for O
genotype O
- O
phenotype O
correlations O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
. O

inactivation O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
product O
initiates O
colorectal O
tumorigenesis O
. O

patients O
with O
familial B-Disease
apc I-Disease
( O
fap B-Disease
) O
carry O
germ O
- O
line O
mutations O
in O
the O
apc B-Disease
gene O
and O
develop O
multiple O
colorectal B-Disease
adenomas I-Disease
and O
subsequent O
carcinomas B-Disease
early O
in O
life O
. O

together O
with O
the O
fact O
that O
both O
germ O
- O
line O
and O
sporadic O
apc B-Disease
mutations O
cluster O
in O
the O
central O
region O
of O
the O
apc B-Disease
gene O
, O
this O
points O
to O
a O
dominant O
negative O
effect O
of O
certain O
apc B-Disease
mutants O
. O

loss O
of O
apc B-Disease
function O
was O
recently O
shown O
to O
result O
in O
enhanced O
beta O
- O
catenin O
- O
/ O
tcf O
- O
mediated O
transcription O
in O
colon O
epithelial O
cells O
. O

here O
, O
we O
provide O
experimental O
evidence O
for O
a O
dominant O
negative O
effect O
of O
apc B-Disease
gene O
products O
associated O
with O
severe O
polyposis B-Disease
. O

wild O
- O
type O
apc B-Disease
activity O
in O
beta O
- O
catenin O
- O
/ O
tcf O
- O
mediated O
transcription O
was O
strongly O
inhibited O
by O
a O
mutant O
apc B-Disease
that O
is O
truncated O
at O
codon O
1309 O
. O

in O
contrast O
, O
mutant O
apc B-Disease
gene O
products O
that O
are O
associated O
with O
attenuated B-Disease
polyposis I-Disease
( O
codon O
386 O
or O
1465 O
) O
interfered O
only O
weakly O
with O
wild O
- O
type O
apc B-Disease
activity O
. O

these O
results O
suggest O
a O
molecular O
explanation O
for O
the O
genotype O
- O
phenotype O
correlation O
in O
fap B-Disease
patients O
and O
support O
the O
idea O
that O
colorectal B-Disease
tumor I-Disease
growth O
might O
be O
, O
in O
part O
, O
driven O
by O
selection O
for O
a O
mutation O
in O
the O
mutation O
cluster O
region O
. O

germ O
- O
line O
mutations O
in O
the O
brca1 O
tumor O
- O
suppressor O
gene O
are O
associated O
with O
an O
increased O
susceptibility O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

combined B-Disease
genetic I-Disease
deficiency I-Disease
of I-Disease
c6 I-Disease
and I-Disease
c7 I-Disease
in O
man O
. O

by O
routine O
screening O
of O
sera O
, O
a O
subject O
was O
discovered O
who O
showed O
a O
sub B-Disease
- I-Disease
total I-Disease
deficiency I-Disease
of I-Disease
c6 I-Disease
and I-Disease
c7 I-Disease
. O

no O
clinical O
disease O
was O
associated O
with O
this O
deficiency O
which O
was O
transmitted O
through O
the O
subjects O
family O
as O
a O
single O
genetic O
characteristic O
, O
the O
c6 B-Disease
deficiency I-Disease
being O
associated O
with O
a O
silent O
allele O
at O
the O
structural O
locus O
. O

changes O
at O
p183 O
of O
emerin O
weaken O
its O
protein O
- O
protein O
interactions O
resulting O
in O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O

emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
muscular I-Disease
dystrophy I-Disease
characterized O
by O
early O
contractures B-Disease
of I-Disease
the I-Disease
elbows I-Disease
, I-Disease
achilles I-Disease
tendons I-Disease
and I-Disease
spine I-Disease
, O
slowly O
progressive O
muscle B-Disease
wasting I-Disease
and O
weakness B-Disease
, O
and O
cardiomyopathy B-Disease
associated O
with O
cardiac B-Disease
conduction I-Disease
defects I-Disease
. O

mutations O
spanning O
the O
emerin O
gene O
have O
been O
identified O
in O
patients O
with O
edmd B-Disease
. O

we O
present O
here O
the O
effect O
, O
on O
emerin O
protein O
expression O
, O
of O
two O
missense O
mutations O
identified O
in O
unrelated O
edmd B-Disease
patients O
. O

in O
comparison O
with O
the O
usual O
edmd B-Disease
phenotype O
, O
patients O
with O
p183 O
missense O
mutations O
have O
a O
later O
age O
at O
onset O
of O
first O
symptoms O
, O
elbow B-Disease
contractures I-Disease
, O
ankle B-Disease
contractures I-Disease
, O
upper B-Disease
limb I-Disease
weakness I-Disease
and O
lower B-Disease
limb I-Disease
weakness I-Disease
, O
but O
there O
is O
no O
difference O
for O
the O
age O
at O
onset O
of O
cardiac B-Disease
involvement I-Disease
. O

this O
is O
the O
first O
report O
of O
protein O
studies O
on O
patients O
with O
missense O
mutations O
resulting O
in O
the O
clinical O
features O
of O
edmd B-Disease
. O

microdeletions O
at O
chromosome O
bands O
1q32 O
- O
q41 O
as O
a O
cause O
of O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
. O

van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
( O
vws B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
comprising O
cleft B-Disease
lip I-Disease
and O
/ O
or O
cleft B-Disease
palate I-Disease
and O
lip B-Disease
pits I-Disease
. O

along O
with O
cleft B-Disease
lip I-Disease
/ I-Disease
palate I-Disease
and O
lip B-Disease
pits I-Disease
, O
affected O
relatives O
exhibit O
developmental B-Disease
delays I-Disease
, O
suggesting O
that O
the O
function O
of O
a O
gene O
nearby O
may O
also O
be O
disrupted O
. O

to O
further O
localize O
the O
vws B-Disease
gene O
we O
searched O
for O
other O
deletions O
that O
cause O
vws B-Disease
. O

in O
this O
family O
, O
the O
phenotype O
in O
three O
generations O
of O
affected O
individuals O
was O
confined O
to O
the O
cardinal O
signs O
of O
vws B-Disease
. O

2 O
- O
1 O
mb O
beyond O
the O
proximal O
breakpoint O
for O
the O
deletion O
described O
previously O
. O

no O
deletions O
were O
detected O
in O
seven O
cases O
of O
popliteal B-Disease
pterygia I-Disease
syndrome I-Disease
, O
76 O
cases O
of O
mixed O
syndromic B-Disease
forms I-Disease
of I-Disease
cleft I-Disease
lip I-Disease
and I-Disease
palate I-Disease
, O
and O
178 O
cases O
of O
nonsyndromic B-Disease
cleft I-Disease
lip I-Disease
and I-Disease
palate I-Disease
. O

splicing O
defects O
in O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
, O
atm O
: O
underlying O
mutations O
and O
consequences O
. O

mutations O
resulting O
in O
defective O
splicing O
constitute O
a O
significant O
proportion O
( O
30 O
/ O
62 O
[ O
48 O
% O
] O
) O
of O
a O
new O
series O
of O
mutations O
in O
the O
atm O
gene O
in O
patients O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
at B-Disease
) O
that O
were O
detected O
by O
the O
protein O
- O
truncation O
assay O
followed O
by O
sequence O
analysis O
of O
genomic O
dna O
. O

no O
atm O
protein O
was O
detected O
by O
western O
blotting O
in O
any O
at B-Disease
cell O
line O
in O
which O
splicing O
mutations O
were O
identified O
. O

alpha O
- O
cardiac O
actin O
is O
a O
novel O
disease O
gene O
in O
familial B-Disease
hypertrophic I-Disease
cardiomyopathy I-Disease
. O

we O
identified O
the O
alpha O
- O
cardiac O
actin O
gene O
( O
actc O
) O
as O
a O
novel O
disease O
gene O
in O
a O
pedigree O
suffering O
from O
familial B-Disease
hypertrophic I-Disease
cardiomyopathy I-Disease
( O
fhc B-Disease
) O
. O

linkage O
analyses O
excluded O
all O
the O
previously O
reported O
fhc B-Disease
loci O
as O
possible O
disease O
loci O
in O
the O
family O
studied O
, O
with O
lod O
scores O
varying O
between O
- O
2 O
. O

mutation O
analysis O
of O
actc O
revealed O
an O
ala295ser O
mutation O
in O
exon O
5 O
close O
to O
2 O
missense O
mutations O
recently O
described O
to O
cause O
the O
inherited O
form O
of O
idiopathic B-Disease
dilated I-Disease
cardiomyopathy I-Disease
( O
idc B-Disease
) O
. O

overgrowth B-Disease
of I-Disease
oral I-Disease
mucosa I-Disease
and I-Disease
facial I-Disease
skin I-Disease
, O
a O
novel O
feature O
of O
aspartylglucosaminuria B-Disease
. O

aspartylglucosaminuria B-Disease
( O
agu B-Disease
) O
is O
a O
lysosomal B-Disease
storage I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
aspartylglucosaminidase I-Disease
( O
aga O
) O
. O

the O
main O
symptom O
is O
progressive O
mental B-Disease
retardation I-Disease
. O

we O
were O
able O
to O
examine O
66 O
finnish O
agu B-Disease
patients O
for O
changes O
in O
the O
oral O
mucosa O
and O
44 O
of O
these O
for O
changes O
in O
facial O
skin O
. O

biopsy O
specimens O
of O
16 O
oral O
lesions O
, O
12 O
of O
them O
associated O
with O
the O
teeth O
, O
plus O
two O
facial B-Disease
lesions I-Disease
were O
studied O
histologically O
. O

skin O
was O
seborrhoeic O
in O
adolescent O
and O
adult O
patients O
, O
with O
erythema B-Disease
of I-Disease
the I-Disease
facial I-Disease
skin I-Disease
already O
common O
in O
childhood O
. O

of O
44 O
patients O
, O
nine O
( O
20 O
% O
) O
had O
facial B-Disease
angiofibromas I-Disease
, O
tumours B-Disease
primarily O
occurring O
in O
association O
with O
tuberous B-Disease
sclerosis I-Disease
. O

oedemic B-Disease
buccal I-Disease
mucosa I-Disease
( O
leucoedema B-Disease
) O
and O
gingival B-Disease
overgrowths I-Disease
were O
more O
frequent O
in O
agu B-Disease
patients O
than O
in O
controls O
( O
p O
< O
0 O
. O
001 O
) O
. O

of O
16 O
oral B-Disease
mucosal I-Disease
lesions I-Disease
studied O
histologically O
, O
15 O
represented O
fibroepithelial B-Disease
or I-Disease
epithelial I-Disease
hyperplasias I-Disease
and O
were O
reactive O
in O
nature O
. O

immunohistochemically O
, O
expression O
of O
aga O
in O
agu B-Disease
patients O
mucosal B-Disease
lesions I-Disease
did O
not O
differ O
from O
that O
seen O
in O
corresponding O
lesions O
of O
normal O
subjects O
. O

thus O
, O
the O
high O
frequency O
of O
mucosal B-Disease
overgrowth I-Disease
in O
agu B-Disease
patients O
does O
not O
appear O
to O
be O
directly O
associated O
with O
lysosomal O
storage O
or O
with O
alterations O
in O
the O
level O
of O
aga O
expression O
. O

characterization O
of O
a O
germline O
mosaicism O
in O
families O
with O
lowe B-Disease
syndrome I-Disease
, O
and O
identification O
of O
seven O
novel O
mutations O
in O
the O
ocrl1 O
gene O
. O

the O
oculocerebrorenal B-Disease
syndrome I-Disease
of I-Disease
lowe I-Disease
( O
ocrl B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
characterized O
by O
major O
abnormalities B-Disease
of I-Disease
eyes I-Disease
, I-Disease
nervous I-Disease
system I-Disease
, I-Disease
and I-Disease
kidneys I-Disease
. O

we O
have O
examined O
the O
ocrl1 O
gene O
in O
eight O
unrelated O
patients O
with O
ocrl B-Disease
and O
have O
found O
seven O
new O
mutations O
and O
one O
recurrent O
in O
- O
frame O
deletion O
. O

this O
observation O
has O
direct O
implications O
for O
genetic O
counseling O
of O
lowe B-Disease
syndrome I-Disease
families O
. O
. O

mefv O
- O
gene O
analysis O
in O
armenian O
patients O
with O
familial B-Disease
mediterranean I-Disease
fever I-Disease
: O
diagnostic O
value O
and O
unfavorable O
renal O
prognosis O
of O
the O
m694v O
homozygous O
genotype O
- O
genetic O
and O
therapeutic O
implications O
. O

familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
is O
a O
recessively B-Disease
inherited I-Disease
disorder I-Disease
that O
is O
common O
in O
patients O
of O
armenian O
ancestry O
. O

to O
date O
, O
its O
diagnosis O
, O
which O
can O
be O
made O
only O
retrospectively O
, O
is O
one O
of O
exclusion O
, O
based O
entirely O
on O
nonspecific O
clinical O
signs O
that O
result O
from O
serosal B-Disease
inflammation I-Disease
and O
that O
may O
lead O
to O
unnecessary O
surgery O
. O

renal B-Disease
amyloidosis I-Disease
, O
prevented O
by O
colchicine O
, O
is O
the O
most O
severe O
complication O
of O
fmf B-Disease
, O
a O
disorder O
associated O
with O
mutations O
in O
the O
mefv O
gene O
. O

to O
evaluate O
the O
diagnostic O
and O
prognostic O
value O
of O
mefv O
- O
gene O
analysis O
, O
we O
investigated O
90 O
armenian O
fmf B-Disease
patients O
from O
77 O
unrelated O
families O
that O
were O
not O
selected O
through O
genetic O
- O
linkage O
analysis O
. O

eight O
mutations O
, O
one O
of O
which O
( O
r408q O
) O
is O
new O
, O
were O
found O
to O
account O
for O
93 O
% O
of O
the O
163 O
independent O
fmf B-Disease
alleles O
, O
with O
both O
fmf B-Disease
alleles O
identified O
in O
89 O
% O
of O
the O
patients O
. O

the O
m694v O
homozygous O
genotype O
was O
found O
to O
be O
associated O
with O
a O
higher O
prevalence O
of O
renal B-Disease
amyloidosis I-Disease
and O
arthritis B-Disease
, O
compared O
with O
other O
genotypes O
( O
p O
= O
. O
0002 O
and O
p O
= O
. O
006 O
, O
respectively O
) O
. O

noninvasive O
test O
for O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
using O
hair O
root O
analysis O
. O

identification O
of O
the O
fmr1 O
gene O
and O
the O
repeat O
- O
amplification O
mechanism O
causing O
fragile B-Disease
x I-Disease
syndrome I-Disease
led O
to O
development O
of O
reliable O
dna O
- O
based O
diagnostic O
methods O
, O
including O
southern O
blot O
hybridization O
and O
pcr O
. O

using O
an O
immunocytochemical O
technique O
on O
blood O
smears O
, O
we O
recently O
developed O
a O
novel O
test O
for O
identification O
of O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

here O
we O
describe O
a O
new O
diagnostic O
test O
to O
identify O
male O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
on O
the O
basis O
of O
lack O
of O
fmrp O
in O
their O
hair O
roots O
. O

expression O
of O
fmrp O
in O
hair O
roots O
was O
studied O
by O
use O
of O
an O
fmrp O
- O
specific O
antibody O
test O
, O
and O
the O
percentage O
of O
fmrp O
- O
expressing O
hair O
roots O
in O
controls O
and O
in O
male O
fragile B-Disease
x I-Disease
patients O
was O
determined O
. O

control O
individuals O
showed O
clear O
expression O
of O
fmrp O
in O
nearly O
every O
hair O
root O
, O
whereas O
male O
fragile B-Disease
x I-Disease
patients O
lacked O
expression O
of O
fmrp O
in O
almost O
all O
their O
hair O
roots O
. O

mentally B-Disease
retarded I-Disease
female O
patients O
with O
a O
full O
mutation O
showed O
fmrp O
expression O
in O
only O
some O
of O
their O
hair O
roots O
( O
< O
55 O
% O
) O
, O
and O
no O
overlap O
with O
normal O
female O
controls O
was O
observed O
. O

the O
advantages O
of O
this O
test O
are O
( O
1 O
) O
plucking O
of O
hair O
follicles O
does O
no O
appreciable O
harm O
to O
the O
mentally B-Disease
retarded I-Disease
patient O
, O
( O
2 O
) O
hairs O
can O
be O
sent O
in O
a O
simple O
envelope O
to O
a O
diagnostic O
center O
, O
and O
( O
3 O
) O
the O
result O
of O
the O
test O
is O
available O
within O
5 O
h O
of O
plucking O
. O

in O
addition O
, O
this O
test O
enabled O
us O
to O
identify O
two O
fragile B-Disease
x I-Disease
patients O
who O
did O
not O
show O
the O
full O
mutation O
by O
analysis O
of O
dna O
isolated O
from O
blood O
cells O
. O
. O

in O
swedish O
families O
with O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
, O
linkage O
to O
the O
hpc1 O
locus O
on O
chromosome O
1q24 O
- O
25 O
is O
restricted O
to O
families O
with O
early O
- O
onset O
prostate B-Disease
cancer I-Disease
. O

prostate B-Disease
cancer I-Disease
clusters O
in O
some O
families O
, O
and O
an O
estimated O
5 O
% O
- O
10 O
% O
of O
all O
cases O
are O
estimated O
to O
result O
from O
inheritance O
of O
prostate O
cancer O
- O
susceptibility O
genes O
. O

we O
previously O
reported O
evidence O
of O
linkage O
to O
the O
1q24 O
- O
25 O
region O
( O
hpc1 O
) O
in O
91 O
north O
american O
and O
swedish O
families O
each O
with O
multiple O
cases O
of O
prostate B-Disease
cancer I-Disease
( O
smith O
et O
al O
. O
1996 O
) O
. O

in O
the O
present O
report O
we O
analyze O
40 O
( O
12 O
original O
and O
28 O
newly O
identified O
) O
swedish O
families O
with O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
( O
hpc B-Disease
) O
that O
, O
on O
the O
basis O
of O
40 O
markers O
spanning O
a O
25 O
- O
cm O
interval O
within O
1q24 O
- O
25 O
, O
have O
evidence O
of O
linkage O
. O

these O
results O
are O
consistent O
with O
the O
hypothesis O
of O
linkage O
to O
hpc1 O
in O
a O
subset O
of O
families O
with O
prostate B-Disease
cancer I-Disease
, O
particularly O
those O
with O
an O
early O
age O
at O
diagnosis O
. O

molecular O
basis O
of O
feline O
beta B-Disease
- I-Disease
glucuronidase I-Disease
deficiency I-Disease
: O
an O
animal O
model O
of O
mucopolysaccharidosis B-Disease
vii I-Disease
. O

a O
family O
of O
domestic O
cats O
was O
found O
that O
exhibited O
clinical O
and O
biochemical O
abnormalities O
consistent O
with O
mucopolysaccharidosis B-Disease
vii I-Disease
, O
an O
autosomal B-Disease
recessive I-Disease
lysosomal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
beta B-Disease
- I-Disease
glucuronidase I-Disease
deficiency I-Disease
. O

carriers O
identified O
in O
this O
manner O
produced O
affected O
kittens O
in O
prospective O
breedings O
, O
and O
a O
feline O
mps B-Disease
vii I-Disease
breeding O
colony O
has O
been O
established O
. O
. O

a O
common O
molecular O
basis O
for O
rearrangement B-Disease
disorders I-Disease
on O
chromosome O
22q11 O
. O

the O
chromosome O
22q11 O
region O
is O
susceptible O
to O
rearrangements O
that O
are O
associated O
with O
congenital B-Disease
anomaly I-Disease
disorders I-Disease
and O
malignant B-Disease
tumors I-Disease
. O

three O
congenital B-Disease
anomaly I-Disease
disorders I-Disease
, O
cat B-Disease
- I-Disease
eye I-Disease
syndrome I-Disease
, O
der B-Disease
( I-Disease
) I-Disease
syndrome I-Disease
and O
velo B-Disease
- I-Disease
cardio I-Disease
- I-Disease
facial I-Disease
syndrome I-Disease
/ O
digeorge B-Disease
syndrome I-Disease
( O
vcfs B-Disease
/ O
dgs B-Disease
) O
are O
associated O
with O
tetrasomy O
, O
trisomy O
or O
monosomy O
, O
respectively O
, O
for O
part O
of O
chromosome O
22q11 O
. O

vcfs B-Disease
/ O
dgs B-Disease
is O
the O
most O
common O
syndrome O
associated O
with O
22q11 O
rearrangements O
. O

in O
order O
to O
determine O
whether O
there O
are O
particular O
regions O
on O
22q11 O
that O
are O
prone O
to O
rearrangements O
, O
the O
deletion O
end O
- O
points O
in O
a O
large O
number O
of O
vcfs B-Disease
/ O
dgs B-Disease
patients O
were O
defined O
by O
haplotype O
analysis O
. O

most O
vcfs B-Disease
/ O
dgs B-Disease
patients O
have O
a O
similar O
3 O
mb O
deletion O
, O
some O
have O
a O
nested O
distal O
deletion O
breakpoint O
resulting O
in O
a O
1 O
. O

to O
investigate O
this O
hypothesis O
, O
we O
developed O
hamster O
- O
human O
somatic O
hybrid O
cell O
lines O
from O
vcfs B-Disease
/ O
dgs B-Disease
patients O
with O
all O
three O
classes O
of O
deletions O
and O
we O
now O
show O
that O
the O
breakpoints O
occur O
within O
similar O
low O
copy O
repeats O
, O
termed O
lcr22s O
. O

to O
support O
this O
idea O
further O
, O
we O
identified O
a O
family O
that O
carries O
an O
interstitial O
duplication O
of O
the O
same O
3 O
mb O
region O
that O
is O
deleted O
in O
vcfs B-Disease
/ O
dgs B-Disease
patients O
. O

we O
present O
models O
to O
explain O
how O
the O
lcr22s O
can O
mediate O
different O
homologous O
recombination O
events O
, O
thereby O
generating O
a O
number O
of O
rearrangements O
that O
are O
associated O
with O
congenital B-Disease
anomaly I-Disease
disorders I-Disease
. O

functional O
consequences O
of O
mutations O
in O
the O
early O
growth O
response O
2 O
gene O
( O
egr2 O
) O
correlate O
with O
severity O
of O
human O
myelinopathies B-Disease
. O

this O
idea O
is O
based O
partly O
on O
the O
phenotype O
of O
homozygous O
krox20 O
( O
egr2 O
) O
knockout O
mice O
, O
which O
display O
hypomyelination B-Disease
of I-Disease
the I-Disease
pns I-Disease
and O
a O
block O
of O
schwann O
cells O
at O
an O
early O
stage O
of O
differentiation O
. O

mutations O
in O
the O
human O
egr2 O
gene O
have O
recently O
been O
associated O
with O
the O
inherited B-Disease
peripheral I-Disease
neuropathies I-Disease
charcot B-Disease
- I-Disease
marie I-Disease
- I-Disease
tooth I-Disease
type I-Disease
1 I-Disease
, O
dejerine B-Disease
- I-Disease
sottas I-Disease
syndrome I-Disease
and O
congenital B-Disease
hypomyelinating I-Disease
neuropathy I-Disease
. O

autosomal B-Disease
recessive I-Disease
familial I-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
with O
continued O
secretion O
of O
mutant O
weakly O
active O
vasopressin O
. O

familial B-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
post O
- O
natal O
development O
of O
arginine B-Disease
vasopressin I-Disease
( I-Disease
avp I-Disease
) I-Disease
deficiency I-Disease
due O
to O
mutations O
in O
the O
avp O
gene O
. O

all O
published O
mutations O
affect O
the O
signal O
peptide O
or O
the O
neurophysin O
- O
ii O
carrier O
protein O
and O
are O
presumed O
to O
interfere O
with O
processing O
of O
the O
preprohormone O
, O
leading O
to O
neuronal B-Disease
damage I-Disease
. O

we O
studied O
an O
unusual O
palestinian O
family O
consisting O
of O
asymptomatic O
first O
cousin O
parents O
and O
three O
children O
affected O
with O
neurohypophyseal B-Disease
diabetes I-Disease
insipidus I-Disease
, O
suggesting O
autosomal O
recessive O
inheritance O
. O

the O
youngest O
child O
( O
2 O
years O
old O
) O
was O
only O
mildly O
affected O
but O
had O
leu O
- O
avp O
levels O
similar O
to O
her O
severely O
affected O
8 O
- O
year O
- O
old O
brother O
, O
suggesting O
that O
unknown O
mechanisms O
may O
partially O
compensate O
for O
a O
deficiency B-Disease
of I-Disease
active I-Disease
avp I-Disease
in O
very O
young O
children O
. O
. O

a O
somatic O
mutation O
in O
the O
x O
linked O
piga O
gene O
is O
responsible O
for O
the O
deficiency B-Disease
of I-Disease
glycosyl I-Disease
phosphatidylinositol I-Disease
( I-Disease
gpi I-Disease
) I-Disease
- I-Disease
anchored I-Disease
proteins I-Disease
on O
blood O
cells O
from O
patients O
with O
paroxysmal B-Disease
nocturnal I-Disease
hemoglobinuria I-Disease
. O

no O
inherited O
form O
of O
gpi B-Disease
- I-Disease
anchor I-Disease
deficiency I-Disease
has O
been O
described O
. O

because O
conventional O
piga O
gene O
knockout O
is O
associated O
with O
high O
embryonic B-Disease
lethality I-Disease
in O
chimeric O
mice O
, O
we O
used O
the O
cre O
/ O
loxp O
system O
. O

piga O
( O
- O
) O
cells O
had O
no O
growth O
advantage O
, O
suggesting O
that O
other O
factors O
are O
needed O
for O
their O
clonal O
dominance O
in O
patients O
with O
paroxysmal B-Disease
nocturnal I-Disease
hemoglobinuria I-Disease
. O

the O
c282y O
mutation O
causing O
hereditary B-Disease
hemochromatosis I-Disease
does O
not O
produce O
a O
null O
allele O
. O

targeted O
mutagenesis O
was O
used O
to O
produce O
two O
mutations O
in O
the O
murine O
hemochromatosis B-Disease
gene O
( O
hfe O
) O
locus O
. O

this O
mutation O
is O
identical O
to O
the O
disease O
- O
causing O
mutation O
in O
patients O
with O
hereditary B-Disease
hemochromatosis I-Disease
. O

genotype O
- O
phenotype O
analysis O
in O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
and O
identification O
of O
a O
missense O
mutation O
associated O
with O
a O
milder O
phenotype O
. O

direct O
sequencing O
of O
the O
emerin O
gene O
in O
22 O
families O
with O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
emd B-Disease
) O
revealed O
mutations O
in O
21 O
( O
95 O
% O
) O
, O
confirming O
that O
emerin O
mutations O
can O
be O
identified O
in O
the O
majority O
of O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
emd I-Disease
. O

age O
at O
onset O
was O
later O
for O
first O
symptoms O
and O
for O
development O
of O
ankle B-Disease
contractures I-Disease
and O
muscle B-Disease
weakness I-Disease
. O

severe O
clinical O
expression O
in O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
is O
a O
relatively O
rare O
benign B-Disease
neuromuscular I-Disease
disorder I-Disease
which O
can O
vary O
remarkably O
in O
onset O
, O
course O
and O
severity O
. O

in O
the O
present O
study O
, O
a O
tctac O
deletion O
spanning O
the O
nucleotides O
631 O
- O
635 O
of O
the O
emerin O
gene O
caused O
an O
unusually O
severe O
disease O
phenotype O
including O
loss B-Disease
of I-Disease
ambulation I-Disease
and O
severe O
muscle B-Disease
wasting I-Disease
in O
two O
affected O
brothers O
. O

the O
interfamilial O
heterogeneity O
in O
distribution O
and O
in O
severity O
of O
the O
features O
in O
the O
two O
families O
point O
to O
environmental O
or O
genetic O
modification O
as O
the O
cause O
of O
clinical O
variability O
in O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O
. O

common O
mutations O
in O
brca1 O
and O
brca2 O
do O
not O
contribute O
to O
early O
prostate B-Disease
cancer I-Disease
in O
jewish O
men O
. O

background O
families O
with O
a O
high O
incidence O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
, O
and O
subsequently O
shown O
to O
have O
terminating O
mutations O
in O
brca1 O
or O
brca2 O
, O
appear O
to O
have O
a O
higher O
incidence O
of O
prostate B-Disease
cancer I-Disease
among O
male O
relatives O
. O

we O
aimed O
to O
determine O
whether O
the O
common O
germline O
mutations O
of O
brca1 O
or O
brca2 O
in O
ashkenazi O
jewish O
men O
predisposed O
them O
to O
prostate B-Disease
cancer I-Disease
. O

methods O
we O
examined O
genomic O
dna O
from O
83 O
( O
for O
brca1 O
185delag O
) O
or O
82 O
( O
for O
brca2 O
6174delt O
) O
ashkenazi O
jewish O
prostate B-Disease
cancer I-Disease
patients O
, O
most O
of O
whom O
were O
treated O
at O
a O
relatively O
young O
age O
, O
for O
the O
most O
common O
germline O
mutation O
in O
each O
gene O
seen O
in O
the O
ashkenazi O
population O
. O

results O
our O
study O
should O
have O
been O
able O
to O
detect O
a O
4 O
- O
5 O
- O
fold O
increase O
in O
the O
risk O
of O
prostate B-Disease
cancer I-Disease
due O
to O
mutation O
of O
brca1 O
or O
brca2 O
. O

conclusions O
the O
incidence O
of O
each O
of O
the O
germline O
mutations O
in O
these O
prostate B-Disease
cancer I-Disease
patients O
closely O
matched O
their O
incidence O
( O
about O
1 O
% O
) O
in O
the O
general O
ashkenazi O
jewish O
population O
. O

this O
suggests O
that O
unlike O
cases O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
, O
mutations O
in O
brca1 O
or O
brca2 O
do O
not O
significantly O
predispose O
men O
to O
prostate B-Disease
cancer I-Disease

beta O
- O
catenin O
accumulation O
and O
mutation O
of O
the O
ctnnb1 O
gene O
in O
hepatoblastoma B-Disease
. O

hepatoblastoma B-Disease
is O
a O
rare O
malignant B-Disease
tumor I-Disease
of I-Disease
the I-Disease
liver I-Disease
that O
occurs O
in O
children O
at O
an O
average O
age O
of O
2 O
to O
3 O
years O
. O

epidemiologic O
studies O
have O
shown O
an O
increased O
frequency O
of O
this O
tumor B-Disease
type O
in O
families O
affected O
by O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
. O

in O
addition O
to O
the O
epidemiologic O
data O
, O
molecular O
genetic O
studies O
suggest O
that O
inactivation O
of O
the O
apc B-Disease
tumor I-Disease
suppressor O
may O
be O
involved O
in O
hepatoblastoma B-Disease
tumorigenesis O
. O

in O
an O
ongoing O
immunohistochemical O
study O
of O
beta O
- O
catenin O
expression O
in O
sporadic O
cases O
of O
tumor B-Disease
types O
that O
are O
associated O
with O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
, O
we O
observed O
increased O
beta O
- O
catenin O
levels O
in O
the O
cytoplasm O
and O
in O
the O
nuclei O
of O
three O
investigated O
hepatoblastomas B-Disease
. O

sequencing O
of O
exon O
3 O
of O
the O
beta O
- O
catenin O
gene O
( O
ctnnb1 O
) O
revealed O
an O
activating O
mutation O
in O
one O
of O
the O
tumor B-Disease
samples O
. O

our O
data O
indicate O
for O
the O
first O
time O
that O
beta O
- O
catenin O
accumulation O
may O
play O
a O
role O
in O
the O
development O
of O
hepatoblastoma B-Disease
and O
that O
activating O
mutations O
of O
the O
beta O
- O
catenin O
gene O
may O
substitute O
biallelic O
apc O
inactivation O
in O
this O
tumor B-Disease
type O
. O

decrease O
in O
gtp O
cyclohydrolase O
i O
gene O
expression O
caused O
by O
inactivation O
of O
one O
allele O
in O
hereditary B-Disease
progressive I-Disease
dystonia I-Disease
with O
marked O
diurnal O
fluctuation O
. O

hereditary B-Disease
progressive I-Disease
dystonia I-Disease
with O
marked O
diurnal O
fluctuation O
( O
hpd B-Disease
; O
dopa B-Disease
- I-Disease
responsive I-Disease
dystonia I-Disease
, O
drd B-Disease
) O
have O
been O
recently O
found O
to O
be O
caused O
by O
a O
genetic B-Disease
defect I-Disease
in O
the O
gtp O
cyclohydrolase O
i O
( O
gch1 O
) O
gene O
. O

these O
results O
suggest O
that O
some O
novel O
mutations O
should O
exist O
on O
one O
of O
the O
alleles O
in O
some O
unknown O
region O
of O
the O
gch1 O
gene O
, O
and O
may O
decrease O
the O
gch1 O
mrna O
causing O
the O
hpd B-Disease
/ O
drd B-Disease
symptoms O
. O
. O

sulfate O
transport O
is O
not O
impaired O
in O
pendred B-Disease
syndrome I-Disease
thyrocytes O
. O

pendred B-Disease
syndrome I-Disease
is O
the O
most O
common O
form O
of O
syndromic B-Disease
deafness I-Disease
, O
characterized O
by O
dyshormonogenic B-Disease
goiter I-Disease
associated O
with O
sensory B-Disease
- I-Disease
neural I-Disease
deafness I-Disease
. O

the O
gene O
responsible O
for O
the O
disease O
( O
pds B-Disease
) O
has O
been O
cloned O
, O
but O
its O
function O
is O
as O
yet O
unknown O
and O
the O
connection O
between O
thyroid B-Disease
goiter I-Disease
and O
sensory B-Disease
- I-Disease
neural I-Disease
deafness I-Disease
remains O
an O
enigma O
. O

we O
tested O
sulfate O
transport O
in O
thyrocytes O
obtained O
from O
pendred B-Disease
syndrome I-Disease
patients O
and O
found O
that O
it O
was O
not O
defective O
. O

small O
deletions O
in O
the O
type O
ii O
collagen O
triple O
helix O
produce O
kniest B-Disease
dysplasia I-Disease
. O

kniest B-Disease
dysplasia I-Disease
is O
a O
moderately O
severe O
type B-Disease
ii I-Disease
collagenopathy I-Disease
, O
characterized O
by O
short O
trunk O
and O
limbs O
, O
kyphoscoliosis B-Disease
, O
midface B-Disease
hypoplasia I-Disease
, O
severe O
myopia B-Disease
, O
and O
hearing B-Disease
loss I-Disease
. O

mutations O
in O
the O
gene O
that O
encodes O
type O
ii O
collagen O
( O
col2a1 O
) O
, O
the O
predominant O
protein O
of O
cartilage O
, O
have O
been O
identified O
in O
a O
number O
of O
individuals O
with O
kniest B-Disease
dysplasia I-Disease
. O

we O
used O
heteroduplex O
analysis O
to O
identify O
sequence O
anomalies O
in O
five O
individuals O
with O
kniest B-Disease
dysplasia I-Disease
. O

sequencing O
of O
the O
index O
patients O
genomic O
dna O
identified O
four O
new O
dominant O
mutations O
in O
col2a1 O
that O
result O
in O
kniest B-Disease
dysplasia I-Disease
a O
21 O
- O
bp O
deletion O
in O
exon O
16 O
, O
an O
18 O
- O
bp O
deletion O
in O
exon O
19 O
, O
and O
4 O
- O
bp O
deletions O
in O
the O
splice O
donor O
sites O
of O
introns O
14 O
and O
20 O
. O

these O
data O
suggest O
that O
kniest B-Disease
dysplasia I-Disease
results O
from O
shorter O
type O
ii O
collagen O
monomers O
, O
and O
support O
the O
hypothesis O
that O
alteration O
of O
a O
specific O
col2a1 O
domain O
, O
which O
may O
span O
from O
exons O
12 O
to O
24 O
, O
leads O
to O
the O
kniest B-Disease
dysplasia I-Disease
phenotype O
. O
. O

classical B-Disease
galactosemia I-Disease
and O
mutations O
at O
the O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
( O
galt O
) O
gene O
. O

classical B-Disease
galactosemia I-Disease
is O
caused O
by O
a O
deficiency O
in O
activity O
of O
the O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
( O
galt O
) O
, O
which O
, O
in O
turn O
, O
is O
caused O
by O
mutations O
at O
the O
galt O
gene O
. O

the O
considerable O
genetic O
heterogeneity O
documented O
to O
date O
undoubtedly O
contributes O
to O
the O
phenotypic O
heterogeneity O
that O
is O
observed O
in O
galactosemia B-Disease
. O

mutations O
of O
the O
vhl B-Disease
gene O
in O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
: O
definition O
of O
a O
risk O
factor O
for O
vhl B-Disease
patients O
to O
develop O
an O
rcc B-Disease
. O

to O
investigate O
the O
nature O
of O
somatic O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( O
vhl B-Disease
) O
mutations O
, O
we O
analyzed O
173 O
primary O
sporadic O
human O
renal B-Disease
cell I-Disease
carcinomas I-Disease
for O
mutations O
of O
the O
vhl B-Disease
tumor I-Disease
suppressor O
gene O
, O
using O
polymerase O
chain O
reaction O
( O
pcr O
) O
and O
single O
- O
strand O
conformational O
polymorphism O
analysis O
( O
sscp O
) O
of O
dna O
. O

among O
these O
mutations O
, O
50 O
% O
correspond O
to O
new O
mutations O
. O

vhl B-Disease
mutations O
were O
found O
only O
in O
the O
nonpapillary B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
( O
rcc B-Disease
) O
subtype O
, O
as O
previously O
reported O
. O

to O
compare O
somatic O
and O
germline O
mutations O
, O
we O
used O
the O
vhl B-Disease
database O
, O
which O
includes O
507 O
mutations O
. O

we O
postulated O
that O
a O
specific O
pattern O
of O
vhl B-Disease
mutations O
is O
associated O
with O
sporadic B-Disease
rcc I-Disease
. O

we O
then O
analyzed O
the O
occurrence O
of O
rcc B-Disease
in O
vhl B-Disease
families O
, O
based O
on O
the O
nature O
of O
mutations O
. O

we O
observed O
rcc B-Disease
in O
at O
least O
one O
member O
of O
the O
vhl B-Disease
families O
in O
77 O
% O
of O
cases O
with O
mutations O
leading O
to O
truncated O
proteins O
versus O
55 O
% O
in O
cases O
with O
missense O
mutations O
( O
p O
< O
0 O
. O
05 O
) O
. O

thus O
, O
mutations O
resulting O
in O
truncated O
proteins O
may O
lead O
to O
a O
higher O
risk O
of O
rcc B-Disease
in O
vhl B-Disease
patients O

defective O
ctla O
- O
4 O
cycling O
pathway O
in O
chediak B-Disease
- I-Disease
higashi I-Disease
syndrome I-Disease
: O
a O
possible O
mechanism O
for O
deregulation O
of O
t O
lymphocyte O
activation O
. O

chediak B-Disease
- I-Disease
higashi I-Disease
syndrome I-Disease
( O
chs B-Disease
) O
is O
an O
inherited B-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
lysosomal O
trafficking O
regulator O
gene O
, O
lyst O
. O

it O
results O
in O
defective O
membrane O
targeting O
of O
the O
proteins O
present O
in O
secretory O
lysosomes O
, O
and O
it O
is O
associated O
with O
a O
variety O
of O
features O
, O
including O
a O
lymphoproliferative B-Disease
syndrome I-Disease
with O
hemophagocytosis B-Disease
. O

the O
murine O
equivalent O
of O
chs B-Disease
, O
beige O
mice O
, O
present O
similar O
characteristics O
but O
do O
not O
develop O
the O
lymphoproliferative B-Disease
syndrome I-Disease
. O

we O
show O
herein O
that O
ctla O
- O
4 O
is O
present O
in O
enlarged O
, O
abnormal O
vesicles O
in O
chs B-Disease
t O
cells O
and O
is O
not O
properly O
expressed O
at O
the O
cell O
surface O
after O
t O
cell O
activation O
, O
whereas O
its O
surface O
expression O
is O
not O
impaired O
. O

it O
is O
therefore O
proposed O
that O
the O
defective O
surface O
expression O
of O
ctla O
- O
4 O
by O
chs B-Disease
t O
cells O
is O
involved O
in O
the O
generation O
of O
lymphoproliferative B-Disease
disease I-Disease
. O

proteolipoprotein O
gene O
analysis O
in O
82 O
patients O
with O
sporadic O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
: O
duplications O
, O
the O
major O
cause O
of O
the O
disease O
, O
originate O
more O
frequently O
in O
male O
germ O
cells O
, O
but O
point O
mutations O
do O
not O
. O

the O
clinical O
european O
network O
on O
brain B-Disease
dysmyelinating I-Disease
disease I-Disease
. O

pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
developmental I-Disease
defect I-Disease
of I-Disease
myelination I-Disease
affecting O
the O
central O
nervous O
system O
and O
segregating O
with O
the O
proteolipoprotein O
( O
plp O
) O
locus O
. O

chromosome O
breakage O
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
and I-Disease
angelman I-Disease
syndromes I-Disease
involves O
recombination O
between O
large O
, O
transcribed O
repeats O
at O
proximal O
and O
distal O
breakpoints O
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
and O
angelman B-Disease
syndrome I-Disease
( O
as B-Disease
) O
are O
distinct O
neurobehavioral B-Disease
disorders I-Disease
that O
most O
often O
arise O
from O
a O
4 O
- O
mb O
deletion O
of O
chromosome O
15q11 O
- O
q13 O
during O
paternal O
or O
maternal O
gametogenesis O
, O
respectively O
. O

one O
of O
five O
pws B-Disease
/ O
as B-Disease
patients O
analyzed O
to O
date O
has O
an O
identifiable O
, O
rearranged O
herc2 O
transcript O
derived O
from O
the O
deletion O
event O
. O

linkage O
analysis O
in O
a O
large O
brazilian O
family O
with O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
suggests O
the O
existence O
of O
a O
susceptibility O
locus O
for O
cleft B-Disease
palate I-Disease
at O
17p11 O
. O
2 O
- O
11 O
. O
1 O
. O

van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
( O
vws B-Disease
) O
, O
which O
has O
been O
mapped O
to O
1q32 O
- O
41 O
, O
is O
characterized O
by O
pits B-Disease
and I-Disease
/ I-Disease
or I-Disease
sinuses I-Disease
of I-Disease
the I-Disease
lower I-Disease
lip I-Disease
, O
cleft B-Disease
lip I-Disease
/ I-Disease
palate I-Disease
( O
cl B-Disease
/ I-Disease
p I-Disease
) O
, O
cleft B-Disease
palate I-Disease
( O
cp B-Disease
) O
, O
bifid B-Disease
uvula I-Disease
, O
and O
hypodontia B-Disease
( O
h B-Disease
) O
. O

both O
the O
occurrence O
of O
cl B-Disease
/ I-Disease
p I-Disease
and O
cp B-Disease
within O
the O
same O
genealogy O
and O
a O
recurrence O
risk O
< O
40 O
% O
for O
cp B-Disease
among O
descendants O
with O
vws B-Disease
have O
suggested O
that O
the O
development O
of O
clefts B-Disease
in O
this O
syndrome O
is O
influenced O
by O
modifying O
genes O
at O
other O
loci O
. O

to O
test O
this O
hypothesis O
, O
we O
have O
conducted O
linkage O
analysis O
in O
a O
large O
brazilian O
kindred O
with O
vws B-Disease
, O
considering O
as O
affected O
the O
individuals O
with O
cp B-Disease
, O
regardless O
of O
whether O
it O
is O
associated O
with O
other O
clinical O
signs O
of O
vws B-Disease
. O

1 O
, O
together O
with O
the O
vws B-Disease
gene O
at O
1p32 O
- O
41 O
, O
enhances O
the O
probability O
of O
cp B-Disease
in O
an O
individual O
carrying O
the O
two O
at O
- O
risk O
genes O
. O

if O
this O
hypothesis O
is O
confirmed O
in O
other O
vws B-Disease
pedigrees O
, O
it O
will O
represent O
one O
of O
the O
first O
examples O
of O
a O
gene O
, O
mapped O
through O
linkage O
analysis O
, O
which O
modifies O
the O
expression O
of O
a O
major O
gene O
. O

the O
gene O
for O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
, O
atm O
, O
spans O
about O
150 O
kb O
of O
genomic O
dna O
. O

using O
dna O
as O
the O
starting O
material O
, O
we O
screened O
the O
atm O
gene O
in O
92 O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
using O
an O
optimized O
single O
- O
strand O
conformation O
polymorphism O
( O
sscp O
) O
technique O
that O
detected O
all O
previously O
known O
mutations O
in O
the O
polymerase O
chain O
reaction O
( O
pcr O
) O
segments O
being O
analyzed O
. O

a O
novel O
frameshift O
mutation O
in O
the O
mcleod B-Disease
syndrome I-Disease
gene O
in O
a O
japanese O
family O
. O

we O
report O
a O
novel O
mutation O
in O
the O
xk O
gene O
( O
xk O
) O
in O
a O
japanese O
patient O
with O
mcleod B-Disease
syndrome I-Disease
. O

a O
50 O
- O
year O
- O
old O
man O
showed O
progressive O
muscular B-Disease
atrophy I-Disease
, O
choreic B-Disease
movement I-Disease
, O
elevated O
level O
of O
serum O
creatinine O
kinase O
, O
and O
acanthocytosis B-Disease
. O

we O
conclude O
this O
single O
- O
base O
deletion O
causes O
defective O
kx O
protein O
, O
which O
is O
responsible O
for O
the O
mcleod B-Disease
phenotype O
in O
this O
patient O
. O

brca1 O
encodes O
a O
tumor B-Disease
suppressor O
that O
is O
mutated O
in O
familial B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

formation O
of O
irradiation O
- O
induced O
foci O
positive O
for O
brca1 O
, O
hrad50 O
, O
hmre11 O
, O
or O
p95 O
was O
dramatically O
reduced O
in O
hcc O
/ O
1937 O
breast B-Disease
cancer I-Disease
cells O
carrying O
a O
homozygous O
mutation O
in O
brca1 O
but O
was O
restored O
by O
transfection O
of O
wild O
- O
type O
brca1 O
. O

relationship O
among O
genotype O
, O
biochemical O
phenotype O
, O
and O
cognitive O
performance O
in O
females O
with O
phenylalanine B-Disease
hydroxylase I-Disease
deficiency I-Disease
: O
report O
from O
the O
maternal B-Disease
phenylketonuria I-Disease
collaborative O
study O
. O

objective O
to O
examine O
the O
relationship O
of O
phenylalanine O
hydroxylase O
( O
pah O
) O
genotypes O
to O
biochemical O
phenotype O
and O
cognitive O
development O
in O
maternal B-Disease
phenylketonuria I-Disease
( O
pku B-Disease
) O
. O

methodology O
pah O
gene O
mutations O
were O
examined O
in O
222 O
hyperphenylalaninemic B-Disease
females O
enrolled O
in O
the O
maternal B-Disease
pku I-Disease
collaborative O
study O
( O
mpkucs O
) O
. O

based O
on O
previous O
knowledge O
about O
mutation O
- O
phenotype O
associations O
, O
78 O
of O
the O
mutations O
could O
be O
assigned O
to O
one O
of O
four O
classes O
of O
severity O
( O
severe O
pku B-Disease
, O
moderate O
pku B-Disease
, O
mild O
pku B-Disease
, O
and O
mild B-Disease
hyperphenylalaninemia I-Disease
[ O
mhp B-Disease
] O
) O
. O

the O
iq O
of O
pah B-Disease
- I-Disease
deficient I-Disease
mothers O
with O
a O
severe O
pku B-Disease
mutation O
in O
combination O
with O
a O
mhp B-Disease
mutation O
or O
a O
mild O
pku B-Disease
mutation O
was O
99 O
and O
96 O
, O
respectively O
, O
whereas O
the O
iq O
of O
pku B-Disease
mothers O
with O
two O
severe O
pku B-Disease
mutations O
or O
with O
one O
severe O
and O
one O
moderate O
pku B-Disease
mutation O
was O
83 O
and O
84 O
, O
respectively O
. O

of O
the O
patients O
with O
pku B-Disease
, O
92 O
% O
had O
been O
treated O
during O
childhood O
. O

females O
with O
moderate O
or O
mild O
pku B-Disease
who O
were O
treated O
early O
and O
treated O
for O
> O
6 O
years O
showed O
iq O
scores O
10 O
points O
above O
average O
for O
their O
group O
. O

conclusions O
the O
reproductive O
outcome O
in O
maternal B-Disease
phenylketonuria I-Disease
is O
dependent O
on O
prenatal O
metabolic O
control O
and O
postnatal O
environmental O
circumstances O
. O

the O
significant O
relationship O
among O
genotype O
, O
biochemical O
phenotype O
, O
and O
cognitive O
performance O
observed O
in O
the O
present O
study O
is O
of O
importance O
for O
the O
development O
of O
an O
optimal O
strategy O
for O
future O
treatment O
of O
females O
with O
pku B-Disease
who O
plan O
pregnancy O
. O
. O

spinal B-Disease
xanthomatosis I-Disease
: O
a O
variant O
of O
cerebrotendinous B-Disease
xanthomatosis I-Disease
. O

we O
describe O
seven O
dutch O
patients O
from O
six O
families O
with O
a O
slowly O
progressive O
, O
mainly O
spinal B-Disease
cord I-Disease
syndrome I-Disease
that O
remained O
for O
many O
years O
the O
sole O
expression O
of O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

mri O
demonstrated O
white B-Disease
matter I-Disease
abnormalities I-Disease
in O
the O
lateral O
and O
dorsal O
columns O
of O
the O
spinal O
cord O
. O

we O
conclude O
that O
spinal B-Disease
xanthomatosis I-Disease
is O
a O
clinical O
and O
radiological O
separate O
entity O
of O
ctx B-Disease
that O
should O
be O
included O
in O
the O
differential O
diagnosis O
of O
chronic B-Disease
myelopathy I-Disease
. O
. O

a O
transgene O
insertion O
creating O
a O
heritable O
chromosome O
deletion O
mouse O
model O
of O
prader B-Disease
- I-Disease
willi I-Disease
and I-Disease
angelman I-Disease
syndromes I-Disease
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
and O
angelman B-Disease
syndrome I-Disease
( O
as B-Disease
) O
result O
from O
the O
loss O
of O
function O
of O
imprinted O
genes O
in O
human O
chromosome O
15q11 O
- O
q13 O
. O

we O
report O
here O
the O
characterization O
of O
a O
transgene O
insertion O
( O
epstein O
- O
barr O
virus O
latent O
membrane O
protein O
2a O
, O
lmp2a O
) O
into O
mouse O
chromosome O
7c O
, O
which O
has O
resulted O
in O
mouse O
models O
for O
pws B-Disease
and O
as B-Disease
dependent O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

epigenotype O
( O
allelic O
expression O
and O
dna O
methylation O
) O
and O
fluorescence O
in O
situ O
hybridization O
analyses O
indicate O
that O
the O
transgene O
- O
induced O
mutation O
has O
generated O
a O
complete O
deletion O
of O
the O
pws B-Disease
/ O
as B-Disease
- O
homologous O
region O
but O
has O
not O
deleted O
flanking O
loci O
. O

because O
the O
intact O
chromosome O
7 O
, O
opposite O
the O
deleted O
homolog O
, O
maintains O
the O
correct O
imprint O
in O
somatic O
cells O
of O
pws B-Disease
and O
as B-Disease
mice O
and O
establishes O
the O
correct O
imprint O
in O
male O
and O
female O
germ O
cells O
of O
as B-Disease
mice O
, O
homologous O
association O
and O
replication O
asynchrony O
are O
not O
part O
of O
the O
imprinting O
mechanism O
. O

this O
heritable O
- O
deletion O
mouse O
model O
will O
be O
particularly O
useful O
for O
the O
identification O
of O
the O
etiological O
genes O
and O
mechanisms O
, O
phenotypic O
basis O
, O
and O
investigation O
of O
therapeutic O
approaches O
for O
pws B-Disease
. O

linkage O
analysis O
of O
5 O
novel O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
kindreds O
to O
1q32 O
- O
q41 O
markers O
further O
supports O
locus O
homogeneity O
of O
the O
disease O
trait O
. O

van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
( O
vws B-Disease
, O
mim O
119300 O
) O
is O
a O
rare O
autosomal B-Disease
dominant I-Disease
clefting I-Disease
condition I-Disease
with O
cardinal O
features O
of O
mucous B-Disease
cysts I-Disease
( O
lower B-Disease
- I-Disease
lip I-Disease
pits I-Disease
) O
and O
clefts B-Disease
to I-Disease
the I-Disease
lip I-Disease
and I-Disease
/ I-Disease
or I-Disease
palate I-Disease
. O

the O
vws B-Disease
gene O
has O
been O
assigned O
to O
a O
locus O
in O
1q32 O
- O
q41 O
by O
linkage O
analysis O
and O
physical O
mapping O
. O

we O
have O
investigated O
5 O
novel O
vws B-Disease
families O
through O
probands O
attended O
for O
cleft B-Disease
lip I-Disease
and I-Disease
/ I-Disease
or I-Disease
palate I-Disease
repair O
at O
the O
department O
of O
maxillofacial O
surgery O
of O
hopital O
trousseau O
, O
paris O
, O
in O
order O
to O
tentatively O
refine O
the O
genetic O
map O
of O
the O
vws B-Disease
region O
in O
1q32 O
- O
q41 O
and O
possibly O
identify O
unlinked O
pedigrees O
. O

our O
results O
support O
linkage O
of O
vws B-Disease
within O
a O
region O
of O
tightly O
linked O
markers O
and O
do O
not O
favour O
locus O
heterogeneity O
of O
the O
disease O
trait O
. O

null O
mutation O
of O
the O
murine O
atp7b O
( O
wilson B-Disease
disease I-Disease
) O
gene O
results O
in O
intracellular B-Disease
copper I-Disease
accumulation I-Disease
and O
late B-Disease
- I-Disease
onset I-Disease
hepatic I-Disease
nodular I-Disease
transformation I-Disease
. O

mutations O
in O
the O
atp7b O
gene O
lead O
to O
wilson B-Disease
disease I-Disease
, O
a O
copper B-Disease
toxicity I-Disease
disorder I-Disease
characterized O
by O
dramatic O
build O
- O
up O
of O
intracellular O
hepatic O
copper O
with O
subsequent O
hepatic B-Disease
and I-Disease
neuro I-Disease
- I-Disease
logical I-Disease
abnormalities I-Disease
. O

using O
homologous O
recombination O
to O
disrupt O
the O
normal O
translation O
of O
atp7b O
, O
we O
have O
generated O
a O
strain O
of O
mice O
that O
are O
homozygous O
mutants O
( O
null O
) O
for O
the O
wilson B-Disease
disease I-Disease
gene O
. O

an O
increase O
in O
copper O
concentration O
was O
also O
observed O
in O
the O
kidney O
, O
brain O
, O
placenta O
and O
lactating O
mammary O
glands O
of O
homo O
- O
zygous O
mutants O
, O
although O
milk O
from O
the O
mutant O
glands O
was O
copper B-Disease
deficient I-Disease
. O

morphological B-Disease
abnormalities I-Disease
resembling O
cirrhosis B-Disease
developed O
in O
the O
majority O
of O
the O
livers O
from O
homozygous O
mutants O
older O
than O
7 O
months O
of O
age O
. O

progeny O
of O
the O
homozygous O
mutant O
females O
demonstrated O
neurological B-Disease
abnormalities I-Disease
and O
growth B-Disease
retardation I-Disease
characteristic O
of O
copper B-Disease
deficiency I-Disease
. O

in O
summary O
, O
inactivation O
of O
the O
murine O
atp7b O
gene O
produces O
a O
form O
of O
cirrhotic B-Disease
liver I-Disease
disease I-Disease
that O
resembles O
wilson B-Disease
disease I-Disease
in O
humans O
and O
the O
toxic O
milk O
phenotype O
in O
the O
mouse O
. O
. O

french O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
patients O
do O
not O
exhibit O
gametic O
segregation O
distortion O
: O
a O
sperm O
typing O
analysis O
. O

segregation O
distortion O
has O
been O
reported O
to O
occur O
in O
a O
number O
of O
the O
trinucleotide B-Disease
repeat I-Disease
disorders I-Disease
. O

on O
the O
basis O
of O
a O
sperm O
typing O
study O
performed O
in O
patients O
of O
japanese O
descent O
with O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
, O
it O
was O
reported O
that O
disease O
alleles O
are O
preferentially O
transmitted O
during O
meiosis O
. O

however O
, O
analysis O
of O
the O
variance O
in O
repeat O
number O
in O
sperm O
from O
the O
french O
mjd B-Disease
patients O
overlapped O
significantly O
with O
the O
variance O
in O
repeat O
number O
observed O
in O
the O
c O
/ O
c O
homozygous O
japanese O
patients O
. O

missense O
mutation O
in O
the O
alternative O
splice O
region O
of O
the O
pax6 O
gene O
in O
eye B-Disease
anomalies I-Disease
. O

the O
pax6 O
gene O
is O
involved O
in O
ocular O
morphogenesis O
, O
and O
pax6 O
mutations O
have O
been O
detected O
in O
various O
types O
of O
ocular B-Disease
anomalies I-Disease
, O
including O
aniridia B-Disease
, O
peters B-Disease
anomaly I-Disease
, O
corneal B-Disease
dystrophy I-Disease
, O
congenital B-Disease
cataract I-Disease
, O
and O
foveal B-Disease
hypoplasia I-Disease
. O

we O
ascertained O
a O
novel O
missense O
mutation O
in O
four O
pedigrees O
with O
peters B-Disease
anomaly I-Disease
, O
congenital B-Disease
cataract I-Disease
, O
axenfeldt B-Disease
anomaly I-Disease
, O
and O
/ O
or O
foveal B-Disease
hypoplasia I-Disease
, O
which O
, O
to O
our O
knowledge O
, O
is O
the O
first O
mutation O
identified O
in O
the O
splice O
- O
variant O
region O
. O

penetrances O
of O
brca1 O
1675dela O
and O
1135insa O
with O
respect O
to O
breast B-Disease
cancer I-Disease
and O
ovarian B-Disease
cancer I-Disease
. O

for O
genetic O
counseling O
and O
predictive O
testing O
in O
families O
with O
inherited B-Disease
breast I-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
, O
penetrances O
and O
expressions O
of O
the O
underlying O
mutations O
should O
be O
known O
. O

index O
cases O
for O
the O
present O
study O
were O
found O
two O
different O
ways O
through O
a O
series O
of O
consecutive O
ovarian B-Disease
cancers I-Disease
( O
n O
= O
16 O
) O
and O
through O
our O
family O
cancer B-Disease
clinic O
( O
n O
= O
14 O
) O
. O

their O
relatives O
were O
described O
with O
respect O
to O
absence O
/ O
presence O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

the O
overall O
findings O
were O
that O
disease O
started O
to O
occur O
at O
age O
30 O
years O
and O
that O
by O
age O
50 O
years O
48 O
% O
of O
the O
mutation O
- O
carrying O
women O
had O
experienced O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

more O
ovarian B-Disease
cancers I-Disease
than O
breast B-Disease
cancers I-Disease
were O
recorded O
. O

both O
penetrance O
and O
expression O
( O
breast B-Disease
cancer I-Disease
vs O
. O
ovarian B-Disease
cancer I-Disease
) O
were O
different O
from O
those O
in O
reports O
of O
the O
ashkenazi O
founder O
mutations O
. O

the O
dermatofibrosarcoma B-Disease
protuberans I-Disease
- O
associated O
collagen O
type O
ialpha1 O
/ O
platelet O
- O
derived O
growth O
factor O
( O
pdgf O
) O
b O
- O
chain O
fusion O
gene O
generates O
a O
transforming O
protein O
that O
is O
processed O
to O
functional O
pdgf O
- O
bb O
. O

dermatofibrosarcoma B-Disease
protuberans I-Disease
( O
dfsp B-Disease
) O
displays O
chromosomal O
rearrangements O
involving O
chromosome O
17 O
and O
22 O
, O
which O
fuse O
the O
collagen O
type O
ialpha1 O
( O
colia1 O
) O
gene O
to O
the O
platelet O
- O
derived O
growth O
factor O
( O
pdgf O
) O
b O
- O
chain O
( O
pdgfb O
) O
gene O
. O

finally O
, O
colia1 O
/ O
pdgfb O
- O
expressing O
cells O
generated O
tumors B-Disease
after O
s O
. O

c O
c O
. O
injection O
into O
nude O
mice O
, O
and O
tumor B-Disease
growth O
was O
reduced O
by O
treatment O
with O
cgp57148b O
. O

we O
conclude O
that O
the O
colia1 O
/ O
pdgfb O
fusion O
associated O
with O
dfsp B-Disease
contributes O
to O
tumor B-Disease
development O
through O
ectopic O
production O
of O
pdgf O
- O
bb O
and O
the O
formation O
of O
an O
autocrine O
loop O
. O

our O
findings O
, O
thus O
, O
suggest O
that O
pdgf O
receptors O
could O
be O
a O
target O
for O
pharmacological O
treatment O
of O
dfsp B-Disease
and O
giant B-Disease
cell I-Disease
fibroblastoma I-Disease
, O
e O
. O
g O
. O
, O
through O
the O
use O
of O
pdgf O
receptor O
kinase O
inhibitors O
such O
as O
cgp57148b O
. O

identification O
of O
a O
common O
pex1 O
mutation O
in O
zellweger B-Disease
syndrome I-Disease
. O

the O
zellweger B-Disease
spectrum I-Disease
of I-Disease
disease I-Disease
, O
encompassing O
zellweger B-Disease
syndrome I-Disease
and O
the O
progressively O
milder O
phenotypes O
of O
neonatal B-Disease
adrenoleukodystrophy I-Disease
and O
infantile B-Disease
refsum I-Disease
disease I-Disease
, O
is O
due O
to O
a O
failure O
to O
form O
functional O
peroxisomes O
. O

however O
, O
previous O
studies O
have O
focused O
on O
mildly O
affected O
patients O
and O
there O
is O
still O
no O
report O
of O
two O
mutant O
pex1 O
alleles O
in O
any O
zellweger B-Disease
syndrome I-Disease
patient O
. O

furthermore O
, O
mutations O
in O
the O
pmp70 O
gene O
have O
also O
been O
identified O
in O
two O
zellweger B-Disease
syndrome I-Disease
patients O
from O
cg1 O
, O
raising O
the O
possibility O
that O
cg1 O
patients O
may O
represent O
a O
mixture O
of O
pex1 O
- O
deficient O
and O
pmp70 O
- O
deficient O
individuals O
. O

to O
address O
the O
molecular O
basis O
of O
disease O
in O
zellweger B-Disease
syndrome I-Disease
patients O
from O
cg1 O
, O
we O
examined O
all O
24 O
pex1 O
exons O
in O
four O
patients O
, O
including O
both O
patients O
that O
have O
mutations O
in O
pmp70 O
. O

subsequent O
studies O
demonstrated O
that O
this O
mutation O
is O
present O
in O
one O
- O
half O
of O
all O
cg1 O
patients O
and O
correlates O
with O
the O
zellweger B-Disease
syndrome I-Disease
phenotype O
. O

as O
this O
mutation O
leads O
to O
a O
loss O
of O
protein O
function O
its O
frequency O
makes O
it O
the O
most O
common O
cause O
of O
zellweger B-Disease
syndrome I-Disease
, O
helping O
to O
explain O
the O
high O
percentage O
of O
patients O
that O
belong O
to O
cg1 O
. O

novel O
mutations O
in O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
gene O
and O
their O
effects O
on O
transcriptional O
, O
translational O
, O
and O
clinical O
phenotypes O
. O

wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
immunodeficiency I-Disease
characterized O
by O
thrombocytopenia B-Disease
, O
eczema B-Disease
, O
and O
recurrent O
infections O
, O
and O
caused O
by O
mutations O
in O
the O
was B-Disease
protein O
( O
wasp O
) O
gene O
. O

no O
protein O
was O
detected O
in O
two O
individuals O
with O
severe O
was B-Disease
. O

reduced O
levels O
of O
a O
normal O
- O
size O
wasp O
with O
a O
missense O
mutation O
were O
seen O
in O
two O
individuals O
with O
xlt B-Disease
. O

duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
is O
caused O
by O
mutations O
in O
the O
dystrophin O
gene O
, O
leading O
to O
the O
absence O
of O
the O
dystrophin O
protein O
in O
striated O
muscle O
. O

on O
the O
basis O
of O
the O
observation O
that O
aminoglycoside O
treatment O
can O
suppress O
stop O
codons O
in O
cultured O
cells O
, O
we O
tested O
the O
effect O
of O
gentamicin O
on O
cultured O
muscle O
cells O
from O
the O
mdx O
mouse O
- O
an O
animal O
model O
for O
dmd B-Disease
that O
possesses O
a O
premature O
stop O
codon O
in O
the O
dystrophin O
gene O
. O

we O
identified O
a O
treatment O
regimen O
that O
resulted O
in O
the O
presence O
of O
dystrophin O
in O
the O
cell O
membrane O
in O
all O
striated O
muscles O
examined O
and O
that O
provided O
functional O
protection O
against O
muscular B-Disease
injury I-Disease
. O

furthermore O
, O
these O
results O
raise O
the O
possibility O
of O
a O
novel O
treatment O
regimen O
for O
muscular B-Disease
dystrophy I-Disease
and O
other O
diseases O
caused O
by O
premature O
stop O
codon O
mutations O
. O

this O
treatment O
could O
prove O
effective O
in O
up O
to O
15 O
% O
of O
patients O
with O
dmd B-Disease
. O
. O

loss O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
product O
causes O
oxidative O
damage O
in O
target O
organs O
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
characterized O
by O
a O
markedly O
increased O
sensitivity O
to O
ionizing O
radiation O
, O
increased O
incidence O
of O
cancer B-Disease
, O
and O
neurodegeneration B-Disease
, O
especially O
of O
the O
cerebellar O
purkinje O
cells O
. O

we O
therefore O
hypothesized O
that O
a B-Disease
- I-Disease
t I-Disease
is O
due O
to O
oxidative O
damage O
resulting O
from O
loss O
of O
function O
of O
the O
a B-Disease
- I-Disease
t I-Disease
gene O
product O
. O

to O
assess O
this O
hypothesis O
, O
we O
employed O
an O
animal O
model O
of O
a B-Disease
- I-Disease
t I-Disease
, O
the O
mouse O
with O
a O
disrupted O
atm O
gene O
. O

these O
observations O
provide O
a O
mechanistic O
basis O
for O
the O
a B-Disease
- I-Disease
t I-Disease
phenotype O
and O
lay O
a O
rational O
foundation O
for O
therapeutic O
intervention O
. O
. O

recessively O
inherited O
multiple B-Disease
epiphyseal I-Disease
dysplasia I-Disease
with O
normal O
stature O
, O
club B-Disease
foot I-Disease
, O
and O
double B-Disease
layered I-Disease
patella I-Disease
caused O
by O
a O
dtdst O
mutation O
. O

we O
have O
observed O
over O
25 O
different O
mutations O
in O
the O
diastrophic B-Disease
dysplasia I-Disease
sulphate O
transporter O
gene O
( O
dtdst O
) O
in O
association O
with O
the O
recessive B-Disease
disorders I-Disease
achondrogenesis B-Disease
1b I-Disease
, O
atelosteogenesis B-Disease
2 I-Disease
, O
and O
diastrophic B-Disease
dysplasia I-Disease
. O

we O
had O
not O
seen O
a O
case O
of O
homozygosity O
for O
c862t O
( O
r279w O
) O
until O
we O
analysed O
dna O
from O
a O
36 O
year O
old O
male O
with O
tall O
- O
normal O
stature O
( O
180 O
cm O
) O
who O
asked O
for O
genetic O
counselling O
for O
suspected O
multiple B-Disease
epiphyseal I-Disease
dysplasia I-Disease
. O

he O
was O
treated O
for O
club B-Disease
foot I-Disease
and O
hip B-Disease
dysplasia I-Disease
at O
birth O
. O

skeletal O
changes O
consistent O
with O
multiple B-Disease
epiphyseal I-Disease
dysplasia I-Disease
, O
with O
the O
peculiar O
finding O
of O
a O
double B-Disease
layered I-Disease
patella I-Disease
, O
were O
recognised O
during O
childhood O
. O

cleft B-Disease
palate I-Disease
, O
swelling B-Disease
of I-Disease
the I-Disease
ear I-Disease
pinna I-Disease
, O
and O
hitch B-Disease
hiker I-Disease
thumb I-Disease
were O
absent O
. O

he O
was O
found O
to O
be O
homozygous O
, O
and O
both O
healthy O
parents O
heterozygous O
, O
for O
the O
r279w O
mutation O
in O
dtdst O
, O
and O
his O
fibroblasts O
showed O
a O
sulphate O
incorporation O
defect O
typical O
of O
dtdst B-Disease
disorders I-Disease
. O

counselling O
was O
given O
for O
a O
recessive B-Disease
disorder I-Disease
, O
thereby O
considerably O
reducing O
the O
probability O
of O
affected O
offspring O
. O

multiple B-Disease
epiphyseal I-Disease
dysplasia I-Disease
is O
more O
frequently O
caused O
by O
dominant O
mutations O
in O
the O
comp O
( O
edm1 B-Disease
, O
mckusick O
132400 O
) O
and O
col9a2 O
genes O
( O
edm2 B-Disease
, O
mckusick O
600204 O
) O
. O

a O
few O
other O
patients O
and O
families O
with O
features O
similar O
to O
our O
proband O
have O
been O
described O
previously O
and O
considered O
to O
have O
autosomal O
recessive O
med B-Disease
( O
edm4 B-Disease
, O
mckusick O
226900 O
) O
. O

homozygosity O
for O
a O
novel O
dtdst O
mutation O
in O
a O
child O
with O
a O
' O
broad O
bone O
- O
platyspondylic O
' O
variant O
of O
diastrophic B-Disease
dysplasia I-Disease
. O

atypical O
or O
variant O
forms O
of O
well O
- O
known O
chondrodysplasias B-Disease
may O
pose O
diagnostic O
problems O
. O

we O
report O
on O
a O
girl O
with O
clinical O
features O
suggesting O
diastrophic B-Disease
dysplasia I-Disease
but O
with O
unusual O
radiographic O
features O
including O
severe O
platyspondyly B-Disease
, O
wide O
metaphyses O
, O
and O
fibular O
overgrowth O
, O
which O
are O
partially O
reminiscent O
of O
metatropic B-Disease
dysplasia I-Disease
. O

the O
type O
of O
somatic O
mutation O
at O
apc O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
is O
determined O
by O
the O
site O
of O
the O
germline O
mutation O
: O
a O
new O
facet O
to O
knudson O
' O
s O
' O
two O
- O
hit O
' O
hypothesis O
. O

apc O
is O
often O
cited O
as O
a O
prime O
example O
of O
a O
tumor B-Disease
suppressor O
gene O
. O

truncating O
germline O
and O
somatic O
mutations O
( O
or O
, O
infrequently O
, O
allelic O
loss O
) O
occur O
in O
tumors B-Disease
in O
fap B-Disease
( O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
) O
. O

most O
sporadic B-Disease
colorectal I-Disease
cancers I-Disease
also O
have O
two O
apc B-Disease
mutations O
. O

clues O
from O
attenuated B-Disease
polyposis I-Disease
, O
missense O
germline O
variants O
with O
mild O
disease O
and O
the O
somatic O
mutation O
cluster O
region O
( O
codons O
1 O
, O
250 O
- O
1 O
, O
450 O
) O
indicate O
, O
however O
, O
that O
apc B-Disease
mutations O
might O
not O
result O
in O
simple O
loss O
of O
protein O
function O
. O

we O
have O
found O
that O
fap B-Disease
patients O
with O
germline O
apc B-Disease
mutations O
within O
a O
small O
region O
( O
codons O
1 O
, O
194 O
- O
1 O
, O
392 O
at O
most O
) O
mainly O
show O
allelic O
loss O
in O
their O
colorectal B-Disease
adenomas I-Disease
, O
in O
contrast O
to O
other O
fap B-Disease
patients O
, O
whose O
second O
hits O
tend O
to O
occur O
by O
truncating O
mutations O
in O
the O
mutation O
cluster O
region O
. O

a O
different O
germline O
- O
somatic O
apc B-Disease
mutation O
association O
exists O
in O
fap B-Disease
desmoids I-Disease
. O

apc O
is O
not O
, O
therefore O
, O
a O
classical O
tumor B-Disease
suppressor O
. O

our O
findings O
also O
indicate O
a O
new O
mechanism O
for O
disease O
severity O
if O
a O
broader O
spectrum O
of O
mutations O
is O
selected O
in O
tumors B-Disease
, O
the O
somatic O
mutation O
rate O
is O
effectively O
higher O
and O
more O
tumors B-Disease
grow O
. O
. O

mxi1 O
mutations O
in O
human O
neurofibrosarcomas B-Disease
. O

mxi1 O
is O
thought O
to O
negatively O
regulate O
myc O
function O
and O
may O
therefore O
be O
a O
potential O
tumor B-Disease
suppressor O
gene O
. O

little O
effort O
has O
yet O
been O
made O
to O
find O
alterations O
involving O
this O
gene O
in O
human O
solid B-Disease
tumors I-Disease
. O

we O
screened O
31 O
human O
gastric B-Disease
cancers I-Disease
, O
7 O
esophageal B-Disease
cancers I-Disease
, O
85 O
bone B-Disease
and I-Disease
soft I-Disease
tissue I-Disease
tumors I-Disease
of O
various O
types O
, O
including O
4 O
neurofibrosarcomas B-Disease
. O

we O
also O
examined O
29 O
human O
tumor B-Disease
cell O
lines O
consisting O
of O
12 O
esophageal B-Disease
cancers I-Disease
, O
7 O
glioma B-Disease
/ O
glioblastomas B-Disease
and O
10 O
others O
for O
mxi1 O
mutations O
in O
exons O
1 O
, O
2 O
, O
4 O
( O
hlh O
domain O
) O
, O
5 O
and O
6 O
. O

we O
discovered O
a O
missense O
mutation O
, O
gca O
to O
gta O
( O
ala O
54 O
val O
) O
, O
in O
exon O
2 O
in O
a O
neurofibrosarcoma B-Disease
patient O
( O
case O
1 O
) O
, O
two O
missense O
mutations O
, O
aaa O
to O
caa O
( O
lys O
118 O
gln O
) O
and O
gaa O
to O
gga O
( O
glu O
154 O
gly O
) O
in O
exon O
5 O
of O
another O
neurofibrosarcoma B-Disease
patient O
( O
case O
2 O
) O
, O
and O
3 O
amino O
acid O
substitutions O
, O
gtg O
to O
gcg O
( O
val O
179 O
ala O
) O
, O
gtt O
to O
gct O
( O
val O
181 O
ala O
) O
and O
ttc O
to O
ctc O
( O
phe O
186 O

leu O
) O
, O
in O
a O
third O
neurofibrosarcoma B-Disease
patient O
( O
case O
3 O
) O
. O

our O
data O
demonstrate O
that O
mutations O
occur O
in O
the O
mxi1 O
gene O
in O
neurofibrosarcoma B-Disease
. O

missense O
mutations O
in O
the O
functional O
domain O
of O
mxi1 O
in O
these O
cases O
may O
be O
involved O
in O
the O
pathogenesis O
of O
neurofibrosarcoma B-Disease
. O

a O
population O
- O
based O
study O
of O
the O
clinical O
expression O
of O
the O
hemochromatosis B-Disease
gene O
. O

background O
and O
methods O
hereditary B-Disease
hemochromatosis I-Disease
is O
associated O
with O
homozygosity O
for O
the O
c282y O
mutation O
in O
the O
hemochromatosis B-Disease
( O
hfe O
) O
gene O
on O
chromosome O
6 O
, O
elevated O
serum O
transferrin O
saturation O
, O
and O
excess B-Disease
iron I-Disease
deposits I-Disease
throughout O
the O
body O
. O

four O
of O
the O
homozygous O
subjects O
had O
previously O
been O
given O
a O
diagnosis O
of O
hemochromatosis B-Disease
, O
and O
12 O
had O
not O
. O

eleven O
of O
the O
16 O
homozygous O
subjects O
underwent O
liver O
biopsy O
; O
3 O
had O
hepatic B-Disease
fibrosis I-Disease
, O
and O
1 O
, O
who O
had O
a O
history O
of O
excessive B-Disease
alcohol I-Disease
consumption I-Disease
, O
had O
cirrhosis B-Disease
and O
mild O
microvesicular B-Disease
steatosis I-Disease
. O

eight O
of O
the O
16 O
homozygous O
subjects O
had O
clinical O
findings O
that O
were O
consistent O
with O
the O
presence O
of O
hereditary B-Disease
hemochromatosis I-Disease
, O
such O
as O
hepatomegaly B-Disease
, O
skin B-Disease
pigmentation I-Disease
, O
and O
arthritis B-Disease
. O

however O
, O
only O
half O
of O
those O
who O
were O
homozygous O
had O
clinical O
features O
of O
hemochromatosis B-Disease
, O
and O
one O
quarter O
had O
serum O
ferritin O
levels O
that O
remained O
normal O
over O
a O
four O
- O
year O
period O
. O

the O
clinical O
use O
of O
molecular O
analyses O
in O
recessive B-Disease
disorders I-Disease
relies O
on O
the O
exact O
characterization O
of O
both O
mutant O
alleles O
in O
the O
affected O
patient O
. O

we O
present O
a O
child O
in O
whom O
phenylketonuria B-Disease
was O
apparently O
caused O
by O
homozygosity O
for O
the O
mutation O
e390g O
in O
exon O
11 O
of O
the O
phenylalanine O
hydroxylase O
( O
pah O
) O
gene O
. O

early O
onset O
of O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
in O
a O
boy O
with O
emerin O
gene O
deletion O
. O

a O
boy O
developed O
contractures B-Disease
of I-Disease
the I-Disease
achilles I-Disease
tendons I-Disease
at O
3 O
years O
and O
of O
the O
postcervical O
muscles O
at O
7 O
years O
, O
although O
neither O
contractures B-Disease
of I-Disease
the I-Disease
elbows I-Disease
nor O
cardiac B-Disease
abnormality I-Disease
were O
recognized O
by O
the O
age O
of O
9 O
years O
. O

these O
results O
confirmed O
the O
diagnosis O
of O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
, O
and O
reinforce O
the O
necessity O
of O
molecular O
genetic O
diagnosis O
of O
the O
membrane O
protein O
emerin O
in O
younger O
patients O
with O
possible O
edmd B-Disease
before O
appearance O
of O
the O
typical O
symptoms O
, O
to O
avoid O
sudden B-Disease
cardiac I-Disease
death I-Disease
. O
. O

duchenne B-Disease
/ I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
: O
correlation O
of O
phenotype O
by O
electroretinography O
with O
sites O
of O
dystrophin O
mutations O
. O

the O
dark O
- O
adapted O
electroretinogram O
( O
erg O
) O
of O
patients O
with O
duchenne B-Disease
and I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
/ O
bmd B-Disease
) O
shows O
a O
marked O
reduction O
in O
b O
- O
wave O
amplitude O
. O

genotype O
- O
phenotype O
studies O
of O
mouse O
models O
for O
dmd B-Disease
show O
position O
- O
specific O
effects O
of O
the O
mutations O
upon O
the O
phenotype O
mice O
with O
5 O
defects O
of O
dystrophin O
have O
normal O
ergs O
, O
those O
with O
defects O
in O
the O
central O
region O
have O
a O
normal O
b O
- O
wave O
amplitude O
associated O
with O
prolonged O
implicit O
times O
for O
both O
the O
b O
- O
wave O
and O
oscillatory O
potentials O
, O
and O
mice O
with O
3 O
defects O
have O
a O
phenotype O
similar O
to O
that O
seen O
in O
dmd B-Disease
/ O
bmd B-Disease
patients O
. O

we O
have O
undertaken O
a O
systematic O
evaluation O
of O
dmd B-Disease
/ O
bmd B-Disease
patients O
through O
clinical O
examination O
and O
review O
of O
the O
literature O
in O
order O
to O
determine O
whether O
the O
position O
- O
specific O
effects O
of O
mutations O
noted O
in O
the O
mouse O
are O
present O
in O
man O
. O

we O
have O
found O
that O
, O
in O
man O
, O
a O
wider O
variation O
of O
dmd B-Disease
defects I-Disease
correlate O
with O
reductions O
in O
the O
b O
- O
wave O
amplitude O
. O

our O
results O
suggest O
that O
the O
most O
important O
determinant O
in O
the O
erg O
b O
- O
wave O
phenotype O
is O
the O
mutation O
position O
, O
rather O
than O
muscle B-Disease
disease I-Disease
severity O
. O

cis O
and O
trans O
effects O
of O
the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
mutation O
in O
a O
cell O
culture O
model O
. O

the O
mutation O
causing O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
has O
been O
identified O
as O
a O
ctg O
expansion O
in O
the O
3 O
- O
untranslated O
region O
( O
3 O
- O
utr O
) O
of O
the O
dm B-Disease
protein O
kinase O
gene O
( O
dmpk O
) O
, O
but O
the O
mechanism O
( O
s O
) O
of O
pathogenesis O
remain O
unknown O
. O

therefore O
, O
to O
study O
the O
effects O
of O
the O
dm B-Disease
mutation O
in O
a O
controlled O
environment O
, O
we O
have O
established O
a O
cell O
culture O
model O
system O
using O
c2c12 O
mouse O
myoblasts O
. O

by O
expressing O
chimeric O
reporter O
constructs O
containing O
a O
reporter O
gene O
fused O
to O
a O
human O
dmpk O
3 O
- O
utr O
, O
we O
identified O
both O
cis O
and O
trans O
effects O
that O
are O
mediated O
by O
the O
dm B-Disease
mutation O
. O

these O
results O
provide O
evidence O
that O
the O
dm B-Disease
mutation O
acts O
in O
cis O
to O
reduce O
protein O
production O
( O
consistent O
with O
dmpk B-Disease
haploinsufficiency I-Disease
) O
and O
in O
trans O
as O
a O
riboregulator O
to O
inhibit O
myogenesis O
. O

coats B-Disease
' I-Disease
disease I-Disease
of O
the O
retina O
( O
unilateral B-Disease
retinal I-Disease
telangiectasis I-Disease
) O
caused O
by O
somatic O
mutation O
in O
the O
ndp O
gene O
: O
a O
role O
for O
norrin O
in O
retinal O
angiogenesis O
. O

coats B-Disease
disease I-Disease
is O
characterized O
by O
abnormal B-Disease
retinal I-Disease
vascular I-Disease
development I-Disease
( O
so O
- O
called O
retinal B-Disease
telangiectasis I-Disease
) O
which O
results O
in O
massive O
intraretinal B-Disease
and I-Disease
subretinal I-Disease
lipid I-Disease
accumulation I-Disease
( O
exudative B-Disease
retinal I-Disease
detachment I-Disease
) O
. O

the O
classical O
form O
of O
coats B-Disease
disease I-Disease
is O
almost O
invariably O
isolated O
, O
unilateral O
and O
seen O
in O
males O
. O

a O
female O
with O
a O
unilateral O
variant O
of O
coats B-Disease
disease I-Disease
gave O
birth O
to O
a O
son O
affected O
by O
norrie B-Disease
disease I-Disease
. O

subsequently O
analysis O
of O
the O
retinas O
of O
nine O
enucleated O
eyes O
from O
males O
with O
coats B-Disease
disease I-Disease
demonstrated O
in O
one O
a O
somatic O
mutation O
in O
the O
ndp O
gene O
which O
was O
not O
present O
within O
non O
- O
retinal O
tissue O
. O

we O
suggest O
that O
coats B-Disease
telangiectasis I-Disease
is O
secondary O
to O
somatic O
mutation O
in O
the O
ndp O
gene O
which O
results O
in O
a O
deficiency B-Disease
of I-Disease
norrin I-Disease
( O
the O
protein O
product O
of O
the O
ndp O
gene O
) O
within O
the O
developing O
retina O
. O

hereditary O
tp53 O
codon O
292 O
and O
somatic O
p16ink4a O
codon O
94 O
mutations O
in O
a O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
family O
. O

li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
that O
is O
characterized O
by O
various O
types O
of O
cancer B-Disease
in O
childhood O
and O
adult O
cases O
. O

although O
hereditary O
tp53 O
mutation O
is O
very O
rare O
in O
different O
human O
cancers B-Disease
, O
it O
has O
been O
frequently O
reported O
in O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
. O

on O
the O
other O
hand O
, O
hereditary O
mutations O
of O
tp57kip2 O
, O
p15ink4b O
, O
and O
p16ink4a O
, O
which O
affect O
the O
cell O
cycle O
similar O
to O
tp53 O
, O
were O
observed O
in O
some O
types O
of O
cancer B-Disease
. O

in O
a O
turkish O
family O
with O
the O
diagnosis O
of O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
, O
we O
analyzed O
the O
mutation O
pattern O
of O
tp53 O
, O
p57kip2 O
, O
p15ink4b O
, O
and O
p16ink4a O
in O
the O
peripheral O
blood O
, O
and O
loss O
of O
heterozygosity O
( O
homo O
/ O
hemizygous O
deletion O
) O
pattern O
of O
tp53 O
and O
p15ink4b O
/ O
p16ink4a O
in O
two O
tumor B-Disease
tissues O
. O

the O
propositus O
had O
a O
seminoma B-Disease
, O
his O
daughter O
a O
medulloblastoma B-Disease
, O
and O
one O
of O
his O
healthy O
cousins O
, O
a O
tp53 O
codon O
292 O
missense O
point O
mutation O
( O
aaa O
- O
- O
> O
ata O
; O
lys O
- O
- O
> O
ile O
) O
in O
the O
peripheral O
blood O
cells O
. O

tumor O
tissue O
obtained O
from O
the O
propositus O
with O
the O
seminoma B-Disease
revealed O
loss O
of O
heterozygosity O
in O
the O
tp53 O
gene O
. O

in O
the O
analyses O
of O
tumor B-Disease
tissues O
from O
the O
propositus O
and O
his O
daughter O
, O
a O
p16ink4a O
codon O
94 O
missense O
point O
mutation O
( O
gcg O
- O
- O
> O
gag O
; O
ala O
- O
- O
> O
glu O
) O
was O
observed O
with O
the O
hereditary O
tp53 O
mutation O
. O

p16ink4a O
codon O
94 O
mutation O
observed O
in O
our O
family O
is O
a O
novel O
mutation O
in O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
. O

existence O
of O
the O
p16ink4a O
mutation O
and O
the O
hereditary O
tp53 O
mutation O
with O
or O
without O
loss O
of O
heterozygosity O
in O
the O
tp53 O
gene O
( O
seminoma B-Disease
/ O
medulloblastoma B-Disease
) O
may O
be O
evidence O
for O
a O
common O
mechanism O
involved O
in O
tumorogenesis B-Disease
. O

the O
gene O
alterations O
in O
tp53 O
and O
p16ink4a O
genes O
may O
be O
used O
as O
tumor B-Disease
markers O
in O
our O
family O
. O
. O

a O
novel O
mutation O
in O
the O
sodium O
/ O
iodide O
symporter O
gene O
in O
the O
largest O
family O
with O
iodide B-Disease
transport I-Disease
defect I-Disease
. O

we O
previously O
reported O
nine O
children O
with O
an O
autosomally O
recessive O
form O
of O
congenital B-Disease
hypothyroidism I-Disease
due O
to O
an O
iodide B-Disease
transport I-Disease
defect I-Disease
in O
a O
large O
hutterite O
family O
with O
extensive O
consanguinity O
living O
in O
central O
canada O
. O

since O
the O
original O
report O
, O
we O
have O
diagnosed O
congenital B-Disease
hypothyroidism I-Disease
by O
newborn O
tsh O
screening O
in O
9 O
additional O
children O
from O
the O
family O
. O

we O
identified O
a O
novel O
nis O
gene O
mutation O
, O
g395r O
( O
gly395 O
- O
- O
> O
arg O
; O
gga O
- O
- O
> O
aga O
) O
, O
in O
10 O
patients O
examined O
in O
the O
present O
study O
. O

expression O
experiments O
by O
transfection O
of O
the O
mutant O
nis O
complimentary O
dna O
into O
cos O
- O
7 O
cells O
showed O
no O
perchlorate O
- O
sensitive O
iodide O
uptake O
, O
confirming O
that O
the O
mutation O
is O
the O
direct O
cause O
of O
the O
iodide B-Disease
transport I-Disease
defect I-Disease
in O
these O
patients O
. O

it O
is O
now O
possible O
to O
use O
gene O
diagnostics O
of O
this O
unique O
nis O
mutation O
to O
identify O
patients O
with O
congenital B-Disease
hypothyroidism I-Disease
due O
to O
an O
iodide B-Disease
transport I-Disease
defect I-Disease
in O
this O
family O
and O
to O
determine O
the O
carrier O
state O
of O
potential O
parents O
for O
genetic O
counseling O
and O
arranging O
rapid O
and O
early O
diagnosis O
of O
their O
infants O
. O

molecular O
analysis O
in O
familial B-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
: O
early O
diagnosis O
of O
an O
asymptomatic O
carrier O
. O

familial B-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
( O
fndi B-Disease
) O
is O
an O
inherited O
deficiency B-Disease
of I-Disease
the I-Disease
hormone I-Disease
arginine I-Disease
vasopressin I-Disease
( O
avp O
) O
and O
is O
transmitted O
as O
an O
autosomal O
dominant O
trait O
. O

the O
alteration O
found O
in O
the O
second O
exon O
of O
the O
gene O
in O
this O
family O
seems O
to O
be O
responsible O
for O
the O
disease O
, O
as O
all O
individuals O
harboring O
the O
mutation O
had O
been O
previously O
diagnosed O
or O
have O
eventually O
developed O
fndi B-Disease
. O

deficit O
of O
in O
vivo O
mitochondrial O
atp O
production O
in O
patients O
with O
friedreich B-Disease
ataxia I-Disease
. O

friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
, O
the O
most O
common O
of O
the O
inherited B-Disease
ataxias I-Disease
, O
is O
an O
autosomal B-Disease
recessive I-Disease
degenerative I-Disease
disorder I-Disease
, O
characterized O
clinically O
by O
onset O
before O
the O
age O
of O
25 O
of O
progressive B-Disease
gait I-Disease
and I-Disease
limb I-Disease
ataxia I-Disease
, O
absence B-Disease
of I-Disease
deep I-Disease
tendon I-Disease
reflexes I-Disease
, O
extensor B-Disease
plantar I-Disease
responses I-Disease
, O
and O
loss B-Disease
of I-Disease
position I-Disease
and I-Disease
vibration I-Disease
sense I-Disease
in O
the O
lower O
limbs O
. O

frda B-Disease
is O
caused O
by O
a O
gaa O
triplet O
expansion O
in O
the O
first O
intron O
of O
the O
frda B-Disease
gene O
on O
chromosome O
9q13 O
in O
97 O
% O
of O
patients O
. O

the O
frda B-Disease
gene O
encodes O
a O
widely O
expressed O
210 O
- O
aa O
protein O
, O
frataxin O
, O
which O
is O
located O
in O
mitochondria O
and O
is O
severely O
reduced O
in O
frda B-Disease
patients O
. O

here O
we O
report O
in O
vivo O
evidence O
of O
impaired O
mitochondrial O
respiration O
in O
skeletal O
muscle O
of O
frda B-Disease
patients O
. O

using O
phosphorus O
magnetic O
resonance O
spectroscopy O
we O
demonstrated O
a O
maximum O
rate O
of O
muscle O
mitochondrial O
atp O
production O
( O
v O
( O
max O
) O
) O
below O
the O
normal O
range O
in O
all O
12 O
frda B-Disease
patients O
and O
a O
strong O
negative O
correlation O
between O
mitochondrial O
v O
( O
max O
) O
and O
the O
number O
of O
gaa O
repeats O
in O
the O
smaller O
allele O
. O

our O
results O
show O
that O
frda B-Disease
is O
a O
nuclear O
- O
encoded O
mitochondrial B-Disease
disorder I-Disease
affecting O
oxidative O
phosphorylation O
and O
give O
a O
rationale O
for O
treatments O
aimed O
to O
improve O
mitochondrial O
function O
in O
this O
condition O
. O
. O

identification O
of O
a O
novel O
r21x O
mutation O
in O
the O
liver O
- O
type O
arginase O
gene O
( O
arg1 O
) O
in O
four O
portuguese O
patients O
with O
argininemia B-Disease
. O

argininemia B-Disease
is O
a O
rare O
autossomal B-Disease
recessive I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
in I-Disease
the I-Disease
cytosolic I-Disease
liver I-Disease
- I-Disease
type I-Disease
arginase I-Disease
enzyme I-Disease
( O
l O
- O
arginine O
urea O
- O
hydrolase O
; O
e O
. O
c O
. O
3 O
. O
5 O
. O
3 O
. O
1 O
) O
. O

in O
order O
to O
investigate O
the O
molecular O
basis O
for O
argininemia B-Disease
in O
four O
unrelated O
portuguese O
patients O
( O
two O
from O
northern O
portugal O
and O
two O
from O
madeira O
island O
) O
we O
performed O
a O
dna O
sequence O
analysis O
of O
all O
the O
exons O
and O
exon O
/ O
intron O
boundaries O
of O
the O
liver O
- O
type O
arginase O
gene O
( O
arg1 O
) O
. O

mutation O
of O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
results O
in O
truncation O
of O
mrna O
expressed O
in O
leucocytes O
in O
a O
japanese O
family O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
. O

objectives O
a O
japanese O
family O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
was O
investigated O
for O
a O
sequence O
alteration O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
. O

the O
application O
of O
blood O
leucocytes O
can O
be O
a O
simple O
technique O
on O
analysing O
a O
constructive O
abnormality B-Disease
of I-Disease
cyp27 I-Disease
mrna O
. O
. O

clinical O
and O
molecular O
genetic O
analysis O
of O
19 O
wolfram B-Disease
syndrome I-Disease
kindreds O
demonstrating O
a O
wide O
spectrum O
of O
mutations O
in O
wfs1 O
. O

wolfram B-Disease
syndrome I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
neurodegenerative I-Disease
disorder I-Disease
characterized O
by O
juvenile B-Disease
- I-Disease
onset I-Disease
diabetes I-Disease
mellitus I-Disease
and O
progressive O
optic B-Disease
atrophy I-Disease
. O

direct O
dna O
sequencing O
was O
done O
to O
screen O
the O
entire O
coding O
region O
of O
the O
wfs1 O
gene O
in O
30 O
patients O
from O
19 O
british O
kindreds O
with O
wolfram B-Disease
syndrome I-Disease
. O

hence O
, O
molecular O
screening O
for O
wolfram B-Disease
syndrome I-Disease
in O
affected O
families O
and O
for O
wolfram B-Disease
syndrome I-Disease
- O
carrier O
status O
in O
subjects O
with O
psychiatric B-Disease
disorders I-Disease
or O
diabetes B-Disease
mellitus I-Disease
will O
require O
complete O
analysis O
of O
exon O
8 O
and O
upstream O
exons O
. O

late O
- O
onset O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
: O
a O
subset O
with O
distinct O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O
. O

to O
determine O
the O
prevalence O
and O
characterize O
demographic O
, O
clinical O
, O
and O
genetic O
features O
of O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
of O
late O
onset O
, O
all O
patients O
experiencing O
their O
first O
fmf B-Disease
attack O
at O
age O
40 O
years O
or O
more O
were O
identified O
using O
the O
computerized O
registry O
of O
our O
fmf B-Disease
clinic O
, O
and O
then O
thoroughly O
interviewed O
and O
examined O
. O

the O
control O
group O
consisted O
of O
40 O
consecutive O
fmf B-Disease
patients O
, O
who O
arrived O
at O
the O
fmf B-Disease
clinic O
for O
their O
regular O
follow O
- O
up O
visit O
and O
were O
40 O
years O
of O
age O
or O
older O
at O
the O
time O
of O
the O
examination O
. O

mutational O
analysis O
in O
the O
fmf B-Disease
gene O
was O
performed O
using O
a O
commercial O
kit O
. O

only O
20 O
of O
4000 O
( O
0 O
. O
5 O
% O
) O
patients O
had O
late O
- O
onset O
fmf B-Disease
. O

none O
had O
chronic O
or O
prolonged O
manifestations O
of O
fmf B-Disease
, O
for O
example O
, O
amyloidosis B-Disease
, O
chronic B-Disease
arthritis I-Disease
, O
or O
protracted O
myalgia B-Disease
, O
p O
< O
0 O
. O

01 O
, O
compared O
to O
our O
regular O
fmf B-Disease
population O
. O

we O
conclude O
that O
the O
onset O
of O
fmf B-Disease
in O
a O
late O
age O
defines O
a O
milder O
form O
of O
disease O
with O
typical O
clinical O
, O
demographic O
, O
and O
molecular O
genetic O
characteristics O

the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
syndrome I-Disease
is O
associated O
with O
a O
high O
frequency O
of O
brca1 O
mutations O
. O

maternal B-Disease
uniparental I-Disease
disomy I-Disease
for I-Disease
chromosome I-Disease
14 I-Disease
in O
a O
boy O
with O
a O
normal O
karyotype O
. O

we O
report O
on O
a O
boy O
with O
a O
maternal B-Disease
uniparental I-Disease
disomy I-Disease
for I-Disease
chromosome I-Disease
14 I-Disease
( O
upd B-Disease
( O
14 O
) O
) O
. O

at O
7 O
years O
of O
age O
he O
was O
referred O
to O
us O
by O
the O
paediatrician O
because O
of O
symptoms O
of O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

he O
showed O
short B-Disease
stature I-Disease
, O
obesity B-Disease
, O
mild O
developmental B-Disease
delay I-Disease
, O
cryptorchidism B-Disease
, O
and O
some O
mild O
dysmorphic B-Disease
features I-Disease
. O

the O
history O
further O
indicated O
intrauterine B-Disease
growth I-Disease
retardation I-Disease
at O
the O
end O
of O
the O
pregnancy O
. O

after O
birth O
he O
showed O
hypotonia B-Disease
with O
poor O
sucking O
, O
for O
which O
gavage O
feeding O
was O
needed O
. O

after O
1 O
year O
he O
became O
obese B-Disease
despite O
a O
normal O
appetite O
. O

recurrent O
middle B-Disease
ear I-Disease
infections I-Disease
, O
a O
high O
pain O
threshold O
, O
and O
a O
great O
skill O
with O
jigsaw O
puzzles O
were O
reported O
. O

dna O
analysis O
for O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
showed O
no O
abnormalities O
. O

two O
years O
later O
he O
was O
re O
- O
examined O
because O
we O
thought O
his O
features O
fitted O
the O
pws B-Disease
- O
like O
phenotype O
associated O
with O
maternal O
upd B-Disease
( O
14 O
) O
. O

dna O
analysis O
showed O
maternal B-Disease
heterodisomy I-Disease
for O
chromosome O
14 O
. O

in O
all O
the O
previously O
described O
11 O
cases O
with O
maternal O
upd B-Disease
( O
14 O
) O
, O
a O
robertsonian O
translocation O
involving O
chromosome O
14 O
was O
detected O
cytogenetically O
before O
dna O
analysis O
. O

this O
is O
the O
first O
report O
of O
diagnosis O
of O
maternal O
upd B-Disease
( O
14 O
) O
based O
on O
clinical O
features O
. O

this O
finding O
underlines O
the O
importance O
of O
dna O
analysis O
for O
maternal O
upd O
( O
14 O
) O
in O
patients O
with O
a O
similar O
pws B-Disease
- O
like O
phenotype O
even O
without O
previous O
identification O
of O
a O
robertsonian O
translocation O
involving O
chromosome O
14 O
. O

clinical O
and O
genetic O
study O
of O
friedreich B-Disease
ataxia I-Disease
in O
an O
australian O
population O
. O

friedreich B-Disease
ataxia I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
caused O
by O
mutations O
in O
the O
frda B-Disease
gene O
that O
encodes O
a O
210 O
- O
amino O
acid O
protein O
called O
frataxin O
. O

we O
found O
a O
correlation O
between O
the O
size O
of O
the O
smaller O
of O
the O
two O
expanded O
alleles O
and O
age O
at O
onset O
, O
age O
into O
wheelchair O
, O
scoliosis B-Disease
, O
impaired O
vibration O
sense O
, O
and O
the O
presence O
of O
foot B-Disease
deformity I-Disease
. O

there O
was O
no O
significant O
correlation O
between O
the O
size O
of O
the O
smaller O
allele O
and O
cardiomyopathy B-Disease
, O
diabetes B-Disease
mellitus I-Disease
, O
loss B-Disease
of I-Disease
proprioception I-Disease
, O
or O
bladder B-Disease
symptoms I-Disease
. O

the O
larger O
allele O
size O
correlated O
with O
bladder B-Disease
symptoms I-Disease
and O
the O
presence O
of O
foot B-Disease
deformity I-Disease
. O

the O
duration O
of O
disease O
is O
correlated O
with O
wheelchair O
use O
and O
the O
presence O
of O
diabetes B-Disease
, O
scoliosis B-Disease
, O
bladder B-Disease
symptoms I-Disease
and O
impaired B-Disease
proprioception I-Disease
, O
and O
vibration O
sense O
but O
no O
other O
complications O
studied O
. O
. O

novel O
mutations O
in O
xlrs1 O
causing O
retinoschisis B-Disease
, O
including O
first O
evidence O
of O
putative O
leader O
sequence O
change O
. O

juvenile B-Disease
retinoschisis I-Disease
is O
an O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
disease I-Disease
caused O
by O
mutations O
in O
the O
xlrs1 O
gene O
. O

we O
screened O
31 O
new O
unrelated O
patients O
and O
families O
for O
xlrs1 O
mutations O
in O
addition O
to O
previously O
reported O
mutations O
for O
60 O
of O
our O
families O
( O
retinoschisis B-Disease
consortium O
, O
hum O
mol O
genet O
1998 O
; O
7 O
1185 O
- O
1192 O
) O
. O

667t O
- O
- O
> O
c O
( O
c223r O
) O
, O
respectively O
, O
present O
the O
first O
genetic O
evidence O
for O
the O
functional O
significance O
of O
the O
putative O
leader O
peptide O
sequence O
and O
for O
the O
functional O
significance O
at O
the O
carboxyl O
terminal O
of O
the O
xlrs1 O
protein O
beyond O
the O
discoidin O
domain O
. O

growth O
hormone O
treatment O
increases O
co O
( O
2 O
) O
response O
, O
ventilation O
and O
central O
inspiratory O
drive O
in O
children O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

conclusion O
treatment O
of O
children O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
seems O
to O
have O
a O
stimulatory O
effect O
on O
central O
respiratory O
structures O
. O

the O
observed O
increase O
in O
ventilation O
and O
inspiratory O
drive O
may O
contribute O
to O
the O
improved O
activity O
level O
reported O
by O
parents O
of O
pws B-Disease
children O
during O
growth O
hormone O
therapy O

g130v O
, O
a O
common O
frda B-Disease
point O
mutation O
, O
appears O
to O
have O
arisen O
from O
a O
common O
founder O
. O

friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
is O
the O
most O
common O
inherited B-Disease
ataxia I-Disease
. O

g130v O
, O
when O
present O
with O
an O
expanded O
gaa O
repeat O
on O
the O
other O
allele O
, O
is O
associated O
with O
an O
atypical O
frda B-Disease
phenotype O
. O

haplotype O
analysis O
was O
undertaken O
on O
the O
four O
families O
who O
have O
been O
described O
with O
this O
mutation O
. O

most O
fragile B-Disease
x I-Disease
syndrome I-Disease
patients O
have O
expansion O
of O
a O
( O
cgg O
) O
( O
n O
) O
sequence O
with O
> O
200 O
repeats O
( O
full O
mutation O
) O
in O
the O
fmr1 O
gene O
responsible O
for O
this O
condition O
. O

constitutional O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( O
vhl B-Disease
) O
gene O
deletions O
detected O
in O
vhl B-Disease
families O
by O
fluorescence O
in O
situ O
hybridization O
. O

von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
disease I-Disease
is O
an O
autosomal B-Disease
dominantly I-Disease
inherited I-Disease
cancer I-Disease
syndrome I-Disease
predisposing O
to O
a O
variety O
of O
tumor B-Disease
types O
that O
include O
retinal O
hemangioblastomas B-Disease
, O
hemangioblastomas B-Disease
of O
the O
central O
nervous O
system O
, O
renal B-Disease
cell I-Disease
carcinomas I-Disease
, O
pancreatic B-Disease
cysts I-Disease
and I-Disease
tumors I-Disease
, O
pheochromocytomas B-Disease
, O
endolymphatic B-Disease
sac I-Disease
tumors I-Disease
, O
and O
epididymal B-Disease
cystadenomas I-Disease
[ O
w O
. O

the O
vhl B-Disease
gene O
was O
localized O
to O
chromosome O
3p25 O
- O
26 O
and O
cloned O
[ O
f O
. O
latif O
et O
al O
. O
, O
science O
( O
washington O
dc O
) O
, O
260 O
1317 O
- O
1320 O
, O
1993 O
] O
. O

germline O
mutations O
in O
the O
vhl B-Disease
gene O
have O
been O
detected O
in O
the O
majority O
of O
vhl B-Disease
kindreds O
. O

the O
reported O
frequency O
of O
detection O
of O
vhl B-Disease
germline O
mutations O
has O
varied O
from O
39 O
to O
80 O
% O
( O
j O
. O
m O
. O
whaley O
et O
al O
. O
, O
am O
. O
j O
. O
hum O
. O
genet O
. O
, O
55 O
1092 O
- O
1102 O
, O
1994 O
; O
clinical O
research O
group O
for O
japan O
, O
hum O
. O
mol O
. O
genet O
. O
, O
4 O
2233 O
- O
2237 O
, O
1995 O
; O
f O
. O
chen O
et O
al O
. O
, O
hum O
. O
mutat O
. O
, O
5 O
66 O
- O
75 O
, O
1995 O
; O
e O
. O
r O
. O
maher O
et O
al O
. O
, O
j O
. O
med O
. O
genet O
. O
, O
33 O
328 O
- O
332 O
, O
1996 O
; O
b O
. O

in O
the O
present O
study O
, O
we O
report O
the O
use O
of O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
as O
a O
method O
to O
detect O
and O
characterize O
vhl B-Disease
germline O
deletions O
. O

we O
reexamined O
a O
group O
of O
vhl B-Disease
patients O
shown O
previously O
by O
single O
- O
strand O
conformation O
and O
sequencing O
analysis O
not O
to O
harbor O
point O
mutations O
in O
the O
vhl B-Disease
locus O
. O

we O
found O
constitutional O
deletions O
in O
29 O
of O
30 O
vhl B-Disease
patients O
in O
this O
group O
using O
cosmid O
and O
p1 O
probes O
that O
cover O
the O
vhl B-Disease
locus O
. O

we O
then O
tested O
six O
phenotypically O
normal O
offspring O
from O
four O
of O
these O
vhl B-Disease
families O
two O
were O
found O
to O
carry O
the O
deletion O
and O
the O
other O
four O
were O
deletion O
- O
free O
. O

in O
addition O
, O
germline O
mosaicism O
of O
the O
vhl B-Disease
gene O
was O
identified O
in O
one O
family O
. O

in O
sum O
, O
fish O
was O
found O
to O
be O
a O
simple O
and O
reliable O
method O
to O
detect O
vhl B-Disease
germline O
deletions O
and O
practically O
useful O
in O
cases O
where O
other O
methods O
of O
screening O
have O
failed O
to O
detect O
a O
vhl B-Disease
gene I-Disease
abnormality I-Disease

spectrum O
of O
hsnf5 O
/ O
ini1 O
somatic O
mutations O
in O
human O
cancer B-Disease
and O
genotype O
- O
phenotype O
correlations O
. O

the O
hsnf5 O
/ O
ini1 O
gene O
which O
encodes O
a O
member O
of O
the O
swi O
/ O
snf O
chromatin O
atp O
- O
dependent O
remodeling O
complex O
, O
is O
a O
new O
tumor B-Disease
suppressor O
gene O
localized O
on O
chromosome O
22q11 O
. O

2 O
and O
recently O
shown O
to O
be O
mutated O
in O
malignant B-Disease
rhabdoid I-Disease
tumors I-Disease
. O

we O
have O
searched O
for O
hsnf5 O
/ O
ini1 O
mutations O
in O
229 O
tumors B-Disease
of O
various O
origins O
using O
a O
screening O
method O
based O
on O
denaturing O
high O
- O
performance O
liquid O
chromatography O
. O

mutations O
were O
retrieved O
in O
most O
rhabdoid B-Disease
tumors I-Disease
, O
whatever O
their O
sites O
of O
occurrence O
, O
indicating O
the O
common O
pathogenetic O
origin O
of O
these O
tumors B-Disease
. O

recurrent O
hsnf5 O
/ O
ini1 O
alterations O
were O
also O
observed O
in O
choroid B-Disease
plexus I-Disease
carcinomas I-Disease
and O
in O
a O
subset O
of O
central O
primitive O
neuroectodermal B-Disease
tumors I-Disease
( O
cpnets O
) O
and O
medulloblastomas B-Disease
. O

in O
contrast O
, O
hsnf5 O
/ O
ini1 O
point O
mutations O
were O
not O
detected O
in O
breast B-Disease
cancers I-Disease
, O
wilms B-Disease
tumors I-Disease
, O
gliomas B-Disease
, O
ependymomas B-Disease
, O
sarcomas B-Disease
and O
other O
tumor B-Disease
types O
, O
even O
though O
most O
analyzed O
cases O
harbored O
loss O
of O
heterozygosity O
at O
22q11 O
. O

these O
results O
suggest O
that O
rhabdoid B-Disease
tumors I-Disease
, O
choroid B-Disease
plexus I-Disease
carcinomas I-Disease
and O
a O
subset O
of O
medulloblastomas B-Disease
and O
cpnets O
share O
common O
pathways O
of O
oncogenesis O
related O
to O
hsnf5 O
/ O
ini1 O
alteration O
and O
that O
hsnf5 O
/ O
ini1 O
mutations O
define O
a O
genetically O
homogeneous O
family O
of O
highly O
aggressive O
cancers B-Disease
mainly O
occurring O
in O
young O
children O
and O
frequently O
, O
but O
not O
always O
, O
exhibiting O
a O
rhabdoid B-Disease
phenotype O

spinocerebellar B-Disease
ataxia I-Disease
type I-Disease
- I-Disease
3 I-Disease
or O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
sca3 B-Disease
/ O
mjd B-Disease
) O
is O
a O
member O
of O
the O
cag B-Disease
/ I-Disease
polyglutamine I-Disease
repeat I-Disease
disease I-Disease
family O
. O

experimental O
models O
of O
polyglutamine B-Disease
disease I-Disease
implicate O
the O
nucleus O
in O
pathogenesis O
; O
however O
, O
the O
link O
between O
intranuclear O
expression O
of O
expanded O
polyglutamine O
and O
neuronal B-Disease
dysfunction I-Disease
remains O
unclear O
. O

here O
we O
demonstrate O
that O
ataxin O
- O
3 O
, O
the O
disease O
protein O
in O
sca3 B-Disease
/ O
mjd B-Disease
, O
adopts O
a O
unique O
conformation O
when O
expressed O
within O
the O
nucleus O
of O
transfected O
cells O
. O

these O
data O
suggest O
that O
an O
early O
event O
in O
the O
pathogenesis O
of O
sca3 B-Disease
/ O
mjd B-Disease
may O
be O
an O
altered O
conformation O
of O
ataxin O
- O
3 O
within O
the O
nucleus O
that O
exposes O
the O
polyglutamine O
domain O
. O
. O

the O
human O
magel2 O
gene O
and O
its O
mouse O
homologue O
are O
paternally O
expressed O
and O
mapped O
to O
the O
prader B-Disease
- I-Disease
willi I-Disease
region O
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
is O
a O
complex O
neurogenetic B-Disease
disorder I-Disease
. O

the O
phenotype O
is O
likely O
to O
be O
a O
contiguous B-Disease
gene I-Disease
syndrome I-Disease
involving O
genes O
which O
are O
paternally O
expressed O
only O
, O
located O
in O
the O
human O
15q11 O
- O
q13 O
region O
. O

four O
mouse O
models O
of O
pws B-Disease
have O
been O
reported O
but O
these O
do O
not O
definitively O
allow O
the O
delineation O
of O
the O
critical O
region O
and O
the O
associated O
genes O
involved O
in O
the O
aetiology O
of O
pws B-Disease
. O

moreover O
, O
targeted O
mutagenesis O
of O
mouse O
homologues O
of O
the O
human O
candidate O
pws B-Disease
genes O
does O
not O
appear O
to O
result O
in O
any O
of O
the O
features O
of O
pws B-Disease
. O

therefore O
, O
the O
isolation O
of O
new O
genes O
in O
this O
region O
remains O
crucial O
for O
a O
better O
understanding O
of O
the O
molecular O
basis O
of O
pws B-Disease
. O

moreover O
, O
magel2 O
/ O
magel2 O
are O
expressed O
only O
from O
the O
paternal O
allele O
in O
brain O
, O
suggesting O
a O
potential O
role O
in O
the O
aetiology O
of O
pws B-Disease
and O
its O
mouse O
model O
, O
respectively O
. O

alveolar B-Disease
rhabdomyosarcoma I-Disease
is O
an O
aggressive O
pediatric B-Disease
cancer I-Disease
of I-Disease
striated I-Disease
muscle I-Disease
characterized O
in O
60 O
% O
of O
cases O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
. O

relevance O
of O
this O
model O
was O
suggested O
by O
verification O
that O
three O
of O
these O
genes O
( O
igfbp5 O
, O
hsix1 O
, O
and O
slug O
) O
were O
also O
expressed O
in O
alveolar B-Disease
rhabdomyosarcoma I-Disease
cell O
lines O
. O

experimental O
hemochromatosis B-Disease
due O
to O
mhc O
class O
i O
hfe B-Disease
deficiency I-Disease
: O
immune O
status O
and O
iron O
metabolism O
. O

the O
puzzling O
linkage O
between O
genetic O
hemochromatosis B-Disease
and O
histocompatibility O
loci O
became O
even O
more O
so O
when O
the O
gene O
involved O
, O
hfe O
, O
was O
identified O
. O

hfe B-Disease
- I-Disease
deficient I-Disease
animals O
were O
analyzed O
for O
a O
comprehensive O
set O
of O
metabolic O
and O
immune O
parameters O
. O

faithfully O
mimicking O
human O
hemochromatosis B-Disease
, O
mice O
homozygous O
for O
this O
deletion O
develop O
iron O
overload O
, O
characterized O
by O
a O
higher O
plasma O
iron O
content O
and O
a O
raised O
transferrin O
saturation O
as O
well O
as O
an O
elevated O
hepatic O
iron O
load O
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
is O
a O
rare O
genetic B-Disease
disorder I-Disease
associated O
with O
immune B-Disease
deficiency I-Disease
, O
chromosome B-Disease
instability I-Disease
, O
and O
a O
predisposition O
to O
lymphoid B-Disease
malignancy I-Disease
. O

these O
findings O
as O
well O
as O
data O
obtained O
by O
others O
for O
patients O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
suggest O
that O
structural O
rearrangement O
of O
14q O
is O
the O
initial O
chromosomal O
change O
in O
lymphocyte O
clones O
of O
patients O
with O
this O
disorder O
. O

chromosomes O
of O
lymphocytes O
from O
one O
of O
the O
patients O
were O
studied O
before O
and O
after O
the O
onset O
of O
chronic B-Disease
lymphocytic I-Disease
leukemia I-Disease
. O

before O
leukemia B-Disease
was O
diagnosed O
, O
the O
patient O
had O
a O
lymphocyte O
clone O
with O
a O
14q O
translocation O
. O

this O
clone O
appears O
to O
have O
given O
rise O
to O
the O
leukemic B-Disease
cells O
. O

we O
hypothesize O
that O
structural O
rearrangement O
of O
14q O
is O
directly O
related O
to O
abnormal O
growth O
of O
lymphocytes O
and O
that O
it O
may O
be O
a O
step O
toward O
the O
development O
of O
lymphoid B-Disease
malignancies I-Disease
. O

increasing O
evidence O
, O
provided O
by O
others O
, O
for O
the O
nonrandom O
involvement O
of O
14q O
in O
african O
- O
type O
burkitts B-Disease
lymphoma I-Disease
and O
other O
lymphoid B-Disease
neoplasms I-Disease
further O
strengthens O
this O
hypothesis O
. O
. O

exon O
9 O
mutations O
in O
the O
wt1 O
gene O
, O
without O
influencing O
kts O
splice O
isoforms O
, O
are O
also O
responsible O
for O
frasier B-Disease
syndrome I-Disease
. O

we O
report O
new O
mutations O
in O
exon O
9 O
of O
the O
wt1 O
gene O
that O
did O
not O
alter O
the O
ratio O
of O
+ O
/ O
- O
kts O
splice O
isoforms O
in O
two O
unrelated O
patients O
with O
frasier B-Disease
syndrome I-Disease
( O
fs B-Disease
) O
. O

the O
mutations O
found O
in O
our O
cases O
occurred O
in O
the O
same O
exon O
of O
the O
wt1 O
gene O
as O
detected O
in O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
( O
dds B-Disease
) O
and O
could O
not O
be O
explained O
by O
the O
previously O
proposed O
mechanism O
. O

the O
results O
suggest O
that O
the O
two O
syndromes O
originate O
from O
the O
same O
wt1 B-Disease
gene I-Disease
abnormality I-Disease
. O

from O
a O
molecular O
biological O
point O
of O
view O
, O
we O
concluded O
that O
the O
two O
diseases O
were O
not O
separable O
, O
and O
that O
fs B-Disease
should O
be O
included O
as O
an O
atypical O
form O
of O
dds B-Disease
. O

splice O
- O
site O
mutation O
in O
the O
pds B-Disease
gene O
may O
result O
in O
intrafamilial O
variability O
for O
deafness B-Disease
in O
pendred B-Disease
syndrome I-Disease
. O

pendred B-Disease
syndrome I-Disease
is O
a O
recessive B-Disease
inherited I-Disease
disorder I-Disease
that O
consists O
of O
developmental B-Disease
abnormalities I-Disease
of I-Disease
the I-Disease
cochlea I-Disease
, O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
, O
and O
diffuse B-Disease
thyroid I-Disease
enlargement I-Disease
( O
goiter B-Disease
) O
. O

this O
disorder O
may O
account O
for O
up O
to O
10 O
% O
of O
cases O
of O
hereditary B-Disease
deafness I-Disease
. O

the O
disease O
gene O
( O
pds B-Disease
) O
has O
been O
mapped O
to O
chromosome O
7q22 O
- O
q31 O
, O
and O
encodes O
a O
chloride O
- O
iodide O
transport O
protein O
. O

we O
performed O
mutation O
analysis O
of O
individual O
exons O
of O
the O
pds B-Disease
gene O
in O
one O
spanish O
family O
that O
shows O
intrafamilial O
variability O
of O
the O
deafness B-Disease
phenotype O
( O
two O
patients O
with O
profound O
and O
one O
with O
moderate O
- O
severe O
deafness B-Disease
) O
. O

we O
identified O
a O
new O
splice O
- O
site O
mutation O
affecting O
intron O
4 O
of O
the O
pds B-Disease
gene O
, O
at O
nucleotide O
position O
639 O
+ O
7 O
. O

since O
the O
newly O
created O
donor O
splice O
site O
is O
likely O
to O
compete O
with O
the O
normal O
one O
, O
variations O
of O
the O
levels O
of O
normal O
and O
aberrant O
transcripts O
of O
the O
pds B-Disease
gene O
in O
the O
cochlea O
may O
explain O
the O
variability O
in O
the O
deafness B-Disease
presentation O
. O

the O
molecular O
basis O
of O
sjogren B-Disease
- I-Disease
larsson I-Disease
syndrome I-Disease
: O
mutation O
analysis O
of O
the O
fatty O
aldehyde O
dehydrogenase O
gene O
. O

sjogren B-Disease
- I-Disease
larsson I-Disease
syndrome I-Disease
( O
sls B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
ichthyosis B-Disease
, O
mental B-Disease
retardation I-Disease
, O
spasticity B-Disease
, O
and O
deficient B-Disease
activity I-Disease
of I-Disease
fatty I-Disease
aldehyde I-Disease
dehydrogenase I-Disease
( O
faldh O
) O
. O

to O
define O
the O
molecular O
defects O
causing O
sls B-Disease
, O
we O
performed O
mutation O
analysis O
of O
the O
faldh O
gene O
in O
probands O
from O
63 O
kindreds O
with O
sls B-Disease
. O

all O
of O
the O
patients O
with O
sls B-Disease
were O
found O
to O
carry O
mutations O
. O

at O
least O
four O
of O
the O
common O
mutations O
( O
551c O
- O
- O
> O
t O
, O
682c O
- O
- O
> O
t O
, O
733g O
- O
- O
> O
a O
, O
and O
798 O
+ O
1delg O
) O
were O
associated O
with O
multiple O
snp O
haplotypes O
, O
suggesting O
that O
these O
mutations O
originated O
independently O
on O
more O
than O
one O
occasion O
or O
were O
ancient O
sls B-Disease
genes O
that O
had O
undergone O
intragenic O
recombination O
. O

our O
results O
demonstrate O
that O
sls B-Disease
is O
caused O
by O
a O
strikingly O
heterogeneous O
group O
of O
mutations O
in O
the O
faldh O
gene O
and O
provide O
a O
framework O
for O
understanding O
the O
genetic O
basis O
of O
sls B-Disease
and O
the O
development O
of O
dna O
- O
based O
diagnostic O
tests O
. O
. O

loss O
- O
of O
- O
function O
mutations O
in O
the O
cathepsin O
c O
gene O
result O
in O
periodontal B-Disease
disease I-Disease
and O
palmoplantar B-Disease
keratosis I-Disease
. O

papillon B-Disease
- I-Disease
lefevre I-Disease
syndrome I-Disease
, O
or O
keratosis B-Disease
palmoplantaris I-Disease
with O
periodontopathia B-Disease
( O
pls B-Disease
, O
mim O
245000 O
) O
, O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
that O
is O
mainly O
ascertained O
by O
dentists O
because O
of O
the O
severe O
periodontitis B-Disease
that O
afflicts O
patients O
. O

both O
the O
deciduous O
and O
permanent O
dentitions O
are O
affected O
, O
resulting O
in O
premature O
tooth B-Disease
loss I-Disease
. O

palmoplantar B-Disease
keratosis I-Disease
, O
varying O
from O
mild O
psoriasiform O
scaly O
skin O
to O
overt O
hyperkeratosis B-Disease
, O
typically O
develops O
within O
the O
first O
three O
years O
of O
life O
. O

keratosis B-Disease
also O
affects O
other O
sites O
such O
as O
elbows O
and O
knees O
. O

most O
pls B-Disease
patients O
display O
both O
periodontitis B-Disease
and O
hyperkeratosis B-Disease
. O

some O
patients O
have O
only O
palmoplantar B-Disease
keratosis I-Disease
or O
periodontitis B-Disease
, O
and O
in O
rare O
individuals O
the O
periodontitis B-Disease
is O
mild O
and O
of O
late O
onset O
. O

two O
of O
these O
families O
we O
used O
a O
functional O
assay O
to O
demonstrate O
an O
almost O
total O
loss O
of O
cathepsin O
c O
activity O
in O
pls B-Disease
patients O
and O
reduced O
activity O
in O
obligate O
carriers O
. O

confirmation O
of O
linkage O
of O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
to O
chromosome O
1q32 O
: O
evidence O
of O
association O
with O
str O
alleles O
suggests O
possible O
unique O
origin O
of O
the O
disease O
mutation O
. O

van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
( O
vws B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
craniofacial I-Disease
disorder I-Disease
with O
high O
penetrance O
and O
variable O
expression O
. O

its O
clinical O
features O
are O
variably O
expressed O
, O
but O
include O
cleft B-Disease
lip I-Disease
and O
/ O
or O
cleft B-Disease
palate I-Disease
, O
lip B-Disease
pits I-Disease
and O
hypodontia B-Disease
. O

all O
vws B-Disease
families O
studied O
to O
date O
map O
the O
disease O
gene O
to O
a O
< O
2 O
cm O
region O
of O
chromosome O
1q32 O
, O
with O
no O
evidence O
of O
locus O
heterogeneity O
. O

the O
aim O
of O
this O
study O
is O
to O
refine O
the O
localization O
of O
the O
vws B-Disease
gene O
and O
to O
further O
assess O
possible O
heterogeneity O
. O

we O
analyzed O
four O
multiplex O
vws B-Disease
families O
. O

all O
available O
members O
were O
clinically O
assessed O
and O
genotyped O
for O
19 O
short O
tandem O
repeat O
markers O
on O
chromosome O
1 O
in O
the O
vws B-Disease
candidate O
gene O
region O
. O

our O
assay O
method O
for O
short O
tandem O
repeat O
( O
str O
) O
markers O
provided O
highly O
accurate O
size O
estimation O
of O
marker O
allele O
fragment O
sizes O
, O
and O
therefore O
enabled O
us O
to O
determine O
the O
specific O
alleles O
segregating O
with O
the O
vws B-Disease
gene O
in O
each O
of O
our O
four O
families O
. O

we O
observed O
a O
striking O
pattern O
of O
str O
allele O
sharing O
at O
several O
closely O
linked O
loci O
among O
our O
four O
caucasian O
vws B-Disease
families O
recruited O
at O
three O
different O
locations O
in O
the O
us O
. O

these O
results O
suggest O
the O
possibility O
of O
a O
unique O
origin O
for O
a O
mutation O
responsible O
for O
many O
or O
most O
cases O
of O
vws B-Disease
. O

a O
new O
platelet O
- O
specific O
alloantigen O
, O
termed O
sit O
( O
a O
) O
, O
was O
identified O
in O
a O
severe O
case O
of O
neonatal B-Disease
alloimmune I-Disease
thrombocytopenia I-Disease
. O

mutations O
of O
the O
cathepsin O
c O
gene O
are O
responsible O
for O
papillon B-Disease
- I-Disease
lefevre I-Disease
syndrome I-Disease
. O

papillon B-Disease
- I-Disease
lefevre I-Disease
syndrome I-Disease
( O
pls B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterised O
by O
palmoplantar B-Disease
hyperkeratosis I-Disease
and O
severe O
early O
onset O
periodontitis B-Disease
that O
results O
in O
the O
premature O
loss O
of O
the O
primary O
and O
secondary O
dentitions O
. O

a O
major O
gene O
locus O
for O
pls B-Disease
has O
been O
mapped O
to O
a O
2 O
. O

by O
rt O
- O
pcr O
, O
we O
found O
ctsc O
is O
also O
expressed O
in O
epithelial O
regions O
commonly O
affected O
by O
pls B-Disease
, O
including O
the O
palms O
, O
soles O
, O
knees O
, O
and O
oral O
keratinised O
gingiva O
. O

sequence O
analysis O
of O
ctsc O
from O
subjects O
affected O
with O
pls B-Disease
from O
five O
consanguineous O
turkish O
families O
identified O
four O
different O
mutations O
. O

all O
pls B-Disease
patients O
were O
homozygous O
for O
cathepsin O
c O
mutations O
inherited O
from O
a O
common O
ancestor O
. O

parents O
and O
sibs O
heterozygous O
for O
cathepsin O
c O
mutations O
do O
not O
show O
either O
the O
palmoplantar B-Disease
hyperkeratosis I-Disease
or O
severe O
early O
onset O
periodontitis B-Disease
characteristic O
of O
pls B-Disease
. O

a O
more O
complete O
understanding O
of O
the O
functional O
physiology O
of O
cathepsin O
c O
carries O
significant O
implications O
for O
understanding O
normal O
and O
abnormal O
skin O
development O
and O
periodontal B-Disease
disease I-Disease
susceptibility O

mutational O
analysis O
of O
the O
hgo O
gene O
in O
finnish O
alkaptonuria B-Disease
patients O
. O

alkaptonuria B-Disease
( O
aku B-Disease
) O
, O
the O
prototypic O
inborn B-Disease
error I-Disease
of I-Disease
metabolism I-Disease
, O
has O
recently O
been O
shown O
to O
be O
caused O
by O
loss O
of O
function O
mutations O
in O
the O
homogentisate O
- O
1 O
, O
2 O
- O
dioxygenase O
gene O
( O
hgo O
) O
. O

so O
far O
17 O
mutations O
have O
been O
characterised O
in O
aku B-Disease
patients O
of O
different O
ethnic O
origin O
. O

we O
describe O
three O
novel O
mutations O
( O
r58fs O
, O
r330s O
, O
and O
h371r O
) O
and O
one O
common O
aku B-Disease
mutation O
( O
m368v O
) O
, O
detected O
by O
mutational O
and O
polymorphism O
analysis O
of O
the O
hgo O
gene O
in O
five O
finnish O
aku B-Disease
pedigrees O
. O

the O
three O
novel O
aku B-Disease
mutations O
are O
most O
likely O
specific O
for O
the O
finnish O
population O
and O
have O
originated O
recently O
. O
. O

the O
identical O
5 O
' O
splice O
- O
site O
acceptor O
mutation O
in O
five O
attenuated B-Disease
apc I-Disease
families O
from O
newfoundland O
demonstrates O
a O
founder O
effect O
. O

inherited O
mutations O
of O
the O
apc B-Disease
gene O
predispose O
carriers O
to O
multiple O
adenomatous B-Disease
polyps I-Disease
of I-Disease
the I-Disease
colon I-Disease
and I-Disease
rectum I-Disease
and O
to O
colorectal B-Disease
cancer I-Disease
. O

mutations O
located O
at O
the O
extreme O
5 O
end O
of O
the O
apc B-Disease
gene O
, O
however O
, O
are O
associated O
with O
a O
less O
severe O
disease O
known O
as O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
( O
aapc B-Disease
) O
. O

many O
individuals O
with O
aapc B-Disease
develop O
relatively O
few O
colorectal B-Disease
polyps I-Disease
but O
are O
still O
at O
high O
risk O
for O
colorectal B-Disease
cancer I-Disease
. O

we O
report O
here O
the O
identification O
of O
a O
5 O
apc B-Disease
germline O
mutation O
in O
five O
separately O
ascertained O
aapc B-Disease
families O
from O
newfoundland O
, O
canada O
. O

this O
disease O
- O
causing O
mutation O
is O
a O
single O
basepair O
change O
( O
g O
to O
a O
) O
in O
the O
splice O
- O
acceptor O
region O
of O
apc B-Disease
intron O
3 O
that O
creates O
a O
mutant O
rna O
without O
exon O
4 O
of O
apc O
. O

furthermore O
, O
the O
identification O
of O
this O
germline O
mutation O
strengthens O
the O
correlation O
between O
the O
5 O
location O
of O
an O
apc B-Disease
disease O
- O
causing O
mutation O
and O
the O
attenuated B-Disease
polyposis I-Disease
phenotype O
. O
. O

alstrom B-Disease
syndrome I-Disease
: O
further O
evidence O
for O
linkage O
to O
human O
chromosome O
2p13 O
. O

alstrom B-Disease
syndrome I-Disease
is O
a O
rare O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
retinal B-Disease
degeneration I-Disease
, O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
, O
early O
- O
onset O
obesity B-Disease
, O
and O
non B-Disease
- I-Disease
insulin I-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
. O

the O
gene O
for O
alstrom B-Disease
syndrome I-Disease
( O
alms1 O
) O
has O
been O
previously O
localized O
to O
human O
chromosome O
2p13 O
by O
homozygosity O
mapping O
in O
two O
distinct O
isolated O
populations O
- O
french O
acadian O
and O
north O
african O
. O

to O
confirm O
these O
findings O
, O
a O
large O
linkage O
study O
was O
performed O
in O
twelve O
additional O
families O
segregating O
for O
alstrom B-Disease
syndrome I-Disease
. O

pendred B-Disease
syndrome I-Disease
: O
phenotypic O
variability O
in O
two O
families O
carrying O
the O
same O
pds B-Disease
missense O
mutation O
. O

pendred B-Disease
syndrome I-Disease
comprises O
congenital B-Disease
sensorineural I-Disease
hearing I-Disease
loss I-Disease
, O
thyroid B-Disease
goiter I-Disease
, O
and O
positive O
perchlorate O
discharge O
test O
. O

recently O
, O
this O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
was O
shown O
to O
be O
caused O
by O
mutations O
in O
the O
pds B-Disease
gene O
, O
which O
encodes O
an O
anion O
transporter O
called O
pendrin O
. O

molecular O
analysis O
of O
the O
pds B-Disease
gene O
was O
performed O
in O
two O
consanguineous O
large O
families O
from O
southern O
tunisia O
comprising O
a O
total O
of O
23 O
individuals O
affected O
with O
profound O
congenital B-Disease
deafness I-Disease
; O
the O
same O
missense O
mutation O
, O
l445w O
, O
was O
identified O
in O
all O
affected O
individuals O
. O

a O
widened B-Disease
vestibular I-Disease
aqueduct I-Disease
was O
found O
in O
all O
patients O
who O
underwent O
computed O
tomography O
( O
ct O
) O
scan O
exploration O
of O
the O
inner O
ear O
. O

in O
contrast O
, O
goiter B-Disease
was O
present O
in O
only O
11 O
affected O
individuals O
, O
who O
interestingly O
had O
a O
normal O
result O
of O
the O
perchlorate O
discharge O
test O
whenever O
performed O
. O

the O
present O
results O
question O
the O
sensitivity O
of O
the O
perchlorate O
test O
for O
the O
diagnosis O
of O
pendred B-Disease
syndrome I-Disease
and O
support O
the O
use O
of O
a O
molecular O
analysis O
of O
the O
pds B-Disease
gene O
in O
the O
assessment O
of O
individuals O
with O
severe O
to O
profound O
congenital B-Disease
hearing I-Disease
loss I-Disease
associated O
with O
inner B-Disease
ear I-Disease
morphological I-Disease
anomaly I-Disease
even O
in O
the O
absence O
of O
a O
thyroid B-Disease
goiter I-Disease
. O
. O

knobloch B-Disease
syndrome I-Disease
involving O
midline B-Disease
scalp I-Disease
defect I-Disease
of I-Disease
the I-Disease
frontal I-Disease
region I-Disease
. O

we O
report O
on O
a O
4 O
- O
year O
- O
old O
boy O
with O
knobloch B-Disease
syndrome I-Disease
. O

he O
has O
vitreoretinal B-Disease
degeneration I-Disease
, O
high B-Disease
myopia I-Disease
, O
cataract B-Disease
, O
telecanthus B-Disease
, O
hypertelorism B-Disease
, O
and O
a O
high B-Disease
- I-Disease
arched I-Disease
palate I-Disease
. O

he O
also O
has O
a O
defect B-Disease
of I-Disease
the I-Disease
anterior I-Disease
midline I-Disease
scalp I-Disease
with O
involvement O
of O
the O
frontal O
bone O
as O
documented O
by O
a O
computed O
tomography O
( O
ct O
) O
scan O
. O

our O
patient O
illustrates O
the O
importance O
of O
investigating O
for O
underlying O
ocular O
and O
central O
nervous O
system O
pathology O
whenever O
midline B-Disease
scalp I-Disease
defects I-Disease
are O
present O
. O
. O

the O
dna O
double O
- O
strand O
break O
repair O
gene O
hmre11 O
is O
mutated O
in O
individuals O
with O
an O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
- I-Disease
like I-Disease
disorder I-Disease
. O

we O
show O
that O
hypomorphic O
mutations O
in O
hmre11 O
, O
but O
not O
in O
atm O
, O
are O
present O
in O
certain O
individuals O
with O
an O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
- I-Disease
like I-Disease
disorder I-Disease
( O
atld B-Disease
) O
. O

the O
cellular O
features O
resulting O
from O
these O
hmre11 O
mutations O
are O
similar O
to O
those O
seen O
in O
a B-Disease
- I-Disease
t I-Disease
as O
well O
as O
nbs B-Disease
and O
include O
hypersensitivity B-Disease
to I-Disease
ionizing I-Disease
radiation I-Disease
, O
radioresistant O
dna O
synthesis O
, O
and O
abrogation O
of O
atm O
- O
dependent O
events O
, O
such O
as O
the O
activation O
of O
jun O
kinase O
following O
exposure O
to O
gamma O
irradiation O
. O

these O
data O
demonstrate O
that O
atm O
and O
the O
hmre11 O
/ O
hrad50 O
/ O
nbs1 O
protein O
complex O
act O
in O
the O
same O
dna O
damage O
response O
pathway O
and O
link O
hmre11 O
to O
the O
complex O
pathology O
of O
a B-Disease
- I-Disease
t I-Disease
. O
. O

mutations O
in O
tnfrsf11a O
, O
affecting O
the O
signal O
peptide O
of O
rank O
, O
cause O
familial B-Disease
expansile I-Disease
osteolysis I-Disease
. O

familial B-Disease
expansile I-Disease
osteolysis I-Disease
( O
feo B-Disease
, O
mim O
174810 O
) O
is O
a O
rare O
, O
autosomal B-Disease
dominant I-Disease
bone I-Disease
disorder I-Disease
characterized O
by O
focal O
areas O
of O
increased B-Disease
bone I-Disease
remodelling I-Disease
. O

the O
osteolytic B-Disease
lesions I-Disease
, O
which O
develop O
usually O
in O
the O
long O
bones O
during O
early O
adulthood O
, O
show O
increased O
osteoblast O
and O
osteoclast O
activity O
. O

our O
previous O
linkage O
studies O
mapped O
the O
gene O
responsible O
for O
feo B-Disease
to O
an O
interval O
of O
less O
than O
5 O
cm O
between O
d18s64 O
and O
d18s51 O
on O
chromosome O
18q21 O
. O

we O
identified O
two O
heterozygous O
insertion O
mutations O
in O
exon O
1 O
of O
tnfrsf11a O
in O
affected O
members O
of O
four O
families O
with O
feo B-Disease
or O
familial B-Disease
paget I-Disease
disease I-Disease
of I-Disease
bone I-Disease
( O
pdb B-Disease
) O
. O

cardiac O
na O
( O
+ O
) O
channel O
dysfunction O
in O
brugada B-Disease
syndrome I-Disease
is O
aggravated O
by O
beta O
( O
1 O
) O
- O
subunit O
. O

background O
mutations O
in O
the O
gene O
encoding O
the O
human O
cardiac O
na O
( O
+ O
) O
channel O
alpha O
- O
subunit O
( O
hh1 O
) O
are O
responsible O
for O
chromosome O
3 O
- O
linked O
congenital B-Disease
long I-Disease
- I-Disease
qt I-Disease
syndrome I-Disease
( O
lqt3 B-Disease
) O
and O
idiopathic B-Disease
ventricular I-Disease
fibrillation I-Disease
( O
ivf B-Disease
) O
. O

here O
, O
we O
characterize O
the O
altered O
effects O
of O
a O
human O
beta O
( O
1 O
) O
- O
subunit O
( O
hbeta O
( O
1 O
) O
) O
on O
the O
heterologously O
expressed O
hh1 O
mutation O
( O
t1620m O
) O
previously O
associated O
with O
ivf B-Disease
. O

methods O
and O
results O
when O
expressed O
alone O
in O
xenopus O
oocytes O
, O
t1620m O
exhibited O
no O
persistent O
currents O
, O
in O
contrast O
to O
the O
lqt3 B-Disease
mutant O
channels O
, O
but O
the O
midpoint O
of O
steady O
- O
state O
inactivation O
( O
v O
( O
1 O
/ O
2 O
) O
) O
was O
significantly O
shifted O
toward O
more O
positive O
potentials O
than O
for O
wild O
- O
type O
hh1 O
. O

meiotic O
segregation O
analysis O
of O
rb1 O
alleles O
in O
retinoblastoma B-Disease
pedigrees O
by O
use O
of O
single O
- O
sperm O
typing O
. O

in O
hereditary B-Disease
retinoblastoma I-Disease
, O
different O
epidemiological O
studies O
have O
indicated O
a O
preferential O
paternal O
transmission O
of O
mutant O
retinoblastoma B-Disease
alleles O
to O
offspring O
, O
suggesting O
the O
occurrence O
of O
a O
meiotic O
drive O
. O

to O
investigate O
this O
mechanism O
, O
we O
analyzed O
sperm O
samples O
from O
six O
individuals O
from O
five O
unrelated O
families O
affected O
with O
hereditary B-Disease
retinoblastoma I-Disease
. O

single O
- O
sperm O
typing O
techniques O
were O
performed O
for O
each O
sample O
by O
study O
of O
two O
informative O
short O
tandem O
repeats O
located O
either O
in O
or O
close O
to O
the O
retinoblastoma B-Disease
gene O
( O
rb1 O
) O
. O

friedreich B-Disease
ataxia I-Disease
, O
an O
autosomal B-Disease
recessive I-Disease
neurodegenerative I-Disease
disease I-Disease
, O
is O
the O
most O
common O
of O
the O
inherited B-Disease
ataxias I-Disease
. O

the O
recent O
discovery O
of O
the O
gene O
that O
is O
mutated O
in O
this O
condition O
, O
frda O
, O
has O
led O
to O
rapid O
advances O
in O
the O
understanding O
of O
the O
pathogenesis O
of O
friedreich B-Disease
ataxia I-Disease
. O

there O
is O
mounting O
evidence O
to O
suggest O
that O
friedreich B-Disease
ataxia I-Disease
is O
the O
result O
of O
accumulation O
of O
iron O
in O
mitochondria O
leading O
to O
excess O
production O
of O
free O
radicals O
, O
which O
then O
results O
in O
cellular O
damage O
and O
death O
. O

the O
discovery O
of O
the O
frda B-Disease
gene O
and O
its O
possible O
function O
has O
raised O
hope O
that O
rational O
therapeutic O
strategies O
will O
be O
developed O
. O
. O

x B-Disease
- I-Disease
linked I-Disease
retinoschisis I-Disease
with O
point O
mutations O
in O
the O
xlrs1 O
gene O
. O

background O
x B-Disease
- I-Disease
linked I-Disease
retinoschisis I-Disease
( O
xlrs B-Disease
) O
is O
a O
relatively O
rare O
vitreoretinal B-Disease
dystrophy I-Disease
that O
causes O
visual B-Disease
loss I-Disease
in O
young O
men O
. O

conclusions O
the O
discovery O
of O
new O
point O
mutations O
in O
this O
study O
increases O
the O
available O
information O
regarding O
the O
spectrum O
of O
genetic B-Disease
abnormalities I-Disease
and O
clinical O
manifestations O
of O
xlrs B-Disease
. O

clinical O
relevance O
identification O
of O
mutations O
in O
the O
xlrs1 O
gene O
and O
expanded O
information O
on O
clinical O
manifestations O
will O
facilitate O
early O
diagnosis O
, O
appropriate O
early O
therapy O
, O
and O
genetic O
counseling O
regarding O
the O
prognosis O
of O
xlrs B-Disease
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
is O
a O
hereditary B-Disease
multisystemic I-Disease
disease I-Disease
resulting O
from O
mutations O
of O
ataxia B-Disease
telangiectasia I-Disease
, O
mutated O
( O
atm O
) O
and O
is O
characterized O
by O
neurodegeneration B-Disease
, O
cancer B-Disease
, O
immune B-Disease
defects I-Disease
, O
and O
hypersensitivity B-Disease
to I-Disease
ionizing I-Disease
radiation I-Disease
. O

the O
molecular O
details O
of O
atm O
function O
in O
the O
nervous O
system O
are O
unclear O
, O
although O
the O
neurological B-Disease
lesion I-Disease
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
becomes O
apparent O
early O
in O
life O
, O
suggesting O
a O
developmental O
origin O
. O

haim B-Disease
- I-Disease
munk I-Disease
syndrome I-Disease
and O
papillon B-Disease
- I-Disease
lefevre I-Disease
syndrome I-Disease
are O
allelic O
mutations O
in O
cathepsin O
c O
. O

of O
the O
many O
palmoplantar B-Disease
keratoderma I-Disease
( I-Disease
ppk I-Disease
) I-Disease
conditions I-Disease
, O
only O
papillon B-Disease
- I-Disease
lefevre I-Disease
syndrome I-Disease
( O
pls B-Disease
) O
and O
haim B-Disease
- I-Disease
munk I-Disease
syndrome I-Disease
( O
hms B-Disease
) O
are O
associated O
with O
premature O
periodontal O
destruction O
. O

although O
both O
pls B-Disease
and O
hms B-Disease
share O
the O
cardinal O
features O
of O
ppk B-Disease
and O
severe O
periodontitis B-Disease
, O
a O
number O
of O
additional O
findings O
are O
reported O
in O
hms B-Disease
including O
arachnodactyly B-Disease
, O
acro B-Disease
- I-Disease
osteolysis I-Disease
, O
atrophic B-Disease
changes I-Disease
of I-Disease
the I-Disease
nails I-Disease
, O
and O
a O
radiographic B-Disease
deformity I-Disease
of I-Disease
the I-Disease
fingers I-Disease
. O

while O
pls B-Disease
cases O
have O
been O
identified O
throughout O
the O
world O
, O
hms B-Disease
has O
only O
been O
described O
among O
descendants O
of O
a O
religious O
isolate O
originally O
from O
cochin O
, O
india O
. O

although O
autosomal O
recessive O
transmission O
of O
pls B-Disease
is O
evident O
, O
a O
more O
" O
complex O
" O
autosomal O
recessive O
pattern O
of O
inheritance O
with O
phenotypic O
influences O
from O
a O
closely O
linked O
modifying O
locus O
has O
been O
hypothesised O
for O
hms B-Disease
. O

recently O
, O
mutations O
of O
the O
cathepsin O
c O
gene O
have O
been O
identified O
as O
the O
underlying O
genetic B-Disease
defect I-Disease
in O
pls B-Disease
. O

to O
determine O
if O
a O
cathepsin O
c O
mutation O
is O
also O
responsible O
for O
hms B-Disease
, O
we O
sequenced O
the O
gene O
in O
affected O
and O
unaffected O
subjects O
from O
the O
cochin O
isolate O
in O
which O
both O
the O
pls B-Disease
and O
hms B-Disease
phenotypes O
appear O
. O

this O
mutation O
segregates O
with O
hms B-Disease
in O
four O
nuclear O
families O
. O

this O
finding O
supports O
simple O
autosomal O
recessive O
inheritance O
for O
hms B-Disease
in O
these O
families O
. O

we O
also O
report O
a O
mutation O
of O
the O
same O
exon O
6 O
ctsc O
codon O
( O
2126c O
- O
- O
> O
t O
) O
in O
a O
turkish O
family O
with O
classical O
pls B-Disease
. O

these O
findings O
provide O
evidence O
that O
pls B-Disease
and O
hms B-Disease
are O
allelic O
variants O
of O
cathepsin O
c O
gene O
mutations O
. O
. O

atm O
- O
heterozygous O
germline O
mutations O
contribute O
to O
breast B-Disease
cancer I-Disease
- O
susceptibility O
. O

mutations O
in O
the O
atm O
gene O
are O
responsible O
for O
the O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
( O
mim O
208900 O
) O
. O

the O
finding O
that O
atm O
- O
heterozygotes O
have O
an O
increased O
relative O
risk O
for O
breast B-Disease
cancer I-Disease
was O
supported O
by O
some O
studies O
but O
not O
confirmed O
by O
others O
. O

in O
view O
of O
this O
discrepancy O
, O
we O
examined O
the O
frequency O
of O
atm O
germline O
mutations O
in O
a O
selected O
group O
of O
dutch O
patients O
with O
breast B-Disease
cancer I-Disease
. O

a O
high O
percentage O
of O
atm O
germline O
mutations O
was O
demonstrated O
among O
patients O
with O
sporadic B-Disease
breast I-Disease
cancer I-Disease
. O

the O
82 O
patients O
included O
in O
this O
study O
had O
developed O
breast B-Disease
cancer I-Disease
at O
age O
< O
45 O
and O
had O
survived O
> O
/ O
= O
5 O
years O
( O
mean O
15 O
years O
) O
, O
and O
in O
33 O
( O
40 O
% O
) O
of O
the O
patients O
a O
contralateral O
breast O
tumor O
had O
been O
diagnosed O
. O

inherited O
g6pd B-Disease
deficiency I-Disease
is O
associated O
with O
either O
episodic B-Disease
hemolytic I-Disease
anemia I-Disease
( O
triggered O
by O
fava O
beans O
or O
other O
agents O
) O
or O
life B-Disease
- I-Disease
long I-Disease
hemolytic I-Disease
anemia I-Disease
. O

from O
the O
alignment O
of O
the O
amino O
acid O
( O
aa O
) O
sequence O
of O
52 O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
species O
from O
42 O
different O
organisms O
, O
we O
found O
a O
striking O
correlation O
between O
the O
aa O
replacements O
that O
cause O
g6pd B-Disease
deficiency I-Disease
in O
humans O
and O
the O
sequence O
conservation O
of O
g6pd O
two O
- O
thirds O
of O
such O
replacements O
are O
in O
highly O
and O
moderately O
conserved O
( O
50 O
- O
99 O
% O
) O
aa O
; O
relatively O
few O
are O
in O
fully O
conserved O
aa O
( O
where O
they O
might O
be O
lethal O
) O
or O
in O
poorly O
conserved O
aa O
, O
where O
presumably O
they O
simply O
would O
not O
cause O
g6pd B-Disease
deficiency I-Disease
. O

constitutive O
and O
regulated O
modes O
of O
splicing O
produce O
six O
major O
myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
( O
dmpk O
) O
isoforms O
with O
distinct O
properties O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
the O
most O
prevalent O
inherited B-Disease
neuromuscular I-Disease
disease I-Disease
in O
adults O
. O

the O
genetic B-Disease
defect I-Disease
is O
a O
ctg O
triplet O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
the O
myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
( O
dmpk O
) O
gene O
, O
consisting O
of O
15 O
exons O
. O

information O
on O
dmpk O
mrna O
and O
protein O
isoform O
expression O
patterns O
will O
be O
useful O
for O
recognizing O
differential O
effects O
of O
( O
ctg O
) O
( O
n O
) O
expansion O
in O
dm B-Disease
manifestation O
. O
. O

genetic O
analysis O
, O
phenotypic O
diagnosis O
, O
and O
risk O
of O
venous B-Disease
thrombosis I-Disease
in O
families O
with O
inherited O
deficiencies B-Disease
of I-Disease
protein I-Disease
s I-Disease
. O

protein B-Disease
s I-Disease
deficiency I-Disease
is O
a O
recognized O
risk O
factor O
for O
venous B-Disease
thrombosis I-Disease
. O

of O
all O
the O
inherited O
thrombophilic B-Disease
conditions I-Disease
, O
it O
remains O
the O
most O
difficult O
to O
diagnose O
because O
of O
phenotypic O
variability O
, O
which O
can O
lead O
to O
inconclusive O
results O
. O

twenty O
- O
eight O
index O
patients O
with O
protein B-Disease
s I-Disease
deficiency I-Disease
and O
a O
pros1 B-Disease
gene I-Disease
defect I-Disease
were O
studied O
, O
together O
with O
109 O
first O
- O
degree O
relatives O
. O

in O
this O
group O
of O
relatives O
, O
a O
low O
free O
protein O
s O
level O
was O
the O
most O
reliable O
predictor O
of O
a O
pros1 B-Disease
gene I-Disease
defect I-Disease
( O
sensitivity O
97 O
. O
7 O
% O
, O
specificity O
100 O
% O
) O
. O

first O
- O
degree O
relatives O
with O
a O
pros1 B-Disease
gene I-Disease
defect I-Disease
had O
a O
5 O
. O

0 O
- O
fold O
higher O
risk O
of O
thrombosis B-Disease
( O
95 O
% O
confidence O
interval O
, O
1 O
. O
5 O
- O
16 O
. O
8 O
) O
than O
those O
with O
a O
normal O
pros1 O
gene O
and O
no O
other O
recognized O
thrombophilic B-Disease
defect I-Disease
. O

although O
pregnancy O
/ O
puerperium O
and O
immobility O
/ O
trauma B-Disease
were O
important O
precipitating O
factors O
for O
thrombosis B-Disease
, O
almost O
half O
of O
the O
events O
were O
spontaneous O
. O

relatives O
with O
splice O
- O
site O
or O
major O
structural O
defects B-Disease
in I-Disease
the I-Disease
pros1 I-Disease
gene I-Disease
were O
more O
likely O
to O
have O
had O
a O
thrombotic O
event O
and O
had O
significantly O
lower O
total O
and O
free O
protein O
s O
levels O
than O
those O
relatives O
having O
missense O
mutations O
. O

we O
conclude O
that O
persons O
with O
pros1 B-Disease
gene I-Disease
defects I-Disease
and O
protein B-Disease
s I-Disease
deficiency I-Disease
are O
at O
increased O
risk O
of O
thrombosis B-Disease
and O
that O
free O
protein O
s O
estimation O
offers O
the O
most O
reliable O
way O
of O
diagnosing O
the O
deficiency O
. O

autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
( O
alps B-Disease
) O
in O
a O
child O
from O
consanguineous O
parents O
: O
a O
dominant O
or O
recessive O
disease O
? O

autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
( O
alps B-Disease
) O
is O
characterized O
by O
autoimmune O
features O
and O
lymphoproliferations O
and O
is O
generally O
caused O
by O
defective O
fas O
- O
mediated O
apoptosis O
. O

this O
report O
describes O
a O
child O
with O
clinical O
features O
of O
alps B-Disease
without O
detectable O
fas O
expression O
on O
freshly O
isolated O
blood O
leukocytes O
. O

the O
patient O
reported O
here O
is O
a O
human O
homologue O
of O
the O
fas O
- O
null O
mouse O
, O
inasmuch O
as O
she O
carries O
an O
autosomal O
homozygous O
mutation O
in O
the O
fas O
gene O
and O
she O
shows O
the O
severe O
and O
accelerated O
alps B-Disease
phenotype O
. O

the O
heterozygous O
family O
members O
did O
not O
have O
the O
alps B-Disease
phenotype O
, O
indicating O
that O
the O
disease O
- O
causing O
fas O
mutation O
in O
this O
family O
is O
autosomal O
recessive O
. O
. O

identification O
of O
novel O
imprinted O
transcripts O
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
and O
angelman B-Disease
syndrome I-Disease
deletion O
region O
: O
further O
evidence O
for O
regional O
imprinting O
control O
. O

deletions O
and O
other O
abnormalities O
of O
human O
chromosome O
15q11 O
- O
q13 O
are O
associated O
with O
two O
developmental O
disorders O
, O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
and O
angelman B-Disease
syndrome I-Disease
( O
as B-Disease
) O
. O

loss O
of O
expression O
of O
imprinted O
, O
paternally O
expressed O
genes O
has O
been O
implicated O
in O
pws B-Disease
. O

however O
, O
the O
number O
of O
imprinted O
genes O
that O
contribute O
to O
pws B-Disease
, O
and O
the O
range O
over O
which O
the O
imprinting O
signal O
acts O
to O
silence O
one O
copy O
of O
the O
gene O
in O
a O
parent O
- O
of O
- O
origin O
- O
specific O
manner O
, O
are O
unknown O
. O

to O
identify O
additional O
imprinted O
genes O
that O
could O
contribute O
to O
the O
pws B-Disease
phenotype O
and O
to O
understand O
the O
regional O
control O
of O
imprinting O
in O
15q11 O
- O
q13 O
, O
we O
have O
constructed O
an O
imprinted O
transcript O
map O
of O
the O
pws O
- O
as O
deletion O
interval O
. O

combined O
analysis O
of O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
linkage O
to O
1q24 O
- O
25 O
: O
results O
from O
772 O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
families O
from O
the O
international O
consortium O
for O
prostate B-Disease
cancer I-Disease
genetics O
. O

a O
previous O
linkage O
study O
provided O
evidence O
for O
a O
prostate B-Disease
cancer I-Disease
- O
susceptibility O
locus O
at O
1q24 O
- O
25 O
. O

in O
addition O
, O
evidence O
for O
locus O
heterogeneity O
has O
been O
provided O
by O
the O
identification O
of O
other O
putative O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
loci O
on O
xq27 O
- O
28 O
, O
1q42 O
- O
43 O
, O
and O
1p36 O
. O

the O
present O
study O
describes O
a O
combined O
analysis O
for O
six O
markers O
in O
the O
1q24 O
- O
25 O
region O
in O
772 O
families O
affected O
by O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
and O
ascertained O
by O
the O
members O
of O
the O
international O
consortium O
for O
prostate B-Disease
cancer I-Disease
genetics O
( O
icpcg O
) O
from O
north O
america O
, O
australia O
, O
finland O
, O
norway O
, O
sweden O
, O
and O
the O
united O
kingdom O
. O

these O
results O
support O
the O
finding O
of O
a O
prostate B-Disease
cancer I-Disease
- O
susceptibility O
gene O
linked O
to O
1q24 O
- O
25 O
, O
albeit O
in O
a O
defined O
subset O
of O
prostate B-Disease
cancer I-Disease
families O
. O

although O
hpc1 O
accounts O
for O
only O
a O
small O
proportion O
of O
all O
families O
affected O
by O
hereditary B-Disease
prostate I-Disease
cancer I-Disease
, O
it O
appears O
to O
play O
a O
more O
prominent O
role O
in O
the O
subset O
of O
families O
with O
several O
members O
affected O
at O
an O
early O
age O
and O
with O
male O
- O
to O
- O
male O
disease O
transmission O
. O

a O
recurrent O
expansion O
of O
a O
maternal O
allele O
with O
36 O
cag O
repeats O
causes O
huntington B-Disease
disease I-Disease
in O
two O
sisters O
. O

large O
intergenerational O
repeat O
expansions O
of O
the O
cag O
trinucleotide O
repeat O
in O
the O
hd B-Disease
gene O
have O
been O
well O
documented O
for O
the O
male O
germline O
. O

we O
describe O
a O
recurrent O
large O
expansion O
of O
a O
maternal O
allele O
with O
36 O
cag O
repeats O
( O
to O
66 O
and O
57 O
repeats O
, O
respectively O
, O
in O
two O
daughters O
) O
associated O
with O
onset O
of O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
in O
the O
second O
and O
third O
decade O
in O
a O
family O
without O
history O
of O
hd B-Disease
. O

motor B-Disease
incoordination I-Disease
, O
immune B-Disease
deficiencies I-Disease
, O
and O
an O
increased O
risk O
of O
cancer B-Disease
are O
the O
characteristic O
features O
of O
the O
hereditary B-Disease
disease I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
which O
is O
caused O
by O
mutations O
in O
the O
atm O
gene O
. O

in O
contrast O
to O
other O
atm O
mutant O
mice O
, O
atm O
( O
y O
/ O
y O
) O
mice O
show O
a O
lower O
incidence O
of O
thymic B-Disease
lymphoma I-Disease
and O
survive O
beyond O
a O
few O
months O
of O
age O
. O

atm O
( O
y O
/ O
y O
) O
mice O
exhibit O
deficits O
in O
motor O
learning O
indicative O
of O
cerebellar B-Disease
dysfunction I-Disease
. O

even O
though O
we O
found O
no O
gross O
cerebellar B-Disease
degeneration I-Disease
in O
older O
atm O
( O
y O
/ O
y O
) O
animals O
, O
ectopic O
and O
abnormally O
differentiated O
purkinje O
cells O
were O
apparent O
in O
mutant O
mice O
of O
all O
ages O
. O

these O
findings O
establish O
that O
some O
neuropathological B-Disease
abnormalities I-Disease
seen O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
also O
are O
present O
in O
atm O
mutant O
mice O
. O

in O
addition O
, O
we O
report O
a O
previously O
unrecognized O
effect O
of O
atm B-Disease
deficiency I-Disease
on O
development O
or O
maintenance O
of O
cd4 O
( O
+ O
) O
8 O
( O
+ O
) O
thymocytes O
. O

we O
discuss O
these O
findings O
in O
the O
context O
of O
the O
hypothesis O
that O
abnormal O
development O
of O
purkinje O
cells O
and O
lymphocytes O
contributes O
to O
the O
pathogenesis O
of O
a B-Disease
- I-Disease
t I-Disease
. O
. O

novel O
mutations O
of O
the O
atp7b O
gene O
in O
japanese O
patients O
with O
wilson B-Disease
disease I-Disease
. O

wilson B-Disease
disease I-Disease
( O
wd B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
copper O
accumulation O
in O
the O
liver O
, O
brain O
, O
kidneys O
, O
and O
corneas O
, O
and O
culminating O
in O
copper O
toxication O
in O
these O
organs O
. O

in O
this O
study O
, O
we O
analyzed O
mutations O
of O
the O
responsible O
gene O
, O
atp7b O
, O
in O
four O
japanese O
patients O
with O
wd B-Disease
. O

therefore O
, O
the O
accumulation O
of O
the O
types O
of O
mutations O
in O
japanese O
patients O
with O
wd B-Disease
will O
facilitate O
the O
fast O
and O
effective O
genetic O
diagnosis O
of O
wd B-Disease
in O
japanese O
patients O
. O
. O

autoinhibition O
and O
activation O
mechanisms O
of O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
. O

the O
rho O
- O
family O
gtpase O
, O
cdc42 O
, O
can O
regulate O
the O
actin O
cytoskeleton O
through O
activation O
of O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
( O
wasp O
) O
family O
members O
. O

mutations O
in O
the O
brca1 O
( O
ref O
. O
1 O
) O
tumour B-Disease
suppressor O
gene O
are O
found O
in O
almost O
all O
of O
the O
families O
with O
inherited B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
and O
about O
half O
of O
the O
families O
with O
only O
breast B-Disease
cancer I-Disease
. O

machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
belongs O
to O
a O
group O
of O
clinically O
and O
genetically O
heterogeneous O
neurodegenerative B-Disease
disorders I-Disease
characterized O
by O
progressive B-Disease
cerebellar I-Disease
ataxia I-Disease
. O

in O
caucasians O
, O
repeat O
expansions O
in O
the O
mjd1 O
gene O
have O
also O
been O
found O
in O
patients O
with O
the O
clinically O
distinct O
autosomal O
dominant O
spinocerebellar B-Disease
ataxia I-Disease
type I-Disease
3 I-Disease
( O
sca3 B-Disease
) O
. O

analyzing O
the O
expression O
level O
of O
the O
sca3 O
gene O
in O
several O
human O
brain O
sections O
revealed O
no O
significant O
higher O
mrna O
level O
in O
regions O
predominantly O
affected O
in O
mjd B-Disease
. O

thus O
additional O
molecules O
and O
/ O
or O
regulatory O
events O
are O
necessary O
to O
explain O
the O
exclusive O
degeneration B-Disease
of I-Disease
certain I-Disease
brain I-Disease
areas I-Disease
. O

emerin B-Disease
, I-Disease
deficiency I-Disease
of O
which O
causes O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
, O
is O
localized O
at O
the O
inner O
nuclear O
membrane O
. O

x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
is O
an O
inherited B-Disease
muscle I-Disease
disorder I-Disease
characterized O
by O
the O
clinical O
triad O
of O
progressive O
wasting B-Disease
of I-Disease
humero I-Disease
- I-Disease
peroneal I-Disease
muscles I-Disease
, O
early O
contractures B-Disease
of I-Disease
the I-Disease
elbows I-Disease
, I-Disease
achilles I-Disease
tendons I-Disease
and I-Disease
postcervical I-Disease
muscles I-Disease
, O
and O
cardiac B-Disease
conduction I-Disease
block I-Disease
with O
a O
high O
risk O
of O
sudden B-Disease
death I-Disease
. O

the O
gene O
for O
edmd B-Disease
on O
xq28 O
encodes O
a O
novel O
protein O
named O
emerin O
that O
localizes O
at O
the O
nuclear O
membrane O
of O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
and O
some O
other O
non O
- O
muscle O
tissues O
. O

locus O
heterogeneity O
in O
friedreich B-Disease
ataxia I-Disease
. O

friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
is O
the O
most O
common O
form O
of O
autosomal B-Disease
recessive I-Disease
ataxia I-Disease
. O

to O
date O
most O
data O
suggest O
locus O
homogeneity O
in O
frda B-Disease
. O

we O
now O
provide O
strong O
evidence O
of O
a O
second O
frda B-Disease
locus O
. O

studying O
two O
siblings O
with O
frda B-Disease
from O
two O
families O
we O
did O
not O
detect O
a O
mutation O
in O
stm7 O
/ O
x25 O
. O

although O
the O
patients O
studied O
had O
typical O
frda B-Disease
, O
one O
sibpair O
had O
the O
uncommon O
symptom O
of O
retained O
tendon O
reflexes O
. O

in O
order O
to O
investigate O
whether O
retained O
tendon O
reflexes O
are O
characteristic O
of O
frda B-Disease
caused O
by O
the O
second O
locus O
, O
frda2 O
, O
we O
studied O
an O
unrelated O
frda B-Disease
patient O
with O
retained O
tendon O
reflexes O
. O

the O
observation O
of O
typical O
mutations O
in O
stm7 O
/ O
x25 O
( O
gaa O
expansions O
) O
in O
this O
patient O
demonstrates O
that O
the O
two O
genetically O
different O
forms O
of O
frda B-Disease
cannot O
be O
distinguished O
clinically O
. O

glycerol O
as O
a O
correlate O
of O
impaired B-Disease
glucose I-Disease
tolerance I-Disease
: O
dissection O
of O
a O
complex O
system O
by O
use O
of O
a O
simple O
genetic O
trait O
. O

impaired B-Disease
glucose I-Disease
tolerance I-Disease
( O
igt B-Disease
) O
and O
hypertriglyceridemia B-Disease
are O
associated O
with O
an O
increased O
risk O
of O
diabetes B-Disease
mellitus I-Disease
and O
cardiovascular B-Disease
disease I-Disease
. O

family O
screening O
in O
the O
initial O
cohort O
identified O
18 O
men O
from O
five O
families O
with O
severe O
hyperglycerolemia B-Disease
( O
values O
above O
2 O
. O
0 O
mmol O
/ O
liter O
) O
and O
demonstrated O
an O
x O
- O
linked O
pattern O
of O
inheritance O
. O

clinical O
and O
molecular O
genetics O
of O
primary B-Disease
dystonias I-Disease
. O

primary B-Disease
dystonias I-Disease
are O
movement B-Disease
disorders I-Disease
with O
dystonia B-Disease
as O
a O
major O
symptom O
. O

to O
date O
gene O
loci O
have O
been O
identified O
in O
at O
least O
six O
autosomal O
dominant O
forms O
, O
i O
. O
e O
. O
, O
in O
idiopathic B-Disease
torsion I-Disease
dystonia I-Disease
( O
9q34 O
) O
, O
focal B-Disease
dystonia I-Disease
( O
18p O
) O
, O
adult O
- O
onset O
idiopathic B-Disease
torsion I-Disease
dystonia I-Disease
of O
mixed O
type O
( O
8p21 O
- O
q22 O
) O
, O
dopa B-Disease
- I-Disease
responsive I-Disease
dystonia I-Disease
( O
14q22 O
. O
1 O
- O
q22 O
. O
2 O
) O
, O
and O
paroxysmal B-Disease
dystonic I-Disease
choreoathetosis I-Disease
( O
2q25 O
- O
q33 O
; O
1p21 O
- O
p13 O
. O
3 O

) O
. O

1 O
in O
the O
x B-Disease
- I-Disease
linked I-Disease
dystonia I-Disease
parkinsonism I-Disease
syndrome I-Disease
and O
to O
xq22 O
in O
x B-Disease
- I-Disease
linked I-Disease
sensorineural I-Disease
deafness I-Disease
, O
dystonia B-Disease
, O
and O
mental B-Disease
retardation I-Disease
. O

mutations O
in O
a O
gene O
coding O
for O
an O
atp O
- O
binding O
protein O
were O
detected O
in O
idiopathic B-Disease
torsion I-Disease
dystonia I-Disease
( O
dyt1 O
) O
, O
and O
the O
gtp O
cyclohydrolase O
1 O
gene O
is O
mutated O
in O
dopa B-Disease
- I-Disease
responsive I-Disease
dystonia I-Disease
( O
dyt5 O
) O
. O

in O
sensorineural B-Disease
deafness I-Disease
, O
dystonia B-Disease
, O
and O
mental B-Disease
retardation I-Disease
, O
mutations O
were O
found O
in O
the O
gene O
ddp O
coding O
for O
a O
polypeptide O
of O
unknown O
function O
. O

this O
article O
reviews O
the O
clinical O
and O
molecular O
genetics O
of O
primary B-Disease
dystonias I-Disease
, O
critically O
discusses O
present O
findings O
, O
and O
proposes O
referring O
to O
the O
known O
forms O
, O
most O
of O
which O
can O
be O
distinguished O
by O
genetic O
criteria O
, O
as O
dystonias B-Disease
1 I-Disease
- I-Disease
12 I-Disease
. O

determination O
of O
30 O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
mutations O
, O
including O
15 O
not O
previously O
described O
. O

x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
x B-Disease
- I-Disease
ald I-Disease
) O
is O
the O
most O
frequent O
peroxisomal B-Disease
disease I-Disease
. O

of O
particular O
concern O
are O
female O
members O
of O
kindreds O
segregating O
x B-Disease
- I-Disease
ald I-Disease
mutations O
, O
because O
normal O
vlcfa O
levels O
do O
not O
guarantee O
lack O
of O
carrier O
status O
. O

we O
describe O
a O
fast O
method O
for O
detection O
of O
x B-Disease
- I-Disease
ald I-Disease
mutations O
. O

using O
this O
methodology O
we O
have O
found O
x B-Disease
- I-Disease
ald I-Disease
mutations O
in O
30 O
kindreds O
, O
including O
15 O
not O
previously O
reported O
. O

beta O
- O
galactosidase O
gene O
mutations O
affecting O
the O
lysosomal O
enzyme O
and O
the O
elastin O
- O
binding O
protein O
in O
gm1 B-Disease
- I-Disease
gangliosidosis I-Disease
patients O
with O
cardiac B-Disease
involvement I-Disease
. O

gm1 B-Disease
- I-Disease
gangliosidosis I-Disease
is O
a O
lysosomal B-Disease
storage I-Disease
disorder I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
acid I-Disease
beta I-Disease
- I-Disease
galactosidase I-Disease
( O
glb1 O
) O
. O

six O
of O
the O
eight O
patients O
with O
the O
infantile O
, O
severe O
form O
of O
the O
disease O
presented O
cardiac B-Disease
involvement I-Disease
, O
a O
feature O
rarely O
associated O
with O
gm1 B-Disease
- I-Disease
gangliosidosis I-Disease
. O

interestingly O
, O
all O
patients O
with O
cardiac B-Disease
involvement I-Disease
were O
homozygous O
for O
one O
of O
these O
mutations O
r59h O
, O
y591c O
, O
y591n O
, O
or O
ivs14 O
- O
2a O
> O
g O
. O

although O
we O
could O
not O
directly O
correlate O
the O
presence O
of O
cardiac B-Disease
abnormalities I-Disease
with O
specific O
genetic B-Disease
lesions I-Disease
, O
the O
mutations O
identified O
in O
patients O
with O
cardiomyopathy B-Disease
fell O
in O
the O
glb1 O
cdna O
region O
common O
to O
the O
lysosomal O
enzyme O
and O
the O
hbeta O
- O
gal O
- O
related O
protein O
, O
also O
known O
as O
the O
elastin O
binding O
protein O
( O
ebp O
) O
. O

in O
vivo O
modulation O
of O
hmgic O
reduces O
obesity B-Disease
. O

it O
is O
disrupted O
and O
misexpressed O
in O
a O
number O
of O
mesenchymal B-Disease
tumour I-Disease
cell O
types O
, O
including O
fat B-Disease
- I-Disease
cell I-Disease
tumours I-Disease
( O
lipomas B-Disease
) O
. O

to O
study O
its O
role O
in O
adipogenesis O
and O
obesity B-Disease
, O
we O
examined O
hmgic O
expression O
in O
the O
adipose O
tissue O
of O
adult O
, O
obese B-Disease
mice O
. O

mice O
with O
a O
partial B-Disease
or I-Disease
complete I-Disease
deficiency I-Disease
of I-Disease
hmgic I-Disease
resisted O
diet O
- O
induced O
obesity B-Disease
. O

disruption O
of O
hmgic O
caused O
a O
reduction O
in O
the O
obesity B-Disease
induced O
by O
leptin B-Disease
deficiency I-Disease
( O
lepob O
/ O
lepob O
) O
in O
a O
gene O
- O
dose O
- O
dependent O
manner O
. O

our O
studies O
implicate O
a O
role O
for O
hmgic O
in O
fat O
- O
cell O
proliferation O
, O
indicating O
that O
it O
may O
be O
an O
adipose O
- O
specific O
target O
for O
the O
treatment O
of O
obesity B-Disease
. O

molecular O
analysis O
of O
the O
genotype O
- O
phenotype O
relationship O
in O
factor B-Disease
x I-Disease
deficiency I-Disease
. O

factor B-Disease
x I-Disease
deficiency I-Disease
is O
a O
rare O
haemorrhagic B-Disease
condition I-Disease
, O
normally O
inherited O
as O
an O
autosomal O
recessive O
trait O
, O
in O
which O
a O
variable O
clinical O
presentation O
correlates O
poorly O
with O
laboratory O
phenotype O
. O

the O
factor O
x O
( O
f10 O
) O
genes O
of O
14 O
unrelated O
individuals O
with O
factor B-Disease
x I-Disease
deficiency I-Disease
( O
12 O
familial O
and O
two O
sporadic O
cases O
) O
were O
sequenced O
yielding O
a O
total O
of O
13 O
novel O
mutations O
. O

transgenic O
mice O
expressing O
a O
truncated O
form O
of O
the O
high O
mobility O
group O
i O
- O
c O
protein O
develop O
adiposity O
and O
an O
abnormally O
high O
prevalence O
of O
lipomas B-Disease
. O

chromosomal O
translocations O
in O
human O
lipomas B-Disease
frequently O
create O
fusion O
transcripts O
encoding O
high O
mobility O
group O
( O
hmg O
) O
i O
- O
c O
dna O
- O
binding O
domains O
and O
c O
- O
terminal O
sequences O
from O
different O
presumed O
transcription O
factors O
, O
suggesting O
a O
potential O
role O
for O
hmg O
i O
- O
c O
in O
the O
development O
of O
lipomas B-Disease
. O

despite O
the O
ubiquitous O
expression O
of O
the O
truncated O
hmg O
i O
- O
c O
protein O
, O
the O
transgenic O
mice O
develop O
a O
selective O
abundance O
of O
fat O
tissue O
early O
in O
life O
, O
show O
marked O
adipose B-Disease
tissue I-Disease
inflammation I-Disease
, O
and O
have O
an O
abnormally O
high O
incidence O
of O
lipomas B-Disease
. O

these O
findings O
demonstrate O
that O
the O
dna O
- O
binding O
domains O
of O
hmg O
i O
- O
c O
, O
in O
the O
absence O
of O
a O
c O
- O
terminal O
fusion O
partner O
, O
are O
sufficient O
to O
perturb O
adipogenesis O
and O
predispose O
to O
lipomas B-Disease
. O

we O
provide O
data O
supporting O
the O
central O
utility O
of O
this O
animal O
model O
as O
a O
tool O
to O
understand O
the O
molecular O
mechanisms O
underlying O
the O
development O
of O
one O
of O
the O
most O
common O
kind O
of O
human O
benign B-Disease
tumors I-Disease
. O

the O
rare B-Disease
diseases I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
at B-Disease
) O
, O
caused O
by O
mutations O
in O
the O
atm O
gene O
, O
and O
nijmegen B-Disease
breakage I-Disease
syndrome I-Disease
( O
nbs B-Disease
) O
, O
with O
mutations O
in O
the O
p95 O
/ O
nbs1 O
gene O
, O
share O
a O
variety O
of O
phenotypic B-Disease
abnormalities I-Disease
such O
as O
chromosomal B-Disease
instability I-Disease
, O
radiation O
sensitivity O
and O
defects O
in O
cell O
- O
cycle O
checkpoints O
in O
response O
to O
ionizing O
radiation O
. O

activation O
of O
the O
atm O
kinase O
by O
ionizing O
radiation O
and O
induction O
of O
atm O
- O
dependent O
responses O
in O
nbs B-Disease
cells O
indicated O
that O
p95 O
/ O
nbs1 O
may O
not O
be O
required O
for O
signalling O
to O
atm O
after O
ionizing O
radiation O
. O

understanding O
the O
molecular O
basis O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
, O
a O
common O
form O
of O
inherited B-Disease
mental I-Disease
retardation I-Disease
, O
is O
mainly O
caused O
by O
massive O
expansion O
of O
cgg O
triplet O
repeats O
located O
in O
the O
5 O
- O
untranslated O
region O
of O
the O
fragile B-Disease
x I-Disease
mental I-Disease
retardation I-Disease
- O
1 O
( O
fmr1 O
) O
gene O
. O

in O
patients O
with O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
the O
expanded O
cgg O
triplet O
repeats O
are O
hypermethylated O
and O
the O
expression O
of O
the O
fmr1 O
gene O
is O
repressed O
, O
which O
leads O
to O
the O
absence O
of O
fmr1 O
protein O
( O
fmrp O
) O
and O
subsequent O
mental B-Disease
retardation I-Disease
. O

haploinsufficiency B-Disease
of I-Disease
the I-Disease
transcription I-Disease
factors I-Disease
foxc1 I-Disease
and I-Disease
foxc2 I-Disease
results O
in O
aberrant O
ocular O
development O
. O

anterior B-Disease
segment I-Disease
developmental I-Disease
disorders I-Disease
, O
including O
axenfeld B-Disease
- I-Disease
rieger I-Disease
anomaly I-Disease
( O
ara B-Disease
) O
, O
variably O
associate O
with O
harmfully O
elevated O
intraocular O
pressure O
( O
iop O
) O
, O
which O
causes O
glaucoma B-Disease
. O

clinically O
observed O
dysgenesis O
does O
not O
correlate O
with O
iop O
, O
however O
, O
and O
the O
etiology O
of O
glaucoma B-Disease
development O
is O
not O
understood O
. O

mutations O
in O
the O
human O
homolog O
of O
foxc1 O
, O
fkhl7 O
, O
cause O
dominant O
anterior B-Disease
segment I-Disease
defects I-Disease
and O
glaucoma B-Disease
in O
various O
families O
. O

we O
show O
that O
foxc1 O
( O
+ O
/ O
- O
) O
mice O
have O
anterior B-Disease
segment I-Disease
abnormalities I-Disease
similar O
to O
those O
reported O
in O
human O
patients O
. O

these O
abnormalities O
include O
small O
or O
absent O
schlemms O
canal O
, O
aberrantly O
developed O
trabecular O
meshwork O
, O
iris B-Disease
hypoplasia I-Disease
, O
severely O
eccentric O
pupils O
and O
displaced O
schwalbes O
line O
. O

similar O
abnormalities O
were O
found O
in O
foxc2 O
( O
+ O
/ O
- O
) O
mice O
, O
but O
no O
disease O
- O
associated O
mutations O
were O
identified O
in O
the O
human O
homolog O
fkhl14 O
in O
32 O
ara B-Disease
patients O
. O

foxc1 O
( O
+ O
/ O
- O
) O
and O
foxc2 O
( O
+ O
/ O
- O
) O
mice O
are O
useful O
models O
for O
studying O
anterior O
segment O
development O
and O
its O
anomalies O
, O
and O
may O
allow O
identification O
of O
genes O
that O
interact O
with O
foxc1 O
and O
foxc2 O
( O
or O
fkhl7 O
and O
fkhl14 O
) O
to O
produce O
a O
phenotype O
with O
elevated O
iop O
and O
glaucoma B-Disease
. O

( O
over O
) O
correction O
of O
fmr1 B-Disease
deficiency I-Disease
with O
yac O
transgenics O
: O
behavioral O
and O
physical O
features O
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
is O
a O
common O
cause O
of O
mental B-Disease
retardation I-Disease
involving O
loss O
of O
expression O
of O
the O
fmr1 O
gene O
. O

fmr1 O
knockout O
mice O
exhibit O
a O
phenotype O
with O
some O
similarities O
to O
humans O
, O
such O
as O
macroorchidism B-Disease
and O
behavioral O
abnormalities O
. O

as O
a O
step O
toward O
understanding O
the O
function O
of O
fmr1 O
and O
the O
determination O
of O
the O
potential O
for O
therapeutic O
approaches O
to O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
yeast O
artificial O
chromosome O
( O
yac O
) O
transgenic O
mice O
were O
generated O
in O
order O
to O
determine O
whether O
the O
fmr1 O
knockout O
mouse O
phenotype O
could O
be O
rescued O
. O

we O
observed O
that O
the O
yac O
transgene O
supported O
production O
of O
the O
human O
protein O
( O
fmrp O
) O
which O
was O
present O
at O
levels O
10 O
to O
15 O
times O
that O
of O
endogenous O
protein O
and O
was O
expressed O
in O
a O
cell O
- O
and O
tissue O
- O
specific O
manner O
. O

given O
the O
complex O
behavioral O
phenotype O
in O
fragile B-Disease
x I-Disease
patients O
and O
the O
mild O
phenotype O
previously O
reported O
for O
the O
fmr1 O
knockout O
mouse O
, O
we O
performed O
a O
more O
thorough O
evaluation O
of O
the O
fmr1 O
knockout O
phenotype O
using O
additional O
behavioral O
assays O
that O
had O
not O
previously O
been O
reported O
for O
this O
animal O
model O
. O

the O
mouse O
displayed O
reduced O
anxiety B-Disease
- O
related O
responses O
with O
increased O
exploratory O
behavior O
. O

these O
findings O
have O
significant O
implications O
for O
gene O
therapy O
for O
fragile B-Disease
x I-Disease
syndrome I-Disease
since O
overexpression O
of O
the O
gene O
may O
harbor O
its O
own O
phenotype O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
caused O
by O
a O
ctg O
repeat O
expansion O
in O
the O
3utr O
of O
the O
dm B-Disease
protein O
kinase O
( O
dmpk O
) O
gene O
. O

furthermore O
, O
tissues O
from O
dm B-Disease
patients O
exhibit O
somatic O
mosaicism O
that O
increases O
with O
age O
. O

we O
generated O
transgenic O
mice O
carrying O
large O
human O
genomic O
sequences O
with O
20 O
, O
55 O
or O
> O
300 O
ctg O
, O
cloned O
from O
patients O
from O
the O
same O
affected O
dm B-Disease
family O
. O

although O
we O
did O
not O
observe O
dramatic O
expansions O
( O
or O
big O
jumps O
over O
several O
hundred O
ctg O
repeats O
) O
as O
in O
congenital O
forms O
of O
dm B-Disease
, O
our O
model O
carrying O
> O
300 O
ctg O
is O
the O
first O
to O
show O
instability O
so O
close O
to O
the O
human O
dm B-Disease
situation O
. O

inactivation O
of O
the O
friedreich B-Disease
ataxia I-Disease
mouse O
gene O
leads O
to O
early O
embryonic B-Disease
lethality I-Disease
without O
iron O
accumulation O
. O

friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
, O
the O
most O
common O
autosomal B-Disease
recessive I-Disease
ataxia I-Disease
, O
is O
caused O
in O
almost O
all O
cases O
by O
homozygous O
intronic O
expansions O
resulting O
in O
the O
loss O
of O
frataxin O
, O
a O
mitochondrial O
protein O
conserved O
through O
evolution O
, O
and O
involved O
in O
mitochondrial O
iron O
homeostasis O
. O

yeast O
knockout O
models O
, O
and O
histological O
and O
biochemical O
data O
from O
patient O
heart O
biopsies O
or O
autopsies O
indicate O
that O
the O
frataxin O
defect O
causes O
a O
specific O
iron B-Disease
- I-Disease
sulfur I-Disease
protein I-Disease
deficiency I-Disease
and O
mitochondrial O
iron O
accumulation O
leading O
to O
the O
pathological O
changes O
. O

to O
study O
the O
mechanism O
of O
the O
disease O
, O
we O
generated O
a O
mouse O
model O
by O
deletion O
of O
exon O
4 O
leading O
to O
inactivation O
of O
the O
frda B-Disease
gene O
product O
. O

we O
show O
that O
homozygous O
deletions O
cause O
embryonic B-Disease
lethality I-Disease
a O
few O
days O
after O
implantation O
, O
demonstrating O
an O
important O
role O
for O
frataxin O
during O
early O
development O
. O

gaucher B-Disease
disease I-Disease
: O
the O
origins O
of O
the O
ashkenazi O
jewish O
n370s O
and O
84gg O
acid O
beta O
- O
glucosidase O
mutations O
. O

type O
1 O
gaucher B-Disease
disease I-Disease
( O
gd B-Disease
) O
, O
a O
non O
- O
neuronopathic O
lysosomal B-Disease
storage I-Disease
disorder I-Disease
, O
results O
from O
the O
deficient O
activity O
of O
acid O
beta O
- O
glucosidase O
( O
gba O
) O
. O

on O
the O
basis O
of O
the O
linkage O
disequilibrium O
( O
ld O
) O
delta O
values O
, O
the O
non O
- O
jewish O
european O
n370s O
chromosomes O
had O
greater O
haplotype O
diversity O
and O
less O
ld O
at O
the O
markers O
flanking O
the O
conserved O
haplotype O
than O
did O
the O
aj O
n370s O
chromosomes O
. O

hla O
b27 O
and O
the O
genetics O
of O
ankylosing B-Disease
spondylitis I-Disease
. O

one O
hundred O
and O
twenty O
- O
eight O
of O
145 O
patients O
with O
ankylosing B-Disease
spondylitis I-Disease
( O
as B-Disease
) O
were O
found O
to O
be O
hla O
b27 O
positive O
. O

five O
patients O
had O
evidence O
of O
a O
sero O
- O
negative O
peripheral B-Disease
arthritis I-Disease
resembling O
peripheral B-Disease
psoriatic I-Disease
arthritis I-Disease
and O
3 O
of O
these O
were O
b27 O
negative O
. O

one O
further O
b27 O
negative O
patients O
had O
a O
sister O
with O
ankylosing B-Disease
spondylitis I-Disease
and O
ulcerative B-Disease
colitis I-Disease
and O
a O
mother O
with O
ulcerative B-Disease
colitis I-Disease
. O

these O
findings O
are O
interpreted O
as O
suggesting O
some O
degree O
of O
clinical O
and O
genetic O
heterogeneity O
in O
ankylosing B-Disease
spondylitis I-Disease
with O
genes O
for O
psoriasis B-Disease
and O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
being O
important O
in O
some O
individuals O
, O
particularly O
those O
who O
are O
b27 O
negative O
. O

twenty O
- O
five O
first O
- O
degree O
relatives O
with O
ankylosing B-Disease
spondylitis I-Disease
were O
all O
b27 O
positive O
. O

the O
only O
instance O
of O
disassociation O
of O
b27 O
and O
spondylitis B-Disease
in O
a O
family O
was O
where O
the O
proband O
had O
ulcerative B-Disease
colitis I-Disease
as O
well O
as O
spondylitis B-Disease
. O

of O
13 O
b27 O
positive O
fathers O
3 O
could O
be O
diagnosed O
as O
having O
definite O
ankylosing B-Disease
spondylitis I-Disease
( O
23 O
% O
) O
. O

these O
findings O
are O
thought O
to O
provide O
evidence O
against O
the O
concept O
that O
the O
gene O
for O
ankylosing B-Disease
spondylitis I-Disease
is O
not O
b27 O
but O
a O
closely O
linked O
gene O
and O
favour O
the O
occurrence O
of O
an O
environmental O
event O
affecting O
approximately O
one O
- O
fifth O
of O
b27 O
positive O
males O
to O
result O
in O
disease O
. O

founder O
mutations O
in O
the O
brca1 O
gene O
in O
polish O
families O
with O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
. O

the O
study O
group O
consisted O
of O
66 O
polish O
families O
with O
cancer B-Disease
who O
have O
at O
least O
three O
related O
females O
affected O
with O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
and O
who O
had O
cancer B-Disease
diagnosed O
, O
in O
at O
least O
one O
of O
the O
three O
affected O
females O
, O
at O
age O
< O
50 O
years O
. O

a O
total O
of O
26 O
families O
had O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
, O
4 O
families O
had O
ovarian B-Disease
cancers I-Disease
only O
, O
and O
36 O
families O
had O
breast B-Disease
cancers I-Disease
only O
. O

brca1 B-Disease
abnormalities I-Disease
were O
identified O
in O
all O
four O
families O
with O
ovarian B-Disease
cancer I-Disease
only O
, O
in O
67 O
% O
of O
27 O
families O
with O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
and O
in O
34 O
% O
of O
35 O
families O
with O
breast B-Disease
cancer I-Disease
only O
. O

the O
single O
family O
with O
a O
brca2 O
mutation O
had O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
syndrome I-Disease
. O

three O
brca1 B-Disease
abnormalities I-Disease
- O
5382insc O
, O
c61g O
, O
and O
4153dela O
- O
accounted O
for O
51 O
% O
, O
20 O
% O
, O
and O
11 O
% O
of O
the O
identified O
mutations O
, O
respectively O
. O
. O

molecular O
basis O
of O
very B-Disease
long I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coa I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
three O
israeli O
patients O
: O
identification O
of O
a O
complex O
mutant O
allele O
with O
p65l O
and O
k247q O
mutations O
, O
the O
former O
being O
an O
exonic O
mutation O
causing O
exon O
3 O
skipping O
. O

very B-Disease
long I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coa I-Disease
dehydrogenase I-Disease
( I-Disease
vlcad I-Disease
) I-Disease
deficiency I-Disease
is O
a O
life O
- O
threatening O
disorder O
of O
mitochondrial O
fatty O
acid O
beta O
- O
oxidation O
. O

all O
patients O
had O
the O
severe O
childhood O
form O
of O
vlcad B-Disease
deficiency I-Disease
with O
early O
onset O
and O
high O
mortality O
. O

submicroscopic O
deletion O
in O
cousins O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
causes O
a O
grandmatrilineal O
inheritance O
pattern O
: O
effects O
of O
imprinting O
. O

the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
critical O
region O
on O
15q11 O
- O
q13 O
is O
subject O
to O
imprinting O
. O

pws B-Disease
becomes O
apparent O
when O
genes O
on O
the O
paternally O
inherited O
chromosome O
are O
not O
expressed O
. O

familial B-Disease
pws I-Disease
is O
rare O
. O

we O
report O
on O
a O
family O
in O
which O
a O
male O
and O
a O
female O
paternal O
first O
cousin O
both O
have O
pws B-Disease
with O
cytogenetically O
normal O
karyotypes O
. O

dna O
methylation O
analysis O
of O
d15s63 O
is O
consistent O
with O
an O
abnormality O
of O
the O
imprinting O
center O
associated O
with O
pws B-Disease
. O

in O
this O
case O
, O
pws B-Disease
does O
not O
become O
evident O
as O
long O
as O
the O
deletion O
is O
passed O
through O
the O
matrilineal O
line O
. O

human O
glycine O
decarboxylase O
gene O
( O
gldc O
) O
and O
its O
highly O
conserved O
processed O
pseudogene O
( O
psigldc O
) O
: O
their O
structure O
and O
expression O
, O
and O
the O
identification O
of O
a O
large O
deletion O
in O
a O
family O
with O
nonketotic B-Disease
hyperglycinemia I-Disease
. O

mutations O
in O
the O
glycine O
decarboxylase O
gene O
( O
gldc O
) O
cause O
nonketotic B-Disease
hyperglycinemia I-Disease
( O
nkh B-Disease
) O
, O
an O
in B-Disease
- I-Disease
born I-Disease
error I-Disease
of I-Disease
metabolism I-Disease
characterized O
by O
severe O
neurological B-Disease
disturbance I-Disease
. O

we O
have O
determined O
the O
structure O
of O
gldc O
and O
of O
its O
pseudogene O
( O
psigldc O
) O
and O
studied O
their O
expression O
for O
a O
molecular O
analysis O
of O
nkh B-Disease
. O

structural O
information O
of O
gldc O
and O
psigldc O
should O
facilitate O
the O
molecular O
analysis O
of O
nkh B-Disease
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
is O
a O
neurogenetic B-Disease
disease I-Disease
characterized O
by O
infantile B-Disease
hypotonia I-Disease
, O
gonadal B-Disease
hypoplasia I-Disease
, O
obsessive O
behaviour O
and O
neonatal O
feeding O
difficulties O
followed O
by O
hyperphagia B-Disease
, O
leading O
to O
profound O
obesity B-Disease
. O

pws B-Disease
is O
due O
to O
a O
lack O
of O
paternal O
genetic O
information O
at O
15q11 O
- O
q13 O
( O
ref O
. O
2 O
) O
. O

five O
imprinted O
, O
paternally O
expressed O
genes O
map O
to O
the O
pws B-Disease
region O
, O
mkrn3 O
( O
ref O
. O
3 O
) O
, O
ndn O
( O
ref O
. O
4 O
) O
, O
ndnl1 O
( O
ref O
. O
5 O
) O
, O
snrpn O
( O
refs O
6 O
- O
8 O
) O
and O
ipw O
( O
ref O
. O
9 O
) O
, O
as O
well O
as O
two O
poorly O
characterized O
framents O
designated O
par O
- O
1 O
and O
par O
- O
5 O
( O
ref O
. O
10 O
) O
. O

deletion O
of O
the O
snrpn O
promoter O
/ O
exon O
1 O
region O
( O
the O
pws B-Disease
ic O
element O
) O
appears O
to O
impair O
the O
establishment O
of O
the O
paternal O
imprint O
in O
the O
male O
germ O
line O
and O
leads O
to O
pws B-Disease
. O

here O
we O
report O
a O
pws B-Disease
family O
in O
which O
the O
father O
is O
mosaic O
for O
an O
ic O
deletion O
on O
his O
paternal O
chromosome O
. O

our O
studies O
demonstrate O
that O
the O
pws B-Disease
ic O
element O
is O
not O
only O
required O
for O
the O
establishment O
of O
the O
paternal O
imprint O
, O
but O
also O
for O
its O
postzygotic O
maintenance O
. O
. O

mice O
deficient B-Disease
in I-Disease
six5 I-Disease
develop O
cataracts B-Disease
: O
implications O
for O
myotonic B-Disease
dystrophy I-Disease
. O

expansion O
of O
a O
ctg O
trinucleotide O
repeat O
in O
the O
3 O
utr O
of O
the O
gene O
dmpk O
at O
the O
dm1 O
locus O
on O
chromosome O
19 O
causes O
myotonic B-Disease
dystrophy I-Disease
, O
a O
dominantly B-Disease
inherited I-Disease
disease I-Disease
characterized O
by O
skeletal O
muscle B-Disease
dystrophy I-Disease
and O
myotonia B-Disease
, O
cataracts B-Disease
and O
cardiac B-Disease
conduction I-Disease
defects I-Disease
. O

targeted O
deletion O
of O
dm15 O
, O
the O
mouse O
orthologue O
of O
human O
dmpk O
, O
produced O
mice O
with O
a O
mild O
myopathy B-Disease
and O
cardiac B-Disease
conduction I-Disease
abnormalities I-Disease
, O
but O
without O
other O
features O
of O
myotonic B-Disease
dystrophy I-Disease
, O
such O
as O
myotonia B-Disease
and O
cataracts B-Disease
. O

to O
determine O
whether O
six5 B-Disease
deficiency I-Disease
contributes O
to O
the O
myotonic B-Disease
dystrophy I-Disease
phenotype O
, O
we O
disrupted O
mouse O
six5 O
by O
replacing O
the O
first O
exon O
with O
a O
beta O
- O
galactosidase O
reporter O
. O

homozygous O
mutant O
mice O
had O
no O
apparent O
abnormalities B-Disease
of I-Disease
skeletal I-Disease
muscle I-Disease
function I-Disease
, O
but O
developed O
lenticular B-Disease
opacities I-Disease
at O
a O
higher O
rate O
than O
controls O
. O

our O
results O
suggest O
that O
six5 B-Disease
deficiency I-Disease
contributes O
to O
the O
cataract B-Disease
phenotype O
in O
myotonic B-Disease
dystrophy I-Disease
, O
and O
that O
myotonic B-Disease
dystrophy I-Disease
represents O
a O
multigenic B-Disease
disorder I-Disease
. O
. O

heterozygous O
loss O
of O
six5 O
in O
mice O
is O
sufficient O
to O
cause O
ocular O
cataracts B-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
skeletal O
muscle B-Disease
wasting I-Disease
, O
myotonia B-Disease
, O
cardiac B-Disease
arrhythmia I-Disease
, O
hyperinsulinaemia B-Disease
, O
mental B-Disease
retardation I-Disease
and O
ocular O
cataracts B-Disease
. O

the O
genetic B-Disease
defect I-Disease
in O
dm B-Disease
is O
a O
ctg O
repeat O
expansion O
located O
in O
the O
3 O
untranslated O
region O
of O
dmpk O
and O
5 O
of O
a O
homeodomain O
- O
encoding O
gene O
, O
six5 O
( O
formerly O
dmahp O
; O
refs O
2 O
- O
5 O
) O
. O

there O
are O
three O
mechanisms O
by O
which O
ctg O
expansion O
can O
result O
in O
dm B-Disease
. O

previous O
studies O
have O
demonstrated O
that O
a O
dose O
- O
dependent O
loss O
of O
dm15 O
( O
the O
mouse O
dmpk O
homologue O
) O
in O
mice O
produces O
a O
partial O
dm B-Disease
phenotype O
characterized O
by O
decreased O
development O
of O
skeletal O
muscle O
force O
and O
cardiac B-Disease
conduction I-Disease
disorders I-Disease
. O

to O
test O
the O
role O
of O
six5 O
loss O
in O
dm B-Disease
, O
we O
have O
analysed O
a O
strain O
of O
mice O
in O
which O
six5 O
was O
deleted O
. O

our O
results O
demonstrate O
that O
the O
rate O
and O
severity O
of O
cataract B-Disease
formation O
is O
inversely O
related O
to O
six5 O
dosage O
and O
is O
temporally O
progressive O
. O

thus O
, O
altered O
ion O
homeostasis O
within O
the O
lens O
may O
contribute O
to O
cataract B-Disease
formation O
. O

as O
ocular O
cataracts B-Disease
are O
a O
characteristic O
feature O
of O
dm B-Disease
, O
these O
results O
demonstrate O
that O
decreased O
six5 O
transcription O
is O
important O
in O
the O
aetiology O
of O
dm B-Disease
. O

mutations O
in O
the O
gene O
atm O
are O
responsible O
for O
the O
genetic B-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
which O
is O
characterized O
by O
cerebellar B-Disease
dysfunction I-Disease
, O
radiosensitivity O
, O
chromosomal O
instability O
and O
cancer B-Disease
predisposition O
. O

both O
the O
a B-Disease
- I-Disease
t I-Disease
phenotype O
and O
the O
similarity O
of O
the O
atm O
protein O
to O
other O
dna O
- O
damage O
sensors O
suggests O
a O
role O
for O
atm O
in O
biochemical O
pathways O
involved O
in O
the O
recognition O
, O
signalling O
and O
repair O
of O
dna O
double O
- O
strand O
breaks O
( O
dsbs O
) O
. O

there O
are O
strong O
parallels O
between O
the O
pattern O
of O
radiosensitivity O
, O
chromosomal O
instability O
and O
cancer B-Disease
predisposition O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
and O
that O
in O
patients O
with O
nijmegen B-Disease
breakage I-Disease
syndrome I-Disease
( O
nbs B-Disease
) O
. O

the O
protein O
defective O
in O
nbs B-Disease
, O
nibrin O
( O
encoded O
by O
nbs1 O
) O
, O
forms O
a O
complex O
with O
mre11 O
and O
rad50 O
( O
refs O
1 O
, O
2 O
) O
. O

the O
overlap O
between O
clinical O
and O
cellular O
phenotypes O
in O
a B-Disease
- I-Disease
t I-Disease
and O
nbs B-Disease
suggests O
that O
atm O
and O
nibrin O
may O
function O
in O
the O
same O
biochemical O
pathway O
. O

this O
response O
is O
abrogated O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
that O
either O
do O
not O
express O
atm O
protein O
or O
express O
near O
full O
- O
length O
mutant O
protein O
. O

phosphorylation O
of O
this O
site O
appears O
to O
be O
functionally O
important O
because O
mutated O
nibrin O
( O
s343a O
) O
does O
not O
completely O
complement O
radiosensitivity O
in O
nbs B-Disease
cells O
. O

our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
a B-Disease
- I-Disease
t I-Disease
and O
nbs B-Disease
. O
. O

clinicopathologic O
features O
of O
brca B-Disease
- I-Disease
linked I-Disease
and I-Disease
sporadic I-Disease
ovarian I-Disease
cancer I-Disease
. O

context O
most O
hereditary B-Disease
ovarian I-Disease
cancers I-Disease
are O
associated O
with O
germline O
mutations O
in O
brca1 O
or O
brca2 O
. O

attempts O
to O
define O
the O
clinical O
significance O
of O
brca O
mutation O
status O
in O
ovarian B-Disease
cancer I-Disease
have O
produced O
conflicting O
results O
, O
especially O
regarding O
survival O
. O

objective O
to O
determine O
whether O
hereditary B-Disease
ovarian I-Disease
cancers I-Disease
have O
distinct O
clinical O
and O
pathological O
features O
compared O
with O
sporadic B-Disease
( I-Disease
nonhereditary I-Disease
) I-Disease
ovarian I-Disease
cancers I-Disease
. O

design O
and O
setting O
retrospective O
cohort O
study O
of O
a O
consecutive O
series O
of O
933 O
ovarian B-Disease
cancers I-Disease
diagnosed O
and O
treated O
at O
our O
institution O
, O
which O
is O
a O
comprehensive O
cancer B-Disease
center O
as O
designated O
by O
the O
national O
cancer B-Disease
institute O
, O
over O
a O
12 O
- O
year O
period O
( O
december O
1986 O
to O
august O
1998 O
) O
. O

the O
remaining O
101 O
cases O
from O
the O
same O
series O
not O
associated O
with O
a O
brca O
mutation O
and O
2 O
additional O
groups O
( O
gynecologic O
oncology O
group O
protocols O
52 O
and O
111 O
) O
with O
ovarian B-Disease
cancer I-Disease
from O
clinical O
trials O
( O
for O
the O
survival O
analysis O
) O
were O
included O
for O
comparison O
. O

results O
hereditary B-Disease
cancers I-Disease
were O
rarely O
diagnosed O
before O
age O
40 O
years O
and O
were O
common O
after O
age O
60 O
years O
, O
with O
mean O
age O
at O
diagnosis O
being O
significantly O
younger O
for O
brca1 O
- O
vs O
brca2 O
- O
linked O
patients O
( O
54 O
vs O
62 O
years O
; O
p O
= O
. O
04 O
) O
. O

those O
with O
hereditary B-Disease
cancers I-Disease
had O
improved O
survival O
compared O
with O
the O
nonhereditary O
group O
( O
p O
= O
. O
004 O
) O
. O

for O
stage B-Disease
iii I-Disease
cancers I-Disease
, O
brca O
mutation O
status O
was O
an O
independent O
prognostic O
variable O
( O
p O
= O
. O
03 O
) O
. O

conclusions O
although O
brca B-Disease
- I-Disease
associated I-Disease
hereditary I-Disease
ovarian I-Disease
cancers I-Disease
in O
this O
population O
have O
surgical O
and O
pathological O
characteristics O
similar O
to O
those O
of O
sporadic B-Disease
cancers I-Disease
, O
advanced B-Disease
- I-Disease
stage I-Disease
hereditary I-Disease
cancer I-Disease
patients O
survive O
longer O
than O
nonhereditary B-Disease
cancer I-Disease
patients O
. O

age O
penetrance O
is O
greater O
for O
brca1 B-Disease
- I-Disease
linked I-Disease
than I-Disease
for I-Disease
brca2 I-Disease
- I-Disease
linked I-Disease
cancers I-Disease
in O
this O
population O
. O

the O
gene O
for O
familial B-Disease
mediterranean I-Disease
fever I-Disease
, O
mefv O
, O
is O
expressed O
in O
early O
leukocyte O
development O
and O
is O
regulated O
in O
response O
to O
inflammatory O
mediators O
. O

familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
is O
a O
recessive B-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever B-Disease
and O
neutrophil B-Disease
- I-Disease
mediated I-Disease
serosal I-Disease
inflammation I-Disease
. O

we O
recently O
identified O
the O
gene O
causing O
fmf B-Disease
, O
designated O
mefv O
, O
and O
found O
it O
to O
be O
expressed O
in O
mature O
neutrophils O
, O
suggesting O
that O
it O
functions O
as O
an O
inflammatory O
regulator O
. O

biochemical O
and O
structural O
analysis O
of O
missense O
mutations O
in O
n O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
causing O
mucopolysaccharidosis B-Disease
iva I-Disease
phenotypes O
. O

mucopolysaccharidosis B-Disease
iva I-Disease
( O
mps B-Disease
iva I-Disease
; O
omim O
# O
253000 O
) O
, O
a O
lysosomal B-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
n I-Disease
- I-Disease
acetylgalactosamine I-Disease
- I-Disease
6 I-Disease
- I-Disease
sulfate I-Disease
sulfatase I-Disease
( O
galns O
) O
, O
has O
variable O
clinical O
phenotypes O
. O

to O
date O
we O
have O
identified O
65 O
missense O
mutations O
in O
the O
galns O
gene O
from O
mps B-Disease
iva I-Disease
patients O
, O
but O
the O
correlation O
between O
genotype O
and O
phenotype O
has O
remained O
unclear O
. O

these O
studies O
shed O
further O
light O
on O
the O
genotype O
- O
phenotype O
correlation O
of O
mps B-Disease
iva I-Disease
and O
structure O
- O
function O
relationship O
in O
the O
sulfatase O
family O
. O

mutations O
at O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
locus O
and O
clinical O
phenotypes O
of O
a B-Disease
- I-Disease
t I-Disease
patients O
. O

mutations O
at O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
locus O
on O
chromosome O
band O
11q22 O
cause O
a O
distinctive O
autosomal B-Disease
recessive I-Disease
syndrome I-Disease
in O
homozygotes O
and O
predispose O
heterozygotes O
to O
cancer B-Disease
, O
ischemic B-Disease
heart I-Disease
disease I-Disease
, O
and O
early O
mortality O
. O

pcr O
amplification O
from O
genomic O
dna O
and O
automated O
sequencing O
of O
the O
entire O
coding O
region O
( O
66 O
exons O
) O
and O
splice O
junctions O
detected O
77 O
mutations O
( O
85 O
% O
) O
in O
90 O
a B-Disease
- I-Disease
t I-Disease
chromosomes O
. O

heteroduplex O
analysis O
detected O
another O
42 O
mutations O
at O
the O
a B-Disease
- I-Disease
t I-Disease
locus O
. O

most O
( O
58 O
/ O
71 O
, O
82 O
% O
) O
mutations O
were O
frameshift O
and O
nonsense O
mutations O
that O
are O
predicted O
to O
cause O
truncation O
of O
the O
a B-Disease
- I-Disease
t I-Disease
protein O
; O
the O
less O
common O
mutation O
types O
were O
missense O
( O
9 O
/ O
71 O
, O
13 O
% O
) O
, O
splicing O
( O
3 O
/ O
71 O
, O
4 O
% O
) O
and O
one O
in O
- O
frame O
deletion O
, O
2546 O
3 O
( O
1 O
/ O
71 O
, O
1 O
% O
) O
. O

the O
mean O
survival O
and O
height O
distribution O
of O
134 O
a B-Disease
- I-Disease
t I-Disease
patients O
correlated O
significantly O
with O
the O
specific O
mutations O
present O
in O
the O
patients O
. O

alterations O
of O
the O
length O
or O
amino O
acid O
composition O
of O
the O
a B-Disease
- I-Disease
t I-Disease
gene O
product O
affect O
the O
a B-Disease
- I-Disease
t I-Disease
clinical O
phenotype O
in O
different O
ways O
. O

mutation O
analysis O
at O
the O
a B-Disease
- I-Disease
t I-Disease
locus O
may O
help O
estimate O
the O
prognosis O
of O
a B-Disease
- I-Disease
t I-Disease
patients O
. O
. O

isolation O
, O
genomic O
organization O
, O
and O
expression O
analysis O
of O
the O
mouse O
and O
rat O
homologs O
of O
mefv O
, O
the O
gene O
for O
familial B-Disease
mediterranean I-Disease
fever I-Disease
. O

familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
is O
a O
recessive B-Disease
disorder I-Disease
characterized O
by O
episodes O
of O
fever B-Disease
with O
serositis B-Disease
or O
synovitis B-Disease
. O

recently O
the O
fmf B-Disease
gene O
( O
mefv O
) O
was O
cloned O
; O
the O
protein O
product O
, O
pyrin O
/ O
marenostrin O
, O
is O
thought O
to O
regulate O
inflammation O
in O
myeloid O
cells O
. O

2 O
domain O
, O
in O
which O
most O
fmf B-Disease
- O
associated O
mutations O
have O
been O
found O
in O
human O
mefv O
. O

additional O
copies O
of O
the O
proteolipid O
protein O
gene O
causing O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
arise O
by O
separate O
integration O
into O
the O
x O
chromosome O
. O

mutations O
and O
duplications O
of O
this O
gene O
are O
associated O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
. O

here O
we O
describe O
two O
new O
families O
in O
which O
males O
affected O
with O
pmd B-Disease
were O
found O
to O
have O
a O
copy O
of O
plp O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
, O
in O
addition O
to O
a O
normal O
copy O
on O
xq22 O
. O

in O
a O
second O
unrelated O
family O
with O
signs O
of O
pmd B-Disease
, O
cytogenetic O
analysis O
showed O
a O
pericentric O
inversion O
of O
the O
x O
chromosome O
. O

the O
identification O
of O
three O
separate O
families O
in O
which O
plp O
is O
duplicated O
at O
a O
noncontiguous O
site O
suggests O
that O
such O
duplications O
could O
be O
a O
relatively O
common O
but O
previously O
undetected O
cause O
of O
genetic B-Disease
disorders I-Disease
. O

to O
do O
this O
, O
a O
collaborative O
screening O
study O
was O
set O
up O
that O
involved O
39 O
institutions O
from O
19 O
countries O
and O
included O
3 O
, O
580 O
unrelated O
individuals O
with O
a O
family O
history O
of O
the O
disease O
and O
934 O
early O
- O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
cases O
. O

genotype O
- O
phenotype O
correlations O
in O
families O
with O
deletions O
in O
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( O
vhl B-Disease
) O
gene O
. O

von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
disease I-Disease
is O
a O
hereditary B-Disease
tumor I-Disease
syndrome I-Disease
characterized O
by O
predisposition O
for O
bilateral B-Disease
and I-Disease
multi I-Disease
- I-Disease
centric I-Disease
hemangioblastoma I-Disease
in O
the O
retina O
and O
central O
nervous O
system O
, O
pheochromocytoma B-Disease
, O
renal B-Disease
cell I-Disease
carcinoma I-Disease
, O
and O
cysts B-Disease
in I-Disease
the I-Disease
kidney I-Disease
, I-Disease
pancreas I-Disease
, I-Disease
and I-Disease
epididymis I-Disease
. O

we O
describe O
five O
families O
for O
which O
direct O
sequencing O
of O
the O
coding O
region O
of O
the O
vhl B-Disease
gene O
had O
failed O
to O
identify O
the O
family O
- O
specific O
mutation O
. O

further O
molecular O
analysis O
revealed O
deletions O
involving O
the O
vhl B-Disease
gene O
in O
each O
of O
these O
families O
. O

in O
the O
fifth O
family O
, O
fish O
analysis O
demonstrated O
the O
deletion O
of O
the O
entire O
vhl B-Disease
gene O
. O

our O
results O
show O
that O
( O
quantitative O
) O
southern O
blot O
analysis O
is O
a O
sensitive O
method O
for O
detecting O
germline O
deletions O
of O
the O
vhl B-Disease
gene O
and O
should O
be O
implemented O
in O
routine O
dna O
diagnosis O
for O
vhl B-Disease
disease I-Disease
. O

our O
data O
support O
the O
previously O
established O
observation O
that O
families O
with O
a O
germline O
deletion O
have O
a O
low O
risk O
for O
pheochromocytoma B-Disease
. O

further O
unraveling O
of O
genotype O
- O
phenotype O
correlations O
in O
vhl B-Disease
disease I-Disease
has O
revealed O
that O
families O
with O
a O
full O
or O
partial O
deletion O
of O
the O
vhl B-Disease
gene O
exhibit O
a O
phenotype O
with O
a O
preponderance O
of O
central B-Disease
nervous I-Disease
system I-Disease
hemangioblastoma I-Disease
. O

age O
of O
the O
intronic O
gaa O
triplet O
repeat O
expansion O
mutation O
in O
friedreich B-Disease
ataxia I-Disease
. O

friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
, O
the O
most O
frequently O
inherited B-Disease
ataxia I-Disease
, O
is O
due O
in O
the O
vast O
majority O
of O
cases O
to O
a O
large O
expansion O
of O
an O
intronic O
gaa O
repeat O
. O

using O
linkage O
disequilibrium O
analysis O
based O
on O
haplotype O
data O
of O
seven O
polymorphic O
markers O
close O
to O
the O
frataxin O
gene O
, O
the O
age O
of O
frda B-Disease
founding O
mutational O
event O
( O
s O
) O
is O
estimated O
to O
be O
at O
least O
682 O
+ O
/ O
- O
203 O
generations O
( O
95 O
% O
confidence O
interval O
564 O
- O
801 O
g O
) O
, O
a O
dating O
which O
is O
consistent O
with O
little O
or O
no O
negative O
selection O
and O
provides O
further O
evidence O
for O
an O
ancient O
spread O
of O
a O
pre O
- O
mutation O
( O
at O
- O
risk O
alleles O
) O
in O
western O
europe O
. O
. O

functional O
link O
between O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
and O
nijmegen B-Disease
breakage I-Disease
syndrome I-Disease
gene O
products O
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
and O
nijmegen B-Disease
breakage I-Disease
syndrome I-Disease
( O
nbs B-Disease
) O
are O
recessive B-Disease
genetic I-Disease
disorders I-Disease
with O
susceptibility O
to O
cancer B-Disease
and O
similar O
cellular O
phenotypes O
. O

the O
protein O
product O
of O
the O
gene O
responsible O
for O
a B-Disease
- I-Disease
t I-Disease
, O
designated O
atm O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
characterized O
by O
a O
carboxy O
- O
terminal O
phosphatidylinositol O
3 O
- O
kinase O
- O
like O
domain O
. O

the O
nbs1 O
protein O
is O
specifically O
mutated O
in O
patients O
with O
nijmegen B-Disease
breakage I-Disease
syndrome I-Disease
and O
forms O
a O
complex O
with O
the O
dna O
repair O
proteins O
rad50 O
and O
mrel1 O
. O

this O
response O
includes O
s O
- O
phase O
checkpoint O
activation O
, O
formation O
of O
the O
nbs1 O
/ O
mrel1 O
/ O
rad50 O
nuclear O
foci O
and O
rescue O
of O
hypersensitivity B-Disease
to I-Disease
ionizing I-Disease
radiation I-Disease
. O

together O
, O
these O
results O
demonstrate O
a O
biochemical O
link O
between O
cell O
- O
cycle O
checkpoints O
activated O
by O
dna O
damage O
and O
dna O
repair O
in O
two O
genetic B-Disease
diseases I-Disease
with O
overlapping O
phenotypes O
. O
. O

homozygosity O
mapping O
in O
a O
family O
with O
microcephaly B-Disease
, O
mental B-Disease
retardation I-Disease
, O
and O
short B-Disease
stature I-Disease
to O
a O
cohen B-Disease
syndrome I-Disease
region O
on O
8q21 O
. O
3 O
- O
8q22 O
. O
1 O
: O
redefining O
a O
clinical O
entity O
. O

a O
syndrome O
of O
microcephaly B-Disease
, O
progressive O
postnatal B-Disease
growth I-Disease
deficiency I-Disease
, O
and O
mental B-Disease
retardation I-Disease
was O
observed O
in O
two O
brothers O
and O
their O
cousin O
from O
a O
multiply O
consanguineous O
kindred O
of O
lebanese O
descent O
. O

hypotonia B-Disease
, O
chorioretinal B-Disease
dystrophy I-Disease
, O
and O
myopia B-Disease
were O
also O
identified O
. O

because O
of O
absence O
of O
a O
distinctive O
facial O
appearance O
, O
the O
degree O
of O
mental B-Disease
retardation I-Disease
, O
and O
short B-Disease
stature I-Disease
, O
the O
initially O
considered O
clinical O
diagnosis O
of O
cohen B-Disease
syndrome I-Disease
was O
withdrawn O
and O
a O
novel O
genetic O
entity O
was O
assumed O
. O

intriguingly O
enough O
, O
the O
identified O
gene O
region O
overlaps O
the O
refined O
gene O
region O
for O
cohen B-Disease
syndrome I-Disease
( O
coh1 O
) O
[ O
kolehmainen O
et O
al O
. O
, O
1997 O
euro O
j O
hum O
genet O
5 O
206 O
- O
213 O
] O
. O

this O
fact O
encourages O
the O
hypothesis O
that O
the O
described O
kindred O
segregates O
for O
a O
variant O
of O
cohen B-Disease
syndrome I-Disease
and O
suggests O
a O
redefinition O
of O
its O
phenotype O

polymorphisms O
of O
the O
cyp2d6 O
gene O
increase O
susceptibility O
to O
ankylosing B-Disease
spondylitis I-Disease
. O

ankylosing B-Disease
spondylitis I-Disease
( O
as B-Disease
) O
is O
a O
common O
and O
highly O
familial O
rheumatic B-Disease
disorder I-Disease
. O

we O
performed O
a O
linkage O
study O
of O
chromosome O
22 O
in O
200 O
families O
with O
as B-Disease
affected O
sibling O
- O
pairs O
. O

heterozygosity O
for O
the O
most O
frequent O
poor O
metabolizer O
allele O
( O
cyp2d6 O
* O
4 O
) O
was O
not O
associated O
with O
increased O
susceptibility O
to O
as B-Disease
. O

functional O
differences O
of O
the O
pds B-Disease
gene O
product O
are O
associated O
with O
phenotypic O
variation O
in O
patients O
with O
pendred B-Disease
syndrome I-Disease
and O
non B-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
( O
dfnb4 B-Disease
) O
. O

the O
pds B-Disease
gene O
encodes O
a O
transmembrane O
protein O
, O
known O
as O
pendrin O
, O
which O
functions O
as O
a O
transporter O
of O
iodide O
and O
chloride O
. O

mutations O
in O
this O
gene O
are O
responsible O
for O
pendred B-Disease
syndrome I-Disease
and O
autosomal B-Disease
recessive I-Disease
non I-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
at O
the O
dfnb4 B-Disease
locus O
on O
chromosome O
7q31 O
. O

a O
screen O
of O
20 O
individuals O
from O
the O
midwestern O
usa O
with O
non B-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
and O
dilated O
vestibular O
aqueducts O
identified O
three O
people O
( O
15 O
% O
) O
with O
pds B-Disease
mutations O
. O

to O
determine O
whether O
pds B-Disease
mutations O
in O
individuals O
with O
pendred B-Disease
syndrome I-Disease
differ O
functionally O
from O
pds B-Disease
mutations O
in O
individuals O
with O
non B-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
, O
we O
compared O
three O
common O
pendred B-Disease
syndrome I-Disease
allele O
variants O
( O
l236p O
, O
t416p O
and O
e384g O
) O
, O
with O
three O
pds B-Disease
mutations O
reported O
only O
in O
individuals O
with O
non B-Disease
- I-Disease
syndromic I-Disease
hearing I-Disease
loss I-Disease
( O
v480d O
, O
v653a O
and O
i490l O
/ O
g497s O
) O
. O

the O
mutations O
associated O
with O
pendred B-Disease
syndrome I-Disease
have O
complete O
loss O
of O
pendrin O
- O
induced O
chloride O
and O
iodide O
transport O
, O
while O
alleles O
unique O
to O
people O
with O
dfnb4 B-Disease
are O
able O
to O
transport O
both O
iodide O
and O
chloride O
, O
albeit O
at O
a O
much O
lower O
level O
than O
wild O
- O
type O
pendrin O
. O

we O
hypothesize O
that O
this O
residual O
level O
of O
anion O
transport O
is O
sufficient O
to O
eliminate O
or O
postpone O
the O
onset O
of O
goiter B-Disease
in O
individuals O
with O
dfnb4 B-Disease
. O

germline O
mutations O
are O
the O
major O
source O
of O
genetic O
variation O
that O
allows O
a O
species O
to O
evolve O
over O
time O
but O
at O
the O
cost O
of O
mendelian B-Disease
disease I-Disease
and O
genetic O
predisposition O
to O
multifactorial B-Disease
diseases I-Disease
. O

here O
, O
we O
compare O
the O
pattern O
of O
germline O
mutation O
in O
a O
population O
of O
hemophilia B-Disease
b I-Disease
patients O
from O
mainland O
china O
( O
n O
= O
66 O
) O
to O
that O
in O
u O
. O

heterozygous O
mutations O
encoding O
abnormal O
forms O
of O
the O
death O
receptor O
fas O
dominantly O
interfere O
with O
fas O
- O
induced O
lymphocyte O
apoptosis O
in O
human O
autoimmune B-Disease
lymphoproliferative I-Disease
syndrome I-Disease
. O

determination O
of O
carrier O
status O
for O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
by O
flow O
cytometric O
analysis O
of O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
expression O
in O
peripheral O
blood O
mononuclear O
cells O
. O

the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
caused O
by O
defects O
in O
the O
was B-Disease
protein O
( O
wasp O
) O
gene O
on O
the O
x O
chromosome O
. O

previous O
study O
disclosed O
that O
flow O
cytometric O
analysis O
of O
intracellular O
wasp O
expression O
( O
fcm O
- O
wasp O
analysis O
) O
in O
lymphocytes O
was O
useful O
for O
the O
diagnosis O
of O
was B-Disease
patients O
. O

lymphocytes O
from O
all O
was B-Disease
patients O
showed O
waspdim O
instead O
of O
waspbright O
. O

here O
we O
report O
that O
fcm O
- O
wasp O
analysis O
in O
monocytes O
could O
be O
a O
useful O
tool O
for O
the O
was B-Disease
carrier O
diagnosis O
. O

monocytes O
from O
all O
nine O
was B-Disease
carriers O
showed O
varied O
population O
of O
waspdim O
together O
with O
waspbright O
. O

the O
difference O
of O
the O
waspdim O
population O
in O
monocytes O
and O
lymphocytes O
observed O
in O
was B-Disease
carriers O
suggests O
that O
wasp O
plays O
a O
more O
critical O
role O
in O
the O
development O
of O
lymphocytes O
than O
in O
that O
of O
monocytes O
. O

restoration O
of O
photoreceptor O
ultrastructure O
and O
function O
in O
retinal B-Disease
degeneration I-Disease
slow O
mice O
by O
gene O
therapy O
. O

mutations O
in O
prph2 O
have O
been O
shown O
to O
result O
in O
a O
variety O
of O
photoreceptor B-Disease
dystrophies I-Disease
, O
including O
autosomal B-Disease
dominant I-Disease
retinitis I-Disease
pigmentosa I-Disease
and O
macular B-Disease
dystrophy I-Disease
. O

a O
common O
feature O
of O
these O
diseases O
is O
the O
loss O
of O
photoreceptor O
function O
, O
also O
seen O
in O
the O
retinal B-Disease
degeneration I-Disease
slow O
( O
rds O
or O
prph2 O
rd2 O
/ O
rd2 O
) O
mouse O
, O
which O
is O
homozygous O
for O
a O
null O
mutation O
in O
prph2 O
. O

mutations O
in O
the O
fibrinogen O
aalpha O
gene O
account O
for O
the O
majority O
of O
cases O
of O
congenital B-Disease
afibrinogenemia I-Disease
. O

congenital B-Disease
afibrinogenemia I-Disease
is O
a O
rare O
, O
autosomal B-Disease
, I-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
the O
complete O
absence O
of O
detectable O
fibrinogen O
. O

consequently O
, O
86 O
% O
of O
afibrinogenemia B-Disease
alleles O
analyzed O
to O
date O
have O
truncating O
mutations O
of O
fga O
, O
though O
mutations O
in O
all O
3 O
fibrinogen O
genes O
, O
fgg O
, O
fga O
, O
and O
fgb O
, O
might O
be O
predicted O
to O
cause O
congenital B-Disease
afibrinogenemia I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
: O
the O
role O
of O
the O
cug O
triplet O
repeats O
in O
splicing O
of O
a O
novel O
dmpk O
exon O
and O
altered O
cytoplasmic O
dmpk O
mrna O
isoform O
ratios O
. O

the O
mechanism O
by O
which O
( O
ctg O
) O
n O
expansion O
in O
the O
3 O
utr O
of O
the O
dmpk O
gene O
causes O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
unknown O
. O

expression O
and O
imprinting O
of O
magel2 O
suggest O
a O
role O
in O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
and O
the O
homologous O
murine O
imprinting O
phenotype O
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
is O
caused O
by O
the O
loss O
of O
expression O
of O
imprinted O
genes O
in O
chromosome O
15q11 O
- O
q13 O
. O

affected O
individuals O
exhibit O
neonatal B-Disease
hypotonia I-Disease
, O
developmental B-Disease
delay I-Disease
and O
childhood B-Disease
- I-Disease
onset I-Disease
obesity I-Disease
. O

necdin O
, O
a O
protein O
implicated O
in O
the O
terminal O
differentiation O
of O
neurons O
, O
is O
the O
only O
pws B-Disease
candidate O
gene O
to O
reduce O
viability O
when O
disrupted O
in O
a O
mouse O
model O
. O

in O
this O
study O
, O
we O
have O
characterized O
magel2 O
( O
also O
known O
as O
ndnl1 O
) O
, O
a O
gene O
with O
51 O
% O
amino O
acid O
sequence O
similarity O
to O
necdin O
and O
located O
41 O
kb O
distal O
to O
ndn O
in O
the O
pws B-Disease
deletion O
region O
. O

magel2 O
is O
expressed O
predominantly O
in O
brain O
, O
the O
primary O
tissue O
affected O
in O
pws B-Disease
and O
in O
several O
fetal O
tissues O
as O
shown O
by O
northern O
blot O
analysis O
. O

magel2 O
is O
imprinted O
with O
monoallelic O
expression O
in O
control O
brain O
, O
and O
paternal O
- O
only O
expression O
in O
the O
central O
nervous O
system O
as O
demonstrated O
by O
its O
lack O
of O
expression O
in O
brain O
from O
a O
pws B-Disease
- O
affected O
individual O
. O

we O
hypothesize O
that O
, O
although O
loss O
of O
necdin O
expression O
may O
be O
important O
in O
the O
neonatal O
presentation O
of O
pws B-Disease
, O
loss O
of O
magel2 O
may O
be O
critical O
to O
abnormalities B-Disease
in I-Disease
brain I-Disease
development I-Disease
and O
dysmorphic B-Disease
features I-Disease
in O
individuals O
with O
pws B-Disease
. O
. O

retinoschisin O
, O
the O
x B-Disease
- I-Disease
linked I-Disease
retinoschisis I-Disease
protein O
, O
is O
a O
secreted O
photoreceptor O
protein O
, O
and O
is O
expressed O
and O
released O
by O
weri O
- O
rb1 O
cells O
. O

x B-Disease
- I-Disease
linked I-Disease
retinoschisis I-Disease
is O
characterized O
by O
microcystic O
- O
like O
changes O
of O
the O
macular O
region O
and O
schisis O
within O
the O
inner O
retinal O
layers O
, O
leading O
to O
visual B-Disease
deterioration I-Disease
in O
males O
. O

furthermore O
, O
differentiated O
retinoblastoma B-Disease
cells O
( O
weri O
- O
rb1 O
cells O
) O
were O
found O
to O
express O
rs1 O
mrna O
and O
to O
release O
retinoschisin O
. O

thus O
, O
x B-Disease
- I-Disease
linked I-Disease
retinoschisis I-Disease
is O
caused O
by O
abnormalities O
in O
a O
putative O
secreted O
photoreceptor O
protein O
and O
is O
the O
first O
example O
of O
a O
secreted O
photo O
- O
receptor O
protein O
associated O
with O
a O
retinal B-Disease
dystrophy I-Disease
. O
. O

study O
of O
the O
voltage O
- O
gated O
sodium O
channel O
beta O
1 O
subunit O
gene O
( O
scn1b O
) O
in O
the O
benign B-Disease
familial I-Disease
infantile I-Disease
convulsions I-Disease
syndrome I-Disease
( O
bfic B-Disease
) O
. O

benign B-Disease
familial I-Disease
infantile I-Disease
convulsions I-Disease
( O
bfic B-Disease
) O
is O
a O
rare O
autosomal B-Disease
dominant I-Disease
epilepsy I-Disease
syndrome I-Disease
. O

the O
seizures O
usually O
spontaneously O
cease O
after O
one O
year O
without O
treatment O
, O
leaving O
no O
neurological B-Disease
abnormalities I-Disease
. O

we O
have O
mapped O
bfic B-Disease
to O
chromosome O
19q O
in O
five O
italian O
pedigrees O
. O

the O
sodium O
channel O
beta1 O
subunit O
gene O
( O
scn1b O
) O
maps O
to O
this O
candidate O
region O
and O
has O
been O
shown O
to O
be O
involved O
in O
one O
australian O
pedigree O
with O
generalized B-Disease
epilepsy I-Disease
and I-Disease
febrile I-Disease
seizures I-Disease
" I-Disease
plus I-Disease
" I-Disease
( O
gefs O
+ O
) O
. O

bfic B-Disease
and O
gefs O
+ O
have O
clinical O
features O
in O
common O
, O
therefore O
scn1b O
is O
a O
candidate O
gene O
for O
bfic B-Disease
. O

we O
studied O
scn1b O
exons O
1 O
, O
2 O
, O
3 O
, O
4 O
, O
and O
5 O
, O
using O
four O
sscp O
methods O
in O
10 O
caucasian O
bfic B-Disease
probands O
of O
western O
europe O
. O

one O
variant O
was O
identified O
in O
intron O
5 O
( O
ivs5 O
- O
10c O
> O
g O
) O
, O
which O
did O
not O
segregate O
with O
bfic B-Disease
and O
was O
observed O
in O
9 O
. O

it O
was O
rare O
, O
as O
not O
observed O
in O
controls O
, O
but O
not O
segregating O
with O
the O
bfic B-Disease
phenotype O
. O

inactivation O
of O
germline O
mutant O
apc B-Disease
alleles O
by O
attenuated O
somatic O
mutations O
: O
a O
molecular O
genetic O
mechanism O
for O
attenuated B-Disease
familial I-Disease
adenomatous I-Disease
polyposis I-Disease
. O

germline O
mutations O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
apc I-Disease
) I-Disease
tumor I-Disease
- O
suppressor O
gene O
result O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
. O

patients O
with O
fap B-Disease
typically O
develop O
hundreds O
to O
thousands O
of O
benign B-Disease
colorectal I-Disease
tumors I-Disease
and O
early O
- O
onset O
colorectal B-Disease
cancer I-Disease
. O

a O
subset O
of O
germline O
apc B-Disease
mutations O
results O
in O
an O
attenuated B-Disease
fap I-Disease
( O
afap B-Disease
) O
phenotype O
, O
in O
which O
patients O
develop O
fewer O
tumors B-Disease
and O
develop O
them O
at O
an O
older O
age O
. O

although O
a O
genotype O
- O
phenotype O
correlation O
between O
the O
locations O
of O
apc B-Disease
germline O
mutations O
and O
the O
development O
of O
afap B-Disease
has O
been O
well O
documented O
, O
the O
mechanism O
for O
afap B-Disease
has O
not O
been O
well O
defined O
. O

we O
investigated O
the O
mechanism O
for O
afap B-Disease
in O
patients O
carrying O
a O
mutant O
apc B-Disease
allele O
( O
apc O
( O
as9 O
) O
) O
that O
has O
a O
mutation O
in O
the O
alternatively O
spliced O
region O
of O
exon O
9 O
. O

apc O
( O
as9 O
) O
was O
found O
to O
down O
- O
regulate O
beta O
- O
catenin O
- O
regulated O
transcription O
, O
the O
major O
tumor B-Disease
- O
suppressor O
function O
of O
apc O
, O
as O
did O
the O
wild O
- O
type O
apc O
. O

mutation O
analysis O
showed O
that O
both O
apc O
( O
as9 O
) O
and O
the O
wild O
- O
type O
apc B-Disease
alleles O
were O
somatically O
mutated O
in O
most O
colorectal B-Disease
tumors I-Disease
from O
these O
patients O
. O

functional O
analysis O
showed O
that O
4666insa O
, O
a O
common O
somatic O
mutation O
in O
apc O
( O
as9 O
) O
in O
these O
tumors B-Disease
, O
did O
not O
inactivate O
the O
wild O
- O
type O
apc O
. O

our O
results O
indicate O
that O
carriers O
of O
apc O
( O
as9 O
) O
develop O
fewer O
colorectal B-Disease
tumors I-Disease
than O
do O
typical O
patients O
with O
fap B-Disease
because O
somatic O
inactivation O
of O
both O
apc B-Disease
alleles O
is O
necessary O
for O
colorectal O
tumorigenesis O
. O

however O
, O
these O
patients O
develop O
colorectal B-Disease
tumors I-Disease
more O
frequently O
than O
does O
the O
general O
population O
because O
apc O
( O
as9 O
) O
is O
inactivated O
by O
mutations O
that O
do O
not O
inactivate O
the O
wild O
- O
type O
apc O
. O

iron O
- O
dependent O
self O
- O
assembly O
of O
recombinant O
yeast O
frataxin O
: O
implications O
for O
friedreich B-Disease
ataxia I-Disease
. O

frataxin B-Disease
deficiency I-Disease
is O
the O
primary O
cause O
of O
friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
, O
an O
autosomal B-Disease
recessive I-Disease
cardiodegenerative I-Disease
and I-Disease
neurodegenerative I-Disease
disease I-Disease
. O

genetic O
inactivation O
of O
the O
yeast O
frataxin O
homologue O
( O
yfh1p O
) O
results O
in O
mitochondrial B-Disease
iron I-Disease
accumulation I-Disease
and O
hypersensitivity B-Disease
to I-Disease
oxidative I-Disease
stress I-Disease
. O

increased O
iron O
deposition O
and O
evidence O
of O
oxidative O
damage O
have O
also O
been O
observed O
in O
cardiac O
tissue O
and O
cultured O
fibroblasts O
from O
patients O
with O
frda B-Disease
. O

a O
mutation O
in O
the O
pleckstrin O
homology O
( O
ph O
) O
domain O
of O
the O
fgd1 O
gene O
in O
an O
italian O
family O
with O
faciogenital B-Disease
dysplasia I-Disease
( O
aarskog B-Disease
- I-Disease
scott I-Disease
syndrome I-Disease
) O
. O

aarskog B-Disease
- I-Disease
scott I-Disease
syndrome I-Disease
( O
aas B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
characterised O
by O
short B-Disease
stature I-Disease
and O
multiple O
facial B-Disease
, I-Disease
limb I-Disease
and I-Disease
genital I-Disease
abnormalities I-Disease
. O

a O
gene O
, O
fgd1 O
, O
altered O
in O
a O
patient O
with O
aas B-Disease
phenotype O
, O
has O
been O
identified O
and O
found O
to O
encode O
a O
protein O
with O
homology O
to O
rho O
/ O
rac O
guanine O
nucleotide O
exchange O
factors O
( O
rho O
/ O
rac O
gef O
) O
. O

however O
, O
since O
this O
original O
report O
on O
identification O
of O
a O
mutated O
fgd1 O
gene O
in O
an O
aas B-Disease
patient O
, O
no O
additional O
mutations O
in O
the O
fgd1 O
gene O
have O
been O
described O
. O

we O
analysed O
13 O
independent O
patients O
with O
clinical O
diagnosis O
of O
aas B-Disease
. O

the O
same O
residue O
is O
often O
mutated O
in O
the O
brutons O
tyrosine O
kinase O
( O
btk O
) O
gene O
in O
patients O
with O
an O
x B-Disease
- I-Disease
linked I-Disease
agammaglobulinemia I-Disease
. O

huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
is O
caused O
by O
expansion O
of O
a O
glutamine O
repeat O
in O
the O
amino O
- O
terminal O
region O
of O
huntingtin O
. O

here O
we O
report O
that O
, O
in O
mutant O
mice O
expressing O
hd B-Disease
repeats O
, O
the O
production O
and O
aggregation O
of O
n O
- O
terminal O
huntingtin O
fragments O
preferentially O
occur O
in O
hd B-Disease
- O
affected O
neurons O
and O
their O
processes O
and O
axonal O
terminals O
. O

n O
- O
terminal O
fragments O
of O
mutant O
huntingtin O
form O
aggregates O
and O
induce O
neuritic B-Disease
degeneration I-Disease
in O
cultured O
striatal O
neurons O
. O

the O
specific O
processing O
and O
accumulation O
of O
toxic O
fragments O
of O
n O
- O
terminal O
huntingtin O
in O
hd B-Disease
- O
affected O
striatal O
neurons O
, O
especially O
in O
their O
neuronal O
processes O
and O
axonal O
terminals O
, O
may O
contribute O
to O
the O
selective O
neuropathology O
of O
hd B-Disease
. O
. O

brca1 O
is O
associated O
with O
a O
human O
swi O
/ O
snf O
- O
related O
complex O
: O
linking O
chromatin O
remodeling O
to O
breast B-Disease
cancer I-Disease
. O

germline O
mutations O
in O
the O
tumor B-Disease
suppressor O
gene O
, O
brca1 O
, O
predispose O
individuals O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

moreover O
, O
p53 O
- O
mediated O
stimulation O
of O
transcription O
by O
brca1 O
was O
completely O
abrogated O
by O
either O
a O
dominant O
- O
negative O
mutant O
of O
brg1 O
or O
the O
cancer B-Disease
- O
causing O
deletion O
in O
exon O
11 O
of O
brca1 O
. O

asef O
, O
a O
link O
between O
the O
tumor B-Disease
suppressor O
apc O
and O
g O
- O
protein O
signaling O
. O

the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
gene O
( O
apc O
) O
is O
mutated O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
and O
in O
sporadic O
colorectal B-Disease
tumors I-Disease
. O

here O
the O
apc B-Disease
gene O
product O
is O
shown O
to O
bind O
through O
its O
armadillo O
repeat O
domain O
to O
a O
rac O
- O
specific O
guanine O
nucleotide O
exchange O
factor O
( O
gef O
) O
, O
termed O
asef O
. O

the O
axonal O
chemoattractant O
netrin O
- O
1 O
guides O
spinal O
commissural O
axons O
by O
activating O
its O
receptor O
dcc O
( O
deleted O
in O
colorectal B-Disease
cancer I-Disease
) O
. O

myotonic B-Disease
dystrophy I-Disease
in O
transgenic O
mice O
expressing O
an O
expanded O
cug O
repeat O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
, O
the O
most O
common O
form O
of O
muscular B-Disease
dystrophy I-Disease
in O
adult O
humans O
, O
results O
from O
expansion O
of O
a O
ctg O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
dmpk O
gene O
. O

mice O
that O
expressed O
expanded O
cug O
repeats O
developed O
myotonia B-Disease
and O
myopathy B-Disease
, O
whereas O
mice O
expressing O
a O
nonexpanded O
repeat O
did O
not O
. O

genomic O
rearrangements O
of O
the O
apc B-Disease
tumor I-Disease
- O
suppressor O
gene O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
. O

germline O
mutations O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( I-Disease
apc I-Disease
) I-Disease
tumor I-Disease
- O
suppressor O
gene O
result O
in O
the O
hereditary B-Disease
colorectal I-Disease
cancer I-Disease
syndrome I-Disease
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
. O

almost O
all O
apc B-Disease
mutations O
that O
have O
been O
identified O
are O
single O
- O
nucleotide O
alterations O
, O
small O
insertions O
, O
or O
small O
deletions O
that O
would O
truncate O
the O
protein O
product O
of O
the O
gene O
. O

no O
well O
- O
characterized O
intragenic O
rearrangement O
of O
apc O
has O
been O
described O
, O
and O
the O
prevalence O
of O
this O
type O
of O
mutation O
in O
fap B-Disease
patients O
is O
not O
clear O
. O

the O
identification O
of O
four O
genomic O
rearrangements O
among O
30 O
mutations O
suggests O
that O
genomic O
rearrangements O
are O
frequent O
germline O
apc B-Disease
mutations O
. O

detection O
of O
a O
novel O
missense O
mutation O
and O
second O
recurrent O
mutation O
in O
the O
cacna1a O
gene O
in O
individuals O
with O
ea B-Disease
- I-Disease
2 I-Disease
and O
fhm B-Disease
. O

mutations O
in O
the O
brain O
specific O
p O
/ O
q O
type O
ca2 O
+ O
channel O
alpha1 O
subunit O
gene O
, O
cacna1a O
, O
have O
been O
identified O
in O
three O
clinically O
distinct O
disorders O
, O
viz O
. O
episodic B-Disease
ataxia I-Disease
type I-Disease
2 I-Disease
( O
ea B-Disease
- I-Disease
2 I-Disease
) O
, O
familial B-Disease
hemiplegic I-Disease
migraine I-Disease
( O
fhm B-Disease
) O
and O
spinocerebellar B-Disease
ataxia I-Disease
6 I-Disease
( O
sca6 B-Disease
) O
. O

for O
individuals O
with O
ea B-Disease
- I-Disease
2 I-Disease
, O
the O
mutations O
described O
thus O
far O
are O
presumed O
to O
result O
in O
a O
truncated O
protein O
product O
. O

several O
different O
missense O
mutations O
have O
been O
identified O
in O
patients O
with O
fhm B-Disease
. O

we O
have O
characterised O
a O
novel O
missense O
mutation O
, O
g5260a O
, O
in O
exon O
32 O
in O
a O
family O
segregating O
for O
ea B-Disease
- I-Disease
2 I-Disease
. O

furthermore O
, O
this O
mutation O
has O
been O
detected O
in O
a O
family O
member O
with O
mild O
clinical O
signs O
including O
only O
migraine B-Disease
. O

additionally O
, O
a O
second O
previously O
identified O
recurrent O
muta O
tion O
, O
c2272t O
, O
in O
exon O
16 O
has O
been O
discovered O
in O
a O
patient O
with O
fhm B-Disease
. O
. O

analbuminemia B-Disease
in O
a O
neonate O
. O

a O
small O
- O
for O
- O
gestational O
- O
age O
infant O
, O
found O
to O
have O
analbuminemia B-Disease
in O
the O
neonatal O
period O
, O
is O
reported O
and O
the O
twelve O
cases O
recorded O
in O
the O
world O
literature O
are O
reviewed O
. O

patients O
lacking O
this O
serum O
protein O
are O
essentially O
asymptomatic O
, O
apart O
from O
minimal O
ankle B-Disease
edema I-Disease
and O
ease B-Disease
of I-Disease
fatigue I-Disease
. O

apparent O
compensatory O
mechanisms O
which O
come O
into O
play O
when O
serum O
albumin O
is O
low O
include O
prolonged O
half O
- O
life O
of O
albumin O
and O
transferrin O
, O
an O
increase O
in O
serum O
globulins O
, O
beta O
lipoprotein O
, O
and O
glycoproteins O
, O
arterial B-Disease
hypotension I-Disease
with O
reduced O
capillary O
hydrostatic O
pressure O
, O
and O
the O
ability O
to O
respond O
with O
rapid O
sodium O
and O
chloride O
diuresis O
in O
response O
to O
small O
volume O
changes O
. O

examination O
of O
plasma O
amino O
acids O
, O
an O
investigation O
not O
previously O
reported O
, O
revealed O
an O
extremely O
low O
plasma O
tryptophan O
level O
, O
a O
finding O
which O
may O
be O
important O
in O
view O
of O
the O
role O
of O
tryptophan O
in O
albumin O
synthesis O
. O
. O

histidinemia B-Disease
. O

two O
brothers O
, O
6 O
and O
13 O
years O
old O
, O
had O
histidinemia B-Disease
. O

carrier O
detection O
of O
pyruvate B-Disease
carboxylase I-Disease
deficiency I-Disease
in O
fibroblasts O
and O
lymphocytes O
. O

pyruvate O
carboxylase O
( O
e O
. O
c O
. O
6 O
. O
4 O
. O
1 O
. O
1 O
) O
activity O
was O
determined O
in O
the O
circulating O
peripheral O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
from O
the O
family O
of O
a O
patient O
with O
hepatic O
, O
cerebral O
, O
renal O
cortical O
, O
leukocyte O
, O
and O
fibroblast O
pyruvate B-Disease
carboxylase I-Disease
deficiency I-Disease
( O
pc B-Disease
portland I-Disease
deficiency I-Disease
) O
. O

glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variants O
from O
italian O
subjects O
associated O
with O
severe B-Disease
neonatal I-Disease
jaundice I-Disease
. O

screening O
for O
the O
g6pd B-Disease
deficiency I-Disease
was O
carried O
out O
at O
the O
maternity O
division O
of O
the O
galliera O
hospital O
in O
genoa O
, O
italy O
. O

two O
groups O
of O
subjects O
with O
hyperbilirubinaemia B-Disease
of O
non O
- O
immunological O
origin O
were O
examined O
( O
a O
) O
302 O
newborn O
babies O
of O
sardinian O
extraction O
( O
on O
cord O
blood O
) O
and O
( O
b O
) O
201 O
newborn O
babies O
of O
south O
italian O
ancestry O
( O
on O
peripheral O
blood O
) O
. O

in O
the O
present O
work O
these O
three O
cases O
, O
each O
with O
severe B-Disease
neonatal I-Disease
jaundice I-Disease
, O
are O
reported O
. O

cytogenetic O
investigations O
in O
families O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
. O

chromosomal O
studies O
were O
performed O
on O
peripheral O
blood O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
from O
five O
israeli O
- O
moroccan O
families O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
. O

prenatal O
diagnosis O
of O
wolman B-Disease
disease I-Disease
. O

two O
pregnancies O
at O
risk O
for O
wolman B-Disease
disease I-Disease
were O
monitored O
by O
assay O
and O
electrophoresis O
of O
acid O
lipase O
in O
cultured O
amniotic O
- O
fluid O
cells O
. O

electrophoresis O
of O
cell O
extracts O
revealed O
the O
absence O
of O
the O
a O
form O
of O
acid O
lipase O
, O
consistent O
with O
the O
diagnosis O
of O
wolman B-Disease
disease I-Disease
. O

the O
results O
suggest O
that O
the O
prenatal O
diagnosis O
of O
wolman B-Disease
disease I-Disease
be O
made O
using O
the O
radioassay O
of O
acid O
lipase O
and O
/ O
or O
electrophoresis O
. O
. O

malignant B-Disease
neoplasms I-Disease
in O
the O
families O
of O
patients O
with O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
. O

ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
syndrome I-Disease
associated O
with O
a O
greatly O
increased O
incidence O
of O
malignant B-Disease
neoplasms I-Disease
in O
homozygous O
affected O
individuals O
. O

heterozygotes O
for O
the O
gene O
for O
a B-Disease
- I-Disease
t I-Disease
are O
thought O
to O
comprise O
about O
1 O
% O
of O
the O
general O
population O
and O
, O
therefore O
, O
it O
is O
important O
to O
know O
whether O
this O
gene O
also O
predisposes O
the O
heterozygous O
carrier O
to O
cancers B-Disease
. O

heterozygous O
carriers O
of O
this O
gene O
are O
common O
among O
the O
close O
relatives O
of O
patients O
with O
a B-Disease
- I-Disease
t I-Disease
, O
although O
individual O
carriers O
cannot O
be O
identified O
by O
any O
clinical O
criterion O
or O
laboratory O
test O
. O

for O
this O
reason O
, O
we O
compared O
the O
incidence O
of O
death O
from O
malignant B-Disease
neoplasms I-Disease
in O
2 O
families O
of O
patients O
with O
a B-Disease
- I-Disease
t I-Disease
to O
that O
expected O
in O
a O
random O
sample O
of O
the O
general O
population O
. O

there O
were O
59 O
deaths O
from O
malignant B-Disease
neoplasms I-Disease
in O
relatives O
dying O
before O
age O
75 O
, O
compared O
to O
42 O
. O

for O
a B-Disease
- I-Disease
t I-Disease
heterozygotes O
younger O
than O
age O
45 O
, O
the O
risk O
of O
dying O
from O
a O
malignant B-Disease
neoplasm I-Disease
was O
estimated O
to O
be O
greater O
than O
5 O
times O
the O
risk O
for O
the O
general O
population O
. O

a B-Disease
- I-Disease
t I-Disease
heterozygotes O
may O
comprise O
more O
than O
5 O
% O
of O
all O
persons O
dying O
from O
a O
cancer B-Disease
before O
age O
45 O
. O

the O
incidence O
of O
ovarian B-Disease
, I-Disease
gastric I-Disease
, I-Disease
and I-Disease
biliary I-Disease
system I-Disease
carcinomas I-Disease
and O
of O
leukemia B-Disease
and O
lymphoma B-Disease
was O
increased O
in O
these O
a B-Disease
- I-Disease
t I-Disease
families O
. O

other O
neoplasms B-Disease
that O
may O
be O
associated O
with O
this O
gene O
in O
heterozygotes O
include O
pancreatic B-Disease
, I-Disease
basal I-Disease
cell I-Disease
, I-Disease
colonic I-Disease
, I-Disease
breast I-Disease
, I-Disease
and I-Disease
cervical I-Disease
carcinomas I-Disease
. O

striking O
prevalence O
of O
ankylosing B-Disease
spondylitis I-Disease
in O
" O
healthy O
" O
w27 O
positive O
males O
and O
females O
. O

ankylosing B-Disease
spondylitis I-Disease
is O
diagnosed O
once O
or O
twice O
in O
each O
1000 O
males O
and O
one O
tenth O
as O
frequently O
in O
females O
, O
but O
the O
true O
prevalence O
is O
unknown O
. O

evaluation O
by O
postal O
questionnaires O
, O
and O
pelvic O
radiography O
of O
78 O
hl O
- O
a O
27w O
- O
positive O
blood O
donors O
selected O
from O
a O
group O
of O
apparently O
healthy O
subjects O
revealed O
14 O
who O
satisfied O
the O
criteria O
for O
definite O
ankylosing B-Disease
spondylitis I-Disease
. O

for O
a O
person O
of O
either O
sex O
with O
hl O
- O
a O
w27 O
, O
there O
appears O
to O
be O
about O
a O
20 O
per O
cent O
chance O
that O
ankylosing B-Disease
spondylitis I-Disease
will O
develop O
, O
suggesting O
a O
prevalence O
of O
10 O
to O
15 O
per O
thousand O
. O

analbuminemia B-Disease
in O
an O
american O
indian O
girl O
. O

analbuminemia B-Disease
was O
fortuitously O
detected O
in O
a O
nonedematous O
12 O
- O
year O
- O
old O
american O
indian O
girl O
with O
atopic B-Disease
dermatitis I-Disease
, O
mild O
bronchial B-Disease
asthma I-Disease
, O
a O
mild O
seizure B-Disease
disorder I-Disease
, O
and O
hyperlipoproteinemia B-Disease
with O
a O
corneal B-Disease
arcus I-Disease
. O

the O
pedigree O
and O
clinical O
findings O
were O
compatible O
with O
autosomal O
recessive O
transmission O
of O
analbuminemia B-Disease
. O

gc O
- O
protein O
levels O
were O
normal O
in O
the O
patient O
and O
together O
with O
normal O
chromosomal O
banding O
studies O
make O
it O
unlikely O
that O
a O
chromosomal O
deletion O
caused O
analbuminemia B-Disease
. O

gc O
- O
types O
in O
the O
family O
were O
compatible O
with O
, O
but O
did O
not O
prove O
, O
linkage O
of O
analbuminemia B-Disease
to O
the O
gc O
- O
locus O
. O

these O
findings O
suggest O
a O
" O
thalassemia B-Disease
" O
- O
like O
mutation O
for O
this O
disorder O
. O
. O

deletion O
of O
the O
kit O
and O
pdgfra O
genes O
in O
a O
patient O
with O
piebaldism B-Disease
. O

we O
have O
previously O
shown O
that O
human O
piebaldism B-Disease
results O
from O
mutations O
of O
the O
kit O
gene O
, O
which O
encodes O
the O
receptor O
for O
the O
mast O
/ O
stem O
cell O
growth O
factor O
and O
is O
located O
in O
chromosome O
segment O
4q12 O
. O

using O
dna O
of O
a O
patient O
with O
piebaldism B-Disease
, O
mental B-Disease
retardation I-Disease
, O
and O
multiple B-Disease
congenital I-Disease
anomalies I-Disease
associated O
with O
a O
46 O
, O
xy O
, O
del O
( O
4 O
) O
( O
q12q21 O
. O
1 O
) O
karyotype O
, O
we O
carried O
out O
quantitative O
southern O
blot O
hybridization O
analyses O
of O
the O
kit O
gene O
and O
the O
adjacent O
pdgfra O
( O
platelet O
- O
derived O
growth O
factor O
receptor O
alpha O
subunit O
) O
genes O
. O

therefore O
, O
deletion O
of O
the O
kit O
and O
pdgfra O
genes O
may O
account O
for O
the O
piebald B-Disease
phenotype O
in O
this O
patient O
. O

a O
germ O
line O
mutation O
within O
the O
coding O
sequence O
for O
the O
putative O
5 O
- O
phosphoribosyl O
- O
1 O
- O
pyrophosphate O
binding O
site O
of O
hypoxanthine O
- O
guanine O
phosphoribosyltransferase O
( O
hprt O
) O
in O
a O
lesch B-Disease
- I-Disease
nyhan I-Disease
patient O
: O
missense O
mutations O
within O
a O
functionally O
important O
region O
probably O
cause O
disease O
. O

lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
caused O
by O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
hypoxanthine I-Disease
guanine I-Disease
phosphoribosyltransferase I-Disease
( O
hprt O
) O
is O
the O
result O
of O
a O
heterogeneous O
group O
of O
germ O
line O
mutations O
. O

we O
report O
here O
a O
newly O
identified O
hprt O
mutation O
in O
a O
japanese O
patient O
with O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

missense O
mutations O
in O
human O
hprt B-Disease
deficient I-Disease
patients O
thus O
far O
reported O
tend O
to O
accumulate O
in O
this O
functionally O
active O
region O
. O

characterisation O
of O
a O
new O
rare O
fragile O
site O
easily O
confused O
with O
the O
fragile B-Disease
x I-Disease
. O

the O
fragile O
site O
is O
not O
associated O
with O
mental B-Disease
retardation I-Disease
, O
it O
does O
not O
give O
abnormal O
results O
when O
subjected O
to O
southern O
analysis O
with O
probe O
pfxa3 O
which O
detects O
the O
unstable O
dna O
sequence O
characteristic O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O

the O
distinction O
between O
the O
two O
fragile O
sites O
is O
important O
clinically O
since O
cytogenetic O
detection O
of O
fraxe O
, O
without O
molecular O
analysis O
, O
could O
result O
in O
misdiagnosis O
of O
fragile B-Disease
x I-Disease
syndrome I-Disease
. O
. O

the O
norrie B-Disease
disease I-Disease
gene O
maps O
to O
a O
150 O
kb O
region O
on O
chromosome O
xp11 O
. O
3 O
. O

norrie B-Disease
disease I-Disease
is O
a O
human O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
disorder I-Disease
of O
unknown O
etiology O
characterized O
by O
congenital B-Disease
blindness I-Disease
, O
sensory B-Disease
neural I-Disease
deafness I-Disease
and O
mental B-Disease
retardation I-Disease
. O

we O
report O
here O
fine O
physical O
mapping O
of O
the O
obligate O
region O
containing O
the O
norrie B-Disease
disease I-Disease
gene O
( O
ndp O
) O
defined O
by O
a O
recombination O
and O
by O
the O
smallest O
submicroscopic O
chromosomal O
deletion O
associated O
with O
norrie B-Disease
disease I-Disease
identified O
to O
date O
. O

molecular O
basis O
of O
phenylketonuria B-Disease
and O
related O
hyperphenylalaninemias B-Disease
: O
mutations O
and O
polymorphisms O
in O
the O
human O
phenylalanine O
hydroxylase O
gene O
. O

mutations O
in O
the O
human O
phenylalanine O
hydroxylase O
gene O
producing O
phenylketonuria B-Disease
or O
hyperphenylalaninemia B-Disease
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

a O
glycine250 O
- O
- O
> O
aspartate O
substitution O
in O
the O
alpha O
- O
subunit O
of O
hexosaminidase O
a O
causes O
juvenile O
- O
onset O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
in O
a O
lebanese O
- O
canadian O
family O
. O

the O
mutation O
causing O
juvenile O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
in O
two O
sibs O
of O
lebanese O
- O
maronite O
origin O
is O
described O
. O

the O
predicted O
protein O
environment O
in O
which O
the O
mutation O
occurs O
is O
compared O
to O
that O
of O
the O
adult O
- O
onset O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
mutation O
caused O
by O
a O
gly269 O
- O
- O
> O
ser O
substitution O
in O
exon O
7 O
. O

novel O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
mutations O
from O
china O
. O

we O
describe O
three O
hexa O
mutations O
associated O
with O
infantile O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
in O
three O
unrelated O
nonconsanguineous O
chinese O
families O
. O

two O
missense O
mutations O
causing O
mild O
hyperphenylalaninemia B-Disease
associated O
with O
dna O
haplotype O
12 O
. O

the O
genetic B-Disease
defects I-Disease
responsible O
for O
most O
phenylketonuria B-Disease
( O
pku B-Disease
) O
and O
hyperphenylalaninemia B-Disease
( O
hpa B-Disease
) O
cases O
are O
located O
in O
the O
phenylalanine O
hydroxylase O
( O
pah O
) O
gene O
. O

we O
hypothesized O
that O
there O
is O
at O
least O
one O
mild O
mutation O
linked O
to O
haplotype O
12 O
in O
the O
swedish O
pku B-Disease
/ O
hpa B-Disease
population O
, O
since O
7 O
of O
8 O
patients O
carrying O
haplotype O
12 O
had O
mild O
hpa B-Disease
. O

mutations O
at O
the O
phenylalanine O
hydroxylase O
( O
pah O
) O
locus O
are O
the O
major O
cause O
of O
hyperphenylalaninemia B-Disease
. O

homozygosity O
for O
m1v O
and O
codominant O
inheritance O
of O
i65t O
/ O
r408w O
were O
both O
associated O
with O
classical B-Disease
phenylketonuria I-Disease
. O
. O

molecular O
basis O
of O
hexosaminidase B-Disease
a I-Disease
deficiency I-Disease
and O
pseudodeficiency O
in O
the O
berks O
county O
pennsylvania O
dutch O
. O

following O
the O
birth O
of O
two O
infants O
with O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
, O
a O
non O
- O
jewish O
, O
pennsylvania O
dutch O
kindred O
was O
screened O
for O
tsd B-Disease
carriers O
using O
the O
biochemical O
assay O
. O

a O
high O
frequency O
of O
individuals O
who O
appeared O
to O
be O
tsd B-Disease
heterozygotes O
was O
detected O
( O
kelly O
et O
al O
. O
, O
1975 O
) O
. O

one O
allele O
, O
reported O
originally O
in O
a O
french O
tsd B-Disease
patient O
( O
akli O
et O
al O
. O
, O
1991 O
) O
, O
is O
a O
gt O
- O
- O
> O
at O
transition O
at O
the O
donor O
splice O
- O
site O
of O
intron O
9 O
. O

a O
mutation O
common O
in O
non O
- O
jewish O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
: O
frequency O
and O
rna O
studies O
. O

tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
genetic I-Disease
disorder I-Disease
resulting O
from O
mutation O
of O
the O
hexa O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
lysosomal O
enzyme O
, O
beta O
- O
n O
- O
acetylhexosaminidase O
a O
( O
hex O
a O
) O
. O

we O
have O
discovered O
that O
a O
tay B-Disease
- I-Disease
sachs I-Disease
mutation O
, O
ivs O
- O
9 O
+ O
1 O
g O
- O
- O
> O
a O
, O
first O
detected O
by O
akli O
et O
al O
. O

it O
was O
not O
identified O
among O
12 O
black O
american O
tsd B-Disease
alleles O
or O
in O
any O
of O
18 O
ashkenazi O
jewish O
, O
enzyme O
- O
defined O
carriers O
who O
did O
not O
carry O
any O
of O
the O
mutations O
common O
to O
this O
population O
. O

together O
with O
a O
recently O
identified O
allele O
responsible O
for O
hex O
a O
pseudodeficiency O
( O
triggs O
- O
raine O
et O
al O
. O
am O
j O
hum O
genet O
, O
1992 O
) O
, O
these O
two O
alleles O
accounted O
for O
almost O
50 O
% O
( O
29 O
/ O
64 O
) O
of O
tsd B-Disease
or O
carrier O
alleles O
ascertained O
by O
enzyme O
screening O
tests O
in O
non O
- O
jewish O
caucasians O
. O
. O

aberrant O
splicing O
of O
the O
chm B-Disease
gene O
is O
a O
significant O
cause O
of O
choroideremia B-Disease
. O

choroideremia B-Disease
( O
chm B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
progressive I-Disease
degeneration I-Disease
of I-Disease
the I-Disease
choroid I-Disease
and I-Disease
retina I-Disease
. O

12 O
% O
of O
unrelated O
male O
patients O
carry O
deletions O
of O
the O
partially O
cloned O
chm B-Disease
gene O
. O

in O
finland O
, O
there O
are O
more O
than O
120 O
living O
chm B-Disease
patients O
belonging O
to O
eight O
apparently O
unrelated O
pedigrees O
. O

molecular O
deletions O
involving O
the O
chm B-Disease
gene O
have O
been O
detected O
in O
three O
families O
. O

our O
findings O
provide O
additional O
evidence O
for O
the O
pathogenetic O
role O
of O
chm B-Disease
mutations O
and O
provide O
a O
diagnostic O
tool O
for O
one O
fifth O
of O
the O
worlds O
known O
chm B-Disease
patients O
. O
. O

germline O
intronic O
and O
exonic O
mutations O
in O
the O
wilms B-Disease
' I-Disease
tumour I-Disease
gene O
( O
wt1 O
) O
affecting O
urogenital O
development O
. O

denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
is O
a O
rare O
human O
developmental B-Disease
disorder I-Disease
affecting O
the O
urogenital O
system O
and O
leading O
to O
renal B-Disease
failure I-Disease
, O
intersex B-Disease
disorders I-Disease
and O
wilms B-Disease
tumour I-Disease
. O

in O
this O
report O
, O
four O
individuals O
with O
this O
syndrome O
are O
described O
carrying O
germline O
point O
mutations O
in O
the O
wilms B-Disease
tumour I-Disease
suppressor O
gene O
, O
wt1 O
. O

characterization O
of O
the O
myotonic B-Disease
dystrophy I-Disease
region O
predicts O
multiple O
protein O
isoform O
- O
encoding O
mrnas O
. O

the O
mutation O
underlying O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
has O
been O
identified O
as O
an O
expansion O
of O
a O
polymorphic O
ctg O
- O
repeat O
in O
a O
gene O
encoding O
protein O
kinase O
activity O
. O

fragile B-Disease
x I-Disease
syndrome I-Disease
without O
ccg O
amplification O
has O
an O
fmr1 O
deletion O
. O

we O
describe O
a O
patient O
with O
typical O
clinical O
features O
of O
the O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
but O
without O
cytogenetic O
expression O
of O
the O
fragile B-Disease
x I-Disease
or O
an O
amplified O
ccg O
trinucleotide O
repeat O
fragment O
. O

this O
finding O
confirms O
that O
the O
fragile B-Disease
x I-Disease
phenotype O
can O
exist O
, O
without O
amplification O
of O
the O
ccg O
repeat O
or O
cytogenetic O
expression O
of O
the O
fragile B-Disease
x I-Disease
, O
and O
that O
fragile B-Disease
x I-Disease
syndrome I-Disease
is O
a O
genetically O
homogeneous O
disorder O
involving O
fmr1 O
. O

cloning O
of O
the O
huntington B-Disease
disease I-Disease
region O
in O
yeast O
artificial O
chromosomes O
. O

the O
gene O
responsible O
for O
huntington B-Disease
disease I-Disease
has O
been O
localized O
to O
a O
2 O
. O

as O
part O
of O
a O
strategy O
to O
clone O
the O
hd B-Disease
gene O
on O
the O
basis O
of O
its O
chromosomal O
location O
, O
we O
isolated O
genomic O
dna O
from O
the O
hd B-Disease
region O
as O
a O
set O
of O
overlapping O
yeast O
artificial O
chromosome O
( O
yac O
) O
clones O
. O

we O
assembled O
the O
yac O
clones O
into O
overlapping O
sets O
by O
hybridizing O
them O
to O
a O
large O
number O
of O
dna O
probes O
from O
the O
hd B-Disease
region O
, O
including O
the O
stss O
. O

2 O
mb O
of O
the O
hd B-Disease
region O
in O
yacs O
, O
including O
one O
continuous O
segment O
of O
2 O
. O

0 O
mb O
covering O
the O
region O
that O
most O
likely O
contains O
the O
hd B-Disease
gene O
. O

characterization O
of O
a O
yac O
containing O
part O
or O
all O
of O
the O
norrie B-Disease
disease I-Disease
locus O
. O

a O
series O
of O
subclones O
prepared O
from O
a O
phage O
library O
( O
lambda O
dash O
ii O
) O
of O
the O
yac O
have O
been O
characterised O
and O
have O
been O
employed O
to O
determine O
the O
end O
point O
of O
the O
deletion O
of O
a O
norrie B-Disease
disease I-Disease
( O
ndp B-Disease
) O
patient O
who O
has O
been O
shown O
to O
lack O
both O
dxs7 O
and O
mao O
coding O
sequences O
. O

both O
mutations O
in O
g6pd O
a O
- O
are O
necessary O
to O
produce O
the O
g6pd B-Disease
deficient I-Disease
phenotype O
. O

the O
high O
prevalence O
of O
glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
african O
populations O
is O
due O
almost O
entirely O
to O
the O
enzyme O
variant O
a O
- O
, O
which O
differs O
from O
the O
wild O
- O
type O
g6pd O
b O
by O
two O
amino O
acid O
replacements O
, O
68 O
val O
- O
- O
> O
met O
and O
126 O
asn O
- O
- O
> O
asp O
. O

this O
could O
be O
because O
the O
68 O
val O
- O
- O
> O
met O
mutation O
happened O
to O
arise O
in O
an O
a O
gene O
in O
the O
first O
instance O
, O
or O
because O
the O
68 O
val O
- O
- O
> O
met O
mutation O
alone O
is O
not O
sufficient O
to O
cause O
g6pd B-Disease
deficiency I-Disease
. O

we O
infer O
that O
the O
coexistence O
of O
the O
two O
mutations O
is O
responsible O
for O
enzyme B-Disease
deficiency I-Disease
in I-Disease
g6pd I-Disease
a O
- O
because O
they O
act O
synergistically O
in O
causing O
instability O
of O
the O
enzyme O
. O

small O
nuclear O
ribonucleoprotein O
polypeptide O
n O
( O
snrpn O
) O
, O
an O
expressed O
gene O
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
critical O
region O
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
is O
associated O
with O
paternally O
derived O
chromosomal O
deletions O
in O
region O
15q11 O
- O
13 O
or O
with O
maternal B-Disease
disomy I-Disease
for I-Disease
chromosome I-Disease
15 I-Disease
. O

furthermore O
, O
snrpn O
was O
mapped O
to O
the O
minimal O
deletion O
interval O
that O
is O
critical O
for O
pws B-Disease
. O

the O
fact O
that O
the O
mouse O
snrpn O
gene O
is O
maternally O
imprinted O
in O
brain O
suggests O
that O
loss O
of O
the O
paternally O
derived O
snrpn O
allele O
may O
be O
involved O
in O
the O
pws B-Disease
phenotype O
. O

the O
presence O
of O
two O
different O
infantile O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
mutations O
in O
a O
cajun O
population O
. O

a O
study O
was O
undertaken O
to O
characterize O
the O
mutation O
( O
s O
) O
responsible O
for O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
in O
a O
cajun O
population O
in O
southwest O
louisiana O
and O
to O
identify O
the O
origins O
of O
these O
mutations O
. O

eleven O
of O
12 O
infantile O
tsd B-Disease
alleles O
examined O
in O
six O
families O
had O
the O
beta O
- O
hexosaminidase O
a O
( O
hex O
a O
) O
alpha O
- O
subunit O
exon O
11 O
insertion O
mutation O
that O
is O
present O
in O
approximately O
70 O
% O
of O
ashkenazi O
jewish O
tsd B-Disease
heterozygotes O
. O

to O
determine O
the O
origins O
of O
these O
two O
mutations O
in O
the O
cajun O
population O
, O
the O
tsd B-Disease
carrier O
status O
was O
enzymatically O
determined O
for O
90 O
members O
of O
four O
of O
the O
six O
families O
, O
and O
extensive O
pedigrees O
were O
constructed O
for O
all O
carriers O
. O

mutations O
in O
the O
candidate O
gene O
for O
norrie B-Disease
disease I-Disease
. O

recently O
, O
we O
and O
others O
have O
isolated O
a O
candidate O
gene O
for O
x B-Disease
linked I-Disease
norrie I-Disease
disease I-Disease
( O
nd B-Disease
) O
which O
was O
found O
to O
be O
deleted O
or O
disrupted O
in O
several O
patients O
. O

these O
findings O
, O
and O
the O
absence O
of O
functionally O
relevant O
base O
changes O
in O
healthy O
controls O
, O
emphasize O
the O
causal O
role O
of O
this O
candidate O
gene O
in O
norrie B-Disease
disease I-Disease
and O
pave O
the O
way O
for O
reliable O
diagnosis O
and O
carrier O
detection O
. O

co O
- O
amplification O
of O
11 O
exons O
from O
genomic O
dna O
of O
duchenne B-Disease
and I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
/ O
bmd B-Disease
) O
patients O
with O
no O
deletion O
or O
duplication O
was O
performed O
and O
the O
samples O
subjected O
to O
multiple O
sscp O
analysis O
. O

we O
report O
the O
case O
of O
a O
nonsense O
mutation O
in O
a O
duchenne B-Disease
patient O
identified O
by O
this O
approach O
. O

high O
level O
expression O
of O
the O
nm23 O
- O
h1 O
gene O
, O
which O
encodes O
for O
a O
nucleoside O
diphosphate O
kinase O
, O
has O
been O
found O
to O
correlate O
with O
diminished O
metastasis O
in O
some O
tumors B-Disease
but O
not O
in O
others O
. O

in O
neuroblastoma B-Disease
, O
higher O
levels O
of O
p19 O
/ O
nm23 O
, O
which O
are O
associated O
with O
amplification O
of O
the O
n O
- O
myc O
oncogene O
, O
large O
tumor B-Disease
mass O
, O
and O
metastasis O
, O
were O
observed O
in O
advanced O
stage O
tumors B-Disease
compared O
with O
limited O
stage O
disease O
. O

because O
of O
the O
variable O
expression O
of O
nm23 O
- O
h1 O
in O
different O
tumors B-Disease
, O
we O
have O
investigated O
the O
relationship O
between O
amounts O
of O
the O
protein O
and O
cell O
proliferation O
. O

the O
levels O
of O
p19 O
/ O
nm23 O
were O
compared O
between O
resting O
and O
mitotically O
stimulated O
normal O
human O
pbls O
and O
in O
leukemia B-Disease
cells O
. O

in O
leukemia B-Disease
cells O
obtained O
from O
patients O
with O
different O
subtypes O
of O
acute B-Disease
leukemia I-Disease
, O
p19 O
/ O
nm23 O
levels O
were O
also O
increased O
relative O
to O
resting O
normal O
lymphocytes O
. O

treatment O
of O
mitotically O
stimulated O
lymphocytes O
with O
cyclosporin O
, O
which O
inhibits O
proliferation O
, O
blocked O
the O
increase O
in O
p19 O
/ O
nm23 O
; O
treatment O
of O
the O
leukemia B-Disease
cell O
line O
hl O
- O
60 O
with O
dimethylsulfoxide O
, O
which O
induces O
terminal O
differentiation O
, O
resulted O
in O
diminished O
levels O
of O
p19 O
/ O
nm23 O
. O

an O
intrachromosomal O
insertion O
causing O
5q22 O
deletion O
and O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
in O
two O
generations O
. O

we O
report O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
( O
fapc B-Disease
) O
with O
epidermoid B-Disease
cysts I-Disease
, O
osteomata B-Disease
, O
and O
areas O
of O
congenital B-Disease
hypertrophy I-Disease
of I-Disease
the I-Disease
retinal I-Disease
pigment I-Disease
epithelium I-Disease
( O
chrpes B-Disease
) O
in O
a O
male O
patient O
and O
his O
maternal O
aunt O
, O
both O
of O
whom O
suffered O
a O
mild O
to O
moderate O
degree O
of O
mental B-Disease
handicap I-Disease
. O

as O
expected O
, O
the O
molecular O
analyses O
indicate O
loss O
of O
one O
allele O
at O
the O
mcc O
and O
apc B-Disease
loci O
. O

the O
apc B-Disease
gene O
is O
located O
within O
band O
5q22 O
. O

chromosome O
mapping O
of O
the O
rod O
photoreceptor O
cgmp O
phosphodiesterase O
beta O
- O
subunit O
gene O
in O
mouse O
and O
human O
: O
tight O
linkage O
to O
the O
huntington B-Disease
disease I-Disease
region O
( O
4p16 O
. O
3 O
) O
. O

the O
retinal B-Disease
degeneration I-Disease
mouse O
( O
gene O
symbol O
, O
rd O
) O
is O
an O
animal O
model O
for O
certain O
forms O
of O
human O
hereditary B-Disease
retinopathies I-Disease
. O

3 O
, O
very O
close O
to O
the O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
region O
. O

analysis O
of O
the O
comparative O
map O
for O
mice O
and O
humans O
shows O
that O
the O
mouse O
homologue O
of O
the O
hd B-Disease
gene O
will O
reside O
on O
chromosome O
5 O
. O

3 O
region O
is O
maintained O
but O
gene O
order O
is O
not O
, O
suggesting O
at O
least O
three O
possible O
sites O
for O
the O
corresponding O
mouse O
hd B-Disease
gene O
. O

coincident O
kaposi B-Disease
sarcoma I-Disease
and O
t B-Disease
- I-Disease
cell I-Disease
lymphoma I-Disease
in O
a O
patient O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O

a O
24 O
year O
old O
male O
with O
a O
history O
of O
eczema B-Disease
, O
recurrent O
mild O
infections O
, O
and O
thrombocytopenia B-Disease
consistent O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
presented O
with O
a O
mediastinal O
mass O
, O
generalized O
lymphadenopathy B-Disease
, O
splenomegaly B-Disease
, O
and O
severe O
thrombocytopenia B-Disease
. O

however O
, O
their O
proliferative O
responses O
to O
anti O
- O
cd43 O
antibody O
and O
periodate O
were O
diminished O
, O
consistent O
with O
the O
clinical O
diagnosis O
of O
was B-Disease
. O

an O
initial O
inguinal O
lymph O
node O
biopsy O
surprisingly O
revealed O
kaposi B-Disease
sarcoma I-Disease
. O

however O
, O
following O
splenectomy O
to O
increase O
the O
platelet O
count O
, O
biopsy O
of O
the O
mediastinal O
mass O
revealed O
t B-Disease
- I-Disease
cell I-Disease
large I-Disease
cell I-Disease
lymphoma I-Disease
. O

studies O
of O
biopsied O
tissue O
for O
the O
presence O
of O
epstein B-Disease
- I-Disease
barr I-Disease
virus I-Disease
and O
cytomegalovirus B-Disease
were O
negative O
, O
as O
were O
studies O
of O
blood O
, O
including O
the O
polymerase O
chain O
reaction O
, O
for O
the O
presence O
of O
the O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
( O
hiv B-Disease
) O
. O

this O
is O
the O
first O
report O
of O
kaposi B-Disease
sarcoma I-Disease
arising O
in O
a O
patient O
with O
a O
congenital B-Disease
immunodeficiency I-Disease
syndrome I-Disease
. O

although O
kaposi B-Disease
sarcoma I-Disease
can O
arise O
in O
the O
face O
of O
the O
severe O
immunosuppression O
that O
follows O
allograft O
transplantation O
and O
in O
patients O
infected O
with O
hiv B-Disease
, O
we O
postulate O
that O
longevity O
in O
the O
face O
of O
mild O
immunosuppression O
was O
the O
major O
factor O
in O
the O
development O
of O
kaposi B-Disease
sarcoma I-Disease
in O
this O
patient O
. O
. O

the O
apc B-Disease
gene O
, O
responsible O
for O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
, O
is O
mutated O
in O
human O
gastric B-Disease
cancer I-Disease
. O

although O
gastric B-Disease
cancer I-Disease
is O
the O
most O
common O
cancer B-Disease
in O
the O
world O
, O
genetic O
changes O
during O
its O
carcinogenesis O
are O
not O
well O
understood O
. O

since O
some O
gastric B-Disease
cancers I-Disease
are O
considered O
to O
originate O
from O
the O
intestinal O
metaplasia O
, O
it O
is O
likely O
that O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
, O
the O
mutation O
of O
which O
causes O
adenomatous B-Disease
polyps I-Disease
in I-Disease
the I-Disease
colon I-Disease
, O
is O
associated O
with O
carcinogenesis O
of O
gastric B-Disease
cancer I-Disease
. O

based O
on O
this O
idea O
, O
dnas O
isolated O
from O
gastric B-Disease
cancers I-Disease
were O
examined O
by O
means O
of O
a O
rnase O
protection O
analysis O
coupled O
with O
polymerase O
chain O
reaction O
followed O
by O
sequencing O
of O
the O
polymerase O
chain O
reaction O
products O
. O

by O
screening O
nearly O
one O
- O
half O
of O
the O
coding O
region O
of O
the O
apc B-Disease
gene O
in O
44 O
tumors B-Disease
, O
somatic O
mutations O
were O
detected O
in O
three O
tumors B-Disease
a O
missense O
mutation O
, O
a O
nonsense O
mutation O
, O
and O
a O
5 O
- O
base O
pair O
deletion O
resulting O
in O
a O
frame O
shift O
which O
causes O
truncation O
of O
the O
gene O
product O
. O

these O
results O
suggest O
that O
the O
mutation O
of O
the O
apc B-Disease
gene O
also O
plays O
an O
important O
role O
during O
the O
carcinogenesis O
of O
at O
least O
some O
gastric B-Disease
cancers I-Disease
. O
. O

a O
71 O
- O
kilodalton O
protein O
is O
a O
major O
product O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
in O
brain O
and O
other O
nonmuscle O
tissues O
. O

the O
known O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
products O
, O
the O
muscle O
- O
and O
brain O
- O
type O
dystrophin O
isoforms O
, O
are O
427 O
- O
kda O
proteins O
translated O
from O
14 O
- O
kilobase O
( O
kb O
) O
mrnas O
. O

recently O
we O
described O
a O
6 O
. O

5 O
- O
kb O
mrna O
that O
also O
is O
transcribed O
from O
the O
dmd B-Disease
gene O
. O

8 O
- O
kda O
protein O
that O
is O
a O
major O
product O
of O
the O
dmd B-Disease
gene O
. O

correlation O
between O
the O
location O
of O
germ O
- O
line O
mutations O
in O
the O
apc B-Disease
gene O
and O
the O
number O
of O
colorectal B-Disease
polyps I-Disease
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
patients O
. O

recently O
we O
have O
isolated O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
which O
causes O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
, O
and O
its O
germ O
- O
line O
mutations O
in O
a O
substantial O
number O
of O
fap B-Disease
patients O
have O
been O
identified O
. O

on O
the O
basis O
of O
this O
information O
, O
we O
compared O
the O
location O
of O
germ O
- O
line O
mutations O
in O
the O
apc B-Disease
gene O
in O
22 O
unrelated O
patients O
( O
12 O
of O
whom O
have O
been O
reported O
previously O
) O
with O
the O
number O
of O
colorectal B-Disease
polyps I-Disease
developed O
in O
fap B-Disease
patients O
; O
17 O
were O
sparse O
types O
and O
five O
were O
profuse O
types O
. O

the O
location O
of O
the O
germ O
- O
line O
mutations O
seems O
to O
correlate O
with O
the O
two O
clinical O
types O
; O
germ O
- O
line O
mutations O
in O
five O
fap B-Disease
patients O
with O
profuse O
polyps B-Disease
were O
observed O
between O
codon O
1250 O
and O
codon O
1464 O
, O
whereas O
mutations O
in O
17 O
fap B-Disease
patients O
with O
fewer O
polyps B-Disease
were O
observed O
in O
the O
other O
regions O
of O
the O
apc B-Disease
gene O
. O

the O
result O
suggests O
that O
the O
number O
of O
colorectal B-Disease
polyps I-Disease
in O
fap B-Disease
patients O
may O
be O
associated O
with O
a O
difference O
in O
the O
stability O
or O
biological O
function O
of O
the O
truncated O
apc B-Disease
protein O
. O
. O

identification O
and O
rapid O
detection O
of O
three O
tay B-Disease
- I-Disease
sachs I-Disease
mutations O
in O
the O
moroccan O
jewish O
population O
. O

infantile O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
is O
caused O
by O
mutations O
in O
the O
hexa O
gene O
that O
result O
in O
the O
complete O
absence O
of O
beta O
- O
hexosaminidase O
a O
activity O
. O

it O
is O
well O
known O
that O
an O
elevated O
frequency O
of O
tsd B-Disease
mutations O
exists O
among O
ashkenazi O
jews O
. O

more O
recently O
it O
has O
become O
apparent O
that O
elevated O
carrier O
frequencies O
for O
tsd B-Disease
also O
occur O
in O
several O
other O
ethnic O
groups O
, O
including O
moroccan O
jews O
, O
a O
subgroup O
of O
sephardic O
jews O
. O

elsewhere O
we O
reported O
an O
in O
- O
frame O
deletion O
of O
one O
of O
the O
two O
adjacent O
phenylalanine O
codons O
at O
position O
304 O
or O
305 O
( O
delta O
f304 O
/ O
305 O
) O
in O
one O
hexa O
allele O
of O
a O
moroccan O
jewish O
tsd B-Disease
patient O
and O
in O
three O
obligate O
carriers O
from O
six O
unrelated O
moroccan O
jewish O
families O
. O

we O
have O
now O
identified O
two O
additional O
mutations O
within O
exon O
5 O
of O
the O
hexa O
gene O
that O
account O
for O
the O
remaining O
tsd B-Disease
alleles O
in O
the O
patient O
and O
carriers O
. O

this O
mutation O
is O
at O
a O
cpg O
site O
in O
a O
japanese O
infant O
with O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
and O
was O
described O
elsewhere O
. O

molecular O
characterization O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
by O
natural O
and O
amplification O
created O
restriction O
sites O
: O
five O
mutations O
account O
for O
most O
g6pd B-Disease
deficiency I-Disease
cases O
in O
taiwan O
. O

we O
have O
developed O
a O
rapid O
and O
simple O
method O
to O
diagnose O
the O
molecular O
defects O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
chinese O
in O
taiwan O
. O

ninety O
- O
four O
chinese O
males O
with O
g6pd B-Disease
deficiency I-Disease
were O
studied O
. O

these O
results O
show O
that O
the O
former O
five O
mutations O
account O
for O
more O
than O
90 O
% O
of O
g6pd B-Disease
deficiency I-Disease
cases O
in O
taiwan O
. O

familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
a O
dominantly O
inherited O
condition O
predisposing O
to O
colorectal B-Disease
cancer I-Disease
. O

the O
recent O
isolation O
of O
the O
responsible O
gene O
( O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
or O
apc B-Disease
) O
has O
facilitated O
the O
search O
for O
germ O
line O
mutations O
in O
affected O
individuals O
. O

dgge O
analysis O
of O
10 O
apc B-Disease
exons O
( O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10 O
, O
12 O
, O
13 O
, O
14 O
, O
and O
part O
of O
15 O
) O
in O
33 O
unrelated O
dutch O
fap B-Disease
patients O
has O
led O
to O
the O
identification O
of O
eight O
novel O
germ O
line O
mutations O
resulting O
in O
stop O
codons O
or O
frameshifts O
. O

the O
results O
reported O
here O
indicate O
that O
( O
1 O
) O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
is O
caused O
by O
an O
extremely O
heterogeneous O
spectrum O
of O
point O
mutations O
; O
( O
2 O
) O
all O
the O
mutations O
found O
in O
this O
study O
are O
chain O
terminating O
; O
and O
( O
3 O
) O
dgge O
represents O
a O
rapid O
and O
sensitive O
technique O
for O
the O
detection O
of O
mutations O
in O
the O
unusually O
large O
apc B-Disease
gene O
. O

such O
intragenic O
polymorphisms O
offer O
a O
practical O
approach O
to O
a O
more O
rapid O
procedure O
for O
presymptomatic O
diagnosis O
of O
fap B-Disease
by O
linkage O
analysis O
in O
informative O
families O
. O

yeast O
artificial O
chromosomes O
for O
the O
molecular O
analysis O
of O
the O
familial B-Disease
polyposis I-Disease
apc I-Disease
gene O
region O
. O

1 O
megabase O
pairs O
of O
dna O
around O
the O
mcc O
( O
for O
mutated O
in O
colorectal B-Disease
carcinoma I-Disease
) O
and O
apc B-Disease
( O
for O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
) O
genes O
at O
5q21 O
have O
been O
isolated O
and O
characterized O
. O

starting O
from O
the O
mcc O
gene O
, O
a O
strategy O
was O
undertaken O
to O
identify O
constitutional O
submicroscopic O
deletions O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
patients O
that O
might O
considerably O
narrow O
down O
the O
position O
of O
the O
apc B-Disease
gene O
. O

this O
screening O
approach O
led O
to O
the O
confirmation O
of O
a O
small O
heterozygous O
deletion O
in O
a O
polyposis B-Disease
patient O
that O
overlaps O
one O
of O
the O
two O
isolated O
yacs O
. O

this O
yac O
has O
been O
shown O
to O
contain O
the O
entire O
apc B-Disease
gene O
, O
in O
addition O
to O
a O
significant O
portion O
of O
dna O
flanking O
the O
5 O
end O
of O
the O
gene O
, O
and O
should O
therefore O
prove O
a O
valuable O
resource O
for O
functional O
studies O
by O
transfer O
to O
colorectal B-Disease
tumor I-Disease
- O
derived O
cell O
lines O
. O

inherited O
wt1 O
mutation O
in O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
. O

patients O
with O
the O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
( O
wilms B-Disease
tumor I-Disease
, O
genital B-Disease
anomalies I-Disease
, O
and O
nephropathy B-Disease
) O
have O
been O
demonstrated O
to O
carry O
de O
novo O
constitutional O
mutations O
in O
wt1 O
, O
the O
wilms B-Disease
tumor I-Disease
gene O
at O
chromosome O
11p13 O
. O

this O
observation O
indicates O
that O
the O
wt1 O
exon O
9 O
mutation O
affecting O
394arg O
demonstrated O
in O
over O
one O
- O
half O
of O
the O
patients O
with O
the O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
may O
exhibit O
incomplete O
penetrance O
. O

fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
with O
biotin O
- O
labeled O
probes O
mapping O
to O
11p13 O
has O
been O
used O
for O
the O
molecular O
analysis O
of O
deletions O
of O
the O
wagr B-Disease
( O
wilms B-Disease
tumor I-Disease
, O
aniridia B-Disease
, O
genitourinary B-Disease
abnormalities I-Disease
, O
and O
mental B-Disease
retardation I-Disease
) O
locus O
. O

we O
have O
detected O
a O
submicroscopic O
11p13 O
deletion O
in O
a O
child O
with O
inherited O
aniridia B-Disease
who O
subsequently O
presented O
with O
wilms B-Disease
tumor I-Disease
in O
a O
horseshoe O
kidney O
, O
only O
revealed O
at O
surgery O
. O

the O
mother O
, O
who O
has O
aniridia B-Disease
, O
was O
also O
found O
to O
carry O
a O
deletion O
including O
both O
the O
aniridia B-Disease
candidate O
gene O
( O
an2 O
) O
and O
the O
wilms B-Disease
tumor I-Disease
predisposition O
gene O
( O
wt1 O
) O
. O

wilms B-Disease
tumor I-Disease
has O
so O
far O
only O
been O
associated O
with O
sporadic O
de O
novo O
aniridia B-Disease
cases O
. O

we O
have O
shown O
that O
a O
cosmid O
probe O
for O
a O
candidate O
aniridia B-Disease
gene O
, O
homologous O
to O
the O
mouse O
pax O
- O
6 O
gene O
, O
is O
deleted O
in O
cell O
lines O
from O
aniridia B-Disease
patients O
with O
previously O
characterized O
deletions O
at O
11p13 O
, O
while O
another O
cosmid O
marker O
mapping O
between O
two O
aniridia B-Disease
- O
associated O
translocation O
breakpoints O
( O
and O
hence O
a O
second O
candidate O
marker O
) O
is O
present O
on O
both O
chromosomes O
. O

linkage O
of O
gene O
for O
c2 B-Disease
deficiency I-Disease
and O
the O
major O
histocompatibility O
complex O
mhc O
in O
man O
. O

close O
linkage O
between O
hl O
- O
a O
and O
c2 B-Disease
deficiency I-Disease
was O
first O
reported O
by O
fu O
and O
co O
- O
workers O
in O
1974 O
. O

we O
present O
here O
a O
pedigree O
of O
a O
31 O
- O
year O
- O
old O
c2 B-Disease
- I-Disease
deficient I-Disease
individual O
with O
clinical O
manifestations O
of O
hodgkins B-Disease
disease I-Disease
. O

in O
addition O
to O
close O
linkage O
between O
hl O
- O
a O
and O
c2 B-Disease
deficiency I-Disease
, O
both O
parents O
were O
heterozygous O
for O
bf O
( O
hl O
- O
a O
linked O
, O
electrophoretic O
variation O
of O
b O
) O
. O

the O
two O
hl O
- O
a O
haplotypes O
closely O
linked O
to O
c2 B-Disease
deficiency I-Disease
are O
different O
2 O
, O
w18 O
and O
w24 O
, O
w18 O
. O

screening O
for O
germ O
- O
line O
mutations O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
patients O
: O
61 O
new O
patients O
and O
a O
summary O
of O
150 O
unrelated O
patients O
. O

we O
report O
here O
the O
result O
of O
a O
screening O
for O
germ O
- O
line O
mutations O
in O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
in O
61 O
new O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
patients O
as O
well O
as O
a O
summary O
of O
the O
results O
of O
150 O
patients O
. O

examination O
of O
the O
entire O
coding O
region O
of O
the O
apc B-Disease
gene O
, O
based O
on O
a O
ribonuclease O
protection O
assay O
coupled O
with O
the O
polymerase O
chain O
reaction O
( O
pcr O
) O
, O
disclosed O
mutations O
that O
were O
considered O
to O
cause O
significant O
defects O
in O
the O
apc B-Disease
product O
in O
97 O
of O
150 O
unrelated O
fap B-Disease
patients O
. O

our O
findings O
revealed O
the O
following O
characteristics O
of O
the O
germ O
- O
line O
mutations O
of O
apc O
1 O
) O
the O
great O
majority O
of O
the O
mutations O
were O
found O
to O
truncate O
the O
apc B-Disease
product O
; O
2 O
) O
almost O
all O
of O
the O
mutations O
were O
located O
within O
the O
first O
half O
of O
the O
coding O
region O
; O
3 O
) O
no O
correlation O
was O
observed O
between O
the O
locations O
of O
germ O
- O
line O
mutations O
and O
extracolonic O
manifestations O
in O
fap B-Disease
patients O
; O
4 O
) O
more O
than O
80 O
% O
of O
base O
substitutions O
in O
the O
apc B-Disease
gene O
were O
from O
cytosine O
to O
other O
nucleotides O
, O
nearly O
one O
- O
third O
of O
which O
occurred O
at O
the O
gpg O
site O
. O

our O
results O
provide O
information O
helpful O
to O
an O
understanding O
of O
the O
apc B-Disease
gene O
and O
will O
also O
contribute O
to O
presymptomatic O
diagnosis O
of O
members O
in O
fap B-Disease
families O
. O

somatic O
mutations O
of O
the O
apc B-Disease
gene O
in O
colorectal B-Disease
tumors I-Disease
: O
mutation O
cluster O
region O
in O
the O
apc B-Disease
gene O
. O

we O
examined O
somatic O
mutations O
of O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
in O
63 O
colorectal B-Disease
tumors I-Disease
( O
16 O
adenomas B-Disease
and O
47 O
carcinomas B-Disease
) O
developed O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
and O
non O
- O
fap O
patients O
. O

in O
addition O
to O
loss O
of O
heterozygosity O
( O
loh O
) O
at O
the O
apc B-Disease
locus O
in O
30 O
tumors B-Disease
, O
43 O
other O
somatic O
mutations O
were O
detected O
. O

twenty O
- O
two O
tumors B-Disease
had O
frameshift O
mutations O
due O
to O
deletion O
or O
insertion O
; O
nineteen O
of O
them O
were O
deletions O
of O
one O
to O
31 O
bp O
and O
three O
were O
a O
1 O
- O
bp O
insertion O
. O

one O
tumor B-Disease
had O
a O
1 O
- O
bp O
deletion O
in O
an O
intron O
near O
the O
splicing O
site O
. O

hence O
, O
41 O
( O
95 O
% O
) O
of O
43 O
mutations O
resulted O
in O
truncation O
of O
the O
apc B-Disease
protein O
. O

over O
60 O
% O
of O
the O
somatic O
mutations O
in O
the O
apc B-Disease
gene O
were O
clustered O
within O
a O
small O
region O
of O
exon O
15 O
, O
designated O
as O
mcr O
( O
mutation O
cluster O
region O
) O
, O
which O
accounted O
for O
less O
than O
10 O
% O
of O
the O
coding O
region O
. O

combining O
these O
data O
and O
the O
results O
of O
loh O
, O
more O
than O
80 O
% O
of O
tumors B-Disease
( O
14 O
adenomas B-Disease
and O
39 O
carcinomas B-Disease
) O
had O
at O
least O
one O
mutation O
in O
the O
apc B-Disease
gene O
, O
of O
which O
more O
than O
60 O
% O
( O
9 O
adenomas B-Disease
and O
23 O
carcinomas B-Disease
) O
had O
two O
mutations O
. O

these O
results O
strongly O
suggest O
that O
somatic O
mutations O
of O
the O
apc B-Disease
gene O
are O
associated O
with O
development O
of O
a O
great O
majority O
of O
colorectal B-Disease
tumors I-Disease
. O

constitutional O
mutations O
in O
the O
wt1 O
gene O
in O
patients O
with O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
. O

the O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
is O
characterised O
by O
a O
typical O
nephropathy B-Disease
, O
genital B-Disease
abnormalities I-Disease
and O
also O
predisposes O
to O
the O
development O
of O
wilms B-Disease
tumor I-Disease
. O

these O
patients O
eventually O
go O
into O
end O
stage O
renal B-Disease
failure I-Disease
. O

a O
candidate O
wilms B-Disease
tumor I-Disease
gene O
, O
wt1 O
, O
from O
the O
11p13 O
chromosome O
region O
has O
recently O
been O
cloned O
. O

linkage O
disequilibrium O
mapping O
in O
isolated O
founder O
populations O
: O
diastrophic B-Disease
dysplasia I-Disease
in O
finland O
. O

using O
these O
methods O
, O
we O
report O
striking O
linkage O
disequilibrium O
for O
diastrophic B-Disease
dysplasia I-Disease
( O
dtd B-Disease
) O
in O
finland O
indicating O
that O
the O
dtd B-Disease
gene O
should O
lie O
within O
0 O
. O

the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
: O
refinement O
of O
the O
localization O
on O
xp O
and O
identification O
of O
another O
closely O
linked O
marker O
locus O
, O
oatl1 O
. O

the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
has O
previously O
been O
mapped O
to O
the O
proximal O
short O
arm O
of O
the O
x O
chromosome O
between O
the O
dxs14 O
and O
dxs7 O
loci O
. O

in O
this O
study O
, O
further O
segregation O
analysis O
has O
been O
performed O
using O
a O
newly O
identified O
was B-Disease
family O
as O
well O
as O
an O
additional O
marker O
probe O
, O
hoatl1 O
. O

the O
results O
indicate O
close O
linkage O
between O
the O
was B-Disease
and O
oatl1 O
loci O
( O
z O
= O
6 O
. O
08 O
at O
theta O
= O
0 O
. O
00 O
) O
and O
localize O
the O
timp O
, O
oatl1 O
, O
dxs255 O
, O
and O
was B-Disease
loci O
distal O
to O
dxs146 O
and O
the O
oatl1 O
and O
was B-Disease
loci O
proximal O
to O
timp O
. O

these O
linkage O
data O
narrow O
the O
boundaries O
within O
which O
the O
was B-Disease
locus O
maps O
to O
the O
chromosomal O
region O
bracketed O
by O
timp O
and O
dxs146 O
and O
support O
the O
loci O
order O
xpter O
- O
dxs7 O
- O
timp O
- O
( O
oatl1 O
, O
was O
, O
dxs255 O
) O
- O
dxs146 O
. O

detection O
of O
an O
unstable O
fragment O
of O
dna O
specific O
to O
individuals O
with O
myotonic B-Disease
dystrophy I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
dystrophy I-Disease
, O
with O
a O
prevalence O
of O
2 O
- O
14 O
per O
100 O
, O
000 O
individuals O
. O

the O
disease O
is O
characterized O
by O
progressive O
muscle B-Disease
weakness I-Disease
and O
sustained B-Disease
muscle I-Disease
contraction I-Disease
, O
often O
with O
a O
wide O
range O
of O
accompanying O
symptoms O
. O

it O
is O
flanked O
by O
the O
tightly O
linked O
genetic O
markers O
ercc1 O
proximally O
and O
d19s51 O
distally O
; O
these O
define O
the O
dm B-Disease
critical O
region O
. O

to O
learn O
about O
causative O
mechanisms O
, O
we O
have O
cloned O
and O
sequenced O
the O
breakpoints O
of O
a O
cytologically O
balanced O
constitutional O
reciprocal O
translocation O
, O
t O
( O
x O
; O
4 O
) O
( O
p21 O
. O
2 O
; O
q31 O
. O
22 O
) O
, O
present O
in O
a O
girl O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

a O
genetic O
etiology O
for O
digeorge B-Disease
syndrome I-Disease
: O
consistent O
deletions O
and O
microdeletions O
of O
22q11 O
. O

digeorge B-Disease
syndrome I-Disease
( O
dgs B-Disease
) O
, O
a O
developmental O
field O
defect O
of O
the O
third O
and O
fourth O
pharyngeal O
pouches O
, O
is O
characterized O
by O
aplasia B-Disease
or I-Disease
hypoplasia I-Disease
of I-Disease
the I-Disease
thymus I-Disease
and I-Disease
parathyroid I-Disease
glands I-Disease
and O
by O
conotruncal B-Disease
cardiac I-Disease
malformations I-Disease
. O

in O
the O
present O
study O
, O
we O
report O
the O
results O
of O
clinical O
, O
cytogenetic O
, O
and O
molecular O
studies O
of O
14 O
patients O
with O
dgs B-Disease
. O

a O
third O
locus O
, O
d22s66 O
, O
is O
deleted O
in O
the O
eight O
dgs B-Disease
probands O
tested O
. O

on O
the O
basis O
of O
these O
families O
, O
and O
of O
six O
maternally O
and O
five O
paternally O
derived O
unbalanced O
- O
translocation O
dgs B-Disease
probands O
in O
the O
literature O
, O
parent O
of O
origin O
or O
imprinting O
does O
not O
appear O
to O
play O
an O
important O
role O
in O
the O
pathogenesis O
of O
dgs B-Disease
. O

deletion O
of O
the O
same O
three O
loci O
in O
all O
14 O
dgs B-Disease
probands O
begins O
to O
delineate O
the O
region O
of O
chromosome O
22 O
critical O
for O
dgs B-Disease
and O
confirms O
the O
hypothesis O
that O
submicroscopic O
deletions O
of O
22q11 O
are O
etiologic O
in O
the O
vast O
majority O
of O
cases O
. O
. O

loss O
of O
normal O
allele O
of O
the O
apc B-Disease
gene O
in O
an O
adrenocortical B-Disease
carcinoma I-Disease
from O
a O
patient O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
. O

endocrine B-Disease
neoplasms I-Disease
have O
been O
reported O
occasionally O
in O
patients O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
. O

an O
adrenocorotical B-Disease
carcinoma I-Disease
was O
studied O
in O
a O
patient O
with O
a O
family O
history O
of O
fap B-Disease
. O

loss O
of O
heterozygosity O
( O
loh O
) O
in O
the O
region O
close O
to O
the O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
was O
detected O
in O
this O
carcinoma B-Disease
, O
and O
evidence O
was O
obtained O
that O
there O
was O
a O
loss O
of O
the O
normal O
allele O
of O
the O
apc B-Disease
gene O
. O

this O
is O
the O
first O
demonstration O
of O
loh O
at O
the O
apc B-Disease
locus O
in O
adrenocortical B-Disease
tumors I-Disease
. O

the O
present O
results O
and O
our O
previous O
data O
on O
loh O
in O
a O
recurring O
desmoid B-Disease
tumor I-Disease
suggest O
that O
the O
heterozygous O
mutant O
/ O
wild O
- O
type O
condition O
of O
the O
apc B-Disease
gene O
may O
give O
rise O
to O
benign B-Disease
tumors I-Disease
, O
and O
that O
functional O
loss O
of O
this O
gene O
leads O
to O
development O
of O
tumors B-Disease
not O
only O
in O
the O
colon O
but O
also O
in O
other O
various O
parts O
of O
the O
body O
in O
fap B-Disease
patients O
. O
. O

oncogenic O
point O
mutations O
in O
exon O
20 O
of O
the O
rb1 O
gene O
in O
families O
showing O
incomplete O
penetrance O
and O
mild O
expression O
of O
the O
retinoblastoma B-Disease
phenotype O
. O

the O
retinoblastoma B-Disease
- O
predisposition O
gene O
, O
rb1 O
, O
segregates O
as O
an O
autosomal O
dominant O
trait O
with O
high O
( O
90 O
% O
) O
penetrance O
. O

certain O
families O
, O
however O
, O
show O
an O
unusual O
low O
- O
penetrance O
phenotype O
with O
many O
individuals O
being O
unaffected O
, O
unilaterally O
affected O
, O
or O
with O
evidence O
of O
spontaneously O
regressed O
tumors B-Disease
. O

late O
- O
onset O
metachromatic B-Disease
leukodystrophy I-Disease
: O
molecular O
pathology O
in O
two O
siblings O
. O

we O
report O
on O
a O
new O
allele O
at O
the O
arylsulfatase O
a O
( O
arsa O
) O
locus O
causing O
late O
- O
onset O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
. O

in O
contrast O
to O
alleles O
that O
cause O
early O
- O
onset O
mld B-Disease
, O
the O
arginine84 O
to O
glutamine O
substitution O
is O
associated O
with O
some O
residual O
arsa O
activity O
. O

a O
comparison O
of O
genotypes O
, O
arsa O
activities O
, O
and O
clinical O
data O
on O
4 O
individuals O
carrying O
the O
allele O
of O
81 O
patients O
with O
mld B-Disease
examined O
, O
further O
validates O
the O
concept O
that O
different O
degrees O
of O
residual O
arsa O
activity O
are O
the O
basis O
of O
phenotypical O
variation O
in O
mld B-Disease
. O
. O

trisomy B-Disease
15 I-Disease
with O
loss O
of O
the O
paternal O
15 O
as O
a O
cause O
of O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
due O
to O
maternal B-Disease
disomy I-Disease
. O

uniparental B-Disease
disomy I-Disease
has O
recently O
been O
recognized O
to O
cause O
human O
disorders O
, O
including O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

we O
describe O
a O
particularly O
instructive O
case O
which O
raises O
important O
issues O
concerning O
the O
mechanisms O
producing O
uniparental B-Disease
disomy I-Disease
and O
whose O
evaluation O
provides O
evidence O
that O
trisomy O
may O
precede O
uniparental B-Disease
disomy I-Disease
in O
a O
fetus O
. O

chorionic O
villus O
sampling O
performed O
for O
advanced O
maternal O
age O
revealed O
trisomy B-Disease
15 I-Disease
in O
all O
direct O
and O
cultured O
cells O
, O
though O
the O
fetus O
appeared O
normal O
. O

the O
child O
was O
hypotonic B-Disease
at O
birth O
, O
and O
high O
- O
resolution O
banding O
failed O
to O
reveal O
the O
deletion O
of O
15q11 O
- O
13 O
, O
a O
deletion O
which O
is O
found O
in O
50 O
% O
- O
70 O
% O
of O
patients O
with O
pws B-Disease
. O

over O
time O
, O
typical O
features O
of O
pws B-Disease
developed O
. O

maternal O
nondisjunction O
with O
fertilization O
of O
a O
disomic O
egg O
by O
a O
normal O
sperm O
, O
followed O
by O
loss O
of O
the O
paternal O
15 O
, O
is O
a O
likely O
cause O
of O
confined O
placental O
mosaicism O
and O
uniparental B-Disease
disomy I-Disease
in O
this O
case O
of O
pws B-Disease
, O
and O
advanced O
maternal O
age O
may O
be O
a O
predisposing O
factor O
. O

genetic O
heterogeneity O
in O
x B-Disease
- I-Disease
linked I-Disease
amelogenesis I-Disease
imperfecta I-Disease
. O

3 O
encodes O
for O
the O
enamel O
protein O
amelogenin O
and O
has O
been O
implicated O
as O
the O
gene O
responsible O
for O
the O
inherited B-Disease
dental I-Disease
abnormality I-Disease
x B-Disease
- I-Disease
linked I-Disease
amelogenesis I-Disease
imperfecta I-Disease
( O
xai B-Disease
) O
. O

three O
families O
with O
xai B-Disease
have O
been O
investigated O
using O
polymorphic O
dna O
markers O
flanking O
the O
position O
of O
amelx O
. O

using O
two O
- O
point O
linkage O
analysis O
, O
linkage O
was O
established O
between O
xai B-Disease
and O
several O
of O
these O
markers O
in O
two O
families O
, O
with O
a O
combined O
lod O
score O
of O
6 O
. O

this O
supports O
the O
involvement O
of O
amelx O
, O
located O
close O
to O
dxs16 O
, O
in O
the O
xai B-Disease
disease I-Disease
process O
( O
aih1 O
) O
in O
those O
families O
. O

using O
multipoint O
linkage O
analysis O
, O
the O
combined O
maximum O
lod O
score O
for O
these O
two O
families O
was O
7 O
. O

there O
was O
significant O
evidence O
against O
linkage O
to O
this O
region O
in O
the O
third O
family O
, O
indicating O
locus O
heterogeneity O
in O
xai B-Disease
. O

multiple O
origins O
for O
phenylketonuria B-Disease
in O
europe O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
, O
a O
disorder B-Disease
of I-Disease
amino I-Disease
acid I-Disease
metabolism I-Disease
prevalent O
among O
caucasians O
and O
other O
ethnic O
groups O
, O
is O
caused O
primarily O
by O
a O
deficiency B-Disease
of I-Disease
the I-Disease
hepatic I-Disease
enzyme I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

pku B-Disease
is O
a O
highly O
heterogeneous O
disorder O
, O
with O
more O
than O
60 O
molecular O
lesions O
identified O
in O
the O
pah O
gene O
. O

the O
haplotype O
associations O
, O
relative O
frequencies O
, O
and O
distributions O
of O
five O
prevalent O
pah O
mutations O
( O
r158q O
, O
r261q O
, O
ivs10nt546 O
, O
r408w O
, O
and O
ivs12n1 O
) O
were O
established O
in O
a O
comprehensive O
european O
sample O
population O
and O
subsequently O
were O
examined O
to O
determine O
the O
potential O
roles O
of O
several O
genetic O
mechanisms O
in O
explaining O
the O
present O
distribution O
of O
the O
major O
pku B-Disease
alleles O
. O

together O
, O
these O
data O
suggest O
that O
there O
were O
multiple O
, O
geographically O
and O
ethnically O
distinct O
origins O
for O
pku B-Disease
within O
the O
european O
population O
. O

complement B-Disease
factor I-Disease
2 I-Disease
deficiency I-Disease
: O
a O
clinical O
and O
serological O
family O
study O
. O

inherited B-Disease
complement I-Disease
deficiencies I-Disease
are O
associated O
with O
a O
variety O
of O
connective O
tissue O
diseases O
. O

a O
family O
with O
inherited B-Disease
deficiency I-Disease
of I-Disease
complement I-Disease
factor I-Disease
2 I-Disease
( O
c2 O
) O
is O
described O
in O
which O
two O
family O
members O
with O
homozygous O
c2 B-Disease
deficiency I-Disease
developed O
cutaneous B-Disease
vasculitis I-Disease
and O
sicca B-Disease
syndrome I-Disease
. O

the O
other O
family O
members O
had O
heterozygous O
c2 B-Disease
deficiency I-Disease
and O
each O
member O
had O
the O
hla O
- O
a25 O
, O
b18 O
, O
dr2 O
( O
w15 O
) O
haplotype O
. O

the O
mother O
had O
seropositive B-Disease
rheumatoid I-Disease
arthritis I-Disease
. O

new O
variant O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
( O
plp O
) O
gene O
in O
a O
family O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

a O
c O
- O
- O
greater O
than O
g O
transversion O
has O
been O
found O
in O
exon O
3 O
of O
the O
plp O
gene O
of O
affected O
males O
and O
their O
mother O
in O
a O
single O
sibship O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
. O

the O
cause O
of O
disease O
in O
this O
family O
remains O
unknown O
, O
but O
the O
association O
between O
this O
rare O
mutation O
and O
pmd B-Disease
is O
intriguing O
. O

uncoupling O
of O
hypomyelination B-Disease
and O
glial B-Disease
cell I-Disease
death I-Disease
by O
a O
mutation O
in O
the O
proteolipid O
protein O
gene O
. O

neurological O
mutant O
mice O
can O
often O
provide O
model O
systems O
for O
human O
genetic B-Disease
disorders I-Disease
. O

mutations O
of O
the O
x O
- O
chromosome O
- O
linked O
plp O
gene O
are O
lethal O
, O
identified O
first O
in O
the O
jimpy O
mouse O
and O
subsequently O
in O
patients O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

the O
unexplained O
phenotype O
of O
these O
mutations O
includes O
degeneration B-Disease
and I-Disease
premature I-Disease
cell I-Disease
death I-Disease
of I-Disease
oligodendrocytes I-Disease
with O
associated O
hypomyelination B-Disease
. O

surprisingly O
, O
rumpshaker O
mice O
, O
although O
myelin B-Disease
- I-Disease
deficient I-Disease
, O
have O
normal O
longevity O
and O
a O
full O
complement O
of O
morphologically O
normal O
oligodendrocytes O
. O

hypomyelination B-Disease
can O
thus O
be O
genetically O
separated O
from O
the O
plp O
- O
dependent O
oligodendrocyte B-Disease
degeneration I-Disease
. O

we O
suggest O
that O
plp O
has O
a O
vital O
function O
in O
glial O
cell O
development O
, O
distinct O
from O
its O
later O
role O
in O
myelin O
assembly O
, O
and O
that O
this O
dichotomy O
of O
action O
may O
explain O
the O
clinical O
spectrum O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

a O
pseudodeficiency O
allele O
common O
in O
non O
- O
jewish O
tay B-Disease
- I-Disease
sachs I-Disease
carriers O
: O
implications O
for O
carrier O
screening O
. O

deficiency B-Disease
of I-Disease
beta I-Disease
- I-Disease
hexosaminidase I-Disease
a I-Disease
( O
hex O
a O
) O
activity O
typically O
results O
in O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
. O

however O
, O
healthy O
subjects O
found O
to O
be O
deficient B-Disease
in I-Disease
hex I-Disease
a I-Disease
activity O
( O
i O
. O
e O
. O
, O
pseudodeficient O
) O
by O
means O
of O
in O
vitro O
biochemical O
tests O
have O
been O
described O
. O

we O
analyzed O
the O
hexa O
gene O
of O
one O
pseudodeficient O
subject O
and O
identified O
both O
a O
c739 O
- O
to O
- O
t O
substitution O
that O
changes O
arg247 O
- O
- O
- O
- O
trp O
on O
one O
allele O
and O
a O
previously O
identified O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
mutation O
on O
the O
second O
allele O
. O

this O
allele O
accounted O
for O
32 O
% O
( O
20 O
/ O
62 O
) O
of O
non O
- O
jewish O
enzyme O
- O
defined O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
carriers O
but O
for O
none O
of O
36 O
jewish O
enzyme O
- O
defined O
carriers O
who O
did O
not O
have O
one O
of O
three O
known O
mutations O
common O
to O
this O
group O
. O

the O
c739 O
- O
to O
- O
t O
allele O
, O
together O
with O
a O
" O
true O
" O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
allele O
, O
causes O
hex O
a O
pseudodeficiency O
. O

given O
both O
the O
large O
proportion O
of O
non O
- O
jewish O
carriers O
with O
this O
allele O
and O
that O
standard O
biochemical O
screening O
cannot O
differentiate O
between O
heterozygotes O
for O
the O
c739 O
- O
to O
- O
t O
mutations O
and O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
carriers O
, O
dna O
testing O
for O
this O
mutation O
in O
at O
- O
risk O
couples O
is O
essential O
. O

pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
: O
detection O
of O
mutations O
thr181 O
- O
- O
- O
- O
pro O
and O
leu223 O
- O
- O
- O
- O
pro O
in O
the O
proteolipid O
protein O
gene O
, O
and O
prenatal O
diagnosis O
. O

a O
family O
with O
an O
apparent O
history O
of O
x O
- O
linked O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
presented O
for O
genetic O
counseling O
, O
requesting O
carrier O
detection O
and O
prenatal O
diagnosis O
. O

these O
results O
provide O
further O
examples O
of O
mutations O
in O
plp O
that O
cause O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
and O
illustrate O
the O
value O
of O
sscp O
in O
genetic O
analysis O
. O

von B-Disease
willebrand I-Disease
disease I-Disease
type I-Disease
b I-Disease
: O
a O
missense O
mutation O
selectively O
abolishes O
ristocetin O
- O
induced O
von B-Disease
willebrand I-Disease
factor O
binding O
to O
platelet O
glycoprotein O
ib O
. O

von B-Disease
willebrand I-Disease
factor O
( O
vwf O
) O
is O
a O
multimeric O
glycoprotein O
that O
mediates O
the O
adhesion O
of O
platelets O
to O
the O
subendothelium O
by O
binding O
to O
platelet O
glycoprotein O
ib O
. O

a O
missense O
mutation O
, O
gly O
- O
561 O
- O
- O
> O
ser O
, O
was O
identified O
within O
the O
proposed O
glycoprotein O
ib O
binding O
domain O
of O
vwf O
in O
the O
proband O
with O
von B-Disease
willebrand I-Disease
disease I-Disease
type I-Disease
b I-Disease
, O
a O
unique O
variant O
characterized O
by O
no O
ristocetin O
- O
induced O
, O
but O
normal O
botrocetin O
- O
induced O
, O
binding O
to O
glycoprotein O
ib O
. O

the O
corresponding O
mutant O
recombinant O
protein O
, O
rvwf O
( O
g561s O
) O
, O
formed O
normal O
multimers O
and O
exhibited O
the O
same O
functional O
defect O
as O
the O
patients O
plasma O
vwf O
, O
confirming O
that O
this O
mutation O
causes O
von B-Disease
willebrand I-Disease
disease I-Disease
type I-Disease
b I-Disease
. O

the O
normal O
botrocetin O
- O
induced O
binding O
and O
the O
defective O
ristocetin O
- O
induced O
binding O
of O
rvwf O
( O
g561s O
) O
suggest O
that O
the O
primary O
defect O
in O
von B-Disease
willebrand I-Disease
disease I-Disease
type I-Disease
b I-Disease
may O
be O
a O
failure O
of O
normal O
allosteric O
regulation O
of O
the O
glycoprotein O
ib O
binding O
function O
of O
vwf O
. O

typical O
and O
partial O
cat B-Disease
eye I-Disease
syndrome I-Disease
: O
identification O
of O
the O
marker O
chromosome O
by O
fish O
. O

three O
children O
are O
reported O
with O
typical O
cat B-Disease
eye I-Disease
syndrome I-Disease
( O
ces B-Disease
) O
and O
three O
more O
children O
with O
partial O
ces B-Disease
because O
of O
absence O
of O
coloboma O
, O
in O
which O
the O
supernumerary O
marker O
chromosome O
was O
studied O
by O
fish O
. O

using O
a O
genomic O
library O
, O
and O
also O
a O
centromeric O
and O
particularly O
a O
cosmid O
probe O
of O
22q11 O
, O
partial O
tetrasomy B-Disease
was O
shown O
in O
all O
cases O
. O
. O

[ O
genetic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
: O
mutant O
alleles O
of O
g6pd O
in O
the O
shekii O
district O
of O
azerbaijan O
] O

examination O
on O
g6pd B-Disease
deficiency I-Disease
in O
349 O
patients O
of O
shekii O
district O
hospital O
( O
azerbaijan O
) O
revealed O
16 O
hemi O
- O
, O
4 O
homo O
- O
and O
9 O
heterozygotic O
carriers O
of O
the O
defect O
. O

carriers O
of O
g6pd B-Disease
deficiency I-Disease
are O
residents O
of O
11 O
villages O
located O
in O
alasani O
- O
aphtalan O
valley O
, O
highly O
endemic O
with O
malaria B-Disease
in O
the O
past O
; O
nearly O
all O
marriages O
are O
endogamic O
. O

craniofrontonasal B-Disease
dysplasia I-Disease
. O

we O
report O
on O
nine O
patients O
with O
craniofrontonasal B-Disease
dysplasia I-Disease
( O
cfnd B-Disease
) O
. O

seven O
classical O
cases O
had O
facial O
features O
suggestive O
of O
frontonasal B-Disease
dysplasia I-Disease
and O
coronal B-Disease
craniosynostosis I-Disease
. O

extracranial B-Disease
abnormalities I-Disease
such O
as O
brittle B-Disease
nails I-Disease
with I-Disease
prominent I-Disease
longitudinal I-Disease
grooves I-Disease
or O
syndactyly B-Disease
of I-Disease
fingers I-Disease
and I-Disease
toes I-Disease
were O
observed O
in O
individual O
patients O
. O

hypotonia B-Disease
and O
laxity B-Disease
of I-Disease
joints I-Disease
are O
common O
and O
may O
necessitate O
supportive O
measures O
. O

mild O
developmental B-Disease
delay I-Disease
was O
noted O
in O
three O
out O
of O
six O
classical O
cases O
studied O
in O
detail O
. O

unlike O
almost O
all O
other O
x B-Disease
- I-Disease
linked I-Disease
disorders I-Disease
, O
clinical O
expression O
in O
cfnd B-Disease
is O
generally O
much O
more O
severe O
in O
females O
than O
in O
males O
. O

the O
intron O
7 O
donor O
splice O
site O
transition O
: O
a O
second O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
mutation O
in O
french O
canada O
. O

mutations O
at O
the O
hexosaminidase O
a O
( O
hexa O
) O
gene O
which O
cause O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
have O
elevated O
frequency O
in O
the O
ashkenazi O
jewish O
and O
french O
- O
canadian O
populations O
. O

we O
report O
a O
novel O
tsd B-Disease
allele O
in O
the O
french O
- O
canadian O
population O
associated O
with O
the O
infantile O
form O
of O
the O
disease O
. O

the O
intron O
7 O
+ O
1 O
mutation O
occurs O
in O
the O
base O
adjacent O
to O
the O
site O
of O
the O
adult O
- O
onset O
tsd B-Disease
mutation O
( O
g805a O
) O
. O

this O
mutation O
thus O
has O
a O
different O
geographic O
centre O
of O
diffusion O
and O
is O
probably O
less O
common O
than O
the O
exon O
1 O
deletion O
tsd B-Disease
mutation O
in O
french O
canadians O
. O

aspartylglucosaminuria B-Disease
( O
agu B-Disease
) O
is O
a O
recessive O
autosomally O
inherited O
lysosomal B-Disease
storage I-Disease
disorder I-Disease
due O
to O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
aspartylglucosaminidase I-Disease
( O
aga O
) O
. O

resolution O
of O
the O
two O
loci O
for O
autosomal O
dominant O
aniridia B-Disease
, O
an1 O
and O
an2 O
, O
to O
a O
single O
locus O
on O
chromosome O
11p13 O
. O

two O
distinct O
loci O
have O
been O
proposed O
for O
aniridia B-Disease
; O
an1 O
for O
autosomal O
dominant O
aniridia B-Disease
on O
chromosome O
2p O
and O
an2 O
for O
the O
aniridia B-Disease
in O
the O
wagr B-Disease
contiguous I-Disease
gene I-Disease
syndrome I-Disease
on O
chromosome O
11p13 O
. O

in O
this O
report O
, O
the O
kindred O
segregating O
for O
autosomal O
dominant O
aniridia B-Disease
, O
which O
suggested O
linkage O
to O
acid O
phosphatase O
- O
1 O
( O
acp1 O
) O
and O
led O
to O
the O
assignment O
of O
the O
an1 O
locus O
on O
chromosome O
2p O
, O
has O
been O
updated O
and O
expanded O
. O

linkage O
analysis O
between O
the O
aniridia B-Disease
phenotype O
and O
acp1 O
does O
not O
support O
the O
original O
linkage O
results O
, O
excluding O
linkage O
up O
to O
theta O
= O
0 O
. O

apob O
, O
d2s71 O
, O
d2s5 O
, O
and O
d2s1 O
, O
also O
excluded O
linkage O
to O
aniridia B-Disease
. O

markers O
that O
have O
been O
isolated O
from O
the O
chromosome O
11p13 O
region O
were O
then O
analyzed O
in O
this O
aniridia B-Disease
family O
. O

these O
data O
suggest O
that O
a O
locus O
for O
aniridia B-Disease
( O
an1 O
) O
on O
chromosome O
2p O
has O
been O
misassigned O
and O
that O
this O
autosomal O
dominant O
aniridia B-Disease
family O
is O
segregating O
for O
an O
aniridia B-Disease
mutation O
linked O
to O
markers O
in O
the O
11p13 O
region O
. O

fatal O
pyoderma B-Disease
gangrenosum I-Disease
in O
association O
with O
c7 B-Disease
deficiency I-Disease
. O

although O
pyoderma B-Disease
gangrenosum I-Disease
( O
pg B-Disease
) O
is O
often O
associated O
with O
systemic B-Disease
diseases I-Disease
, O
it O
has O
not O
been O
reported O
in O
association O
with O
congenital B-Disease
complement I-Disease
deficiencies I-Disease
. O

we O
describe O
an O
aggressive O
and O
ultimately O
fatal O
case O
of O
pg B-Disease
in O
a O
patient O
with O
a O
congenital O
c7 B-Disease
deficiency I-Disease
. O

deficiencies B-Disease
of I-Disease
c7 I-Disease
can O
be O
associated O
with O
decreased O
neutrophil O
chemotaxis O
, O
phagocytosis O
, O
and O
opsonization O
, O
similar O
to O
the O
immunologic B-Disease
abnormalities I-Disease
described O
in O
patients O
with O
pg B-Disease
. O

our O
patients O
decreased O
complement O
level O
, O
if O
not O
directly O
related O
to O
the O
development O
of O
pg B-Disease
, O
may O
have O
contributed O
to O
the O
aggressive O
nature O
of O
her O
disease O
. O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
; I-Disease
ec I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
the O
most O
common O
human O
enzymopathy B-Disease
, O
affecting O
more O
than O
200 O
million O
people O
worldwide O
. O

although O
greater O
than O
400 O
variants O
have O
been O
described O
based O
on O
clinical O
and O
biochemical O
criteria O
, O
little O
is O
known O
about O
the O
molecular O
basis O
of O
these O
g6pd B-Disease
deficiencies I-Disease
. O

the O
1376 O
g O
- O
- O
- O
- O
t O
mutation O
seems O
to O
be O
the O
dominant O
allele O
that O
causes O
g6pd B-Disease
deficiency I-Disease
in O
taiwan O
. O

our O
studies O
provide O
the O
direct O
proof O
of O
the O
genetic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
in O
the O
chinese O
populations O
of O
taiwan O
and O
the O
pcr O
/ O
re O
digestion O
method O
is O
suitable O
for O
simultaneous O
detection O
of O
the O
487 O
g O
- O
- O
- O
- O
a O
and O
493 O
a O
- O
- O
- O
- O
g O
mutations O
. O

an O
error O
in O
dystrophin O
mrna O
processing O
in O
golden B-Disease
retriever I-Disease
muscular I-Disease
dystrophy I-Disease
, O
an O
animal O
homologue O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
. O

golden B-Disease
retriever I-Disease
muscular I-Disease
dystrophy I-Disease
( O
grmd B-Disease
) O
is O
a O
spontaneous O
, O
x O
- O
linked O
, O
progressively O
fatal O
disease O
of O
dogs O
and O
is O
also O
a O
homologue O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

analysis O
of O
the O
canine O
dystrophin O
gene O
in O
normal O
and O
grmd B-Disease
dogs O
has O
failed O
to O
demonstrate O
any O
detectable O
loss O
of O
exons O
. O

here O
, O
we O
have O
demonstrated O
a O
rna O
processing O
error O
in O
grmd B-Disease
that O
results O
from O
a O
single O
base O
change O
in O
the O
3 O
consensus O
splice O
site O
of O
intron O
6 O
. O

this O
is O
the O
first O
example O
of O
dystrophin B-Disease
deficiency I-Disease
caused O
by O
a O
splice O
- O
site O
mutation O
. O

type B-Disease
i I-Disease
human I-Disease
complement I-Disease
c2 I-Disease
deficiency I-Disease
. O

two O
variants O
of O
a O
genetic O
deficiency B-Disease
of I-Disease
complement I-Disease
protein I-Disease
c2 I-Disease
( O
c2d O
) O
have O
been O
previously O
identified O
. O

type B-Disease
i I-Disease
c2 I-Disease
deficiency I-Disease
was O
described O
in O
a O
family O
in O
which O
the O
c2 O
null O
allele O
( O
c2q0 O
) O
is O
associated O
with O
the O
major O
histocompatibility O
haplotype O
/ O
complotype O
hla O
- O
a25 O
, O
b18 O
, O
c2q0 O
, O
bfs O
, O
c4a4 O
, O
c4b2 O
, O
drw2 O
; O
this O
extended O
haplotype O
occurs O
in O
over O
90 O
% O
of O
c2 B-Disease
- I-Disease
deficient I-Disease
individuals O
( O
common O
complotype O
/ O
haplotype O
) O
. O

to O
determine O
the O
molecular O
basis O
of O
type B-Disease
i I-Disease
c2 I-Disease
deficiency I-Disease
, O
the O
c2 O
gene O
and O
cdna O
were O
characterized O
from O
a O
homozygous O
type B-Disease
i I-Disease
c2 I-Disease
- I-Disease
deficient I-Disease
individual O
with O
the O
common O
associated O
haplotype O
/ O
complotype O
. O

in O
studies O
of O
eight O
kindred O
, O
the O
28 O
- O
base O
pair O
deletion O
was O
observed O
in O
all O
c2q0 O
alleles O
associated O
with O
the O
common O
type O
i O
deficient O
complotype O
/ O
haplotype O
; O
this O
deletion O
was O
not O
present O
in O
normal O
c2 O
nor O
in O
type B-Disease
ii I-Disease
c2 I-Disease
- I-Disease
deficient I-Disease
genes O
. O

these O
data O
demonstrate O
that O
1 O
) O
type B-Disease
i I-Disease
human I-Disease
complement I-Disease
c2 I-Disease
deficiency I-Disease
is O
caused O
by O
a O
28 O
- O
base O
pair O
genomic O
deletion O
that O
causes O
skipping O
of O
exon O
6 O
during O
rna O
splicing O
, O
resulting O
in O
generation O
of O
a O
premature O
termination O
codon O
, O
2 O
) O
the O
28 O
- O
base O
pair O
deletion O
in O
the O
type O
i O
c2q0 O
gene O
is O
strongly O
associated O
with O
the O
hla O
haplotype O
/ O
complotype O
a25 O
, O
b18 O
, O
c2q0 O
, O
bfs O
, O
c4a4 O
, O
c4b2 O
, O
drw2 O
, O
suggesting O
that O
all O
c2 B-Disease
- I-Disease
deficient I-Disease
individuals O
with O
this O

haplotype O
/ O
complotype O
will O
harbor O
the O
28 O
- O
base O
pair O
c2 O
gene O
deletion O
, O
and O
3 O
) O
type B-Disease
ii I-Disease
c2 I-Disease
deficiency I-Disease
is O
caused O
by O
a O
different O
, O
as O
yet O
uncharacterized O
, O
molecular O
genetic B-Disease
defect I-Disease
. O
. O

molecular O
characterization O
of O
two O
galactosemia B-Disease
mutations O
and O
one O
polymorphism O
: O
implications O
for O
structure O
- O
function O
analysis O
of O
human O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
. O

we O
report O
here O
the O
molecular O
characterization O
of O
two O
galactosemia B-Disease
mutations O
, O
l74p O
and O
f171s O
, O
and O
one O
polymorphism O
, O
s135l O
, O
in O
human O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
galt O
) O
. O

both O
galactosemia B-Disease
mutations O
result O
in O
reduced O
enzymatic O
activity O
when O
reconstructed O
in O
the O
cdna O
and O
overexpressed O
. O

our O
data O
further O
support O
the O
notion O
of O
molecular O
heterogeneity O
of O
galactosemia B-Disease
and O
suggest O
that O
galactosemia B-Disease
mutations O
and O
galt O
polymorphisms O
may O
be O
useful O
tools O
in O
highlighting O
different O
functional O
domains O
in O
human O
galt O
. O
. O

linkage O
relationship O
of O
c2 B-Disease
deficiency I-Disease
, O
hla O
and O
glyoxalase O
i O
loci O
. O

immunogenetic O
analysis O
of O
a O
homozygous O
c2 B-Disease
- I-Disease
deficient I-Disease
individual O
and O
family O
members O
demonstrated O
linkage O
of O
hla O
- O
a25 O
, O
b18 O
and O
c2o O
. O

hla O
- O
d O
typing O
showed O
that O
5 O
members O
typed O
with O
homozygous O
dw2 O
typing O
cells O
from O
an O
individual O
with O
c2 B-Disease
deficiency I-Disease
but O
not O
with O
dw2 O
typing O
cells O
from O
2 O
individuals O
with O
normal O
c2 O
. O

the O
homozygous O
c2 B-Disease
- I-Disease
deficient I-Disease
propositus O
and O
brother O
were O
hla O
- O
a O
and O
b O
homozygous O
but O
heterozygous O
at O
the O
hla O
- O
d O
and O
glyoxalase O
i O
loci O
. O

germline O
mutations O
in O
the O
wilms B-Disease
' I-Disease
tumor I-Disease
suppressor O
gene O
are O
associated O
with O
abnormal O
urogenital O
development O
in O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
. O

denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
is O
a O
rare O
human O
condition O
in O
which O
severe O
urogenital B-Disease
aberrations I-Disease
result O
in O
renal B-Disease
failure I-Disease
, O
pseudohermaphroditism B-Disease
, O
and O
wilms B-Disease
tumor I-Disease
( O
nephroblastoma B-Disease
) O
. O

to O
investigate O
its O
possible O
role O
, O
we O
have O
analyzed O
the O
coding O
exons O
of O
the O
wilms B-Disease
tumor I-Disease
suppressor O
gene O
( O
wt1 O
) O
for O
germline O
mutations O
. O

in O
ten O
independent O
cases O
of O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
, O
point O
mutations O
in O
the O
zinc O
finger O
domains O
of O
one O
wt1 O
gene O
copy O
were O
found O
. O

wilms B-Disease
tumors I-Disease
from O
three O
individuals O
and O
one O
juvenile O
granulosa O
cell O
tumor B-Disease
demonstrate O
reduction O
to O
homozygosity O
for O
the O
mutated O
wt1 O
allele O
. O

our O
results O
provide O
evidence O
of O
a O
direct O
role O
for O
wt1 O
in O
denys B-Disease
- I-Disease
drash I-Disease
syndrome I-Disease
and O
thus O
urogenital O
system O
development O
. O

linkage O
analysis O
in O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
and O
application O
in O
post O
- O
and O
prenatal O
diagnosis O
. O

we O
have O
performed O
linkage O
analysis O
with O
the O
dna O
markers O
dxs52 O
and O
the O
clotting O
factor O
viii O
gene O
( O
f8c O
) O
, O
in O
several O
large O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
. O

f8c O
was O
also O
tightly O
linked O
to O
ald B-Disease
with O
a O
maximal O
lod O
score O
of O
7 O
. O

multipoint O
linkage O
analysis O
with O
the O
markers O
dxs304 O
, O
dxs52 O
, O
and O
f8c O
indicated O
that O
both O
the O
gene O
for O
ald B-Disease
and O
for O
f8c O
are O
distal O
to O
dxs52 O
. O

in O
four O
patients O
with O
ald B-Disease
, O
no O
major O
structural O
rearrangement O
in O
the O
xqter O
region O
was O
observed O
; O
in O
particular O
, O
there O
were O
no O
abnormalities B-Disease
in I-Disease
the I-Disease
vision I-Disease
blindness I-Disease
genes I-Disease
. O

two O
distinct O
mutations O
at O
a O
single O
bamhi O
site O
in O
phenylketonuria B-Disease
. O

classical B-Disease
phenylketonuria I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disease I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
hepatic I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

the O
present O
study O
supports O
the O
view O
that O
the O
clinical O
heterogeneity O
in O
pku B-Disease
is O
accounted O
for O
by O
the O
large O
variety O
of O
mutant O
genotypes O
associated O
with O
pah B-Disease
deficiencies I-Disease
. O

a O
detailed O
10 O
- O
point O
map O
of O
the O
4p16 O
region O
constructed O
from O
the O
ceph O
panel O
provides O
evidence O
for O
heterogeneity O
in O
the O
linkage O
maps O
constructed O
from O
families O
segregating O
for O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
. O

carrier O
detection O
and O
prenatal O
diagnosis O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
using O
a O
combination O
of O
anonymous O
dna O
polymorphisms O
and O
the O
proteolipid O
protein O
( O
plp O
) O
gene O
cdna O
. O

we O
report O
carrier O
identification O
and O
a O
prenatal O
diagnosis O
using O
dna O
polymorphisms O
in O
2 O
families O
with O
x B-Disease
- I-Disease
linked I-Disease
pelizaeus I-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
. O

in O
the O
case O
of O
the O
prenatal O
diagnosis O
, O
the O
fetus O
was O
shown O
by O
cytogenetic O
analysis O
to O
be O
a O
female O
, O
who O
we O
predict O
will O
be O
a O
noncarrier O
of O
pmd B-Disease
based O
on O
her O
genotype O
with O
the O
plp O
intragenic O
polymorphism O
. O
. O

identification O
of O
deletion O
mutations O
and O
three O
new O
genes O
at O
the O
familial B-Disease
polyposis I-Disease
locus O
. O

small O
( O
100 O
- O
260 O
kb O
) O
, O
nested O
deletions O
were O
characterized O
in O
dna O
from O
two O
unrelated O
patients O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
. O

exclusion O
of O
linkage O
between O
familial B-Disease
mediterranean I-Disease
fever I-Disease
and O
the O
human O
serum O
amyloid O
a O
( O
saa O
) O
gene O
cluster O
. O

we O
studied O
the O
relationship O
between O
the O
autosomal O
recessive O
trait O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
and O
the O
serum O
amyloid O
a O
( O
saa O
) O
genes O
by O
comparing O
alleles O
of O
a O
highly O
polymorphic O
dinucleotide O
repeat O
and O
a O
conventional O
restriction O
fragment O
length O
polymorphism O
( O
rflp O
) O
in O
the O
saa O
gene O
cluster O
in O
israeli O
fmf B-Disease
kindreds O
. O

by O
haplotype O
analysis O
, O
our O
data O
indicate O
a O
minimum O
crossover O
frequency O
of O
22 O
% O
between O
the O
saa O
gene O
marker O
and O
fmf B-Disease
. O

4 O
cm O
including O
and O
surrounding O
the O
saa O
gene O
cluster O
as O
the O
site O
of O
the O
fmf B-Disease
mutation O
although O
saa O
proteins O
are O
prominent O
physiologic O
markers O
of O
the O
acute O
attacks O
. O

prad1 O
, O
a O
candidate O
bcl1 O
oncogene O
: O
mapping O
and O
expression O
in O
centrocytic B-Disease
lymphoma I-Disease
. O

rearrangement O
of O
the O
bcl1 O
( O
b O
- O
cell O
lymphoma O
1 O
) O
region O
on O
chromosome O
11q13 O
appears O
to O
be O
highly O
characteristic O
of O
centrocytic B-Disease
lymphoma I-Disease
and O
also O
is O
found O
infrequently O
in O
other O
b B-Disease
- I-Disease
cell I-Disease
neoplasms I-Disease
. O

prad1 O
, O
previously O
designated O
d11s287e O
, O
was O
identified O
on O
11q13 O
as O
a O
chromosomal O
breakpoint O
region O
rearranged O
with O
the O
parathyroid O
hormone O
gene O
in O
a O
subset O
of O
parathyroid B-Disease
adenomas I-Disease
; O
this O
highly O
conserved O
putative O
oncogene O
, O
which O
encodes O
a O
novel O
cyclin O
, O
has O
been O
linked O
to O
bcl1 O
and O
implicated O
also O
in O
subsets O
of O
breast B-Disease
and I-Disease
squamous I-Disease
cell I-Disease
neoplasms I-Disease
with O
11q13 O
amplification O
. O

prad1 O
mrna O
is O
abundantly O
expressed O
in O
seven O
of O
seven O
centrocytic B-Disease
lymphomas I-Disease
( O
kiel O
classification O
) O
, O
in O
contrast O
to O
13 O
closely O
related O
but O
noncentrocytic B-Disease
lymphomas I-Disease
. O

three O
of O
the O
seven O
centrocytic B-Disease
lymphomas I-Disease
had O
detectable O
bcl1 O
dna O
rearrangement O
. O

thus O
, O
prad1 O
is O
an O
excellent O
candidate O
" O
bcl1 O
oncogene O
. O

" O
its O
overexpression O
may O
be O
a O
key O
consequence O
of O
rearrangement O
of O
the O
bcl1 O
vicinity O
in O
b B-Disease
- I-Disease
cell I-Disease
neoplasms I-Disease
and O
a O
unifying O
pathogenetic O
feature O
in O
centrocytic B-Disease
lymphoma I-Disease
. O

two O
new O
arylsulfatase O
a O
( O
arsa O
) O
mutations O
in O
a O
juvenile O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
patient O
. O

fragments O
of O
the O
arylsulfatase O
a O
( O
arsa O
) O
gene O
from O
a O
patient O
with O
juvenile O
- O
onset O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
were O
amplified O
by O
pcr O
and O
ligated O
into O
mp13 O
cloning O
vectors O
. O

a O
collection O
of O
dna O
samples O
from O
known O
or O
suspected O
mld B-Disease
patients O
, O
members O
of O
their O
families O
, O
and O
normal O
controls O
was O
screened O
for O
these O
mutations O
. O

four O
additional O
individuals O
carrying O
each O
of O
the O
mutations O
were O
found O
among O
the O
nearly O
100 O
mld B-Disease
patients O
in O
the O
sample O
. O

the O
splice O
- O
site O
mutation O
following O
exon O
7 O
produces O
late O
- O
infantile O
mld B-Disease
when O
combined O
with O
other O
enzyme O
- O
null O
mutations O
, O
implying O
that O
it O
is O
completely O
silent O
enzymatically O
. O

analysis O
of O
x O
- O
chromosome O
inactivation O
and O
presumptive O
expression O
of O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
gene O
in O
hematopoietic O
cell O
lineages O
of O
a O
thrombocytopenic O
carrier O
female O
of O
was B-Disease
. O

we O
report O
on O
a O
thrombocytopenic B-Disease
female O
belonging O
to O
a O
pedigree O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

restriction O
fragment O
length O
polymorphism O
( O
rflp O
) O
analysis O
with O
probe O
m27 O
beta O
, O
closely O
linked O
to O
the O
was B-Disease
gene O
, O
demonstrated O
that O
she O
is O
a O
carrier O
of O
was B-Disease
. O

both O
small O
- O
sized O
and O
normal O
- O
sized O
platelets O
were O
present O
, O
suggesting O
that O
, O
unlike O
the O
vast O
majority O
of O
was B-Disease
carriers O
, O
she O
does O
not O
manifest O
nonrandom O
x O
- O
chromosome O
inactivation O
in O
the O
thrombopoietic O
cell O
lineage O
. O

while O
this O
is O
the O
first O
complete O
report O
on O
the O
occurrence O
of O
thrombocytopenia B-Disease
in O
a O
carrier O
female O
of O
was B-Disease
as O
the O
result O
of O
atypical O
lyonization O
, O
it O
also O
suggests O
that O
expression O
of O
the O
was B-Disease
gene O
occurs O
at O
( O
or O
extends O
up O
to O
) O
a O
later O
stage O
than O
the O
multipotent O
stem O
cell O
along O
the O
hematopoietic O
differentiation O
pathway O
. O

a O
new O
mutation O
in O
the O
proteolipid O
protein O
( O
plp O
) O
gene O
in O
a O
german O
family O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

a O
c O
- O
to O
- O
t O
transition O
in O
exon O
4 O
of O
the O
plp O
gene O
was O
found O
in O
2 O
affected O
males O
and O
two O
obligate O
carriers O
in O
a O
german O
family O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

a O
3 O
- O
base O
pair O
in O
- O
frame O
deletion O
of O
the O
phenylalanine O
hydroxylase O
gene O
results O
in O
a O
kinetic O
variant O
of O
phenylketonuria B-Disease
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disease I-Disease
due O
to O
deficiency B-Disease
of I-Disease
a I-Disease
hepatic I-Disease
enzyme I-Disease
, I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

the O
absence O
of O
pah O
activity O
results O
in O
typical O
pku B-Disease
while O
persistence O
of O
a O
residual O
enzyme O
activity O
gives O
rise O
to O
variant O
forms O
of O
the O
disease O
. O

finally O
, O
since O
none O
of O
the O
98 O
pku B-Disease
patients O
tested O
were O
found O
to O
carry O
this O
particular O
deletion O
, O
our O
study O
suggests O
that O
this O
molecular O
event O
probably O
occurred O
recently O
on O
the O
background O
of O
a O
haplotype O
2 O
gene O
in O
portugal O
. O

mutation O
of O
the O
kit O
( O
mast O
/ O
stem O
cell O
growth O
factor O
receptor O
) O
protooncogene O
in O
human O
piebaldism B-Disease
. O

piebaldism B-Disease
is O
an O
autosomal B-Disease
dominant I-Disease
genetic I-Disease
disorder I-Disease
characterized O
by O
cogenital O
patches O
of O
skin O
and O
hair O
from O
which O
melanocytes O
are O
completely O
absent O
. O

we O
identified O
a O
kit O
gene O
mutation O
in O
a O
proband O
with O
classic O
autosomal O
dominant O
piebaldism B-Disease
. O

this O
substitution O
was O
not O
seen O
in O
any O
normal O
individuals O
and O
was O
completely O
linked O
to O
the O
piebald B-Disease
phenotype O
in O
the O
probands O
family O
. O

piebaldism B-Disease
in O
this O
family O
thus O
appears O
to O
be O
the O
human O
homologue O
to O
dominant O
white O
spotting O
( O
w O
) O
of O
the O
mouse O
. O
. O

genetic O
analysis O
of O
a O
japanese O
family O
with O
normotriglyceridemic B-Disease
abetalipoproteinemia I-Disease
indicates O
a O
lack O
of O
linkage O
to O
the O
apolipoprotein O
b O
gene O
. O

normotriglyceridemic B-Disease
abetalipoproteinemia I-Disease
is O
a O
rare O
familial B-Disease
disorder I-Disease
characterized O
by O
an O
isolated O
deficiency B-Disease
of I-Disease
apob I-Disease
- I-Disease
100 I-Disease
. O

to O
elucidate O
the O
genetic B-Disease
abnormalities I-Disease
in O
this O
family O
, O
we O
studied O
the O
linkage O
of O
apob O
gene O
using O
three O
genetic O
markers O
. O

localisation O
of O
the O
gene O
for O
norrie B-Disease
disease I-Disease
to O
between O
dxs7 O
and O
dxs426 O
on O
xp O
. O

23 O
, O
has O
been O
used O
to O
refine O
further O
the O
localisation O
of O
the O
gene O
for O
norrie B-Disease
disease I-Disease
( O
ndp B-Disease
) O
. O

in O
conjunction O
with O
information O
from O
2 O
ndp B-Disease
patients O
who O
have O
a O
deletion O
for O
dxs7 O
but O
not O
for O
dsx426 O
, O
our O
data O
indicate O
that O
the O
ndp B-Disease
gene O
lies O
between O
dxs7 O
and O
dxs426 O
on O
proximal O
xp O
. O

aberrant O
splicing O
of O
phenylalanine O
hydroxylase O
mrna O
: O
the O
major O
cause O
for O
phenylketonuria B-Disease
in O
parts O
of O
southern O
europe O
. O

because O
of O
the O
high O
frequency O
of O
these O
particular O
haplotypes O
in O
bulgaria O
, O
italy O
, O
and O
turkey O
, O
it O
appears O
to O
be O
one O
of O
the O
more O
frequent O
defects O
in O
the O
pah O
gene O
causing O
classical O
phenylketonuria B-Disease
in O
this O
part O
of O
europe O
. O

gardner B-Disease
syndrome I-Disease
in O
a O
boy O
with O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
. O

we O
described O
a O
15 O
- O
year O
- O
old O
boy O
with O
gardner B-Disease
syndrome I-Disease
( O
gs B-Disease
) O
, O
mental B-Disease
retardation I-Disease
, O
and O
craniofacial B-Disease
abnormalities I-Disease
. O

the O
breakpoints O
in O
the O
present O
case O
and O
in O
3 O
previously O
reported O
5q O
- O
patients O
with O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
suggest O
that O
the O
gene O
responsible O
for O
gs B-Disease
/ O
or O
familial B-Disease
polyposis I-Disease
coli I-Disease
( O
fpc B-Disease
) O
is O
in O
the O
5q22 O
region O
, O
a O
result O
consistent O
with O
the O
findings O
of O
linkage O
studies O

huntington B-Disease
disease I-Disease
and O
childhood O
- O
onset O
tourette B-Disease
syndrome I-Disease
. O

a O
40 O
- O
year O
- O
old O
man O
with O
childhood O
- O
onset O
tourette B-Disease
syndrome I-Disease
( O
ts B-Disease
) O
developed O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
. O

we O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
childhood O
- O
onset O
ts B-Disease
with O
adult O
onset O
hd B-Disease
. O

sequence O
of O
dna O
flanking O
the O
exons O
of O
the O
hexa O
gene O
, O
and O
identification O
of O
mutations O
in O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
. O

the O
rapid O
identification O
of O
mutations O
causing O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
requires O
the O
capacity O
to O
readily O
screen O
the O
regions O
of O
the O
hexa O
gene O
most O
likely O
to O
be O
affected O
by O
mutation O
. O

five O
novel O
mutations O
from O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
patients O
were O
detected O
a O
5 O
- O
bp O
deletion O
of O
tctcc O
in O
ivs O
- O
9 O
; O
a O
2 O
- O
bp O
deletion O
of O
tg O
in O
exon O
5 O
; O
g78 O
to O
a O
, O
giving O
a O
stop O
codon O
in O
exon O
1 O
; O
g533 O
to O
t O
in O
exon O
5 O
, O
producing O
the O
third O
amino O
acid O
substitution O
detected O
at O
this O
site O
; O
and O
g O
to O
c O
at O
position O
1 O
of O
ivs O
- O
2 O
, O
expected O
to O
produce O
abnormal O
splicing O
. O

molecular O
characterization O
of O
two O
galactosemia B-Disease
mutations O
: O
correlation O
of O
mutations O
with O
highly O
conserved O
domains O
in O
galactose O
- O
1 O
- O
phosphate O
uridyl O
transferase O
. O

galactosemia B-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
of I-Disease
human I-Disease
galactose I-Disease
metabolism I-Disease
caused O
by O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
galactose I-Disease
- I-Disease
1 I-Disease
- I-Disease
phosphate I-Disease
uridyl I-Disease
transferase I-Disease
( O
galt O
) O
. O

the O
arginine O
188 O
mutation O
is O
the O
most O
common O
galactosemia B-Disease
mutation O
characterized O
to O
date O
. O

it O
accounts O
for O
one O
- O
fourth O
of O
the O
galactosemia B-Disease
alleles O
studied O
. O

our O
data O
provide O
further O
evidence O
for O
the O
heterogeneity O
of O
galactosemia B-Disease
at O
the O
molecular O
level O
, O
heterogeneity O
which O
might O
be O
related O
to O
the O
variable O
clinical O
outcome O
observed O
in O
this O
disorder O
. O
. O

hypoxanthine B-Disease
- I-Disease
guanine I-Disease
phosphoribosyltransferase I-Disease
deficiency I-Disease
: O
analysis O
of O
hprt O
mutations O
by O
direct O
sequencing O
and O
allele O
- O
specific O
amplification O
. O

the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
is O
a O
severe O
x B-Disease
chromosome I-Disease
- I-Disease
linked I-Disease
human I-Disease
disease I-Disease
caused O
by O
a O
virtual O
absence B-Disease
of I-Disease
hypoxanthine I-Disease
- I-Disease
guanine I-Disease
phosphoribosyltransferase I-Disease
( I-Disease
hprt I-Disease
) I-Disease
activity I-Disease
. O

a O
partial O
deficiency O
in O
the O
activity O
of O
this O
enzyme O
can O
result O
in O
gouty B-Disease
arthritis I-Disease
. O

to O
determine O
the O
genetic O
basis O
for O
reduction O
or O
loss O
of O
enzyme O
activity O
, O
we O
have O
amplified O
and O
sequenced O
the O
coding O
region O
of O
hprt O
cdna O
from O
four O
patients O
one O
with O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
( O
hprtperth O
) O
and O
three O
with O
partial B-Disease
deficiencies I-Disease
of I-Disease
hprt I-Disease
activity I-Disease
, O
which O
have O
been O
designated O
hprturangan O
, O
hprtswan O
and O
hprttoowong O
. O

molecular O
and O
metabolic O
basis O
for O
the O
metabolic B-Disease
disorder I-Disease
normotriglyceridemic B-Disease
abetalipoproteinemia I-Disease
. O

we O
have O
previously O
described O
a O
disorder O
, O
normotriglyceridemic B-Disease
abetalipoproteinemia I-Disease
, O
that O
is O
characterized O
by O
the O
virtual O
absence O
of O
plasma O
low O
density O
lipoproteins O
and O
complete O
absence O
of O
apob O
- O
100 O
, O
but O
with O
apparently O
normal O
secretion O
of O
triglyceride O
- O
rich O
lipoproteins O
containing O
apob O
- O
48 O
. O

thus O
, O
this O
is O
a O
rare O
example O
of O
homozygous B-Disease
hypobetalipoproteinemia I-Disease
. O

a O
single O
origin O
of O
phenylketonuria B-Disease
in O
yemenite O
jews O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
a O
metabolic B-Disease
disease I-Disease
caused O
by O
recessive O
mutations O
of O
the O
gene O
encoding O
the O
hepatic O
enzyme O
phenylalanine O
hydroxylase O
( O
pah O
) O
. O

the O
incidence O
of O
pku B-Disease
varies O
widely O
across O
different O
geographic O
areas O
, O
and O
is O
highest O
( O
about O
1 O
in O
5 O
, O
000 O
live O
births O
) O
in O
ireland O
and O
western O
scotland O
, O
and O
among O
yemenite O
jews O
. O

a O
limited O
number O
of O
point O
mutations O
account O
for O
most O
of O
the O
pku B-Disease
cases O
in O
the O
european O
population O
. O

here O
we O
report O
that O
a O
single O
molecular O
defect O
- O
- O
a O
deletion O
spanning O
the O
third O
exon O
of O
the O
pah O
gene O
- O
- O
is O
responsible O
for O
all O
the O
pku B-Disease
cases O
among O
the O
yemenite O
jews O
. O

although O
the O
deleted O
pah O
gene O
was O
traced O
to O
25 O
different O
locations O
throughout O
yemen O
, O
family O
histories O
and O
official O
documents O
of O
the O
yemenite O
jewish O
community O
showed O
that O
the O
common O
ancestor O
of O
all O
the O
carriers O
of O
this O
genetic B-Disease
defect I-Disease
lived O
in O
sana O
, O
the O
capital O
of O
yemen O
, O
before O
the O
eighteenth O
century O
. O
. O

linkage O
of O
aspartylglucosaminuria B-Disease
( O
agu B-Disease
) O
to O
marker O
loci O
on O
the O
long O
arm O
of O
chromosome O
4 O
. O

aspartylglucosaminuria B-Disease
( O
agu B-Disease
) O
is O
caused O
by O
deficient O
activity O
of O
the O
enzyme O
aspartylglucosaminidase O
( O
aga O
) O
. O

restriction O
fragment O
length O
polymorphism O
alleles O
for O
the O
adh2 O
, O
adh3 O
, O
egf O
, O
fg O
alpha O
and O
fg O
beta O
loci O
and O
blood O
group O
antigens O
for O
the O
mns O
locus O
were O
determined O
in O
a O
panel O
of O
12 O
finnish O
agu B-Disease
families O
. O

loose O
linkage O
of O
the O
agu B-Disease
locus O
to O
the O
fg O
and O
mns O
loci O
was O
observed O
( O
z O
= O
1 O
. O
16 O
, O
z O
= O
1 O
. O
39 O
, O
respectively O
) O
. O

linkage O
relationships O
of O
the O
apolipoprotein O
c1 O
gene O
and O
a O
cytochrome O
p450 O
gene O
( O
cyp2a O
) O
to O
myotonic B-Disease
dystrophy I-Disease
. O

we O
have O
studied O
the O
genetic O
linkage O
of O
two O
markers O
, O
the O
apolipoprotein O
c1 O
( O
apoc1 O
) O
gene O
and O
a O
cytochrome O
p450 O
( O
cyp2a O
) O
gene O
, O
in O
relation O
to O
the O
gene O
for O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

genetic O
linkage O
map O
of O
six O
polymorphic O
dna O
markers O
around O
the O
gene O
for O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
on O
chromosome O
5 O
. O

a O
genetic O
linkage O
map O
of O
six O
polymorphic O
dna O
markers O
close O
to O
the O
gene O
( O
apc O
) O
for O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
on O
chromosome O
5q O
is O
reported O
. O

one O
hundred O
fifty O
- O
five O
typed O
members O
of O
nine O
fap B-Disease
kindred O
provided O
more O
than O
90 O
meioses O
for O
linkage O
analysis O
. O

48 O
, O
but O
published O
deletion O
mapping O
in O
colorectal B-Disease
carcinomas I-Disease
and O
linkage O
analysis O
in O
fap B-Disease
suggest O
that O
yn5 O
. O

44 O
locus O
lies O
very O
close O
to O
the O
apc B-Disease
gene O
. O

these O
data O
not O
only O
allow O
use O
of O
flanking O
markers O
for O
presymptomatic O
diagnosis O
of O
fap B-Disease
but O
also O
provide O
a O
high O
- O
density O
map O
of O
the O
region O
for O
isolation O
of O
the O
apc B-Disease
gene O
itself O
and O
for O
further O
assessment O
of O
the O
role O
of O
chromosome O
5 O
deletions O
in O
the O
biology O
of O
sporadic O
colorectal B-Disease
cancer I-Disease
. O

serum O
amyloid O
a O
and O
p O
protein O
genes O
in O
familial B-Disease
mediterranean I-Disease
fever I-Disease
. O

two O
recent O
studies O
have O
suggested O
the O
involvement O
of O
serum O
amyloid O
a O
( O
saa O
) O
and O
p O
( O
apcs O
) O
genes O
in O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
mef B-Disease
) O
. O

to O
test O
the O
role O
of O
saa O
and O
apcs O
in O
mef B-Disease
and O
mef B-Disease
- I-Disease
amyloidosis I-Disease
, O
we O
studied O
17 O
informative O
families O
( O
15 O
armenians O
, O
2 O
non O
- O
ashkenazi O
jews O
) O
and O
8 O
mef B-Disease
patients O
with O
amyloidosis B-Disease
using O
a O
candidate O
gene O
approach O
. O

no O
evidence O
for O
any O
mef B-Disease
- O
associated O
polymorphism O
was O
found O
in O
any O
of O
the O
41 O
armenian O
and O
jewish O
mef B-Disease
patients O
tested O
. O

our O
family O
studies O
allowed O
us O
to O
rule O
out O
tight O
linkage O
between O
saa O
and O
mef B-Disease
( O
lod O
score O
= O
- O
2 O
. O
16 O
, O
theta O
less O
than O
or O
equal O
to O
0 O
. O
06 O
) O
. O

for O
apcs O
we O
found O
that O
the O
allele O
frequency O
in O
the O
mef B-Disease
- I-Disease
amyloidosis I-Disease
patients O
was O
similar O
to O
that O
in O
18 O
unrelated O
mef B-Disease
patients O
without O
amyloidosis B-Disease
and O
their O
33 O
healthy O
parents O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
appears O
to O
be O
fairly O
common O
in O
mexico O
. O

two O
other O
mexican O
males O
with O
g6pd B-Disease
deficiency I-Disease
were O
found O
to O
have O
the O
same O
mutation O
. O

hereditary O
deficiency B-Disease
of I-Disease
c5 I-Disease
in O
association O
with O
discoid B-Disease
lupus I-Disease
erythematosus I-Disease
. O

a O
29 O
- O
year O
- O
old O
woman O
with O
discoid B-Disease
lupus I-Disease
erythematosus I-Disease
had O
undetectable O
classic O
pathway O
complement O
activity O
. O

hypocomplementemia B-Disease
was O
due O
to O
selective O
deficiency B-Disease
of I-Disease
c5 I-Disease
. O

to O
our O
knowledge O
this O
is O
the O
first O
documented O
case O
of O
an O
association O
between O
discoid B-Disease
lupus I-Disease
erythematosus I-Disease
and O
c5 B-Disease
deficiency I-Disease
. O
. O

founder O
effect O
of O
a O
prevalent O
phenylketonuria B-Disease
mutation O
in O
the O
oriental O
population O
. O

a O
missense O
mutation O
has O
been O
identified O
in O
the O
human O
phenylalanine O
hydroxylase O
[ O
pah O
; O
phenylalanine O
4 O
- O
monooxygenase O
; O
l O
- O
phenylalanine O
, O
tetrahydrobiopterin O
oxygen O
oxidoreductase O
( O
4 O
- O
hydroxylating O
) O
, O
ec O
1 O
. O
14 O
. O
16 O
. O
1 O
] O
gene O
in O
a O
chinese O
patient O
with O
classic O
phenylketonuria B-Disease
( O
pku B-Disease
) O
. O

this O
mutation O
( O
r413p O
) O
results O
in O
negligible O
enzymatic O
activity O
when O
expressed O
in O
heterologous O
mammalian O
cells O
and O
is O
compatible O
with O
a O
classic O
pku B-Disease
phenotype O
in O
the O
patient O
. O

8 O
% O
of O
northern O
chinese O
and O
27 O
% O
of O
japanese O
pku B-Disease
alleles O
, O
but O
it O
is O
rare O
in O
southern O
chinese O
( O
2 O
. O
2 O
% O
) O
and O
is O
absent O
in O
the O
caucasian O
population O
. O

glucose B-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
caused O
by O
a O
defect O
in O
the O
na O
+ O
/ O
glucose O
cotransporter O
. O

glucose B-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
( O
ggm B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disease I-Disease
manifesting O
within O
the O
first O
weeks O
of O
life O
and O
characterized O
by O
a O
selective O
failure O
to O
absorb O
dietary O
glucose O
and O
galactose O
from O
the O
intestine O
. O

the O
consequent O
severe O
diarrhoea B-Disease
and O
dehydration B-Disease
are O
usually O
fatal O
unless O
these O
sugars O
are O
eliminated O
from O
the O
diet O
. O

intestinal O
biopsies O
of O
ggm B-Disease
patients O
have O
revealed O
a O
specific O
defect O
in O
na O
( O
+ O
) O
- O
dependent O
absorption O
of O
glucose O
in O
the O
brush O
border O
. O

a O
de O
novo O
unbalanced O
reciprocal O
translocation O
identified O
as O
paternal O
in O
origin O
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

interstitial O
cytogenetic O
deletions O
involving O
the O
paternally O
derived O
chromosome O
15q11 O
- O
13 O
have O
been O
described O
in O
patients O
with O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

we O
report O
a O
child O
with O
pws B-Disease
and O
a O
de O
novo O
unbalanced O
karyotype O
- O
45 O
, O
xy O
, O
- O
9 O
, O
- O
15 O
, O
+ O
der O
( O
9 O
) O
t O
( O
9 O
; O
15 O
) O
( O
q34 O
; O
q13 O
) O
. O

molecular O
studies O
with O
the O
dna O
probe O
pml34 O
confirmed O
that O
only O
a O
single O
prader B-Disease
willi I-Disease
critical O
region O
( O
pwcr O
15q11 O
. O
2 O
- O
q12 O
) O
copy O
was O
present O
. O

localisation O
of O
the O
myotonic B-Disease
dystrophy I-Disease
locus O
to O
19q13 O
. O
2 O
- O
19q13 O
. O
3 O
and O
its O
relationship O
to O
twelve O
polymorphic O
loci O
on O
19q O
. O

we O
report O
here O
the O
linkage O
relationship O
of O
the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
locus O
to O
twelve O
of O
these O
markers O
as O
studied O
in O
45 O
families O
with O
dm B-Disease
. O

ten O
of O
the O
twelve O
markers O
have O
been O
shown O
to O
be O
proximal O
to O
the O
dm B-Disease
gene O
and O
two O
, O
prkcg O
and O
d19s22 O
, O
distal O
but O
at O
distances O
of O
approximately O
25 O
cm O
and O
15 O
cm O
, O
respectively O
. O

the O
distance O
between O
apoc2 O
, O
ckm O
and O
dm B-Disease
( O
of O
the O
order O
of O
2 O
million O
base O
pairs O
) O
and O
their O
known O
orientation O
should O
permit O
directional O
chromosome O
walking O
and O
jumping O
. O

the O
data O
presented O
here O
should O
enable O
us O
to O
determine O
whether O
or O
not O
new O
markers O
are O
distal O
to O
apoc2 O
/ O
ckm O
and O
thus O
potentially O
flank O
the O
dm B-Disease
gene O
. O
. O

the O
human O
gene O
for O
histidase O
( O
histidine O
ammonia O
- O
lyase O
; O
hal O
) O
, O
the O
enzyme O
deficient O
in O
histidinemia B-Disease
, O
was O
assigned O
to O
human O
chromosome O
12 O
by O
southern O
blot O
analysis O
of O
human O
x O
mouse O
somatic O
cell O
hybrid O
dna O
. O

determination O
of O
the O
mutations O
responsible O
for O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
in O
17 O
subjects O
. O

the O
direct O
sequencing O
of O
the O
polymerase O
chain O
reaction O
- O
amplified O
product O
of O
reverse O
- O
transcribed O
hprt O
mrna O
enabled O
the O
rapid O
identification O
of O
the O
mutations O
found O
in O
17 O
previously O
uncharacterized O
cell O
lines O
derived O
from O
patients O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O
. O

linkage O
of O
dna O
markers O
at O
xq28 O
to O
adrenoleukodystrophy B-Disease
and O
adrenomyeloneuropathy B-Disease
present O
within O
the O
same O
family O
. O

we O
present O
a O
large O
kindred O
that O
contained O
patients O
with O
either O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
or O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
. O

the O
pedigree O
clearly O
supported O
the O
x O
- O
linked O
mode O
of O
inheritance O
of O
the O
nonneonatal O
form O
of O
ald B-Disease
/ O
amn B-Disease
. O

analysis O
with O
dna O
markers O
at O
xq28 O
suggested O
segregation O
of O
both O
ald B-Disease
and O
amn B-Disease
with O
an O
identical O
haplotype O
. O

this O
indicated O
that O
nonneonatal O
ald B-Disease
and O
amn B-Disease
are O
caused O
by O
a O
mutation O
in O
the O
same O
gene O
at O
xq28 O
. O

the O
maximal O
lod O
score O
for O
linkage O
of O
the O
ald B-Disease
/ O
amn B-Disease
gene O
and O
the O
multiallelic O
anonymous O
dna O
marker O
at O
dxs52 O
was O
3 O
. O

skewed O
x O
inactivation O
in O
a O
female O
mz O
twin O
results O
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
. O

one O
of O
female O
mz O
twins O
presented O
with O
muscular B-Disease
dystrophy I-Disease
. O

physical O
examination O
, O
creatine O
phosphokinase O
levels O
, O
and O
muscle O
biopsy O
were O
consistent O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

however O
, O
because O
of O
her O
sex O
she O
was O
diagnosed O
as O
having O
limb B-Disease
- I-Disease
girdle I-Disease
muscular I-Disease
dystrophy I-Disease
. O

with O
cdna O
probes O
to O
the O
dmd B-Disease
gene O
, O
a O
gene O
deletion O
was O
detected O
in O
the O
twins O
and O
their O
mother O
. O

these O
data O
indicate O
that O
the O
affected O
twin O
is O
a O
manifesting O
carrier O
of O
an O
abnormal O
dmd B-Disease
gene O
, O
her O
myopathy B-Disease
being O
a O
direct O
result O
of O
underexpression O
of O
dystrophin O
. O

both O
linkage O
analysis O
and O
dna O
fingerprint O
analysis O
revealed O
that O
each O
twin O
has O
two O
different O
x O
chromosomes O
, O
eliminating O
the O
possibility O
of O
uniparental B-Disease
disomy I-Disease
as O
a O
mechanism O
for O
dmd B-Disease
expression O
. O

adrenoleukodystrophy B-Disease
and O
adrenomyeloneuropathy B-Disease
associated O
with O
partial O
adrenal B-Disease
insufficiency I-Disease
in O
three O
generations O
of O
a O
kindred O
. O

four O
cases O
of O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
and O
one O
case O
of O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
have O
developed O
in O
a O
kindred O
over O
three O
generations O
demonstrating O
that O
amn B-Disease
is O
a O
clinical O
variant O
of O
ald B-Disease
. O

pituitary O
- O
adrenal O
function O
studies O
were O
performed O
in O
10 O
family O
members O
, O
including O
two O
affected O
males O
and O
four O
females O
identified O
as O
carriers O
of O
ald B-Disease
/ O
amn B-Disease
. O

no O
pituitary B-Disease
- I-Disease
adrenal I-Disease
abnormality I-Disease
was O
found O
in O
the O
carriers O
. O

however O
, O
basal O
morning O
plasma O
adrenocorticotropic O
hormone O
( O
acth O
) O
levels O
were O
markedly O
elevated O
in O
the O
two O
males O
with O
ald B-Disease
and O
amn B-Disease
, O
despite O
the O
fact O
that O
they O
had O
no O
clinical O
signs O
of O
adrenal B-Disease
insufficiency I-Disease
and O
that O
morning O
plasma O
cortisol O
levels O
and O
their O
response O
to O
maximal O
exogenous O
acth O
stimulation O
appeared O
to O
be O
normal O
. O

thus O
, O
people O
with O
ald B-Disease
and O
amn B-Disease
may O
have O
subclinical O
partial O
adrenocrotical B-Disease
insufficiency I-Disease
. O

no O
other O
endocrinologic B-Disease
dysfunction I-Disease
was O
identified O
. O

regional O
localisation O
of O
the O
friedreich B-Disease
ataxia I-Disease
locus O
to O
human O
chromosome O
9q13 O
- O
- O
- O
- O
q21 O
. O
1 O
. O

we O
have O
previously O
assigned O
the O
friedreich B-Disease
ataxia I-Disease
locus O
( O
frda O
) O
to O
chromosome O
9 O
; O
the O
current O
maximal O
lod O
score O
between O
frda O
and O
mct112 O
( O
d9s15 O
) O
is O
greater O
than O
50 O
at O
a O
recombination O
fraction O
of O
theta O
= O
0 O
. O

we O
recently O
described O
a O
japanese O
family O
with O
increased O
hdl O
levels O
and O
cetp B-Disease
deficiency I-Disease
due O
to O
a O
splicing O
defect O
of O
the O
cetp O
gene O
. O

family O
members O
homozygous O
for O
cetp B-Disease
deficiency I-Disease
( O
n O
= O
10 O
) O
had O
moderate O
hypercholesterolemia B-Disease
( O
mean O
total O
cholesterol O
level O
[ O
+ O
/ O
- O
sd O
] O
, O
7 O
. O
01 O
+ O
/ O
- O
0 O
. O
83 O
mmol O
per O
liter O
) O
, O
markedly O
increased O
levels O
of O
hdl O
cholesterol O
( O
4 O
. O
24 O
+ O
/ O
- O
1 O
. O
01 O
mmol O
per O
liter O
) O
and O
apolipoprotein O
a O
- O
i O
, O
and O
decreased O
levels O
of O
low O
- O
density O
lipoprotein O
cholesterol O
( O
1 O
. O
99 O
+ O
/ O
- O
0 O
. O
80 O
mmol O
per O
liter O
) O
and O

cetp B-Disease
deficiency I-Disease
was O
not O
found O
in O
six O
unrelated O
subjects O
with O
elevated O
hdl O
cholesterol O
levels O
who O
were O
from O
different O
parts O
of O
the O
united O
states O
. O

cetp B-Disease
deficiency I-Disease
appears O
to O
be O
a O
frequent O
cause O
of O
increased O
hdl O
levels O
in O
the O
population O
of O
japan O
, O
possibly O
because O
of O
a O
founder O
effect O
. O

there O
was O
no O
evidence O
of O
premature B-Disease
atherosclerosis I-Disease
in O
the O
families O
with O
cetp B-Disease
deficiency I-Disease
. O

in O
fact O
, O
the O
lipoprotein O
profile O
of O
persons O
with O
cetp B-Disease
deficiency I-Disease
is O
potentially O
antiatherogenic O
and O
may O
be O
associated O
with O
an O
increased O
life O
span O
. O

further O
mapping O
of O
an O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
locus O
to O
the O
chromosome O
11q23 O
region O
. O

we O
recently O
mapped O
the O
gene O
for O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
group O
a O
( O
ata O
) O
to O
chromosome O
11q22 O
- O
23 O
by O
linkage O
analysis O
, O
using O
the O
genetic O
markers O
thy1 O
and O
pynb3 O
. O

the O
present O
paper O
describes O
further O
mapping O
of O
the O
at B-Disease
locus O
by O
means O
of O
a O
panel O
of O
10 O
markers O
that O
span O
approximately O
60 O
cm O
in O
the O
11q22 O
- O
23 O
region O
centered O
around O
s144 O
and O
thy1 O
. O

location O
scores O
indicate O
that O
three O
contiguous O
subsegments O
within O
the O
[ O
s144 O
- O
thy1 O
] O
segment O
, O
as O
well O
as O
three O
contiguous O
segments O
telomeric O
to O
thy1 O
, O
are O
each O
unlikely O
to O
contain O
the O
at B-Disease
locus O
, O
while O
the O
more O
centromeric O
[ O
stmy O
- O
s144 O
] O
segment O
is O
most O
likely O
to O
contain O
the O
at B-Disease
locus O
. O

recurrent O
meningitis B-Disease
in O
a O
patient O
with O
congenital B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
c9 I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

first O
case O
of O
c9 B-Disease
deficiency I-Disease
in O
europe O
. O

we O
describe O
the O
first O
cases O
, O
to O
our O
knowledge O
, O
of O
c9 B-Disease
deficiency I-Disease
in O
europe O
that O
were O
detected O
in O
a O
swiss O
family O
, O
of O
which O
two O
members O
- O
- O
one O
with O
a O
complete O
deficiency O
and O
the O
other O
with O
approximately O
half O
- O
normal O
c9 O
levels O
- O
- O
experienced O
bacterial B-Disease
meningitis I-Disease
. O

the O
index O
patient O
, O
a O
56 O
- O
year O
- O
old O
white O
man O
with O
a O
history O
of O
purulent B-Disease
meningitis I-Disease
at O
the O
age O
of O
23 O
years O
, O
presented O
with O
an O
acute B-Disease
meningococcal I-Disease
meningitis I-Disease
. O

no O
impairment B-Disease
of I-Disease
cellular I-Disease
immunity I-Disease
or O
immunoglobulin B-Disease
deficiency I-Disease
could O
be O
found O
. O

complement O
assays O
showed O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
c9 I-Disease
component I-Disease
, O
while O
the O
other O
individual O
component O
levels O
were O
normal O
and O
the O
hemolytic O
activity O
( O
measured O
using O
the O
ch50 O
assay O
) O
was O
only O
slightly O
reduced O
. O

a O
family O
study O
revealed O
complete B-Disease
c9 I-Disease
deficiency I-Disease
in O
the O
patients O
healthy O
brother O
and O
half O
- O
normal O
c9 O
concentrations O
in O
his O
sister O
, O
his O
son O
( O
who O
also O
had O
experienced O
an O
episode O
of O
bacterial B-Disease
meningitis I-Disease
) O
, O
and O
his O
niece O
, O
consistent O
with O
an O
inherited O
c9 B-Disease
deficiency I-Disease
. O

this O
first O
case O
of O
recurrent B-Disease
meningitis I-Disease
in O
a O
white O
patient O
with O
complete B-Disease
c9 I-Disease
deficiency I-Disease
suggests O
that O
this O
complement B-Disease
defect I-Disease
may O
also O
be O
a O
risk O
factor O
for O
bacterial B-Disease
, I-Disease
especially I-Disease
neisserial I-Disease
, I-Disease
infections I-Disease
. O
. O

detection O
of O
98 O
% O
of O
dmd B-Disease
/ O
bmd B-Disease
gene O
deletions O
by O
polymerase O
chain O
reaction O
. O

when O
used O
in O
conjunction O
with O
an O
existing O
primer O
set O
, O
these O
two O
multiplex O
reactions O
detect O
about O
98 O
% O
of O
deletions O
in O
patients O
with O
duchenne B-Disease
or I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
, O
bmd B-Disease
) O
. O

thus O
, O
use O
of O
these O
pcr O
- O
based O
assays O
will O
allow O
deletion O
detection O
and O
prenatal O
diagnosis O
for O
most O
dmd B-Disease
/ O
bmd B-Disease
patients O
in O
a O
fraction O
of O
the O
time O
required O
for O
southern O
blot O
analysis O
. O

of O
these O
, O
31 O
had O
severe O
g6pd B-Disease
deficiency I-Disease
, O
nine O
had O
mild O
to O
moderate O
deficiency O
, O
and O
three O
had O
a O
non O
- O
deficient O
electrophoretic O
variant O
. O

the O
overall O
rate O
of O
g6pd B-Disease
deficiency I-Disease
was O
2 O
. O

the O
frequency O
of O
g6pd B-Disease
deficiency I-Disease
, O
ranging O
from O
7 O
. O

biochemical O
characterization O
has O
shown O
that O
most O
of O
the O
g6pd B-Disease
deficiency I-Disease
in O
this O
population O
is O
accounted O
for O
by O
g6pd O
mediterranean O
. O

these O
data O
provide O
further O
evidence O
for O
the O
marked O
genetic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
within O
a O
relatively O
narrow O
geographic O
area O
and O
they O
prove O
the O
presence O
in O
the O
italian O
peninsula O
of O
a O
gene O
( O
gda O
- O
) O
regarded O
as O
characteristically O
african O
. O

deficiency B-Disease
of I-Disease
the I-Disease
murine I-Disease
fifth I-Disease
complement I-Disease
component I-Disease
( I-Disease
c5 I-Disease
) I-Disease
. O

to O
ascertain O
the O
molecular O
mechanism O
that O
causes O
murine O
c5 B-Disease
deficiency I-Disease
, O
genomic O
and O
cdna O
libraries O
were O
constructed O
from O
mouse O
liver O
dna O
and O
mrna O
employing O
the O
congenic O
strains O
b10 O
. O

d2 O
/ O
osnj O
that O
are O
sufficient O
and O
deficient B-Disease
for I-Disease
c5 I-Disease
, O
respectively O
. O

genomic O
fragments O
were O
isolated O
which O
correspond O
to O
pvuii O
and O
hindiii O
restriction O
fragment O
length O
polymorphisms O
associated O
with O
c5 B-Disease
deficiency I-Disease
. O

sequence O
analyses O
demonstrated O
that O
each O
of O
these O
polymorphisms O
resulted O
from O
single O
base O
pair O
substitutions O
and O
that O
neither O
substitution O
would O
probably O
cause O
or O
contribute O
to O
the O
c5 B-Disease
deficiency I-Disease
. O

six O
c5 B-Disease
- I-Disease
deficient I-Disease
strains O
, O
a O
/ O
hej O
, O
akr O
/ O
j O
, O
dba O
/ O
2j O
, O
nzb O
/ O
b1nj O
, O
swr O
/ O
j O
, O
and O
b10 O
. O

these O
data O
demonstrate O
that O
1 O
) O
there O
is O
an O
identical O
2 O
- O
base O
pair O
deletion O
in O
an O
exon O
of O
the O
c5 O
gene O
in O
several O
different O
c5 B-Disease
- I-Disease
deficient I-Disease
mouse O
strains O
; O
2 O
) O
the O
mrna O
transcribed O
from O
the O
c5d O
gene O
retains O
this O
deletion O
; O
and O
3 O
) O
this O
mutation O
should O
result O
in O
c5 B-Disease
protein I-Disease
deficiency I-Disease
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
a O
genetic B-Disease
disorder I-Disease
secondary O
to O
a O
deficiency B-Disease
of I-Disease
hepatic I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

a O
new O
molecular B-Disease
lesion I-Disease
has O
been O
identified O
in O
exon O
7 O
of O
the O
pah O
gene O
in O
a O
hungarian O
pku B-Disease
patient O
by O
direct O
sequencing O
of O
pcr O
- O
amplified O
dna O
. O

the O
red O
- O
green O
visual O
pigment O
gene O
region O
in O
adrenoleukodystrophy B-Disease
. O

although O
recent O
data O
established O
that O
a O
specific O
very O
- O
long O
- O
chain O
fatty O
acyl O
- O
coa O
synthetase O
is O
defective O
in O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
, O
the O
ald B-Disease
gene O
is O
still O
unidentified O
. O

the O
ald B-Disease
locus O
has O
been O
mapped O
to O
xq28 O
, O
like O
the O
red O
and O
green O
color O
pigment O
genes O
. O

abnormal B-Disease
color I-Disease
vision I-Disease
has O
been O
observed O
in O
12 O
of O
27 O
patients O
with O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
, O
a O
milder O
form O
of O
ald B-Disease
. O

furthermore O
, O
rearrangements O
of O
the O
color O
vision O
gene O
cluster O
were O
found O
in O
four O
of O
eight O
ald B-Disease
kindreds O
. O

this O
led O
us O
to O
propose O
that O
a O
single O
dna O
rearrangement O
could O
underlie O
both O
ald B-Disease
and O
abnormal B-Disease
color I-Disease
vision I-Disease
in O
these O
patients O
. O

study O
of O
34 O
french O
ald B-Disease
patients O
failed O
to O
reveal O
a O
higher O
than O
expected O
frequency O
of O
green O
/ O
red O
visual O
pigment O
rearrangements O
3 O
to O
the O
red O
/ O
green O
color O
vision O
gene O
complex O
. O

the O
previous O
report O
of O
such O
rearrangements O
was O
based O
on O
small O
numbers O
and O
lack O
of O
knowledge O
that O
the O
frequency O
of O
" O
abnormal O
" O
color O
vision O
arrays O
on O
molecular O
analysis O
was O
twice O
as O
high O
as O
expected O
on O
the O
basis O
of O
the O
frequency O
of O
phenotypic B-Disease
color I-Disease
vision I-Disease
defects I-Disease
. O

the O
r O
/ O
gcp O
region O
was O
also O
analyzed O
in O
29 O
french O
and O
seven O
north O
american O
ald B-Disease
patients O
by O
using O
six O
genomic O
dna O
probes O
, O
isolated O
from O
a O
cosmid O
walk O
, O
that O
flank O
the O
color O
vision O
genes O
. O

one O
of O
the O
eight O
previously O
reported O
ald B-Disease
individuals O
has O
a O
long O
deletion O
5 O
of O
the O
red O
pigment O
gene O
, O
a O
deletion O
causing O
blue O
cone O
monochromacy O
. O

this O
finding O
and O
the O
previous O
findings O
of O
a O
45 O
% O
frequency O
of O
phenotypic O
color O
vision O
defects O
in O
patients O
with O
amn B-Disease
may O
suggest O
that O
the O
ald B-Disease
/ O
amn B-Disease
gene O
lies O
5 O
to O
the O
red O
pigment O
gene O
and O
that O
the O
frequent O
phenotypic O
color B-Disease
vision I-Disease
anomalies I-Disease
owe O
their O
origin O
to O
deleted O
dna O
that O
includes O
regulatory O
genes O
for O
color O
vision O
. O

it O
is O
possible O
, O
however O
, O
that O
phenotypic O
color B-Disease
vision I-Disease
anomalies I-Disease
in O
amn B-Disease
may O
be O
phenocopies O
secondary O
to O
retinal O
or O
neural O
involvement O
by O
the O
disease O
. O

paroxysmal B-Disease
nocturnal I-Disease
haemoglobinuria I-Disease
with O
coexisting O
deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
complement I-Disease
: O
lack O
of O
massive O
haemolytic B-Disease
attack I-Disease
. O

a O
47 O
- O
year O
- O
old O
woman O
with O
paroxysmal B-Disease
nocturnal I-Disease
haemoglobinuria I-Disease
( O
pnh B-Disease
) O
was O
found O
to O
have O
an O
inherited B-Disease
deficiency I-Disease
in I-Disease
the I-Disease
ninth I-Disease
complement I-Disease
component I-Disease
( O
c9 O
) O
. O

surprisingly O
, O
she O
has O
suffered O
only O
mild O
haemolysis B-Disease
and O
has O
never O
experienced O
massive O
spontaneous O
haemolysis B-Disease
. O

gross O
haemoglobinuria B-Disease
and O
jaundice B-Disease
occurred O
only O
after O
receiving O
postoperative O
transfusion O
of O
whole O
blood O
. O

these O
observations O
indicated O
that O
c9 O
may O
play O
a O
critical O
role O
in O
haemolytic B-Disease
attacks I-Disease
in O
patients O
with O
pnh B-Disease
and O
that O
characteristic O
haemolysis B-Disease
in O
pnh B-Disease
may O
be O
tempered O
by O
coexisting O
c9 B-Disease
deficiency I-Disease
. O

duplicational O
mutation O
at O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
locus O
: O
its O
frequency O
, O
distribution O
, O
origin O
, O
and O
phenotypegenotype O
correlation O
. O

partial O
gene O
deletion O
is O
the O
major O
cause O
of O
mutation O
leading O
to O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
and O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
( O
bmd B-Disease
) O
. O

a O
shift O
of O
the O
reading O
frame O
was O
predicted O
in O
four O
of O
the O
six O
dmd B-Disease
cases O
and O
in O
one O
of O
the O
two O
intermediate O
cases O
, O
while O
the O
reading O
frame O
remained O
uninterrupted O
in O
both O
bmd B-Disease
cases O
. O

glucose O
6 O
- O
phosphate O
dehydrogenase O
variants O
: O
gd O
( O
+ O
) O
alexandra O
associated O
with O
neonatal B-Disease
jaundice I-Disease
and O
gd O
( O
- O
) O
camperdown O
in O
a O
young O
man O
with O
lamellar B-Disease
cataracts I-Disease
. O

the O
first O
, O
of O
italian O
extraction O
, O
suffered O
from O
severe O
neonatal B-Disease
jaundice I-Disease
following O
maternal O
ingestion O
of O
fresh O
broad O
beans O
( O
vicia O
fava O
) O
both O
prenatally O
and O
postnatally O
the O
expression O
of O
the O
enzymatic O
defect O
was O
much O
more O
severe O
in O
the O
neonatal O
period O
than O
on O
retesting O
in O
adolescence O
, O
when O
biochemical O
characterization O
showed O
unique O
features O
which O
justify O
designation O
as O
a O
new O
variant O
gd O
( O
+ O
) O
alexandra O
. O

the O
second O
patient O
, O
a O
boy O
of O
maltese O
extraction O
who O
was O
found O
to O
have O
bilateral B-Disease
lamellar I-Disease
cataracts I-Disease
at O
the O
age O
of O
4 O
years O
, O
was O
identified O
as O
g6pd B-Disease
deficient I-Disease
only O
as O
a O
result O
of O
a O
survey O
of O
children O
of O
mediterranean O
origin O
with O
unexplained O
cataract B-Disease
formation O
; O
he O
has O
approximately O
15 O
% O
of O
normal O
enzyme O
activity O
, O
with O
another O
unique O
combination O
of O
biochemical O
characteristics O
which O
has O
led O
to O
its O
designation O
as O
gd O
( O
- O
) O
camperdown O
. O

although O
this O
association O
may O
be O
coincidental O
, O
it O
prompts O
further O
attention O
to O
the O
possibility O
that O
under O
certain O
circumstances O
g6pd B-Disease
deficiency I-Disease
may O
favor O
cataract B-Disease
formation O
. O

statistical O
analysis O
of O
the O
two O
stage O
mutation O
model O
in O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
, O
and O
in O
sporadic B-Disease
cerebellar I-Disease
haemangioblastoma I-Disease
and O
renal B-Disease
cell I-Disease
carcinoma I-Disease
. O

analysis O
of O
the O
age O
incidence O
curves O
for O
unilateral B-Disease
and I-Disease
bilateral I-Disease
retinoblastoma I-Disease
led O
knudson O
to O
propose O
that O
hereditary B-Disease
tumours I-Disease
may O
arise O
by O
a O
single O
event O
and O
sporadic B-Disease
tumours I-Disease
by O
a O
two O
stage O
mutation O
process O
. O

it O
has O
been O
suggested O
recently O
that O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
may O
arise O
from O
a O
two O
stage O
mutation O
process O
. O

we O
analysed O
the O
age O
incidence O
curves O
for O
symptomatic O
renal B-Disease
cell I-Disease
carcinoma I-Disease
( O
n O
= O
26 O
) O
and O
cerebellar B-Disease
haemangioblastoma I-Disease
( O
n O
= O
68 O
) O
in O
109 O
patients O
with O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
disease I-Disease
, O
and O
compared O
them O
to O
104 O
patients O
with O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
and O
43 O
patients O
with O
sporadic B-Disease
cerebellar I-Disease
haemangioblastoma I-Disease
. O

the O
age O
incidence O
curves O
for O
renal B-Disease
cell I-Disease
carcinoma I-Disease
and O
cerebellar B-Disease
haemangioblastoma I-Disease
in O
vhl B-Disease
disease I-Disease
were O
compatible O
with O
a O
single O
mutation O
model O
, O
whereas O
the O
age O
incidence O
curves O
for O
sporadic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
and O
cerebellar B-Disease
haemangioblastoma I-Disease
suggested O
a O
two O
stage O
mutation O
process O
. O

these O
data O
are O
compatible O
with O
the O
vhl B-Disease
gene O
functioning O
as O
a O
recessive O
tumour B-Disease
suppressor O
gene O
. O

sporadic B-Disease
cerebellar I-Disease
haemangioblastoma I-Disease
and O
some O
renal B-Disease
cell I-Disease
carcinoma I-Disease
may O
arise O
from O
somatic O
mutations O
inactivating O
both O
alleles O
at O
the O
vhl B-Disease
locus O
. O
. O

screening O
for O
carriers O
of O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
among O
ashkenazi O
jews O
. O

the O
prevention O
of O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
gm2 B-Disease
gangliosidosis I-Disease
, I-Disease
type I-Disease
1 I-Disease
) O
depends O
on O
the O
identification O
of O
carriers O
of O
the O
gene O
for O
this O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
. O

we O
compared O
the O
enzyme O
- O
based O
test O
widely O
used O
in O
screening O
for O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
with O
a O
test O
based O
on O
analysis O
of O
dna O
. O

we O
developed O
methods O
to O
detect O
the O
three O
mutations O
in O
the O
hexa O
gene O
that O
occur O
with O
high O
frequency O
among O
ashkenazi O
jews O
two O
mutations O
cause O
infantile O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
, O
and O
the O
third O
causes O
the O
adult O
- O
onset O
form O
of O
the O
disease O
. O

among O
62 O
ashkenazi O
obligate O
carriers O
of O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
, O
the O
three O
specific O
mutations O
accounted O
for O
all O
but O
one O
of O
the O
mutant O
alleles O
( O
98 O
percent O
) O
. O

the O
increased O
specificity O
and O
predictive O
value O
of O
the O
dna O
- O
based O
test O
make O
it O
a O
useful O
adjunct O
to O
the O
diagnostic O
tests O
currently O
used O
to O
screen O
for O
carriers O
of O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
. O

total B-Disease
deficiency I-Disease
of I-Disease
plasma I-Disease
cholesteryl I-Disease
ester I-Disease
transfer I-Disease
protein I-Disease
in O
subjects O
homozygous O
and O
heterozygous O
for O
the O
intron O
14 O
splicing O
defect O
. O

the O
molecular O
basis O
of O
cholesteryl B-Disease
ester I-Disease
transfer I-Disease
protein I-Disease
( I-Disease
cetp I-Disease
) I-Disease
deficiency I-Disease
was O
investigated O
in O
4 O
unrelated O
cetp B-Disease
- I-Disease
deficient I-Disease
families O
. O

thus O
, O
other O
genetic B-Disease
defects I-Disease
or O
metabolic O
factors O
influencing O
cetp O
expression O
are O
implicated O
. O

the O
data O
suggest O
that O
the O
g O
- O
to O
- O
a O
mutation O
may O
be O
common O
in O
human O
plasma O
cetp B-Disease
deficiency I-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
; I-Disease
e I-Disease
. I-Disease
c I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
the O
most O
common O
human O
enzymopathy B-Disease
; O
more O
than O
300 O
different O
biochemical O
variants O
of O
the O
enzyme O
have O
been O
described O
. O

in O
many O
parts O
of O
the O
world O
the O
mediterranean O
type O
of O
g6pd B-Disease
deficiency I-Disease
is O
prevalent O
. O

a O
normal O
male O
with O
an O
inherited O
deletion O
of O
one O
exon O
within O
the O
dmd B-Disease
gene O
. O

we O
describe O
two O
brothers O
with O
identical O
inherited O
deletions O
of O
one O
single O
exon O
within O
the O
middle O
of O
the O
dmd B-Disease
gene O
; O
one O
brother O
has O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
diagnosed O
at O
11 O
years O
of O
age O
, O
whereas O
the O
older O
brother O
is O
normal O
at O
18 O
. O

these O
results O
have O
implications O
for O
genetic O
counselling O
and O
prenatal O
diagnosis O
in O
families O
with O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
. O

duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
expression O
in O
normal O
and O
diseased O
human O
muscle O
. O

a O
probe O
for O
the O
5 O
end O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
was O
used O
to O
study O
expression O
of O
the O
gene O
in O
normal O
human O
muscle O
, O
myogenic O
cell O
cultures O
, O
and O
muscle O
from O
patients O
with O
dmd B-Disease
. O

in O
dmd B-Disease
muscle O
, O
expression O
of O
this O
portion O
of O
the O
gene O
was O
also O
revealed O
by O
in O
situ O
rna O
hybridization O
, O
particularly O
in O
regenerating O
muscle O
fibers O
. O
. O

molecular O
and O
phenotypic O
analysis O
of O
patients O
with O
deletions O
within O
the O
deletion O
- O
rich O
region O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
. O

eighty O
unrelated O
individuals O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
or O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
( O
bmd B-Disease
) O
were O
found O
to O
have O
deletions O
in O
the O
major O
deletion O
- O
rich O
region O
of O
the O
dmd B-Disease
locus O
. O

thirty O
- O
eight O
independent O
patients O
were O
old O
enough O
to O
be O
classified O
as O
dmd B-Disease
, O
bmd B-Disease
, O
or O
intermediate O
phenotype O
and O
had O
deletions O
of O
exons O
with O
sequenced O
intron O
/ O
exon O
boundaries O
. O

of O
these O
, O
eight O
bmd B-Disease
patients O
and O
one O
intermediate O
patient O
had O
gene O
deletions O
predicted O
to O
leave O
the O
reading O
frame O
intact O
, O
while O
21 O
dmd B-Disease
patients O
, O
7 O
intermediate O
patients O
, O
and O
1 O
bmd B-Disease
patient O
had O
gene O
deletions O
predicted O
to O
disrupt O
the O
reading O
frame O
. O

chromosome O
translocations O
involving O
11p13 O
have O
been O
associated O
with O
familial B-Disease
aniridia I-Disease
in O
two O
kindreds O
highlighting O
the O
chromosomal O
localization O
of O
the O
an2 O
locus O
. O

this O
locus O
is O
also O
part O
of O
the O
wagr B-Disease
complex O
( O
wilms B-Disease
tumor I-Disease
, O
aniridia B-Disease
, O
genitourinary B-Disease
abnormalities I-Disease
, O
and O
mental B-Disease
retardation I-Disease
) O
. O

linkage O
analysis O
of O
the O
apolipoprotein O
c2 O
gene O
and O
myotonic B-Disease
dystrophy I-Disease
on O
human O
chromosome O
19 O
reveals O
linkage O
disequilibrium O
in O
a O
french O
- O
canadian O
population O
. O

the O
gene O
for O
human O
apolipoprotein O
c2 O
( O
apoc2 O
) O
, O
situated O
on O
the O
proximal O
long O
arm O
of O
chromosome O
19 O
, O
is O
closely O
linked O
to O
the O
gene O
for O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
dystrophy I-Disease
, O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

we O
have O
conducted O
a O
comprehensive O
dm B-Disease
linkage O
study O
utilizing O
all O
six O
rflps O
and O
involving O
50 O
families O
and O
372 O
individuals O
. O

phenylalanine O
hydroxylase O
gene O
haplotypes O
in O
polynesians O
: O
evolutionary O
origins O
and O
absence O
of O
alleles O
associated O
with O
severe O
phenylketonuria B-Disease
. O

the O
absence O
of O
severe O
phenylketonuria B-Disease
( O
pku B-Disease
) O
in O
both O
polynesians O
and O
southeast O
asians O
is O
consistent O
with O
the O
lack O
of O
pah O
haplotypes O
2 O
and O
3 O
, O
on O
which O
the O
severe O
pku B-Disease
mutants O
have O
arisen O
among O
caucasians O
. O

preferential O
germline O
mutation O
of O
the O
paternal O
allele O
in O
retinoblastoma B-Disease
. O

the O
event O
triggering O
malignant O
proliferation O
in O
70 O
% O
of O
retinoblastoma B-Disease
tumours I-Disease
is O
loss O
of O
heterozygosity O
for O
chromosome O
13q14 O
, O
whereby O
the O
normal O
retinoblastoma B-Disease
gene O
( O
rb1 O
) O
allele O
is O
lost O
and O
an O
already O
mutated O
rb1 O
allele O
remains O
in O
the O
tumour B-Disease
. O

most O
bilateral O
patients O
have O
no O
family O
history O
of O
retinoblastoma B-Disease
and O
are O
presumed O
to O
have O
new O
germline O
mutations O
which O
arose O
in O
the O
egg O
, O
sperm O
or O
early O
embryo O
. O

we O
have O
determined O
the O
parental O
origin O
of O
the O
retained O
allele O
in O
nine O
retinoblastoma B-Disease
tumours I-Disease
from O
eight O
unrelated O
non O
- O
familial O
cases O
by O
using O
rb1 O
- O
linked O
genetic O
markers O
. O

six O
tumours B-Disease
retained O
the O
paternal O
allele O
and O
three O
retained O
the O
maternal O
allele O
. O

of O
the O
three O
unilateral B-Disease
tumours I-Disease
, O
only O
one O
retained O
the O
paternal O
rb1 O
allele O
. O

thus O
, O
there O
is O
no O
evidence O
that O
the O
paternal O
rb1 O
allele O
is O
preferentially O
retained O
in O
retinoblastoma B-Disease
, O
as O
has O
been O
suggested O
to O
be O
the O
case O
in O
osteosarcoma B-Disease
. O

by O
contrast O
, O
tumours B-Disease
from O
four O
of O
the O
five O
bilateral O
patients O
retained O
the O
paternal O
rb1 O
allele O
. O

haplotype O
analysis O
of O
the O
phenylalanine O
hydroxylase O
gene O
in O
turkish O
phenylketonuria B-Disease
families O
. O

we O
have O
estimated O
the O
haplotype O
distribution O
of O
mutant O
and O
normal O
phenylalanine O
hydroxylase O
( O
pah O
) O
alleles O
for O
17 O
turkish O
phenylketonuria B-Disease
( O
pku B-Disease
) O
families O
20 O
normal O
and O
27 O
mutated O
pah O
alleles O
could O
be O
identified O
. O

huntington B-Disease
disease I-Disease
: O
no O
evidence O
for O
locus O
heterogeneity O
. O

a O
total O
of O
63 O
families O
with O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
were O
examined O
for O
linkage O
between O
hd B-Disease
and O
g8 O
( O
d4s10 O
) O
. O

these O
data O
suggest O
that O
there O
is O
only O
one O
hd B-Disease
locus O
, O
although O
a O
second O
rare O
locus O
cannot O
be O
ruled O
out O
. O

haplotype O
and O
multipoint O
linkage O
analysis O
in O
finnish O
choroideremia B-Disease
families O
. O

multipoint O
linkage O
analysis O
of O
choroideremia B-Disease
( O
tcd B-Disease
) O
and O
seven O
x O
chromosomal O
restriction O
fragment O
length O
polymorphisms O
( O
rflps O
) O
was O
carried O
out O
in O
18 O
finnish O
tcd B-Disease
families O
. O

the O
data O
place O
tcd B-Disease
distal O
to O
pgk O
and O
dxs72 O
, O
very O
close O
to O
dxys1 O
and O
dxys5 O
( O
zmax O
= O
24 O
at O
theta O
= O
0 O
) O
and O
proximal O
to O
dxys4 O
and O
dxys12 O
. O

all O
the O
tcd B-Disease
males O
and O
carrier O
females O
studied O
have O
the O
same O
dxys1 O
allele O
in O
coupling O
with O
tcd B-Disease
. O

in O
northeastern O
finland O
, O
66 O
/ O
69 O
chromosomes O
carrying O
tcd B-Disease
had O
the O
same O
haplotype O
at O
loci O
dxs72 O
, O
dxys1 O
, O
dxys4 O
, O
and O
dxys12 O
. O

the O
same O
haplotype O
is O
seen O
in O
only O
15 O
/ O
99 O
chromosomes O
not O
carrying O
tcd B-Disease
. O

moreover O
, O
in O
71 O
/ O
104 O
non O
- O
tcd O
chromosomes O
, O
the O
haplotype O
at O
six O
marker O
loci O
is O
different O
from O
those O
seen O
in O
any O
of O
the O
76 O
tcd B-Disease
chromosomes O
. O

this O
supports O
the O
previously O
described O
hypothesis O
that O
the O
large O
northern O
finnish O
choroideremia B-Disease
pedigrees O
, O
comprising O
a O
total O
of O
over O
80 O
living O
patients O
representing O
more O
than O
a O
fifth O
of O
all O
tcd B-Disease
patients O
described O
worldwide O
, O
carry O
the O
same O
mutation O
. O

autosomal O
dominant O
aniridia B-Disease
linked O
to O
the O
chromosome O
11p13 O
markers O
catalase O
and O
d11s151 O
in O
a O
large O
dutch O
family O
. O

in O
a O
large O
pedigree O
with O
autosomal O
dominant O
aniridia B-Disease
, O
we O
found O
close O
linkage O
between O
the O
aniridia B-Disease
locus O
an2 O
and O
the O
markers O
catalase O
( O
cat O
) O
( O
zeta O
= O
7 O
. O
27 O
at O
theta O
= O
0 O
. O
00 O
) O
and O
d11s151 O
( O
zeta O
= O
3 O
. O
86 O
at O
theta O
= O
0 O
. O
10 O
) O
flanking O
the O
an2 O
locus O
on O
11p13 O
. O

we O
conclude O
that O
the O
autosomal O
dominant O
aniridia B-Disease
in O
this O
family O
is O
due O
to O
a O
mutation O
at O
the O
an2 O
locus O
on O
11p13 O
. O

we O
have O
excluded O
linkage O
( O
zeta O
less O
than O
- O
2 O
at O
theta O
less O
than O
0 O
. O
18 O
) O
between O
the O
aniridia B-Disease
and O
the O
chromosome O
2p25 O
marker O
d2s1 O
( O
linked O
to O
acp1 O
) O
. O

recombination O
events O
that O
locate O
myotonic B-Disease
dystrophy I-Disease
distal O
to O
apoc2 O
on O
19q O
. O

we O
previously O
reported O
a O
recombination O
in O
an O
individual O
with O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
which O
placed O
the O
markers O
d19s19 O
and O
apoc2 O
on O
the O
same O
side O
of O
the O
dm B-Disease
locus O
. O

haplotyping O
of O
this O
family O
with O
more O
recently O
characterized O
probes O
which O
are O
either O
tightly O
linked O
to O
dm B-Disease
or O
distal O
to O
the O
linkage O
group O
at O
q13 O
. O

2 O
shows O
that O
the O
dm B-Disease
locus O
is O
distal O
to O
apoc2 O
. O

the O
consequences O
of O
this O
probe O
order O
for O
antenatal O
diagnosis O
and O
future O
research O
aiming O
to O
isolate O
the O
gene O
which O
is O
affected O
in O
dm B-Disease
are O
discussed O
. O

inactivation O
of O
both O
alleles O
of O
the O
rb1 O
gene O
during O
normal O
retinal O
development O
initiates O
the O
formation O
of O
a O
retinoblastoma B-Disease
( I-Disease
rb I-Disease
) I-Disease
tumor I-Disease
. O

to O
identify O
the O
mutations O
which O
inactivate O
rb1 O
, O
21 O
rb B-Disease
tumors I-Disease
isolated O
from O
19 O
patients O
were O
analyzed O
with O
the O
polymerase O
chain O
reaction O
or O
an O
rnase O
protection O
assay O
or O
both O
. O

mutations O
were O
identified O
in O
13 O
of O
21 O
rb B-Disease
tumors I-Disease
; O
in O
8 O
tumors B-Disease
, O
the O
precise O
errors O
in O
nucleotide O
sequence O
were O
characterized O
. O

we O
were O
unable O
to O
detect O
expression O
of O
the O
mutant O
allele O
in O
lymphoblasts O
of O
three O
bilaterally O
affected O
patients O
, O
although O
the O
mutation O
was O
present O
in O
the O
genomic O
dna O
and O
transcripts O
containing O
the O
mutations O
were O
obvious O
in O
the O
rb B-Disease
tumors I-Disease
in O
the O
absence O
of O
a O
normal O
rb1 O
allele O
. O

partial O
deletion O
8q O
without O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
: O
a O
recognisable O
syndrome O
. O

the O
clinical O
features O
were O
similar O
and O
there O
were O
no O
obvious O
stigmata O
of O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
( O
lgs B-Disease
) O
. O

there O
are O
three O
other O
cases O
reported O
with O
a O
deletion O
of O
chromosome O
8 O
at O
approximately O
the O
same O
breakpoint O
, O
one O
without O
lgs B-Disease
and O
some O
similarities O
to O
our O
cases O
, O
the O
other O
two O
with O
lgs B-Disease
. O

our O
findings O
would O
support O
the O
observation O
that O
the O
critical O
segment O
for O
the O
assignment O
of O
lgs B-Disease
is O
proximal O
to O
or O
involves O
the O
proximal O
part O
of O
8q24 O
. O

1 O
, O
but O
a O
review O
of O
published O
reports O
suggests O
that O
the O
aetiology O
of O
lgs B-Disease
may O
be O
a O
more O
complex O
issue O

myotonic B-Disease
dystrophy I-Disease
is O
closely O
linked O
to O
the O
gene O
for O
muscle O
- O
type O
creatine O
kinase O
( O
ckmm O
) O
. O

we O
have O
studied O
genetic O
linkage O
between O
the O
gene O
for O
creatine O
kinase O
muscle O
type O
( O
ckmm O
) O
and O
the O
gene O
for O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

in O
a O
panel O
of O
65 O
myotonic B-Disease
dystrophy I-Disease
families O
from O
canada O
and O
the O
netherlands O
, O
a O
maximum O
lod O
score O
( O
zmax O
) O
of O
22 O
. O

this O
establishes O
ckmm O
as O
a O
useful O
marker O
for O
myotonic B-Disease
dystrophy I-Disease

color B-Disease
vision I-Disease
defects I-Disease
in O
adrenomyeloneuropathy B-Disease
. O

the O
relationship O
between O
abnormal B-Disease
color I-Disease
vision I-Disease
and O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
was O
investigated O
in O
27 O
amn B-Disease
patients O
and O
31 O
age O
- O
matched O
controls O
by O
using O
the O
farnsworth O
- O
munsell O
100 O
hue O
test O
. O

the O
axes O
of O
bipolarity O
determined O
by O
the O
testing O
differed O
widely O
between O
the O
patients O
with O
abnormal O
scores O
, O
compatible O
with O
the O
notion O
that O
different O
alterations O
in O
visual O
pigment O
genes O
occur O
in O
different O
amn B-Disease
kindreds O
. O

these O
observations O
confirm O
our O
earlier O
impression O
that O
the O
frequency O
of O
abnormal B-Disease
color I-Disease
vision I-Disease
is O
increased O
in O
these O
kindreds O
, O
and O
it O
supports O
our O
contentions O
that O
( O
1 O
) O
amn B-Disease
( O
and O
its O
companion O
, O
adrenoleukodystrophy B-Disease
) O
are O
very O
closely O
linked O
to O
the O
visual O
pigment O
loci O
at O
xq28 O
and O
( O
2 O
) O
this O
proximity O
might O
provide O
the O
opportunity O
to O
observe O
contiguous B-Disease
gene I-Disease
defects I-Disease
. O
. O

molecular O
analysis O
of O
a O
female O
lesch B-Disease
- I-Disease
nyhan I-Disease
patient O
. O

we O
report O
the O
identification O
of O
a O
female O
patient O
with O
the O
x O
- O
linked O
recessive O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
( O
hypoxanthine B-Disease
phosphoribosyltransferase I-Disease
[ I-Disease
hprt I-Disease
] I-Disease
deficiency I-Disease
) O
. O

pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
: O
an O
x B-Disease
- I-Disease
linked I-Disease
neurologic I-Disease
disorder I-Disease
of I-Disease
myelin I-Disease
metabolism I-Disease
with O
a O
novel O
mutation O
in O
the O
gene O
encoding O
proteolipid O
protein O
. O

the O
nosology O
of O
the O
inborn B-Disease
errors I-Disease
of I-Disease
myelin I-Disease
metabolism I-Disease
has O
been O
stymied O
by O
the O
lack O
of O
molecular O
genetic O
analysis O
. O

historically O
, O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
has O
encompassed O
a O
host O
of O
neurologic B-Disease
disorders I-Disease
that O
present O
with O
a O
deficit B-Disease
of I-Disease
myelin I-Disease
, O
the O
membrane O
elaborated O
by O
glial O
cells O
that O
encircles O
and O
successively O
enwraps O
axons O
. O

we O
describe O
here O
a O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
pedigree O
of O
the O
classical O
type O
, O
with O
x O
- O
linked O
inheritance O
, O
a O
typical O
clinical O
progression O
, O
and O
a O
pathologic O
loss O
of O
myelinating O
cells O
and O
myelin O
in O
the O
central O
nervous O
system O
. O

to O
discriminate O
variants O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
, O
a O
set O
of O
oligonucleotide O
primers O
was O
constructed O
to O
polymerase O
- O
chain O
- O
reaction O
( O
pcr O
) O
amplify O
and O
sequence O
the O
gene O
encoding O
proteolipid O
protein O
( O
plp O
) O
, O
a O
structural O
protein O
that O
comprises O
half O
of O
the O
protein O
of O
the O
myelin O
sheath O
. O

our O
results O
delineate O
the O
clinical O
features O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
, O
define O
the O
possible O
molecular O
pathology O
of O
this O
dysmyelinating B-Disease
disorder I-Disease
, O
and O
address O
the O
molecular O
classification O
of O
inborn B-Disease
errors I-Disease
of I-Disease
myelin I-Disease
metabolism I-Disease
. O

patients O
with O
the O
classical O
form O
( O
type O
i O
) O
and O
the O
more O
severely O
affected O
, O
connatal O
variant O
of O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( I-Disease
type I-Disease
ii I-Disease
) I-Disease
would O
be O
predicted O
to O
display O
mutation O
at O
the O
plp O
locus O
. O

the O
other O
variants O
( O
types O
iii O
- O
vi O
) O
, O
which O
have O
sometimes O
been O
categorized O
as O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
, O
may O
represent O
mutations O
in O
genes O
encoding O
other O
structural O
myelin O
proteins O
or O
proteins O
critical O
to O
myelination O
. O
. O

molecular O
basis O
of O
human O
von B-Disease
willebrand I-Disease
disease I-Disease
: O
analysis O
of O
platelet O
von B-Disease
willebrand I-Disease
factor O
mrna O
. O

von B-Disease
willebrand I-Disease
disease I-Disease
( O
vwd B-Disease
) O
, O
the O
most O
common O
inherited B-Disease
bleeding I-Disease
disorder I-Disease
in O
humans O
, O
can O
result O
from O
either O
a O
quantitative O
or O
a O
qualitative O
defect O
in O
the O
adhesive O
glycoprotein O
, O
von B-Disease
willebrand I-Disease
factor O
( O
vwf O
) O
. O

molecular O
studies O
of O
vwd B-Disease
have O
been O
limited O
by O
the O
large O
size O
of O
the O
vwf O
gene O
and O
difficulty O
in O
obtaining O
the O
vwf O
mrna O
from O
patients O
. O

in O
two O
type B-Disease
iia I-Disease
vwd I-Disease
patients O
, O
two O
different O
but O
adjacent O
missense O
mutations O
were O
identified O
, O
the O
locations O
of O
which O
may O
identify O
an O
important O
vwf O
functional O
domain O
. O

expression O
in O
heterologous O
cells O
of O
recombinant O
vwf O
containing O
one O
of O
these O
latter O
mutations O
reproduced O
the O
characteristic O
structural O
abnormality O
seen O
in O
type B-Disease
iia I-Disease
vwd I-Disease
plasma O
. O

familial B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
associated O
with O
recurrent O
meningococcal B-Disease
infections I-Disease
. O

we O
describe O
an O
11 O
- O
year O
- O
old O
girl O
suffering O
from O
recurrent B-Disease
meningitis I-Disease
with O
a O
complete O
absence B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c7 O
) O
. O

the O
relatives O
( O
parents O
and O
one O
sister O
) O
had O
half O
- O
normal O
levels O
of O
both O
immunochemically O
and O
functionally O
determined O
c7 O
, O
indicating O
a O
heterozygous O
state O
for O
c7 B-Disease
deficiency I-Disease
. O
. O

translocation O
t O
( O
5 O
; O
11 O
) O
( O
q13 O
. O
1 O
; O
p13 O
) O
associated O
with O
familial O
isolated B-Disease
aniridia I-Disease
. O

a O
father O
and O
daughter O
with O
isolated B-Disease
aniridia I-Disease
were O
observed O
to O
have O
an O
apparently O
balanced O
, O
reciprocal O
translocation O
involving O
chromosomes O
5 O
and O
11 O
[ O
t O
( O
5 O
; O
11 O
) O
( O
q13 O
. O
1 O
; O
p13 O
) O
] O
. O

this O
finding O
, O
in O
association O
with O
3 O
other O
instances O
of O
single O
breaks O
at O
11p13 O
and O
aniridia B-Disease
, O
supports O
the O
assignment O
of O
an2 O
to O
11p13 O
. O

homozygous B-Disease
hypobetalipoproteinemia I-Disease
: O
a O
disease O
distinct O
from O
abetalipoproproteinemia B-Disease
at O
the O
molecular O
level O
. O

apob O
dna O
, O
rna O
, O
and O
protein O
from O
two O
patients O
with O
homozygous B-Disease
hypobetalipoproteinemia I-Disease
( O
hbl B-Disease
) O
were O
evaluated O
and O
compared O
with O
normal O
individuals O
. O

northern O
and O
slot O
blot O
analyses O
of O
total O
liver O
mrna O
from O
hbl B-Disease
patients O
documented O
a O
normal O
size O
apob O
mrna O
that O
was O
present O
in O
greatly O
reduced O
quantities O
. O

no O
apob O
was O
detectable O
in O
the O
plasma O
of O
hbl B-Disease
individuals O
with O
an O
elisa O
assay O
. O

these O
data O
are O
most O
consistent O
with O
a O
mutation O
in O
the O
coding O
portion O
of O
the O
apob O
gene O
in O
hbl B-Disease
patients O
, O
leading O
to O
an O
abnormal O
apob O
protein O
and O
apob O
mrna O
instability O
. O

these O
results O
are O
distinct O
from O
those O
previously O
noted O
in O
abetalipoproteinemia B-Disease
, O
which O
was O
characterized O
by O
an O
elevated O
level O
of O
hepatic O
apob O
mrna O
and O
accumulation O
of O
intracellular O
hepatic O
apob O
protein O
. O
. O

spontaneous O
reversion O
of O
novel O
lesch B-Disease
- I-Disease
nyhan I-Disease
mutation O
by O
hprt O
gene O
rearrangement O
. O

molecular O
analysis O
of O
an O
unusual O
patient O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
has O
suggested O
that O
the O
mutation O
is O
due O
to O
a O
partial O
hprt O
gene O
duplication O
. O

growth O
of O
epstein B-Disease
- I-Disease
barr I-Disease
virus O
- O
transformed O
lymphoblasts O
from O
this O
patient O
in O
selective O
medium O
has O
permitted O
isolation O
of O
spontaneous O
hprt O
+ O
revertants O
of O
this O
mutation O
. O

this O
may O
explain O
the O
relatively O
mild O
symptoms O
of O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
exhibited O
by O
this O
patient O
. O

complex B-Disease
glycerol I-Disease
kinase I-Disease
deficiency I-Disease
: O
molecular O
- O
genetic O
, O
cytogenetic O
, O
and O
clinical O
studies O
of O
five O
japanese O
patients O
. O

five O
male O
japanese O
patients O
with O
complex B-Disease
glycerol I-Disease
kinase I-Disease
deficiency I-Disease
( O
cgkd B-Disease
) O
and O
their O
relatives O
were O
studied O
clinically O
, O
cytogenetically O
, O
and O
molecular O
- O
genetically O
. O

all O
patients O
had O
muscular B-Disease
dystrophy I-Disease
or O
muscle B-Disease
weakness I-Disease
, O
mental B-Disease
retardation I-Disease
, O
congenital B-Disease
adrenal I-Disease
hypoplasia I-Disease
, O
and O
glycerol B-Disease
kinase I-Disease
deficiency I-Disease
. O

a O
comparison O
of O
the O
clinical O
manifestations O
of O
the O
present O
five O
patients O
and O
reported O
cgkd B-Disease
or O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
patients O
with O
dna O
deletion O
suggests O
the O
existence O
of O
a O
certain O
gene O
responsible O
for O
gonadotropin B-Disease
deficiency I-Disease
( O
gtd B-Disease
) O
. O

the O
result O
of O
the O
present O
study O
and O
results O
of O
previous O
studies O
suggest O
that O
genes O
for O
ornithine O
transcarbamylase O
( O
otc O
) O
, O
dmd B-Disease
, O
and O
gk O
and O
putative O
genes O
responsible O
for O
congenital B-Disease
adrenal I-Disease
hypoplasia I-Disease
( O
ahc B-Disease
) O
and O
gtd B-Disease
are O
arranged O
from O
telomere O
to O
centromere O
as O
pter O
- O
- O
gtd O
- O
- O
ahc O
- O
- O
gk O
- O
- O
dmd O
- O
- O
otc O
- O
- O
cen O

genetically O
determined O
low O
c4 O
: O
a O
predisposing O
factor O
to O
autoimmune B-Disease
chronic I-Disease
active I-Disease
hepatitis I-Disease
. O

of O
26 O
patients O
with O
autoimmune B-Disease
chronic I-Disease
active I-Disease
hepatitis I-Disease
( O
cah B-Disease
) O
starting O
in O
childhood O
18 O
( O
69 O
% O
) O
had O
low O
c4 O
and O
5 O
( O
19 O
% O
) O
had O
low O
c3 O
serum O
levels O
. O

these O
results O
suggest O
that O
low O
c4 O
levels O
in O
cah B-Disease
are O
genetically O
determined O
. O

c4 O
phenotyping O
in O
20 O
patients O
and O
in O
26 O
parents O
showed O
that O
90 O
% O
and O
81 O
% O
, O
respectively O
, O
had O
null O
allotypes O
at O
either O
the O
c4a O
or O
c4b O
locus O
compared O
with O
59 O
% O
in O
controls O
, O
indicating O
that O
defective O
expression O
of O
structural O
genes O
may O
contribute O
to O
the O
observed O
c4 B-Disease
deficiency I-Disease
. O

an O
amino O
- O
acid O
substitution O
involved O
in O
phenylketonuria B-Disease
is O
in O
linkage O
disequilibrium O
with O
dna O
haplotype O
2 O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
human I-Disease
genetic I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
hepatic I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
, O
phenylalanine O
4 O
- O
monooxygenase O
, O
ec O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

pku B-Disease
is O
a O
common O
inborn B-Disease
error I-Disease
of I-Disease
amino I-Disease
- I-Disease
acid I-Disease
metabolism I-Disease
in O
caucasian O
populations O
and O
approximately O
1 O
in O
50 O
individuals O
are O
carriers O
of O
a O
pku B-Disease
allele O
. O

to O
define O
the O
molecular O
basis O
of O
pku B-Disease
, O
we O
characterized O
twelve O
restriction O
fragment O
- O
length O
polymorphism O
( O
rflp O
) O
haplotypes O
of O
the O
pah O
locus O
in O
the O
northern O
european O
population O
and O
observed O
that O
90 O
% O
of O
the O
pku B-Disease
alleles O
in O
this O
population O
are O
confined O
to O
four O
common O
rflp O
haplotypes O
. O

we O
now O
report O
the O
molecular B-Disease
lesion I-Disease
associated O
with O
the O
rflp O
haplotype O
2 O
mutant O
allele O
. O

choroideremia B-Disease
: O
close O
linkage O
to O
dxys1 O
and O
dxys12 O
demonstrated O
by O
segregation O
analysis O
and O
historical O
- O
genealogical O
evidence O
. O

linkage O
studies O
using O
restriction O
fragment O
length O
polymorphisms O
were O
conducted O
in O
the O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
, O
choroideremia B-Disease
, O
designated O
tcd B-Disease
for O
progressive B-Disease
tapeto I-Disease
- I-Disease
choroidal I-Disease
dystrophy I-Disease
. O

in O
addition O
, O
locus O
dxys12 O
was O
found O
to O
be O
closely O
linked O
with O
tcd B-Disease
( O
lod O
3 O
. O
31 O
at O
0 O
recombination O
distance O
) O
. O

all O
36 O
patients O
and O
48 O
carriers O
tested O
from O
the O
three O
kindreds O
had O
the O
same O
haplotype O
( O
tcd B-Disease
/ O
dxys1 O
, O
11kb O
/ O
dxys12 O
, O
1 O
. O
6kb O
) O
. O

given O
that O
at O
least O
105 O
female O
meioses O
transmitting O
tcd B-Disease
have O
occurred O
since O
1650 O
in O
these O
kindreds O
, O
extremely O
close O
linkage O
between O
tcd B-Disease
, O
dxys1 O
and O
dxys12 O
is O
suggested O
. O

the O
above O
haplotype O
is O
a O
very O
useful O
diagnostic O
tool O
in O
these O
tcd B-Disease
families O
. O

we O
suggest O
that O
our O
historical O
- O
genealogical O
approach O
to O
linkage O
analysis O
may O
be O
possible O
elsewhere O
in O
similar O
isolated O
populations O

von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
maps O
to O
the O
region O
of O
chromosome O
3 O
associated O
with O
renal B-Disease
cell I-Disease
carcinoma I-Disease
. O

von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
( O
vhl B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
with O
inherited O
susceptibility O
to O
various O
forms O
of O
cancer B-Disease
, O
including O
hemangioblastomas B-Disease
of O
the O
central O
nervous O
system O
, O
phaeochromocytomas B-Disease
, O
pancreatic B-Disease
malignancies I-Disease
, O
and O
renal B-Disease
cell I-Disease
carcinomas I-Disease
. O

renal B-Disease
cell I-Disease
carcinomas I-Disease
constitute O
a O
particularly O
frequent O
cause O
of O
death O
in O
this O
disorder O
, O
occurring O
as O
bilateral B-Disease
and I-Disease
multifocal I-Disease
tumours I-Disease
, O
and O
presenting O
at O
an O
earlier O
age O
than O
in O
sporadic O
, O
non O
- O
familial O
cases O
of O
this O
tumour B-Disease
type O
. O

we O
report O
here O
that O
the O
vhl B-Disease
gene O
is O
linked O
to O
the O
locus O
encoding O
the O
human O
homologoue O
of O
the O
raf1 O
oncogene O
, O
which O
maps O
to O
chromosome O
3p25 O
( O
ref O
. O
4 O
) O
. O

crossovers O
with O
the O
vhl B-Disease
locus O
suggest O
that O
the O
defect O
responsible O
for O
the O
vhl B-Disease
phenotype O
is O
not O
a O
mutation O
in O
the O
raf1 O
gene O
itself O
. O

an O
alternative O
or O
prior O
event O
to O
oncogene O
activation O
in O
tumour B-Disease
formation O
may O
be O
the O
inactivation O
of O
a O
putative O
tumour B-Disease
suppressor O
which O
can O
be O
associated O
with O
both O
the O
inherited B-Disease
and I-Disease
sporadic I-Disease
forms I-Disease
of I-Disease
the I-Disease
cancer I-Disease
. O

sporadic B-Disease
renal I-Disease
cell I-Disease
carcinomas I-Disease
have O
previously O
been O
associated O
with O
the O
loss O
of O
regions O
on O
chromosome O
3p O
( O
refs O
5 O
, O
6 O
) O
. O

consequently O
, O
sporadic O
and O
vhl O
- O
associated O
forms O
of O
renal B-Disease
cell I-Disease
carcinoma I-Disease
might O
both O
result O
from O
alterations O
causing O
loss O
of O
function O
of O
the O
same O
tumour B-Disease
suppressor O
gene O
on O
this O
chromosome O
. O

tightly O
linked O
flanking O
markers O
for O
the O
lowe B-Disease
oculocerebrorenal I-Disease
syndrome I-Disease
, O
with O
application O
to O
carrier O
assessment O
. O

the O
lowe B-Disease
oculocerebrorenal I-Disease
syndrome I-Disease
( O
ocrl B-Disease
) O
is O
characterized O
by O
congenital O
cataract B-Disease
, O
mental B-Disease
retardation I-Disease
, O
and O
defective B-Disease
renal I-Disease
tubular I-Disease
function I-Disease
. O

a O
map O
assignment O
of O
ocrl B-Disease
to O
xq24 O
- O
q26 O
has O
been O
made O
previously O
by O
linkage O
analysis O
with O
dxs42 O
at O
xq24 O
- O
q26 O
( O
theta O
= O
0 O
, O
z O
= O
5 O
. O
09 O
) O
and O
with O
dxs10 O
at O
xq26 O
( O
theta O
= O
0 O
, O
z O
= O
6 O
. O
45 O
) O
. O

with O
additional O
ocrl B-Disease
families O
made O
informative O
for O
dxs42 O
, O
theta O
remained O
0 O
with O
z O
= O
6 O
. O

evidence O
for O
placing O
ocrl O
at O
xq25 O
also O
comes O
from O
a O
female O
with O
lowe B-Disease
syndrome I-Disease
and O
an O
x O
; O
3 O
translocation O
. O

the O
markers O
dxs10 O
and O
dxs42 O
therefore O
show O
tight O
linkage O
with O
ocrl B-Disease
in O
six O
families O
and O
flank O
the O
xq25 O
breakpoint O
in O
a O
female O
patient O
with O
an O
x O
; O
3 O
translocation O
. O

linkage O
analysis O
with O
flanking O
markers O
was O
used O
to O
assess O
ocrl B-Disease
carrier O
status O
in O
women O
at O
risk O
. O

identification O
of O
a O
single O
nucleotide O
change O
in O
the O
hypoxanthine O
- O
guanine O
phosphoribosyltransferase O
gene O
( O
hprtyale O
) O
responsible O
for O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

complete O
deficiency B-Disease
of I-Disease
hypoxanthine I-Disease
- I-Disease
guanine I-Disease
phosphoribosyltransferase I-Disease
( O
hprt O
) O
causes O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

previous O
characterization O
of O
a O
mutant O
form O
of O
hprt O
, O
hprtyale O
, O
from O
a O
subject O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
revealed O
normal O
mrna O
and O
protein O
concentrations O
, O
no O
residual O
catalytic O
activity O
, O
and O
cathodal O
migration O
upon O
page O
. O

g6pd B-Disease
deficiency I-Disease
in O
different O
geographical O
areas O
appears O
to O
have O
arisen O
through O
independent O
mutational O
events O
, O
but O
within O
the O
same O
population O
it O
may O
also O
be O
heterogeneous O
. O

we O
cloned O
and O
sequenced O
the O
four O
g6pd O
variants O
from O
sardinia O
and O
found O
that O
only O
two O
mutations O
are O
responsible O
for O
g6pd B-Disease
deficiency I-Disease
in O
this O
area O
one O
mutation O
is O
the O
cause O
of O
the O
g6pd B-Disease
seattle I-Disease
- I-Disease
like I-Disease
phenotype I-Disease
, O
a O
milder O
form O
of O
g6pd B-Disease
deficiency I-Disease
; O
the O
other O
mutation O
is O
responsible O
for O
all O
forms O
of O
very O
severe O
g6pd B-Disease
deficiency I-Disease
in O
sardinia O
and O
, O
possibly O
, O
in O
the O
mediterranean O
. O
. O

chronic B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
( O
cnsha B-Disease
) O
and O
glucose B-Disease
6 I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
a O
patient O
with O
familial B-Disease
amyloidotic I-Disease
polyneuropathy I-Disease
( O
fap B-Disease
) O
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
variant O
with O
severe O
erythrocytic B-Disease
g6pd I-Disease
deficiency I-Disease
and O
a O
unique O
ph O
optimum O
is O
described O
in O
a O
young O
patient O
with O
chronic B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
( O
cnsha B-Disease
) O
and O
familial B-Disease
amyloidotic I-Disease
polyneuropathy I-Disease
( O
fap B-Disease
) O
. O

chronic B-Disease
hemolysis I-Disease
was O
present O
in O
the O
absence O
of O
infections O
, O
oxidant O
drugs O
or O
ingestion O
of O
faba O
beans O
. O

molecular O
detection O
of O
chromosomal O
translocations O
that O
disrupt O
the O
putative O
retinoblastoma B-Disease
susceptibility O
locus O
. O

a O
candidate O
dna O
sequence O
with O
many O
of O
the O
properties O
predicted O
for O
the O
retinoblastoma B-Disease
susceptibility O
( O
rb1 O
) O
locus O
has O
been O
cloned O
( O
s O
. O
h O
. O
friend O
, O
r O
. O
bernards O
, O
s O
. O
rogelj O
, O
r O
. O
a O
. O
weinberg O
, O
j O
. O
m O
. O
rapaport O
, O
d O
. O
m O
. O
albert O
, O
and O
t O
. O
p O
. O
dryja O
, O
nature O
[ O
london O
] O
323 O
643 O
- O
645 O
, O
1986 O
) O
. O

here O
we O
used O
field O
inversion O
gel O
electrophoresis O
( O
fige O
) O
to O
construct O
a O
restriction O
map O
of O
approximately O
1 O
, O
000 O
kb O
of O
dna O
surrounding O
the O
rb1 O
locus O
and O
to O
detect O
the O
translocation O
breakpoints O
in O
three O
retinoblastoma B-Disease
patients O
. O

the O
detection O
and O
mapping O
of O
the O
translocation O
breakpoints O
of O
all O
three O
retinoblastoma B-Disease
patients O
to O
within O
the O
putative O
rb1 O
gene O
substantiated O
the O
authenticity O
of O
this O
candidate O
sequence O
and O
demonstrated O
the O
utility O
of O
fige O
in O
detecting O
chromosomal O
rearrangements O
affecting O
this O
locus O
. O

inherited O
c3 B-Disease
deficiency I-Disease
with O
recurrent O
infections O
and O
glomerulonephritis B-Disease
. O

a O
10 O
- O
year O
- O
old O
laotian O
boy O
had O
homozygous O
deficiency B-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
and O
recurrent O
bacterial B-Disease
infections I-Disease
beginning O
at O
age O
5 O
months O
. O

in O
vitro O
addition O
of O
purified O
c3 O
to O
patient O
serum O
restored O
hemolytic O
complement O
to O
normal O
levels O
, O
and O
plasma O
infusion O
during O
each O
of O
four O
episodes O
of O
pneumonia B-Disease
significantly O
enhanced O
serum O
opsonic O
activity O
for O
as O
long O
as O
36 O
hours O
. O

a O
renal O
biopsy O
specimen O
revealed O
mesangiopathic B-Disease
glomerulonephritis I-Disease
, O
although O
significant O
levels O
of O
circulating O
igg O
immune O
complexes O
were O
not O
detected O
. O

these O
findings O
further O
support O
the O
association O
of O
c3 B-Disease
deficiency I-Disease
with O
immune B-Disease
- I-Disease
complex I-Disease
disease I-Disease
and O
suggest O
that O
plasma O
infusion O
may O
be O
an O
adjunct O
to O
antibiotic O
therapy O
in O
the O
management O
of O
severe O
pyogenic B-Disease
infections I-Disease
in O
patients O
with O
c3 B-Disease
deficiency I-Disease
. O

a O
deficiency B-Disease
of I-Disease
aat I-Disease
in O
individuals O
homozygous O
for O
the O
pi O
z O
allele O
occurs O
in O
about O
1 O
in O
2 O
, O
000 O
- O
8 O
, O
000 O
caucasians O
and O
is O
associated O
with O
an O
increased O
risk O
of O
early O
adult O
onset O
emphysema B-Disease
and O
liver B-Disease
disease I-Disease
in O
childhood O
. O

segregation O
analysis O
of O
a O
marker O
localised O
xp21 O
. O
2 O
- O
xp21 O
. O
3 O
in O
duchenne B-Disease
and I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
families O
. O

3 O
, O
has O
been O
studied O
in O
kindreds O
segregating O
for O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
and O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
( O
bmd B-Disease
) O
. O

in O
dmd B-Disease
families O
four O
crossovers O
were O
observed O
in O
38 O
informative O
meioses O
between O
c7 O
and O
the O
dmd B-Disease
locus O
( O
theta O
= O
0 O
. O
12 O
, O
z O
max O
= O
+ O
2 O
. O
72 O
) O
. O

in O
bmd B-Disease
families O
no O
recombinants O
were O
observed O
in O
the O
16 O
informative O
meioses O
studied O
. O

c7 O
and O
754 O
thus O
provide O
good O
bridging O
markers O
for O
the O
diagnosis O
of O
dmd B-Disease
and O
bmd B-Disease

isolation O
of O
molecular O
probes O
associated O
with O
the O
chromosome O
15 O
instability O
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

flow O
cytometry O
and O
recombinant O
dna O
techniques O
have O
been O
used O
to O
obtain O
reagents O
for O
a O
molecular O
analysis O
of O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

2 O
and O
are O
shown O
to O
be O
deleted O
in O
dna O
of O
one O
of O
two O
patients O
examined O
with O
the O
pws B-Disease
. O

2 O
may O
elucidate O
the O
molecular O
basis O
for O
the O
instability O
of O
this O
chromosomal O
region O
in O
patients O
with O
the O
pws B-Disease
or O
other O
diseases O
associated O
with O
chromosomal B-Disease
abnormalities I-Disease
in O
the O
proximal O
long O
arm O
of O
human O
chromosome O
15 O

analysis O
of O
deletions O
in O
dna O
from O
patients O
with O
becker B-Disease
and I-Disease
duchenne I-Disease
muscular I-Disease
dystrophy I-Disease
. O

duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
genetic I-Disease
disorder I-Disease
for O
which O
the O
biochemical O
defect O
is O
as O
yet O
unknown O
. O

both O
of O
these O
cloned O
segments O
were O
described O
as O
tightly O
linked O
to O
the O
locus O
and O
were O
capable O
of O
detecting O
deletions O
in O
the O
dna O
of O
boys O
affected O
with O
dmd B-Disease
. O

in O
an O
attempt O
to O
determine O
more O
precisely O
the O
occurrence O
of O
these O
deletions O
within O
a O
large O
population O
of O
dmd B-Disease
patients O
and O
the O
accuracy O
of O
one O
of O
the O
segments O
, O
dxs164 O
( O
pert87 O
) O
, O
in O
determining O
the O
inheritance O
of O
the O
dmd B-Disease
x O
chromosome O
, O
the O
subclones O
1 O
, O
8 O
and O
15 O
were O
made O
available O
to O
many O
investigators O
throughout O
the O
world O
. O

here O
we O
describe O
the O
combined O
results O
of O
more O
than O
20 O
research O
laboratories O
with O
respect O
to O
the O
occurrence O
of O
deletions O
at O
the O
dxs164 O
locus O
in O
dna O
samples O
isolated O
from O
patients O
with O
dmd B-Disease
and O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
( O
bmd B-Disease
) O
. O

the O
results O
indicate O
that O
the O
dxs164 O
locus O
apparently O
recombines O
with O
dmd B-Disease
5 O
% O
of O
the O
time O
, O
but O
is O
probably O
located O
between O
independent O
sites O
of O
mutation O
which O
yield O
dmd B-Disease
. O

the O
breakpoints O
of O
some O
deletions O
are O
delineated O
within O
the O
dxs164 O
locus O
, O
and O
it O
is O
evident O
that O
the O
deletions O
at O
the O
dmd B-Disease
locus O
are O
frequent O
and O
extremely O
large O
. O

a O
potential O
animal O
model O
for O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
through O
introduction O
of O
hprt O
mutations O
into O
mice O
. O

the O
human O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
is O
a O
rare O
neurological B-Disease
and I-Disease
behavioural I-Disease
disorder I-Disease
, O
affecting O
only O
males O
, O
which O
is O
caused O
by O
an O
inherited B-Disease
deficiency I-Disease
in O
the O
level O
of O
activity O
of O
the O
purine O
salvage O
enzyme O
hypoxanthine O
- O
guanosine O
phosphoribosyl O
transferase O
( O
hprt O
) O
. O

how O
the O
resulting O
alterations O
in O
purine O
metabolism O
lead O
to O
the O
severe O
symptoms O
characteristic O
of O
lesch B-Disease
- I-Disease
nyhan I-Disease
patients O
is O
still O
not O
understood O
. O


to O
derive O
an O
animal O
model O
for O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
, O
we O
have O
used O
cultured O
mouse O
embryonic O
stem O
cells O
, O
mutagenized O
by O
retroviral O
insertion O
and O
selected O
for O
loss O
of O
hprt O
activity O
, O
to O
construct O
chimaeric O
mice O
. O

two O
clonal O
lines O
carrying O
different O
mutant O
hprt O
alleles O
have O
given O
rise O
to O
germ O
cells O
in O
chimaeras O
, O
allowing O
the O
derivation O
of O
strains O
of O
mutant O
mice O
having O
the O
same O
biochemical O
defect O
as O
lesch B-Disease
- I-Disease
nyhan I-Disease
patients O
. O

re O
- O
evaluation O
of O
the O
sublocalization O
of O
esterase O
d O
and O
its O
relation O
to O
the O
retinoblastoma B-Disease
locus O
by O
in O
situ O
hybridization O
. O

a O
deletion O
in O
an O
individual O
with O
retinoblastoma B-Disease
was O
reported O
to O
separate O
the O
closely O
linked O
esd O
and O
retinoblastoma B-Disease
( O
rb1 O
) O
loci O
, O
placing O
esd O
proximal O
to O
rb1 O
. O

hereditary B-Disease
c2 I-Disease
deficiency I-Disease
associated O
with O
common O
variable O
immunodeficiency B-Disease
. O

homozygous O
c2 B-Disease
deficiency I-Disease
in O
a O
19 O
- O
year O
- O
old O
boy O
was O
associated O
with O
variable O
immunodeficiency B-Disease
manifested O
by O
marked O
hypoimmunoglobulinemia B-Disease
and O
impaired O
antibody O
responses O
, O
normal O
circulating O
b O
lymphocytes O
, O
and O
subnormal O
t O
- O
cell O
functions O
. O

neither O
antilymphocytic O
autoantibodies O
nor O
chromosomal B-Disease
abnormalities I-Disease
were O
found O
. O

serum O
immunoglobulin O
levels O
were O
within O
normal O
limits O
in O
his O
parents O
and O
brother O
who O
were O
heterozygous O
for O
c2 B-Disease
deficiency I-Disease
. O

mild O
and O
severe O
muscular B-Disease
dystrophy I-Disease
associated O
with O
deletions O
in O
xp21 O
of O
the O
human O
x O
chromosome O
. O

we O
have O
analysed O
over O
300 O
patients O
suffering O
from O
duchenne B-Disease
or I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
or O
bmd B-Disease
) O
. O

these O
loci O
have O
been O
shown O
to O
lie O
within O
the O
dmd B-Disease
region O
covering O
several O
hundred O
kilobases O
( O
kb O
) O
of O
dna O
. O

one O
mildly O
affected O
bmd B-Disease
patient O
possesses O
a O
deletion O
of O
at O
least O
110 O
kb O
including O
exons O
of O
the O
dmd B-Disease
gene O
. O

other O
patients O
with O
similar O
exon O
deletions O
, O
or O
smaller O
deletions O
, O
show O
the O
more O
severe O
phenotype O
typical O
of O
dmd B-Disease
. O

patterns O
of O
exon O
deletions O
in O
duchenne B-Disease
and I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
. O

a O
panel O
of O
patients O
with O
duchenne B-Disease
and I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
and O
bmd B-Disease
) O
has O
been O
screened O
with O
the O
cdna O
probes O
cf56a O
and O
cf23a O
, O
which O
detect O
exons O
in O
the O
central O
part O
of O
the O
dmd B-Disease
gene O
. O

deletions O
specific O
to O
dmd B-Disease
and O
to O
bmd B-Disease
are O
described O
. O

half O
of O
all O
bmd B-Disease
patients O
have O
a O
deletion O
of O
one O
particular O
small O
group O
of O
exons O
; O
smaller O
deletions O
within O
this O
same O
group O
produce O
the O
more O
severe O
dmd B-Disease
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
child O
with O
fever B-Disease
, O
skin B-Disease
rash I-Disease
, O
and O
arthralgias B-Disease
: O
response O
to O
transfusion O
of O
whole O
blood O
. O

a O
previously O
well O
34 O
- O
month O
- O
old O
male O
presenting O
with O
fever B-Disease
, O
skin B-Disease
rash I-Disease
, O
and O
arthralgias B-Disease
was O
found O
to O
lack O
c3 O
by O
immunochemical O
( O
undetectable O
) O
and O
hemolytic O
( O
1 O
% O
normal O
) O
assays O
. O

a O
transfusion O
of O
320 O
ml O
1 O
- O
hour O
- O
old O
normal O
whole O
blood O
on O
the O
fifty O
- O
second O
day O
resulted O
in O
transitory O
elevation O
of O
the O
c3 O
level O
to O
25 O
mg O
/ O
dl O
with O
a O
fall O
- O
off O
( O
approximately O
2 O
1 O
/ O
2 O
% O
per O
hour O
) O
to O
undetectable O
levels O
by O
69 O
hours O
; O
it O
was O
followed O
by O
disappearance O
of O
the O
skin B-Disease
rash I-Disease
and O
arthralgias B-Disease
and O
return O
to O
normal O
of O
the O
previously O
elevated O
temperature O
and O
crp O
levels O
. O

c3 O
levels O
in O
family O
members O
( O
seven O
of O
24 O
half O
- O
normal O
) O
, O
lack O
of O
anti O
- O
c3 O
activity O
, O
normal O
c3b O
- O
ina O
levels O
and O
a O
normal O
rate O
of O
catabolism O
of O
transfused O
c3 O
indicated O
that O
the O
deficiency O
was O
inherited O
with O
autosomal O
codominance O
and O
involved O
decreased B-Disease
synthesis I-Disease
of I-Disease
c3 I-Disease
. O

thus O
, O
this O
child O
is O
a O
unique O
individual O
with O
inherited B-Disease
c3 I-Disease
deficiency I-Disease
presenting O
with O
absence O
of O
repeated O
infections O
, O
whose O
symptoms O
of O
fever B-Disease
, O
skin B-Disease
rash I-Disease
, O
and O
arthralgia B-Disease
were O
abated O
by O
whole O
blood O
transfusion O
. O

erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
was O
characterized O
in O
blood O
samples O
obtained O
from O
97 O
randomly O
selected O
males O
with O
enzyme B-Disease
deficiency I-Disease
from O
various O
regions O
of O
guangdong O
province O
, O
china O
. O

the O
results O
demonstrated O
that O
the O
genetic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
was O
high O
in O
this O
area O
. O

homozygous O
and O
heterozygous O
deletions O
of O
the O
von B-Disease
willebrand I-Disease
factor O
gene O
in O
patients O
and O
carriers O
of O
severe B-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
. O

severe B-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
is O
characterized O
by O
undetectable O
or O
trace O
quantities O
of O
von B-Disease
willebrand I-Disease
factor O
in O
plasma O
and O
tissue O
stores O
. O

the O
second O
group O
was O
comprised O
of O
a O
family O
in O
which O
there O
was O
a O
complete O
heterozygous O
deletion O
of O
the O
vwf O
gene O
in O
the O
proband O
and O
one O
asymptomatic O
parent O
, O
suggesting O
that O
a O
different O
type O
of O
genetic B-Disease
abnormality I-Disease
was O
inherited O
from O
the O
other O
parent O
. O

thus O
, O
the O
patient O
appeared O
to O
be O
doubly O
heterozygous O
for O
interacting O
genetic B-Disease
abnormalities I-Disease
affecting O
vwf O
expression O
. O

these O
techniques O
should O
prove O
useful O
in O
identifying O
carriers O
of O
severe B-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
and O
also O
in O
defining O
patients O
predictably O
at O
risk O
of O
developing O
alloantibodies O
to O
vwf O
. O

sjogren B-Disease
- I-Disease
larsson I-Disease
syndrome I-Disease
. O

lipid O
metabolism O
was O
studied O
in O
cultured O
skin O
fibroblasts O
from O
patients O
with O
the O
inherited B-Disease
disorder I-Disease
, O
sjogren B-Disease
- I-Disease
larsson I-Disease
syndrome I-Disease
( O
sls B-Disease
) O
. O

intact O
sls B-Disease
fibroblasts O
incubated O
in O
the O
presence O
of O
[ O
1 O
- O
14c O
] O
palmitate O
accumulated O
more O
radioactive O
hexadecanol O
than O
did O
normal O
cells O
, O
whereas O
incorporation O
of O
radioactivity O
into O
other O
cellular O
lipids O
was O
unaltered O
. O

the O
half O
- O
life O
of O
intracellular O
hexadecanol O
loaded O
into O
sls B-Disease
fibroblasts O
was O
increased O
( O
70 O
min O
) O
compared O
with O
normal O
( O
15 O
min O
) O
, O
and O
intact O
sls B-Disease
fibroblasts O
showed O
impaired O
oxidation O
of O
[ O
14c O
] O
- O
hexadecanol O
to O
fatty O
acid O
. O

fatty O
alcohol O
nad O
+ O
oxidoreductase O
, O
the O
enzyme O
catalyzing O
this O
reaction O
, O
was O
deficient O
in O
sls B-Disease
fibroblasts O
. O

mean O
total O
activity O
in O
sls B-Disease
fibroblasts O
( O
n O
= O
5 O
) O
was O
13 O
% O
of O
that O
in O
normal O
fibroblasts O
, O
and O
palmitoyl O
coa O
- O
inhibitable O
activity O
was O
1 O
% O
of O
normal O
. O

fibroblasts O
from O
two O
obligate O
sls B-Disease
heterozygotes O
had O
enzyme O
activities O
intermediate O
between O
that O
in O
normal O
fibroblasts O
and O
individuals O
with O
sls B-Disease
. O

these O
results O
suggest O
that O
the O
primary O
defect O
in O
sls B-Disease
is O
deficiency B-Disease
of I-Disease
fatty I-Disease
alcohol I-Disease
nad I-Disease
+ I-Disease
oxidoreductase I-Disease
. O

sls B-Disease
represents O
the O
first O
inherited B-Disease
disorder I-Disease
in O
man O
associated O
with O
an O
isolated O
abnormality B-Disease
in I-Disease
fatty I-Disease
alcohol I-Disease
metabolism I-Disease
. O

germinal O
mosaicism O
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
. O

we O
have O
identified O
a O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
pedigree O
where O
the O
disease O
is O
associated O
with O
a O
molecular O
deletion O
within O
the O
dmd B-Disease
locus O
. O

these O
studies O
show O
that O
this O
female O
has O
transmitted O
three O
distinct O
types O
of O
x O
chromosome O
to O
her O
offspring O
. O

nebulin O
seen O
in O
dmd B-Disease
males O
including O
one O
patient O
with O
a O
large O
dna O
deletion O
encompassing O
the O
dmd B-Disease
gene O
. O

the O
presence O
of O
nebulin O
in O
a O
muscle O
specimen O
from O
a O
patient O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
due O
to O
a O
large O
deletion O
precludes O
the O
possibility O
that O
this O
protein O
is O
the O
dmd B-Disease
gene O
product O
. O

expression O
of O
the O
murine O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
in O
muscle O
and O
brain O
. O

5 O
kilobases O
of O
the O
murine O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd O
) O
messenger O
rna O
( O
mrna O
) O
. O

dmd O
mrna O
is O
also O
present O
, O
but O
at O
much O
lower O
than O
normal O
levels O
, O
in O
both O
the O
muscle O
and O
brain O
of O
three O
different O
strains O
of O
dystrophic B-Disease
mdx O
mice O
. O

the O
identification O
of O
dmd O
mrna O
in O
brain O
raises O
the O
possibility O
of O
a O
relation O
between O
human O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
expression O
and O
the O
mental B-Disease
retardation I-Disease
found O
in O
some O
dmd B-Disease
males O
. O

glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
and O
incidence O
of O
hematologic B-Disease
malignancy I-Disease
. O

we O
have O
evaluated O
the O
hypothesis O
of O
a O
negative O
association O
between O
glucose B-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
and O
cancer B-Disease
in O
a O
cohort O
of O
481 O
sardinian O
males O
with O
hematological B-Disease
malignancies I-Disease
. O

the O
frequency O
of O
g6pd B-Disease
deficiency I-Disease
in O
the O
patients O
was O
not O
different O
from O
the O
incidence O
in O
a O
group O
of O
16 O
, O
219 O
controls O
. O

the O
same O
conclusion O
resulted O
from O
the O
comparison O
of O
the O
frequency O
of O
expression O
of O
the O
gdb O
gene O
in O
23 O
heterozygous O
women O
having O
a O
clonal O
hematologic B-Disease
disease I-Disease
and O
a O
control O
group O
of O
37 O
healthy O
heterozygotes O
. O

therefore O
at O
present O
there O
is O
no O
evidence O
that O
g6pd B-Disease
deficiency I-Disease
has O
a O
protective O
effect O
against O
development O
of O
hematologic B-Disease
neoplasms I-Disease
. O

hepatoblastoma B-Disease
, O
pigmented B-Disease
ocular I-Disease
fundus I-Disease
lesions I-Disease
and O
jaw B-Disease
lesions I-Disease
in O
gardner B-Disease
syndrome I-Disease
. O

hepatoblastoma B-Disease
is O
a O
rare O
neoplasm B-Disease
of O
infants O
and O
children O
only O
recently O
documented O
in O
association O
with O
hereditary B-Disease
adenomatous I-Disease
polyposis I-Disease
of I-Disease
the I-Disease
colon I-Disease
[ O
kingston O
et O
al O
. O
, O
1983 O
] O
. O

we O
report O
four O
children O
with O
hepatoblastoma B-Disease
from O
four O
unrelated O
families O
with O
gardner B-Disease
syndrome I-Disease
( O
gs B-Disease
) O
. O

one O
child O
, O
now O
19 O
years O
old O
, O
survived O
after O
a O
resection O
of O
a O
hepatoblastoma B-Disease
in O
infancy O
and O
recently O
was O
found O
to O
have O
gs B-Disease
. O

he O
has O
an O
associated O
odontoma B-Disease
and O
pigmented B-Disease
ocular I-Disease
fundus I-Disease
lesions I-Disease
, O
both O
of O
which O
have O
been O
shown O
to O
be O
clinical O
markers O
of O
gs B-Disease
. O

many O
individuals O
in O
these O
four O
gs B-Disease
families O
, O
both O
affected O
and O
at O
risk O
, O
have O
osteomatous B-Disease
jaw I-Disease
lesions I-Disease
and O
pigmented B-Disease
ocular I-Disease
fundus I-Disease
lesions I-Disease
. O

a O
search O
for O
colonic B-Disease
polyps I-Disease
should O
be O
made O
in O
families O
of O
infants O
and O
children O
with O
hepatoblastoma B-Disease
. O

if O
the O
child O
survives O
, O
he O
or O
she O
should O
be O
monitored O
for O
the O
later O
appearance O
of O
colonic B-Disease
polyps I-Disease
. O

the O
finding O
of O
jaw B-Disease
lesions I-Disease
and O
/ O
or O
pigmented B-Disease
ocular I-Disease
fundus I-Disease
lesions I-Disease
in O
relatives O
at O
risk O
are O
indications O
of O
the O
possible O
presence O
of O
the O
gs B-Disease
gene O
. O

identification O
of O
an O
altered O
splice O
site O
in O
ashkenazi O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
. O

tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
genetic I-Disease
disorder I-Disease
resulting O
from O
mutation O
of O
the O
hexa O
gene O
encoding O
the O
alpha O
- O
subunit O
of O
the O
lysosomal O
enzyme O
, O
beta O
- O
n O
- O
acetylhexosaminidase O
a O
( O
ref O
. O
1 O
) O
. O

a O
test O
for O
the O
mutant O
allele O
based O
on O
amplification O
of O
dna O
by O
the O
polymerase O
chain O
rection O
and O
cleavage O
of O
a O
ddei O
restriction O
site O
generated O
by O
the O
mutation O
revealed O
that O
this O
case O
and O
two O
other O
cases O
of O
the O
ashkenazi O
, O
infantile O
form O
of O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
are O
heterozygous O
for O
two O
different O
mutations O
. O

x B-Disease
- I-Disease
linked I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
mus O
musculus O
. O

a O
mouse O
with O
x B-Disease
- I-Disease
linked I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
has O
been O
recovered O
in O
offspring O
of O
1 O
- O
ethyl O
- O
1 O
- O
nitrosourea O
- O
treated O
male O
mice O
. O

this O
is O
presently O
the O
only O
animal O
model O
for O
x B-Disease
- I-Disease
linked I-Disease
g6pd I-Disease
deficiency I-Disease
in O
humans O
. O

diverse O
point O
mutations O
in O
the O
human O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
gene O
cause O
enzyme B-Disease
deficiency I-Disease
and O
mild O
or O
severe O
hemolytic B-Disease
anemia I-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
; I-Disease
ec I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
deficiency I-Disease
is O
a O
common O
genetic B-Disease
abnormality I-Disease
affecting O
an O
estimated O
400 O
million O
people O
worldwide O
. O

the O
other O
six O
mutants O
investigated O
were O
all O
associated O
with O
enzyme B-Disease
deficiency I-Disease
. O

in O
one O
of O
the O
commonest O
, O
g6pd O
mediterranean O
, O
which O
is O
associated O
with O
favism B-Disease
among O
other O
clinical O
manifestations O
, O
a O
single O
amino O
acid O
replacement O
was O
found O
( O
serine O
- O
- O
- O
- O
phenylalanine O
) O
it O
must O
be O
responsible O
for O
the O
decreased O
stability O
and O
the O
reduced O
catalytic O
efficiency O
of O
this O
enzyme O
. O

single O
point O
mutations O
were O
also O
found O
in O
g6pd O
metaponto O
( O
southern O
italy O
) O
and O
in O
g6pd O
ilesha O
( O
nigeria O
) O
, O
which O
are O
asymptomatic O
, O
and O
in O
g6pd O
chatham O
, O
which O
was O
observed O
in O
an O
indian O
boy O
with O
neonatal B-Disease
jaundice I-Disease
. O

in O
g6pd O
santiago O
, O
a O
de O
novo O
mutation O
( O
glycine O
- O
- O
- O
- O
arginine O
) O
is O
associated O
with O
severe O
chronic O
hemolytic B-Disease
anemia I-Disease
. O

thus O
, O
diverse O
point O
mutations O
may O
account O
largely O
for O
the O
phenotypic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
. O

tight O
linkage O
between O
myotonic B-Disease
dystrophy I-Disease
and O
apolipoprotein O
e O
genes O
revealed O
with O
allele O
- O
specific O
oligonucleotides O
. O

in O
16 O
families O
with O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
a O
novel O
approach O
based O
on O
use O
of O
allele O
- O
specific O
oligonucleotides O
has O
been O
employed O
to O
study O
the O
linkage O
relationship O
between O
the O
apolipoprotein O
e O
( O
apoe O
) O
gene O
and O
dm B-Disease
. O

these O
results O
suggest O
that O
, O
in O
addition O
to O
apoc2 O
, O
apoe O
is O
a O
useful O
marker O
for O
presymptomatic O
dm B-Disease
diagnosis O
. O

regional O
localization O
of O
polymorphic O
dna O
loci O
on O
the O
proximal O
long O
arm O
of O
the O
x O
chromosome O
using O
deletions O
associated O
with O
choroideremia B-Disease
. O

in O
two O
unrelated O
families O
, O
males O
have O
been O
identified O
who O
suffer O
from O
choroideremia B-Disease
and O
at O
the O
same O
time O
have O
an O
interstitial O
deletion O
on O
the O
proximal O
long O
arm O
of O
the O
x O
chromosome O
. O

by O
southern O
blot O
analysis O
we O
have O
mapped O
ten O
different O
polymorphic O
dna O
loci O
relative O
to O
the O
position O
of O
the O
deletion O
and O
the O
choroideremia B-Disease
locus O
tcd O
. O

the O
following O
order O
of O
the O
loci O
was O
suggested O
by O
deletion O
mapping O
cen O
- O
dxs106 O
- O
dxs72 O
- O
tcd O
- O
( O
dxys1 O
/ O
dxys23 O
/ O
dxys5 O
) O
- O
dxys2 O
- O
( O
dxys12 O
/ O
dxs3 O
) O
- O
( O
dxs17 O
/ O
dxs101 O
) O
- O
xqter O
. O

retroviral O
- O
mediated O
gene O
transfer O
of O
human O
phenylalanine O
hydroxylase O
into O
nih O
3t3 O
and O
hepatoma B-Disease
cells O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
caused O
by O
deficiency B-Disease
of I-Disease
the I-Disease
hepatic I-Disease
enzyme I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

the O
recombinant O
virus O
is O
also O
capable O
of O
infecting O
a O
mouse O
hepatoma B-Disease
cell O
line O
that O
does O
not O
normally O
synthesize O
pah O
. O

pah O
activity O
is O
present O
in O
the O
cellular O
extracts O
and O
the O
entire O
hydroxylation O
system O
is O
reconstituted O
in O
the O
hepatoma B-Disease
cells O
infected O
with O
the O
recombinant O
viruses O
. O

thus O
, O
recombinant O
viruses O
containing O
human O
pah O
cdna O
provide O
a O
means O
for O
introducing O
functional O
pah O
into O
mammalian O
cells O
of O
hepatic O
origin O
and O
can O
potentially O
be O
introduced O
into O
whole O
animals O
as O
a O
model O
for O
somatic O
gene O
therapy O
for O
pku B-Disease
. O

estimation O
of O
the O
male O
to O
female O
ratio O
of O
mutation O
rates O
from O
the O
segregation O
of O
x O
- O
chromosomal O
dna O
haplotypes O
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
families O
. O

a O
novel O
procedure O
is O
presented O
to O
estimate O
the O
ratio O
of O
male O
to O
female O
mutation O
rates O
for O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

x O
- O
specific O
restriction O
fragment O
length O
polymorphisms O
are O
used O
to O
establish O
dna O
haplotypes O
in O
three O
- O
generation O
dmd B-Disease
families O
. O

from O
the O
proportion O
of O
dmd B-Disease
patients O
who O
have O
inherited O
their O
maternal O
grandfathers O
x O
chromosome O
, O
the O
ratio O
of O
mutation O
rates O
can O
be O
calculated O
. O

deletions O
of O
a O
dna O
sequence O
in O
retinoblastomas B-Disease
and O
mesenchymal B-Disease
tumors I-Disease
: O
organization O
of O
the O
sequence O
and O
its O
encoded O
protein O
. O

retinoblastoma B-Disease
is O
a O
childhood B-Disease
tumor I-Disease
that O
can O
arise O
because O
of O
mutant O
alleles O
acquired O
as O
somatic O
or O
germinal O
mutations O
. O

we O
have O
reported O
isolation O
of O
a O
cdna O
fragment O
that O
recognizes O
chromosomal O
sequences O
possessing O
many O
of O
the O
attributes O
of O
the O
retinoblastoma B-Disease
gene O
associated O
with O
the O
rb1 O
locus O
. O

we O
now O
report O
that O
this O
segment O
is O
additionally O
the O
target O
of O
somatic O
mutations O
in O
mesenchymal B-Disease
tumors I-Disease
among O
patients O
having O
no O
apparent O
predisposition O
to O
retinoblastoma B-Disease
and O
no O
previous O
evidence O
of O
retinoblastoma B-Disease
. O

these O
tumors B-Disease
provide O
additional O
evidence O
that O
the O
cloned O
sequences O
are O
representative O
of O
a O
gene O
that O
is O
a O
frequent O
target O
of O
inactivation O
during O
tumorigenesis O
. O

treatment O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
with O
growth O
hormone O
inhibitors O
. O

a O
controlled O
, O
double O
- O
blind O
therapeutic O
trial O
with O
the O
drug O
mazindol O
, O
a O
growth O
hormone O
inhibitor O
, O
was O
performed O
in O
a O
pair O
of O
7 O
1 O
/ O
2 O
year O
- O
old O
monozygotic O
twins O
, O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

the O
rationale O
for O
this O
trial O
was O
based O
on O
a O
patient O
( O
reported O
previously O
) O
affected O
simultaneously O
with O
dmd B-Disease
and O
growth B-Disease
hormone I-Disease
( I-Disease
gh I-Disease
) I-Disease
deficiency I-Disease
, O
who O
is O
showing O
a O
benign O
course O
of O
the O
dystrophic B-Disease
process I-Disease
and O
is O
still O
walking O
at O
18 O
years O
. O

identification O
and O
localization O
of O
mutations O
at O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
locus O
by O
ribonuclease O
a O
cleavage O
. O

the O
recently O
described O
ribonuclease O
a O
cleavage O
procedure O
, O
with O
a O
polyuridylic O
acid O
- O
paper O
affinity O
chromatography O
step O
, O
has O
been O
used O
to O
identify O
the O
mutational O
lesions O
in O
the O
hypoxanthine O
phosphoribosyltransferase O
( O
hprt O
) O
messenger O
rnas O
of O
patients O
with O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

distinctive O
ribonuclease O
a O
cleavage O
patterns O
were O
identified O
in O
messenger O
rna O
from O
5 O
of O
14 O
lesch B-Disease
- I-Disease
nyhan I-Disease
patients O
who O
were O
chosen O
because O
no O
hprt O
southern O
or O
northern O
blotting O
pattern O
changes O
had O
been O
found O
. O

this O
approach O
now O
allows O
hprt O
mutation O
detection O
in O
50 O
percent O
of O
the O
cases O
of O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

two O
new O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
associated O
with O
hereditary B-Disease
non I-Disease
- I-Disease
spherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
: O
g6pd O
wayne O
and O
g6pd O
huron O
. O

two O
new O
deficient O
variants O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
causing O
hereditary B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
( O
hnsha B-Disease
) O
are O
described O
. O

the O
patients O
with O
g6pd O
huron O
were O
under O
medical O
observation O
for O
a O
considerable O
period O
of O
time O
without O
the O
diagnosis O
of O
g6pd B-Disease
deficiency I-Disease
being O
entertained O
because O
the O
family O
was O
of O
northern O
european O
origin O
. O

since O
sporadic O
variants O
of O
g6pd O
causing O
hnsha B-Disease
show O
no O
special O
racial O
predilection O
, O
the O
diagnosis O
of O
g6pd B-Disease
deficiency I-Disease
should O
always O
be O
considered O
in O
patients O
with O
this O
syndrome O
. O

sialophorin O
, O
a O
surface O
sialoglycoprotein O
defective O
in O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
, O
is O
involved O
in O
human O
t O
lymphocyte O
proliferation O
. O

the O
mab O
l10 O
was O
used O
to O
determine O
the O
distribution O
and O
the O
function O
of O
sialophorin O
, O
the O
heavily O
glycosylated O
surface O
molecule O
that O
is O
deficient O
/ O
defective O
in O
lymphocytes O
of O
patients O
with O
the O
x B-Disease
- I-Disease
linked I-Disease
immunodeficiency I-Disease
wiskott I-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O

hypopigmentation B-Disease
in O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

cutaneous B-Disease
and I-Disease
ocular I-Disease
pigmentation I-Disease
were O
evaluated O
in O
29 O
individuals O
with O
the O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

criteria O
for O
hypopigmentation B-Disease
included O
the O
presence O
of O
type O
i O
or O
ii O
skin O
, O
the O
lightest O
skin O
type O
in O
the O
family O
by O
history O
, O
and O
iris O
translucency O
on O
globe O
transillumination O
. O

on O
the O
basis O
of O
these O
criteria O
, O
48 O
% O
of O
the O
pws B-Disease
individuals O
were O
hypopigmented B-Disease
. O

the O
presence O
of O
hypopigmentation B-Disease
correlated O
with O
a O
small O
interstitial O
deletion O
on O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
; O
however O
, O
this O
deletion O
was O
also O
found O
in O
individuals O
who O
did O
not O
meet O
the O
full O
criteria O
for O
hypopigmentation B-Disease
. O

hairbulb O
tyrosinase O
activity O
and O
glutathione O
content O
, O
as O
well O
as O
urine O
cysteinyldopa O
excretion O
, O
were O
low O
in O
pws B-Disease
individuals O
with O
and O
without O
hypopigmentation B-Disease
and O
did O
not O
separate O
these O
two O
groups O
. O

we O
conclude O
that O
hypopigmentation B-Disease
is O
found O
in O
a O
significant O
proportion O
of O
individuals O
with O
pws B-Disease
and O
that O
the O
hypopigmentation B-Disease
may O
be O
associated O
with O
a O
deletion O
of O
the O
long O
arm O
of O
chromosome O
15 O
. O

the O
mechanism O
for O
the O
hypopigmentation B-Disease
is O
unknown O
. O
. O

phenotype O
heterogeneity O
among O
hemizygotes O
in O
a O
family O
biochemically O
screened O
for O
adrenoleukodystrophy B-Disease
. O

we O
report O
on O
two O
clinically O
, O
neurologically O
normal O
relatives O
of O
a O
boy O
affected O
by O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
; O
they O
were O
found O
repeatedly O
to O
have O
the O
biochemical O
defect O
of O
an O
ald B-Disease
hemizygote O
. O

while O
no O
evidence O
of O
neurologic B-Disease
disease I-Disease
( O
leukodystrophy B-Disease
or O
myeloneuropathy B-Disease
) O
was O
present O
in O
these O
hemizygotes O
, O
adrenocortical B-Disease
insufficiency I-Disease
provoking O
compensatory O
high O
acth O
release O
was O
found O
in O
both O
. O

the O
mapping O
of O
a O
cdna O
from O
the O
human O
x B-Disease
- I-Disease
linked I-Disease
duchenne I-Disease
muscular I-Disease
dystrophy I-Disease
gene O
to O
the O
mouse O
x O
chromosome O
. O

the O
recent O
discovery O
of O
sequences O
at O
the O
site O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
in O
humans O
has O
opened O
up O
the O
possibility O
of O
a O
detailed O
molecular O
analysis O
of O
the O
genes O
in O
humans O
and O
in O
related O
mammalian O
species O
. O

until O
relatively O
recently O
, O
there O
was O
no O
obvious O
mouse O
model O
of O
this O
genetic B-Disease
disease I-Disease
for O
the O
development O
of O
therapeutic O
strategies O
. O

the O
identification O
of O
a O
mouse O
x O
- O
linked O
mutant O
showing O
muscular B-Disease
dystrophy I-Disease
, O
mdx O
, O
has O
provided O
a O
candidate O
mouse O
genetic O
homologue O
to O
the O
dmd B-Disease
locus O
; O
the O
relatively O
mild O
pathological O
features O
of O
mdx O
suggest O
it O
may O
have O
more O
in O
common O
with O
mutations O
of O
the O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
type O
at O
the O
same O
human O
locus O
, O
however O
. O

but O
the O
close O
genetic O
linkage O
of O
mdx O
to O
g6pd O
and O
hprt O
on O
the O
mouse O
x O
chromosome O
, O
coupled O
with O
its O
comparatively O
mild O
pathology O
, O
have O
suggested O
that O
the O
mdx O
mutation O
may O
instead O
correspond O
to O
emery B-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
which O
itself O
is O
closely O
linked O
to O
dna O
markers O
at O
xq28 O
- O
qter O
in O
the O
region O
of O
g6pd O
on O
the O
human O
x O
chromosome O
. O

using O
an O
interspecific O
mouse O
domesticus O
/ O
spretus O
cross O
, O
segregating O
for O
a O
variety O
of O
markers O
on O
the O
mouse O
x O
chromosome O
, O
we O
have O
positioned O
on O
the O
mouse O
x O
chromosome O
sequences O
homologous O
to O
a O
dmd B-Disease
cdna O
clone O
. O

these O
sequences O
map O
provocatively O
close O
to O
the O
mdx O
mutation O
and O
unexpectedly O
distant O
from O
sparse O
fur O
, O
spf O
, O
the O
mouse O
homologue O
of O
otc O
( O
ornithine O
transcarbamylase O
) O
which O
is O
closely O
linked O
to O
dmd B-Disease
on O
the O
human O
x O
chromosome O
. O
. O

localization O
of O
the O
region O
homologous O
to O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
locus O
on O
the O
mouse O
x O
chromosome O
. O

recent O
progress O
has O
resulted O
in O
part O
of O
the O
gene O
mutated O
in O
duchenne B-Disease
and I-Disease
the I-Disease
milder I-Disease
becker I-Disease
muscular I-Disease
dystrophies I-Disease
being O
cloned O
and O
has O
suggested O
that O
the O
gene O
itself O
extends O
over O
1 O
, O
000 O
to O
2 O
, O
000 O
kilobases O
( O
kb O
) O
. O

the O
mouse O
mdx O
mutation O
affects O
muscle O
and O
confers O
a O
mild O
dystrophic B-Disease
syndrome I-Disease
, O
but O
it O
is O
not O
clear O
whether O
this O
mutation O
is O
equivalent O
to O
duchenne B-Disease
/ I-Disease
becker I-Disease
muscular I-Disease
dystrophy I-Disease
in O
man O
. O

here O
we O
describe O
the O
use O
of O
two O
sequences O
from O
the O
human O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
that O
cross O
- O
hybridize O
to O
mouse O
x O
- O
linked O
sequences O
to O
localize O
the O
gene O
homologous O
to O
dmd B-Disease
in O
the O
mouse O
. O

by O
analogy O
with O
the O
human O
x O
- O
chromosome O
, O
we O
conclude O
that O
the O
region O
in O
the O
mouse O
around O
the O
g6pd O
and O
st14 O
- O
1 O
loci O
may O
contain O
two O
genes O
corresponding O
to O
distinct O
human O
myopathies B-Disease
emery B-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
which O
is O
known O
to O
be O
closely O
linked O
to O
st14 O
- O
1 O
in O
man O
and O
the O
dmd B-Disease
homologue O
described O
here O
. O
. O

gt O
to O
at O
transition O
at O
a O
splice O
donor O
site O
causes O
skipping O
of O
the O
preceding O
exon O
in O
phenylketonuria B-Disease
. O

classical B-Disease
phenylketonuria I-Disease
( O
pku B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
human I-Disease
genetic I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
hepatic I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

conservation O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
in O
mice O
and O
humans O
. O

a O
portion O
of O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
gene O
transcript O
from O
human O
fetal O
skeletal O
muscle O
and O
mouse O
adult O
heart O
was O
sequenced O
, O
representing O
approximately O
25 O
percent O
of O
the O
total O
, O
14 O
- O
kb O
dmd B-Disease
transcript O
. O

the O
amino O
acid O
sequence O
that O
is O
predicted O
from O
this O
portion O
of O
the O
dmd B-Disease
gene O
indicates O
that O
the O
protein O
product O
might O
serve O
a O
structural O
role O
in O
muscle O
, O
but O
the O
abundance O
and O
tissue O
distribution O
of O
the O
messenger O
rna O
suggests O
that O
the O
dmd B-Disease
protein O
is O
not O
nebulin O
. O

familial O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
with O
apparently O
normal O
chromosomes O
. O

we O
report O
on O
4 O
sibs O
( O
2f O
, O
2m O
) O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

the O
other O
child O
had O
died O
at O
age O
10 O
months O
with O
a O
history O
and O
clinical O
findings O
typical O
of O
first O
phase O
of O
pws B-Disease
. O

the O
implications O
of O
this O
unusual O
familial O
occurrence O
for O
our O
understanding O
of O
pws B-Disease
are O
discussed O
. O

nebulin O
and O
titin O
expression O
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
appears O
normal O
. O

monoclonal O
antibodies O
which O
recognize O
different O
epitopes O
on O
either O
titin O
or O
nebulin O
show O
normal O
staining O
patterns O
on O
frozen O
sections O
of O
three O
muscle O
biopsies O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

since O
the O
donor O
of O
one O
of O
these O
biopsies O
has O
a O
large O
deletion O
of O
the O
5 O
- O
region O
of O
the O
dmd B-Disease
gene O
, O
our O
results O
argue O
against O
the O
recent O
proposal O
that O
nebulin O
is O
the O
gene O
mutated O
in O
dmd B-Disease
. O

heterozygous B-Disease
c2 I-Disease
deficiency I-Disease
associated O
with O
angioedema B-Disease
, O
myasthenia B-Disease
gravis I-Disease
, O
and O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
. O

we O
describe O
a O
patient O
with O
myasthenia B-Disease
gravis I-Disease
, O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
and O
angioedema B-Disease
associated O
with O
heterozygous O
complement B-Disease
factor I-Disease
2 I-Disease
( I-Disease
c2 I-Disease
) I-Disease
deficiency I-Disease
. O

the O
significance O
of O
this O
association O
is O
controversial O
, O
though O
the O
association O
of O
c2 B-Disease
deficiency I-Disease
with O
certain O
histocompatibility O
antigens O
suggests O
possible O
linkage O
to O
immune O
response O
genes O
. O

to O
our O
knowledge O
this O
is O
the O
first O
report O
of O
heterozygous O
c2 B-Disease
deficiency I-Disease
in O
association O
with O
this O
combination O
of O
autoimmune B-Disease
disorders I-Disease
, O
and O
we O
discuss O
the O
aetiological O
implications O
. O

genetic O
analysis O
of O
an O
inherited O
deficiency B-Disease
of I-Disease
the I-Disease
third I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
brittany O
spaniel O
dogs O
. O

genetically O
determined O
c3 B-Disease
deficiency I-Disease
in O
brittany O
spaniel O
dogs O
shares O
a O
number O
of O
biochemical O
and O
clinical O
characteristics O
with O
the O
human O
disorder O
. O

in O
humans O
, O
the O
gene O
for O
c3 B-Disease
deficiency I-Disease
is O
a O
null O
gene O
that O
is O
allelic O
to O
the O
structural O
gene O
for O
c3 O
and O
is O
not O
linked O
to O
the O
major O
histocompatibility O
locus O
. O

the O
current O
study O
used O
allotype O
analysis O
of O
canine O
c3 O
in O
order O
to O
demonstrate O
that O
the O
gene O
for O
c3 B-Disease
deficiency I-Disease
in O
these O
dogs O
is O
also O
a O
null O
gene O
allelic O
to O
the O
structural O
gene O
for O
c3 O
. O

in O
addition O
, O
preliminary O
pedigree O
analysis O
suggests O
that O
the O
gene O
for O
canine O
c3 B-Disease
deficiency I-Disease
is O
apparently O
not O
closely O
linked O
to O
the O
major O
histocompatibility O
complex O
of O
the O
dog O
. O

thus O
, O
it O
appears O
that O
c3 B-Disease
deficiency I-Disease
in O
brittany O
spaniel O
dogs O
not O
only O
shares O
biochemical O
and O
clinical O
features O
with O
c3 B-Disease
deficiency I-Disease
in O
humans O
, O
but O
also O
shares O
some O
genetic O
characteristics O
with O
the O
human O
disorder O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
caused O
by O
a O
genetic O
deficiency B-Disease
of I-Disease
the I-Disease
enzyme I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
) O
. O

regional O
mapping O
of O
the O
phenylalanine O
hydroxylase O
gene O
and O
the O
phenylketonuria B-Disease
locus O
in O
the O
human O
genome O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
of O
amino O
acid O
metabolism O
caused O
by O
a O
deficiency B-Disease
of I-Disease
the I-Disease
hepatic I-Disease
enzyme I-Disease
phenylalanine I-Disease
hydroxylase I-Disease
( O
pah O
; O
phenylalanine O
4 O
- O
monooxygenase O
, O
ec O
1 O
. O
14 O
. O
16 O
. O
1 O
) O
. O

heterogeneity O
of O
type B-Disease
i I-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
: O
evidence O
for O
a O
subgroup O
with O
an O
abnormal O
von B-Disease
willebrand I-Disease
factor O
. O

type B-Disease
i I-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
( O
vwd B-Disease
) O
is O
characterized O
by O
equally O
low O
plasma O
concentrations O
of O
von B-Disease
willebrand I-Disease
factor O
antigen O
( O
vwf O
ag O
) O
and O
ristocetin O
cofactor O
( O
ricof O
) O
and O
by O
the O
presence O
of O
all O
vwf O
multimers O
in O
sodium O
dodecyl O
sulfate O
( O
sds O
) O
- O
agarose O
gel O
electrophoresis O
. O

these O
findings O
demonstrated O
that O
there O
can O
be O
an O
abnormal O
vwf O
( O
ricof O
less O
than O
vwf O
ag O
) O
even O
in O
type B-Disease
i I-Disease
vwd I-Disease
, O
coexisting O
with O
a O
complete O
set O
of O
vwf O
multimers O
( O
platelet O
discordant O
) O
; O
that O
the O
abnormal O
vwf O
can O
be O
shown O
more O
clearly O
in O
platelets O
than O
in O
plasma O
or O
else O
in O
plasma O
after O
ddavp O
infusion O
; O
and O
that O
ddavp O
normalizes O
the O
bt O
only O
in O
those O
patients O
with O
normal O
platelet O
levels O
of O
both O
vwf O
ag O
and O
ricof O
( O
platelet O
normal O
) O
. O

genetic O
analysis O
in O
families O
with O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
. O

we O
have O
brought O
together O
information O
on O
864 O
affected O
individuals O
in O
164 O
families O
( O
including O
three O
new O
pedigrees O
) O
reported O
in O
the O
137 O
year O
period O
since O
1845 O
when O
demarquay O
first O
described O
a O
family O
with O
what O
was O
later O
called O
van B-Disease
der I-Disease
woude I-Disease
syndrome I-Disease
( O
vws B-Disease
) O
. O

both O
types O
of O
oral B-Disease
cleft I-Disease
, O
cleft B-Disease
palate I-Disease
( O
cp B-Disease
) O
and O
cleft B-Disease
lip I-Disease
with O
or O
without O
cp B-Disease
( O
clp B-Disease
) O
, O
segregate O
in O
these O
families O
together O
with O
lower O
lip B-Disease
pits I-Disease
or O
fistulae B-Disease
in O
an O
autosomal O
dominant O
mode O
with O
high O
penetrance O
estimated O
to O
be O
k O
= O
. O

cleft O
types O
( O
clp B-Disease
and O
cp B-Disease
) O
occur O
in O
vws B-Disease
in O
the O
same O
proportions O
as O
in O
the O
general O
non O
- O
vws O
population O
, O
ie O
, O
about O
twice O
as O
many O
cleft O
- O
bearing O
individuals O
have O
clp B-Disease
as O
have O
cp B-Disease
. O

on O
the O
other O
hand O
, O
we O
do O
not O
find O
the O
usually O
observed O
excess O
of O
females O
with O
cp B-Disease
and O
excess O
of O
males O
with O
clp B-Disease
; O
in O
vws B-Disease
the O
sex O
ratios O
are O
more O
nearly O
equal O
. O

lip B-Disease
pits I-Disease
also O
are O
equally O
distributed O
between O
the O
sexes O
. O

affected O
males O
and O
females O
are O
equally O
likely O
to O
transmit O
vws B-Disease
. O

for O
a O
vws B-Disease
gene O
carrier O
the O
relative O
risk O
of O
transmitting O
a O
cleft O
is O
26 O
. O

45 O
% O
; O
that O
of O
transmitting O
lower O
lip B-Disease
pits I-Disease
is O
23 O
. O

55 O
% O
. O

three O
pedigrees O
of O
lip B-Disease
pits I-Disease
in O
the O
literature O
show O
no O
clefts O
among O
a O
significant O
number O
of O
affected O
individuals O
. O

control O
of O
gene O
expression O
in O
vws B-Disease
in O
the O
three O
target O
tissues O
appears O
to O
be O
independent O
and O
separately O
designated O
. O

mutation O
rate O
of O
the O
vws B-Disease
gene O
is O
calculated O
to O
be O
1 O
. O

hereditary B-Disease
c7 I-Disease
deficiency I-Disease
. O

the O
serum O
of O
a O
44 O
- O
yr O
- O
old O
woman O
of O
french O
- O
canadian O
descent O
having O
a O
b O
- O
27 O
positive O
ankylosing B-Disease
spondylitis I-Disease
was O
deficient B-Disease
in I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c7 O
) O
as O
determined O
by O
hemolytic O
and O
immunochemical O
methods O
. O

the O
seven O
other O
siblings O
were O
heterozygous O
for O
c7 B-Disease
deficiency I-Disease
, O
while O
the O
paternal O
aunt O
had O
a O
normal O
c7 O
level O
. O

studies O
of O
the O
hla O
antigens O
in O
all O
the O
22 O
subjects O
and O
in O
three O
spouses O
indicated O
no O
close O
linkage O
between O
the O
cm B-Disease
deficienty I-Disease
and O
the O
hla O
system O
. O

in O
addition O
, O
the O
simultaneous O
occurrence O
of O
two O
hereditary O
complement B-Disease
deficiencies I-Disease
( I-Disease
c2 I-Disease
and I-Disease
c7 I-Disease
) I-Disease
was O
discovered O
in O
one O
family O
of O
this O
remarkable O
kindred O
. O

genetic O
defect B-Disease
in I-Disease
secretion I-Disease
of I-Disease
complement I-Disease
c5 I-Disease
in O
mice O
. O

a O
genetic O
deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
( I-Disease
c5 I-Disease
) I-Disease
component I-Disease
of I-Disease
complement1 I-Disease
- I-Disease
3 I-Disease
, O
a O
serum O
glycoprotein O
of O
molecular O
weight O
( O
mw O
) O
220 O
, O
000 O
( O
ref O
. O
4 O
) O
, O
has O
been O
found O
in O
39 O
% O
of O
inbred O
strains O
of O
mice3 O
. O

using O
similar O
methods O
, O
we O
now O
find O
that O
c5 B-Disease
deficiency I-Disease
in O
each O
of O
five O
different O
mouse O
strains O
( O
akr O
, O
swr O
, O
dba O
/ O
2j8 O
a O
/ O
hej O
and O
b10 O
. O
d2 O
/ O
old O
line O
) O
is O
due O
to O
a O
failure O
in O
secretion O
of O
c5 O
protein O
and O
not O
to O
a O
failure O
in O
biosynthesis O
of O
pro O
- O
c5 O

recurrent O
meningococcal B-Disease
meningitis I-Disease
with O
absence B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
: O
an O
evaluation O
of O
underlying O
immunologic O
mechanisms O
. O

a O
51 O
/ O
2 O
- O
year O
- O
old O
black O
girl O
with O
recurrent O
meningococcal B-Disease
meningitis I-Disease
and O
absence B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c6 O
) O
is O
reported O
. O

to O
explore O
the O
pathogenesis O
of O
recurrent O
neisserial B-Disease
infections I-Disease
in O
c6 B-Disease
deficiency I-Disease
, O
a O
detailed O
analysis O
of O
her O
immune O
competence O
was O
conducted O
. O

in O
addition O
, O
her O
c6 B-Disease
- I-Disease
deficient I-Disease
serum O
was O
indistinguishable O
from O
normal O
serum O
in O
a O
complement O
- O
dependent O
assay O
of O
phagocyte O
bactericidal O
activity O
. O

absent O
bacteriolysis O
remains O
the O
only O
consistent O
defect O
associated O
with O
recurrent O
neisserial B-Disease
infections I-Disease
and O
absence O
of O
one O
of O
the O
late O
- O
acting O
complement O
components O
. O

deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
human O
subjects O
. O

the O
discovery O
of O
a O
large O
kindred O
with O
a O
heritable O
deficiency B-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c5 O
) O
has O
permitted O
the O
accumulation O
of O
new O
clinical O
, O
genetic O
and O
immunologic O
data O
concerning O
the O
role O
of O
c5 O
in O
human O
subjects O
. O

the O
proband O
, O
who O
has O
had O
nine O
episodes O
of O
disseminated O
gonococcal B-Disease
infection I-Disease
, O
has O
a O
hemolytic O
c5 O
level O
of O
approximately O
0 O
. O

no O
chemotactic O
activity O
for O
polymorphonuclear O
leukocytes O
could O
be O
generated O
in O
the O
c5 B-Disease
- I-Disease
deficient I-Disease
serums O
upon O
activation O
of O
either O
the O
classic O
or O
alternative O
pathways O
, O
again O
demonstrating O
the O
importance O
of O
c5 O
in O
human O
subjects O
for O
the O
production O
of O
chemotactic O
factors O
. O

no O
linkage O
for O
c5 B-Disease
deficiency I-Disease
and O
the O
a O
or O
b O
loci O
of O
the O
major O
histocompatibility O
complex O
could O
be O
found O
. O

these O
data O
suggest O
an O
autosomal O
codominant O
mode O
of O
inheritance O
of O
c5 B-Disease
deficiency I-Disease
. O

deficiency B-Disease
of I-Disease
c5 I-Disease
is O
compatible O
with O
good O
health O
, O
but O
it O
can O
be O
associated O
with O
repeated O
disseminated O
gonococcal B-Disease
infection I-Disease

a O
total O
of O
3000 O
men O
living O
in O
yamaguchi O
were O
screened O
for O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
using O
beutlers O
spot O
test O
and O
three O
types O
of O
starch O
gel O
electrophoresis O
. O

fifteen O
g6pd B-Disease
- I-Disease
deficient I-Disease
variants O
were O
found O
at O
the O
rate O
of O
0 O
. O

these O
three O
variants O
had O
a O
mild O
to O
moderate O
g6pd B-Disease
deficiency I-Disease
and O
were O
not O
associated O
with O
any O
clinical O
signs O
. O

utilization O
of O
purines O
by O
an O
hprt O
variant O
in O
an O
intelligent O
, O
nonmutilative O
patient O
with O
features O
of O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

chr O
. O

b O
. O
, O
was O
among O
the O
first O
reported O
with O
hyperuricemia B-Disease
and O
central B-Disease
nervous I-Disease
system I-Disease
symptoms I-Disease
. O

he O
has O
been O
found O
to O
have O
a O
variant O
of O
hypoxanthine O
guanine O
phosphoribosyl O
transferase O
( O
hprt O
; O
e O
. O
c O
. O
2 O
. O
4 O
. O
2 O
. O
8 O
) O
distinct O
from O
the O
enzyme O
present O
in O
patients O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

the O
patient O
had O
chroeoathetosis B-Disease
, O
spasticity B-Disease
, O
dysarthric B-Disease
speech I-Disease
, O
and O
hyperuricemia B-Disease
. O

in O
contrast O
, O
cells O
from O
patients O
with O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
were O
virtually O
completely O
unable O
to O
convert O
hypoxanthine O
to O
nucleotides O
. O

the O
growth O
of O
the O
cultured O
fibroblasts O
of O
this O
patient O
was O
intermediate O
in O
media O
containing O
hypoxanthine O
aminopterin O
thymidine O
( O
hat O
) O
, O
whereas O
the O
growth O
of O
lesch B-Disease
- I-Disease
nyhan I-Disease
cells O
was O
inhibited O
and O
normal O
cells O
grew O
normally O
. O

similarly O
in O
8 O
- O
azaguanine O
, O
6 O
- O
thioguanine O
, O
and O
8 O
- O
azahypoxanthine O
, O
the O
growth O
of O
the O
patients O
cells O
was O
intermediate O
between O
normal O
and O
lesch B-Disease
- I-Disease
nyhan I-Disease
cells O
. O

they O
document O
that O
this O
famous O
patient O
did O
not O
have O
the O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease

localisation O
of O
the O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
by O
linkage O
to O
cloned O
dna O
sequences O
. O

a O
linkage O
study O
in O
30 O
becker B-Disease
muscular I-Disease
dystrophy I-Disease
( O
bmd B-Disease
) O
kindreds O
using O
three O
cloned O
dna O
sequences O
from O
the O
x O
chromosome O
which O
demonstrate O
restriction O
fragment O
length O
polymorphisms O
( O
rflps O
) O
, O
suggests O
that O
the O
bmd B-Disease
gene O
is O
located O
on O
the O
short O
arm O
of O
the O
x O
chromosome O
, O
in O
the O
p21 O
region O
. O

the O
genes O
for O
becker B-Disease
and I-Disease
duchenne I-Disease
dystrophies I-Disease
must O
therefore O
be O
closely O
linked O
, O
if O
not O
allelic O
, O
and O
any O
future O
dna O
probes O
found O
to O
be O
of O
practical O
use O
in O
one O
disorder O
should O
be O
equally O
applicable O
to O
the O
other O
. O

molecular O
evidence O
for O
new O
mutation O
at O
the O
hprt O
locus O
in O
lesch B-Disease
- I-Disease
nyhan I-Disease
patients O
. O

partial O
hprt B-Disease
deficiencies I-Disease
are O
associated O
with O
gouty B-Disease
arthritis I-Disease
, O
while O
absence O
of O
activity O
results O
in O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
( O
l B-Disease
- I-Disease
n I-Disease
) O
. O

l B-Disease
- I-Disease
n I-Disease
patients O
fail O
to O
reproduce O
and O
the O
heterozygous O
state O
appears O
to O
confer O
no O
selective O
advantage O
. O

thus O
, O
haldanes O
principle O
predicts O
that O
new O
mutations O
at O
the O
hprt O
locus O
must O
occur O
frequently O
in O
order O
for O
l B-Disease
- I-Disease
n I-Disease
syndrome I-Disease
to O
be O
maintained O
in O
the O
population O
. O

this O
constant O
introduction O
of O
new O
mutations O
would O
be O
expected O
to O
result O
in O
a O
heterogeneous O
collection O
of O
genetic B-Disease
lesions I-Disease
, O
some O
of O
which O
may O
be O
novel O
. O

as O
we O
report O
here O
, O
the O
mutations O
in O
the O
hprt O
gene O
of O
seven O
l B-Disease
- I-Disease
n I-Disease
patients O
, O
selected O
from O
an O
initial O
survey O
of O
28 O
patients O
, O
have O
been O
characterized O
and O
all O
were O
found O
to O
be O
distinctly O
different O
, O
as O
predicted O
. O

allelic O
exclusion O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
in O
platelets O
and O
t O
lymphocytes O
from O
a O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
carrier O
. O

an O
obligate O
carrier O
of O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
who O
was O
also O
heterozygous O
for O
the O
a O
and O
b O
types O
of O
x O
- O
linked O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
was O
found O
. O

with O
her O
it O
became O
possible O
to O
determine O
whether O
allelic O
exclusion O
occurs O
in O
particular O
cell O
- O
types O
of O
the O
was B-Disease
carrier O
. O

these O
findings O
suggest O
that O
selection O
against O
the O
was B-Disease
gene O
occurs O
in O
platelets O
and O
thymus O
- O
derived O
t O
lymphocytes O
and O
that O
the O
defects O
associated O
with O
was B-Disease
expressed O
in O
these O
cell O
- O
types O
may O
be O
implicated O
in O
the O
genesis O
of O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O

complement B-Disease
deficiency I-Disease
and O
nephritis B-Disease
. O

a O
family O
is O
described O
in O
which O
three O
children O
had O
homozygous O
deficiency B-Disease
of I-Disease
c3 I-Disease
and O
in O
which O
both O
parents O
and O
two O
other O
children O
were O
heterozygous O
for O
the O
c3 O
null O
gene O
. O

one O
child O
with O
heterozygous O
c3 B-Disease
deficiency I-Disease
was O
found O
to O
have O
membranoproliferative O
glomerulonephritis B-Disease
; O
proteinuria B-Disease
and O
/ O
or O
microscopical O
haematuria B-Disease
was O
present O
in O
all O
three O
homozygous O
c3 B-Disease
- I-Disease
deficient I-Disease
children O
. O

all O
children O
with O
homozygous O
or O
heterozygous O
c3 B-Disease
deficiency I-Disease
were O
, O
to O
a O
varying O
degree O
, O
susceptible O
to O
infection O
. O

the O
only O
child O
of O
the O
family O
with O
normal O
complement O
had O
no O
increased O
risk O
of O
infection O
and O
no O
renal B-Disease
disease I-Disease
. O

this O
family O
study O
provides O
further O
support O
for O
the O
proposal O
that O
c3 B-Disease
deficiency I-Disease
predisposes O
to O
nephritis B-Disease
. O

heterogeneity O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
algeria O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
was O
found O
in O
3 O
. O

g6pd B-Disease
deficiency I-Disease
is O
heterogeneous O
in O
northern O
algeria O
where O
autochtonous O
variants O
seem O
to O
prevail O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
inhibits O
in O
vitro O
growth O
of O
plasmodium O
falciparum O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
; I-Disease
ec I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
1 I-Disease
. I-Disease
49 I-Disease
) I-Disease
- I-Disease
deficient I-Disease
red O
blood O
cells O
from O
male O
hemizygotes O
and O
female O
heterozygotes O
from O
the O
island O
of O
sardinia O
were O
studied O
for O
their O
ability O
to O
support O
growth O
in O
vitro O
of O
the O
malaria B-Disease
- O
causing O
organism O
plasmodium O
falciparum O
. O

parasite O
growth O
was O
approximately O
one O
- O
third O
of O
normal O
in O
both O
hemi O
- O
and O
heterozygotes O
for O
g6pd B-Disease
deficiency I-Disease
. O

in O
sardinians O
with O
the O
beta O
0 O
- O
thalassemia O
trait O
, O
parasite O
growth O
was O
normal O
except O
when O
g6pd B-Disease
deficiency I-Disease
occurred O
together O
with O
the O
thalassemia B-Disease
trait O
. O

the O
data O
support O
the O
hypothesis O
that O
g6pd B-Disease
deficiency I-Disease
may O
confer O
a O
selective O
advantage O
in O
a O
malarious B-Disease
area O
; O
the O
female O
heterozygote O
may O
be O
at O
a O
particular O
advantage O
because O
resistance O
to O
malaria B-Disease
equals O
that O
of O
male O
hemizygotes O
, O
but O
the O
risk O
of O
fatal B-Disease
hemolysis I-Disease
may O
be O
less O
. O

bone O
marrow O
transplant O
in O
adrenoleukodystrophy B-Disease
. O

an O
allogeneic O
bone O
marrow O
transplant O
( O
bmt O
) O
from O
a O
normal O
hla O
identical O
sibling O
donor O
was O
performed O
in O
a O
13 O
- O
year O
- O
old O
boy O
with O
rapidly O
progressive O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
. O

engraftment O
and O
complete O
hematologic O
recovery O
occurred O
within O
4 O
weeks O
, O
but O
neurologic B-Disease
deterioration I-Disease
continued O
. O

the O
patient O
died O
of O
an O
adenovirus B-Disease
infection I-Disease
141 O
days O
after O
bmt O
. O

ald B-Disease
is O
characterized O
by O
abnormally O
high O
plasma O
levels O
of O
very O
long O
chain O
fatty O
acids O
( O
vlcfa O
) O
as O
a O
result O
of O
impaired O
capacity O
to O
degrade O
them O
. O

ten O
days O
after O
bmt O
, O
the O
white O
blood O
cell O
vlcfa O
levels O
and O
enzyme O
activity O
became O
normal O
; O
after O
3 O
months O
, O
there O
was O
progressive O
reduction O
of O
plasma O
vlcfa O
to O
levels O
only O
slightly O
above O
normal O
. O
. O

[ O
gd O
- O
allele O
distribution O
patterns O
in O
azerbaijan O
. O
iii O
. O
the O
identification O
of O
mutant O
forms O
of O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
] O

in O
28 O
families O
with O
g6pd B-Disease
deficiency I-Disease
living O
in O
3 O
settlements O
of O
shekii O
district O
of O
azerbaijan O
11 O
g6pd O
variants O
of O
ii O
and O
iii O
classes O
differing O
by O
kinetic O
properties O
were O
identified O
according O
who O
program O
. O

9 O
of O
them O
are O
characterized O
with O
the O
same O
electrophoretic O
mobility O
. O

comparison O
of O
g6pd O
spectra O
in O
two O
subpopulations O
and O
in O
a O
mixed O
group O
permits O
to O
make O
a O
conclusion O
about O
existence O
of O
common O
and O
rare O
g6pd O
alleles O
in O
examined O
population O
. O

they O
distribute O
by O
gene O
drift O
supported O
by O
natural O
selection O
. O

among O
7 O
samples O
of O
g6pd O
with O
normal O
and O
increased O
activity O
two O
new O
variants O
of O
iv O
class O
- O
- O
nukha O
and O
bash O
- O
kungut O
- O
- O
were O
found O
. O
. O

adrenoleukodystrophy B-Disease
: O
survey O
of O
303 O
cases O
: O
biochemistry O
, O
diagnosis O
, O
and O
therapy O
. O

adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
is O
a O
genetically O
determined O
disorder O
associated O
with O
progressive B-Disease
central I-Disease
demyelination I-Disease
and O
adrenal B-Disease
cortical I-Disease
insufficiency I-Disease
. O

all O
affected O
persons O
show O
increased O
levels O
of O
saturated O
unbranched O
very O
- O
long O
- O
chain O
fatty O
acids O
, O
particularly O
hexacosanoate O
( O
c26 O
0 O
) O
, O
because O
of O
impaired O
capacity O
to O
degrade O
these O
acids O
. O

this O
degradation O
normally O
takes O
place O
in O
a O
subcellular O
organelle O
called O
the O
peroxisome O
, O
and O
ald B-Disease
, O
together O
with O
zellwegers B-Disease
cerebrohepatorenal I-Disease
syndrome I-Disease
, O
is O
now O
considered O
to O
belong O
to O
the O
newly O
formed O
category O
of O
peroxisomal B-Disease
disorders I-Disease
. O

biochemical O
assays O
permit O
prenatal O
diagnosis O
, O
as O
well O
as O
identification O
of O
most O
heterozygotes O
. O

we O
have O
identified O
303 O
patients O
with O
ald B-Disease
in O
217 O
kindreds O
. O

these O
patients O
show O
a O
wide O
phenotypic O
variation O
. O

sixty O
percent O
of O
patients O
had O
childhood O
ald B-Disease
and O
17 O
% O
adrenomyeloneuropathy B-Disease
, O
both O
of O
which O
are O
x O
- O
linked O
, O
with O
the O
gene O
mapped O
to O
xq28 O
. O

neonatal B-Disease
ald I-Disease
, O
a O
distinct O
entity O
with O
autosomal O
recessive O
inheritance O
and O
points O
of O
resemblance O
to O
zellwegers B-Disease
syndrome I-Disease
, O
accounted O
for O
7 O
% O
of O
the O
cases O
. O

although O
excess O
c26 O
0 O
in O
the O
brain O
of O
patients O
with O
ald B-Disease
is O
partially O
of O
dietary O
origin O
, O
dietary O
c26 O
0 O
restriction O
did O
not O
produce O
clear O
benefit O
. O

bone O
marrow O
transplant O
lowered O
the O
plasma O
c26 O
0 O
level O
but O
failed O
to O
arrest O
neurological O
progression O
. O
. O

genetic O
polymorphism O
of O
g6pd O
in O
a O
bulgarian O
population O
. O

considerable O
genetic O
heterogeneity O
in O
g6pd O
was O
found O
in O
the O
bulgarian O
population O
- O
14 O
g6pd O
variants O
isolated O
from O
117 O
hemizygous O
carriers O
of O
g6pd B-Disease
deficiency I-Disease
. O

of O
these O
, O
g6pd O
mediterranean O
type O
was O
a O
polymorphic O
variant O
and O
g6pd O
corinth O
occurred O
with O
high O
frequency O
. O

two O
new O
variants O
were O
identified O
- O
g6pd O
rudosem O
and O
g6pd O
nedelino O
. O

in O
a O
selected O
group O
of O
78 O
subjects O
with O
clinical O
manifestations O
, O
four O
variants O
were O
established O
g6pd O
mediterranian O
, O
g6pd O
corinth O
, O
g6pd O
seattle O
and O
g6pd O
ohut O
ii O
. O
. O

clinical O
use O
of O
dna O
markers O
linked O
to O
the O
gene O
for O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
. O

seventy O
families O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
known O
to O
the O
institute O
of O
child O
health O
fall O
into O
three O
categories O
with O
respect O
to O
potential O
linkage O
analysis O
with O
the O
x O
chromosome O
dna O
markers O
rc8 O
and O
l1 O
. O

28 O
that O
bridge O
the O
dmd B-Disease
gene O
. O

families O
in O
which O
there O
is O
at O
least O
one O
obligatory O
female O
heterozygote O
( O
n O
= O
13 O
) O
. O

here O
prediction O
and O
exclusion O
of O
dmd B-Disease
gene O
transmission O
may O
be O
possible O
, O
the O
accuracy O
being O
dependent O
on O
the O
closeness O
of O
the O
linkage O
of O
the O
dna O
marker O
( O
s O
) O
to O
the O
dmd B-Disease
gene O
; O
an O
illustrative O
case O
is O
reported O
. O

families O
in O
which O
there O
is O
a O
single O
affected O
boy O
, O
who O
also O
has O
one O
or O
more O
healthy O
brothers O
( O
n O
= O
26 O
) O
. O

given O
an O
informative O
restriction O
fragment O
length O
polymorphism O
( O
rflp O
) O
, O
the O
probability O
that O
the O
boy O
represents O
a O
new O
mutation O
can O
be O
reassessed O
; O
it O
is O
also O
possible O
to O
exclude O
the O
dmd B-Disease
gene O
in O
a O
sister O
. O

families O
with O
a O
single O
affected O
boy O
with O
no O
brother O
( O
n O
= O
30 O
) O
. O

here O
exclusion O
of O
the O
dmd B-Disease
gene O
in O
a O
sister O
may O
be O
possible O
. O

only O
in O
one O
family O
was O
there O
no O
possibility O
of O
useful O
linkage O
analysis O
. O

the O
linkage O
analysis O
required O
is O
described O
, O
and O
the O
need O
to O
check O
dmd B-Disease
families O
for O
informative O
rflps O
is O
stressed O
. O

family O
studies O
in O
bechterew B-Disease
' I-Disease
s I-Disease
syndrome I-Disease
( O
ankylosing B-Disease
spondylitis I-Disease
) O
iii O
. O

genetics O
. O

the O
results O
of O
segregation O
analyses O
in O
75 O
families O
where O
the O
proband O
had O
ankylosing B-Disease
spondylitis I-Disease
, O
are O
presented O
. O

of O
the O
278 O
adult O
, O
living O
first O
degree O
relatives O
, O
approximately O
85 O
% O
cooperated O
in O
the O
study O
. O

clinical O
and O
radiographical O
examinations O
were O
performed O
and O
hla O
typing O
was O
conducted O
. O

the O
results O
were O
in O
agreement O
with O
our O
hypothesis O
that O
ankylosing B-Disease
spondylitis I-Disease
is O
part O
of O
a O
syndrome O
where O
different O
genetic O
factors O
interact O
. O

such O
known O
factors O
are O
hla O
b27 O
associated O
disease O
susceptibility O
, O
susceptibility O
to O
psoriatic B-Disease
arthropathy I-Disease
and O
susceptibility O
to O
entero B-Disease
- I-Disease
arthropathy I-Disease
. O

radiographical O
sacro B-Disease
- I-Disease
iliitis I-Disease
was O
restricted O
to O
hla O
b27 O
positive O
relatives O
, O
and O
was O
more O
frequently O
found O
in O
relatives O
to O
probands O
with O
psoriasis B-Disease
than O
in O
relatives O
to O
probands O
without O
psoriasis B-Disease
. O

environmental O
factors O
( O
intestinal O
bacteria O
) O
are O
known O
to O
trigger O
the O
disease O
at O
least O
in O
some O
persons O
, O
and O
we O
have O
postulated O
that O
all O
or O
most O
of O
them O
have O
the O
predisposition O
to O
develop O
disease O
. O

thus O
, O
the O
syndrome O
has O
a O
multifactorial O
etiology O
. O

the O
phenotypic O
expressions O
of O
the O
different O
genetic O
predispositions O
involved O
, O
include O
sacro B-Disease
- I-Disease
iliitis I-Disease
, O
psoriasis B-Disease
, O
acute B-Disease
anterior I-Disease
uveitis I-Disease
, O
peripheral O
arthropathy B-Disease
and O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
. O

we O
suggest O
the O
descriptive O
name O
hereditary B-Disease
multifocal I-Disease
relapsing I-Disease
inflammation I-Disease
( O
hemri B-Disease
) O
for O
this O
syndrome O
. O

ankylosing B-Disease
spondylitis I-Disease
, O
psoriatic B-Disease
arthropathy I-Disease
and O
entero B-Disease
- I-Disease
arthropathy I-Disease
may O
be O
regarded O
as O
clinical O
sub O
- O
types O
of O
the O
syndrome O
. O
. O

prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
and O
chromosome O
15 O
. O

a O
clinical O
discussion O
of O
20 O
cases O
. O

a O
chromosome B-Disease
15 I-Disease
anomaly I-Disease
was O
observed O
in O
12 O
of O
20 O
patients O
, O
17 O
of O
whom O
were O
clinically O
suspected O
of O
having O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

the O
clinical O
features O
of O
eight O
cases O
with O
15q11 O
- O
12 O
deletion O
were O
very O
similar O
to O
those O
originally O
described O
in O
pws B-Disease
. O

on O
the O
other O
hand O
, O
the O
group O
of O
normal O
karyotype O
patients O
is O
heterogeneous O
, O
and O
their O
features O
do O
not O
strictly O
correspond O
to O
the O
clinical O
definition O
of O
pws B-Disease
. O

however O
, O
the O
hypothesis O
that O
pws B-Disease
is O
associated O
with O
deletion O
of O
15q11 O
- O
12 O
can O
neither O
explain O
the O
apparently O
balanced O
translocations O
of O
chromosome O
15 O
nor O
account O
for O
the O
small O
supernumerary O
metacentric O
chromosomes O
corresponding O
to O
an O
isochromosome O
15 O
for O
band O
15q11 O
observed O
in O
some O
cases O
. O
. O

the O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
gene O
in O
north O
american O
jewish O
populations O
: O
geographic O
variations O
and O
origin O
. O

from O
data O
collected O
in O
a O
north O
american O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
heterozygote O
screening O
program O
, O
the O
tsd B-Disease
carrier O
frequency O
among O
46 O
, O
304 O
jewish O
individuals O
was O
found O
to O
be O
. O

0324 O
( O
1 O
in O
31 O
individuals O
) O
. O

this O
frequency O
is O
consistent O
with O
earlier O
estimates O
based O
on O
tsd B-Disease
incidence O
data O
. O

tsd B-Disease
carrier O
frequencies O
were O
then O
examined O
by O
single O
country O
and O
single O
region O
of O
origin O
in O
28 O
, O
029 O
jews O
within O
this O
sample O
for O
whom O
such O
data O
were O
available O
for O
analysis O
. O

jews O
with O
polish O
and O
/ O
or O
russian O
ancestry O
constituted O
88 O
% O
of O
this O
sample O
and O
had O
a O
tsd B-Disease
carrier O
frequency O
of O
. O

0327 O
. O

no O
tsd B-Disease
carriers O
were O
observed O
among O
the O
166 O
jews O
of O
near O
eastern O
origins O
. O

relative O
to O
jews O
of O
polish O
and O
russian O
origins O
, O
there O
was O
at O
least O
a O
twofold O
increase O
in O
the O
tsd B-Disease
carrier O
frequency O
in O
jews O
of O
austrian O
, O
hungarian O
, O
and O
czechoslovakian O
origins O
( O
p O
less O
than O
. O
005 O
) O
. O

these O
findings O
suggest O
that O
the O
tsd B-Disease
gene O
proliferated O
among O
the O
antecedents O
of O
modern O
ashkenazi O
jewry O
after O
the O
second O
diaspora O
( O
70 O
a O
. O
d O
. O
) O
and O
before O
their O
major O
migrations O
to O
regions O
of O
poland O
and O
russia O
( O
before O
1100 O
a O
. O
d O
. O
) O
. O

human O
deficiency B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
patient O
with O
meningococcal B-Disease
meningitis I-Disease
and O
no O
haemostasis B-Disease
abnormality I-Disease
. O

a O
case O
of O
human O
complete O
c6 B-Disease
deficiency I-Disease
is O
reported O
. O

the O
patient O
, O
a O
31 O
year O
old O
white O
male O
, O
was O
seen O
on O
the O
occasion O
of O
an O
isolated O
episode O
of O
meningococcal B-Disease
meningitis I-Disease
. O

serum O
complement O
hemolytic O
and O
bactericidal O
activities O
were O
lacking O
and O
could O
be O
restored O
to O
normal O
by O
addition O
of O
appropriate O
amounts O
of O
purified O
c6 O
. O

no O
hemostatic B-Disease
abnormalities I-Disease
were O
observed O
. O
. O

absence B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
a O
patient O
with O
chronic B-Disease
meningococcemia I-Disease
presenting O
as O
vasculitis B-Disease
. O

a O
previously O
healthy O
40 O
- O
year O
- O
old O
man O
presenting O
with O
fever B-Disease
, O
arthritis B-Disease
, O
and O
cutaneous B-Disease
vasculitis I-Disease
was O
found O
to O
have O
chronic B-Disease
meningococcemia I-Disease
. O

evaluation O
of O
his O
complement O
system O
showed O
an O
absence O
of O
functional O
and O
antigenic O
c7 O
, O
compatible O
with O
a O
complete O
deficiency B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

study O
of O
the O
patients O
family O
spanning O
four O
generations O
showed O
heterozygous O
deficiency B-Disease
of I-Disease
c7 I-Disease
in O
five O
members O
. O

chronic B-Disease
neisserial I-Disease
infection I-Disease
can O
be O
associated O
with O
c7 B-Disease
deficiency I-Disease
and O
must O
be O
distinguished O
from O
other O
causes O
of O
cutaneous B-Disease
vasculitis I-Disease
. O
. O

familial B-Disease
discoid I-Disease
lupus I-Disease
erythematosus I-Disease
associated O
with O
heterozygote O
c2 B-Disease
deficiency I-Disease
. O

two O
siblings O
with O
chronic B-Disease
discoid I-Disease
lupus I-Disease
erythematosus I-Disease
and O
several O
family O
members O
were O
found O
with O
heterozygous O
c2 B-Disease
deficiency I-Disease
. O

an O
association O
with O
histocompatibility O
markers O
hla O
- O
b18 O
and O
hla O
- O
dw2 O
was O
demonstrated O
, O
and O
the O
slow O
allotype O
of O
factor O
b O
was O
present O
. O

linkage O
studies O
in O
this O
family O
suggested O
a O
close O
linkage O
between O
the O
c2 B-Disease
deficiency I-Disease
gene O
and O
genes O
coding O
for O
b18 O
, O
dw2 O
, O
and O
bfs O
antigens O
. O

one O
hla O
- O
acb O
/ O
dbf O
recombinant O
was O
observed O
showing O
closer O
linkage O
between O
hla O
- O
d O
and O
bf O
than O
between O
hla O
- O
b O
and O
bf O
. O
. O

severe B-Disease
- I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
associated O
with O
chronic O
hemolytic B-Disease
anemia I-Disease
, O
granulocyte B-Disease
dysfunction I-Disease
, O
and O
increased O
susceptibility O
to O
infections O
: O
description O
of O
a O
new O
molecular O
variant O
( O
g6pd O
barcelona O
) O
. O

molecular O
, O
kinetic O
, O
and O
functional O
studies O
were O
carried O
out O
on O
erythrocytes O
and O
leukocytes O
in O
a O
spanish O
male O
with O
g6pd B-Disease
deficiency I-Disease
, O
congenital B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
( O
cnsha B-Disease
) O
, O
and O
increased O
susceptibility O
to O
infections O
. O

g6pd O
activity O
was O
absent O
in O
patients O
red O
cells O
and O
was O
about O
2 O
% O
of O
normal O
in O
leukocytes O
. O

molecular O
studies O
using O
standard O
methods O
( O
who O
, O
1967 O
) O
showed O
g6pd O
in O
the O
patient O
to O
have O
a O
slightly O
fast O
electrophoretic O
mobility O
at O
ph O
8 O
. O

0 O
with O
otherwise O
normal O
properties O
( O
heat O
stability O
at O
46 O
degrees O
c O
, O
apparent O
affinity O
for O
substrates O
, O
optimum O
ph O
, O
and O
utilization O
of O
substrate O
analogues O
) O
. O

other O
tests O
showed O
the O
patients O
granulocytes O
to O
engulf O
latex O
particles O
normally O
, O
but O
to O
have O
impaired O
reduction O
of O
nitroblue O
tetrazolium O
and O
ferricytochrome O
- O
c O
as O
well O
as O
reduced O
iodination O
. O

chemotaxis O
and O
random O
migration O
of O
the O
patients O
granulocytes O
were O
normal O
as O
were O
myeloperoxidase O
, O
leukocyte O
alkaline O
phosphatase O
( O
lap O
) O
, O
and O
ultrastructural O
features O
. O

the O
molecular O
characteristics O
of O
g6pd O
in O
the O
patient O
differed O
from O
those O
of O
all O
previously O
reported O
variants O
associated O
with O
cnsha B-Disease
, O
so O
the O
present O
variant O
was O
provisionally O
called O
g6pd O
barcelona O
to O
distinguish O
it O
from O
other O
g6pd O
variants O
previously O
described O
. O

possible O
mechanisms O
for O
the O
severe O
deficiency B-Disease
of I-Disease
g6pd I-Disease
in O
erythrocytes O
and O
granulocytes O
was O
investigated O
by O
studies O
on O
the O
immunologic O
specific O
activity O
of O
the O
mutant O
enzyme O
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
papua O
new O
guinea O
. O

the O
description O
of O
13 O
new O
variants O
. O

a O
total O
of O
362 O
males O
from O
various O
regions O
of O
papua O
new O
guinea O
were O
screened O
for O
red O
cell O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
activity O
. O

twenty O
- O
six O
g6pd B-Disease
deficient I-Disease
individuals O
were O
identified O
. O

biochemical O
characterization O
of O
g6pd O
purified O
from O
these O
subjects O
has O
revealed O
13 O
new O
variants O
and O
several O
copies O
of O
previously O
described O
forms O
of O
g6pd O
. O

this O
study O
illustrates O
the O
extreme O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
among O
the O
people O
of O
papua O
new O
guinea O
. O
. O

heterogeneity O
of O
" O
mediterranean O
type O
" O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
spain O
and O
description O
of O
two O
new O
variants O
associated O
with O
favism B-Disease
. O

glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
; O
ec O
1 O
. O

1 O
. O

1 O
. O

49 O
from O
thirty O
- O
six O
unrelated O
spanish O
males O
was O
partially O
purified O
from O
blood O
, O
and O
the O
variants O
were O
characterized O
biochemically O
and O
electrophoretically O
according O
to O
the O
methods O
recommended O
by O
the O
world O
health O
organization O
. O

subjects O
were O
from O
multiple O
geographic O
regions O
within O
spain O
, O
and O
all O
suffered O
from O
hemolytic B-Disease
anemia I-Disease
, O
either O
acute O
( O
34 O
cases O
) O
or O
chronic O
nonspherocytic O
( O
2 O
cases O
) O
. O

almost O
all O
the O
variants O
studied O
presented O
residual O
erythrocyte O
g6pd O
activity O
ranging O
from O
0 O
to O
10 O
% O
of O
normal O
, O
and O
five O
different O
mutants O
were O
responsible O
for O
the O
deficient O
phenotype O
. O

three O
variants O
were O
similar O
to O
others O
previously O
described O
g6pd O
mediterranean O
( O
11 O
cases O
) O
, O
g6pd O
athens O
- O
like O
( O
3 O
cases O
) O
, O
and O
g6pd O
union O
( O
2 O
cases O
) O
. O

the O
remaining O
variants O
were O
different O
from O
the O
numerous O
variants O
already O
reported O
and O
have O
been O
considered O
as O
new O
mutants O
. O

provisionally O
they O
are O
called O
g6pd O
betica O
( O
19 O
cases O
) O
and O
g6pd O
menorca O
( O
1 O
case O
) O
. O

the O
present O
study O
constitutes O
the O
first O
attempt O
to O
characterize O
the O
deficient B-Disease
g6pd I-Disease
variants O
found O
in O
spain O
and O
supplies O
new O
data O
on O
the O
relationship O
between O
molecular O
characteristics O
of O
deficient O
variants O
and O
their O
clinical O
manifestations O
. O

the O
most O
important O
findings O
can O
be O
summarized O
as O
follows O
( O
1 O
) O
the O
spanish O
population O
is O
characterized O
by O
an O
important O
heterogeneity O
in O
g6pd B-Disease
deficiency I-Disease
. O

( O
2 O
) O
although O
g6pd O
mediterranean O
is O
very O
frequent O
, O
it O
presents O
a O
relatively O
high O
degree O
of O
polymorphism O
. O

( O
3 O
) O
favism B-Disease
has O
been O
observed O
associated O
with O
all O
kinds O
of O
variants O
described O
here O
. O

( O
4 O
) O
g6pd O
betica O
, O
which O
is O
the O
most O
frequent O
variant O
found O
in O
subjects O
of O
southern O
spanish O
origin O
, O
has O
been O
observed O
associated O
with O
favism B-Disease
in O
all O
cases O
except O
one O
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
variant O
( O
g6pd O
nagano O
) O
associated O
with O
congenital B-Disease
hemolytic I-Disease
anemia I-Disease
. O

a O
new O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
variant O
associated O
with O
chronic B-Disease
nonspherocytic I-Disease
hemolytic I-Disease
anemia I-Disease
was O
reported O
. O

the O
patient O
, O
a O
6 O
- O
year O
- O
old O
japanese O
male O
, O
was O
noticed O
to O
have O
hemolytic B-Disease
anemia I-Disease
soon O
after O
birth O
, O
and O
a O
diagnosis O
of O
g6pd B-Disease
deficiency I-Disease
was O
made O
at O
the O
age O
of O
2 O
. O

he O
had O
episodes O
of O
hemolytic B-Disease
crisis I-Disease
several O
times O
after O
upper B-Disease
respiratory I-Disease
infection I-Disease
. O

g6pd O
activity O
of O
the O
patient O
was O
5 O
. O

5 O
% O
of O
normal O
. O

the O
enzymatic O
characteristics O
were O
examined O
when O
he O
was O
5 O
years O
old O
, O
and O
his O
g6pd O
showed O
faster O
- O
than O
- O
normal O
electrophoretic O
mobility O
, O
low O
km O
g6p O
, O
high O
km O
nadp O
, O
low O
ki O
nadph O
, O
normal O
utilization O
of O
substrate O
analogues O
, O
heat O
instability O
, O
and O
a O
normal O
ph O
optimum O
curve O
. O

from O
these O
results O
, O
this O
was O
considered O
to O
be O
a O
new O
variant O
and O
was O
designated O
g6pd O
nagano O
. O

infection O
- O
induced O
hemolysis B-Disease
and O
chronic B-Disease
hemolytic I-Disease
anemia I-Disease
seem O
to O
be O
due O
to O
markedly O
impaired O
enzyme O
activity O
and O
thermal O
instability O
. O

heterozygous O
c2 B-Disease
- I-Disease
deficiency I-Disease
and O
myasthenia B-Disease
gravis I-Disease
. O

complement B-Disease
deficiency I-Disease
states O
in O
myasthenia B-Disease
gravis I-Disease
( O
mg B-Disease
) O
have O
not O
been O
reported O
previously O
. O

we O
describe O
a O
19 O
- O
year O
- O
old O
woman O
with O
typical O
mg B-Disease
and O
heterozygous O
c2 B-Disease
deficiency I-Disease
, O
along O
with O
hla O
typing O
of O
the O
patient O
and O
her O
immediate O
family O
. O
. O

adrenoleukodystrophy B-Disease
: O
increased O
plasma O
content O
of O
saturated O
very O
long O
chain O
fatty O
acids O
. O

with O
a O
new O
method O
we O
measured O
the O
saturated O
very O
long O
chain O
fatty O
acids O
in O
the O
plasma O
of O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
hemizygotes O
, O
ald B-Disease
heterozygotes O
, O
and O
controls O
. O

ald B-Disease
hemizygotes O
showed O
increased O
levels O
of O
hexacosanoate O
( O
c26 O
fatty O
acid O
) O
which O
represented O
0 O
. O

081 O
+ O
/ O
- O
0 O
. O

0066 O
% O
( O
sem O
) O
of O
total O
fatty O
acids O
, O
compared O
to O
0 O
. O

015 O
+ O
/ O
- O
0 O
. O

0032 O
% O
in O
the O
controls O
. O

c25 O
, O
c24 O
, O
and O
c23 O
fatty O
acids O
were O
also O
increased O
, O
but O
the O
c22 O
and O
c20 O
fatty O
acids O
were O
normal O
. O

c26 O
levels O
were O
also O
increased O
in O
most O
ald B-Disease
heterozygotes O
, O
with O
a O
mean O
level O
0 O
. O

057 O
+ O
/ O
- O
0 O
. O

0063 O
% O
of O
total O
fatty O
acids O
. O

the O
technique O
can O
be O
used O
for O
diagnosis O
and O
carrier O
identification O
, O
and O
in O
the O
evaluation O
of O
therapy O
. O

abnormal O
high O
density O
lipoproteins O
in O
cerebrotendinous B-Disease
xanthomatosis I-Disease
. O

the O
plasma O
lipoprotein O
profiles O
and O
high O
density O
lipoproteins O
( O
hdl O
) O
were O
characterized O
in O
patients O
with O
the O
genetic B-Disease
disease I-Disease
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

abnormalities B-Disease
in I-Disease
the I-Disease
hdl I-Disease
may O
contribute O
to O
their O
increased O
atherogenesis O
and O
excessive O
deposits O
of O
tissue O
sterols O
in O
the O
presence O
of O
low O
or O
low O
- O
normal O
concentrations O
of O
plasma O
cholesterol O
( O
165 O
+ O
/ O
- O
25 O
mg O
/ O
dl O
) O
and O
low O
density O
lipoproteins O
( O
ldl O
) O
. O

the O
mean O
hdl O
- O
cholesterol O
concentration O
in O
the O
ctx B-Disease
plasmas O
was O
14 O
. O

5 O
+ O
/ O
- O
3 O
. O

2 O
mg O
/ O
dl O
, O
about O
one O
- O
third O
the O
normal O
value O
. O

the O
low O
hdl O
- O
cholesterol O
reflects O
a O
low O
concentration O
and O
an O
abnormal O
lipid O
composition O
of O
the O
plasma O
hdl O
. O

relative O
to O
normal O
hdl O
, O
the O
cholesteryl O
esters O
are O
low O
, O
free O
cholesterol O
and O
phospholipids O
essentially O
normal O
, O
and O
triglycerides O
increased O
. O

the O
ratio O
of O
apoprotein O
( O
apo O
) O
to O
total O
cholesterol O
in O
the O
hdl O
of O
ctx B-Disease
was O
two O
to O
three O
times O
greater O
than O
normal O
. O

in O
the O
ctx B-Disease
hdl O
, O
the O
ratio O
of O
apoai O
to O
apoaii O
was O
high O
, O
the O
proportion O
of O
apoc O
low O
, O
and O
a O
normally O
minor O
form O
of O
apoai O
increased O
relative O
to O
other O
forms O
. O

the O
hdl O
in O
electron O
micrographs O
appeared O
normal O
morphologically O
and O
in O
particle O
size O
. O

the O
abnormalities O
in O
lipoprotein O
distribution O
profile O
and O
composition O
of O
the O
plasma O
hdl O
result O
from O
metabolic O
defects O
that O
are O
not O
understood O
but O
may O
be O
linked O
to O
the O
genetic B-Disease
defect I-Disease
in O
bile O
acid O
synthesis O
in O
ctx B-Disease
. O

as O
a O
consequence O
, O
it O
is O
probable O
that O
the O
normal O
functions O
of O
the O
hdl O
, O
possibly O
including O
modulation O
of O
ldl O
- O
cholesterol O
uptake O
and O
the O
removal O
of O
excess O
cholesterol O
from O
peripheral O
tissues O
, O
are O
perturbed O
significantly O
in O
this O
disease O
. O

genetics O
of O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
: O
an O
autosomal O
recessive O
trait O
with O
high O
gene O
frequency O
in O
sephardim O
of O
moroccan O
origin O
. O

we O
described O
6 O
patients O
( O
from O
3 O
families O
) O
affected O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

all O
are O
sephardic O
jews O
of O
moroccan O
extraction O
. O

in O
view O
of O
the O
small O
number O
of O
ctx B-Disease
patients O
diagnosed O
in O
the O
world O
( O
a O
total O
of O
50 O
including O
our O
6 O
patients O
) O
, O
we O
are O
probably O
dealing O
with O
an O
ethnic O
subgroup O
with O
a O
high O
ctx O
gene O
frequency O
, O
which O
we O
have O
estimated O
to O
be O
1 O
/ O
108 O
. O

since O
there O
are O
differences O
in O
expression O
in O
this O
disease O
, O
we O
recommend O
cholestanol O
study O
in O
cases O
of O
undiagnosed O
cataract B-Disease
or O
tendinous B-Disease
xanthomas I-Disease
in O
childhood O
or O
early O
adolescence O
. O

the O
diagnosis O
in O
ctx B-Disease
is O
important O
not O
only O
for O
genetic O
counseling O
, O
but O
also O
in O
veiw O
of O
possible O
treatment O
. O
. O

new O
genetic O
variants O
of O
glucose O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
in O
italy O
. O

six O
new O
variants O
of O
human O
erythrocyte O
g6pd O
have O
been O
characterized O
. O

all O
of O
them O
were O
found O
in O
italian O
males O
and O
all O
were O
associated O
with O
enzyme B-Disease
deficiency I-Disease
, O
but O
only O
two O
with O
signs O
of O
haemolysis B-Disease
. O

these O
and O
other O
variants O
reported O
in O
the O
literature O
, O
which O
must O
thus O
far O
be O
regarded O
as O
sporadic O
, O
are O
found O
to O
map O
in O
parts O
of O
italy O
where O
common O
types O
of O
g6pd B-Disease
deficiency I-Disease
are O
also O
prevalent O
. O
. O

variants O
of O
erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
( O
g6pd O
) O
in O
bulgarian O
populations O
. O

ten O
variants O
of O
erythrocyte O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
were O
identified O
in O
22 O
patients O
with O
g6pd B-Disease
deficiency I-Disease
from O
three O
districts O
of O
bulgaria O
. O

corinth O
- O
like O
and O
fayoum O
- O
like O
variants O
were O
the O
most O
frequent O
; O
mediterranean O
, O
ohut O
ii O
, O
kilgore O
, O
boston O
, O
poznan O
, O
and O
panay O
variants O
and O
two O
new O
variants O
, O
petrich O
and O
gotze O
delchev O
, O
were O
each O
found O
in O
one O
or O
two O
carriers O
. O

no O
correlation O
was O
revealed O
between O
clinical O
and O
biochemical O
polymorphism O
. O
. O

nephropathy B-Disease
in O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O

nephropathy B-Disease
was O
detected O
in O
five O
of O
32 O
patients O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
who O
were O
participating O
in O
a O
study O
of O
transfer O
factor O
( O
tf O
) O
therapy O
. O

in O
two O
patients O
, O
nephropathy B-Disease
was O
present O
before O
tf O
and O
did O
not O
appear O
changed O
by O
tf O
therapy O
. O

one O
of O
these O
patients O
subsequently O
developed O
progressive O
renal B-Disease
failure I-Disease
requiring O
dialysis O
beginning O
5 O
1 O
/ O
2 O
years O
after O
tf O
therapy O
. O

in O
two O
patients O
, O
decreased O
renal O
function O
appeared O
very O
soon O
after O
the O
administration O
of O
tf O
. O

one O
patient O
showed O
gradually O
decreasing O
renal O
function O
beginning O
after O
two O
years O
of O
tf O
therapy O
. O

an O
additional O
patient O
was O
identified O
who O
died O
with O
renal B-Disease
failure I-Disease
without O
having O
received O
tf O
. O

the O
results O
suggest O
that O
renal B-Disease
failure I-Disease
occurs O
in O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
more O
frequently O
than O
generally O
recognized O
and O
that O
administration O
of O
tf O
may O
precipitate O
or O
accelerate O
the O
renal B-Disease
disease I-Disease
in O
patients O
with O
this O
syndrome O
. O
. O

wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
: O
cellular O
impairments O
and O
their O
implication O
for O
carrier O
detection O
. O

a O
family O
in O
which O
two O
male O
siblings O
were O
affected O
with O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
was O
studied O
using O
g O
- O
6 O
- O
pd O
isoenzymes O
as O
an O
x O
- O
linked O
marker O
in O
order O
to O
investigate O
the O
nature O
of O
cellular O
abnormalities O
. O

isolated O
peripheral O
blood O
cell O
types O
from O
the O
doubly O
heterozygous O
mother O
of O
the O
affected O
males O
seemingly O
failed O
to O
express O
the O
g O
- O
6 O
- O
pd O
allele O
in O
cis O
position O
with O
the O
was B-Disease
allele O
while O
her O
cultured O
skin O
fibroblasts O
expressed O
both O
g O
- O
6 O
- O
pd O
alleles O
. O

additionally O
, O
a O
histogram O
analysis O
of O
platelet O
size O
revealed O
a O
single O
population O
of O
abnormally O
small O
platelets O
in O
the O
affected O
propositus O
, O
whereas O
the O
heterozygous O
mother O
had O
no O
appreciable O
small O
platelet O
subpopulation O
. O

in O
vitro O
culture O
of O
hemopoietic O
progenitor O
cells O
of O
the O
heterozygous O
mother O
showed O
that O
the O
majority O
of O
progenitor O
cells O
did O
not O
express O
the O
was B-Disease
allele O
. O

however O
, O
a O
small O
number O
of O
cells O
expressing O
the O
g O
- O
6 O
- O
pd O
type O
linked O
with O
the O
was B-Disease
allele O
were O
detected O
. O

the O
proportion O
of O
the O
latter O
progenitors O
was O
significantly O
higher O
among O
more O
primitive O
progenitors O
( O
those O
giving O
rise O
to O
later O
appearing O
colonies O
) O
. O

this O
observation O
suggests O
that O
selection O
against O
cells O
expressing O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
defect I-Disease
takes O
place O
in O
the O
hemopoietic O
system O
of O
the O
heterozygous O
female O
and O
offers O
a O
possible O
means O
of O
carrier O
detection O
in O
some O
women O
. O

linkage O
studies O
in O
this O
family O
revealed O
one O
example O
of O
probable O
recombination O
between O
the O
loci O
for O
was B-Disease
and O
g O
- O
6 O
- O
pd O
among O
three O
informative O
subjects O
, O
suggesting O
that O
these O
two O
loci O
may O
not O
be O
closely O
linked O
on O
the O
x O
- O
chromosome O
. O
. O

a O
new O
ct O
pattern O
in O
adrenoleukodystrophy B-Disease
. O

a O
new O
ct O
pattern O
was O
observed O
in O
2 O
patients O
with O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
. O

this O
pattern O
, O
which O
the O
authors O
call O
type O
ii O
, O
is O
characterized O
by O
the O
absence O
of O
posterior O
periventricular O
areas O
of O
decreased O
attenuation O
around O
the O
trigone O
on O
non O
- O
contrast O
scans O
after O
contrast O
infusion O
, O
however O
, O
there O
is O
striking O
enhancement O
of O
various O
white O
- O
matter O
structures O
( O
tracts O
or O
fiber O
systems O
) O
such O
as O
the O
internal O
capsules O
, O
corpus O
callosum O
, O
corona O
radiata O
, O
forceps O
major O
, O
and O
cerebral O
peduncles O
. O

this O
is O
different O
from O
numerous O
previous O
descriptions O
of O
the O
ct O
pattern O
in O
ald B-Disease
. O

type B-Disease
ii I-Disease
ald I-Disease
does O
not O
appear O
to O
have O
been O
seen O
in O
any O
other O
leukoencephalopathy B-Disease
and O
is O
probably O
specific O
for O
a O
phenotypic O
variant O
or O
an O
evolving O
stage O
of O
ald B-Disease
. O
. O

further O
evidence O
for O
heterogeneity O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
deficiency I-Disease
in O
papua O
new O
guinea O
. O

four O
new O
g6pd O
variants O
have O
been O
characterized O
in O
individuals O
from O
papua O
new O
guinea O
. O

this O
study O
demonstrates O
that O
the O
previously O
reported O
markham O
variant O
and O
the O
newly O
characterized O
salata O
variant O
may O
be O
widely O
distributed O
in O
papua O
new O
guinea O
. O

th O
data O
presented O
here O
together O
with O
those O
of O
previously O
published O
studies O
demonstrate O
a O
degree O
of O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
that O
is O
much O
higher O
than O
that O
in O
other O
regions O
of O
the O
world O
where O
g6pd B-Disease
deficiency I-Disease
is O
common O
. O
. O

increased O
incidence O
of O
cataracts B-Disease
in O
male O
subjects O
deficient B-Disease
in I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
rbcs O
was O
found O
significantly O
more O
frequently O
in O
210 O
male O
cataractous B-Disease
patients O
than O
in O
672 O
control O
subjects O
of O
sardinian O
origin O
. O

the O
frequency O
of O
the O
deficiency O
was O
increasingly O
higher O
in O
presenile O
cataracts B-Disease
. O

in O
the O
g6pd B-Disease
- I-Disease
deficient I-Disease
group O
, O
the O
incidence O
of O
cortical B-Disease
and I-Disease
total I-Disease
cataracts I-Disease
was O
also O
increased O
. O

it O
is O
suggested O
that O
decrease O
of O
the O
g6pd O
activity O
in O
the O
lens O
, O
which O
accompanies O
its O
deficiency O
in O
the O
erythrocyte O
, O
might O
play O
a O
role O
in O
the O
cataracto O
- O
genesis O
of O
these O
patients O
. O

moreover O
, O
g6pd B-Disease
deficiency I-Disease
should O
be O
added O
to O
other O
conditions O
, O
such O
as O
the O
galactosemic B-Disease
states O
and O
riboflavin B-Disease
deficiency I-Disease
, O
where O
cataracts B-Disease
represent O
a O
sensitive O
indicator O
of O
metabolic B-Disease
abnormalities I-Disease
of O
the O
rbc O
. O
. O

molecular O
basis O
of O
human O
mitochondrial O
very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coa I-Disease
dehydrogenase I-Disease
deficiency I-Disease
causing O
cardiomyopathy B-Disease
and O
sudden B-Disease
death I-Disease
in O
childhood O
. O

beta O
- O
oxidation O
of O
long O
- O
chain O
fatty O
acids O
provides O
the O
major O
source O
of O
energy O
in O
the O
heart O
. O

defects O
in O
enzymes O
of O
the O
beta O
- O
oxidation O
pathway O
cause O
sudden B-Disease
, I-Disease
unexplained I-Disease
death I-Disease
in O
childhood O
, O
acute O
hepatic B-Disease
encephalopathy I-Disease
or O
liver B-Disease
failure I-Disease
, O
skeletal B-Disease
myopathy I-Disease
, O
and O
cardiomyopathy B-Disease
. O

very O
- O
long O
- O
chain O
acyl O
- O
coa O
dehydrogenase O
[ O
vlcad O
; O
very O
- O
long O
- O
chain O
- O
acyl O
- O
coa O
( O
acceptor O
) O
2 O
, O
3 O
- O
oxidoreductase O
, O
ec O
1 O
. O
3 O
3 O
. O
99 O
99 O
. O
13 O
] O
catalyzes O
the O
first O
step O
in O
beta O
- O
oxidation O
. O

we O
have O
isolated O
the O
human O
vlcad O
cdna O
and O
gene O
and O
determined O
the O
complete O
nucleotide O
sequences O
. O

polymerase O
chain O
reaction O
amplification O
of O
vlcad O
mrna O
and O
genomic O
exons O
defined O
the O
molecular O
defects O
in O
two O
patients O
with O
vlcad B-Disease
deficiency I-Disease
who O
presented O
with O
unexplained O
cardiac B-Disease
arrest I-Disease
and O
cardiomyopathy B-Disease
. O

in O
one O
, O
a O
homozygous O
mutation O
in O
the O
consensus O
dinucleotide O
of O
the O
donor O
splice O
site O
( O
g O
+ O
1 O
- O
- O
> O
a O
) O
was O
associated O
with O
universal O
skipping O
of O
the O
prior O
exon O
( O
exon O
11 O
) O
. O

the O
second O
patient O
was O
a O
compound O
heterozygote O
, O
with O
a O
missense O
mutation O
, O
c1837 O
- O
- O
> O
t O
, O
changing O
the O
arginine O
at O
residue O
613 O
to O
tryptophan O
on O
one O
allele O
and O
a O
single O
base O
deletion O
at O
the O
intron O
- O
exon O
6 O
boundary O
as O
the O
second O
mutation O
. O

this O
initial O
delineation O
of O
human O
mutations O
in O
vlcad O
suggests O
that O
vlcad B-Disease
deficiency I-Disease
reduces O
myocardial O
fatty O
acid O
beta O
- O
oxidation O
and O
energy O
production O
and O
is O
associated O
with O
cardiomyopathy B-Disease
and O
sudden B-Disease
death I-Disease
in O
childhood O
. O

aberrant O
subcellular O
localization O
of O
brca1 O
in O
breast B-Disease
cancer I-Disease
. O

the O
brca1 O
gene O
product O
was O
identified O
as O
a O
220 O
- O
kilodalton O
nuclear O
phosphoprotein O
in O
normal O
cells O
, O
including O
breast O
ductal O
epithelial O
cells O
, O
and O
in O
18 O
of O
20 O
tumor B-Disease
cell O
lines O
derived O
from O
tissues O
other O
than O
breast O
and O
ovary O
. O

in O
16 O
of O
17 O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
lines O
and O
17 O
of O
17 O
samples O
of O
cells O
obtained O
from O
malignant O
effusions O
, O
however O
, O
brca1 O
localized O
mainly O
in O
cytoplasm O
. O

absence O
of O
brca1 O
or O
aberrant O
subcellular O
location O
was O
also O
observed O
to O
a O
variable O
extent O
in O
histological O
sections O
of O
many O
breast B-Disease
cancer I-Disease
biopsies O
. O

these O
findings O
suggest O
that O
brca1 B-Disease
abnormalities I-Disease
may O
be O
involved O
in O
the O
pathogenesis O
of O
many O
breast B-Disease
cancers I-Disease
, O
sporadic O
as O
well O
as O
familial O
. O
. O

mapping O
of O
the O
mouse O
homologue O
of O
the O
wilson B-Disease
disease I-Disease
gene O
to O
mouse O
chromosome O
8 O
. O

atp7b O
, O
the O
gene O
altered O
in O
wilson B-Disease
disease I-Disease
( O
wd B-Disease
) O
patients O
, O
lies O
in O
a O
block O
of O
homology O
shared O
between O
human O
chromosome O
13q14 O
and O
the O
central O
region O
of O
mouse O
chromosome O
14 O
. O

however O
, O
we O
have O
mapped O
the O
murine O
homologue O
of O
atp7b O
( O
atp7b O
) O
to O
mouse O
chromosome O
8 O
by O
somatic O
cell O
hybrid O
analysis O
. O

analysis O
of O
80 O
interspecific O
backcross O
offspring O
was O
used O
to O
position O
atp7b O
close O
to O
d8mit3 O
and O
another O
atpase O
locus O
, O
atp4b O
, O
on O
mouse O
chromosome O
8 O
. O

atp4b O
lies O
in O
13q34 O
and O
is O
separated O
from O
atp7b O
by O
several O
loci O
whose O
mouse O
homologues O
map O
to O
mouse O
chromosome O
14 O
. O

the O
assignment O
of O
atp7b O
to O
mouse O
chromosome O
8 O
identifies O
a O
previously O
unrecognized O
region O
of O
homology O
between O
this O
chromosome O
and O
human O
chromosome O
13 O
. O

this O
assignment O
suggests O
a O
possible O
location O
for O
the O
toxic O
milk O
mutation O
in O
the O
mouse O
, O
which O
has O
been O
proposed O
as O
a O
homologue O
of O
wd B-Disease
. O
. O

germline O
mutations O
of O
the O
brca1 O
gene O
in O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
families O
provide O
evidence O
for O
a O
genotype O
- O
phenotype O
correlation O
. O

mutations O
in O
the O
brca1 O
gene O
, O
discovered O
in O
1994 O
, O
are O
associated O
with O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
. O

we O
have O
analysed O
60 O
families O
with O
a O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
for O
germline O
mutations O
in O
brca1 O
. O

twenty O
- O
two O
different O
mutations O
were O
detected O
in O
32 O
families O
( O
53 O
% O
) O
, O
of O
which O
14 O
are O
previously O
unreported O
. O

we O
observed O
a O
significant O
correlation O
between O
the O
location O
of O
the O
mutation O
in O
the O
gene O
and O
the O
ratio O
of O
breast B-Disease
to I-Disease
ovarian I-Disease
cancer I-Disease
incidence O
within O
each O
family O
. O

our O
data O
suggest O
a O
transition O
in O
risk O
such O
that O
mutations O
in O
the O
3 O
third O
of O
the O
gene O
are O
associated O
with O
a O
lower O
proportion O
of O
ovarian B-Disease
cancer I-Disease
. O

haplotype O
analysis O
supports O
previous O
data O
which O
suggest O
some O
brca1 O
mutation O
carriers O
have O
common O
ancestors O
; O
however O
, O
we O
have O
found O
at O
least O
two O
examples O
where O
recurrent O
mutations O
appear O
to O
have O
arisen O
independently O
. O
. O

hereditary O
deficiency B-Disease
of I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
and O
recurrent O
meningococcal B-Disease
infection I-Disease
: O
investigations O
of O
an O
irish O
family O
using O
a O
novel O
haemolytic O
screening O
assay O
for O
complement O
activity O
and O
c7 O
m O
/ O
n O
allotyping O
. O

terminal B-Disease
complement I-Disease
component I-Disease
deficiency I-Disease
predisposes O
to O
meningococcal B-Disease
infection I-Disease
and O
is O
inherited O
in O
an O
autosomal O
co O
- O
dominant O
manner O
. O

an O
irish O
family O
is O
described O
, O
in O
which O
2 O
of O
3 O
brothers O
had O
recurrent O
meningococcal B-Disease
infection I-Disease
. O

a O
novel O
screening O
assay O
was O
used O
to O
investigate O
for O
terminal B-Disease
complement I-Disease
deficiency I-Disease
and O
the O
2 O
affected O
brothers O
were O
found O
to O
be O
completely B-Disease
deficient I-Disease
in I-Disease
the I-Disease
seventh I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c7 O
) O
. O

enzyme O
- O
linked O
immunosorbent O
assay O
for O
c7 O
revealed O
lower O
than O
normal O
levels O
in O
the O
remaining O
brother O
and O
parents O
. O

c7 O
m O
/ O
n O
protein O
polymorphism O
allotyping O
, O
used O
to O
investigate O
the O
segregation O
of O
the O
c7 B-Disease
deficiency I-Disease
genes O
, O
showed O
that O
the O
apparently O
complement O
sufficient O
brother O
was O
heterozygous O
c7 B-Disease
deficient I-Disease
and O
a O
carrier O
of O
one O
of O
the O
deficiency O
genes O
. O

complement O
screening O
should O
be O
carried O
out O
in O
any O
individual O
suffering O
recurrent O
meningococcal B-Disease
infection I-Disease
or O
infection O
with O
an O
uncommon O
meningococcal B-Disease
serogroup O
. O

identification O
of O
complement B-Disease
deficient I-Disease
patients O
allows O
the O
implementation O
of O
strategies O
to O
prevent O
recurrent O
infection O
. O
. O

molecular O
basis O
of O
subtotal B-Disease
complement I-Disease
c6 I-Disease
deficiency I-Disease
. O

a O
carboxy O
- O
terminally O
truncated O
but O
functionally O
active O
c6 O
. O

individuals O
with O
subtotal B-Disease
complement I-Disease
c6 I-Disease
deficiency I-Disease
possess O
a O
c6 O
molecule O
that O
is O
14 O
% O
shorter O
than O
normal O
c6 O
and O
present O
in O
low O
but O
detectable O
concentrations O
( O
1 O
- O
2 O
% O
of O
the O
normal O
mean O
) O
. O

we O
now O
show O
that O
this O
dysmorphic O
c6 O
is O
bactericidally O
active O
and O
lacks O
an O
epitope O
that O
was O
mapped O
to O
the O
most O
carboxy O
- O
terminal O
part O
of O
c6 O
using O
c6 O
cdna O
fragments O
expressed O
as O
fusion O
proteins O
in O
the O
puex O
expression O
system O
. O

we O
thus O
predicted O
that O
the O
abnormal O
c6 O
molecule O
might O
be O
carboxy O
- O
terminally O
truncated O
and O
sought O
a O
mutation O
in O
an O
area O
approximately O
14 O
% O
from O
the O
carboxy O
- O
terminal O
end O
of O
the O
coding O
sequence O
. O

by O
sequencing O
pcr O
- O
amplified O
products O
from O
this O
region O
, O
we O
found O
, O
in O
three O
individuals O
from O
two O
families O
, O
a O
mutation O
that O
might O
plausibly O
be O
responsible O
for O
the O
defect O
. O

all O
three O
have O
an O
abnormal O
5 O
splice O
donor O
site O
of O
intron O
15 O
, O
which O
would O
probably O
prevent O
splicing O
. O

an O
in O
- O
frame O
stop O
codon O
is O
found O
17 O
codons O
downstream O
from O
the O
intron O
boundary O
, O
which O
would O
lead O
to O
a O
truncated O
polypeptide O
13 O
. O

5 O
% O
smaller O
than O
normal O
c6 O
. O

this O
result O
was O
unexpected O
, O
as O
earlier O
studies O
mapped O
the O
c5b O
binding O
site O
, O
or O
a O
putative O
enzymatic O
region O
, O
to O
this O
part O
of O
c6 O
. O

interestingly O
, O
all O
three O
subjects O
were O
probably O
heterozygous O
for O
both O
subtotal B-Disease
c6 I-Disease
and I-Disease
complete I-Disease
c6 I-Disease
deficiency I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
: O
evidence O
for O
a O
possible O
dominant O
- O
negative O
rna O
mutation O
. O

the O
trinucleotide O
expansion O
mutation O
causing O
myotonic B-Disease
dystrophy I-Disease
is O
in O
the O
3 O
untranslated O
region O
of O
a O
protein O
kinase O
gene O
. O

the O
molecular O
mechanisms O
by O
which O
the O
expanded O
repeat O
causes O
the O
clinically O
variable O
and O
multisystemic B-Disease
disease I-Disease
, O
myotonic B-Disease
dystrophy I-Disease
, O
are O
not O
understood O
. O

it O
has O
been O
particularly O
difficult O
to O
rationalize O
the O
dominant O
inheritance O
with O
the O
fact O
that O
the O
expansion O
mutation O
lies O
outside O
of O
the O
protein O
- O
encoding O
gene O
elements O
, O
and O
should O
not O
be O
translated O
into O
protein O
. O

here O
we O
use O
muscle O
biopsies O
from O
classical O
adult O
- O
onset O
myotonic B-Disease
dystrophy I-Disease
patients O
to O
study O
the O
accumulation O
of O
transcripts O
from O
both O
the O
normal O
and O
expanded O
dm B-Disease
kinase O
genes O
in O
patient O
muscle O
, O
and O
compare O
the O
results O
to O
normal O
and O
myopathic B-Disease
controls O
. O

we O
found O
relatively O
small O
decreases O
of O
dm B-Disease
kinase O
rna O
in O
the O
total O
rna O
pool O
from O
muscle O
; O
however O
, O
these O
reductions O
were O
not O
disease O
specific O
. O

analysis O
of O
poly O
( O
a O
) O
+ O
rna O
showed O
dramatic O
decreases O
of O
both O
the O
mutant O
and O
normal O
dm B-Disease
kinase O
rnas O
, O
and O
these O
changes O
were O
disease O
- O
specific O
. O

our O
findings O
are O
consistent O
with O
a O
novel O
molecular O
pathogenetic O
mechanism O
for O
myotonic B-Disease
dystrophy I-Disease
both O
the O
normal O
and O
expanded O
dm B-Disease
kinase O
genes O
are O
transcribed O
in O
patient O
muscle O
, O
but O
the O
abnormal O
expansion O
- O
containing O
rna O
has O
a O
dominant O
effect O
on O
rna O
metabolism O
by O
preventing O
the O
accumulation O
of O
poly O
( O
a O
) O
+ O
rna O
. O

the O
ability O
of O
the O
expansion O
mutation O
to O
alter O
accumulation O
of O
poly O
( O
a O
) O
+ O
rna O
in O
trans O
suggests O
that O
myotonic B-Disease
dystrophy I-Disease
may O
be O
the O
first O
example O
of O
a O
dominant O
- O
negative O
mutation O
manifested O
at O
the O
rna O
level O
. O
. O

a O
strong O
candidate O
for O
the O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
. O

a O
strong O
candidate O
for O
the O
17q O
- O
linked O
brca1 O
gene O
, O
which O
influences O
susceptibility O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
has O
been O
identified O
by O
positional O
cloning O
methods O
. O

probable O
predisposing O
mutations O
have O
been O
detected O
in O
five O
of O
eight O
kindreds O
presumed O
to O
segregate O
brca1 O
susceptibility O
alleles O
. O

the O
mutations O
include O
an O
11 O
- O
base O
pair O
deletion O
, O
a O
1 O
- O
base O
pair O
insertion O
, O
a O
stop O
codon O
, O
a O
missense O
substitution O
, O
and O
an O
inferred O
regulatory O
mutation O
. O

the O
brca1 O
gene O
is O
expressed O
in O
numerous O
tissues O
, O
including O
breast O
and O
ovary O
, O
and O
encodes O
a O
predicted O
protein O
of O
1863 O
amino O
acids O
. O

this O
protein O
contains O
a O
zinc O
finger O
domain O
in O
its O
amino O
- O
terminal O
region O
, O
but O
is O
otherwise O
unrelated O
to O
previously O
described O
proteins O
. O

identification O
of O
brca1 O
should O
facilitate O
early O
diagnosis O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
in O
some O
individuals O
as O
well O
as O
a O
better O
understanding O
of O
breast B-Disease
cancer I-Disease
biology O
. O
. O

molecular O
characterization O
of O
galactosemia B-Disease
( O
type O
1 O
) O
mutations O
in O
japanese O
. O

we O
characterized O
two O
novel O
mutations O
of O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
galt O
) O
gene O
in O
two O
japanese O
patients O
with O
galt B-Disease
deficiency I-Disease
and O
identified O
n314d O
and O
r333w O
mutations O
, O
previously O
found O
in O
caucasians O
. O

one O
novel O
missense O
mutation O
was O
an O
g O
- O
to O
- O
a O
transition O
in O
exon O
8 O
, O
resulting O
in O
the O
substitution O
of O
arginine O
by O
histidine O
at O
the O
codon O
231 O
( O
r231h O
) O
. O

galt O
activity O
of O
the O
r231h O
mutant O
construct O
was O
reduced O
to O
15 O
% O
of O
normal O
controls O
in O
a O
cos O
cell O
expression O
system O
. O

the O
other O
was O
a O
splicing O
mutation O
, O
an O
a O
- O
to O
- O
g O
transition O
at O
the O
38th O
nucleotide O
in O
exon O
3 O
( O
318a O
- O
- O
> O
g O
) O
, O
resulting O
in O
a O
38 O
- O
bp O
deletion O
in O
the O
galt O
cdna O
by O
activating O
a O
cryptic O
splice O
acceptor O
site O
. O

in O
seven O
japanese O
families O
( O
14 O
alleles O
for O
classic O
form O
and O
one O
allele O
for O
duarte O
variant O
) O
with O
galt B-Disease
deficiency I-Disease
, O
the O
r231h O
and O
318a O
- O
- O
> O
g O
mutations O
were O
found O
only O
on O
both O
alleles O
of O
the O
proband O
. O

the O
n314d O
and O
r333w O
mutations O
were O
found O
on O
one O
allele O
each O
. O

the O
q188r O
was O
prevalent O
in O
the O
united O
states O
but O
not O
in O
japanese O
patients O
. O

the O
n314d O
mutation O
was O
associated O
with O
the O
duarte O
variant O
in O
japanese O
persons O
, O
as O
well O
as O
in O
the O
united O
states O
. O

we O
speculate O
that O
classic B-Disease
galactosemia I-Disease
mutations O
appear O
to O
differ O
between O
japanese O
and O
caucasian O
patients O
. O

our O
limited O
data O
set O
on O
galactosemia B-Disease
mutations O
in O
japanese O
suggests O
that O
the O
n314d O
galt O
mutation O
encoding O
the O
duarte O
variant O
arose O
before O
asian O
and O
caucasian O
people O
diverged O
and O
that O
classic B-Disease
galactosemia I-Disease
mutations O
arose O
and O
/ O
or O
accumulated O
after O
the O
divergence O
of O
asian O
and O
caucasian O
populations O
. O
. O

three O
novel O
aniridia B-Disease
mutations O
in O
the O
human O
pax6 O
gene O
. O

aniridia B-Disease
( O
iris B-Disease
hypoplasia I-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
congenital I-Disease
disorder I-Disease
of I-Disease
the I-Disease
eye I-Disease
. O

mutations O
in O
the O
human O
aniridia B-Disease
( O
pax6 O
) O
gene O
have O
now O
been O
identified O
in O
many O
patients O
from O
various O
ethnic O
groups O
. O

in O
the O
study O
reported O
here O
we O
describe O
pax6 O
mutations O
in O
one O
sporadic O
and O
five O
familial O
cases O
with O
aniridia B-Disease
. O

of O
the O
four O
different O
mutations O
identified O
, O
one O
was O
identical O
to O
a O
previously O
reported O
mutation O
( O
c O
- O
- O
> O
t O
transition O
at O
codon O
240 O
) O
, O
and O
three O
were O
novel O
two O
in O
the O
glycine O
- O
rich O
region O
and O
one O
in O
the O
proline O
/ O
serine O
/ O
threonine O
- O
rich O
( O
pst O
) O
region O
. O

one O
pax6 O
mutation O
found O
in O
the O
pst O
region O
was O
associated O
with O
cataracts B-Disease
in O
an O
aniridia B-Disease
family O
. O

another O
splice O
mutation O
in O
the O
pst O
domain O
occurred O
in O
an O
aniridia B-Disease
patient O
with O
anosmia B-Disease
( O
inability O
to O
smell O
) O
. O

the O
six O
new O
aniridia B-Disease
cases O
reported O
here O
have O
mutations O
predicted O
to O
generate O
incomplete O
pax6 O
proteins O
. O

these O
results O
support O
the O
theory O
that O
human O
aniridia B-Disease
is O
caused O
by O
haploinsufficiency B-Disease
of I-Disease
pax6 I-Disease
. O
. O

the O
carrier O
frequency O
of O
the O
brca1 O
185delag O
mutation O
is O
approximately O
1 O
percent O
in O
ashkenazi O
jewish O
individuals O
. O

since O
brca1 O
, O
the O
first O
major O
gene O
responsible O
for O
inherited B-Disease
breast I-Disease
cancer I-Disease
, O
was O
cloned O
, O
more O
than O
50 O
unique O
mutations O
have O
been O
detected O
in O
the O
germline O
of O
individuals O
with O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

in O
high O
- O
risk O
pedigrees O
, O
female O
carriers O
of O
brca1 O
mutations O
have O
an O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
, O
and O
a O
40 O
- O
50 O
% O
risk O
of O
ovarian B-Disease
cancer I-Disease
. O

however O
, O
the O
mutation O
stats O
of O
individuals O
unselected O
for O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
has O
not O
been O
determined O
, O
and O
it O
is O
not O
known O
whether O
mutations O
in O
such O
individuals O
confer O
the O
same O
risk O
of O
cancer B-Disease
as O
in O
individuals O
from O
the O
high O
- O
risk O
families O
studied O
so O
far O
. O

following O
the O
finding O
of O
a O
185delag O
frameshift O
mutation O
in O
several O
ashkenazi O
jewish O
breast O
/ O
ovarian O
families O
, O
we O
have O
determined O
the O
frequency O
of O
this O
mutation O
in O
858 O
ashkenazim O
seeking O
genetic O
testing O
for O
conditions O
unrelated O
to O
cancer B-Disease
, O
and O
in O
815 O
reference O
individuals O
not O
selected O
for O
ethnic O
origin O
. O

we O
observed O
the O
185delag O
mutation O
in O
0 O
. O

9 O
% O
of O
ashkenazim O
( O
95 O
% O
confidence O
limit O
, O
0 O
. O
4 O
- O
1 O
. O
8 O
% O
) O
and O
in O
none O
of O
the O
reference O
samples O
. O

our O
results O
suggest O
that O
one O
in O
a O
hundred O
women O
of O
ashkenazi O
descent O
may O
be O
at O
especially O
high O
risk O
of O
developing O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

identification O
and O
localization O
of O
huntingtin O
in O
brain O
and O
human O
lymphoblastoid O
cell O
lines O
with O
anti O
- O
fusion O
protein O
antibodies O
. O

the O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
phenotype O
is O
associated O
with O
expansion O
of O
a O
trinucleotide O
repeat O
in O
the O
it15 O
gene O
, O
which O
is O
predicted O
to O
encode O
a O
348 O
- O
kda O
protein O
named O
huntington O
. O

we O
used O
polyclonal O
and O
monoclonal O
anti O
- O
fusion O
protein O
antibodies O
to O
identify O
native O
huntingtin O
in O
rat O
, O
monkey O
, O
and O
human O
. O

western O
blots O
revealed O
a O
protein O
with O
the O
expected O
molecular O
weight O
which O
is O
present O
in O
the O
soluble O
fraction O
of O
rat O
and O
monkey O
brain O
tissues O
and O
lymphoblastoid O
cells O
from O
control O
cases O
. O

in O
lymphoblastoid O
cell O
lines O
from O
juvenile O
- O
onset O
heterozygote O
hd B-Disease
cases O
, O
both O
normal O
and O
mutant O
huntingtin O
are O
expressed O
, O
and O
increasing O
repeat O
expansion O
leads O
to O
lower O
levels O
of O
the O
mutant O
protein O
. O

immunocytochemistry O
indicates O
that O
huntingtin O
is O
located O
in O
neurons O
throughout O
the O
brain O
, O
with O
the O
highest O
levels O
evident O
in O
larger O
neurons O
. O

in O
the O
human O
striatum O
, O
huntingtin O
is O
enriched O
in O
a O
patch O
- O
like O
distribution O
, O
potentially O
corresponding O
to O
the O
first O
areas O
affected O
in O
hd B-Disease
. O

subcellular O
localization O
of O
huntingtin O
is O
consistent O
with O
a O
cytosolic O
protein O
primarily O
found O
in O
somatodendritic O
regions O
. O

huntingtin O
appears O
to O
particularly O
associate O
with O
microtubules O
, O
although O
some O
is O
also O
associated O
with O
synaptic O
vesicles O
. O

on O
the O
basis O
of O
the O
localization O
of O
huntingtin O
in O
association O
with O
microtubules O
, O
we O
speculate O
that O
the O
mutation O
impairs O
the O
cytoskeletal O
anchoring O
or O
transport O
of O
mitochondria O
, O
vesicles O
, O
or O
other O
organelles O
or O
molecules O
. O
. O

marked O
phenotypic O
heterogeneity O
associated O
with O
expansion O
of O
a O
cag O
repeat O
sequence O
at O
the O
spinocerebellar B-Disease
ataxia I-Disease
3 I-Disease
/ I-Disease
machado I-Disease
- I-Disease
joseph I-Disease
disease I-Disease
locus O
. O

the O
spinocerebellar B-Disease
ataxia I-Disease
3 I-Disease
locus O
( O
sca3 B-Disease
) O
for O
type B-Disease
i I-Disease
autosomal I-Disease
dominant I-Disease
cerebellar I-Disease
ataxia I-Disease
( O
adca B-Disease
type I-Disease
i I-Disease
) O
, O
a O
clinically O
and O
genetically O
heterogeneous O
group O
of O
neurodegenerative B-Disease
disorders I-Disease
, O
has O
been O
mapped O
to O
chromosome O
14q32 O
. O

1 O
1 O
. O

adca B-Disease
type I-Disease
i I-Disease
patients O
from O
families O
segregating O
sca3 B-Disease
share O
clinical O
features O
in O
common O
with O
those O
with O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
, O
the O
gene O
of O
which O
maps O
to O
the O
same O
region O
. O

we O
show O
here O
that O
the O
disease O
gene O
segregating O
in O
each O
of O
three O
french O
adca B-Disease
type I-Disease
i I-Disease
kindreds O
and O
in O
a O
french O
family O
with O
neuropathological O
findings O
suggesting O
the O
ataxochoreic O
form O
of O
dentatorubropallidoluysian B-Disease
atrophy I-Disease
carries O
an O
expanded O
cag O
repeat O
sequence O
located O
at O
the O
same O
locus O
as O
that O
for O
mjd B-Disease
. O

analysis O
of O
the O
mutation O
in O
these O
families O
shows O
a O
strong O
negative O
correlation O
between O
size O
of O
the O
expanded O
cag O
repeat O
and O
age O
at O
onset O
of O
clinical O
disease O
. O

instability O
of O
the O
expanded O
triplet O
repeat O
was O
not O
found O
to O
be O
affected O
by O
sex O
of O
the O
parent O
transmitting O
the O
mutation O
. O

evidence O
was O
found O
for O
somatic O
and O
gonadal O
mosaicism O
for O
alleles O
carrying O
expanded O
trinucleotide O
repeats O
. O

overexpression O
of O
dm20 O
messenger O
rna O
in O
two O
brothers O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
. O

pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
is O
a O
rare B-Disease
, I-Disease
sex I-Disease
- I-Disease
linked I-Disease
recessive I-Disease
, I-Disease
dysmyelinating I-Disease
disease I-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
that O
has O
been O
associated O
with O
mutations O
in O
the O
myelin O
proteolipid O
protein O
( O
plp O
) O
gene O
. O

only O
25 O
% O
of O
patients O
studied O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
have O
exonic O
mutations O
in O
this O
gene O
, O
the O
underlying O
cause O
of O
the O
disease O
in O
the O
remaining O
patients O
is O
unknown O
. O

the O
plp O
gene O
encodes O
two O
major O
alternatively O
spliced O
transcripts O
called O
plp O
and O
dm20 O
. O

plp O
messenger O
rna O
is O
specifically O
expressed O
in O
central O
nervous O
system O
tissue O
, O
whereas O
dm20 O
messenger O
rna O
is O
found O
in O
central O
nervous O
system O
, O
cardiac O
, O
and O
other O
tissues O
. O

we O
studied O
cultured O
skin O
fibroblasts O
from O
2 O
brothers O
with O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
who O
exhibited O
no O
detectable O
exonic O
mutation O
of O
the O
plp O
gene O
. O

examination O
of O
rna O
from O
these O
cells O
showed O
that O
the O
level O
of O
dm20 O
messenger O
rna O
is O
elevated O
sixfold O
relative O
to O
male O
control O
skin O
fibroblasts O
. O

an O
unrelated O
female O
carrier O
, O
also O
with O
no O
detectable O
exonic O
mutation O
, O
showed O
a O
threefold O
increase O
in O
dm20 O
messenger O
rna O
in O
cultured O
skin O
fibroblasts O
. O

our O
findings O
suggest O
that O
in O
some O
patients O
, O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
is O
caused O
by O
overexpression O
of O
plp O
gene O
transcripts O
, O
and O
that O
in O
these O
families O
a O
50 O
% O
increase O
of O
dm20 O
messenger O
rna O
in O
females O
, O
relative O
to O
the O
increase O
in O
affected O
males O
, O
can O
identify O
a O
female O
carrier O
. O
. O

the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
and O
x B-Disease
- I-Disease
linked I-Disease
congenital I-Disease
thrombocytopenia I-Disease
are O
caused O
by O
mutations O
of O
the O
same O
gene O
. O

the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
thrombocytopenia B-Disease
, O
small O
platelets O
, O
eczema B-Disease
, O
recurrent O
infections O
, O
and O
immunodeficiency B-Disease
. O

besides O
the O
classic O
was B-Disease
phenotype O
, O
there O
is O
a O
group O
of O
patients O
with O
congenital B-Disease
x I-Disease
- I-Disease
linked I-Disease
thrombocytopenia I-Disease
( O
xlt B-Disease
) O
who O
have O
small O
platelets O
but O
only O
transient O
eczema B-Disease
, O
if O
any O
, O
and O
minimal O
immune B-Disease
deficiency I-Disease
. O

because O
the O
gene O
responsible O
for O
was B-Disease
has O
been O
sequenced O
, O
it O
was O
possible O
to O
correlate O
the O
was B-Disease
phenotypes O
with O
was B-Disease
gene O
mutations O
. O

using O
a O
fingerprinting O
screening O
technique O
, O
we O
determined O
the O
approximate O
location O
of O
the O
mutation O
in O
13 O
unrelated O
was B-Disease
patients O
with O
mild O
to O
severe O
clinical O
symptoms O
. O

direct O
sequence O
analysis O
of O
cdna O
and O
genomic O
dna O
obtained O
from O
patient O
- O
derived O
cell O
lines O
showed O
12 O
unique O
mutations O
distributed O
throughout O
the O
was B-Disease
gene O
, O
including O
insertions O
, O
deletions O
, O
and O
point O
mutations O
resulting O
in O
amino O
acid O
substitutions O
, O
termination O
, O
exon O
skipping O
, O
or O
splicing O
defects O
. O

of O
4 O
unrelated O
patients O
with O
the O
xlt B-Disease
phenotype O
, O
3 O
had O
missense O
mutations O
affecting O
exon O
2 O
and O
1 O
had O
a O
splice O
- O
site O
mutation O
affecting O
exon O
9 O
. O

patients O
with O
classic O
was B-Disease
had O
more O
complex O
mutations O
, O
resulting O
in O
termination O
codons O
, O
frameshift O
, O
and O
early O
termination O
. O

these O
findings O
provide O
direct O
evidence O
that O
xlt B-Disease
and O
was B-Disease
are O
caused O
by O
mutations O
of O
the O
same O
gene O
and O
suggest O
that O
severe O
clinical O
phenotypes O
are O
associated O
with O
complex O
mutations O
. O
. O

myotonia B-Disease
levior I-Disease
is O
a O
chloride B-Disease
channel I-Disease
disorder I-Disease
. O

the O
group O
of O
dominant B-Disease
non I-Disease
- I-Disease
dystrophic I-Disease
myotonias I-Disease
, O
comprising O
disorders O
characterized O
by O
clinically O
similar O
forms O
of O
myogenic O
muscle O
stiffness O
, O
is O
genetically O
inhomogeneous O
. O

dominant B-Disease
myotonia I-Disease
congenita I-Disease
( O
thomsens B-Disease
disease I-Disease
) O
is O
linked O
to O
clcn1 O
, O
the O
gene O
encoding O
the O
major O
muscle O
chloride O
channel O
, O
localized O
on O
chromosome O
7q35 O
. O

in O
contrast O
, O
dominant B-Disease
myotonias I-Disease
sensitive O
to O
potassium O
are O
caused O
by O
point O
mutations O
in O
scn4a O
on O
chromosome O
17q O
, O
the O
gene O
for O
the O
alpha O
subunit O
of O
the O
adult O
skeletal O
muscle O
sodium O
channel O
. O

no O
linkage O
or O
molecular O
genetic O
data O
are O
as O
yet O
available O
on O
myotonia B-Disease
levior I-Disease
characterized O
by O
milder O
symptoms O
and O
later O
onset O
of O
myotonia B-Disease
than O
in O
thomsens B-Disease
disease I-Disease
, O
and O
absence O
of O
muscle B-Disease
hypertrophy I-Disease
. O

we O
report O
a O
clcn1 O
gln O
- O
552 O
- O
arg O
substitution O
for O
a O
family O
with O
dominant O
inheritance O
previously O
diagnosed O
to O
have O
myotonia B-Disease
levior I-Disease
. O

thus O
, O
this O
disorder O
appears O
as O
a O
variant O
of O
thomsens B-Disease
disease I-Disease
due O
to O
mutations O
leading O
to O
low O
clinical O
expressivity O
. O

in O
addition O
, O
we O
report O
a O
novel O
ile O
- O
290 O
- O
met O
clcn1 O
mutation O
for O
a O
typical O
thomsen O
pedigree O
. O

in O
another O
family O
previously O
diagnosed O
as O
having O
thomsens B-Disease
disease I-Disease
, O
we O
unexpectedly O
found O
a O
clcn1 O
14 O
bp O
deletion O
known O
to O
cause O
recessive B-Disease
myotonia I-Disease
, O
and O
a O
rare O
trp O
- O
118 O
- O
gly O
polymorphism O
. O
. O

southern O
analysis O
reveals O
a O
large O
deletion O
at O
the O
hypoxanthine O
phosphoribosyltransferase O
locus O
in O
a O
patient O
with O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

whole O
genomic O
hprt O
clones O
were O
used O
in O
southern O
analysis O
to O
screen O
the O
integrity O
of O
the O
hprt O
gene O
in O
a O
family O
that O
includes O
a O
patient O
with O
hprt B-Disease
enzyme I-Disease
deficiency I-Disease
causal O
to O
lesch B-Disease
- I-Disease
nyhan I-Disease
syndrome I-Disease
. O

a O
5 O
kb O
dna O
sequence O
deletion O
was O
found O
to O
have O
its O
endpoints O
in O
the O
first O
and O
third O
introns O
. O

the O
probes O
identified O
the O
carrier O
status O
of O
female O
family O
members O
, O
aided O
by O
an O
rflp O
carried O
by O
the O
mothers O
normal O
x O
- O
chromosome O
. O
. O

characterisation O
of O
molecular O
defects O
in O
x B-Disease
- I-Disease
linked I-Disease
amelogenesis I-Disease
imperfecta I-Disease
( O
aih1 O
) O
. O

amelogenins O
are O
an O
heterogenous O
family O
of O
proteins O
produced O
by O
ameloblasts O
of O
the O
enamel O
organ O
during O
tooth O
development O
. O

disturbances O
of O
enamel O
formation O
occur O
in O
amelogenesis B-Disease
imperfecta I-Disease
, O
a O
clinically O
heterogenous O
group O
of O
inherited B-Disease
disorders I-Disease
characterised O
by O
defective O
enamel O
biomineralisation O
. O

an O
amelogenin O
gene O
, O
amgx O
, O
has O
been O
mapped O
to O
the O
short O
of O
the O
x O
chromosome O
( O
xp22 O
. O
1 O
- O
p22 O
. O
3 O
) O
and O
has O
been O
implicated O
in O
the O
molecular O
pathology O
of O
x B-Disease
- I-Disease
linked I-Disease
amelogenesis I-Disease
imperfecta I-Disease
( O
aih1 B-Disease
) O
. O

we O
have O
identified O
three O
families O
exhibiting O
aih1 B-Disease
and O
screened O
the O
amgx O
gene O
for O
mutations O
using O
single O
- O
strand O
conformational O
polymorphism O
analysis O
and O
dna O
sequencing O
. O

three O
novel O
mutations O
were O
identified O
a O
c O
- O
t O
substitution O
in O
exon O
5 O
, O
and O
a O
g O
- O
t O
substitution O
and O
single O
cytosine O
deletion O
in O
exon O
6 O
, O
confirming O
the O
existence O
of O
extensive O
allelic O
heterogeneity O
in O
this O
condition O
. O

the O
identification O
of O
family O
- O
specific O
mutations O
will O
enable O
early O
identification O
of O
affected O
individuals O
and O
correlation O
of O
clinical O
phenotype O
with O
genotype O
will O
facilitate O
an O
objective O
system O
of O
disease O
classification O
. O

frequency O
of O
exon O
15 O
missense O
mutation O
( O
442d O
: O
g O
) O
in O
cholesteryl O
ester O
transfer O
protein O
gene O
in O
hyperalphalipoproteinemic B-Disease
japanese O
subjects O
. O

cholesteryl O
ester O
transfer O
protein O
( O
cetp O
) O
transfers O
cholesteryl O
ester O
from O
high O
density O
lipoprotein O
( O
hdl O
) O
to O
apo O
b O
- O
containing O
lipoproteins O
. O

the O
hyperalphalipoproteinemia B-Disease
caused O
by O
cetp B-Disease
deficiency I-Disease
is O
fairly O
common O
in O
japan O
and O
one O
of O
the O
most O
common O
mutations O
in O
the O
cetp O
gene O
is O
the O
splicing O
defect O
of O
the O
intron O
14 O
, O
the O
allelic O
frequency O
of O
which O
has O
been O
shown O
to O
be O
0 O
. O

0049 O
in O
the O
japanese O
general O
population O
. O

recently O
, O
we O
have O
reported O
a O
missense O
mutation O
in O
exon O
15 O
of O
the O
cetp O
gene O
( O
442d O
g O
) O
, O
showing O
a O
dominant O
effect O
on O
the O
cetp O
activity O
and O
hdl O
- O
cholesterol O
level O
. O

in O
the O
current O
study O
, O
we O
determined O
the O
frequency O
of O
this O
new O
mutation O
in O
japanese O
hyperalphalipoproteinemic B-Disease
( O
hdl O
- O
cholesterol O
> O
or O
= O
100 O
mg O
/ O
dl O
) O
subjects O
. O

a O
rapid O
and O
easy O
screening O
method O
for O
this O
new O
mutation O
was O
developed O
using O
a O
polymerase O
chain O
reaction O
( O
pcr O
) O
- O
mediated O
site O
- O
directed O
mutagenesis O
. O

among O
117 O
japanese O
hyperalphalipoproteinemic B-Disease
subjects O
( O
hdl O
- O
cholesterol O
; O
116 O
. O
7 O
+ O
/ O
- O
16 O
. O
5 O
mg O
/ O
dl O
, O
mean O
+ O
/ O
- O
s O
. O
d O
. O
) O
without O
the O
intron O
14 O
splice O
defect O
, O
three O
homozygotes O
( O
2 O
. O
5 O
% O
) O
and O
34 O
heterozygotes O
( O
29 O
. O
1 O
% O
) O
were O
found O
to O
have O
the O
442d O
g O
mutation O
. O

the O
relative O
allelic O
frequency O
of O
this O
mutation O
was O
calculated O
to O
be O
0 O
. O

17 O
. O

one O
of O
the O
homozygotes O
for O
the O
442d O
g O
mutation O
was O
the O
patient O
previously O
described O
by O
us O
as O
having O
hyperalphalipoproteinemia B-Disease
with O
corneal B-Disease
opacity I-Disease
and O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

this O
was O
the O
first O
reported O
subject O
homozygous O
for O
the O
cetp B-Disease
deficiency I-Disease
who O
also O
demonstrated O
atherosclerotic B-Disease
symptoms I-Disease
. O

in O
homozygous O
subjects O
, O
cetp O
activity O
ranged O
from O
37 O
% O
to O
62 O
% O
of O
the O
normal O
value O
, O
which O
was O
consistent O
with O
the O
results O
obtained O
from O
the O
transient O
expression O
experiment O
previously O
reported O
; O
however O
, O
the O
specific O
activity O
of O
cetp O
was O
not O
as O
low O
as O
expected O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O

mucopolysaccharidosis B-Disease
type I-Disease
iva I-Disease
: O
common O
double O
deletion O
in O
the O
n O
- O
acetylgalactosamine O
- O
6 O
- O
sulfatase O
gene O
( O
galns O
) O
. O

mucopolysaccharidosis B-Disease
iva I-Disease
( O
mps B-Disease
iva I-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
in I-Disease
n I-Disease
- I-Disease
acetylgalactosamine I-Disease
- I-Disease
6 I-Disease
- I-Disease
sulfatase I-Disease
( O
galns O
) O
. O

we O
found O
two O
separate O
deletions O
of O
nearly O
8 O
. O

0 O
and O
6 O
. O

0 O
kb O
in O
the O
galns O
gene O
, O
including O
some O
exons O
. O

there O
are O
alu O
repetitive O
elements O
near O
the O
breakpoints O
of O
the O
8 O
. O

0 O
- O
kb O
deletion O
, O
and O
this O
deletion O
resulted O
from O
an O
alu O
- O
alu O
recombination O
. O

the O
other O
6 O
. O

0 O
- O
kb O
deletion O
involved O
illegitimate O
recombinational O
events O
between O
incomplete O
short O
direct O
repeats O
of O
8 O
bp O
at O
deletion O
breakpoints O
. O

the O
same O
rearrangement O
has O
been O
observed O
in O
a O
heteroallelic O
state O
in O
four O
unrelated O
patients O
. O

this O
is O
the O
first O
documentation O
of O
a O
common O
double O
deletion O
a O
gene O
that O
is O
not O
a O
member O
of O
a O
gene O
cluster O
. O

detection O
of O
eight O
brca1 O
mutations O
in O
10 O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
, O
including O
1 O
family O
with O
male B-Disease
breast I-Disease
cancer I-Disease
. O

genetic O
epidemiological O
evidence O
suggests O
that O
mutations O
in O
brca1 O
may O
be O
responsible O
for O
approximately O
one O
half O
of O
early O
onset O
familial B-Disease
breast I-Disease
cancer I-Disease
and O
the O
majority O
of O
familial B-Disease
breast I-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
. O

the O
recent O
cloning O
of O
brca1 O
allows O
for O
the O
direct O
detection O
of O
mutations O
, O
but O
the O
feasibility O
of O
presymptomatic O
screening O
for O
cancer B-Disease
susceptibility O
is O
unknown O
. O

we O
analyzed O
genomic O
dna O
from O
one O
affected O
individual O
from O
each O
of O
24 O
families O
with O
at O
least O
three O
cases O
of O
ovarian B-Disease
or I-Disease
breast I-Disease
cancer I-Disease
, O
using O
sscp O
assays O
. O

variant O
sscp O
bands O
were O
subcloned O
and O
sequenced O
. O

allele O
- O
specific O
oligonucleotide O
hybridization O
was O
used O
to O
verify O
sequence O
changes O
and O
to O
screen O
dna O
from O
control O
individuals O
. O

six O
frameshift O
and O
two O
missense O
mutations O
were O
detected O
in O
10 O
different O
families O
. O

a O
frameshift O
mutation O
was O
detected O
in O
a O
male O
proband O
affected O
with O
both O
breast B-Disease
and I-Disease
prostate I-Disease
cancer I-Disease
. O

a O
40 O
- O
bp O
deletion O
was O
detected O
in O
a O
patient O
who O
developed O
intra B-Disease
- I-Disease
abdominal I-Disease
carcinomatosis I-Disease
1 O
year O
after O
prophylactic O
oophorectomy O
. O

mutations O
were O
detected O
throughout O
the O
gene O
, O
and O
only O
one O
was O
detected O
in O
more O
than O
a O
single O
family O
. O

these O
results O
provide O
further O
evidence O
that O
inherited B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
can O
occur O
as O
a O
consequence O
of O
a O
wide O
array O
of O
brca1 O
mutations O
. O

these O
results O
suggests O
that O
development O
of O
a O
screening O
test O
for O
brca1 O
mutations O
will O
be O
technically O
challenging O
. O

the O
finding O
of O
a O
mutation O
in O
a O
family O
with O
male B-Disease
breast I-Disease
cancer I-Disease
, O
not O
previously O
thought O
to O
be O
related O
to O
brca1 O
, O
also O
illustrates O
the O
potential O
difficulties O
of O
genetic O
counseling O
for O
individuals O
known O
to O
carry O
mutations O
. O
. O

natural O
selection O
of O
hemi O
- O
and O
heterozygotes O
for O
g6pd B-Disease
deficiency I-Disease
in O
africa O
by O
resistance O
to O
severe O
malaria B-Disease
. O

glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
, O
the O
most O
common O
enzymopathy B-Disease
of O
humans O
, O
affects O
over O
400 O
million O
people O
. O

the O
geographical O
correlation O
of O
its O
distribution O
with O
the O
historical O
endemicity O
of O
malaria B-Disease
suggests O
that O
this O
disorder O
has O
risen O
in O
frequency O
through O
natural O
selection O
by O
malaria B-Disease
. O

however O
, O
attempts O
to O
confirm O
that O
g6pd B-Disease
deficiency I-Disease
is O
protective O
in O
case O
- O
control O
studies O
of O
malaria B-Disease
have O
yielded O
conflicting O
results O
. O

hence O
, O
for O
this O
x B-Disease
- I-Disease
linked I-Disease
disorder I-Disease
, O
it O
is O
unclear O
whether O
both O
male O
hemizygotes O
and O
female O
heterozygotes O
are O
protected O
or O
, O
as O
frequently O
suggested O
, O
only O
females O
. O

furthermore O
, O
how O
much O
protection O
may O
be O
afforded O
is O
unknown O
. O

here O
we O
report O
that O
, O
in O
two O
large O
case O
- O
control O
studies O
of O
over O
2 O
, O
000 O
african O
children O
, O
the O
common O
african O
form O
of O
g6pd B-Disease
deficiency I-Disease
( O
g6pd B-Disease
a I-Disease
- I-Disease
) O
is O
associated O
with O
a O
46 O
- O
58 O
% O
reduction O
in O
risk O
of O
severe O
malaria B-Disease
for O
both O
female O
heterozygotes O
and O
male O
hemizygotes O
. O

a O
mathematical O
model O
incorporating O
the O
measured O
selective O
advantage O
against O
malaria B-Disease
suggests O
that O
a O
counterbalancing O
selective O
disadvantage O
, O
associated O
with O
this O
enzyme B-Disease
deficiency I-Disease
, O
has O
retarded O
its O
rise O
in O
frequency O
in O
malaria B-Disease
- O
endemic O
regions O
. O

although O
g6pd B-Disease
deficiency I-Disease
is O
now O
regarded O
as O
a O
generally O
benign O
disorder O
, O
in O
earlier O
environmental O
conditions O
it O
could O
have O
been O
significantly O
disadvantageous O
. O
. O

the O
alveolar B-Disease
rhabdomyosarcoma I-Disease
pax3 O
/ O
fkhr O
fusion O
protein O
is O
a O
transcriptional O
activator O
. O

chimeric O
transcription O
factors O
, O
created O
by O
gene O
fusions O
as O
the O
result O
of O
chromosomal O
translocations O
, O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
several O
pathologically O
disparate O
solid B-Disease
tumors I-Disease
. O

the O
pax3 O
/ O
fkhr O
fusion O
gene O
, O
formed O
by O
a O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
in O
alveolar B-Disease
rhabdomyosarcoma I-Disease
, O
encodes O
a O
hybrid O
protein O
that O
contains O
both O
pax3 O
dna O
binding O
domains O
, O
the O
paired O
box O
and O
homeodomain O
, O
linked O
to O
the O
bisected O
dna O
binding O
domain O
of O
fkhr O
, O
a O
member O
of O
the O
forkhead O
family O
of O
transcription O
factors O
. O

here O
we O
report O
that O
pax3 O
and O
pax3 O
/ O
fkhr O
display O
similar O
, O
but O
not O
identical O
transactivation O
activities O
when O
tested O
with O
model O
pax O
recognition O
sequences O
. O

no O
functional O
role O
could O
be O
ascribed O
solely O
to O
the O
residual O
fkhr O
binding O
domain O
present O
in O
the O
fusion O
protein O
, O
but O
fkhr O
was O
found O
to O
contribute O
a O
strong O
carboxyl O
terminal O
activation O
domain O
replacing O
the O
one O
located O
in O
the O
unrearranged O
pax3 O
gene O
. O

we O
show O
that O
the O
native O
pax3 O
/ O
fkhr O
protein O
present O
in O
tumor B-Disease
cells O
with O
this O
translocation O
has O
transcriptional O
characteristics O
similar O
to O
the O
in O
vitro O
expressed O
protein O
. O

the O
ability O
of O
the O
pax3 O
/ O
fkhr O
hybrid O
protein O
to O
bind O
dna O
in O
a O
sequence O
specific O
manner O
and O
to O
transactivate O
the O
expression O
of O
artificial O
reporter O
genes O
suggests O
that O
its O
aberrant O
expression O
could O
subvert O
the O
transcriptional O
programs O
that O
normally O
control O
the O
growth O
, O
differentiation O
, O
and O
survival O
of O
primitive O
myogenic O
precursors O
in O
vivo O
. O
. O

a O
p16ink4a O
- O
insensitive O
cdk4 O
mutant O
targeted O
by O
cytolytic O
t O
lymphocytes O
in O
a O
human O
melanoma B-Disease
. O

a O
mutated O
cyclin O
- O
dependent O
kinase O
4 O
( O
cdk4 O
) O
was O
identified O
as O
a O
tumor B-Disease
- O
specific O
antigen O
recognized O
by O
hla O
- O
a2 O
. O

1 O
- O
restricted O
autologous O
cytolytic O
t O
lymphocytes O
( O
ctls O
) O
in O
a O
human O
melanoma B-Disease
. O

the O
mutated O
cdk4 O
allele O
was O
present O
in O
autologous O
cultured O
melanoma B-Disease
cells O
and O
metastasis O
tissue O
, O
but O
not O
in O
the O
patients O
lymphocytes O
. O

the O
mutation O
, O
an O
arginine O
- O
to O
- O
cysteine O
exchange O
at O
residue O
24 O
, O
was O
part O
of O
the O
cdk4 O
peptide O
recognized O
by O
ctls O
and O
prevented O
binding O
of O
the O
cdk4 O
inhibitor O
p16ink4a O
, O
but O
not O
of O
p21 O
or O
of O
p27kip1 O
. O

the O
same O
mutation O
was O
found O
in O
one O
additional O
melanoma B-Disease
among O
28 O
melanomas B-Disease
analyzed O
. O

these O
results O
suggest O
that O
mutation O
of O
cdk4 O
can O
create O
a O
tumor B-Disease
- O
specific O
antigen O
and O
can O
disrupt O
the O
cell O
- O
cycle O
regulation O
exerted O
by O
the O
tumor B-Disease
suppressor O
p16ink4a O
. O
. O

rapid O
detection O
of O
brca1 O
mutations O
by O
the O
protein O
truncation O
test O
. O

more O
than O
75 O
% O
of O
the O
reported O
mutations O
in O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
gene O
, O
brca1 O
, O
result O
in O
truncated O
proteins O
. O

we O
have O
used O
the O
protein O
truncation O
test O
( O
ptt O
) O
to O
screen O
for O
mutations O
in O
exon O
11 O
, O
which O
encodes O
61 O
% O
of O
brca1 O
. O

in O
45 O
patients O
from O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
families O
we O
found O
six O
novel O
mutations O
two O
single O
nucleotide O
insertions O
, O
three O
small O
deletions O
( O
1 O
- O
5 O
bp O
) O
and O
a O
nonsense O
mutation O
identified O
two O
unrelated O
families O
. O

furthermore O
, O
we O
were O
able O
to O
amplify O
the O
remaining O
coding O
region O
by O
rt O
- O
pcr O
using O
lymphocyte O
rna O
. O

combined O
with O
ptt O
, O
we O
detected O
aberrantly O
spliced O
products O
affecting O
exons O
5 O
and O
6 O
in O
one O
of O
two O
brca1 O
- O
linked O
families O
examined O
. O

the O
protein O
truncation O
test O
promises O
to O
become O
a O
valuable O
technique O
in O
detecting O
brca1 O
mutations O
. O
. O

cloning O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
a O
dehydrogenase O
and O
molecular O
characterization O
of O
its O
deficiency O
in O
two O
patients O
. O

two O
overlapping O
cdna O
clones O
( O
1 O
, O
991 O
bp O
and O
736 O
bp O
, O
respectively O
) O
encoding O
the O
precursor O
of O
human O
mitochondrial O
very O
- O
long O
- O
chain O
acyl O
- O
coenzyme O
a O
dehydrogenase O
( O
vlcad O
) O
were O
cloned O
and O
sequenced O
. O

the O
cdna O
inserts O
of O
these O
clones O
together O
encompass O
a O
region O
of O
2 O
, O
177 O
bases O
, O
encoding O
the O
entire O
protein O
of O
655 O
amino O
acids O
, O
including O
a O
40 O
- O
amino O
acid O
leader O
peptide O
and O
a O
615 O
- O
amino O
acid O
mature O
polypeptide O
. O

pcr O
- O
amplified O
vlcad O
cdnas O
were O
sequenced O
in O
cultured O
fibroblasts O
from O
two O
vlcad B-Disease
- I-Disease
deficient I-Disease
patients O
. O

in O
both O
patients O
, O
a O
105 O
- O
bp O
deletion O
encompassing O
bases O
1078 O
- O
1182 O
in O
vlcad O
cdna O
was O
identified O
. O

the O
deletion O
seems O
to O
occur O
due O
to O
exon O
skipping O
during O
processing O
of O
vlcad O
pre O
- O
mrna O
. O

this O
is O
the O
first O
demonstration O
of O
a O
mutation O
causing O
vlcad B-Disease
deficiency I-Disease
. O

quantitative O
cdna O
expression O
of O
normal O
human O
vlcad O
was O
performed O
in O
the O
patients O
fibroblasts O
, O
using O
vaccinia O
viral O
system O
, O
which O
demonstrated O
that O
the O
deficiency B-Disease
of I-Disease
the I-Disease
normal I-Disease
vlcad I-Disease
protein I-Disease
causes O
impaired O
long O
- O
chain O
fatty O
acid O
beta O
- O
oxidation O
activity O
in O
the O
patients O
fibroblasts O
. O

in O
patient O
fibroblasts O
, O
raising O
vlcad O
activity O
to O
approximately O
20 O
% O
of O
normal O
control O
fibroblast O
activity O
raised O
palmitic O
acid O
beta O
- O
oxidation O
flux O
to O
the O
level O
found O
in O
control O
fibroblasts O
, O
which O
may O
offer O
important O
information O
for O
the O
rational O
design O
of O
future O
somatic O
gene O
therapy O
for O
vlcad B-Disease
deficiency I-Disease
. O
. O

brain B-Disease
disease I-Disease
and O
molecular O
analysis O
in O
myotonic B-Disease
dystrophy I-Disease
. O

abnormal O
amplification O
of O
a O
ctg O
repeat O
on O
chromosome O
19 O
is O
the O
molecular O
basis O
of O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

expansion O
of O
the O
repeat O
has O
been O
correlated O
with O
severity O
of O
several O
clinical O
features O
of O
the O
disease O
. O

we O
performed O
extensive O
cognitive O
testing O
, O
cerebral O
magnetic O
resonance O
imaging O
( O
mri O
) O
and O
a O
molecular O
analysis O
in O
28 O
cases O
of O
dm B-Disease
to O
determine O
the O
relationship O
between O
the O
molecular O
defect O
and O
brain B-Disease
disease I-Disease
. O

performance O
in O
two O
or O
more O
cognitive O
tests O
was O
pathological O
in O
10 O
cases O
. O

fourteen O
patients O
had O
subcortical O
white B-Disease
matter I-Disease
lesions I-Disease
on O
mri O
, O
14 O
had O
cerebral B-Disease
atrophy I-Disease
. O

amplification O
of O
the O
ctg O
repeat O
showed O
a O
strong O
correlation O
with O
cognitive O
test O
deficits O
when O
exceeding O
a O
length O
of O
over O
1000 O
trinucleotides O
. O

mri O
lesions O
were O
associated O
with O
impaired O
psychometric O
performance O
, O
but O
mri O
and O
molecular O
findings O
were O
only O
weakly O
related O
. O

disease O
duration O
influenced O
the O
appearance O
and O
amount O
of O
white B-Disease
matter I-Disease
lesions I-Disease
on O
mri O
. O

quantification O
of O
ctg O
repeat O
size O
may O
allow O
an O
early O
estimate O
on O
the O
probability O
of O
brain O
involvement O
in O
dm B-Disease
; O
cognitive B-Disease
dysfunction I-Disease
is O
associated O
with O
white B-Disease
matter I-Disease
lesions I-Disease
and O
cerebral B-Disease
atrophy I-Disease
later O
on O
in O
the O
course O
. O
. O

mutations O
in O
the O
gene O
for O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
in O
patients O
with O
different O
clinical O
phenotypes O
. O

recently O
, O
the O
gene O
for O
the O
most O
common O
peroxisomal B-Disease
disorder I-Disease
, O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
x B-Disease
- I-Disease
ald I-Disease
) O
, O
has O
been O
described O
encoding O
a O
peroxisomal O
membrane O
transporter O
protein O
. O

we O
analyzed O
the O
entire O
protein O
- O
coding O
sequence O
of O
this O
gene O
by O
reverse O
- O
transcription O
pcr O
, O
sscp O
, O
and O
dna O
sequencing O
in O
five O
patients O
with O
different O
clinical O
expression O
of O
x B-Disease
- I-Disease
ald I-Disease
and O
in O
their O
female O
relatives O
; O
these O
clinical O
expressions O
were O
cerebral O
childhood O
ald B-Disease
, O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
, O
and O
" O
addison B-Disease
disease I-Disease
only I-Disease
" O
( O
ado B-Disease
) O
phenotype O
. O

in O
the O
three O
patients O
exhibiting O
the O
classical O
picture O
of O
severe O
childhood O
ald B-Disease
we O
identified O
in O
the O
5 O
portion O
of O
the O
x B-Disease
- I-Disease
ald I-Disease
gene O
a O
38 O
- O
bp O
deletion O
that O
causes O
a O
frameshift O
mutation O
, O
a O
3 O
- O
bp O
deletion O
leading O
to O
a O
deletion O
of O
an O
amino O
acid O
in O
the O
atp O
- O
binding O
domain O
of O
the O
ald B-Disease
protein O
, O
and O
a O
missense O
mutation O
. O

in O
the O
patient O
with O
the O
clinical O
phenotype O
of O
amn B-Disease
, O
a O
nonsense O
mutation O
in O
codon O
212 O
, O
along O
with O
a O
second O
site O
mutation O
at O
codon O
178 O
, O
was O
observed O
. O

analysis O
of O
the O
patient O
with O
the O
ado B-Disease
phenotype O
revealed O
a O
further O
missense O
mutation O
at O
a O
highly O
conserved O
position O
in O
the O
aldp O
/ O
pmp70 O
comparison O
. O

the O
disruptive O
nature O
of O
two O
mutations O
( O
i O
. O
e O
. O
, O
the O
frameshift O
and O
the O
nonsense O
mutation O
) O
in O
patients O
with O
biochemically O
proved O
childhood O
ald B-Disease
and O
amn B-Disease
further O
strongly O
supports O
the O
hypothesis O
that O
alterations O
in O
this O
gene O
play O
a O
crucial O
role O
in O
the O
pathogenesis O
of O
x B-Disease
- I-Disease
ald I-Disease
. O

since O
the O
current O
biochemical O
techniques O
for O
x B-Disease
- I-Disease
ald I-Disease
carrier O
detection O
in O
affected O
families O
lack O
sufficient O
reliability O
, O
our O
procedure O
described O
for O
systematic O
mutation O
scanning O
is O
also O
capable O
of O
improving O
genetic O
counseling O
and O
prenatal O
diagnosis O

duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
and O
myotonic B-Disease
dystrophy I-Disease
in O
the O
same O
patient O
. O

we O
report O
on O
the O
first O
patient O
identified O
with O
myotonic B-Disease
dystrophy I-Disease
and O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

the O
family O
of O
the O
propositus O
had O
a O
strong O
history O
of O
myotonic B-Disease
dystrophy I-Disease
, O
and O
there O
was O
an O
intrafamilial O
pathological O
expansion O
of O
the O
responsible O
ctg O
repeat O
between O
the O
mildly O
affected O
mother O
( O
160 O
repeats O
; O
normal O
27 O
repeats O
) O
and O
her O
more O
severely O
affected O
son O
( O
650 O
repeats O
) O
, O
and O
his O
sister O
( O
650 O
repeats O
) O
. O

the O
propositus O
was O
an O
isolated O
case O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
with O
marked O
dystrophin B-Disease
deficiency I-Disease
in O
muscle O
biopsy O
. O

the O
patient O
was O
still O
ambulatory O
post O
age O
16 O
. O

myotonic B-Disease
dystrophy I-Disease
could O
interfere O
to O
some O
extent O
with O
the O
progression O
of O
duchenne B-Disease
dystrophy I-Disease
. O

however O
, O
other O
interpretations O
are O
possible O
. O

twelve O
percent O
of O
dystrophin O
revertant O
fibers O
as O
observed O
by O
immunohistochemistry O
could O
be O
sufficient O
to O
ameliorate O
typical O
dmd B-Disease
clinical O
severity O
, O
or O
the O
patient O
may O
present O
a O
somatic O
mosaic O
. O

the O
pathophysiological O
interactions O
of O
these O
two O
unlinked O
disorders O
are O
discussed O
at O
the O
clinical O
and O
histopathological O
levels O
. O
. O

age O
at O
diagnosis O
as O
an O
indicator O
of O
eligibility O
for O
brca1 O
dna O
testing O
in O
familial B-Disease
breast I-Disease
cancer I-Disease
. O

we O
searched O
for O
criteria O
that O
could O
indicate O
breast B-Disease
cancer I-Disease
families O
with O
a O
high O
prior O
probability O
of O
being O
caused O
by O
the O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
locus O
brca1 O
on O
chromosome O
17 O
. O

to O
this O
end O
, O
we O
performed O
a O
linkage O
study O
with O
59 O
consecutively O
collected O
dutch O
breast B-Disease
cancer I-Disease
families O
, O
including O
16 O
with O
at O
least O
one O
case O
of O
ovarian B-Disease
cancer I-Disease
. O

we O
used O
an O
intake O
cut O
- O
off O
of O
at O
least O
three O
first O
- O
degree O
relatives O
with O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
at O
any O
age O
. O

significant O
evidence O
for O
linkage O
was O
found O
only O
among O
the O
13 O
breast B-Disease
cancer I-Disease
families O
with O
a O
mean O
age O
at O
diagnosis O
of O
less O
than O
45 O
years O
. O

an O
unexpectedly O
low O
proportion O
of O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
were O
estimated O
to O
be O
linked O
to O
brca1 O
, O
which O
could O
be O
due O
to O
a O
founder O
effect O
in O
the O
dutch O
population O
. O

given O
the O
expected O
logistical O
problems O
in O
clinical O
management O
now O
that O
brca1 O
has O
been O
identified O
, O
we O
propose O
an O
interim O
period O
in O
which O
only O
families O
with O
a O
strong O
positive O
family O
history O
for O
early O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
will O
be O
offered O
brca1 O
mutation O
testing O
. O
. O

linkage O
analysis O
of O
26 O
canadian O
breast B-Disease
and I-Disease
breast I-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

we O
have O
examined O
26 O
canadian O
families O
with O
hereditary B-Disease
breast I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
for O
linkage O
to O
markers O
flanking O
the O
brca1 O
gene O
on O
chromosome O
17q12 O
- O
q21 O
. O

of O
the O
15 O
families O
that O
contain O
cases O
of O
ovarian B-Disease
cancer I-Disease
, O
94 O
% O
were O
estimated O
to O
be O
linked O
to O
brca1 O
. O

in O
contrast O
, O
there O
was O
no O
overall O
evidence O
of O
linkage O
in O
the O
group O
of O
10 O
families O
with O
breast B-Disease
cancer I-Disease
without O
ovarian B-Disease
cancer I-Disease
. O

a O
genetic O
recombinant O
in O
a O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
family O
indicates O
a O
placement O
of O
brca1 O
telomeric O
to O
d17s776 O
, O
and O
helps O
to O
define O
the O
region O
of O
assignment O
of O
the O
cancer B-Disease
susceptibility O
gene O
. O

other O
cancers B-Disease
of O
interest O
that O
appeared O
in O
the O
brca1 O
- O
linked O
families O
included O
primary B-Disease
peritoneal I-Disease
cancer I-Disease
, O
cancer B-Disease
of I-Disease
the I-Disease
fallopian I-Disease
tube I-Disease
, O
and O
malignant B-Disease
melanoma I-Disease
. O
. O

structural O
analysis O
of O
the O
5 O
' O
region O
of O
mouse O
and O
human O
huntington B-Disease
disease I-Disease
genes O
reveals O
conservation O
of O
putative O
promoter O
region O
and O
di O
- O
and O
trinucleotide O
polymorphisms O
. O

we O
have O
previously O
cloned O
and O
characterized O
the O
murine O
homologue O
of O
the O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
gene O
and O
shown O
that O
it O
maps O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
synteny O
with O
human O
chromosome O
4p16 O
. O

3 O
3 O
. O

here O
we O
present O
a O
detailed O
comparison O
of O
the O
sequence O
of O
the O
putative O
promoter O
and O
the O
organization O
of O
the O
5 O
genomic O
region O
of O
the O
murine O
( O
hdh O
) O
and O
human O
hd B-Disease
genes O
encompassing O
the O
first O
five O
exons O
. O

we O
show O
that O
in O
this O
region O
these O
two O
genes O
share O
identical O
exon O
boundaries O
, O
but O
have O
different O
- O
size O
introns O
. O

two O
dinucleotide O
( O
ct O
) O
and O
one O
trinucleotide O
intronic O
polymorphism O
in O
hdh O
and O
an O
intronic O
ca O
polymorphism O
in O
the O
hd B-Disease
gene O
were O
identified O
. O

comparison O
of O
940 O
- O
bp O
sequence O
5 O
to O
the O
putative O
translation O
start O
site O
reveals O
a O
highly O
conserved O
region O
( O
78 O
. O
8 O
% O
nucleotide O
identity O
) O
between O
hdh O
and O
the O
hd B-Disease
gene O
from O
nucleotide O
- O
56 O
to O
- O
206 O
( O
of O
hdh O
) O
. O

neither O
hdh O
nor O
the O
hd B-Disease
gene O
have O
typical O
tata O
or O
ccaat O
elements O
, O
but O
both O
show O
one O
putative O
ap2 O
binding O
site O
and O
numerous O
potential O
sp1 O
binding O
sites O
. O

the O
high O
sequence O
identity O
between O
hdh O
and O
the O
hd B-Disease
gene O
for O
approximately O
200 O
bp O
5 O
to O
the O
putative O
translation O
start O
site O
indicates O
that O
these O
sequences O
may O
play O
a O
role O
in O
regulating O
expression O
of O
the O
huntington B-Disease
disease I-Disease
gene O

the O
protein O
deficient O
in O
lowe B-Disease
syndrome I-Disease
is O
a O
phosphatidylinositol O
- O
4 O
, O
5 O
- O
bisphosphate O
5 O
- O
phosphatase O
. O

lowe B-Disease
syndrome I-Disease
, O
also O
known O
as O
oculocerebrorenal B-Disease
syndrome I-Disease
, O
is O
caused O
by O
mutations O
in O
the O
x O
chromosome O
- O
encoded O
ocrl O
gene O
. O

the O
ocrl O
protein O
is O
51 O
% O
identical O
to O
inositol O
polyphosphate O
5 O
- O
phosphatase O
ii O
( O
5 O
- O
phosphatase O
ii O
) O
from O
human O
platelets O
over O
a O
span O
of O
744 O
aa O
, O
suggesting O
that O
ocrl O
may O
be O
a O
similar O
enzyme O
. O

we O
engineered O
a O
construct O
of O
the O
ocrl O
cdna O
that O
encodes O
amino O
acids O
homologous O
to O
the O
platelet O
5 O
- O
phosphatase O
for O
expression O
in O
baculovirus O
- O
infected O
sf9 O
insect O
cells O
. O

this O
cdna O
encodes O
aa O
264 O
- O
968 O
of O
the O
ocrl O
protein O
. O

the O
recombinant O
protein O
was O
found O
to O
catalyze O
the O
reactions O
also O
carried O
out O
by O
platelet O
5 O
- O
phosphatase O
ii O
. O

thus O
ocrl O
converts O
inositol O
1 O
, O
4 O
, O
5 O
- O
trisphosphate O
to O
inositol O
1 O
, O
4 O
- O
bisphosphate O
, O
and O
it O
converts O
inositol O
1 O
, O
3 O
, O
4 O
, O
5 O
- O
tetrakisphosphate O
to O
inositol O
1 O
, O
3 O
, O
4 O
- O
trisphosphate O
. O

most O
important O
, O
the O
enzyme O
converts O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
to O
phosphatidylinositol O
4 O
- O
phosphate O
. O

the O
relative O
ability O
of O
ocrl O
to O
catalyze O
the O
three O
reactions O
is O
different O
from O
that O
of O
5 O
- O
phosphatase O
ii O
and O
from O
that O
of O
another O
5 O
- O
phosphatase O
isoenzyme O
from O
platelets O
, O
5 O
- O
phosphatase O
i O
. O

the O
recombinant O
ocrl O
protein O
hydrolyzes O
the O
phospholipid O
substrate O
10 O
- O
to O
30 O
- O
fold O
better O
than O
5 O
- O
phosphatase O
ii O
, O
and O
5 O
- O
phosphatase O
i O
does O
not O
cleave O
the O
lipid O
at O
all O
. O

we O
also O
show O
that O
ocrl O
functions O
as O
a O
phosphatidylinositol O
4 O
, O
5 O
- O
bisphosphate O
5 O
- O
phosphatase O
in O
ocrl O
- O
expressing O
sf9 O
cells O
. O

deficiency O
of O
this O
enzyme O
apparently O
causes O
the O
protean O
manifestations O
of O
lowe B-Disease
syndrome I-Disease
. O
. O

new O
founder O
haplotypes O
at O
the O
myotonic B-Disease
dystrophy I-Disease
locus O
in O
southern O
africa O
. O

the O
association O
between O
normal O
alleles O
at O
the O
ctg O
repeat O
and O
two O
nearby O
polymorphisms O
in O
the O
myotonin O
protein O
kinase O
gene O
, O
the O
alu O
insertion O
/ O
deletion O
polymorphism O
and O
the O
myotonic B-Disease
dystrophy I-Disease
kinase O
( O
dmk O
) O
( O
g O
/ O
t O
) O
intron O
9 O
/ O
hinfi O
polymorphism O
, O
has O
been O
analyzed O
in O
south O
african O
negroids O
, O
a O
population O
in O
which O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
has O
not O
been O
described O
. O

discordant O
clinical O
outcome O
in O
myotonic B-Disease
dystrophy I-Disease
relatives O
showing O
( O
ctg O
) O
n O
> O
700 O
repeats O
. O

a O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
family O
is O
described O
in O
which O
discordant O
dm B-Disease
phenotypes O
were O
found O
in O
the O
children O
of O
two O
affected O
sisters O
with O
similar O
ctg O
expansion O
and O
clinical O
manifestations O
. O

the O
seven O
deficient O
fibroblast O
lines O
were O
characterized O
by O
measuring O
acyl O
- O
coenzyme O
a O
dehydrogenation O
activities O
, O
overall O
palmitic O
acid O
oxidation O
, O
and O
vlcad O
protein O
synthesis O
using O
pulse O
- O
chase O
, O
further O
confirming O
the O
diagnosis O
of O
vlcad B-Disease
deficiency I-Disease
. O

clinically O
, O
all O
patients O
with O
vlcad B-Disease
deficiency I-Disease
exhibited O
cardiac B-Disease
disease I-Disease
. O

at O
least O
four O
of O
them O
presented O
with O
hypertrophic B-Disease
cardiomyopathy I-Disease
. O

this O
frequency O
( O
> O
57 O
% O
) O
was O
much O
higher O
than O
that O
observed O
in O
patients O
with O
other O
disorders O
of O
mitochondrial O
long O
- O
chain O
fatty O
acid O
oxidation O
that O
may O
be O
accompanied O
by O
cardiac B-Disease
disease I-Disease
in O
infants O
. O
. O

hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
in O
man O
. O

ii O
. O

biological O
properties O
of O
c5 B-Disease
- I-Disease
deficient I-Disease
human O
serum O
. O

the O
first O
known O
human O
kindred O
with O
hereditary B-Disease
deficiency I-Disease
of I-Disease
the I-Disease
fifth I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c5 O
) O
was O
documented O
in O
the O
accompanying O
report O
. O

this O
study O
examines O
several O
biological O
properties O
of O
c5 B-Disease
- I-Disease
deficient I-Disease
( O
c5d B-Disease
) O
human O
serum O
, O
particularly O
sera O
obtained O
from O
two O
c5d B-Disease
homozygotes O
. O

the O
proband O
, O
who O
has O
inactive O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
is O
completely O
lacking O
c5 O
, O
while O
her O
healthy O
half O
- O
sister O
has O
1 O
- O
2 O
% O
of O
normal O
levels O
. O

sera O
from O
eight O
family O
members O
who O
were O
apparently O
heterozygous O
for O
c5 B-Disease
deficiency I-Disease
gave O
normal O
chemotactic O
scores O
. O

in O
addition O
, O
c5d B-Disease
serum O
was O
capable O
of O
promoting O
normal O
phagocytosis O
and O
intracellular O
killing O
of O
staphylococcus O
aureus O
. O

the O
probands O
serum O
was O
incapable O
of O
mediating O
lysis O
of O
erythrocytes O
from O
a O
patient O
with O
paroxysmal B-Disease
nocturnal I-Disease
hemoglobinuria I-Disease
in O
both O
the O
sucrose O
hemolysia O
and O
acid O
hemolysis O
tests O
, O
and O
also O
lacked O
bactericidal O
activity O
against O
sensitized O
or O
unsensitized O
salmonella O
typhi O
. O

human O
peroxisomal O
targeting O
signal O
- O
1 O
receptor O
restores O
peroxisomal O
protein O
import O
in O
cells O
from O
patients O
with O
fatal O
peroxisomal B-Disease
disorders I-Disease
. O

human O
patients O
with O
fatal O
generalized O
peroxisomal B-Disease
deficiency I-Disease
disorders I-Disease
fall O
into O
at O
least O
nine O
genetic O
complementation O
groups O
. O

the O
pts1r O
cdna O
also O
complements O
the O
pts1 B-Disease
protein I-Disease
- I-Disease
import I-Disease
defect I-Disease
in O
skin O
fibroblasts O
from O
patients O
- O
- O
belonging O
to O
complementation O
group O
two O
- O
- O
diagnosed O
as O
having O
neonatal B-Disease
adrenoleukodystrophy I-Disease
or O
zellweger B-Disease
syndrome I-Disease
. O

the O
pts1r O
gene O
has O
been O
localized O
to O
a O
chromosomal O
location O
where O
no O
other O
peroxisomal B-Disease
disorder I-Disease
genes O
are O
known O
to O
map O
. O

our O
findings O
represent O
the O
only O
case O
in O
which O
the O
molecular O
basis O
of O
the O
protein B-Disease
- I-Disease
import I-Disease
deficiency I-Disease
in O
human O
peroxisomal B-Disease
disorders I-Disease
is O
understood O
. O

spectrum O
of O
germline O
mutations O
in O
the O
rb1 O
gene O
: O
a O
study O
of O
232 O
patients O
with O
hereditary B-Disease
and I-Disease
non I-Disease
hereditary I-Disease
retinoblastoma I-Disease
. O

germline O
mutations O
in O
the O
rb1 O
gene O
confer O
hereditary O
predisposition O
to O
retinoblastoma B-Disease
. O

we O
have O
performed O
a O
mutation O
survey O
of O
the O
rb1 O
gene O
in O
232 O
patients O
with O
hereditary B-Disease
or I-Disease
non I-Disease
hereditary I-Disease
retinoblastoma I-Disease
. O

the O
spectrum O
of O
mutations O
presented O
here O
should O
help O
to O
improve O
the O
clinical O
management O
of O
retinoblastoma B-Disease
and O
to O
understand O
the O
molecular O
mechanisms O
leading O
to O
tumorigenesis O
. O
. O

aniridia B-Disease
- O
associated O
cytogenetic O
rearrangements O
suggest O
that O
a O
position O
effect O
may O
cause O
the O
mutant O
phenotype O
. O

current O
evidence O
suggests O
that O
aniridia B-Disease
( O
absence B-Disease
of I-Disease
iris I-Disease
) O
is O
caused O
by O
loss O
of O
function O
of O
one O
copy O
of O
the O
pax6 O
gene O
, O
which O
maps O
to O
11p13 O
. O

we O
present O
the O
further O
characterisation O
of O
two O
aniridia B-Disease
pedigrees O
in O
which O
the O
disease O
segregates O
with O
chromosomal O
rearrangements O
which O
involve O
11p13 O
but O
do O
not O
disrupt O
the O
pax6 O
gene O
. O

somatic O
mutations O
in O
the O
brca1 O
gene O
in O
sporadic B-Disease
ovarian I-Disease
tumours I-Disease
. O

the O
brca1 O
gene O
on O
chromosome O
17q21 O
is O
responsible O
for O
an O
autosomal B-Disease
dominant I-Disease
syndrome I-Disease
of O
increased O
susceptibility O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
but O
no O
somatic O
mutations O
in O
tumours B-Disease
have O
yet O
been O
described O
. O

to O
study O
the O
potential O
role O
of O
brca1 O
in O
sporadic O
carcinogenesis O
, O
we O
analysed O
the O
genomic O
dna O
of O
tumour B-Disease
and O
normal O
fractions O
of O
47 O
ovarian B-Disease
cancers I-Disease
for O
mutations O
in O
brca1 O
using O
the O
single O
- O
strand O
conformation O
polymorphism O
technique O
. O

we O
now O
describe O
somatic O
mutations O
in O
the O
dna O
of O
four O
tumours B-Disease
which O
also O
had O
loss O
of O
heterozygosity O
( O
loh O
) O
at O
a O
brca1 O
intragenic O
marker O
. O

our O
data O
support O
a O
tumour B-Disease
suppressor O
mechanism O
for O
brca1 O
; O
somatic O
mutations O
and O
loh O
may O
result O
in O
inactivation O
of O
brca1 O
in O
at O
least O
a O
small O
number O
of O
ovarian B-Disease
cancers I-Disease
. O
. O

decreased O
expression O
of O
brca1 O
accelerates O
growth O
and O
is O
often O
present O
during O
sporadic B-Disease
breast I-Disease
cancer I-Disease
progression O
. O

we O
have O
characterized O
expression O
of O
the O
familial B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
gene O
, O
brca1 O
, O
in O
cases O
of O
non B-Disease
- I-Disease
hereditary I-Disease
( I-Disease
sporadic I-Disease
) I-Disease
breast I-Disease
cancer I-Disease
and O
analyzed O
the O
effect O
of O
antisense O
inhibition O
of O
brca1 O
on O
the O
proliferative O
rate O
of O
mammary O
epithelial O
cells O
. O

brca1 O
mrna O
levels O
are O
markedly O
decreased O
during O
the O
transition O
from O
carcinoma B-Disease
in I-Disease
situ I-Disease
to O
invasive B-Disease
cancer I-Disease
. O

these O
studies O
suggest O
that O
brca1 O
may O
normally O
serve O
as O
a O
negative O
regulator O
of O
mammary O
epithelial O
cell O
growth O
whose O
function O
is O
compromised O
in O
breast B-Disease
cancer I-Disease
either O
by O
direct O
mutation O
or O
alterations O
in O
gene O
expression O
. O
. O

additional O
case O
of O
female O
monozygotic O
twins O
discordant O
for O
the O
clinical O
manifestations O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
due O
to O
opposite O
x O
- O
chromosome O
inactivation O
. O

a O
pair O
of O
female O
monozygotic O
( O
mz O
) O
twins O
, O
heterozygous O
carriers O
for O
a O
deletion O
in O
the O
dmd B-Disease
gene O
and O
discordant O
for O
the O
clinical O
manifestations O
of O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
, O
were O
analyzed O
by O
molecular O
studies O
, O
in O
situ O
hybridization O
, O
and O
methylation O
pattern O
of O
x O
chromosomes O
to O
search O
for O
opposite O
x O
inactivation O
as O
an O
explanation O
of O
their O
clinical O
discordance O
. O

a O
review O
shows O
that O
mz O
female O
twins O
discordant O
for O
x B-Disease
- I-Disease
linked I-Disease
diseases I-Disease
are O
not O
uncommon O
. O

x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
: O
a O
novel O
mutation O
of O
the O
ald B-Disease
gene O
in O
6 O
members O
of O
a O
family O
presenting O
with O
5 O
different O
phenotypes O
. O

fragments O
of O
the O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
cdna O
from O
a O
patient O
with O
adolescent B-Disease
ald I-Disease
were O
amplified O
by O
polymerase O
chain O
reaction O
and O
subcloned O
. O

five O
of O
nine O
siblings O
of O
the O
patient O
, O
comprising O
two O
cerebral B-Disease
ald I-Disease
, O
one O
adrenomyeloneuropathy B-Disease
, O
one O
addison B-Disease
only I-Disease
as O
well O
as O
the O
symptomatic O
mother O
( O
all O
accumulating O
very O
long O
chain O
fatty O
acids O
) O
carried O
this O
mutation O
, O
which O
was O
not O
found O
in O
the O
unaffected O
persons O
, O
in O
five O
unrelated O
ald B-Disease
patients O
, O
and O
in O
twenty O
controls O
. O

novel O
mutation O
at O
the O
initiation O
codon O
in O
the O
norrie B-Disease
disease I-Disease
gene O
in O
two O
japanese O
families O
. O

we O
have O
identified O
a O
new O
mutation O
of O
norrie B-Disease
disease I-Disease
( O
nd B-Disease
) O
gene O
in O
two O
japanese O
males O
from O
unrelated O
families O
; O
they O
showed O
typical O
ocular O
features O
of O
nd B-Disease
but O
no O
mental B-Disease
retardation I-Disease
or O
hearing B-Disease
impairment I-Disease
. O

a O
mutation O
was O
found O
in O
both O
patients O
at O
the O
initiation O
codon O
of O
exon O
2 O
of O
the O
nd B-Disease
gene O
( O
atg O
to O
gtg O
) O
, O
with O
otherwise O
normal O
nucleotide O
sequences O
. O

the O
mutation O
of O
the O
initiation O
codon O
would O
cause O
the O
failure O
of O
nd B-Disease
gene O
expression O
or O
a O
defect O
in O
translation O
thereby O
truncating O
the O
amino O
terminus O
of O
nd B-Disease
protein O
. O

in O
view O
of O
the O
rarity O
and O
marked O
heterogeneity O
of O
mutations O
in O
the O
nd B-Disease
gene O
, O
the O
present O
apparently O
unrelated O
japanese O
families O
who O
have O
lived O
in O
the O
same O
area O
for O
over O
two O
centuries O
presumably O
share O
the O
origin O
of O
the O
mutation O
. O

anticipation O
resulting O
in O
elimination O
of O
the O
myotonic B-Disease
dystrophy I-Disease
gene O
: O
a O
follow O
up O
study O
of O
one O
extended O
family O
. O

we O
have O
re O
- O
examined O
an O
extended O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
family O
, O
previously O
described O
in O
1955 O
, O
in O
order O
to O
study O
the O
long O
term O
effects O
of O
anticipation O
in O
dm B-Disease
and O
in O
particular O
the O
implications O
for O
families O
affected O
by O
this O
disease O
. O

clinical O
anticipation O
, O
defined O
as O
the O
cascade O
of O
mild O
, O
adult O
, O
childhood O
, O
or O
congenital B-Disease
disease I-Disease
in O
subsequent O
generations O
, O
appeared O
to O
be O
a O
relentless O
process O
, O
occurring O
in O
all O
affected O
branches O
of O
the O
family O
. O

gene O
loss O
in O
the O
patient O
group O
was O
complete O
, O
owing O
to O
infertility B-Disease
of O
the O
male O
patients O
with O
adult O
onset O
disease O
and O
the O
fact O
that O
mentally B-Disease
retarded I-Disease
patients O
did O
not O
procreate O
. O

therefore O
it O
is O
highly O
probable O
that O
the O
dm B-Disease
gene O
will O
be O
eliminated O
from O
this O
pedigree O
within O
one O
generation O
. O

the O
high O
population O
frequency O
of O
dm B-Disease
can O
at O
present O
not O
be O
explained O
by O
the O
contribution O
of O
asymptomatic O
cases O
in O
the O
younger O
generations O
of O
known O
families O
, O
but O
is O
probably O
caused O
by O
the O
events O
in O
the O
ancestral O
generations O
. O

the O
gene O
for O
spinal B-Disease
cerebellar I-Disease
ataxia I-Disease
3 O
( O
sca3 O
) O
is O
located O
in O
a O
region O
of O
approximately O
3 O
cm O
on O
chromosome O
14q24 O
. O
3 O
- O
q32 O
. O
2 O
. O

sca3 O
, O
the O
gene O
for O
spinal B-Disease
cerebellar I-Disease
ataxia I-Disease
3 O
, O
was O
recently O
mapped O
to O
a O
15 O
- O
cm O
interval O
between O
d14s67 O
and O
d14s81 O
on O
chromosome O
14q O
, O
by O
linkage O
analysis O
in O
two O
families O
of O
french O
ancestry O
. O

2 O
containing O
the O
gene O
for O
the O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
, O
which O
is O
clinically O
related O
to O
the O
phenotype O
determined O
by O
sca3 O
, O
but O
it O
cannot O
yet O
be O
concluded O
that O
both O
diseases O
result O
from O
alterations O
of O
the O
same O
gene O

an O
evaluation O
of O
genetic O
heterogeneity O
in O
145 O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

breast B-Disease
cancer I-Disease
linkage O
consortium O
. O

the O
breast B-Disease
- I-Disease
ovary I-Disease
cancer I-Disease
- I-Disease
family I-Disease
syndrome I-Disease
is O
a O
dominant O
predisposition O
to O
cancer B-Disease
of I-Disease
the I-Disease
breast I-Disease
and I-Disease
ovaries I-Disease
which O
has O
been O
mapped O
to O
chromosome O
region O
17q12 O
- O
q21 O
. O

the O
majority O
, O
but O
not O
all O
, O
of O
breast B-Disease
- I-Disease
ovary I-Disease
cancer I-Disease
families O
show O
linkage O
to O
this O
susceptibility O
locus O
, O
designated O
brca1 O
. O

we O
report O
here O
the O
results O
of O
a O
linkage O
analysis O
of O
145 O
families O
with O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

these O
families O
contain O
either O
a O
total O
of O
three O
or O
more O
cases O
of O
early O
- O
onset O
( O
before O
age O
60 O
years O
) O
breast B-Disease
cancer I-Disease
or O
ovarian B-Disease
cancer I-Disease
. O

all O
families O
contained O
at O
least O
one O
case O
of O
ovarian B-Disease
cancer I-Disease
. O

none O
of O
the O
13 O
families O
with O
cases O
of O
male B-Disease
breast I-Disease
cancer I-Disease
appear O
to O
be O
linked O
, O
but O
it O
is O
estimated O
that O
92 O
% O
( O
95 O
% O
confidence O
interval O
76 O
% O
- O
100 O
% O
) O
of O
families O
with O
no O
male B-Disease
breast I-Disease
cancer I-Disease
and O
with O
two O
or O
more O
ovarian B-Disease
cancers I-Disease
are O
linked O
to O
brca1 O
. O

these O
data O
suggest O
that O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
- I-Disease
family I-Disease
syndrome I-Disease
is O
genetically O
heterogeneous O
. O

however O
, O
the O
large O
majority O
of O
families O
with O
early O
- O
onset O
breast B-Disease
cancer I-Disease
and O
with O
two O
or O
more O
cases O
of O
ovarian B-Disease
cancer I-Disease
are O
likely O
to O
be O
due O
to O
brca1 O
mutations O
. O

molecular O
basis O
of O
essential B-Disease
fructosuria I-Disease
: O
molecular O
cloning O
and O
mutational O
analysis O
of O
human O
ketohexokinase O
( O
fructokinase O
) O
. O

essential B-Disease
fructosuria I-Disease
is O
one O
of O
the O
oldest O
known O
inborn B-Disease
errors I-Disease
of I-Disease
metabolism I-Disease
. O

it O
is O
a O
benign O
condition O
which O
is O
believed O
to O
result O
from O
deficiency B-Disease
of I-Disease
hepatic I-Disease
fructokinase I-Disease
( O
ketohexokinase O
, O
khk O
, O
e O
. O
c O
. O
2 O
. O
7 O
. O
1 O
. O
3 O
) O
. O

despite O
the O
early O
recognition O
of O
this O
disorder O
, O
the O
primary O
structure O
of O
human O
khk O
and O
the O
molecular O
basis O
of O
essential B-Disease
fructosuria I-Disease
have O
not O
been O
previously O
defined O
. O

direct O
evidence O
that O
mutation O
of O
the O
khk O
structural O
gene O
is O
the O
cause O
of O
essential B-Disease
fructosuria I-Disease
was O
also O
obtained O
. O

in O
a O
well O
- O
characterized O
family O
, O
in O
which O
three O
of O
eight O
siblings O
have O
fructosuria B-Disease
, O
all O
affected O
individuals O
are O
compound O
heterozygotes O
for O
two O
mutations O
gly40arg O
and O
ala43thr O
. O

homozygous O
presence O
of O
the O
crossover O
( O
fusion O
gene O
) O
mutation O
identified O
in O
a O
type B-Disease
ii I-Disease
gaucher I-Disease
disease I-Disease
fetus O
: O
is O
this O
analogous O
to O
the O
gaucher O
knock O
- O
out O
mouse O
model O
? O

gaucher B-Disease
disease I-Disease
( O
gd B-Disease
) O
is O
an O
inherited O
deficiency B-Disease
of I-Disease
beta I-Disease
- I-Disease
glucocerebrosidase I-Disease
( O
ec O
3 O
. O
1 O
. O
2 O
. O
45 O
, O
gene O
symbol O
gba O
) O
. O

in O
type B-Disease
i I-Disease
gd I-Disease
, O
the O
cns O
is O
not O
involved O
( O
nonneuronopathic O
) O
, O
whereas O
in O
type B-Disease
ii I-Disease
gd I-Disease
( O
acute O
neuronopathic O
) O
cns O
involvement O
is O
early O
and O
rapidly O
progressive O
, O
while O
in O
type B-Disease
iii I-Disease
gd I-Disease
( O
subacute O
neuronopathic O
) O
cns O
involvement O
occurs O
later O
and O
is O
slowly O
progressive O
. O

the O
t6433c O
( O
l444p O
) O
substitution O
is O
prevalent O
in O
type B-Disease
gd I-Disease
ii I-Disease
. O

using O
this O
procedure O
we O
demonstrated O
the O
fusion O
gene O
in O
homozygous O
form O
for O
the O
first O
time O
, O
in O
a O
macedonian O
/ O
ashkenazi O
jewish O
gd B-Disease
type I-Disease
ii I-Disease
fetus O
. O

a O
previous O
conceptus O
in O
this O
family O
was O
stillborn B-Disease
at O
36 O
weeks O
, O
with O
features O
of O
severe O
type B-Disease
ii I-Disease
gd I-Disease
. O

late O
infantile O
metachromatic B-Disease
leukodystrophy I-Disease
in O
israel O
. O

metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
is O
a O
neurodegenerative B-Disease
disease I-Disease
in O
which O
the O
lysosomal O
enzyme O
, O
aryl O
sulfatase O
a O
( O
arsa O
) O
is O
deficient O
. O

in O
israel O
, O
late O
infantile O
mld B-Disease
was O
found O
to O
be O
very O
frequent O
in O
a O
small O
jewish O
isolate O
, O
the O
habbanite O
jews O
( O
1 O
/ O
75 O
live O
births O
) O
. O

mld B-Disease
is O
also O
frequent O
among O
moslem O
arabs O
in O
jerusalem O
. O

this O
mutation O
has O
been O
reported O
in O
patients O
with O
the O
late O
infantile O
mld B-Disease
from O
different O
ethnic O
groups O
. O

knowledge O
of O
the O
different O
mutations O
causing O
mld B-Disease
in O
these O
defined O
populations O
will O
allow O
a O
carrier O
screening O
program O
to O
be O
carried O
out O
and O
prevent O
the O
birth O
of O
additional O
affected O
children O
. O

a O
single O
amino O
acid O
substitution O
( O
g103d O
) O
in O
the O
type O
ii O
collagen O
triple O
helix O
produces O
kniest B-Disease
dysplasia I-Disease
. O

kniest B-Disease
dysplasia I-Disease
is O
a O
moderately O
severe O
chondrodysplasia B-Disease
phenotype O
that O
results O
from O
mutations O
in O
the O
gene O
for O
type O
ii O
collagen O
, O
col2a1 O
. O

characteristics O
of O
the O
disorder O
include O
a O
short B-Disease
trunk I-Disease
and I-Disease
extremities I-Disease
, O
mid B-Disease
- I-Disease
face I-Disease
hypoplasia I-Disease
, O
cleft B-Disease
palate I-Disease
, O
myopia B-Disease
, O
retinal B-Disease
detachment I-Disease
, O
and O
hearing B-Disease
loss I-Disease
. O

recently O
, O
deletions O
of O
all O
or O
part O
of O
exon O
12 O
have O
been O
identified O
in O
individuals O
with O
kniest B-Disease
dysplasia I-Disease
, O
suggesting O
that O
mutations O
within O
this O
region O
of O
the O
protein O
may O
primarily O
result O
in O
the O
kniest B-Disease
dysplasia I-Disease
phenotype O
. O

we O
used O
sscp O
to O
analyze O
an O
amplified O
genomic O
dna O
fragment O
containing O
exon O
12 O
from O
seven O
individuals O
with O
kniest B-Disease
dysplasia I-Disease
. O

these O
data O
demonstrate O
that O
point O
mutations O
which O
result O
in O
single O
amino O
acid O
substitutions O
can O
produce O
kniest B-Disease
dysplasia I-Disease
and O
further O
support O
the O
hypothesis O
that O
alteration O
of O
a O
domain O
, O
which O
includes O
the O
region O
encoded O
by O
exon O
12 O
, O
in O
the O
type O
ii O
collagen O
protein O
leads O
to O
this O
disorder O
. O
. O

cag O
expansions O
in O
a O
novel O
gene O
for O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
at O
chromosome O
14q32 O
. O
1 O
. O

1 O
, O
the O
genetic O
locus O
for O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
. O

in O
normal O
individuals O
the O
gene O
contains O
between O
13 O
and O
36 O
cag O
repeats O
, O
whereas O
most O
of O
the O
clinically O
diagnosed O
patients O
and O
all O
of O
the O
affected O
members O
of O
a O
family O
with O
the O
clinical O
and O
pathological O
diagnosis O
of O
mjd B-Disease
show O
expansion O
of O
the O
repeat O
- O
number O
( O
from O
68 O
- O
79 O
) O
. O

these O
results O
raise O
the O
possibility O
that O
similar O
abnormalities O
in O
related O
genes O
may O
give O
rise O
to O
diseases O
similar O
to O
mjd B-Disease
. O

mutations O
in O
the O
brca1 O
gene O
in O
families O
with O
early O
- O
onset O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

we O
analysed O
50 O
probands O
with O
a O
family O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
for O
germline O
mutations O
in O
the O
coding O
region O
of O
the O
brca1 O
candidate O
gene O
, O
using O
single O
- O
strand O
conformation O
polymorphism O
( O
sscp O
) O
analysis O
on O
pcr O
- O
amplified O
genomic O
dna O
. O

these O
data O
are O
consistent O
with O
a O
tumour B-Disease
suppressor O
model O
, O
and O
support O
the O
notion O
that O
this O
candidate O
gene O
is O
in O
fact O
brca1 O
. O

confirmation O
of O
brca1 O
by O
analysis O
of O
germline O
mutations O
linked O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
in O
ten O
families O
. O

we O
provide O
genetic O
evidence O
supporting O
the O
identity O
of O
the O
candidate O
gene O
for O
brca1 O
through O
the O
characterization O
of O
germline O
mutations O
in O
63 O
breast B-Disease
cancer I-Disease
patients O
and O
10 O
ovarian B-Disease
cancer I-Disease
patients O
in O
ten O
families O
with O
cancer B-Disease
linked O
to O
chromosome O
17q21 O
. O

the O
four O
families O
with O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
had O
chain O
termination O
mutations O
in O
the O
n O
- O
terminal O
half O
of O
the O
protein O
. O
. O

high O
resolution O
genetic O
analysis O
suggests O
one O
ancestral O
predisposing O
haplotype O
for O
the O
origin O
of O
the O
myotonic B-Disease
dystrophy I-Disease
mutation O
. O

the O
mutation O
causing O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
has O
been O
identified O
as O
an O
amplification O
of O
an O
unstable O
trinucleotide O
( O
ctg O
) O
n O
repeat O
in O
over O
99 O
% O
of O
the O
global O
dm B-Disease
population O
. O

it O
is O
in O
complete O
linkage O
disequilibrium O
with O
an O
alu O
element O
polymorphism O
within O
the O
dm B-Disease
kinase O
gene O
, O
suggesting O
that O
dm B-Disease
is O
a O
consequence O
of O
one O
or O
few O
ancestral O
mutations O
. O

a O
recent O
analysis O
utilizing O
this O
polymorphism O
as O
well O
as O
a O
flanking O
dinucleotide O
marker O
, O
suggested O
that O
similar O
to O
fragile B-Disease
x I-Disease
syndrome I-Disease
, O
dm B-Disease
exhibited O
a O
founder O
effect O
( O
imbert O
et O
al O
. O
, O
1993 O
nature O
genet O
. O
4 O
, O
72 O
- O
76 O
) O
. O

in O
contrast O
, O
the O
low O
reproductive O
fitness O
of O
individuals O
with O
congenital O
dm B-Disease
( O
the O
endpoint O
of O
genetic O
anticipation O
in O
myotonic B-Disease
dystrophy I-Disease
) O
suggests O
a O
higher O
rate O
of O
new O
mutations O
. O

we O
present O
a O
high O
resolution O
genetic O
analysis O
of O
the O
dm B-Disease
locus O
using O
pcr O
based O
assays O
of O
nine O
polymorphisms O
, O
spanning O
a O
physical O
distance O
of O
30 O
kb O
, O
within O
and O
immediately O
flanking O
the O
dm B-Disease
kinase O
gene O
. O

genetic O
instability O
in O
human O
ovarian B-Disease
cancer I-Disease
cell O
lines O
. O

we O
have O
analyzed O
the O
stability O
of O
microsatellites O
in O
cell O
lines O
derived O
from O
human O
ovarian B-Disease
cancers I-Disease
and O
found O
that O
5 O
out O
of O
10 O
of O
the O
ovarian B-Disease
tumor I-Disease
cell O
lines O
are O
genetically O
unstable O
at O
the O
majority O
of O
the O
loci O
analyzed O
. O

in O
clones O
and O
subclones O
derived O
serially O
from O
one O
of O
these O
cell O
lines O
( O
2774 O
; O
serous B-Disease
cystadenocarcinoma I-Disease
) O
, O
a O
very O
high O
proportion O
of O
microsatellites O
distributed O
in O
many O
different O
regions O
of O
the O
genome O
change O
their O
size O
in O
a O
mercurial O
fashion O
. O

we O
conclude O
that O
genomic O
instability O
in O
ovarian B-Disease
tumors I-Disease
is O
a O
dynamic O
and O
ongoing O
process O
whose O
high O
frequency O
may O
have O
been O
previously O
underestimated O
by O
pcr O
- O
based O
allelotyping O
of O
bulk O
tumor B-Disease
tissue O
. O

we O
have O
identified O
the O
source O
of O
the O
genetic O
instability O
in O
one O
ovarian B-Disease
tumor I-Disease
as O
a O
point O
mutation O
( O
r524p O
) O
in O
the O
human O
mismatch O
- O
repair O
gene O
msh2 O
( O
salmonella O
muts O
homologue O
) O
, O
which O
has O
recently O
been O
shown O
to O
be O
involved O
in O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
. O

however O
the O
wild O
- O
type O
allele O
was O
lost O
at O
some O
point O
early O
during O
tumorigenesis O
so O
that O
dna O
isolated O
either O
from O
the O
patients O
ovarian B-Disease
tumor I-Disease
or O
from O
the O
2774 O
cell O
line O
carries O
only O
the O
mutant O
allele O
of O
the O
human O
msh2 O
gene O
. O

the O
genetic O
instability O
observed O
in O
the O
tumor B-Disease
and O
cell O
line O
dna O
, O
together O
with O
the O
germ O
- O
line O
mutation O
in O
a O
mismatch O
- O
repair O
gene O
, O
suggest O
that O
the O
msh2 O
gene O
is O
involved O
in O
the O
onset O
and O
/ O
or O
progression O
in O
a O
subset O
of O
ovarian B-Disease
cancer I-Disease
. O
. O

loss O
of O
heterozygosity O
data O
from O
familial B-Disease
tumors I-Disease
suggest O
that O
brca1 O
, O
a O
gene O
that O
confers O
susceptibility O
to O
ovarian B-Disease
and I-Disease
early I-Disease
- I-Disease
onset I-Disease
breast B-Disease
cancer I-Disease
, O
encodes O
a O
tumor B-Disease
suppressor O
. O

the O
brca1 O
region O
is O
also O
subject O
to O
allelic O
loss O
in O
sporadic B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
, O
an O
indication O
that O
brca1 O
mutations O
may O
occur O
somatically O
in O
these O
tumors B-Disease
. O

the O
brca1 O
coding O
region O
was O
examined O
for O
mutations O
in O
primary O
breast B-Disease
and I-Disease
ovarian I-Disease
tumors I-Disease
that O
show O
allele O
loss O
at O
the O
brca1 O
locus O
. O

mutations O
were O
detected O
in O
3 O
of O
32 O
breast O
and O
1 O
of O
12 O
ovarian B-Disease
carcinomas I-Disease
; O
all O
four O
mutations O
were O
germline O
alterations O
and O
occurred O
in O
early O
- O
onset O
cancers B-Disease
. O

these O
results O
suggest O
that O
mutation O
of O
brca1 O
may O
not O
be O
critical O
in O
the O
development O
of O
the O
majority O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
that O
arise O
in O
the O
absence O
of O
a O
mutant O
germline O
allele O
. O
. O

pax6 O
gene O
dosage O
effect O
in O
a O
family O
with O
congenital B-Disease
cataracts I-Disease
, O
aniridia B-Disease
, O
anophthalmia B-Disease
and O
central B-Disease
nervous I-Disease
system I-Disease
defects I-Disease
. O

the O
human O
eye O
malformation O
aniridia B-Disease
results O
from O
haploinsufficiency B-Disease
of I-Disease
pax6 I-Disease
, O
a O
paired O
box O
dna O
- O
binding O
protein O
. O

to O
study O
this O
dosage O
effect O
, O
we O
characterized O
two O
pax6 O
mutations O
in O
a O
family O
segregating O
aniridia B-Disease
and O
a O
milder O
syndrome O
consisting O
of O
congenital B-Disease
cataracts I-Disease
and O
late O
onset O
corneal B-Disease
dystrophy I-Disease
. O

a O
compound O
heterozygote O
had O
severe O
craniofacial B-Disease
and I-Disease
central I-Disease
nervous I-Disease
system I-Disease
defects I-Disease
and O
no B-Disease
eyes I-Disease
. O

we O
have O
constructed O
a O
physical O
map O
of O
a O
4 O
cm O
region O
on O
chromosome O
17q12 O
- O
21 O
that O
contains O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
gene O
brca1 O
. O

two O
genes O
that O
lie O
within O
a O
narrow O
region O
defined O
by O
meiotic O
breakpoints O
in O
brca1 O
patients O
have O
been O
sequenced O
in O
breast B-Disease
cancer I-Disease
patients O
without O
revealing O
any O
deleterious O
mutations O
. O

the O
lec O
rat O
has O
a O
deletion O
in O
the O
copper O
transporting O
atpase O
gene O
homologous O
to O
the O
wilson B-Disease
disease I-Disease
gene O
. O

the O
long O
- O
evans O
cinnamon O
( O
lec O
) O
rat O
shows O
similarity O
to O
wilson B-Disease
disease I-Disease
in O
many O
clinical O
and O
biochemical O
features O
. O

we O
have O
cloned O
cdnas O
for O
the O
rat O
gene O
( O
atp7b O
) O
homologous O
to O
the O
human O
wilson B-Disease
disease I-Disease
gene O
( O
atp7b O
) O
and O
have O
used O
them O
to O
identify O
a O
partial O
deletion O
in O
the O
atp7b O
gene O
in O
the O
lec O
rat O
. O

our O
results O
provide O
convincing O
evidence O
for O
defining O
the O
lec O
rat O
as O
an O
animal O
model O
for O
wilson B-Disease
disease I-Disease
. O

this O
model O
will O
be O
important O
for O
studying O
liver O
pathophysiology O
, O
for O
developing O
therapy O
for O
wilson B-Disease
disease I-Disease
and O
for O
studying O
the O
pathway O
of O
copper O
transport O
and O
its O
possible O
interaction O
with O
other O
heavy O
metals O
. O

genomic O
organization O
of O
the O
adrenoleukodystrophy B-Disease
gene O
. O

adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
, O
the O
most O
frequent O
peroxisomal B-Disease
disorder I-Disease
, O
is O
a O
severe O
neurodegenerative B-Disease
disease I-Disease
associated O
with O
an O
impairment B-Disease
of I-Disease
very I-Disease
long I-Disease
chain I-Disease
fatty I-Disease
acids I-Disease
beta I-Disease
- I-Disease
oxidation I-Disease
. O

we O
have O
recently O
identified O
by O
positional O
cloning O
the O
gene O
responsible O
for O
ald B-Disease
, O
located O
in O
xq28 O
. O

we O
report O
here O
a O
detailed O
characterization O
of O
the O
ald B-Disease
gene O
structure O
. O

to O
facilitate O
the O
detection O
of O
mutations O
in O
ald B-Disease
patients O
, O
we O
have O
determined O
the O
intronic O
sequences O
flanking O
the O
exons O
as O
well O
as O
the O
sequence O
of O
the O
3 O
untranslated O
region O
and O
of O
the O
immediate O
5 O
promoter O
region O
. O

the O
ald B-Disease
gene O
has O
been O
positioned O
on O
a O
pulsed O
- O
field O
map O
between O
dxs15 O
and O
the O
l1cam O
gene O
, O
about O
650 O
kb O
upstream O
from O
the O
color O
pigment O
genes O
. O

the O
frequent O
occurrence O
of O
color O
vision O
anomalies O
observed O
in O
patients O
with O
adrenomyeloneuropathy B-Disease
( O
the O
adult O
onset O
form O
of O
ald B-Disease
) O
thus O
does O
not O
represent O
a O
contiguous B-Disease
gene I-Disease
syndrome I-Disease
but O
a O
secondary O
manifestation O
of O
ald B-Disease
. O
. O

the O
murine O
homologues O
of O
the O
huntington B-Disease
disease I-Disease
gene O
( O
hdh O
) O
and O
the O
alpha O
- O
adducin O
gene O
( O
add1 O
) O
map O
to O
mouse O
chromosome O
5 O
within O
a O
region O
of O
conserved O
synteny O
with O
human O
chromosome O
4p16 O
. O
3 O
. O

huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
is O
a O
severe O
autosomal B-Disease
dominant I-Disease
neurodegenerative I-Disease
disorder I-Disease
associated O
with O
a O
novel O
gene O
( O
it15 O
) O
. O

genetic O
cholesteryl B-Disease
ester I-Disease
transfer I-Disease
protein I-Disease
deficiency I-Disease
caused O
by O
two O
prevalent O
mutations O
as O
a O
major O
determinant O
of O
increased O
levels O
of O
high O
density O
lipoprotein O
cholesterol O
. O

we O
previously O
described O
plasma O
cholesteryl B-Disease
ester I-Disease
transfer I-Disease
protein I-Disease
( I-Disease
cetp I-Disease
) I-Disease
deficiency I-Disease
due O
to O
an O
intron O
14 O
g O
( O
+ O
1 O
) O
- O
to O
- O
a O
mutation O
( O
int14 O
a O
) O
in O
several O
families O
with O
very O
high O
hdl O
- O
c O
levels O
in O
japan O
. O

cetp B-Disease
deficiency I-Disease
, O
reflecting O
two O
prevalent O
mutations O
( O
d442g O
and O
int14 O
a O
) O
, O
is O
the O
first O
example O
of O
a O
genetic B-Disease
deficiency I-Disease
state O
which O
is O
sufficiently O
common O
to O
explain O
a O
significant O
fraction O
of O
the O
variation O
in O
hdl O
- O
c O
in O
the O
general O
population O
. O

treatment O
of O
cerebrotendinous B-Disease
xanthomatosis I-Disease
: O
effects O
of O
chenodeoxycholic O
acid O
, O
pravastatin O
, O
and O
combined O
use O
. O

treatments O
by O
oral O
administration O
of O
chenodeoxycholic O
acid O
( O
cdca O
) O
alone O
, O
3 O
- O
hydroxy O
- O
3 O
- O
methylglutaryl O
( O
hmg O
) O
coa O
reductase O
inhibitor O
( O
pravastatin O
) O
alone O
, O
and O
combination O
of O
the O
two O
drugs O
were O
attempted O
for O
7 O
patients O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

the O
combination O
of O
cdca O
and O
pravastatin O
was O
a O
good O
treatment O
for O
ctx B-Disease
, O
based O
on O
the O
improvement O
of O
serum O
lipoprotein O
metabolism O
, O
the O
suppression O
of O
cholesterol O
synthesis O
, O
and O
reductions O
of O
cholestanol O
and O
plant O
sterol O
levels O
. O

mutation O
spectrum O
in O
the O
chm B-Disease
gene O
of O
danish O
and O
swedish O
choroideremia B-Disease
patients O
. O

the O
recent O
isolation O
of O
the O
complete O
open O
reading O
frame O
of O
the O
choroideremia B-Disease
( O
chm B-Disease
) O
gene O
and O
the O
characterization O
of O
the O
exon O
- O
intron O
boundaries O
has O
paved O
the O
way O
to O
mutation O
detection O
in O
patients O
with O
classical O
choroideremia B-Disease
. O

we O
have O
performed O
mutation O
screening O
in O
patients O
from O
15 O
danish O
and O
swedish O
families O
by O
using O
southern O
blot O
hybridization O
and O
the O
polymerase O
chain O
reaction O
single O
- O
strand O
conformation O
polymorphism O
( O
pcr O
- O
sscp O
) O
technique O
. O

causative O
mutations O
in O
the O
chm B-Disease
gene O
were O
detected O
in O
at O
least O
12 O
families O
, O
indicating O
that O
a O
substantial O
part O
of O
the O
mutations O
can O
be O
identified O
by O
this O
approach O
. O

interestingly O
, O
all O
chm B-Disease
gene O
mutations O
detected O
thus O
far O
in O
choroideremia B-Disease
patients O
give O
rise O
to O
the O
introduction O
of O
a O
premature O
stop O
codon O
. O
. O

predominance O
of O
the O
adrenomyeloneuropathy B-Disease
phenotype O
of O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
in O
the O
netherlands O
: O
a O
survey O
of O
30 O
kindreds O
. O

x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
x B-Disease
- I-Disease
ald I-Disease
) O
is O
an O
inherited B-Disease
disorder I-Disease
of O
peroxisomal O
beta O
- O
oxidation O
associated O
with O
accumulation O
of O
saturated O
very O
long O
- O
chain O
fatty O
acids O
, O
which O
results O
in O
central O
and O
peripheral O
demyelination B-Disease
and O
in O
impaired B-Disease
function I-Disease
of I-Disease
adrenal I-Disease
cortex I-Disease
and I-Disease
testes I-Disease
. O

the O
phenotypic O
expression O
is O
highly O
variable O
, O
childhood B-Disease
cerebral I-Disease
ald I-Disease
( O
ccald B-Disease
) O
and O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
being O
the O
main O
variants O
. O

we O
explored O
the O
30 O
dutch O
kindreds O
well O
known O
to O
the O
dutch O
x B-Disease
- I-Disease
ald I-Disease
/ O
amn B-Disease
study O
group O
and O
phenotyped O
77 O
male O
patients O
35 O
( O
46 O
% O
) O
had O
amn B-Disease
and O
24 O
( O
31 O
% O
) O
ccald B-Disease
or O
adolescent B-Disease
cerebral I-Disease
ald I-Disease
( O
adolcald B-Disease
) O
. O

these O
percentages O
differ O
significantly O
from O
previous O
reports O
, O
in O
which O
25 O
to O
28 O
% O
of O
the O
patients O
developed O
amn B-Disease
and O
53 O
to O
57 O
% O
ccald B-Disease
or O
adolcald B-Disease
. O

our O
findings O
indicate O
that O
- O
- O
at O
least O
in O
the O
netherlands O
- O
- O
amn B-Disease
may O
be O
the O
most O
frequent O
phenotype O
of O
x B-Disease
- I-Disease
ald I-Disease
. O
. O

adrenoleukodystrophy B-Disease
gene O
encodes O
an O
80 O
kda O
membrane O
protein O
. O

an O
antibody O
against O
the O
synthetic O
c O
- O
terminal O
peptides O
deduced O
from O
the O
cdna O
of O
the O
gene O
responsible O
for O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
was O
produced O
to O
characterize O
the O
product O
of O
the O
ald B-Disease
gene O
. O

the O
antibody O
reacted O
with O
the O
80 O
kda O
band O
protein O
in O
control O
fibroblasts O
, O
while O
no O
bands O
were O
detected O
in O
the O
fibroblasts O
from O
a O
patient O
with O
ald B-Disease
( O
# O
163 O
) O
, O
in O
which O
mrna O
of O
the O
ald B-Disease
gene O
was O
undetectable O
based O
on O
northern O
blot O
analysis O
. O

these O
data O
thus O
indicate O
that O
the O
ald B-Disease
gene O
encodes O
an O
80 O
kda O
membrane O
protein O
. O
. O

isolation O
of O
the O
gene O
for O
mcleod B-Disease
syndrome I-Disease
that O
encodes O
a O
novel O
membrane O
transport O
protein O
. O

mcleod B-Disease
syndrome I-Disease
is O
an O
x B-Disease
- I-Disease
linked I-Disease
multisystem I-Disease
disorder I-Disease
characterized O
by O
abnormalities O
in O
the O
neuromuscular O
and O
hematopoietic O
systems O
. O

we O
have O
assembled O
a O
cosmid O
contig O
of O
360 O
kb O
that O
encompasses O
the O
mcleod B-Disease
gene O
locus O
. O

the O
mrna O
expression O
pattern O
of O
one O
of O
them O
, O
designated O
as O
xk O
, O
correlates O
closely O
to O
the O
mcleod B-Disease
phenotype O
. O

nucleotide O
sequence O
analysis O
of O
xk O
from O
two O
unrelated O
mcleod B-Disease
patients O
has O
identified O
point O
mutations O
at O
conserved O
splice O
donor O
and O
acceptor O
sites O
. O

these O
findings O
provide O
direct O
evidence O
that O
xk O
is O
responsible O
for O
mcleod B-Disease
syndrome I-Disease
. O
. O

x B-Disease
- I-Disease
linked I-Disease
spastic I-Disease
paraplegia I-Disease
and O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
are O
allelic B-Disease
disorders I-Disease
at O
the O
proteolipid O
protein O
locus O
. O

three O
forms O
of O
x B-Disease
- I-Disease
linked I-Disease
spastic I-Disease
paraplegia I-Disease
( O
spg B-Disease
) O
have O
been O
defined O
. O

a O
rare O
x B-Disease
- I-Disease
linked I-Disease
dysmyelinating I-Disease
disorder I-Disease
of O
the O
central O
nervous O
system O
, O
pelizaeus B-Disease
- I-Disease
merzbacher I-Disease
disease I-Disease
( O
pmd B-Disease
) O
, O
has O
also O
been O
mapped O
to O
xq21 O
- O
q22 O
, O
and O
is O
caused O
by O
mutations O
in O
the O
proteolipid O
protein O
gene O
( O
plp O
) O
which O
encodes O
two O
myelin O
proteins O
, O
plp O
and O
dm20 O
. O

it O
appears O
, O
therefore O
, O
that O
spg2 O
and O
pmd B-Disease
are O
allelic B-Disease
disorders I-Disease

canavan B-Disease
disease I-Disease
: O
mutations O
among O
jewish O
and O
non O
- O
jewish O
patients O
. O

canavan B-Disease
disease I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
leukodystrophy I-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
aspartoacylase I-Disease
( O
aspa O
) O
. O

of O
the O
128 O
unrelated O
canavan B-Disease
chromosomes O
analyzed O
, O
88 O
were O
from O
probands O
of O
ashkenazi O
jewish O
descent O
. O

8 O
% O
of O
the O
canavan B-Disease
chromosomes O
of O
ashkenazi O
jewish O
origin O
. O

predominant O
occurrence O
of O
certain O
mutations O
among O
ashkenazi O
jewish O
and O
non O
- O
jewish O
patients O
with O
canavan B-Disease
disease I-Disease
would O
suggest O
a O
founding O
- O
father O
effect O
in O
propagation O
of O
these O
mutant O
chromosomes O

intelligence O
quotient O
profile O
in O
myotonic B-Disease
dystrophy I-Disease
, O
intergenerational O
deficit O
, O
and O
correlation O
with O
ctg O
amplification O
. O

an O
abbreviated O
wechsler O
adult O
intelligence O
scale O
revised O
( O
wais O
- O
r O
) O
was O
used O
to O
assess O
verbal O
and O
arithmetical O
cognitive O
performance O
in O
55 O
subjects O
with O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
, O
covering O
all O
grades O
of O
disease O
severity O
, O
and O
31 O
controls O
at O
50 O
% O
risk O
of O
inheriting O
dm B-Disease
. O

significant O
iq O
differences O
were O
found O
between O
( O
1 O
) O
all O
55 O
dm B-Disease
subjects O
( O
mean O
90 O
. O
2 O
, O
sd O
16 O
. O
1 O
) O
and O
31 O
controls O
( O
102 O
. O
6 O
, O
sd O
9 O
. O
4 O
) O
, O
with O
no O
sex O
differences O
in O
either O
group O
; O
( O
2 O
) O
15 O
affected O
parents O
( O
99 O
. O
3 O
, O
sd O
12 O
. O
2 O
) O
and O
their O
affected O
children O
( O
88 O
. O
1 O
, O
sd O
17 O
. O
2 O
) O
, O
where O
significance O
was O
dependent O
on O
parental O
sex O
being O
female O
; O
and O
( O
3 O
) O
15 O
pairs O
of O
affected O
sibs O
( O
89 O
. O
6 O
, O
sd O
13 O
. O
2 O
) O
and O
their O
normal O
sibs O
( O
100 O
. O
2 O
, O

the O
correlation O
of O
iq O
difference O
and O
ctg O
expansion O
difference O
in O
both O
the O
dm B-Disease
parent O
- O
child O
pairs O
and O
normal O
sib O
- O
affected O
sib O
pairs O
was O
poor O
, O
indicating O
that O
ctg O
expansion O
is O
not O
a O
reliable O
predictor O
of O
iq O
either O
in O
individual O
persons O
or O
families O
. O

adenomatous B-Disease
polyposis I-Disease
coli I-Disease
and O
a O
cytogenetic O
deletion O
of O
chromosome O
5 O
resulting O
from O
a O
maternal O
intrachromosomal O
insertion O
. O

we O
present O
the O
clinical O
and O
laboratory O
findings O
in O
an O
institutionalised O
adult O
patient O
originally O
referred O
for O
autism B-Disease
. O

a O
high O
risk O
of O
colorectal B-Disease
cancer I-Disease
was O
predicted O
when O
an O
interstitial O
deletion O
of O
the O
long O
arm O
of O
chromosome O
5 O
, O
del O
( O
5 O
) O
( O
q15q22 O
. O
3 O
) O
, O
was O
detected O
in O
her O
lymphocytes O
and O
deletion O
of O
the O
mcc O
and O
apc B-Disease
genes O
confirmed O
by O
molecular O
analysis O
. O

adenomatous B-Disease
polyposis I-Disease
coli I-Disease
and O
carcinoma B-Disease
of I-Disease
the I-Disease
rectum I-Disease
were O
subsequently O
diagnosed O
in O
the O
patient O
. O

she O
was O
profoundly O
mentally B-Disease
retarded I-Disease
, O
autistic B-Disease
, O
and O
had O
minor O
dysmorphic B-Disease
features I-Disease
consistent O
with O
those O
of O
previous O
patients O
with O
similar O
deletions O
. O

this O
family O
further O
confirms O
the O
cytogenetic O
mapping O
of O
both O
mcc O
and O
apc B-Disease
genes O
to O
5q22 O
and O
comparison O
with O
other O
recent O
cases O
suggests O
that O
both O
genes O
and O
their O
closely O
linked O
markers O
lie O
within O
the O
5q22 O
. O

familial B-Disease
male I-Disease
breast I-Disease
cancer I-Disease
is O
not O
linked O
to O
the O
brca1 O
locus O
on O
chromosome O
17q O
. O

breast B-Disease
cancer I-Disease
in O
men O
is O
about O
a O
hundredfold O
less O
common O
than O
in O
women O
and O
this O
has O
hindered O
research O
into O
its O
genetic O
basis O
. O

we O
have O
examined O
22 O
families O
with O
at O
least O
one O
case O
of O
male B-Disease
breast I-Disease
cancer I-Disease
for O
linkage O
to O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
locus O
, O
brca1 O
, O
on O
chromosome O
17q O
. O

our O
results O
indicate O
that O
there O
is O
a O
gene O
( O
s O
) O
other O
than O
brca1 O
which O
predisposes O
to O
early O
- O
onset O
breast B-Disease
cancer I-Disease
in O
women O
and O
which O
confers O
a O
higher O
risk O
of O
male B-Disease
breast I-Disease
cancer I-Disease
. O

identification O
of O
additional O
pedigrees O
that O
include O
cases O
of O
male B-Disease
breast I-Disease
cancer I-Disease
may O
therefore O
facilitate O
the O
mapping O
and O
isolation O
of O
this O
gene O
. O

the O
ews O
gene O
, O
involved O
in O
ewing B-Disease
family I-Disease
of I-Disease
tumors I-Disease
, O
malignant B-Disease
melanoma I-Disease
of I-Disease
soft I-Disease
parts I-Disease
and O
desmoplastic B-Disease
small I-Disease
round I-Disease
cell I-Disease
tumors I-Disease
, O
codes O
for O
an O
rna O
binding O
protein O
with O
novel O
regulatory O
domains O
. O

the O
ews O
gene O
, O
which O
maps O
to O
band O
q12 O
of O
human O
chromosome O
22 O
, O
is O
involved O
in O
a O
wide O
variety O
of O
human O
solid B-Disease
tumors I-Disease
including O
ewing B-Disease
sarcoma I-Disease
, O
related O
primitive O
neuroectodermal B-Disease
tumors I-Disease
, O
malignant B-Disease
melanoma I-Disease
of I-Disease
soft I-Disease
parts I-Disease
and O
desmoplastic B-Disease
small I-Disease
round I-Disease
cell I-Disease
tumors I-Disease
. O

in O
these O
tumors B-Disease
, O
the O
ews O
is O
fused O
to O
genes O
encoding O
transcriptional O
activators O
/ O
repressors O
, O
like O
fli O
- O
1 O
or O
erg O
or O
atf O
1 O
or O
wt1 O
. O

an O
ews O
- O
erg O
chimeric O
protein O
, O
which O
is O
found O
in O
ewings B-Disease
sarcoma I-Disease
cells O
, O
functions O
as O
a O
transcriptional O
activator O
. O

canavan B-Disease
disease I-Disease
: O
genomic O
organization O
and O
localization O
of O
human O
aspa O
to O
17p13 O
- O
ter O
and O
conservation O
of O
the O
aspa O
gene O
during O
evolution O
. O

canavan B-Disease
disease I-Disease
, O
or O
spongy B-Disease
degeneration I-Disease
of I-Disease
the I-Disease
brain I-Disease
, O
is O
a O
severe O
leukodystrophy B-Disease
caused O
by O
the O
deficiency B-Disease
of I-Disease
aspartoacylase I-Disease
( O
aspa O
) O
. O

recently O
, O
a O
missense O
mutation O
was O
identified O
in O
human O
aspa O
coding O
sequence O
from O
patients O
with O
canavan B-Disease
disease I-Disease
. O

it O
should O
now O
be O
possible O
to O
identify O
mutations O
in O
the O
noncoding O
genomic O
sequences O
that O
lead O
to O
canavan B-Disease
disease I-Disease
and O
to O
study O
the O
regulation O
of O
aspa O
. O
. O

myotonic B-Disease
dystrophy I-Disease
: O
size O
- O
and O
sex O
- O
dependent O
dynamics O
of O
ctg O
meiotic O
instability O
, O
and O
somatic O
mosaicism O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
a O
progressive O
neuromuscular B-Disease
disorder I-Disease
which O
results O
from O
elongations O
of O
an O
unstable O
( O
ctg O
) O
n O
repeat O
, O
located O
in O
the O
3 O
untranslated O
region O
of O
the O
dm B-Disease
gene O
. O

our O
observation O
of O
differently O
sized O
repeats O
in O
various O
dm B-Disease
tissues O
from O
the O
same O
individual O
may O
explain O
why O
the O
size O
of O
the O
mutation O
observed O
in O
lymphocytes O
does O
not O
necessarily O
correlate O
with O
the O
severity O
and O
nature O
of O
symptoms O
. O

through O
a O
molecular O
and O
genetic O
study O
of O
142 O
families O
including O
418 O
dm B-Disease
patients O
, O
we O
have O
investigated O
the O
dynamics O
of O
the O
ctg O
repeat O
meiotic O
instability O
. O

illegitimate O
transcription O
of O
the O
phenylalanine O
hydroxylase O
gene O
in O
lymphocytes O
for O
identification O
of O
mutations O
in O
phenylketonuria B-Disease
. O

taking O
advantage O
of O
the O
illegitimate O
transcription O
of O
the O
phenylalanine O
hydroxylase O
( O
pah O
) O
gene O
, O
we O
have O
been O
able O
to O
analyse O
the O
pah O
cdna O
sequence O
of O
hyperphenylalaninemic B-Disease
children O
in O
circulating O
lymphocytes O
. O

the O
present O
study O
supports O
the O
view O
that O
circulating O
lymphocytes O
give O
easy O
access O
to O
pah O
gene O
transcripts O
whose O
nucleotide O
sequence O
is O
identical O
to O
that O
reported O
in O
liver O
and O
therefore O
represent O
a O
useful O
tool O
for O
molecular O
genetic O
studies O
in O
phenylketonuria B-Disease
. O
. O

high O
residual O
arylsulfatase O
a O
( O
arsa O
) O
activity O
in O
a O
patient O
with O
late B-Disease
- I-Disease
infantile I-Disease
metachromatic I-Disease
leukodystrophy I-Disease
. O

we O
identified O
a O
patient O
suffering O
from O
late B-Disease
- I-Disease
infantile I-Disease
metachromatic I-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
who O
has O
a O
residual O
arylsulfatase O
a O
( O
arsa O
) O
activity O
of O
about O
10 O
% O
. O

fibroblasts O
of O
the O
patient O
show O
significant O
sulfatide O
degradation O
activity O
exceeding O
that O
of O
adult B-Disease
mld I-Disease
patients O
. O

these O
findings O
are O
in O
contrast O
to O
previous O
results O
showing O
that O
the O
late B-Disease
- I-Disease
infantile I-Disease
type I-Disease
of I-Disease
mld I-Disease
is O
always O
associated O
with O
the O
complete O
absence O
of O
arsa O
activity O
. O

an O
arylsulfatase O
a O
( O
arsa O
) O
missense O
mutation O
( O
t274m O
) O
causing O
late B-Disease
- I-Disease
infantile I-Disease
metachromatic I-Disease
leukodystrophy I-Disease
. O

metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
is O
an O
autosomal B-Disease
recessive I-Disease
lysosomal I-Disease
storage I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
arylsulfatase I-Disease
a I-Disease
( O
arsa O
; O
ec O
3 O
. O
1 O
. O
6 O
. O
8 O
) O
. O

the O
8 O
arsa O
exons O
and O
adjacent O
intron O
boundaries O
from O
a O
patient O
with O
late B-Disease
- I-Disease
infantile I-Disease
metachromatic I-Disease
leukodystrophy I-Disease
were O
polymerase O
chain O
reaction O
( O
pcr O
) O
amplified O
in O
seven O
discrete O
reactions O
. O

analysis O
of O
a O
further O
29 O
mld B-Disease
patients O
revealed O
the O
presence O
of O
five O
additional O
homozygotes O
for O
t274m O
. O

mutations O
in O
the O
pax6 O
gene O
in O
patients O
with O
hereditary O
aniridia B-Disease
. O

the O
14 O
exons O
of O
the O
pax6 O
gene O
have O
been O
analysed O
exon O
- O
by O
- O
exon O
using O
sscp O
in O
6 O
aniridia B-Disease
families O
. O

this O
data O
strongly O
supports O
the O
candidature O
of O
pax6 O
as O
the O
gene O
responsible O
for O
hereditary O
aniridia B-Disease
. O
. O

three O
novel O
mutations O
in O
five O
unrelated O
subjects O
with O
hereditary O
protein B-Disease
s I-Disease
deficiency I-Disease
type I-Disease
i I-Disease
. O

a O
panel O
of O
eight O
unrelated O
subjects O
with O
inherited O
type B-Disease
i I-Disease
protein I-Disease
s I-Disease
deficiency I-Disease
was O
screened O
for O
mutations O
in O
the O
pros1 O
gene O
. O

the O
latter O
indicates O
that O
a O
mrna O
based O
approach O
is O
not O
feasible O
for O
the O
genetic O
analysis O
of O
protein B-Disease
s I-Disease
deficiency I-Disease
type I-Disease
i I-Disease
. O
. O

characteristics O
of O
intergenerational O
contractions O
of O
the O
ctg O
repeat O
in O
myotonic B-Disease
dystrophy I-Disease
. O

in O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
, O
the O
size O
of O
a O
ctg O
repeat O
in O
the O
dm B-Disease
kinase O
gene O
generally O
increases O
in O
successive O
generations O
with O
clinical O
evidence O
of O
anticipation O
. O

we O
examined O
1 O
, O
489 O
dm B-Disease
parent O
- O
offspring O
pairs O
, O
of O
which O
95 O
( O
6 O
. O
4 O
% O
) O
showed O
such O
contractions O
in O
peripheral O
blood O
leukocytes O
( O
pbl O
) O
. O

sixteen O
dm B-Disease
parents O
had O
multiple O
dm B-Disease
offspring O
with O
the O
ctg O
repeat O
contractions O
. O

this O
frequency O
was O
higher O
than O
the O
frequency O
expected O
from O
the O
probability O
of O
the O
repeat O
contractions O
( O
6 O
. O
4 O
% O
) O
and O
the O
size O
of O
dm B-Disease
sib O
population O
( O
1 O
. O
54 O
dm B-Disease
offspring O
per O
dm B-Disease
parent O
, O
in O
968 O
dm B-Disease
parents O
) O
. O

we O
conclude O
that O
( O
1 O
) O
intergenerational O
contractions O
of O
the O
ctg O
repeat O
in O
leukocyte O
dna O
frequently O
accompanies O
apparent O
anticipation O
, O
especially O
when O
dm B-Disease
is O
maternally O
transmitted O
, O
and O
( O
2 O
) O
the O
paternal O
origin O
of O
the O
repeat O
and O
the O
presence O
of O
the O
repeat O
contraction O
in O
a O
sibling O
increase O
the O
probability O
of O
the O
ctg O
repeat O
contraction O

gonosomal O
mosaicism O
in O
myotonic B-Disease
dystrophy I-Disease
patients O
: O
involvement O
of O
mitotic O
events O
in O
( O
ctg O
) O
n O
repeat O
variation O
and O
selection O
against O
extreme O
expansion O
in O
sperm O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
caused O
by O
abnormal O
expansion O
of O
a O
polymorphic O
( O
ctg O
) O
n O
repeat O
, O
located O
in O
the O
dm B-Disease
protein O
kinase O
gene O
. O

we O
determined O
the O
( O
ctg O
) O
n O
repeat O
lengths O
in O
a O
broad O
range O
of O
tissue O
dnas O
from O
patients O
with O
mild O
, O
classical O
, O
or O
congenital O
manifestation O
of O
dm B-Disease
. O

differences O
in O
the O
repeat O
length O
were O
seen O
in O
somatic O
tissues O
from O
single O
dm B-Disease
individuals O
and O
twins O
. O

we O
conclude O
that O
dm B-Disease
patients O
can O
be O
considered O
gonosomal O
mosaics O
, O
i O
. O

regionally O
clustered O
apc B-Disease
mutations O
are O
associated O
with O
a O
severe O
phenotype O
and O
occur O
at O
a O
high O
frequency O
in O
new O
mutation O
cases O
of O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
. O

germline O
mutation O
in O
apc O
at O
5q21 O
- O
22 O
results O
in O
the O
dominantly O
inherited O
syndrome O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
. O

eighteen O
patients O
had O
no O
family O
history O
of O
the O
disease O
; O
of O
these O
11 O
were O
classified O
as O
having O
a O
severe O
phenotype O
, O
based O
on O
an O
early O
age O
at O
presentation O
or O
cancer B-Disease
development O
. O

a O
5 O
bp O
deletion O
at O
codon O
1309 O
reported O
to O
occur O
in O
10 O
- O
15 O
% O
of O
unselected O
apc B-Disease
patients O
worldwide O
, O
was O
found O
in O
5 O
of O
the O
18 O
new O
mutation O
cases O
and O
4 O
of O
the O
27 O
familial O
cases O
all O
nine O
were O
classed O
as O
severe O
. O

in O
contrast O
all O
of O
the O
apc B-Disease
mutations O
detected O
in O
affected O
individuals O
with O
an O
average O
phenotype O
were O
located O
prior O
to O
codon O
1309 O
. O

mutations O
at O
the O
pax6 O
locus O
are O
found O
in O
heterogeneous O
anterior B-Disease
segment I-Disease
malformations I-Disease
including O
peters B-Disease
' I-Disease
anomaly I-Disease
. O

mutation O
or O
deletion O
of O
the O
pax6 O
gene O
underlies O
many O
cases O
of O
aniridia B-Disease
. O

three O
lines O
of O
evidence O
now O
converge O
to O
implicate O
pax6 O
more O
widely O
in O
anterior B-Disease
segment I-Disease
malformations I-Disease
including O
peters B-Disease
anomaly I-Disease
. O

first O
, O
a O
child O
with O
peters B-Disease
anomaly I-Disease
is O
deleted O
for O
one O
copy O
of O
pax6 O
. O

second O
, O
affected O
members O
of O
a O
family O
with O
dominantly O
inherited O
anterior B-Disease
segment I-Disease
malformations I-Disease
, O
including O
peters B-Disease
anomaly I-Disease
are O
heterozygous O
for O
an O
r26g O
mutation O
in O
the O
pax6 O
paired O
box O
. O

third O
, O
a O
proportion O
of O
sey O
/ O
+ O
smalleye O
mice O
, O
heterozygous O
for O
a O
nonsense O
mutation O
in O
murine O
pax O
- O
6 O
, O
have O
an O
ocular O
phenotype O
resembling O
peters B-Disease
anomaly I-Disease
. O

we O
therefore O
propose O
that O
a O
variety O
of O
anterior B-Disease
segment I-Disease
anomalies I-Disease
may O
be O
associated O
with O
pax6 O
mutations O
. O
. O

huntington B-Disease
disease I-Disease
without O
cag O
expansion O
: O
phenocopies O
or O
errors O
in O
assignment O
? O

huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
has O
been O
shown O
to O
be O
associated O
with O
an O
expanded O
cag O
repeat O
within O
a O
novel O
gene O
on O
4p16 O
. O

the O
reasons O
for O
not O
observing O
expansion O
in O
affected O
individuals O
are O
important O
for O
determining O
the O
sensitivity O
of O
using O
repeat O
length O
both O
for O
diagnosis O
of O
affected O
patients O
and O
for O
predictive O
testing O
programs O
and O
may O
have O
biological O
relevance O
for O
the O
understanding O
of O
the O
molecular O
mechanism O
underlying O
hd B-Disease
. O

the O
remaining O
12 O
patients O
represent O
possible O
phenocopies O
for O
hd B-Disease
. O

mutations O
in O
the O
hd B-Disease
gene O
that O
are O
other O
than O
cag O
expansion O
have O
not O
been O
excluded O
for O
the O
remaining O
eight O
cases O
; O
however O
, O
in O
as O
many O
as O
seven O
of O
these O
persons O
, O
retrospective O
review O
of O
these O
patients O
clinical O
features O
identified O
characteristics O
not O
typical O
for O
hd B-Disease
. O

this O
study O
shows O
that O
on O
rare O
occasions O
mutations O
in O
other O
, O
as O
- O
yet O
- O
undefined O
genes O
can O
present O
with O
a O
clinical O
phenotype O
very O
similar O
to O
that O
of O
hd B-Disease

frequent O
detection O
of O
codon O
877 O
mutation O
in O
the O
androgen O
receptor O
gene O
in O
advanced B-Disease
prostate I-Disease
cancers I-Disease
. O

prostatic O
tissue O
specimens O
derived O
from O
transurethral O
resections O
of O
patients O
with O
metastatic B-Disease
prostate I-Disease
cancer I-Disease
were O
analyzed O
for O
genetic O
alterations O
in O
the O
hormone O
- O
binding O
domain O
of O
the O
androgen O
receptor O
( O
ar O
) O
gene O
. O

this O
same O
ar O
mutation O
has O
been O
reported O
previously O
in O
a O
metastatic B-Disease
prostate I-Disease
cancer I-Disease
cell O
line O
, O
lncap O
, O
where O
this O
mutation O
confers O
upon O
the O
ar O
an O
altered O
ligand O
- O
binding O
specificity O
which O
is O
stimulated O
by O
estrogens O
, O
progestagens O
, O
and O
antiandrogens O
. O

it O
is O
possible O
that O
analogous O
to O
an O
activated O
/ O
altered O
growth O
factor O
receptor O
oncogene O
, O
codon O
877 O
mutant O
ar O
with O
altered O
ligand O
binding O
may O
provide O
a O
selective O
growth O
advantage O
in O
the O
genesis O
of O
a O
subset O
of O
advanced B-Disease
prostate I-Disease
cancer I-Disease
. O

although O
estrogens O
are O
used O
infrequently O
, O
antiandrogens O
are O
used O
increasingly O
in O
hormonal O
therapy O
for O
patients O
with O
advanced B-Disease
prostate I-Disease
cancer I-Disease
. O

the O
human O
gene O
for O
alkaptonuria B-Disease
( O
aku B-Disease
) O
maps O
to O
chromosome O
3q O
. O

alkaptonuria B-Disease
( O
aku B-Disease
; O
mckusick O
no O
. O
203500 O
) O
is O
a O
rare O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
caused O
by O
the O
lack O
of O
homogentisic O
acid O
oxidase O
activity O
. O

ochronosis B-Disease
is O
the O
predominant O
clinical O
complication O
of O
the O
disease O
leading O
to O
ochronotic B-Disease
arthropathy I-Disease
, O
dark O
urine O
, O
pigment O
changes O
of O
the O
skin O
, O
and O
other O
clinical O
features O
. O

a O
mutation O
causing O
alkaptonuria B-Disease
in O
the O
mouse O
has O
mapped O
to O
chromosome O
16 O
. O

considering O
conserved O
synteny O
, O
we O
were O
able O
to O
map O
the O
human O
gene O
to O
chromosome O
3q O
in O
six O
alkaptonuria B-Disease
pedigrees O
of O
slovak O
origin O
. O
. O

an O
sglt1 O
missense O
mutation O
underlies O
hereditary B-Disease
glucose I-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
, O
characterized O
by O
potentially O
fatal O
diarrhea B-Disease
; O
conversely O
, O
oral O
rehydration O
therapy O
exploits O
normal O
transport O
to O
alleviate O
life O
- O
threatening O
diarrhea B-Disease
of O
infectious O
origin O
. O

a O
new O
missense O
mutation O
in O
exon O
1 O
causing O
glucose B-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
is O
also O
described O
. O

these O
data O
facilitate O
the O
search O
for O
new O
glucose B-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
- O
related O
mutations O
in O
this O
important O
gene O
and O
provide O
a O
basis O
for O
future O
evolutionary O
comparisons O
with O
other O
na O
( O
+ O
) O
- O
dependent O
cotransporters O
. O
. O

four O
novel O
pepd O
alleles O
causing O
prolidase B-Disease
deficiency I-Disease
. O

mutations O
at O
the O
pepd O
locus O
cause O
prolidase B-Disease
deficiency I-Disease
( O
mckusick O
170100 O
) O
, O
a O
rare O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
iminodipeptiduria B-Disease
, O
skin B-Disease
ulcers I-Disease
, O
mental B-Disease
retardation I-Disease
, O
and O
recurrent O
infections O
. O

our O
results O
indicate O
that O
the O
severe O
form O
of O
prolidase B-Disease
deficiency I-Disease
is O
caused O
by O
multiple O
pepd O
alleles O
. O

recombinations O
in O
individuals O
homozygous O
by O
descent O
localize O
the O
friedreich B-Disease
ataxia I-Disease
locus O
in O
a O
cloned O
450 O
- O
kb O
interval O
. O

the O
locus O
for O
friedreich B-Disease
ataxia I-Disease
( O
frda B-Disease
) O
, O
a O
severe O
neurodegenerative B-Disease
disease I-Disease
, O
is O
tightly O
linked O
to O
markers O
d9s5 O
and O
d9s15 O
, O
and O
analysis O
of O
rare O
recombination O
events O
has O
suggested O
the O
order O
cen O
- O
frda O
- O
d9s5 O
- O
d9s15 O
- O
qter O
. O

in O
order O
to O
map O
these O
markers O
with O
respect O
to O
the O
frda B-Disease
locus O
, O
all O
within O
a O
1 O
- O
cm O
confidence O
interval O
, O
we O
sought O
to O
increase O
the O
genetic O
information O
of O
available O
frda B-Disease
families O
by O
considering O
homozygosity O
by O
descent O
and O
association O
with O
founder O
haplotypes O
in O
isolated O
populations O
. O

this O
approach O
allowed O
us O
to O
identify O
one O
phase O
- O
known O
recombination O
and O
one O
probable O
historic O
recombination O
on O
haplotypes O
from O
reunion O
island O
patients O
, O
both O
of O
which O
place O
three O
of O
the O
five O
markers O
proximal O
to O
frda B-Disease
. O

taken O
together O
, O
the O
results O
place O
the O
frda B-Disease
locus O
in O
a O
450 O
- O
kb O
interval O
, O
which O
is O
small O
enough O
for O
direct O
search O
of O
candidate O
genes O
. O

investigation O
of O
thermoregulatory O
characteristics O
in O
patients O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

a O
survey O
instrument O
is O
used O
to O
assess O
temperature O
regulation O
characteristics O
in O
children O
with O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
compared O
to O
3 O
control O
groups O
sibs O
of O
pws B-Disease
patients O
( O
sib O
) O
, O
neurodevelopmentally B-Disease
handicapped I-Disease
children O
( O
nd O
) O
, O
and O
age O
and O
gender O
matched O
well O
children O
( O
wc O
) O
. O

no O
differences O
were O
noted O
in O
any O
variable O
between O
the O
pws B-Disease
patients O
and O
the O
nd O
controls O
, O
suggesting O
that O
these O
abnormalities O
are O
not O
unique O
to O
pws B-Disease
, O
but O
can O
occur O
in O
any O
neurodevelopmentally B-Disease
handicapped I-Disease
individual O
, O
further O
suggesting O
these O
do O
not O
necessarily O
reflect O
syndrome O
- O
specific O
hypothalamic B-Disease
abnormalities I-Disease
. O
. O

phenotypic O
variation O
including O
retinitis B-Disease
pigmentosa I-Disease
, O
pattern B-Disease
dystrophy I-Disease
, O
and O
fundus B-Disease
flavimaculatus I-Disease
in O
a O
single O
family O
with O
a O
deletion O
of O
codon O
153 O
or O
154 O
of O
the O
peripherin O
/ O
rds O
gene O
. O

background O
and O
objectives O
mutations O
of O
the O
peripherin O
/ O
rds O
gene O
have O
been O
reported O
in O
autosomal B-Disease
dominant I-Disease
retinitis I-Disease
pigmentosa I-Disease
, O
pattern O
macular B-Disease
dystrophy I-Disease
, O
and O
retinitis B-Disease
punctata I-Disease
albescens I-Disease
. O

results O
the O
mother O
presented O
at O
age O
63 O
years O
with O
a O
profoundly O
abnormal O
electroretinogram O
( O
erg O
) O
and O
adult O
- O
onset O
retinitis B-Disease
pigmentosa I-Disease
that O
progressed O
dramatically O
over O
12 O
years O
, O
with O
marked O
loss O
of O
peripheral O
visual O
field O
. O

one O
daughter O
developed O
pattern B-Disease
macular I-Disease
dystrophy I-Disease
at O
age O
31 O
years O
. O

another O
daughter O
presented O
at O
age O
42 O
years O
with O
macular B-Disease
degeneration I-Disease
and O
over O
10 O
years O
developed O
the O
clinical O
picture O
of O
fundus B-Disease
flavimaculatus I-Disease
. O

the O
son O
had O
onset O
of O
macular B-Disease
degeneration I-Disease
at O
age O
44 O
years O
. O

pericentral B-Disease
scotomas I-Disease
were O
present O
and O
the O
erg O
was O
markedly O
abnormal O
. O

in O
two O
patients O
with O
the O
autosomal B-Disease
recessive I-Disease
disease I-Disease
glucose I-Disease
/ I-Disease
galactose I-Disease
malabsorption I-Disease
, O
the O
underlying O
cause O
was O
found O
to O
be O
a O
missense O
mutation O
in O
sglt1 O
, O
and O
the O
asp28 O
- O
- O
> O
asn O
change O
was O
demonstrated O
in O
vitro O
to O
eliminate O
sglt1 O
transport O
activity O
. O

1 O
, O
and O
provide O
an O
example O
of O
the O
utility O
of O
the O
sglt1 O
probe O
as O
a O
diagnostic O
for O
genetic B-Disease
diseases I-Disease
associated O
with O
translocations O
of O
chromosome O
22 O
. O

restriction O
of O
ocular O
fundus O
lesions O
to O
a O
specific O
subgroup O
of O
apc B-Disease
mutations O
in O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
patients O
. O

in O
humans O
, O
alteration O
of O
the O
tumor B-Disease
suppressor O
gene O
, O
apc B-Disease
, O
causes O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
, O
a O
condition O
causing O
predisposition O
to O
colorectal B-Disease
cancer I-Disease
. O

the O
syndrome O
inconsistently O
associates O
characteristic O
patches O
of O
congenital B-Disease
hypertrophy I-Disease
of I-Disease
the I-Disease
retinal I-Disease
pigment I-Disease
epithelium I-Disease
( O
chrpe B-Disease
) O
. O

ocular O
examination O
revealed O
that O
patients O
expressing O
chrpe B-Disease
tend O
to O
cluster O
within O
specific O
families O
. O

the O
exact O
apc B-Disease
mutation O
was O
identified O
in O
42 O
unrelated O
patients O
. O

the O
extent O
of O
chrpe B-Disease
was O
found O
to O
be O
dependent O
on O
the O
position O
of O
the O
mutation O
along O
the O
coding O
sequence O
. O

chrpe B-Disease
lesions O
are O
almost O
always O
absent O
if O
the O
mutation O
occurs O
before O
exon O
9 O
, O
but O
are O
systematically O
present O
if O
it O
occurs O
after O
this O
exon O
. O

the O
authors O
earlier O
findings O
of O
a O
negative O
electroretinogram O
( O
erg O
) O
in O
a O
boy O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
led O
them O
to O
investigate O
dystrophin O
gene O
deletions O
and O
ergs O
in O
five O
boys O
with O
dmd B-Disease
. O

the O
authors O
wanted O
to O
determined O
whether O
there O
were O
similar O
erg O
findings O
in O
an O
animal O
model O
for O
dmd B-Disease
, O
the O
mdx O
mouse O
. O

ganzfeld O
ergs O
were O
recorded O
in O
five O
boys O
with O
dmd B-Disease
after O
a O
complete O
ophthalmic O
examination O
. O

the O
erg O
shows O
promise O
of O
becoming O
a O
noninvasive O
diagnostic O
tool O
for O
dmd B-Disease
and O
its O
milder O
allelic O
forms O
. O
. O

association O
of O
the O
apc B-Disease
tumor I-Disease
suppressor O
protein O
with O
catenins O
. O

mutations O
of O
apc O
appear O
to O
initiate O
sporadic O
and O
inherited O
forms O
of O
human O
colorectal B-Disease
cancer I-Disease
. O

although O
these O
mutations O
have O
been O
well O
characterized O
, O
little O
is O
known O
about O
the O
function O
of O
the O
apc B-Disease
gene O
product O
. O

two O
cellular O
proteins O
that O
associate O
with O
apc B-Disease
were O
identified O
by O
nucleotide O
sequence O
analysis O
and O
peptide O
mapping O
as O
the O
e O
- O
cadherin O
- O
associated O
proteins O
alpha O
- O
and O
beta O
- O
catenin O
. O

these O
results O
suggest O
an O
important O
link O
between O
tumor B-Disease
initiation O
and O
cell O
adhesion O
. O
. O

difference O
in O
methylation O
patterns O
within O
the O
d15s9 O
region O
of O
chromosome O
15q11 O
- O
13 O
in O
first O
cousins O
with O
angelman B-Disease
syndrome I-Disease
and O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
. O

abnormalities O
of O
chromosome O
region O
15q11 O
- O
13 O
are O
associated O
with O
angelman B-Disease
syndrome I-Disease
( O
as B-Disease
) O
and O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

differences O
between O
the O
methylation O
patterns O
of O
the O
region O
of O
chromosome O
15q11 O
- O
13 O
which O
hybridizes O
to O
the O
highly O
conserved O
dna O
, O
dn34 O
, O
in O
normal O
individuals O
and O
in O
patients O
with O
as B-Disease
and O
pws B-Disease
have O
been O
described O
. O

we O
report O
on O
a O
family O
in O
which O
first O
cousins O
are O
affected O
by O
as B-Disease
and O
pws B-Disease
as O
a O
result O
of O
a O
familial O
paracentric O
inversion O
of O
15q11 O
- O
q13 O
. O

haplotype O
studies O
in O
wilson B-Disease
disease I-Disease
. O

in O
51 O
families O
with O
wilson B-Disease
disease I-Disease
, O
we O
have O
studied O
dna O
haplotypes O
of O
dinucleotide O
repeat O
polymorphisms O
( O
ca O
repeats O
) O
in O
the O
13q14 O
. O

3 O
region O
, O
to O
examine O
these O
markers O
for O
association O
with O
the O
wilson B-Disease
disease I-Disease
gene O
( O
wnd B-Disease
) O
. O

in O
addition O
to O
a O
marker O
( O
d13s133 O
) O
described O
elsewhere O
, O
we O
have O
developed O
three O
new O
highly O
polymorphic O
markers O
( O
d13s314 O
, O
d13s315 O
, O
and O
d13s316 O
) O
close O
to O
the O
wnd B-Disease
locus O
. O

these O
findings O
have O
important O
implications O
for O
mutation O
detection O
and O
molecular O
diagnosis O
in O
families O
with O
wilson B-Disease
disease I-Disease
. O

we O
have O
analyzed O
a O
single O
multi O
- O
affected O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
pedigree O
( O
bov3 O
) O
and O
have O
shown O
consistent O
inheritance O
of O
markers O
on O
chromosome O
17q O
with O
the O
disease O
confirming O
that O
this O
family O
is O
due O
to O
the O
brca1 O
gene O
. O

analysis O
of O
17q O
haplotypes O
shows O
a O
recombination O
event O
in O
a O
bilateral O
breast B-Disease
cancer I-Disease
case O
which O
suggests O
that O
the O
brca1 O
gene O
lies O
distal O
to O
d17s857 O
; O
d17s857 O
is O
thus O
the O
new O
proximal O
boundary O
for O
the O
region O
containing O
brca1 O
. O

all O
seven O
breast B-Disease
tumour I-Disease
/ O
blood O
pairs O
examined O
from O
this O
family O
show O
loss O
of O
heterozygosity O
in O
the O
tumours B-Disease
. O

the O
allel O
retained O
in O
each O
tumour B-Disease
was O
from O
the O
disease O
- O
bearing O
chromosome O
implicating O
brca1 O
as O
a O
tumour B-Disease
suppressor O
gene O
. O

myotonic B-Disease
dystrophy I-Disease
kinase O
is O
a O
component O
of O
neuromuscular O
junctions O
. O

the O
clinical O
manifestation O
of O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
correlated O
to O
the O
extent O
of O
expansion O
of O
an O
unstable O
[ O
ctg O
] O
n O
dna O
motif O
. O

recent O
studies O
have O
demonstrated O
that O
this O
trinucleotide O
motif O
forms O
part O
of O
the O
last O
, O
3 O
untranslated O
exon O
of O
a O
gene O
which O
potentially O
encodes O
multiple O
protein O
isoforms O
of O
a O
serine O
/ O
threonine O
protein O
kinase O
( O
myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
, O
dm O
- O
pk O
) O
. O

strikingly O
, O
presence O
of O
the O
protein O
can O
also O
be O
demonstrated O
for O
nmjs O
of O
muscular O
tissues O
of O
adult O
and O
congenital O
cases O
of O
dm B-Disease
, O
with O
no O
gross O
changes O
in O
structural O
organisation O
. O

our O
findings O
provide O
a O
basis O
for O
further O
characterisation O
of O
the O
role O
of O
the O
kinase O
in O
protein O
assembly O
processes O
or O
signal O
mediation O
at O
synaptic O
sites O
and O
ultimately O
for O
the O
understanding O
of O
the O
complex O
pathophysiology O
of O
dm B-Disease
. O
. O

markedly O
accelerated O
catabolism O
of O
apolipoprotein O
a O
- O
ii O
( O
apoa O
- O
ii O
) O
and O
high O
density O
lipoproteins O
containing O
apoa O
- O
ii O
in O
classic O
lecithin O
: O
cholesterol B-Disease
acyltransferase I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
. O

classic B-Disease
( I-Disease
complete I-Disease
) I-Disease
lecithin I-Disease
cholesterol I-Disease
acyltransferase I-Disease
( I-Disease
lcat I-Disease
) I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
( O
partial B-Disease
lcat I-Disease
deficiency I-Disease
) O
are O
genetic O
syndromes O
associated O
with O
markedly O
decreased O
plasma O
levels O
of O
high O
density O
lipoprotein O
( O
hdl O
) O
cholesterol O
but O
not O
with O
an O
increased O
risk O
of O
atherosclerotic B-Disease
cardiovascular I-Disease
disease I-Disease
. O

we O
investigated O
the O
metabolism O
of O
the O
hdl O
apolipoproteins O
( O
apo O
) O
apoa O
- O
i O
and O
apoa O
- O
ii O
in O
a O
total O
of O
five O
patients O
with O
lcat B-Disease
deficiency I-Disease
, O
one O
with O
classic B-Disease
lcat I-Disease
deficiency I-Disease
and O
four O
with O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
. O

in O
summary O
, O
genetic O
syndromes O
of O
either O
complete B-Disease
or I-Disease
partial I-Disease
lcat I-Disease
deficiency I-Disease
result O
in O
low O
levels O
of O
hdl O
through O
preferential O
hypercatabolism O
of O
apoa O
- O
ii O
and O
hdl O
particles O
containing O
apoa O
- O
ii O
. O

because O
lpa O
- O
i O
has O
been O
proposed O
to O
be O
more O
protective O
than O
lpa O
- O
i O
a O
- O
ii O
against O
atherosclerosis B-Disease
, O
this O
selective O
effect O
on O
the O
metabolism O
of O
lpa O
- O
i O
a O
- O
ii O
may O
provide O
a O
potential O
explanation O
why O
patients O
with O
classic B-Disease
lcat I-Disease
deficiency I-Disease
and O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
are O
not O
at O
increased O
risk O
for O
premature O
atherosclerosis B-Disease
despite O
markedly O
decreased O
levels O
of O
hdl O
cholesterol O
and O
apoa O
- O
i O

x B-Disease
linked I-Disease
recessive I-Disease
thrombocytopenia I-Disease
. O

a O
saudi O
arab O
boy O
presented O
in O
early O
childhood O
with O
thrombocytopenia B-Disease
, O
morphologically O
large O
and O
normal O
sized O
platelets O
, O
increased O
mean O
platelet O
volume O
, O
and O
a O
hypermegakaryocytic O
bone O
marrow O
. O

there O
was O
no O
clinical O
and O
laboratory O
evidence O
of O
any O
significant O
immunological B-Disease
abnormalities I-Disease
. O

similar O
findings O
in O
two O
other O
brothers O
suggested O
strongly O
that O
they O
were O
all O
suffering O
from O
an O
x B-Disease
linked I-Disease
recessive I-Disease
thrombocytopenic I-Disease
disorder I-Disease
. O

results O
of O
dna O
analysis O
with O
the O
probe O
m27 O
beta O
are O
consistent O
with O
x O
linkage O
and O
indicate O
also O
that O
the O
locus O
of O
the O
relevant O
gene O
lies O
close O
to O
or O
is O
identical O
to O
the O
locus O
of O
the O
gene O
for O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

because O
of O
various O
features O
which O
include O
the O
presence O
of O
large O
and O
normal O
sized O
platelets O
( O
rather O
than O
small O
platelets O
) O
and O
freedom O
from O
significant O
immune B-Disease
deficiencies I-Disease
, O
it O
is O
likely O
that O
the O
x B-Disease
linked I-Disease
recessive I-Disease
thrombocytopenia I-Disease
in O
this O
family O
is O
an O
isolated O
entity O
quite O
distinct O
from O
the O
classical O
was B-Disease
phenotype O
. O

however O
, O
a O
modified O
expression O
of O
the O
was B-Disease
gene O
producing O
a O
mild O
phenotypic O
variant O
cannot O
be O
excluded O
entirely O
. O
. O

macular B-Disease
dystrophy I-Disease
associated O
with O
mutations O
at O
codon O
172 O
in O
the O
human O
retinal B-Disease
degeneration I-Disease
slow O
gene O
. O

background O
recently O
, O
mutations O
in O
the O
retinal B-Disease
degeneration I-Disease
slow O
( O
rds O
) O
gene O
which O
codes O
for O
peripherin O
- O
rds O
have O
been O
implicated O
as O
a O
cause O
of O
autosomal B-Disease
dominant I-Disease
retinitis I-Disease
pigmentosa I-Disease
. O

mutations O
at O
codon O
172 O
of O
the O
rds O
gene O
have O
been O
identified O
in O
three O
families O
with O
autosomal O
dominantly O
inherited O
, O
progressive O
macular B-Disease
dystrophy I-Disease
. O

results O
in O
all O
but O
one O
affected O
member O
, O
symptoms O
of O
progressive O
central O
visual B-Disease
loss I-Disease
developed O
in O
the O
third O
or O
fourth O
decade O
of O
life O
accompanied O
by O
central B-Disease
scotoma I-Disease
and O
well O
- O
demarcated O
atrophy B-Disease
of I-Disease
the I-Disease
retinal I-Disease
pigment I-Disease
epithelium I-Disease
and O
choriocapillaris B-Disease
of I-Disease
the I-Disease
macula I-Disease
. O

conclusion O
these O
results O
indicate O
that O
mutations O
in O
the O
rds O
gene O
can O
be O
expressed O
as O
a O
macular B-Disease
dystrophy I-Disease
, O
with O
evidence O
of O
primary O
cone B-Disease
dysfunction I-Disease
and O
preservation O
of O
peripheral O
rod O
function O
. O
. O

anonymous O
marker O
loci O
within O
400 O
kb O
of O
hla O
- O
a O
generate O
haplotypes O
in O
linkage O
disequilibrium O
with O
the O
hemochromatosis B-Disease
gene O
( O
hfe O
) O

the O
hemochromatosis B-Disease
gene O
( O
hfe O
) O
maps O
to O
6p21 O
. O

the O
unambiguous O
identification O
of O
a O
crossover O
event O
within O
hemochromatosis B-Disease
families O
is O
very O
difficult O
; O
it O
is O
particularly O
hampered O
by O
the O
variability O
of O
the O
phenotypic O
expression O
as O
well O
as O
by O
the O
sex O
- O
and O
age O
- O
related O
penetrance O
of O
the O
disease O
. O

in O
the O
present O
report O
, O
66 O
hemochromatosis B-Disease
families O
yielding O
151 O
hemochromatosis B-Disease
chromosomes O
and O
182 O
normal O
chromosomes O
were O
rflp O
- O
typed O
with O
a O
battery O
of O
probes O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 O
. O

additionally O
, O
hemochromatosis B-Disease
haplotypes O
possessing O
hla O
- O
a11 O
and O
the O
low O
- O
frequency O
hla O
- O
f O
polymorphism O
( O
allele O
2 O
) O
are O
supportive O
of O
a O
separate O
founder O
chromosome O
containing O
a O
second O
, O
independently O
arising O
mutant O
allele O
. O

overall O
, O
the O
establishment O
of O
a O
likely O
" O
hemochromatosis B-Disease
critical O
region O
" O
centromeric O
boundary O
and O
the O
identification O
of O
a O
linkage O
- O
disequilibrium O
zone O
both O
significantly O
contribute O
to O
a O
reduction O
in O
the O
amount O
of O
dna O
required O
to O
be O
searched O
for O
novel O
coding O
sequences O
constituting O
the O
hfe B-Disease
defect I-Disease

genomic O
structure O
of O
the O
ews O
gene O
and O
its O
relationship O
to O
ewsr1 O
, O
a O
site O
of O
tumor B-Disease
- O
associated O
chromosome O
translocation O
. O

the O
ews O
gene O
has O
been O
identified O
based O
on O
its O
location O
at O
the O
chromosome O
22 O
breakpoint O
of O
the O
t O
( O
11 O
; O
22 O
) O
( O
q24 O
; O
q12 O
) O
translocation O
that O
characterizes O
ewing B-Disease
sarcoma I-Disease
and O
related O
neuroectodermal B-Disease
tumors I-Disease
. O

positions O
of O
the O
chromosome O
22 O
breakpoints O
were O
determined O
for O
19 O
ewing B-Disease
tumors I-Disease
. O

norrie B-Disease
disease I-Disease
gene O
: O
characterization O
of O
deletions O
and O
possible O
function O
. O

positional O
cloning O
experiments O
have O
resulted O
recently O
in O
the O
isolation O
of O
a O
candidate O
gene O
for O
norrie B-Disease
disease I-Disease
( O
pseudoglioma B-Disease
; O
ndp B-Disease
) O
, O
a O
severe O
x B-Disease
- I-Disease
linked I-Disease
neurodevelopmental I-Disease
disorder I-Disease
. O

here O
we O
report O
the O
isolation O
and O
analysis O
of O
human O
genomic O
dna O
clones O
encompassing O
the O
ndp B-Disease
gene O
. O

detailed O
analysis O
of O
genomic O
deletions O
in O
norrie B-Disease
patients O
shows O
that O
they O
are O
heterogeneous O
, O
both O
in O
size O
and O
in O
position O
. O

by O
pcr O
analysis O
, O
we O
found O
that O
expression O
of O
the O
ndp B-Disease
gene O
was O
not O
confined O
to O
the O
eye O
or O
to O
the O
brain O
. O

an O
extensive O
dna O
and O
protein O
sequence O
comparison O
between O
the O
human O
ndp B-Disease
gene O
and O
related O
genes O
from O
the O
database O
revealed O
homology O
with O
cysteine O
- O
rich O
protein O
- O
binding O
domains O
of O
immediate O
- O
- O
early O
genes O
implicated O
in O
the O
regulation O
of O
cell O
proliferation O
. O

the O
normal O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
allele O
, O
or O
a O
closely O
linked O
gene O
, O
influences O
age O
at O
onset O
of O
hd B-Disease
. O

we O
evaluated O
the O
hypothesis O
that O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
is O
influenced O
by O
the O
normal O
hd B-Disease
allele O
by O
comparing O
transmission O
patterns O
of O
genetically O
linked O
markers O
at O
the O
d4s10 O
locus O
in O
the O
normal O
parent O
against O
age O
at O
onset O
in O
the O
affected O
offspring O
. O

these O
findings O
suggest O
that O
the O
expression O
of O
hd B-Disease
is O
modulated O
by O
the O
normal O
hd B-Disease
allele O
or O
by O
a O
closely O
linked O
locus O
. O
. O

further O
investigation O
of O
the O
hexa O
gene O
intron O
9 O
donor O
splice O
site O
mutation O
frequently O
found O
in O
non O
- O
jewish O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
patients O
from O
the O
british O
isles O
. O

in O
a O
previous O
study O
we O
found O
that O
a O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
causing O
mutation O
in O
the O
intron O
9 O
donor O
splice O
site O
of O
the O
hexa O
gene O
occurs O
at O
high O
frequency O
in O
non O
- O
jewish O
patients O
and O
carriers O
from O
the O
british O
isles O
. O

we O
have O
now O
tested O
, O
in O
a O
blind O
study O
, O
26 O
american O
tsd B-Disease
carriers O
and O
28 O
non O
- O
carriers O
who O
have O
british O
ancestry O
for O
the O
intron O
9 O
splice O
site O
mutation O
. O

all O
six O
had O
irish O
ancestry O
, O
compared O
with O
nine O
of O
the O
20 O
other O
( O
intron O
9 O
mutation O
negative O
) O
tsd B-Disease
carriers O
( O
p O
< O
0 O
. O
05 O
) O
. O

these O
results O
confirm O
the O
previously O
found O
high O
frequency O
of O
the O
intron O
9 O
mutation O
in O
non O
- O
jewish O
tsd B-Disease
families O
of O
british O
isles O
, O
particularly O
irish O
, O
origin O
, O
and O
reinforce O
the O
need O
to O
screen O
such O
families O
for O
this O
mutation O
. O

molecular O
mechanisms O
of O
oncogenic O
mutations O
in O
tumors B-Disease
from O
patients O
with O
bilateral B-Disease
and I-Disease
unilateral I-Disease
retinoblastoma I-Disease
. O

the O
rb1 O
gene O
from O
12 O
human O
retinoblastoma B-Disease
tumors I-Disease
has O
been O
analyzed O
exon O
- O
by O
- O
exon O
with O
the O
single O
- O
strand O
conformation O
polymorphism O
technique O
. O

mutations O
were O
found O
in O
all O
tumors B-Disease
, O
and O
one O
- O
third O
of O
the O
tumors B-Disease
had O
independent O
mutations O
in O
both O
alleles O
neither O
of O
which O
were O
found O
in O
the O
germ O
line O
, O
confirming O
their O
true O
sporadic O
nature O
. O

in O
the O
remaining O
two O
- O
thirds O
of O
the O
tumors B-Disease
only O
one O
mutation O
was O
found O
, O
consistent O
with O
the O
loss O
- O
of O
- O
heterozygosity O
theory O
of O
tumorigenesis O
. O

pax6 O
mutations O
in O
aniridia B-Disease
. O

aniridia B-Disease
is O
a O
congenital B-Disease
malformation I-Disease
of I-Disease
the I-Disease
eye I-Disease
, O
chiefly O
characterised O
by O
iris B-Disease
hypoplasia I-Disease
, O
which O
can O
cause O
blindness B-Disease
. O

the O
pax6 O
gene O
was O
isolated O
as O
a O
candidate O
aniridia B-Disease
gene O
by O
positional O
cloning O
from O
the O
smallest O
region O
of O
overlap O
of O
aniridia B-Disease
- O
associated O
deletions O
. O

subsequently O
pax6 O
intragenic O
mutations O
were O
demonstrated O
in O
smalleye O
, O
a O
mouse O
mutant O
which O
is O
an O
animal O
model O
for O
aniridia B-Disease
, O
and O
six O
human O
aniridia B-Disease
patients O
. O

in O
this O
paper O
we O
describe O
four O
additional O
pax6 O
point O
mutations O
in O
aniridia B-Disease
patients O
, O
both O
sporadic O
and O
familial O
. O

in O
addition O
, O
the O
frequency O
at O
which O
we O
have O
found O
pax6 O
mutations O
suggests O
that O
lesions O
in O
pax6 O
will O
account O
for O
most O
cases O
of O
aniridia B-Disease
. O
. O

autosomal B-Disease
dominant I-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
is O
a O
familial O
form O
of O
diabetes B-Disease
insipidus I-Disease
. O

this O
disorder O
is O
associated O
with O
variable O
levels O
of O
arginine O
vasopressin O
( O
avp O
) O
and O
diabetes B-Disease
insipidus I-Disease
of O
varying O
severity O
, O
which O
responds O
to O
exogenous O
avp O
. O

to O
determine O
the O
molecular O
basis O
of O
autosomal B-Disease
dominant I-Disease
neurohypophyseal I-Disease
diabetes I-Disease
insipidus I-Disease
, O
the O
avp O
genes O
of O
members O
of O
a O
large O
kindred O
were O
analyzed O
. O

germinal O
mosaicism O
in O
a O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
family O
: O
implications O
for O
genetic O
counselling O
. O

in O
this O
study O
we O
describe O
a O
three O
- O
generation O
family O
in O
which O
two O
siblings O
were O
affected O
by O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
. O

immunohistochemical O
analysis O
of O
muscle O
dystrophin O
and O
haplotype O
analysis O
of O
the O
dmd B-Disease
locus O
revealed O
that O
the O
x O
chromosome O
carrying O
the O
dmd B-Disease
gene O
was O
transmitted O
from O
the O
healthy O
maternal O
grandfather O
to O
his O
three O
daughters O
, O
including O
the O
probands O
mother O
. O

these O
findings O
indicate O
that O
the O
grandfather O
was O
a O
germinal O
mosaic O
for O
the O
dmd B-Disease
gene O
. O

genetic O
mapping O
of O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
syndrome I-Disease
to O
a O
small O
interval O
on O
chromosome O
17q12 O
- O
21 O
: O
exclusion O
of O
candidate O
genes O
edh17b2 O
and O
rara O
. O

a O
susceptibility O
gene O
for O
hereditary B-Disease
breast I-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
, O
brca1 O
, O
has O
been O
assigned O
by O
linkage O
analysis O
to O
chromosome O
17q21 O
. O

we O
have O
typed O
22 O
breast B-Disease
and I-Disease
breast I-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
with O
eight O
polymorphisms O
from O
the O
chromosome O
17q12 O
- O
21 O
region O
, O
including O
two O
in O
the O
edh17b2 O
gene O
. O

genetic O
recombination O
with O
the O
breast B-Disease
cancer I-Disease
trait O
excludes O
rara O
from O
further O
consideration O
as O
a O
candidate O
gene O
for O
brca1 O
. O

mutations O
in O
the O
edh17b2 O
gene O
, O
therefore O
do O
not O
appear O
to O
be O
responsible O
for O
the O
hereditary B-Disease
breast I-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
syndrome I-Disease
. O

plasma O
hdl O
are O
a O
negative O
risk O
factor O
for O
atherosclerosis B-Disease
. O

subjects O
with O
homozygous O
cetp B-Disease
deficiency I-Disease
caused O
by O
a O
gene O
splicing O
defect O
have O
markedly O
elevated O
hdl O
; O
however O
, O
heterozygotes O
have O
only O
mild O
increases O
in O
hdl O
. O

familial B-Disease
mediterranean I-Disease
fever I-Disease
in O
the O
colchicine O
era O
: O
the O
fate O
of O
one O
family O
. O

in O
order O
to O
demonstrate O
the O
effect O
of O
prophylactic O
colchicine O
treatment O
on O
the O
natural O
history O
of O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
, O
a O
family O
is O
presented O
with O
6 O
out O
of O
9 O
siblings O
affected O
by O
fmf B-Disease
. O

each O
patient O
represents O
a O
different O
stage O
of O
the O
amyloidotic B-Disease
kidney I-Disease
disease I-Disease
of O
fmf B-Disease
and O
the O
effect O
of O
continuous O
colchicine O
treatment O
on O
its O
course O
. O

detection O
of O
a O
new O
submicroscopic O
norrie B-Disease
disease I-Disease
deletion O
interval O
with O
a O
novel O
dna O
probe O
isolated O
by O
differential O
alu O
pcr O
fingerprint O
cloning O
. O

this O
novel O
sequence O
, O
cpxr318 O
( O
dxs742 O
) O
, O
detects O
a O
new O
submicroscopic O
deletion O
interval O
at O
the O
norrie B-Disease
disease I-Disease
locus O
( O
ndp O
) O
. O

finally O
, O
dxs742 O
, O
dsx7 O
, O
dxs77 O
, O
and O
maoa O
were O
integrated O
into O
a O
physical O
map O
spanning O
the O
norrie B-Disease
disease I-Disease
locus O

putative O
x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
gene O
shares O
unexpected O
homology O
with O
abc O
transporters O
. O

adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
is O
an O
x B-Disease
- I-Disease
linked I-Disease
disease I-Disease
affecting O
1 O
/ O
20 O
, O
000 O
males O
either O
as O
cerebral B-Disease
ald I-Disease
in O
childhood O
or O
as O
adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
in O
adults O
. O

childhood O
ald B-Disease
is O
the O
more O
severe O
form O
, O
with O
onset O
of O
neurological O
symptoms O
between O
5 O
- O
12 O
years O
of O
age O
. O

central B-Disease
nervous I-Disease
system I-Disease
demyelination I-Disease
progresses O
rapidly O
and O
death O
occurs O
within O
a O
few O
years O
. O

amn B-Disease
is O
a O
milder O
form O
of O
the O
disease O
with O
onset O
at O
15 O
- O
30 O
years O
of O
age O
and O
a O
more O
progressive O
course O
. O

adrenal B-Disease
insufficiency I-Disease
( O
addisons B-Disease
disease I-Disease
) O
may O
remain O
the O
only O
clinical O
manifestation O
of O
ald B-Disease
. O

the O
normal O
oxidation O
of O
vlcfa O
- O
coa O
in O
patients O
fibroblasts O
suggested O
that O
the O
gene O
coding O
for O
the O
vlcfa O
- O
coa O
synthetase O
could O
be O
a O
candidate O
gene O
for O
ald B-Disease
. O

here O
we O
use O
positional O
cloning O
to O
identify O
a O
gene O
partially O
deleted O
in O
6 O
of O
85 O
independent O
patients O
with O
ald B-Disease
. O

targeted O
modification O
of O
the O
apolipoprotein O
b O
gene O
results O
in O
hypobetalipoproteinemia B-Disease
and O
developmental B-Disease
abnormalities I-Disease
in O
mice O
. O

familial B-Disease
hypobetalipoproteinemia I-Disease
is O
an O
autosomal B-Disease
codominant I-Disease
disorder I-Disease
resulting O
in O
a O
dramatic O
reduction O
in O
plasma O
concentrations O
of O
apolipoprotein O
( O
apo O
) O
b O
, O
cholesterol O
, O
and O
beta O
- O
migrating O
lipoproteins O
. O

a O
benefit O
of O
hypobetalipoproteinemia B-Disease
is O
that O
mildly O
affected O
individuals O
may O
be O
protected O
from O
coronary B-Disease
vascular I-Disease
disease I-Disease
. O

mice O
containing O
this O
allele O
display O
all O
of O
the O
hallmarks O
of O
human O
hypobetalipoproteinemia B-Disease
they O
produce O
a O
truncated O
apob O
protein O
, O
apob70 O
, O
and O
have O
markedly O
decreased O
plasma O
concentrations O
of O
apob O
, O
beta O
- O
lipoproteins O
, O
and O
total O
cholesterol O
. O

in O
addition O
, O
the O
mice O
manifest O
several O
characteristics O
that O
are O
occasionally O
observed O
in O
human O
hypobetalipoproteinemia B-Disease
, O
including O
reduced O
plasma O
triglyceride O
concentrations O
, O
fasting O
chylomicronemia B-Disease
, O
and O
reduced O
high O
density O
lipoprotein O
cholesterol O
. O

an O
unexpected O
finding O
is O
that O
the O
modified O
apob O
allele O
is O
strongly O
associated O
with O
exencephalus B-Disease
and O
hydrocephalus B-Disease
. O

these O
mice O
should O
help O
increase O
our O
understanding O
of O
hypobetalipoproteinemia B-Disease
, O
atherogenesis B-Disease
, O
and O
the O
etiology O
of O
exencephalus B-Disease
and O
hydrocephalus B-Disease
. O
. O

a O
novel O
disease O
with O
deficiency B-Disease
of I-Disease
mitochondrial I-Disease
very I-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coa I-Disease
dehydrogenase I-Disease
. O

two O
of O
the O
patients O
, O
4 O
- O
5 O
month O
old O
boys O
, O
were O
found O
to O
have O
a O
novel O
disease O
, O
vlcad B-Disease
deficiency I-Disease
, O
as O
judged O
from O
the O
results O
of O
very O
low O
palmitoyl O
- O
coa O
dehydrogenase O
activity O
and O
the O
lack O
of O
immunoreactivity O
toward O
antibody O
raised O
to O
purified O
vlcad O
. O
. O

molecular O
characterization O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
deficiency I-Disease
in O
patients O
of O
chinese O
descent O
and O
identification O
of O
new O
base O
substitutions O
in O
the O
human O
g6pd O
gene O
. O

the O
underlying O
dna O
changes O
associated O
with O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( I-Disease
g6pd I-Disease
) I-Disease
- I-Disease
deficient I-Disease
asians O
have O
not O
been O
extensively O
investigated O
. O

to O
fill O
this O
gap O
, O
we O
sequenced O
the O
g6pd O
gene O
of O
43 O
g6pd B-Disease
- I-Disease
deficient I-Disease
chinese O
whose O
g6pd O
was O
well O
characterized O
biochemically O
. O

these O
five O
nucleotide O
substitutions O
account O
for O
over O
83 O
% O
of O
our O
43 O
g6pd B-Disease
- I-Disease
deficient I-Disease
samples O
and O
these O
substitutions O
have O
not O
been O
reported O
in O
non O
- O
asians O
. O

the O
substitutions O
at O
cdna O
1376 O
and O
1388 O
account O
for O
over O
50 O
% O
of O
the O
43 O
samples O
examined O
indicating O
a O
high O
prevalence O
of O
these O
two O
alleles O
among O
g6pd B-Disease
- I-Disease
deficient I-Disease
chinese O
. O

our O
findings O
add O
support O
to O
the O
notion O
that O
diverse O
point O
mutations O
may O
account O
largely O
for O
much O
of O
the O
phenotypic O
heterogeneity O
of O
g6pd B-Disease
deficiency I-Disease
. O
. O

identification O
of O
mutations O
in O
danish O
choroideremia B-Disease
families O
. O

we O
have O
searched O
for O
mutations O
in O
the O
choroideremia B-Disease
gene O
( O
chm B-Disease
) O
in O
patients O
from O
12 O
danish O
families O
in O
which O
chm B-Disease
is O
segregating O
. O

structure O
and O
genomic O
sequence O
of O
the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
kinase O
) O
gene O
. O

the O
mutation O
causing O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
has O
recently O
been O
identified O
as O
an O
unstable O
ctg O
trinucleotide O
repeat O
located O
in O
the O
3 O
untranslated O
region O
of O
a O
gene O
encoding O
for O
a O
protein O
with O
putative O
serine O
- O
threonine O
protein O
kinase O
activity O
. O

in O
this O
report O
we O
present O
the O
genomic O
sequences O
of O
the O
human O
and O
murine O
dm B-Disease
kinase O
gene O
. O

the O
complete O
sequence O
and O
characterization O
of O
the O
structure O
of O
the O
dm B-Disease
kinase O
gene O
, O
as O
well O
as O
the O
identification O
of O
novel O
polymorphisms O
within O
the O
gene O
, O
represent O
an O
important O
step O
in O
a O
further O
understanding O
of O
the O
genetics O
of O
myotonic B-Disease
dystrophy I-Disease
and O
the O
molecular O
biology O
of O
the O
gene O
. O
. O

autosomal O
recessive O
transmission O
of O
hemophilia B-Disease
a I-Disease
due O
to O
a O
von B-Disease
willebrand I-Disease
factor O
mutation O
. O

the O
differential O
diagnosis O
of O
the O
genetic B-Disease
bleeding I-Disease
disorders I-Disease
, O
hemophilia B-Disease
a I-Disease
and O
von B-Disease
willebrand I-Disease
disease I-Disease
, O
is O
occasionally O
confounded O
by O
the O
close O
molecular O
relationship O
of O
coagulation O
factor O
viii O
and O
von B-Disease
willebrand I-Disease
factor O
( O
vwf O
) O
. O

this O
report O
describes O
the O
autosomal O
inheritance O
of O
a O
hemophilia B-Disease
a I-Disease
phenotype O
due O
to O
a O
mutation O
of O
vwf O
that O
results O
in O
defective O
factor O
viii O
binding O
. O

however O
, O
the O
mutant O
failed O
to O
bind O
factor O
viii O
, O
demonstrating O
that O
the O
mutation O
was O
functionally O
related O
to O
the O
observed O
hemophilia B-Disease
phenotype O
. O

the O
family O
we O
describe O
demonstrates O
the O
recessive O
inheritance O
of O
a O
recently O
recognized O
class O
of O
genetic O
bleeding O
disorders O
, O
we O
call O
" O
autosomal O
hemophilia B-Disease
. O

" O
we O
conclude O
that O
vwf O
mutation O
may O
be O
an O
under O
recognized O
cause O
of O
hemophilia B-Disease
, O
especially O
in O
cases O
where O
the O
inheritance O
pattern O
is O
not O
consistent O
with O
x O
- O
linked O
transmission O
. O

somatic O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
mutation O
in O
clear O
cell O
papillary B-Disease
cystadenoma I-Disease
of I-Disease
the I-Disease
epididymis I-Disease
. O

papillary B-Disease
cystadenoma I-Disease
of I-Disease
the I-Disease
epididymis I-Disease
is O
an O
uncommon O
benign O
lesion O
that O
may O
occur O
sporadically O
or O
as O
a O
manifestation O
of O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( I-Disease
vhl I-Disease
) I-Disease
disease I-Disease
. O

neither O
immunohistochemical O
studies O
nor O
molecular O
genetic O
analyses O
of O
the O
vhl B-Disease
gene O
have O
been O
reported O
previously O
for O
this O
lesion O
. O

the O
authors O
describe O
two O
cases O
of O
clear O
cell O
papillary B-Disease
cystadenoma I-Disease
of I-Disease
the I-Disease
epididymis I-Disease
, O
both O
of O
which O
were O
initially O
confused O
with O
metastatic B-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
. O

because O
clear O
cell O
papillary B-Disease
cystadenoma I-Disease
is O
similar O
to O
renal B-Disease
cell I-Disease
carcinoma I-Disease
histologically O
, O
and O
because O
both O
occur O
as O
components O
of O
the O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
disease I-Disease
complex O
, O
the O
authors O
analyzed O
both O
cases O
for O
the O
presence O
of O
mutations O
in O
the O
vhl B-Disease
gene O
. O

a O
somatic O
vhl B-Disease
gene O
mutation O
was O
detected O
in O
one O
of O
the O
two O
tumors B-Disease
by O
polymerase O
chain O
reaction O
followed O
by O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

as O
the O
vhl B-Disease
gene O
is O
believed O
to O
function O
as O
a O
tumor B-Disease
suppressor O
gene O
, O
vhl B-Disease
gene O
mutations O
may O
play O
a O
role O
in O
the O
initiation O
of O
tumorigenesis O
in O
sporadic O
cystadenomas B-Disease
of I-Disease
the I-Disease
epididymis I-Disease
. O

identification O
of O
wasp O
mutations O
in O
patients O
with O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
and O
isolated B-Disease
thrombocytopenia I-Disease
reveals O
allelic O
heterogeneity O
at O
the O
was B-Disease
locus O
. O

mutation O
in O
the O
gene O
encoding O
the O
recently O
isolated O
wasp O
protein O
has O
now O
been O
identified O
as O
the O
genetic B-Disease
defect I-Disease
responsible O
for O
the O
x B-Disease
- I-Disease
linked I-Disease
wiskott I-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
a O
primary O
immunodeficiency B-Disease
disease I-Disease
associated O
with O
extensive O
phenotypic O
variability O
. O

to O
elucidate O
the O
range O
of O
wasp O
mutations O
responsible O
for O
was B-Disease
, O
we O
used O
pcr O
- O
sscp O
analysis O
to O
screen O
for O
wasp O
gene O
mutation O
in O
19 O
unrelated O
boys O
with O
the O
diagnosis O
of O
classical O
or O
attenuated O
was B-Disease
or O
isolated B-Disease
thrombocytopenia I-Disease
. O

however O
, O
a O
missense O
mutation O
which O
results O
in O
substitution O
of O
the O
arginine O
at O
was B-Disease
codon O
86 O
was O
identified O
in O
three O
boys O
with O
severe O
was B-Disease
as O
well O
as O
in O
one O
boy O
presenting O
with O
thrombocytopenia B-Disease
alone O
. O

while O
the O
three O
mutations O
found O
in O
the O
isolated B-Disease
thrombocytopenia I-Disease
patients O
leave O
the O
reading O
frame O
intact O
, O
about O
one O
- O
half O
of O
the O
gene O
alterations O
detected O
in O
both O
severe O
and O
attenuated O
was B-Disease
patients O
result O
in O
frameshifted O
transcript O
and O
premature O
translation O
termination O
. O

these O
findings O
therefore O
confirm O
the O
association O
of O
was B-Disease
with O
wasp O
mutation O
and O
identify O
wasp O
mutation O
as O
a O
cause O
for O
isolated O
congenital B-Disease
thrombocytopenia I-Disease
in O
males O
. O

while O
the O
wasp O
gene O
defects O
responsible O
for O
isolated B-Disease
thrombocytopenia I-Disease
and O
other O
mild O
presentations O
of O
was B-Disease
do O
not O
appear O
distinct O
from O
those O
resulting O
in O
severe O
was B-Disease
, O
these O
data O
indicate O
that O
analysis O
of O
wasp O
gene O
mutation O
provides O
a O
valuable O
tool O
for O
distinguishing O
the O
spectrum O
of O
was B-Disease
patients O
and O
the O
subset O
of O
males O
with O
isolated B-Disease
thrombocytopenia I-Disease
who O
represent O
mild O
cases O
of O
was B-Disease
. O
. O

wasp O
gene O
mutations O
in O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
and O
x B-Disease
- I-Disease
linked I-Disease
thrombocytopenia I-Disease
. O

23 O
and O
shown O
to O
be O
mutated O
in O
three O
patients O
with O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
. O

four O
amino O
acid O
substitutions O
, O
leu27phe O
, O
thr48ile O
, O
val75met O
and O
arg477lys O
, O
were O
found O
in O
patients O
with O
congenital B-Disease
thrombocytopenia I-Disease
and O
no O
clinically O
evident O
immune O
defect O
indicating O
that O
the O
wasp O
gene O
is O
the O
site O
for O
mutations O
in O
x B-Disease
- I-Disease
linked I-Disease
thrombocytopenia I-Disease
as O
well O
as O
in O
was B-Disease
. O

a O
t O
- O
cell O
line O
from O
a O
was B-Disease
patient O
contained O
two O
independent O
dna O
alterations O
, O
a O
constitutional O
frameshift O
mutation O
, O
also O
present O
in O
peripheral O
blood O
leukocytes O
from O
the O
patient O
, O
and O
compensatory O
splice O
site O
mutation O
unique O
to O
the O
cell O
line O
. O

the O
distribution O
of O
eight O
missense O
mutations O
provides O
valuable O
information O
on O
amino O
acids O
which O
are O
essential O
for O
normal O
protein O
function O
, O
and O
suggests O
that O
sites O
in O
the O
first O
two O
exons O
are O
hot O
- O
spots O
for O
mutation O
. O

evidence O
for O
inter O
- O
generational O
instability O
in O
the O
cag O
repeat O
in O
the O
mjd1 O
gene O
and O
for O
conserved O
haplotypes O
at O
flanking O
markers O
amongst O
japanese O
and O
caucasian O
subjects O
with O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
. O

the O
size O
of O
the O
( O
cag O
) O
n O
repeat O
array O
in O
the O
3 O
' O
end O
of O
the O
mjd1 O
gene O
and O
the O
haplotype O
at O
a O
series O
of O
microsatellite O
markers O
surrounding O
the O
mjd1 O
gene O
were O
examined O
in O
a O
large O
cohort O
of O
japanese O
and O
caucasian O
subjects O
affected O
with O
machado B-Disease
- I-Disease
joseph I-Disease
disease I-Disease
( O
mjd B-Disease
) O
. O

our O
data O
provide O
five O
novel O
observations O
. O

first O
, O
mjd B-Disease
is O
associated O
with O
expansion O
fo O
the O
array O
from O
the O
normal O
range O
of O
14 O
- O
37 O
repeats O
to O
68 O
- O
84 O
repeats O
in O
most O
japanese O
and O
caucasian O
subjects O
, O
but O
no O
subjects O
were O
observed O
with O
expansions O
intermediate O
in O
size O
between O
those O
of O
the O
normal O
and O
mjd B-Disease
affected O
groups O
. O

second O
, O
the O
expanded O
allele O
associated O
with O
mjd B-Disease
displays O
inter O
- O
generational O
instability O
, O
particularly O
in O
male O
meioses O
, O
and O
this O
instability O
was O
associated O
with O
the O
clinical O
phenomenon O
of O
anticipation O
. O

third O
, O
the O
size O
of O
the O
expanded O
allele O
is O
not O
only O
inversely O
correlated O
with O
the O
age O
- O
of O
- O
onset O
of O
mjd B-Disease
( O
r O
= O
- O
0 O
. O
738 O
, O
p O
< O
0 O
. O
001 O
) O
, O
but O
is O
also O
correlated O
with O
the O
frequency O
of O
other O
clinical O
features O
[ O
e O
. O
g O
. O
pseudoexophthalmos O
and O
pyramidal O
signs O
were O
more O
frequent O
in O
subjects O
with O
large O
repeats O
( O
p O
< O
0 O
. O
001 O
and O
p O
< O
0 O
. O
05 O
respectively O
) O
] O
. O

fourth O
, O
the O
disease O
phenotype O
is O
significantly O
more O
severe O
and O
had O
an O
early O
age O
of O
onset O
( O
16 O
years O
) O
in O
a O
subject O
homozygous O
for O
the O
expanded O
allele O
, O
which O
contrasts O
with O
huntington B-Disease
disease I-Disease
and O
suggests O
that O
the O
expanded O
allele O
in O
the O
mjd1 O
gene O
could O
exert O
its O
effect O
either O
by O
a O
dominant O
negative O
effect O
( O
putatively O
excluded O
in O
hd B-Disease
) O
or O
by O
a O
gain O
of O
function O
effect O
as O
proposed O
for O
hd B-Disease
. O

a O
4 O
- O
megabase O
yac O
contig O
that O
spans O
the O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
region O
on O
human O
chromosome O
8q24 O
. O
1 O
: O
use O
in O
refining O
the O
location O
of O
the O
trichorhinophalangeal B-Disease
syndrome I-Disease
and O
multiple O
exostoses O
genes O
( O
trps1 O
and O
ext1 O
) O
. O

1 O
and O
used O
this O
map O
to O
refine O
the O
locations O
of O
the O
genes O
responsible O
for O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
. O

the O
minimal O
region O
of O
overlap O
of O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
deletions O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 O
patients O
whose O
deletions O
define O
the O
endpoints O
. O

the O
chromosome O
8 O
breakpoint O
of O
a O
balanced O
t O
( O
8 O
; O
9 O
) O
( O
q24 O
. O
11 O
; O
q33 O
. O
3 O
) O
translocation O
from O
a O
patient O
with O
trichorhinophalangeal B-Disease
syndrome I-Disease
( O
trps B-Disease
i O
) O
was O
found O
to O
be O
located O
just O
within O
the O
proximal O
end O
of O
the O
minimal O
deletion O
region O
. O

3 O
in O
a O
patient O
with O
multiple O
exostoses O
was O
found O
to O
overlap O
the O
distal O
end O
of O
the O
lgs B-Disease
deletion O
region O
, O
indicating O
that O
the O
ext1 O
gene O
is O
distal O
to O
the O
trps1 O
gene O
and O
supporting O
the O
hypothesis O
that O
langer B-Disease
- I-Disease
giedion I-Disease
syndrome I-Disease
is O
due O
to O
loss O
of O
functional O
copies O
of O
both O
the O
trps1 O
and O
the O
ext1 O
genes O

brca1 O
mutations O
in O
a O
population O
- O
based O
sample O
of O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

inherited O
mutations O
in O
the O
brca1 O
gene O
are O
associated O
with O
a O
high O
risk O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
in O
some O
families O
. O

however O
, O
little O
is O
known O
about O
the O
contribution O
of O
brca1 O
mutations O
to O
breast B-Disease
cancer I-Disease
in O
the O
general O
population O
. O

we O
analyzed O
dna O
samples O
from O
women O
enrolled O
in O
a O
population O
- O
based O
study O
of O
early O
- O
onset O
breast B-Disease
cancer I-Disease
to O
assess O
the O
spectrum O
and O
frequency O
of O
germ O
- O
line O
brca1 O
mutations O
in O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

we O
studied O
80 O
women O
in O
whom O
breast B-Disease
cancer I-Disease
was O
diagnosed O
before O
the O
age O
of O
35 O
, O
and O
who O
were O
not O
selected O
on O
the O
basis O
of O
family O
history O
. O

two O
of O
the O
mutations O
and O
three O
of O
the O
rare O
sequence O
variants O
were O
found O
among O
the O
39 O
women O
who O
reported O
no O
family O
history O
of O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

none O
of O
the O
mutations O
and O
only O
one O
of O
the O
rare O
variants O
was O
identified O
in O
a O
reference O
population O
of O
73 O
unrelated O
subjects O
. O

conclusions O
. O

alterations O
in O
brca1 O
were O
identified O
in O
approximately O
10 O
percent O
of O
this O
cohort O
of O
young O
women O
with O
breast B-Disease
cancer I-Disease
. O

the O
risk O
of O
harboring O
a O
mutation O
was O
not O
limited O
to O
women O
with O
family O
histories O
of O
breast B-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

thirty O
- O
seven O
families O
with O
four O
or O
more O
cases O
of O
breast B-Disease
cancer I-Disease
or O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
were O
analyzed O
for O
mutations O
in O
brca1 O
. O

expressivity O
of O
185delag O
in O
these O
families O
varied O
, O
from O
early O
- O
onset O
breast B-Disease
cancer I-Disease
without O
ovarian B-Disease
cancer I-Disease
. O

in O
one O
family O
, O
penetrance O
was O
complete O
, O
with O
females O
developing O
early O
- O
onset O
breast B-Disease
cancer I-Disease
or O
ovarian B-Disease
cancer I-Disease
and O
the O
male O
carrier O
developing O
prostatic B-Disease
cancer I-Disease
, O
whereas O
, O
in O
the O
other O
family O
, O
penetrance O
was O
incomplete O
and O
only O
breast B-Disease
cancer I-Disease
occurred O
, O
diagnosed O
at O
ages O
38 O
- O
81 O
years O
. O

two O
novel O
nonsense O
mutations O
led O
to O
the O
loss O
of O
mutant O
brca1 O
transcript O
in O
families O
with O
10 O
and O
6 O
cases O
of O
early O
- O
onset O
breast B-Disease
cancer I-Disease
and O
ovarian B-Disease
cancer I-Disease
. O

overall O
in O
our O
series O
, O
brca1 O
mutations O
have O
been O
detected O
in O
26 O
families O
16 O
with O
positive O
brca1 O
lod O
scores O
, O
7 O
with O
negative O
lod O
scores O
( O
reflecting O
multiple O
sporadic O
breast B-Disease
cancers I-Disease
) O
, O
and O
3 O
not O
tested O
for O
linkage O
. O

deficiency B-Disease
of I-Disease
glucose I-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
dehydrogenase I-Disease
( O
g6pd O
) O
is O
usually O
found O
at O
high O
frequencies O
in O
areas O
of O
the O
world O
where O
malaria B-Disease
has O
been O
endemic O
. O

the O
frequency O
and O
genetic O
basis O
of O
g6pd B-Disease
deficiency I-Disease
have O
been O
studied O
in O
africa O
, O
around O
the O
mediterranean O
, O
and O
in O
the O
far O
east O
, O
but O
little O
such O
information O
is O
available O
about O
the O
situation O
in O
india O
. O

to O
determine O
the O
extent O
of O
heterogeneity O
of O
g6pd O
, O
we O
have O
studied O
several O
different O
indian O
populations O
by O
screening O
for O
g6pd B-Disease
deficiency I-Disease
, O
followed O
by O
molecular O
analysis O
of O
deficient O
alleles O
. O

the O
frequency O
of O
g6pd B-Disease
deficiency I-Disease
varies O
between O
3 O
% O
and O
15 O
% O
in O
different O
tribal O
and O
urban O
groups O
. O

remarkably O
, O
a O
previously O
unreported O
deficient O
variant O
, O
g6pd O
orissa O
( O
44 O
ala O
- O
- O
> O
gly O
) O
, O
is O
responsible O
for O
most O
of O
the O
g6pd B-Disease
deficiency I-Disease
in O
tribal O
indian O
populations O
but O
is O
not O
found O
in O
urban O
populations O
, O
where O
most O
of O
the O
g6pd B-Disease
deficiency I-Disease
is O
due O
to O
the O
g6pd O
mediterranean O
( O
188 O
ser O
- O
- O
> O
phe O
) O
variant O
. O

evidence O
for O
linkage O
of O
bipolar B-Disease
disorder I-Disease
to O
chromosome O
18 O
with O
a O
parent O
- O
of O
- O
origin O
effect O
. O

a O
susceptibility O
gene O
on O
chromosome O
18 O
and O
a O
parent O
- O
of O
- O
origin O
effect O
have O
been O
suggested O
for O
bipolar B-Disease
affective I-Disease
disorder I-Disease
( O
bpad B-Disease
) O
. O

our O
results O
provide O
further O
support O
for O
linkage O
of O
bpad B-Disease
to O
chromosome O
18 O
and O
the O
first O
molecular O
evidence O
for O
a O
parent O
- O
of O
- O
origin O
effect O
operating O
in O
this O
disorder O
. O

a O
prevalent O
mutation O
for O
galactosemia B-Disease
among O
black O
americans O
. O

results O
we O
found O
a O
48 O
% O
prevalence O
of O
the O
s135l O
mutation O
among O
17 O
black O
american O
patients O
with O
classic B-Disease
galactosemia I-Disease
and O
a O
1 O
% O
prevalence O
in O
a O
population O
of O
50 O
black O
americans O
without O
galactosemia B-Disease
. O

the O
s135l O
mutation O
was O
not O
found O
in O
84 O
white O
patients O
with O
g O
/ O
g O
galactosemia B-Disease
nor O
in O
87 O
white O
control O
subjects O
without O
galactosemia B-Disease
. O

conclusions O
the O
s135l O
mutation O
in O
the O
galt O
gene O
is O
a O
prevalent O
cause O
of O
galactosemia B-Disease
among O
black O
patients O
. O

a O
high O
incidence O
of O
brca1 O
mutations O
in O
20 O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

we O
have O
analyzed O
20 O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
, O
the O
majority O
of O
which O
show O
positive O
evidence O
of O
linkage O
to O
chromosome O
17q12 O
for O
germ O
- O
line O
mutations O
in O
the O
brca1 O
gene O
. O

brca1 O
mutations O
cosegregating O
with O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
were O
identified O
in O
16 O
families O
, O
including O
1 O
family O
with O
a O
case O
of O
male B-Disease
breast I-Disease
cancer I-Disease
. O

it O
is O
expected O
that O
the O
majority O
of O
clear O
examples O
of O
the O
breast B-Disease
- I-Disease
ovarian I-Disease
syndrome I-Disease
will O
be O
associated O
with O
germ O
- O
line O
mutations O
in O
the O
coding O
region O
of O
brca1 O
. O
. O

brca1 B-Disease
deficiency I-Disease
results O
in O
early O
embryonic B-Disease
lethality I-Disease
characterized O
by O
neuroepithelial B-Disease
abnormalities I-Disease
. O

the O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
, O
brca1 O
, O
has O
been O
cloned O
and O
shown O
to O
encode O
a O
zinc O
- O
finger O
protein O
of O
unknown O
function O
. O

mutations O
in O
brca1 O
account O
for O
at O
least O
80 O
% O
of O
families O
with O
both O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
as O
well O
as O
some O
non O
- O
familial O
sporadic O
ovarian B-Disease
cancers I-Disease
. O

the O
loss O
of O
wild O
- O
type O
brca1 O
in O
tumours B-Disease
of O
individuals O
carrying O
one O
nonfunctional O
brca1 O
allele O
suggests O
that O
brca1 O
encodes O
a O
tumour B-Disease
suppressor O
that O
may O
inhibit O
the O
proliferation O
of O
mammary O
epithelial O
cells O
. O

to O
examine O
the O
role O
of O
brca1 O
in O
normal O
tissue O
growth O
and O
differentiation O
, O
and O
to O
generate O
a O
potential O
model O
for O
the O
cancer B-Disease
susceptibility O
associated O
with O
loss O
of O
brca1 O
function O
, O
we O
have O
created O
a O
mouse O
line O
carrying O
a O
mutation O
in O
one O
brca1 O
allele O
. O

abnormalities O
in O
brca1 B-Disease
- I-Disease
deficient I-Disease
embryos O
were O
most O
evident O
in O
the O
neural O
tube O
, O
with O
40 O
% O
of O
the O
embryos O
presenting O
with O
varying O
degrees O
of O
spina B-Disease
bifida I-Disease
and O
anencephaly B-Disease
. O

in O
addition O
, O
the O
neuroepithelium O
in O
brca1 B-Disease
- I-Disease
deficient I-Disease
embryos O
appeared O
disorganized O
, O
with O
signs O
of O
both O
rapid O
proliferation O
and O
excessive O
cell O
death O
. O

identification O
of O
mutations O
in O
the O
ald O
- O
gene O
of O
20 O
families O
with O
adrenoleukodystrophy B-Disease
/ O
adrenomyeloneuropathy B-Disease
. O

adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
, O
an O
x B-Disease
- I-Disease
linked I-Disease
inherited I-Disease
metabolic I-Disease
disorder I-Disease
, O
is O
the O
most O
frequent O
inborn B-Disease
peroxisomal I-Disease
disease I-Disease
. O

it O
leads O
to O
demyelination B-Disease
in I-Disease
the I-Disease
central I-Disease
and I-Disease
peripheral I-Disease
nervous I-Disease
system I-Disease
. O

the O
ald B-Disease
gene O
has O
been O
recently O
identified O
and O
encodes O
a O
745 O
- O
amino O
- O
acid O
protein O
. O

we O
screened O
patients O
with O
adrenoleukodystrophy B-Disease
/ O
adrenomyeloneuropathy B-Disease
( O
ald B-Disease
/ O
amn B-Disease
) O
from O
20 O
kindreds O
for O
mutations O
in O
the O
ald B-Disease
gene O
. O

the O
mutations O
were O
not O
detected O
in O
the O
ald B-Disease
gene O
of O
30 O
healthy O
persons O
. O
. O

the O
murine O
homolog O
of O
the O
human O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
maps O
to O
mouse O
chromosome O
11d O
. O

the O
recently O
cloned O
human O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
, O
brca1 O
, O
is O
located O
on O
human O
chromosome O
17q21 O
. O

atelosteogenesis B-Disease
type I-Disease
ii I-Disease
is O
caused O
by O
mutations O
in O
the O
diastrophic B-Disease
dysplasia I-Disease
sulfate O
- O
transporter O
gene O
( O
dtdst O
) O
: O
evidence O
for O
a O
phenotypic O
series O
involving O
three O
chondrodysplasias B-Disease
. O

atelosteogenesis B-Disease
type I-Disease
ii I-Disease
( O
ao B-Disease
ii I-Disease
) O
is O
a O
neonatally O
lethal O
chondrodysplasia B-Disease
whose O
clinical O
and O
histological O
characteristics O
resemble O
those O
of O
another O
chondrodysplasia B-Disease
, O
the O
much O
less O
severe O
diastrophic B-Disease
dysplasia I-Disease
( O
dtd B-Disease
) O
. O

dtd B-Disease
is O
caused O
by O
mutations O
in O
the O
recently O
identified O
diastrophic B-Disease
dysplasia I-Disease
sulfate O
- O
transporter O
gene O
( O
dtdst O
) O
. O

here O
, O
we O
report O
that O
aoii B-Disease
patients O
also O
have O
dtdst O
mutations O
, O
which O
lead O
to O
defective O
uptake O
of O
inorganic O
sulfate O
and O
insufficient O
sulfation O
of O
macromolecules O
by O
patient O
mesenchymal O
cells O
in O
vitro O
. O

together O
with O
our O
recent O
observation O
that O
a O
third O
even O
more O
severe O
chondrodysplasia B-Disease
, O
achondrogenesis O
type O
ib O
, O
is O
also O
caused O
by O
mutations O
in O
dtdst O
, O
these O
results O
demonstrate O
a O
phenotypic O
series O
of O
three O
chondrodysplasias B-Disease
of O
increasing O
severity O
caused O
by O
lesions O
in O
a O
single O
sulfate O
- O
transporter O
gene O
. O

several O
brca1 O
mutations O
have O
now O
been O
found O
to O
occur O
in O
geographically O
diverse O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

to O
investigate O
mutation O
origin O
and O
mutation O
- O
specific O
phenotypes O
due O
to O
brca1 O
, O
we O
constructed O
a O
haplotype O
of O
nine O
polymorphic O
markers O
within O
or O
immediately O
flanking O
the O
brca1 O
locus O
in O
a O
set O
of O
61 O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
selected O
for O
having O
one O
of O
six O
recurrent O
brca1 O
mutations O
. O

a O
comparison O
of O
the O
six O
mutations O
in O
the O
relative O
proportions O
of O
cases O
of O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
was O
suggestive O
of O
an O
effect O
( O
p O
= O
. O
069 O
) O
, O
with O
57 O
% O
of O
women O
presumed O
affected O
because O
of O
the O
1294 O
del O
40 O
brca1 O
mutation O
having O
ovarian B-Disease
cancer I-Disease
, O
compared O
with O
14 O
% O
of O
affected O
women O
with O
the O
splice O
- O
site O
mutation O
in O
intron O
5 O
of O
brca1 O
. O

the O
brca1 O
gene O
is O
in O
large O
part O
responsible O
for O
hereditary B-Disease
human I-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

the O
isolation O
of O
the O
mouse O
brca1 O
homologue O
will O
facilitate O
the O
creation O
of O
mouse O
models O
for O
germline O
brca1 B-Disease
defects I-Disease
. O
. O

emerin B-Disease
deficiency I-Disease
at O
the O
nuclear O
membrane O
in O
patients O
with O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O

mutations O
in O
the O
sta O
gene O
at O
the O
xq28 O
locus O
have O
been O
found O
in O
patients O
with O
x B-Disease
- I-Disease
linked I-Disease
emery I-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
. O

using O
both O
antisera O
, O
we O
found O
positive O
nuclear O
membrane O
staining O
in O
skeletal O
, O
cardiac O
and O
smooth O
muscles O
in O
the O
normal O
controls O
and O
in O
patients O
with O
neuromuscular B-Disease
diseases I-Disease
other O
than O
edmd B-Disease
. O

in O
contrast O
, O
a O
deficiency O
in O
immunofluorescent O
staining O
of O
skeletal O
and O
cardiac O
muscle O
from O
edmd B-Disease
patients O
was O
observed O
. O

together O
, O
our O
findings O
suggest O
the O
specific O
deficiency B-Disease
of I-Disease
emerin I-Disease
in O
the O
nuclear O
membrane O
of O
muscle O
cells O
in O
patients O
with O
edmd B-Disease
. O
. O

growth B-Disease
retardation I-Disease
and O
tumour B-Disease
inhibition O
by O
brca1 O
. O

inherited O
mutations O
in O
brca1 O
predispose O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
but O
the O
role O
of O
brca1 O
in O
sporadic O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
has O
previously O
been O
elusive O
. O

here O
, O
we O
show O
that O
retroviral O
transfer O
of O
the O
wild O
- O
type O
brca1 O
gene O
inhibits O
growth O
in O
vitro O
of O
all O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
cell O
lines O
tested O
, O
but O
not O
colon B-Disease
or I-Disease
lung I-Disease
cancer I-Disease
cells O
or O
fibroblasts O
. O

mutant O
brca1 O
has O
no O
effect O
on O
growth O
of O
breast B-Disease
cancer I-Disease
cells O
; O
ovarian B-Disease
cancer I-Disease
cell O
growth O
is O
not O
affected O
by O
brca1 O
mutations O
in O
the O
5 O
portion O
of O
the O
gene O
, O
but O
is O
inhibited O
by O
3 O
brca1 O
mutations O
. O

development O
of O
mcf B-Disease
- I-Disease
7 I-Disease
tumours I-Disease
in O
nude O
mice O
is O
inhibited O
when O
mcf O
- O
7 O
cells O
are O
transfected O
with O
wild O
- O
type O
, O
but O
not O
mutant O
, O
brca1 O
. O

most O
importantly O
, O
among O
mice O
with O
established O
mcf B-Disease
- I-Disease
7 I-Disease
tumours I-Disease
, O
peritoneal O
treatment O
with O
a O
retroviral O
vector O
expressing O
wild O
- O
type O
brca1 O
significantly O
inhibits O
tumour B-Disease
growth O
and O
increased O
survival O
. O
